

19.10.2018

12:00 - 13:20	Type: Opening Session Title: Opening session and award lectures	Hall A2 - Room 18
---------------	--	-------------------

13:30 - 15:30	Type: Special session Title: Sharing the power - ESMO Women for Oncology Forum	Hall B4 - Room 24
---------------	---	-------------------

13:30 - 13:35 Welcome

13:35 - 13:50 To be announced

13:50 - 14:05 To be announced

14:05 - 14:20 DGHO Women's working group

14:20 - 14:35 Women for Oncology Italy

14:35 - 14:50 Women for Oncology Greece

14:50 - 15:20 Discussions

15:20 - 15:30 Conclusions

14:00 - 15:30 Type: Educational session Hall A1 - Room 17  
 Title: Standards and advances in rectal cancer  
 Chair(s): M. Koopman, NL

14:00 - 14:22 Imaging of rectal tumours: What is standard (and to be known by the clinician)?  
G. Brown, GB

14:22 - 14:44 Organ preservation and local treatment in localised rectal cancers  
D. Sebag-Montefiore, GB

14:44 - 15:06 Optimal multimodal treatment in advanced rectal cancers  
V. Valentini, IT

15:06 - 15:28 Controlling systemic disease: What is needed, and in which sequence?  
M. Koopman, NL

14:00 - 15:30 Type: Educational session ICM - Room 1  
 Title: Clinical implementation of PARP inhibitors  
 Chair(s): A. Tutt, GB

14:00 - 14:25 Who, when and how to test for BRCA mutations  
D. Stoppa-Lyonnet, CEDEX 5/FR

14:25 - 14:55 What is the true impact of PARP inhibitors in clinical practice?  
A. Tutt, GB

14:55 - 15:15 Managing side effects of PARP inhibitors  
S. Paluch-Shimon, IL

15:15 - 15:30 Discussion

14:00 - 15:00 Type: Poster Discussion session ICM - Room 14b  
 Title: Poster Discussion session - Lung metastatic 1  
 Chair(s): P. Janne, US; R. Califano, GB

14:00 - 14:00 One LBA TBC

14:00 - 14:00 One LBA TBC

14:00 - 14:00 1379PD - Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study

R. Dziadziuszko<sup>1</sup>, T. Mok<sup>2</sup>, D.R. Camidge<sup>3</sup>, A. Shaw<sup>4</sup>, J. Noe<sup>5</sup>, M. Nowicka<sup>5</sup>, T. Liu<sup>5</sup>, E. Mityr<sup>5</sup>, S. Peters<sup>5</sup>; <sup>1</sup>PL, <sup>2</sup>HK, <sup>3</sup>US, <sup>4</sup>MA/US, <sup>5</sup>CH

- 14:00 - 14:00 1380PD - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations  
B. Solomon<sup>1</sup>, J.-F. Martini<sup>2</sup>, S.-H. Ou<sup>2</sup>, R. Chiari<sup>3</sup>, R. Soo<sup>4</sup>, A. Bearz<sup>3</sup>, S. Li<sup>5</sup>, H. Thurm<sup>2</sup>, C.-C. Lin<sup>6</sup>, G. Riely<sup>5</sup>, T. Bauer<sup>7</sup>, A. Shaw<sup>8</sup>; <sup>1</sup>VIC/AU, <sup>2</sup>CA/US, <sup>3</sup>IT, <sup>4</sup>SG, <sup>5</sup>US, <sup>6</sup>TW, <sup>7</sup>TN/US, <sup>8</sup>MA/US
- 14:00 - 14:00 One LBA TBC
- 14:00 - 14:20 Invited Discussant three LBAs TBC, 1379PD and 1380PD  
P. Janne, US
- 14:20 - 14:30 Q&A led by Discussant
- 14:30 - 14:30 One LBA TBC
- 14:30 - 14:30 One LBA TBC
- 14:30 - 14:30 1381PD - Gefitinib With or Without Pemetrexed in Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutation (mut): Final Overall Survival (OS) Results From a Randomized Phase II Study  
J.C.-H. Yang<sup>1</sup>, Y. Cheng<sup>2</sup>, H. Murakami<sup>3</sup>, P.-C. Yang<sup>1</sup>, J. He<sup>2</sup>, K. Nakagawa<sup>3</sup>, J.H. Kang<sup>4</sup>, J.-H. Kim<sup>4</sup>, X. Wnag<sup>2</sup>, S. Enatsu<sup>3</sup>, T. Puri<sup>5</sup>, M. Orlando<sup>6</sup>; <sup>1</sup>TW, <sup>2</sup>CN, <sup>3</sup>JP, <sup>4</sup>KP, <sup>5</sup>IN, <sup>6</sup>AR
- 14:30 - 14:30 1382PD - Phase III Study of Gefitinib (G) versus Gefitinib+Carboplatin+Pemetrexed (GCP) as 1st-line Treatment for Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations (NEJ009)  
M. Seike<sup>1</sup>, A. Inoue<sup>1</sup>, S. Sugawara<sup>2</sup>, S. Morita<sup>1</sup>, Y. Hosomi<sup>1</sup>, S. Ikeda<sup>1</sup>, K. Watanabe<sup>1</sup>, K. Takahashi<sup>1</sup>, Y. Fujita<sup>1</sup>, T. Harada<sup>1</sup>, K. Minato<sup>1</sup>, K. Takamura<sup>1</sup>, K. Kobayashi<sup>1</sup>, T. Nukiwa<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Miyagi/JP
- 14:30 - 14:30 1383PD - An open-label, multicenter, phase 1 study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)  
R. Camidge<sup>1</sup>, R. Heist<sup>2</sup>, J. Goldman<sup>3</sup>, E. Angevin<sup>4</sup>, J. Strickler<sup>2</sup>, D. Morgensztern<sup>2</sup>, M. Barve<sup>5</sup>, T. Bauer<sup>6</sup>, E. Vokes<sup>7</sup>, T. Yi<sup>7</sup>, M. Motwani<sup>7</sup>, A. Parikh<sup>3</sup>, J. Wu<sup>7</sup>, K. Kelly<sup>2</sup>; <sup>1</sup>CO/US, <sup>2</sup>US, <sup>3</sup>CA/US, <sup>4</sup>CEDEX/FR, <sup>5</sup>TX/US, <sup>6</sup>TN/US, <sup>7</sup>IL/US
- 14:30 - 14:30 One LBA TBC
- 14:30 - 14:30 One LBA TBC

14:30 - 14:50 Invited Discussant four LBAs TBC, 1381PD, 1382PD and 1383PD  
R. Califano, GB

14:50 - 15:00 Q&A led by Discussant

14:00 - 15:30 Type: Proffered Paper session ICM - Room 13  
Title: Proffered paper session - Genitourinary tumours, prostate  
Chair(s): S. Gillissen, CH; E. Efstathiou, US

14:00 - 14:15 791O - Updated results of GETUG-12, a phase 3 trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.  
K. Fizazi<sup>1</sup>, A. Carmel<sup>1</sup>, F. Joly<sup>1</sup>, R. Delva<sup>1</sup>, G. Gravis<sup>2</sup>, F. Rolland<sup>3</sup>, F. Priou<sup>2</sup>, J.-M. Ferrero<sup>4</sup>, N. Houede<sup>1</sup>, L. Mourey<sup>5</sup>, C. Theodore<sup>1</sup>, I. Krakowski<sup>3</sup>, J.-F. Berdah<sup>1</sup>, M. Baciuchka Palmaro<sup>6</sup>, B. Laguerre<sup>3</sup>, A. Flechon<sup>3</sup>, A. Ravaud<sup>1</sup>, M. Brihoum<sup>1</sup>, S. Culine<sup>7</sup>, G. Le Teuff<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 9/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 2/FR, <sup>5</sup>Haute-Garonne/FR, <sup>6</sup>CEDEX 20/FR, <sup>7</sup>CEDEX 10/FR

14:15 - 14:30 One LBA TBC

14:30 - 14:45 Invited Discussant 791O and one LBA TBC  
E. Efstathiou, TX/US

14:45 - 15:00 792O - A Randomized Phase 2 Study of Cabazitaxel (CAB) vs (ABI) Abiraterone or (ENZ) Enzalutamide in Poor Prognosis Metastatic Castration-Resistant Prostate Cancer (mCRPC)  
K. Chi<sup>1</sup>, S. Taavitsainen<sup>2</sup>, N. Iqbal<sup>3</sup>, C. Ferrario<sup>4</sup>, M. Ong<sup>2</sup>, D. Wadhwa<sup>2</sup>, S. Hotte<sup>5</sup>, G. Lo<sup>6</sup>, B. Tran<sup>7</sup>, A. Azad<sup>7</sup>, L. Wood<sup>8</sup>, J. Gingerich<sup>8</sup>, S. North<sup>8</sup>, C. Pezaro<sup>9</sup>, D. Ruether<sup>10</sup>, S. Sridhar<sup>5</sup>, M. Annala<sup>2</sup>, J. Bacon<sup>2</sup>, A. Wyatt<sup>8</sup>; <sup>1</sup>British Columbia/CA, <sup>2</sup>BC/CA, <sup>3</sup>SK/CA, <sup>4</sup>QC/CA, <sup>5</sup>Ontario/CA, <sup>6</sup>ON/CA, <sup>7</sup>AU, <sup>8</sup>CA, <sup>9</sup>VIC/AU, <sup>10</sup>Alberta/CA

15:00 - 15:15 Invited Discussant 792O  
S. Oudard, FR

- 14:00 - 15:30 Type: Proffered Paper session Hall A1 - Room 15  
 Title: Proffered paper session - Gynaecological cancers  
 Chair(s): S. Banerjee, GB; S. Pignata, IT
- 14:00 - 14:15 One LBA TBC
- 14:15 - 14:30 932O - Phase III trial of Lurbinectedin versus PLD or Topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial  
S. Gaillard<sup>1</sup>, A. Oaknin<sup>2</sup>, I. Ray-Coquard<sup>3</sup>, I. Vergote<sup>4</sup>, G. Scambia<sup>5</sup>, N. Colombo<sup>5</sup>, S. Ghamande<sup>1</sup>, A. Soto-Matos<sup>2</sup>, C. Fernandez<sup>6</sup>, C. Kahatt<sup>2</sup>, J. Gomez<sup>2</sup>, A. Nieto<sup>2</sup>, N. Torres<sup>2</sup>, B. Pardo-Burdalo<sup>2</sup>, Z. Papai<sup>7</sup>, R. Kristeleit<sup>8</sup>, D. O'Malley<sup>1</sup>, I. Benjamin<sup>1</sup>, P. Pautier<sup>3</sup>, D. Lorusso<sup>5</sup>; <sup>1</sup>US, <sup>2</sup>ES, <sup>3</sup>CEDEX/FR, <sup>4</sup>BE, <sup>5</sup>IT, <sup>6</sup>España/ES, <sup>7</sup>HU, <sup>8</sup>GB
- 14:30 - 14:40 Invited Discussant One LBA TBC and 932O  
S. Pignata, IT
- 14:40 - 14:55 933O - Carboplatin/pegylated liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO Study Group, AGO-Austria, ANZGOG, GINECO, SGCTG).  
J. Pfisterer<sup>1</sup>, A. Dean<sup>2</sup>, K. Baumann<sup>1</sup>, J. Rau<sup>1</sup>, P. Harter<sup>1</sup>, F. Joly<sup>3</sup>, J. Sehouli<sup>1</sup>, U. Canzler<sup>1</sup>, B. Schmalfeldt<sup>1</sup>, C. Shannon<sup>4</sup>, A. Hein<sup>1</sup>, D. Reimer<sup>5</sup>, L. Hanker<sup>1</sup>, T. Petit<sup>3</sup>, F. Marmé<sup>1</sup>, A. El-Balat<sup>1</sup>, R. Glasspool<sup>6</sup>, N. de Gregorio<sup>1</sup>, S. Mahner<sup>1</sup>, J.-E. Kurtz<sup>3</sup>; <sup>1</sup>DE, <sup>2</sup>WA/AU, <sup>3</sup>FR, <sup>4</sup>QLD/AU, <sup>5</sup>AT, <sup>6</sup>GB
- 14:55 - 15:10 934O - Alienor/ENGOT-ov7 randomized trial exploring weekly Paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian Sex Cord tumors (SCT) in relapse  
I. Ray-Coquard<sup>1</sup>, P. Harter<sup>2</sup>, D. Lorusso<sup>3</sup>, C. Dalban<sup>4</sup>, I. Vergote<sup>5</sup>, K. Fujiwara<sup>6</sup>, L. Gladiéff<sup>7</sup>, H.-J. Lueck<sup>2</sup>, A. Floquet<sup>1</sup>, A.F. Lesoin<sup>1</sup>, A. Schnelzer<sup>2</sup>, S. Pignata<sup>3</sup>, F. Selle<sup>4</sup>, J. Sehouli<sup>2</sup>, F. Brocard<sup>4</sup>, G. Mangili<sup>3</sup>, P. Pautier<sup>1</sup>, U. De Giorgi<sup>8</sup>, M. Provansal<sup>4</sup>, P.-E. Heudel<sup>9</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>DE, <sup>3</sup>IT, <sup>4</sup>FR, <sup>5</sup>BE, <sup>6</sup>JP, <sup>7</sup>Haute-Garonne/FR, <sup>8</sup>Forli-Cesena/IT, <sup>9</sup>Cedex 08/FR
- 15:10 - 15:30 Invited Discussant 933O and 934O  
S. Banerjee, GB

14:00 - 15:30 Type: Special session Hall A1 - Room 16  
 Title: Big data in cancer management: Genomics and disease stratification  
 Chair(s): C. Caldas, GB

14:00 - 14:20 Lung cancer  
C. Swanton, GB

14:20 - 14:40 Breast cancer  
C. Caldas, Cambridgeshire/GB

14:40 - 15:00 CNS tumours  
S. Pfister, DE

15:00 - 15:30 Discussion

14:00 - 15:30 Type: Educational session Hall A2 - Room 18  
 Title: Emerging opportunities in cancer immunotherapy  
 Chair(s): I. Melero, ES

14:00 - 14:25 Mutanomes and neoantigens  
M. Bassani-Sternberg, CH/CH

14:25 - 14:50 Host biomarkers that affect response to immunotherapy (genetics and microbiomes)  
L. Zitvogel, CEDEX/FR

14:50 - 15:15 Emerging targets for immunotherapy  
I. Melero, ES

15:15 - 15:30 Discussion

14:00 - 15:30	Type: Proffered Paper session Title: Proffered paper session - Sarcoma Chair(s): R.L. Haas, NL	Hall B3 - Room 21
14:00 - 14:12	1601O - Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. <u>J.-Y. Blay</u> <sup>1</sup> , M. Toulmonde <sup>1</sup> , N. Penel <sup>1</sup> , O. Mir <sup>2</sup> , C. Chevreau <sup>3</sup> , P. Anract <sup>2</sup> , E. Bompas <sup>1</sup> , M. Rios <sup>1</sup> , N. Firmin <sup>2</sup> , A. Italiano <sup>1</sup> , S. Piperno-Neumann <sup>4</sup> , J.-E. Kurtz <sup>2</sup> , F. Duffaud <sup>4</sup> , P. Rosset <sup>2</sup> , F. Bertucci <sup>5</sup> , C. Perrin <sup>1</sup> , C. Chemin <sup>1</sup> , F. Ducimetiere <sup>1</sup> , F. Gouin <sup>2</sup> , A. Le Cesne <sup>1</sup> ; <sup>1</sup> CEDEX/FR, <sup>2</sup> FR, <sup>3</sup> Haute-Garonne/FR, <sup>4</sup> CEDEX 5/FR, <sup>5</sup> CEDEX 9/FR	
14:12 - 14:24	1602O - Outcome following unplanned excision in soft tissue sarcoma. Results of a multicentre study including 728 patients. <u>A. Leithner</u> <sup>1</sup> , P.-U. Tunn <sup>2</sup> , E. Goldenitsch <sup>1</sup> , F. Posch <sup>1</sup> , J. Szkandera <sup>1</sup> , M. Bergovec <sup>1</sup> , B. Liegl-Atzwanger <sup>1</sup> , M. Smolle <sup>1</sup> ; <sup>1</sup> AT, <sup>2</sup> DE	
14:24 - 14:36	One LBA TBC	
14:36 - 14:51	Invited Discussant 1601O, 1602O and one LBA TBC <u>R.L. Haas</u> , NL	
14:51 - 15:03	1603O - Initial Results of Phase 1 Study of DCC-2618, a Broad-spectrum KIT and PDGFRa Inhibitor, in Patients (pts) with Gastrointestinal Stromal Tumor (GIST) by Number of Prior Regimens. <u>S. George</u> <sup>1</sup> , M. Heinrich <sup>1</sup> , P. Chi <sup>1</sup> , A. Razak <sup>2</sup> , M. von Mehren <sup>3</sup> , M. Gordon <sup>4</sup> , K. Ganjoo <sup>1</sup> , N. Somaiah <sup>5</sup> , J.C. Trent <sup>6</sup> , J. Rodon Ahnert <sup>1</sup> , J. Wolf <sup>1</sup> , R. Ruiz-Soto <sup>7</sup> , O. Rosen <sup>7</sup> , F. Janku <sup>6</sup> ; <sup>1</sup> US, <sup>2</sup> ON/CA, <sup>3</sup> PA/US, <sup>4</sup> AZ/US, <sup>5</sup> SC/US, <sup>6</sup> TX/US, <sup>7</sup> MA/US	
15:03 - 15:15	One LBA TBC	
15:15 - 15:30	Invited Discussant 1603O and One LBA TBC	

14:00 - 15:30 Type: Educational session Hall B3 - Room 23  
 Title: Brain and leptomeningeal metastasis: Standard of diagnosis and treatment  
 Chair(s): F. Winkler, DE; C. Balana, ES

14:00 - 14:25 Challenges in the diagnostic work-up of brain and leptomeningeal metastasis  
P. Wesseling, NL

14:25 - 14:50 Multimodality treatment of brain metastasis  
F. Winkler, DE

14:50 - 15:15 Multimodality treatment of leptomeningeal metastasis  
E. Le Rhun, CEDEX/FR

15:15 - 15:30 Discussion

14:00 - 15:30 Type: Joint Symposium Hall B3 - Room 22  
 Title: ESMO-SIOPE: Multidisciplinary management of life-after-cancer issues in adolescent and young adult survivors: Medicine and beyond  
 Chair(s): G. Mountzios, GR; D. Stark, GB

14:00 - 14:05 Introduction  
D. Stark, Yorkshire/GB

14:05 - 14:25 Fertility preservation, parenthood and sexual health in AYA cancer survivors  
F. Peccatori, IT

14:25 - 14:45 Late cardiovascular toxicity of anti-cancer treatment in adolescents and young adults  
K. Rugbjerg, DK

14:45 - 15:05 Going back to school or work after cancer diagnosis: Professional and social re-integration of AYA cancer survivors  
P. Riis Olsen, DK

15:05 - 15:25 Psychosocial, nutritional and physical activity aspects of AYA cancer survivors  
A. Stein, DE

15:25 - 15:30 Conclusions  
G. Mountzios, Neo Psychiko/GR



14:00 - 15:00 Type: Special session ICM - Room  
 Title: Treatment decisions and side effect management of new drugs (including 14a  
 immunotherapy) in lung cancer  
 Chair(s): S. Rauh, LU; P. Garrido Lopez, ES

14:00 - 14:05 Topic 1 case presentation: Pseudo progression versus true progression: When is it time to switch  
 treatment?  
S. Rauh, LU

14:05 - 14:20 General Discussion  
P. Garrido Lopez, ES

14:20 - 14:25 Topic 2 case presentation: Side effects of immunotherapy in lung cancer: Focus on pulmonary toxicity  
S. Rauh, LU

14:25 - 14:40 General Discussion  
P. Garrido Lopez, ES

14:40 - 14:45 Topic 3 case presentation: Side effects of TKI's  
S. Rauh, LU

14:45 - 15:00 General Discussion  
P. Garrido Lopez, ES

14:00 - 15:30 Type: Special session ICM - Room 14c  
 Title: ESMO-MCBS in perspective

14:00 - 14:05 Introduction

14:05 - 14:30 Comparative assessment of clinical benefit using the ESMO-MCBS v1.1 and the ASCO Value  
 Frameworks Net Health Benefit Score

14:30 - 14:55 ESMO-MCBS v1.1 applied in haematological diseases

14:55 - 15:20 How to help countries priorities their cancer systemic therapies –report from the WHO

15:20 - 15:30 Conclusions

14:30 - 15:45 Type: Patient Advocacy Track ICM - Room 5  
 Title: Knowledge is power: Educating patients and advocates  
 Chair(s): J. Geissler, CH

14:30 - 14:45 Welcome to ESMO2018  
B. Ryll, SE

14:45 - 15:05 Reaching patients: The podcast experience  
F. Johansson, Sweden/SE

15:05 - 15:25 The Myeloma Access Atlas: Training programme  
A. Plate, BE

15:25 - 15:45 The CML ECABs: Educating for excellence  
J. Geissler, CH

15:45 - 17:30 Type: Educational session ICM - Room 1  
 Title: State of the art for systemic treatments in kidney and bladder cancers  
 Chair(s): M. De Santis, DE; M. Gizzi, BE

15:45 - 16:10 State of the art of immunotherapy in renal and bladder cancers  
C. Sternberg, IT

16:10 - 16:35 The current use of TKI in renal cancer  
M. Gizzi, BE

16:35 - 17:00 Is there still a role for chemotherapy in bladder cancer?  
M. De Santis, DE

17:00 - 17:25 Abundance of riches in view of health care constraints:  
A. Bex, NL

15:45 - 17:30 Type: Poster Discussion session Hall B3 - Room 21  
 Title: Poster Discussion session -Gastrointestinal, non-colorectal

15:45 - 15:45 616PD - Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase 3 study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer  
I. Chau<sup>1</sup>, S.-E. Al-Batran<sup>2</sup>, A. Luft<sup>3</sup>, R. Kowalyszyn<sup>4</sup>, C. Hernandez<sup>5</sup>, P. Pfeiffer<sup>6</sup>, E. Wojcik<sup>7</sup>, G. Bodoky<sup>8</sup>, A. Madi<sup>9</sup>, B. Brenner<sup>10</sup>, F. De Vita<sup>11</sup>, G. Folprecht<sup>2</sup>, K. Peltola<sup>12</sup>, S. Lorenzen<sup>2</sup>, C. Denlinger<sup>13</sup>, A. Liepa<sup>14</sup>, M. Das<sup>13</sup>, R. Wei<sup>13</sup>, C. Fuchs<sup>15</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>DE, <sup>3</sup>RU, <sup>4</sup>AR, <sup>5</sup>MX, <sup>6</sup>DK, <sup>7</sup>PL, <sup>8</sup>HU, <sup>9</sup>Merseyside/GB, <sup>10</sup>IL, <sup>11</sup>IT, <sup>12</sup>FI, <sup>13</sup>PA/US, <sup>14</sup>US, <sup>15</sup>CT/US

- 15:45 - 15:45 617PD - A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.  
T. Satoh<sup>1</sup>, L.-T. Chen<sup>2</sup>, Y.-K. Kang<sup>3</sup>, Y. Chao<sup>2</sup>, K. Kato<sup>4</sup>, H.C. Chung<sup>5</sup>, J.-S. Chen<sup>2</sup>, K. Muro<sup>6</sup>, W.K. Kang<sup>5</sup>, T. Yoshikawa<sup>4</sup>, S.C. Oh<sup>5</sup>, T. Tamura<sup>4</sup>, K.-W. Lee<sup>5</sup>, N. Boku<sup>7</sup>; <sup>1</sup>Osaka/JP, <sup>2</sup>TW, <sup>3</sup>Songpa-gu/KR, <sup>4</sup>JP, <sup>5</sup>KR, <sup>6</sup>Aichi/JP, <sup>7</sup>Kanagawa/JP
- 15:45 - 15:45 619PD - Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: a pooled analysis of 4 randomised trials  
M. Davidson<sup>1</sup>, A. Wagner<sup>2</sup>, K. Kouvelakis<sup>1</sup>, N. Starling<sup>1</sup>, I. Chau<sup>3</sup>, D. Watkins<sup>1</sup>, S. Rao<sup>1</sup>, C. Peckitt<sup>1</sup>, D. Cunningham<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>CH, <sup>3</sup>Surrey/GB
- 15:45 - 15:55 Invited Discussant 616PD, 617PD and 619PD
- 15:55 - 16:05 Q&A led by Discussant
- 16:05 - 16:05 618PD - Progression-free survival and recurrence results for AGITG DOCTOR. Pre-op cisplatin, 5FU &&  
A. Barbour<sup>1</sup>, E. Walpole<sup>2</sup>, G. Mai<sup>2</sup>, L. Barnes<sup>3</sup>, D. Watson<sup>4</sup>, S. Ackland<sup>3</sup>, V. Wills<sup>3</sup>, J. Martin<sup>3</sup>, M. Burge<sup>2</sup>, C. Karapetis<sup>4</sup>, J. Shannon<sup>3</sup>, L. Nott<sup>1</sup>, V. GebSKI<sup>3</sup>, M. Oostendorp<sup>3</sup>, K. Wilson<sup>3</sup>, J. Thomas<sup>2</sup>, G. Lampe<sup>2</sup>, J. Zalberg<sup>5</sup>, J. Simes<sup>3</sup>, M. Smithers<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>QLD/AU, <sup>3</sup>NSW/AU, <sup>4</sup>SA/AU, <sup>5</sup>VIC/AU
- 16:05 - 16:05 620PD - Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: a prospective, multicenter, randomized controlled study  
T. Li, J. Lyu, G. Zhu, J. Li, R. Zhao, S. Zhu, J. Wang, L. Xing, D. Yang, C. Xie, L.-F. Shen, H.-P. Shi, J. Lang; CN
- 16:05 - 16:15 Invited Discussant 618PD abd 620PD
- 16:15 - 16:25 Q&A led by Discussant
- 16:25 - 16:25 621PD - Phase 2 trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)  
B.-Y. Ryoo<sup>1</sup>, Z. Ren<sup>2</sup>, T.-Y. Kim<sup>3</sup>, H. Pan<sup>4</sup>, K.-M. Rau<sup>2</sup>, H.J. Choi<sup>3</sup>, J.-W. Park<sup>3</sup>, J.H. Kim<sup>5</sup>, C.-J. Yen<sup>2</sup>, B.-H. Kim<sup>3</sup>, D. Zhou<sup>2</sup>, J. Straub<sup>6</sup>, C. Zhao<sup>7</sup>, S. Qin<sup>2</sup>; <sup>1</sup>Songpa-gu/KR, <sup>2</sup>CN, <sup>3</sup>KR, <sup>4</sup>Zhejiang/CN, <sup>5</sup>Gyeonggi-do/KR, <sup>6</sup>DE, <sup>7</sup>US
- 16:25 - 16:25 622PD - Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)  
A. Zhu<sup>1</sup>, R. Finn<sup>2</sup>, P. Galle<sup>3</sup>, J.M. Llovet<sup>4</sup>, J.F. Blanc<sup>5</sup>, T. Okusaka<sup>6</sup>, I. Chau<sup>7</sup>, D. Cella<sup>8</sup>, A. Girvan<sup>9</sup>, J. Gable<sup>1</sup>, L. Bowman<sup>1</sup>, Y. Hsu<sup>1</sup>, P. Abada<sup>1</sup>, M. Kudo<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>DE, <sup>4</sup>ES, <sup>5</sup>FR, <sup>6</sup>JP, <sup>7</sup>Surrey/GB, <sup>8</sup>IL/US, <sup>9</sup>IN/US

- 16:25 - 16:25 One LBA TBC
- 16:25 - 16:40 Invited Discussant 621PD, 622PD and One LBA TBC
- 16:40 - 16:50 Q&A led by Discussant
- 16:50 - 16:50 One LBA TBC
- 16:50 - 16:50 623PD - The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced Biliary Tract Cancer.  
C. Morizane<sup>1</sup>, Y. Komatsu<sup>1</sup>, H. Takahashi<sup>2</sup>, M. Ueno<sup>1</sup>, J. Furuse<sup>1</sup>, T. Kudo<sup>3</sup>, S. Itoh<sup>1</sup>, S. Shimizu<sup>1</sup>, K. Nakamura<sup>1</sup>, K. Kamata<sup>1</sup>, K. Ohtsubo<sup>1</sup>, T. Mizukami<sup>1</sup>, Y. Kagawa<sup>1</sup>, S. Nomura<sup>1</sup>, T. Kuwata<sup>1</sup>, S. Fujii<sup>1</sup>, W. Okamoto<sup>1</sup>, K. Shitara<sup>1</sup>, A. Ohtsu<sup>1</sup>, T. Yoshino<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP, <sup>3</sup>Osaka/JP
- 16:50 - 16:50 624PD - Preliminary Results of a Ph2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)  
Y.-Y. Chen<sup>1</sup>, J.O. Park<sup>2</sup>, W.-C. Su<sup>1</sup>, D.-Y. Oh<sup>2</sup>, K.-P. Kim<sup>2</sup>, Y.-H. Feng<sup>1</sup>, L. Shen<sup>3</sup>, H. Liao<sup>3</sup>, J. Nie<sup>3</sup>, M. Qing<sup>3</sup>, J. Li<sup>3</sup>, P. De Porre<sup>4</sup>; <sup>1</sup>TW, <sup>2</sup>KR, <sup>3</sup>CN, <sup>4</sup>BE
- 16:50 - 17:00 Invited Discussant One LBA TBC, 623PD, 624PD
- 17:00 - 17:10 Q&A led by Discussant
- 17:10 - 17:10 One LBA TBC
- 17:10 - 17:10 625PD - Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase 2 KEYNOTE-158 study  
S. Pruitt<sup>1</sup>, D.-Y. Oh<sup>2</sup>, H.C. Chung<sup>2</sup>, A. Nagrial<sup>3</sup>, A. Marabelle<sup>4</sup>, R. Kelley<sup>5</sup>, L. Xu<sup>1</sup>, J. Mahoney<sup>1</sup>, M. Ueno<sup>6</sup>; <sup>1</sup>NJ/US, <sup>2</sup>KR, <sup>3</sup>NSW/AU, <sup>4</sup>FR, <sup>5</sup>CA/US, <sup>6</sup>JP
- 17:10 - 17:10 626PD - Randomized, Phase III Trial Comparing Adjuvant Gemcitabine (Gem) versus Gem plus Chemoradiation (CCRT) in Curatively Resected Pancreatic Ductal Adenocarcinoma (PDAC) – A Taiwan Cooperative Oncology Group Study  
H.-J. Chang, Y.-F. Chiu, J.-S. Chen, C.-P. Li, C.-L. Ho, Y.-M. Shyr, W.-C. Chiou, C.-N. Yeh, R.-K. Hsieh, Y.-L. Lin, Y.-W. Tien, T.-L. Hwang, Y.-S. Shan, L.-T. Chen; TW
- 17:10 - 17:20 Invited Discussant One LBA TBC, 625PD and 626PD

17:20 - 17:30 Q&A led by Discussant

16:00 - 17:30	Type: Special Symposium Title: Targeting brain metastases Chair(s): S. Singh, CA	Hall A1 - Room 17
---------------	--	-------------------

16:00 - 16:05 Introduction

16:05 - 16:25 Genetic heterogeneity in brain metastases: Therapeutic implications  
P. Brastianos, US

16:25 - 16:45 Therapeutic targeting of the pre-metastatic stage in human lung-to-brain metastasis  
S. Singh, CA

16:45 - 17:05 CTCs: Advancing tools to combat brain metastasis  
D. Marchetti, US

17:05 - 17:25 Lessons from Glioblastoma: DNA repair as a therapeutic target in GBM  
P. Hamerlik, DK

17:25 - 17:30 Conclusions and perspectives  
S. Singh, CA

16:00 - 17:30	Type: Special Symposium Title: Toxicities from specific agents Chair(s): I.-M. Svane, DK	ICM - Room 14b
16:00 - 16:05	Introduction <u>I.-M. Svane</u> , DK	
16:05 - 16:25	Acute and chronic toxicities <u>P. Ascierto</u> , IT	
16:25 - 16:45	TILS therapy <u>I.-M. Svane</u> , DK	
16:45 - 17:05	TCR and CAR in haematological malignancies <u>J. Svoboda</u> , US	
17:05 - 17:25	TCR and CAR in solid tumours <u>F. Thistlethwaite</u> , GB	
17:25 - 17:30	Conclusions and perspectives	

16:00 - 17:30	Type: Proffered Paper session Title: Proffered paper session - Breast cancer, early stage Chair(s): S. Delalogue, FR; C. Caldas, GB	ICM - Room 13
16:00 - 16:12	184O - Distant disease-free survival (DDFS) according to response category in neoadjuvant endocrine therapy (NET): 6-Year analysis in phase III NEOS trial <u>H. Iwata</u> <sup>1</sup> , N. Masuda <sup>2</sup> , Y. Yamamoto <sup>2</sup> , T. Fujisawa <sup>2</sup> , T. Toyama <sup>1</sup> , N. Taira <sup>2</sup> , M. Kashiwaba <sup>3</sup> , S. Ohtani <sup>4</sup> , T. Sakai <sup>2</sup> , Y. Hasegawa <sup>2</sup> , R. Nakamura <sup>2</sup> , H. Akabane <sup>2</sup> , Y. Shibahara <sup>2</sup> , H. Sasano <sup>2</sup> , T. Yamaguchi <sup>5</sup> , Y. Ohashi <sup>2</sup> ; <sup>1</sup> Aichi/JP, <sup>2</sup> JP, <sup>3</sup> Iwate/JP, <sup>4</sup> Hiroshima/JP, <sup>5</sup> Miyagi/JP	
16:12 - 16:24	185O - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort <u>B. PISTILLI</u> <sup>1</sup> , A. PACI <sup>1</sup> , S. Michiels <sup>1</sup> , A. ferreira <sup>2</sup> , V. poinsignon <sup>1</sup> , P. Cottu <sup>3</sup> , F. Lerebours <sup>1</sup> , C. Coutant <sup>4</sup> , A. Lesur <sup>1</sup> , O. Tredan <sup>5</sup> , P. SOULIE <sup>1</sup> , L. Vanlemmens <sup>5</sup> , C. Jouannaud <sup>5</sup> , C. Levy <sup>3</sup> , S. EVERHARD <sup>1</sup> , P. Arveux <sup>1</sup> , A. Partridge <sup>6</sup> , S. Delalogue <sup>1</sup> , F. André <sup>5</sup> , I. Vaz-Luis <sup>1</sup> ; <sup>1</sup> FR, <sup>2</sup> PT, <sup>3</sup> CEDEX 5/FR, <sup>4</sup> Cedex/FR, <sup>5</sup> CEDEX/FR, <sup>6</sup> US	
16:24 - 16:39	Invited Discussant 184O and 185O <u>H. Earl</u> , Cambridgeshire/GB	
16:39 - 16:51	One LBA TBC	
16:51 - 17:03	186O - Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized ShortHER trial. <u>M.V. Dieci</u> <sup>1</sup> , P.F. Conte <sup>1</sup> , G. Bisagni <sup>1</sup> , A. Brandes <sup>1</sup> , A. Frassoldati <sup>1</sup> , L. Cavanna <sup>1</sup> , A. Musolino <sup>1</sup> , F. Giotta <sup>1</sup> , A. Rimanti <sup>1</sup> , O. Garrone <sup>1</sup> , E. Bertone <sup>1</sup> , K. Cagossi <sup>1</sup> , S. Sarti <sup>2</sup> , A. Ferro <sup>1</sup> , C. Omarini <sup>1</sup> , A. Maiorana <sup>1</sup> , E. Orvieto <sup>1</sup> , M. Sanders <sup>3</sup> , R. D'Amico <sup>1</sup> , V. Guarneri <sup>1</sup> ; <sup>1</sup> IT, <sup>2</sup> Forli-Cesena/IT, <sup>3</sup> US	
17:03 - 17:15	187O - High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN): 20-year follow-up of a randomized phase 3 study <u>T. Steenbruggen</u> , L. Steggink, C. Seynaeve, J. van der Hoeven, M. Hooning, A. Jager, I. Konings, J. Kroep, W. Smit, V. Tjan-Heijnen, E. van der Wall, A. Bins, S. Linn, M. Schaapveld, F. van Leeuwen, C.P. Schroder, H. van Tinteren, E.G.E. de Vries, G. Sonke, J. Gietema; NL	
17:15 - 17:30	Invited Discussant one LBA TBC, 186O and 187O <u>J. Cortes Castan</u> , ES	

16:00 - 17:30 Type: Educational session Hall A1 - Room 15  
 Title: Exosomes and other EVs, why are they important?  
 Chair(s): C. Théry, FR

16:00 - 16:25 Extracellular Vesicles/Exosomes in Cancer  
R. Kalluri, US

16:25 - 16:50 Therapeutic potential of exosomes and/or EVs in cancer  
C. Théry, FR

16:50 - 17:15 Tumour educated platelets as cancer biomarkers  
T. Würdinger, NL

17:15 - 17:30 Discussion

16:00 - 17:30 Type: Joint Symposium Hall A1 - Room 16  
 Title: ESMO-ASCO Joint Symposium: Precision medicine and accessibility  
 Chair(s): J. Tabernero, ES

16:00 - 16:05 Introduction

16:05 - 16:25 Basket studies and rapid development in precision oncology  
A. Drilon, NY/US

16:25 - 16:45 The European regulator's point of view  
F. Pignatti, GB

16:45 - 17:05 The potential role of conditional at-risk drug indication approval  
P.G. Casali, IT

17:05 - 17:25 The US regulator's point of view

17:25 - 17:30 Conclusions



16:00 - 17:30 Type: Proffered Paper session Hall A2 - Room 18  
Title: Proffered paper session - NSCLC, metastatic

16:00 - 16:12 One LBA TBC

16:12 - 16:24 One LBA TBC

16:24 - 16:36 One LBA TBC

16:36 - 16:51 Invited Discussant three LBAs TBC  
T.S.K. Mok, HK

16:51 - 17:03 1377O - Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small lung cancer (NSCLC)  
Y.-L. Wu<sup>1</sup>, J. Zhou<sup>2</sup>, S. Lu<sup>2</sup>, Y. Zhang<sup>2</sup>, J. Zhao<sup>2</sup>, H. Pan<sup>2</sup>, Y.-M. Chen<sup>3</sup>, C.-F. Chian<sup>3</sup>, R. Bruns<sup>4</sup>, A. John<sup>4</sup>, J. Scheele<sup>4</sup>, Y. Cheng<sup>5</sup>; <sup>1</sup>Guangdong/CN, <sup>2</sup>CN, <sup>3</sup>TW, <sup>4</sup>DE, <sup>5</sup>Jilin/CN

17:03 - 17:15 One LBA TBC

17:15 - 17:30 Invited Discussant One LBA TBC and 1377O

16:00 - 17:30 Type: Special session Hall B3 - Room 23  
Title: Germline BRCA mutation: ripe for precision oncology?

16:00 - 17:30 Type: Proffered Paper session Hall B3 - Room 20  
 Title: Proffered Paper session - CNS  
 Chair(s): M. Preusser, AT; C. Balana, ES

16:00 - 16:12 3710 - Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: a randomised, open-label trial  
E. Le Rhun<sup>1</sup>, A. Mailliez<sup>2</sup>, J. Wallet<sup>2</sup>, I. Rodrigues<sup>2</sup>, T. Boulanger<sup>2</sup>, I. Desmoulin<sup>3</sup>, J. Barriere<sup>4</sup>, M. Fabbro<sup>5</sup>, S. Taillibert<sup>2</sup>, C. Andre<sup>2</sup>, M.C. Le Deley<sup>2</sup>, M. Weller<sup>6</sup>, J. Bonnetterre<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>Cedex/FR, <sup>4</sup>CEDEX 2/FR, <sup>5</sup>CEDEX 5/FR, <sup>6</sup>CH

16:12 - 16:24 3720 - Mutational and inflammatory microenvironment characteristics in primary and matched local recurrent non-small cell lung cancer brain metastases  
A.S. Berghoff, B. Erguener, M.R. Schuster, U. Rajky, G. Ricken, J. Frischer, B. Gatterbauer, C. Marosi, K. Dieckmann, G. Widhalm, C. Bock, M. Preusser; AT

16:24 - 16:39 Invited Discussant 3710 and 3720  
J. Seoane, ES

16:39 - 16:51 3730 - Results of Phase 2 Trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)  
D. Peereboom<sup>1</sup>, L.B. Nabors<sup>2</sup>, P. Kumthekar<sup>3</sup>, M. Badrudojja<sup>4</sup>, K. Fink<sup>5</sup>, F. Lieberman<sup>6</sup>, S. Phuphanich<sup>4</sup>, E. Dunbar<sup>7</sup>, T. Walbert<sup>8</sup>, D. Schiff<sup>9</sup>, D. Tran<sup>10</sup>, L. Ashby<sup>4</sup>, N. Butowski<sup>11</sup>, F. Iwamoto<sup>12</sup>, R. Lindsay<sup>3</sup>, J. Bullington<sup>12</sup>, M. Schulder<sup>12</sup>, J. Sherman<sup>3</sup>, C. Brooks<sup>3</sup>, D. Reardon<sup>13</sup>; <sup>1</sup>OH/US, <sup>2</sup>AL/US, <sup>3</sup>US, <sup>4</sup>AZ/US, <sup>5</sup>TX/US, <sup>6</sup>PA/US, <sup>7</sup>GA/US, <sup>8</sup>MI/US, <sup>9</sup>VA/US, <sup>10</sup>FL/US, <sup>11</sup>CA/US, <sup>12</sup>NY/US, <sup>13</sup>MA/US

16:51 - 17:03 3740 - Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics  
G. Lombardi<sup>1</sup>, M. Caccese<sup>1</sup>, M. Simonelli<sup>2</sup>, M. Fassan<sup>1</sup>, P. Persico<sup>1</sup>, E. Lorenzi<sup>1</sup>, R. Bertorelle<sup>1</sup>, M.P. Gardiman<sup>1</sup>, L. Bellu<sup>1</sup>, A. Pambuku<sup>1</sup>, A. Santoro<sup>2</sup>, V. Zagonel<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(MI)/IT

17:03 - 17:15 3750 - radiological phenotyping of idh mutation staus in gliomas using dynamic susceptibility contrast perfusion-weighted mri.  
D. Roettger, E. Sanverdi, C. Sudre, S. Brandner, V. Katsaros, S. Bisdas; GB

17:15 - 17:30 Invited Discussant 3730, 3740 and 3750  
M. van den Bent, NL

16:00 - 17:30 Type: Special session Hall B3 - Room 22  
 Title: Best integration of supportive and palliative care in the continuum of care  
 Chair(s): K. Jordan, DE; S. Kaasa, NO

16:00 - 16:05 Introduction  
K. Jordan, DE

16:05 - 16:25 Highlights of the Lancet commission paper: Integration of oncology and palliative care  
S. Kaasa, NO

16:25 - 16:45 Insights of the ESMO position paper on supportive and palliative care  
K. Jordan, DE

16:45 - 17:05 Palliative care in main stream oncology, how and how much- a Canadian perspective  
C. Zimmermann, CA

17:05 - 17:25 The place and content of Supportive and palliative care in a comprehensive cancer center in Europe

17:25 - 17:30 Conclusions  
S. Kaasa, NO

16:00 - 17:30 Type: Patient Advocacy Track ICM - Room 5  
 Title: Immunotherapy checkpoints: What to tell your patients  
 Chair(s): J. Haanen, NL; B. Ryll, SE

16:00 - 16:20 Introduction  
B. Ryll, SE

16:20 - 16:40 How long should we treat patients?  
J. Haanen, NL

16:40 - 17:00 Side effects

17:00 - 17:30 Q&A

17:30 - 18:30 Type: Young Oncologist session ICM - Foyer  
 Title: YO Vesalius: Work / life balance at early stages of young oncologist's career

17:30 - 17:50 Work / life balance at early stages of young oncologist's career  
M. Piccart<sup>1</sup>, A. Cervantes<sup>2</sup>, S. Peters<sup>3</sup>; <sup>1</sup>BE, <sup>2</sup>Valencia/ES, <sup>3</sup>CH

17:45 - 19:15	Type: Patient Advocacy Track Title: Life after cancer Chair(s): I. Lebrocqy, NL	ICM - Room 5
17:45 - 18:00	When is a cancer patient cured? <u>L. Dal Maso</u> , IT	
18:00 - 18:15	What is Europe doing in return to work? <u>A. de Boer</u> , NL	
18:15 - 18:30	The right to be forgotten <u>A. Dumas</u> , FR	
18:30 - 18:45	Advocating for survivors' rights <u>I. Lebrocqy</u> , NL	
18:45 - 19:15	Q&A	
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 1 (TBC)	Hall A1 - Room 17
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 2 (TBC)	ICM - Room 1
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 3 (TBC)	ICM - Room 14b
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 4 (TBC)	ICM - Room 13
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 5 (TBC)	Hall A1 - Room 15
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 6 (TBC)	Hall A1 - Room 16
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 8 (TBC)	Hall B3 - Room 21
18:00 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 7 (TBC)	Hall B3 - Room 20

18:00 - 20:00 Type: Industry Satellite Symposium Hall B3 - Room 22  
Title: Industry satellite symposium 9 (TBC)

18:00 - 20:00 Type: Industry Satellite Symposium Hall B4 - Room 19  
Title: Industry satellite symposium 10 (TBC)

18:00 - 20:00 Type: Industry Satellite Symposium ICM - Room 14a  
Title: Industry satellite symposium 11 (TBC)

18:00 - 20:00 Type: Industry Satellite Symposium ICM - Room 14c  
Title: Industry satellite symposium 12 (TBC)

## 20.10.2018

08:00 - 09:00 Type: Controversy Session Hall A1 - Room 15  
Title: HIPEC- is there a role in ovarian cancer?

08:00 - 08:10 Introduction and 1st vote

08:10 - 08:30 Yes

08:30 - 08:50 No  
A. du Bois, DE

08:50 - 09:00 2nd vote and conclusions

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 21  
Title: Treatment of metastatic castration sensitive prostate cancer  
Chair(s): H. Beltran, US

08:00 - 08:10 Treatment of metastatic castration sensitive prostate cancer  
N. James, GB

08:10 - 09:00 Discussion led by  
H. Beltran, US

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 23  
 Title: Skin toxicity of anticancer treatments: How to diagnose, how to treat  
 Chair(s): P. Feyer, DE

08:00 - 08:10 Skin toxicity of anticancer treatments: How to diagnose, how to treat  
V. Sibaud, Haute-Garonne/FR

08:10 - 09:00 Discussion led by  
P. Feyer, DE

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 20  
 Title: Thymic malignancies: Emerging systemic therapy options  
 Chair(s): H. Wakelee, US

08:00 - 08:10 Thymic malignancies: Emerging systemic therapy options  
N. Girard, FR

08:10 - 09:00 Discussion led by  
H. Wakelee, CA/US

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 22  
 Title: Metabolic targets in cancer

08:00 - 08:10 Metabolic targets in cancer  
E. Gottlieb, IL

08:10 - 09:00 Discussion led by

08:00 - 09:00 Type: Challenge Your Expert (CYE) session ICM - Room 14a  
 Title: Management of challenging patients with meningioma  
 Chair(s): P. Brastianos, US

08:00 - 08:10 Management of challenging patients with meningioma  
M. Preusser, AT

08:10 - 09:00 Discussion led by  
P. Brastianos, US

08:15 - 09:00	Type: Keynote lecture Title: Mutation signatures and targeting the DNA damage response	Hall A1 - Room 17
08:15 - 09:00	Mutation signatures and targeting the DNA damage response <u>T. Helleday</u> , GB	
09:00 - 10:30	Type: Educational session Title: Neo-adjuvant therapy management of early breast cancer Chair(s): J. Cortes Castan, ES; J.-M. Classe, FR	ICM - Room 1
09:00 - 09:18	Neo-adjuvant therapy for ER+/Her2neg disease with endocrine therapy alone or in combination with targeted therapies <u>M. Ellis</u> , TX/US	
09:18 - 09:36	Neo-adjuvant therapies for HER2 + for breast cancer <u>J. Cortes Castan</u> , ES	
09:36 - 09:54	Neo adjuvant therapies for triple negative in breast cancer <u>A. Tutt</u> , GB	
09:54 - 10:12	Surgical management of breast cancer patients after completion of neo-adjuvant therapies <u>J.-M. Classe</u> , CEDEX/FR	
10:12 - 10:30	Discussion	

09:15 - 10:45	Type: Proffered Paper session Title: Proffered paper session - Genitourinary tumours, non prostate Chair(s): K. Fizazi, FR; A. Necchi, IT	Hall A1 - Room 17
09:15 - 09:30	One LBA TBC	
09:30 - 09:45	863O - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results  <u>M. Gross-Goupil</u> <sup>1</sup> , T.G. Kwon <sup>2</sup> , M. Eto <sup>3</sup> , D. Ye <sup>4</sup> , H. Miyake <sup>3</sup> , S. Seo <sup>2</sup> , S. Byun <sup>2</sup> , J. Lee <sup>2</sup> , V. Master <sup>5</sup> , J. Jin <sup>4</sup> , R. Debenedetto <sup>6</sup> , R. Linke <sup>6</sup> , M. Casey <sup>5</sup> , B. Rosbrook <sup>5</sup> , M. Lechuga Freañ <sup>7</sup> , O. Valota <sup>7</sup> , E. Grande <sup>8</sup> , D. Quinn <sup>6</sup> ; <sup>1</sup> FR, <sup>2</sup> KR, <sup>3</sup> JP, <sup>4</sup> CN, <sup>5</sup> US, <sup>6</sup> CA/US, <sup>7</sup> IT, <sup>8</sup> ES	
09:45 - 10:00	Invited Discussant one LBA TBC and 863O  <u>M. Schmidinger</u> , AT	
10:00 - 10:15	864O - Pembrolizumab for High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial  <u>R. de Wit</u> <sup>1</sup> , G. Kulkarni <sup>2</sup> , E. Uchio <sup>3</sup> , E. Singer <sup>4</sup> , L. Krieger <sup>5</sup> , P. Grivas <sup>6</sup> , D. Bajorin <sup>7</sup> , H.K. Seo <sup>8</sup> , L. Mourey <sup>9</sup> , A. Kamat <sup>10</sup> , H. Nishiyama <sup>11</sup> , E. Kapadia <sup>7</sup> , K. Nam <sup>4</sup> , T. Frenkl <sup>4</sup> , A. Balar <sup>7</sup> ; <sup>1</sup> NL, <sup>2</sup> CA, <sup>3</sup> ON/CA, <sup>4</sup> NJ/US, <sup>5</sup> NSW/AU, <sup>6</sup> OH/US, <sup>7</sup> US, <sup>8</sup> KR/KR, <sup>9</sup> Haute-Garonne/FR, <sup>10</sup> TX/US, <sup>11</sup> JP	
10:15 - 10:30	Invited Discussant 864O  <u>S. Shariat</u> , AT	



09:15 - 10:45	Type: Special Symposium Title: Immunotherapy and targeted therapy in the landscape of non-metastatic NSCLC Chair(s): J. Brahmer, US; J. Vansteenkiste, BE	Hall A2 - Room 18
09:15 - 09:20	Introduction <u>J. Vansteenkiste</u> , BE	
09:20 - 09:40	Translating advances in stage IV disease to non-metastatic lung cancer <u>J. Brahmer</u> , MD/US	
09:40 - 10:00	Immunotherapy approaches in early stage disease <u>J. Vansteenkiste</u> , BE	
10:00 - 10:20	TKI approaches in early stage disease <u>M. Tsuboi</u> , Chiba/JP	
10:20 - 10:40	Integrating immunotherapy and TKIs in stage III disease management <u>W. Eberhardt</u> , DE	
10:40 - 10:45	Conclusions and clinical perspectives <u>J. Brahmer</u> , MD/US	

09:15 - 10:45 Type: Proffered Paper session ICM - Room 14b  
Title: Proffered paper session - Translational research

- 09:15 - 09:27 500 - Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the Circulating Cell-Free Genome Atlas (CCGA) study  
M. Liu<sup>1</sup>, E. Klein<sup>1</sup>, E. Hubbell<sup>1</sup>, T. Maddala<sup>1</sup>, A. Aravanis<sup>1</sup>, J. Beausang<sup>2</sup>, D. Filippova<sup>2</sup>, S. Gross<sup>2</sup>, A. Jamshidi<sup>2</sup>, K. Kurtzman<sup>2</sup>, L. Shen<sup>2</sup>, N. Zhang<sup>2</sup>, O. Venn<sup>2</sup>, J. Yecies<sup>2</sup>, S. Patel<sup>2</sup>, D. Smith<sup>3</sup>, T. Yeatman<sup>4</sup>, M. Seiden<sup>5</sup>, A.-R. Hartman<sup>2</sup>, G. Oxnard<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>WA/US, <sup>4</sup>SC/US, <sup>5</sup>TX/US, <sup>6</sup>MA/US
- 09:27 - 09:39 1336O - Unbiased genomewide screening of circulating plasma DNA for cancer detection  
L. Lenaerts, N. Brison, M. Neofytou, H. Che, L. Dehaspe, M. Verheecke, C. Maggen, B. Dewaele, S. Vanderschueren, V. Vandecaveye, P. Vandenberghe, J. Vermeesch, F. Amant; BE
- 09:39 - 09:54 Invited Discussant 500 and 1336O
- 09:54 - 10:06 51O - Pan-cancer assessment of BRCA1/2 genomic alterations (GAs) by comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).  
N. Agarwal<sup>1</sup>, E. Sokol<sup>2</sup>, P. Lara Jr.<sup>1</sup>, J. Ross<sup>1</sup>, V. Miller<sup>2</sup>, A. Welsh<sup>3</sup>, J. Gregg<sup>4</sup>, G. Frampton<sup>2</sup>, S. Ali<sup>2</sup>, J. Chung<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MA/US, <sup>3</sup>NJ/US, <sup>4</sup>CA/US
- 10:06 - 10:18 52O - Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma  
L. Tan<sup>1</sup>, S. Sandhu<sup>1</sup>, R. Lee<sup>2</sup>, J. Li<sup>1</sup>, J. Callahan<sup>1</sup>, J. Raleigh<sup>1</sup>, A. Hatzimihalis<sup>1</sup>, P. Middlehurst<sup>2</sup>, M. Henderson<sup>1</sup>, M. Shackleton<sup>1</sup>, A. Haydon<sup>1</sup>, D. Gyorki<sup>1</sup>, D. Oudit<sup>2</sup>, R. Hicks<sup>1</sup>, P. Lorigan<sup>2</sup>, G. McArthur<sup>1</sup>, R. Marais<sup>2</sup>, S. Wong<sup>1</sup>, S.-J. Dawson<sup>1</sup>; <sup>1</sup>VIC/AU, <sup>2</sup>GB
- 10:18 - 10:30 1830O - Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced Non-small cell lung cancer (aNSCLC): a prospective study.  
L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, M. Verza, L. Pasqualini, G. Pasello, G. Zago, S. Frega, M. Fassan, F. Calabrese, A. Amadori, V. Guarneri, P.F. Conte, S. Indraccolo; IT
- 10:30 - 10:45 Invited Discussant 51O, 52O and 1830O  
C. Dive, GB

09:15 - 10:45 Type: Joint Symposium Hall B3 - Room 23  
Title: ESMO-DGHO Joint Symposium: Access to anti-cancer drugs

09:15 - 09:20 Introduction

09:20 - 09:40 The shortage of essential oncology drugs

A. Eniu, RO

09:40 - 10:00 Access to innovative/expensive drugs

R. Sullivan, GB

10:00 - 10:20 What is a fair price?

C. Bokemeyer, DE

10:20 - 10:40 Strategies in Germany

B. Woermann, DE

10:40 - 10:45 Conclusions

09:15 - 10:30 Type: Poster Discussion session Hall B4 - Room 19  
Title: Poster Discussion session - Public Health  
Chair(s): F. Eskens, NL

09:15 - 09:15 1560PD - Major determinants of delayed access to innovative medicines for metastatic melanoma: the results of Melanoma World Society and European Association of Dermato-oncology survey

L. Kandolf Sekulovic<sup>1</sup>, S. Agarwala<sup>2</sup>, A. Hauschild<sup>3</sup>, J. Guo<sup>4</sup>, G. McArthur<sup>5</sup>, P. Lorigan<sup>6</sup>, G. Cinat<sup>7</sup>, C. Caglevich<sup>8</sup>, C. Lebbe<sup>9</sup>, P. Rutkowski<sup>10</sup>, H. Gogas<sup>11</sup>, R. Dummer<sup>12</sup>, B. Neyns<sup>13</sup>, L. Bastholt<sup>14</sup>, A. Wainstein<sup>15</sup>, D. Herceg<sup>16</sup>, M. Banjin<sup>17</sup>, A. Zhukavets<sup>18</sup>, J. Ocvirk<sup>19</sup>, C. Garbe<sup>20</sup>; <sup>1</sup>RS, <sup>2</sup>PA/US, <sup>3</sup>Schleswig-Holstein/DE, <sup>4</sup>CN, <sup>5</sup>VIC/AU, <sup>6</sup>GB, <sup>7</sup>AR, <sup>8</sup>CL, <sup>9</sup>CEDEX 10/FR, <sup>10</sup>PL, <sup>11</sup>Attiki/GR, <sup>12</sup>CH, <sup>13</sup>BE, <sup>14</sup>DK, <sup>15</sup>BR, <sup>16</sup>HR, <sup>17</sup>BA, <sup>18</sup>BY, <sup>19</sup>SI, <sup>20</sup>DE/DE

09:15 - 09:15 1561PD - Variation in Oncology Drug Approvals in Canada, the United States and Europe

O. Khan<sup>1</sup>, N. Samuel<sup>1</sup>, S. Verma<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>Alberta/CA

09:15 - 09:25 Invited Discussant 1560PD and 1561PD

09:25 - 09:35 Q&A led by Discussant

09:35 - 09:35 1562PD - Magnitude of Clinical Benefit of Cancer Drugs Approved Based on Single-Arm Trials (SAT) by the US Food and Drug Administration (FDA)

C. Molto Valiente<sup>1</sup>, M. Borrell<sup>1</sup>, A. Ocana Fernandez<sup>1</sup>, A. Templeton<sup>2</sup>, L. del Carpio<sup>1</sup>, J. Del Paggio<sup>3</sup>, A. Barnadas<sup>1</sup>, C. Booth<sup>4</sup>, A. Tibau<sup>1</sup>, E. Amir<sup>4</sup>; <sup>1</sup>ES, <sup>2</sup>CH, <sup>3</sup>CA, <sup>4</sup>ON/CA

09:35 - 09:35 1563PD - Magnitude of Clinical Benefit in Trials Supporting US Food and Drug Administration (FDA) Accelerated Approval (AA) and European Medicines Agency (EMA) Conditional Marketing Authorisation (CMA) and Subsequent Trials Supporting Conversion to Full Approval

M. Borrell Puy<sup>1</sup>, C. Molto Valiente<sup>1</sup>, K. Vokinger<sup>2</sup>, T. Hwang<sup>3</sup>, A. Ocana Fernandez<sup>1</sup>, A. Templeton<sup>2</sup>, B. Seruga<sup>4</sup>, I. Gich Saladich<sup>1</sup>, A. Barnadas<sup>1</sup>, E. Amir<sup>5</sup>, A. Tibau<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>CH, <sup>3</sup>US, <sup>4</sup>SI, <sup>5</sup>ON/CA

09:35 - 09:35 1564PD - Magnitude of Clinical Benefit of Trials Supporting US Food and Drug Administration (FDA) Approval of Breakthrough and Non-breakthrough Drugs

C. Molto Valiente<sup>1</sup>, M. Borrell<sup>1</sup>, T. Hwang<sup>2</sup>, I. Gich Saladich<sup>1</sup>, A. Barnadas<sup>1</sup>, E. Amir<sup>3</sup>, A. Kesselheim<sup>4</sup>, A. Tibau<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>US, <sup>3</sup>ON/CA, <sup>4</sup>MA/US

09:35 - 09:35 1565PD - Time to access to novel anticancer therapies in Slovenia in view of the ESMO-MCBS scores  
U. Janzic, L. Knez, A. Janzic, T. Cufer; SI

09:35 - 09:50 Invited Discussant 1563PD, 1564PD and 1565PD

F. Eskens, NL

09:50 - 10:00 Q&A led by Discussant

10:00 - 10:00 1566PD - Cascade BRCA Germline Mutation (BGM) Testing of women with Breast (BC) or Epithelial Ovarian Cancer( EOC) and their families with subsequent Risk Reducing Surgery(RRS): A Canadian Economics Model

P. Hoskins<sup>1</sup>, A. Ecclestone<sup>1</sup>, M. Hurry<sup>1</sup>, M. Dyer<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>GB

10:00 - 10:00 1567PD - Genetic testing of BRCA mutations in breast cancer across Europe: barriers and opportunities

M. Thrift-Perry<sup>1</sup>, S. Ahmed<sup>2</sup>, S. Wait<sup>2</sup>, J. Tate<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>GB

10:00 - 10:00 1568PD - Public awareness of cancer in the Gaza-Strip: a cross-sectional study

M. Elshami<sup>1</sup>, M. Alkhatib<sup>1</sup>, A. Elshami<sup>1</sup>, K. Abu-Nemer<sup>1</sup>, A. Qandeel<sup>1</sup>, M. Hana<sup>1</sup>, N. Alshorbassi<sup>1</sup>, G. Matar<sup>1</sup>, O. Baraka<sup>1</sup>, M. Elblbessy<sup>1</sup>, L. Albarqouni<sup>2</sup>, B. Bottcher<sup>1</sup>; <sup>1</sup>PS, <sup>2</sup>AU

10:00 - 10:15 Invited Discussant 1566PD, 1567PD and 1568PD

10:15 - 10:25 Q&A led by Discussant

09:15 - 10:45	Type: EONS session Title: EONS-ONS Session: Innovation in cancer nursing and leadership Chair(s): L. Sharp, SE	Hall B4 - Room 24
09:15 - 09:25	Introduction and welcome <u>L. Sharp</u> <sup>1</sup> , <u>D. Kelly</u> <sup>2</sup> ; <sup>1</sup> SE, <sup>2</sup> GB	
09:25 - 09:35	Recognizing European Cancer Nursing, RECaN: Results from systematic review and meta-analyses (RECaN Phase 1) <u>D. Kelly</u> , GB	
09:35 - 09:45	Results from case studies from four contrasting counties in Europe (RECaN Phase 2) <u>L. Sharp</u> , SE	
09:45 - 09:55	Promoting cancer nursing across Europe (RECaN Phase 2 qualitative insights and looking ahead to phase 3) <u>D. Kelly</u> , GB	
09:55 - 10:25	Supporting cancer nursing leadership development: The USA experience <u>L. Fennimore</u> , US	
10:25 - 10:45	Discussion	

09:30 - 10:30	Type: Poster Discussion session Title: Poster Discussion session - Gynaecological cancers Chair(s): A. González-Martín, ES	ICM - Room 13
09:30 - 09:30	One LBA TBC	
09:30 - 09:30	One LBA TBC	
09:30 - 09:30	935PD - Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer  <u>A. Oaknin</u> <sup>1</sup> , S. Ellard <sup>2</sup> , C. Leath, III <sup>3</sup> , V. Moreno <sup>1</sup> , R. Kristeleit <sup>4</sup> , W. Guo <sup>3</sup> , S. Lu <sup>3</sup> , D. Jenkins <sup>3</sup> , K. McEachern <sup>3</sup> , K. Yu Jen <sup>3</sup> , S. Dunlap <sup>3</sup> , E. Im <sup>3</sup> , L. Gilbert <sup>5</sup> ; <sup>1</sup> ES, <sup>2</sup> British Columbia/CA, <sup>3</sup> US, <sup>4</sup> GB, <sup>5</sup> CA	
09:30 - 09:30	One LBA TBC	
09:30 - 09:42	Invited Discussant three LBAs TBC and 935PD	
09:42 - 09:52	Q&A led by Discussant	
09:52 - 09:52	One LBA TBC	
09:52 - 09:52	936PD - A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)  <u>J.-M. Lee</u> <sup>1</sup> , C. Annunziata <sup>2</sup> , N. Houston <sup>2</sup> , E. Kohn <sup>2</sup> , S. Lipkowitz <sup>2</sup> , L. Minasian <sup>2</sup> , E. Nichols <sup>2</sup> , J. Trepel <sup>2</sup> , K. Trewhitt <sup>2</sup> , F. Zia <sup>2</sup> , A. Zimmer <sup>1</sup> ; <sup>1</sup> US, <sup>2</sup> MD/US	
09:52 - 09:52	937PD - A phase 2 trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.  <u>J. Liu</u> <sup>1</sup> , C. Herold <sup>1</sup> , W. Luo <sup>1</sup> , R. Penson <sup>1</sup> , N. Horowitz <sup>1</sup> , P. Konstantinopoulos <sup>1</sup> , C. Castro <sup>1</sup> , J. Curtis <sup>1</sup> , U. Matulonis <sup>1</sup> , S. Cannistra <sup>2</sup> , D. Dizon <sup>3</sup> ; <sup>1</sup> MA/US, <sup>2</sup> US, <sup>3</sup> RI/US	
09:52 - 10:04	Invited Discussant One LBA TBC, 936PD and 937PD  <u>A. González Martín</u> , ES	
10:04 - 10:14	Q&A led by Discussant	

09:30 - 10:30 Type: Controversy Session Hall A1 - Room 15  
 Title: Will CAR T cell therapy replace allogenic transplantation in lymphoma?  
 Chair(s): M. Dreyling, DE

09:30 - 09:40 Introduction and 1st vote  
M. Dreyling, DE

09:40 - 10:00 Yes

10:00 - 10:20 No

10:20 - 10:30 2nd vote and conclusions  
M. Dreyling, DE

09:30 - 10:35 Type: Multidisciplinary interactive sessions Hall A1 - Room 16  
 Title: Malignant pheochromocytoma / paraganglioma  
 Chair(s): A. Berruti, IT

09:30 - 09:35 Case presentation  
A. Berruti, IT

09:35 - 09:45 The surgical approach  
M. Walz, DE

09:45 - 09:55 The nuclear medicine specialist perspective  
V. Ambrosini, IT

09:55 - 10:05 The endocrinologist and oncologist perspective  
E. Baudin, CEDEX/FR

10:05 - 10:35 Discussion

09:30 - 10:30	Type: Poster Discussion session Title: Poster Discussion session - Supportive and palliative care 1 Chair(s): D. Keefe, AU; F. Strasser, CH	Hall B3 - Room 21
09:30 - 09:30	1683PD - Factors that influence oncology nutrition efficacy in breast cancer patients under antiestrogenic treatment <u>D. Artene</u> , A. Blidaru; RO	
09:30 - 09:30	1684PD - Physical Activity (PA) and patterns of Quality of Life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC) <u>A. Di Meglio</u> <sup>1</sup> , M. El-Mouhebb <sup>2</sup> , S. Michiels <sup>2</sup> , D. Carene <sup>2</sup> , S. EVERHARD <sup>2</sup> , A.L. Martin <sup>2</sup> , P. Cottu <sup>3</sup> , F. Lerebours <sup>2</sup> , C. Coutant <sup>4</sup> , A. Lesur <sup>2</sup> , O. Tredan <sup>5</sup> , P. SOULIE <sup>2</sup> , L. Vanlemmens <sup>5</sup> , P. Arveux <sup>2</sup> , S. Delalogue <sup>2</sup> , P. Ganz <sup>6</sup> , F. André <sup>5</sup> , A. Partridge <sup>7</sup> , L. Jones <sup>8</sup> , I. Vaz-Luis <sup>2</sup> ; <sup>1</sup> IT, <sup>2</sup> FR, <sup>3</sup> CEDEX 5/FR, <sup>4</sup> Cedex/FR, <sup>5</sup> CEDEX/FR, <sup>6</sup> CA/US, <sup>7</sup> US, <sup>8</sup> NY/US	
09:30 - 09:30	1685PD - Effects of 6-month exercise training on quality of life in pancreatic cancer patients: results from a randomized controlled trial <u>K. Steindorf</u> <sup>1</sup> , D. Clauss <sup>1</sup> , C. Tjaden <sup>1</sup> , F. Herbolzheimer <sup>1</sup> , L. Schneider <sup>1</sup> , C. Ulrich <sup>2</sup> , T. Hackert <sup>1</sup> , J. Wiskemann <sup>1</sup> ; <sup>1</sup> DE, <sup>2</sup> US	
09:30 - 09:30	1513PD - A prospective study examining cachexia predictors in patients with incurable cancer. <u>O.M. Vagnildhaug</u> <sup>1</sup> , C. Brunelli <sup>2</sup> , M. Hjermstad <sup>1</sup> , F. Strasser <sup>3</sup> , V. Baracos <sup>4</sup> , A. Wilcock <sup>5</sup> , M. Nabal <sup>6</sup> , S. Kaasa <sup>1</sup> , B. Laird <sup>5</sup> , T. Solheim <sup>1</sup> ; <sup>1</sup> NO, <sup>2</sup> IT, <sup>3</sup> CH, <sup>4</sup> CA, <sup>5</sup> GB, <sup>6</sup> ES	
09:30 - 09:50	Invited Discussant 1683PD, 1684PD, 1685PD and 1513PD <u>D. Keefe</u> , SA/AU	
09:50 - 10:00	Q&A led by Discussant	
10:00 - 10:00	1514PD - Timing of palliative care referral before and after a cluster randomized controlled trial (RCT) of early palliative care <u>D. Hausner</u> <sup>1</sup> , C. Tricou <sup>2</sup> , D. Wadhwa <sup>3</sup> , A. Pope <sup>1</sup> , M. Giruparajah <sup>1</sup> , N. Swami <sup>1</sup> , M. Krzyzanowska <sup>1</sup> , K. Mah <sup>1</sup> , C. Zimmermann <sup>1</sup> ; <sup>1</sup> CA, <sup>2</sup> ON/CA, <sup>3</sup> BC/CA	
10:00 - 10:00	1515PD - Randomized clinical trial of an individualized intervention promotes cancer patients' prognostic awareness and reduces CPR received in the last month <u>C. Chen</u> , J.-S. Chen, F.-H. Wen, J.W.-C. Chang, W.-C. Chou, C.-H. Hsieh, M.-M. Hou, S.T. Tang; TW	
10:00 - 10:15	Invited Discussant 1514PD and 1515PD <u>F. Strasser</u> , CH	
10:15 - 10:25	Q&A led by Discussant	



09:30 - 10:30 Type: Challenge Your Expert (CYE) session Hall B3 -  
 Title: Leiomyosarcomas: How to choose and sequence treatments, targeted vs non-targeted Room 22  
 therapies, olaratumab yes or no, and other controversies  
 Chair(s): S. Stacchiotti, IT

09:30 - 09:40 Leiomyosarcomas: How to choose and sequence treatments, targeted vs non-targeted therapies,  
 olaratumab yes or no, and other controversies  
I. Ray-Coquard, CEDEX/FR

09:40 - 10:30 Discussion led by  
S. Stacchiotti, IT

11:00 - 12:30 Type: Special Symposium Hall A1 - Room 17  
 Title: New aspects of targeted therapy of NSCLC  
 Chair(s): T.S.K. Mok, HK

11:00 - 11:05 Introduction

11:05 - 11:25 Optimal sequencing in patients with EGFR mutations  
T.S.K. Mok, HK

11:25 - 11:45 Optimal sequencing in patients with ALK/ROS1 alterations  
F. Blackhall, GB

11:45 - 12:05 New aspects in MET inhibition  
S. Ekman, SE

12:05 - 12:25 Targets beyond EGF and ALK inhibition  
F. Cappuzzo, IT

12:25 - 12:30 Conclusions and perspectives  
T.S.K. Mok, HK

11:00 - 12:30 Type: Educational session Hall A1 - Room 15  
 Title: What is new in the management of recurrent ovarian cancer  
 Chair(s): D. Lorusso, IT; I. Ray-Coquard, FR

11:00 - 11:25 When should biology drive treatment decisions?  
I. McNeish, GB

11:25 - 11:50 The role of surgical management in 2018  
P. Harter, DE

11:50 - 12:15 Advances in systemic therapy changing practice  
D. Lorusso, IT

12:15 - 12:30 Discussion

11:00 - 12:30 Type: Proffered Paper session Hall A2 - Room 18  
 Title: Proffered paper session - Breast cancer, metastatic  
 Chair(s): N. El Saghir, LB; F. Penault-Llorca, FR

11:00 - 11:15 One LBA TBC

11:15 - 11:30 One LBA TBC

11:30 - 11:45 Invited Discussant two LBAs TBC  
F. Cardoso, PT

11:45 - 12:00 One LBA TBC

12:00 - 12:15 284O - Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)  
S. Pernas<sup>1</sup>, P. Villagrasa<sup>1</sup>, A. Vivancos<sup>1</sup>, M. Scaltriti<sup>2</sup>, J. Rodon<sup>1</sup>, O. Burgues<sup>1</sup>, P. Nuciforo<sup>1</sup>, J. Canes<sup>3</sup>, M. Dueñas<sup>1</sup>, M. Vidal<sup>1</sup>, A. Lluch<sup>4</sup>, A. Perelló<sup>1</sup>, A. Llombart<sup>1</sup>, J. Dorca<sup>1</sup>, Á. Montaña<sup>1</sup>, M. Oliveira<sup>1</sup>, G. Ribas<sup>1</sup>, I. Rapado<sup>1</sup>, A. Prat<sup>1</sup>, E. Ciruelos<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>NY/US, <sup>3</sup>BARCELONA/ES, <sup>4</sup>Valencia/ES

12:15 - 12:30 Invited Discussant one LBA TBC and 284O

11:00 - 12:30 Type: Special Symposium ICM - Room 1  
 Title: The molecular classification of upper GI cancers: Are we ready to translate them into clinical practice?  
 Chair(s): Y.-K. Kang, KR; I. Chau, GB

11:00 - 11:05 Introduction  
I. Chau, Surrey/GB

11:05 - 11:25 Oesophageal cancer  
A. Cervantes, Valencia/ES

11:25 - 11:45 Gastric cancer  
F. Lordick, DE

11:45 - 12:05 Primary liver tumours  
M. Ducreux, CEDEX/FR

12:05 - 12:25 Pancreatic adenocarcinoma  
I. Chau, Surrey/GB

12:25 - 12:30 Conclusions and clinical perspectives  
Y.-K. Kang, Songpa-gu/KR

11:00 - 12:30 Type: Special Symposium ICM - Room 14b  
 Title: Neo-adjuvant and adjuvant strategies in melanoma  
 Chair(s): P. Rutkowski, PL; P. Lorigan, GB

11:00 - 11:05 Introduction  
P. Lorigan, GB

11:05 - 11:25 Pre-clinical data to prepare early treatment of melanoma  
M. Soengas, ES

11:25 - 11:45 Neo-adjuvant therapy  
C. Blank, NL

11:45 - 12:05 Should we treat our patients with melanoma in the neoadjuvant, adjuvant or metastatic setting?  
C. Lebbe, CEDEX 10/FR

12:05 - 12:25 Adjuvant therapy (2018-2020)  
A. Eggermont, FR

12:25 - 12:30 Conclusions and clinical perspectives  
P. Rutkowski, PL

11:00 - 12:30	Type: Proffered Paper session Title: Proffered paper session - Basic science Chair(s): A. Berns, NL; T. Sorlie, NO	Hall B3 - Room 21
11:00 - 11:12	1891O - Mutational Landscape of Metastatic Cancers Discovered from Prospective Clinical Sequencing at Community Practice Cancer Program. <u>R. Alvarez</u> , A. MORAN, E. Meiri, A. Loaiza-Bonilla, A. Parikh, P. Crilley, J. Elvin, P. Reddy, V. Miller, S. Zook, S. Ali, M. Markman; US	
11:12 - 11:24	1892O - Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase 2 study of tazemetostat (NCT02601950) <u>S. Daigle</u> <sup>1</sup> , S. Stacchiotti <sup>2</sup> , P. Schöffski <sup>3</sup> , V. Villalobos <sup>1</sup> , G. Cote <sup>1</sup> , R. Chugh <sup>1</sup> , T.W.-W. Chen <sup>4</sup> , T. Jahan <sup>1</sup> , E. Loggers <sup>1</sup> , A. Italiano <sup>5</sup> , A. Gupta <sup>6</sup> , M. Agulnik <sup>1</sup> , S. Attia <sup>1</sup> , R. Jones <sup>7</sup> , B. van Tine <sup>8</sup> , G.D. Demetri <sup>9</sup> , A. Clawson <sup>1</sup> , M. Roche <sup>1</sup> , S. Blakemore <sup>1</sup> , M. Gounder <sup>10</sup> ; <sup>1</sup> US, <sup>2</sup> IT, <sup>3</sup> BE, <sup>4</sup> TW, <sup>5</sup> CEDEX/FR, <sup>6</sup> CA, <sup>7</sup> WA/GB, <sup>8</sup> Missouri/US, <sup>9</sup> MA/US, <sup>10</sup> NY/US	
11:24 - 11:36	One LBA TBC	
11:36 - 11:51	Invited Discussant 1891O, 1892O and one LBA TBC <u>S. Turajlic</u> , GB	
11:51 - 12:03	1O - KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies <u>A. Georgiou</u> <sup>1</sup> , A. Stewart <sup>1</sup> , P. Thavasu <sup>1</sup> , E. Coker <sup>1</sup> , S. Poelsterl <sup>1</sup> , B. Al-Lazikani <sup>1</sup> , D. Cunningham <sup>1</sup> , S. Whittaker <sup>1</sup> , U. Banerji <sup>2</sup> ; <sup>1</sup> GB, <sup>2</sup> Surrey/GB	
12:03 - 12:15	2O - Receptor Tyrosine Kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines. <u>P.P. Vitiello</u> <sup>1</sup> , C. Cardone <sup>1</sup> , D. Ciardiello <sup>1</sup> , G. Barra <sup>1</sup> , N. Matrone <sup>1</sup> , V. Belli <sup>1</sup> , G. Martini <sup>2</sup> , L. Poliero <sup>1</sup> , C. Borrelli <sup>1</sup> , M. Terminiello <sup>1</sup> , T. Troiani <sup>1</sup> , F. Morgillo <sup>1</sup> , F. Ciardiello <sup>1</sup> , E. Martinelli <sup>1</sup> ; <sup>1</sup> IT, <sup>2</sup> ES	
12:15 - 12:30	Invited Discussant 1O and 2O <u>A. Bardelli</u> , (TO)/IT	

11:00 - 12:00 Type: Multidisciplinary interactive sessions Hall B3 - Room 23  
 Title: Brain metastases in GU malignancies  
 Chair(s): A. Patrikidou, GB

11:00 - 11:10 Germ cell case presentation and discussion  
A. Patrikidou, Surrey/GB

11:10 - 11:20 Kidney case presentation and discussion  
V. Khoo, GB

11:20 - 11:30 Bladder case presentation and discussion  
J.-C. Tonn, DE

11:30 - 12:00 Discussion

11:00 - 12:00 Type: Multidisciplinary interactive sessions Hall B3 - Room 20  
 Title: Expanding the neurooncologist's toolbox: Case-based discussions of challenges & opportunities  
 Chair(s): E. Cohen-Jonathan Moyal, FR

11:00 - 11:10 Methylation-based tumour profiling: A novel tool for improved diagnosis and treatment  
S. Pfister, DE

11:10 - 11:20 A role for tumor-treating fields?  
P. Roth, CH

11:20 - 11:30 SRS and novel systemic therapies: A fruitful partnership?  
E. Cohen-Jonathan Moyal, CEDEX 3/FR

11:30 - 12:00 Discussion

11:00 - 12:30 Type: Special Symposium Hall B4 - Room 19  
 Title: How to balance efficacy and toxicity in Hodgkin's Lymphoma  
 Chair(s): J. Radford, GB

11:00 - 11:05 Introduction  
J. Radford, GB

11:05 - 11:25 Late toxicities  
F. van Leeuwen, NL

11:25 - 11:45 Limited disease  
J. Radford, GB

11:45 - 12:05 Advanced disease  
D. Eichenauer, DE

12:05 - 12:25 Treatment of relapsed disease with novel agents  
S. Viviani, IT

12:25 - 12:30 Conclusions and perspectives

11:00 - 12:00 Type: EONS session Hall B4 - Room 24  
 Title: Cancer prevention and early detection from a nursing perspective  
 Chair(s): H. Titzer, AT

11:00 - 11:15 Political and commercial barriers to cancer risk reduction  
W. Yared, BE

11:15 - 11:30 HPV vaccination for girls and boys

11:30 - 11:45 Prostate cancer risk in men of different ethnicities  
S. Fry, GB

11:45 - 12:00 Cancer risk reduction in multicultural communities  
A. Leppänen, SE

11:00 - 11:45 Type: Young Oncologist session ICM - Room 14c  
 Title: YO Brunch 1: Fertility and pregnancy in cancer

11:00 - 11:45 Fertility and pregnancy in cancer  
F. Peccatori<sup>1</sup>, M. Lambertini<sup>2</sup>, C. Cardone<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>BE

11:15 - 12:15	Type: Poster Discussion session Title: Poster Discussion session - Gastrointestinal, colorectal 1 Chair(s): F. Ciardiello, IT; S. Stintzing, DE	ICM - Room 13
11:15 - 11:15	453PD - 1st-line mFOLFOXIRI + Panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109). <u>M. Geissler</u> , T. Klingler, J. Riera Knorrenschild, A. Tannapfel, J. Greeve, T. Seufferlein, S. Kanzler, S. Held, V. Heinemann, A. Reinacher-Schick, U. Martens; DE	
11:15 - 11:15	One LBA TBC	
11:15 - 11:15	454PD - Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer. <u>H. Taniguchi</u> <sup>1</sup> , T. Yamanaka <sup>2</sup> , D. Sakai <sup>3</sup> , K. Yamazaki <sup>4</sup> , K. Muro <sup>1</sup> , M. Peeters <sup>5</sup> , T. Price <sup>6</sup> ; <sup>1</sup> Aichi/JP, <sup>2</sup> JP, <sup>3</sup> Osaka/JP, <sup>4</sup> Shizuoka/JP, <sup>5</sup> BE, <sup>6</sup> SA/AU	
11:15 - 11:30	Invited Discussant one LBA TBC, 453PD and 454PD <u>F. Ciardiello</u> , IT	
11:30 - 11:45	Q&A led by Discussant	
11:45 - 11:45	455PD - NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC) <u>S. Winther</u> <sup>1</sup> , H. Skuladottir <sup>1</sup> , E. Hofslid <sup>2</sup> , C.-H. Shah <sup>3</sup> , M. Yilmaz <sup>1</sup> , P. Österlund <sup>4</sup> , Å. Berglund <sup>3</sup> , B. Glimelius <sup>3</sup> , C. Qvortrup <sup>1</sup> , H. Sorbye <sup>2</sup> , P. Pfeiffer <sup>1</sup> ; <sup>1</sup> DK, <sup>2</sup> NO, <sup>3</sup> SE, <sup>4</sup> FI	
11:45 - 11:45	One LBA TBC	
11:45 - 11:45	One LBA TBC	
11:45 - 12:00	Invited Discussant 455PD and two LBAs TBC <u>S. Stintzing</u> , DE	
12:00 - 12:15	Q&A led by Discussant	
12:00 - 13:00	Type: Poster Display session Title: EONS Poster display	Hall B4 - Room 24

- 12:00 - 12:00 CN5 - Patients - power sources for cancer nurses  
C. Beisel, DE
- 12:00 - 12:00 CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care  
J. Koldenhof, S. Vervoort, C. Nierop, K. Suijkerbuijk; NL
- 12:00 - 12:00 CN7 - Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy  
Q. Alnasser<sup>1</sup>, K. Cameron<sup>1</sup>, J. Prouse<sup>2</sup>; <sup>1</sup>SA, <sup>2</sup>AU
- 12:00 - 12:00 CN8 - AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.  
S. Smith, DK
- 12:00 - 12:00 CN9 - Nurse led follow-up for CML patients on oral cancer treatment  
S. De Wilde, J. De Munter, M. Quaghebeur, D. Mazure, A. De Pauw, B. Casteels; BE
- 12:00 - 12:00 CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses – patient-reported evaluation.  
B. Westman, H. Ullgren, L. Sharp; SE
- 12:00 - 12:00 CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.  
E. Mahía, G. Simó, E. Heras, M. Pascual, F. Cobo, J. Pujadas, S. Albiol; AD
- 12:00 - 12:00 CN12 - Systemic Anticancer Therapy Administration Safety  
S. Toland, A. Simons; GB
- 12:00 - 12:00 CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: the role of the nurse practitioner for early recognition and management  
C. Roth, M. Labots, A. Eertwegh; NL
- 12:00 - 12:00 CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method  
H. Ullgren, SE
- 12:00 - 12:00 CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study  
S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR
- 12:00 - 12:00 CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease  
J. De Munter, S. De Wilde, M. Quaghebeur; BE
- 12:00 - 12:00 CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital  
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES
- 12:00 - 12:00 CN18 - Are there differences between nurses' and patients' perceptions of cancer patients' quality of life in Greece?



M. LAVDANITI, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. ZIOGA, K. MARMARA, E. Fradelos; GR

- 12:00 - 12:00 CN19 - How an empowerment program can touch cancer survivor's life by improving posttraumatic growth?  
Y.S. UZAR OZCETIN, TR
- 12:00 - 12:00 CN20 - Organising a general oncology nursing outpatient clinic  
C. Lundgren, A. Lagerquist, M. Högman, U. Östlund; SE
- 12:00 - 12:00 CN21 - Job content of advanced practice nurses in Flanders  
E. Decoene, A. Van Hecke; BE
- 12:00 - 12:00 CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professionals self-efficacy when supporting parents newly diagnosed with cancer who have dependent children  
C. Semple, E. McCaughan; GB
- 12:00 - 12:00 CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals  
J. Bird, M. Nolan, S. Danson; GB
- 12:00 - 12:00 CN24 - Assessing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona  
C. PUIGMARTI, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher; ES
- 12:00 - 12:00 CN28 - Transmural collaborative care in oncology: Experiences of general practitioners  
M. daem, E. van Roekeghem, M. Grypdonck, P. Pype; BE
- 12:00 - 12:00 CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review  
S. Colomer-Lahiguera<sup>1</sup>, D. Bryant-Lukosius<sup>2</sup>, S. Rietkoetter<sup>2</sup>, L. Martelli<sup>2</sup>, K. Ribi<sup>1</sup>, A. Orcurto<sup>1</sup>, R. Juergens<sup>2</sup>, M. Eicher<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>ON/CA
- 12:00 - 12:00 CN30 - Laryngectomized patients caregivers' life experience: a phenomenological study  
V. Bressan, E. Dri, S. Stevanin, L. Cadorin, A. Rizzuto, G. Bulfone, L. Ghirotto; IT
- 12:00 - 12:00 CN31 - Comparing nurses' and patients' research priorities in cancer care: A mixed methods systematic review  
L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT
- 12:00 - 12:00 CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy  
A. Psychogyiou, S. KATSARAGAKIS, C. Lemonidou, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network  
K. Dieperink, M. Kjerholt, P. Riis Olsen; DK

- 12:00 - 12:00 CN34 - Individual network meetings in cancer care - From young people with cancer to adults with brain tumours  
P. Riis Olsen, DK
- 12:00 - 12:00 CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?  
G. Bagcivan, N. Ozen, D. Bayrak, F.I. Cinar; TR
- 12:00 - 12:00 CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment  
C. Johnston, M. Tanay; GB
- 12:00 - 12:00 CN37 - Evaluation of support and information needs for patients with cancer in a Phase I trials unit.  
S. Stapleton, L. O'Leary, M. van Zyl, J. Hanwell, T. Wiseman; GB
- 12:00 - 12:00 CN38 - Dignity of Greek patients with advanced cancer: a cross-sectional study  
S. KATSARAGAKIS, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 CN39 - Development and implementation of national guidelines on lifestyle issues and cancer -Report from an on-going quality improvement project  
K. Vuollet Karlsson, C. Landegren, B. Westman; SE
- 12:00 - 12:00 CN40 - Developing a Patient Reported Experience Measure (PREM) in Secondary Breast Cancer (SBC)  
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke; GB
- 12:00 - 12:00 CN41 - Cancer situation in sub-Saharan Countries: development of educational, diagnosis and treatment plans.  
J. de la Torre-Montero, N. Gil-Gómez, J. RIBES BERNAL, N. Domenech Climent, A. OJER PEREA, P. BEORLEGUI MURILLO, J.M. GAVALA ARJONA, R. CUMPLIDO CORBACHO, I. MAGALLON PEDRERA, M.A. PEÑUELAS SAIZ; ES
- 12:00 - 12:00 CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital.  
J. Duncan<sup>1</sup>, V. Michalarea<sup>2</sup>, T. Coyne<sup>1</sup>, J. Thomas<sup>1</sup>, D. Cunningham<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Surrey/GB
- 12:00 - 12:00 CN43 - Patients' learning and participation in their breast cancer care  
L. Boman, K. Sandelin, Y. Wengström, C. Silén; SE
- 12:00 - 12:00 CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration.  
S.Y. Oh, J.M. Lee, J.W. Kim, S.H. Kim, J.M. Park, G.Y. Yeo, J.E. Hyun, J.-H. Park; KR
- 12:00 - 12:00 CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy  
A. Frade, S. Miguel; PT
- 12:00 - 12:00 CN46 - Safe navigation of CARs in a changing landscape  
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite; GB

- 12:00 - 12:00 CN47 - Patients' interpretations and experiences of participation in cancer care  
J. Jackson, J. Rundgren; SE
- 12:00 - 12:00 CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab  
M. Qiu, Y. Chen, B.-L. Zhang, X.-Y. Wang; CN
- 12:00 - 12:00 CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care  
J. De Munter, P. Crombez; BE
- 12:00 - 12:00 CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre  
M. Foulkes, GB
- 12:00 - 12:00 CN51 - The development and evaluation of an online oncology portal  
J. De Munter, E. Decoene, A. Van Hecke; BE
- 12:00 - 12:00 CN52 - Pilot Study – Nurses' Role in Management of Cutaneous Toxicity in Patients with Targeted Therapies Anti EGFR-Is' Treatment.  
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso; IT
- 12:00 - 12:00 CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?  
D. Oliva, F. Lewin, N. Lewin, M. Nilsson, M. Strandéus, B.-Å. Andersson, L. Sharp; SE
- 12:00 - 12:00 CN58 - Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain and Fatigue in Patients Receiving Oxaliplatin  
N. Izgu, L. Ozdemir, F. Bugdayci Basal; TR
- 12:00 - 12:00 CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital  
C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: a qualitative study  
D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT
- 12:00 - 12:00 CN61 - "It may not affect you" -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.  
M. Tanay, J. Armes; GB
- 12:00 - 12:00 CN62 - App about chemotherapy - helping the patient with cancer  
B. Espersen, DK
- 12:00 - 12:00 CN63 - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing  
P. Fernández- Ortega, Y. Escobar, E. Trigos, R. Blat, M. Cantero, A. Alvarez; ES

- 12:00 - 12:00 CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the Memorial Symptom Assessment Scale  
D. PALITZIKA, E. Fradelos, V. ALIKARI, P. CHARITOUPOULOS, E. ZIOGA, S. ZYGA, M. LAVDANITI; GR
- 12:00 - 12:00 CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®"  
M. Belhadj<sup>1</sup>, E. Kempf<sup>1</sup>, A. Lebel<sup>1</sup>, A. Guillemin<sup>1</sup>, H. Bousson<sup>1</sup>, C. Joly<sup>1</sup>, I. Baumgaertner<sup>2</sup>, E. Assaf<sup>2</sup>, C. Saldana<sup>2</sup>, B. Rousseau<sup>2</sup>, C. Tournigand<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:00 - 12:00 CN66 - Medical makeup in cancer patients and its impact in their quality of life  
R. LECHOU, GR
- 12:30 - 13:30 Type: Poster Display session Hall A3 -  
Title: Poster display session: Biomarkers, Gynaecological cancers, Haematological Poster Area  
malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally Networking  
advanced & metastatic, SCLC, Thoracic malignancies, Translational research Hub
- 12:30 - 12:30 Biomarkers
- 12:30 - 12:30 66P - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.  
T. Looney<sup>1</sup>, G. Lowman<sup>2</sup>, L. Miller<sup>2</sup>, E. Linch<sup>3</sup>; <sup>1</sup>SG, <sup>2</sup>US, <sup>3</sup>CA/US
- 12:30 - 12:30 67P - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors  
A. Awada<sup>1</sup>, F. Morschhauser<sup>2</sup>, J.-P. Machiels<sup>1</sup>, G. Salles<sup>2</sup>, S. Rottey<sup>1</sup>, S. Rule<sup>3</sup>, D. Cunningham<sup>4</sup>, F. Peyrade<sup>5</sup>, C. Fruchart<sup>2</sup>, H.-T. Arkenau<sup>4</sup>, I. Genvresse<sup>6</sup>, K. Koechert<sup>6</sup>, G. Cisternas<sup>6</sup>, C. Granvil<sup>7</sup>, C. Pena<sup>7</sup>, L. Liu<sup>7</sup>; <sup>1</sup>BE, <sup>2</sup>FR, <sup>3</sup>Devon/GB, <sup>4</sup>GB, <sup>5</sup>CEDEX 2/FR, <sup>6</sup>DE, <sup>7</sup>US
- 12:30 - 12:30 68P - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association  
M. Montesin<sup>1</sup>, C. Chung<sup>2</sup>, E. Sokol<sup>3</sup>, S. Khan<sup>4</sup>, H. Kang<sup>5</sup>, L. Albacker<sup>1</sup>, J. Johnson<sup>1</sup>, G. Frampton<sup>3</sup>, V. Miller<sup>3</sup>, J. Ross<sup>3</sup>, S. Ali<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>FL/US, <sup>3</sup>MA/US, <sup>4</sup>TX/US, <sup>5</sup>MD/US
- 12:30 - 12:30 69P - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)  
H. Chang, S. Srinivasan, A. Sasson, R. Golhar, D. Greenawalt, S. Kirov, J. Szustakowski; NJ/US
- 12:30 - 12:30 70P - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC  
E. Smit<sup>1</sup>, J. Aerts<sup>2</sup>, M. Muller<sup>1</sup>, A.-L. Niemeijer<sup>1</sup>, H. Roder<sup>3</sup>, C. Oliveira<sup>3</sup>, J. Roder<sup>3</sup>; <sup>1</sup>NL, <sup>2</sup>Noord Brabant/NL, <sup>3</sup>US
- 12:30 - 12:30 71P - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).

R. Ferguson<sup>1</sup>, A. Archambault<sup>2</sup>, D. Simpson<sup>2</sup>, E. Kazlow<sup>2</sup>, R. Lax<sup>2</sup>, U. Moran<sup>2</sup>, M. Wilson<sup>2</sup>, R. Shapiro<sup>2</sup>, A. Pavlick<sup>2</sup>, I. Osman<sup>1</sup>, D. Polsky<sup>1</sup>, T. Kirchoff<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NY/US

- 12:30 - 12:30 72P - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma  
M. Yang, J. Li, N. Zhang, H. Xing, J. Liu; CN
- 12:30 - 12:30 73P - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness  
C.T. Choy, C.H. Wong, S. Chan; HK
- 12:30 - 12:30 74P - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials  
A. Madi<sup>1</sup>, D. Fisher<sup>2</sup>, T. Maughan<sup>2</sup>, J. Colley<sup>2</sup>, A. Meade<sup>2</sup>, J. Maynard<sup>2</sup>, V. Humphreys<sup>2</sup>, H. Wasan<sup>2</sup>, R. Adams<sup>2</sup>, S. Idziaszczyk<sup>2</sup>, R. Harris<sup>2</sup>, R. Kaplan<sup>2</sup>, J. Cheadle<sup>2</sup>; <sup>1</sup>Merseyside/GB, <sup>2</sup>GB
- 12:30 - 12:30 75P - The landscape of NTRK fusions in Chinese solid tumor patients  
Q. Ling, B. Li, X. Wu, H. Wang, Y. Shen, M. Xiao, Z. Yang, R. Ma, D. Chen, H. Chen, X. Dong, W. Wang, M. Yao; CN
- 12:30 - 12:30 76P - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma  
C.-H. Lee<sup>1</sup>, R. Motzer<sup>2</sup>, H. Glen<sup>3</sup>, M.D. Michaelson<sup>4</sup>, J. Larkin<sup>3</sup>, Y. Minoshima<sup>5</sup>, M. Kanekiyo<sup>5</sup>, R. Dairiki<sup>5</sup>, P. Sachdev<sup>6</sup>, C. Dutcus<sup>6</sup>, Y. Funahashi<sup>1</sup>, M. Voss<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NY/US, <sup>3</sup>GB, <sup>4</sup>MA/US, <sup>5</sup>JP, <sup>6</sup>New Jersey/US
- 12:30 - 12:30 77P - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks  
A. Meier<sup>1</sup>, K. Nekolla<sup>1</sup>, S. Earle<sup>2</sup>, L. Hewitt<sup>3</sup>, T. Aoyama<sup>4</sup>, T. Yoshikawa<sup>4</sup>, G. Schmidt<sup>1</sup>, R. Huss<sup>1</sup>, H. Grabsch<sup>3</sup>; <sup>1</sup>DE, <sup>2</sup>GB, <sup>3</sup>NL, <sup>4</sup>JP
- 12:30 - 12:30 78P - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System  
A. Parikh<sup>1</sup>, S. Ali<sup>1</sup>, A. MORAN<sup>1</sup>, P. Crilley<sup>1</sup>, A. Schrock<sup>1</sup>, A. Tan<sup>2</sup>, P. Reddy<sup>1</sup>, V. Miller<sup>3</sup>, J. Ross<sup>3</sup>, S. Zook<sup>1</sup>, R. Alvarez<sup>1</sup>, M. Markman<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>AZ/US, <sup>3</sup>MA/US
- 12:30 - 12:30 79P - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies  
Y. Li<sup>1</sup>, J. Sun<sup>1</sup>, J. Skoletsy<sup>2</sup>, C. Milbury<sup>1</sup>, C. Burns<sup>2</sup>, W.-K. Yip<sup>1</sup>, N. Dewal<sup>2</sup>, J. He<sup>1</sup>, J. Tuesdell<sup>2</sup>, E. Peters<sup>1</sup>, E. Schleifman<sup>3</sup>, J. Noe<sup>4</sup>, S. Jenkins<sup>5</sup>, J. Elvin<sup>2</sup>, G. Otto<sup>2</sup>, D. Lipson<sup>1</sup>, J. Ross<sup>1</sup>, V. Miller<sup>2</sup>, M. Doherty<sup>2</sup>, C. Vietz<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MA/US, <sup>3</sup>CA/US, <sup>4</sup>CH, <sup>5</sup>GB
- 12:30 - 12:30 80P - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.  
B. Torrejón, M. Pedregal Trujillo, A. Santos, J. Rubio, M. Luque, M. Sanz, C. Carames, S. Zazo, J. Madoz-Gurpide, F. Rojo, J. Garcia Foncillas, C. Ion; ES

- 12:30 - 12:30 81P - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs  
N. Zhang, M. Yang, H. Xing, J. Liu; CN
- 12:30 - 12:30 82P - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma  
M. Khattak<sup>1</sup>, E. Gray<sup>2</sup>, A. Reid<sup>2</sup>, M. Periera<sup>2</sup>, A. McEvoy<sup>2</sup>, C. Aya-Bonilla<sup>2</sup>, T. Meniawy<sup>1</sup>, A. Didan<sup>1</sup>, M. Millward<sup>1</sup>, M. Ziman<sup>2</sup>; <sup>1</sup>WA/AU, <sup>2</sup>AU
- 12:30 - 12:30 83P - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer  
Y.-Z. Liu<sup>1</sup>, D. Hodgson<sup>1</sup>, G. Locker<sup>2</sup>, Z. Lai<sup>1</sup>, D. Balcerzak<sup>1</sup>, A. Sharpe<sup>1</sup>, J.C. Barrett<sup>2</sup>, M. Orr<sup>1</sup>, T. Gutjahr<sup>1</sup>, B. Dougherty<sup>2</sup>, M. Roudier<sup>1</sup>, X. Shi<sup>3</sup>, R. Miller<sup>4</sup>, W.H. Kim<sup>5</sup>, X. Zeng<sup>6</sup>, A. Ochiai<sup>7</sup>, S.-A. Im<sup>5</sup>, R.-H. Xu<sup>6</sup>, N. Boku<sup>8</sup>, Y.-J. Bang<sup>5</sup>; <sup>1</sup>GB, <sup>2</sup>US, <sup>3</sup>MD/US, <sup>4</sup>AZ/US, <sup>5</sup>KR, <sup>6</sup>CN, <sup>7</sup>JP, <sup>8</sup>Kanagawa/JP
- 12:30 - 12:30 84P - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study  
T. Yang, H. Xing, G. Wang, S. Cai, F. Shen; CN
- 12:30 - 12:30 85P - Dissecting Gastric Cancer biology and how and when to use immunotherapy  
M. Das Thakur, K. Okrah, D. Shames, P. Hegde, C. Bais; US
- 12:30 - 12:30 86P - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence  
K. Birkenkamp-Demtröder<sup>1</sup>, E. Christensen<sup>1</sup>, H. Sethi<sup>2</sup>, S. Sharma<sup>2</sup>, H.-T. Wu<sup>2</sup>, A. Taber<sup>1</sup>, M. Agerbæk<sup>1</sup>, R. Swenerton<sup>2</sup>, B. Zimmermann<sup>3</sup>, J. Lin<sup>3</sup>, J. Bjerggaard Jensen<sup>1</sup>, L. Dyrskjøt<sup>1</sup>; <sup>1</sup>DK, <sup>2</sup>CA/US, <sup>3</sup>US
- 12:30 - 12:30 87P - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas  
E. Imyanitov, T. Sokolova, G. Raskin, A. Ivantsov, A. Iyevleva, A. Sokolenko; RU
- 12:30 - 12:30 88P - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group  
M. Del Re<sup>1</sup>, S. Crucitta<sup>1</sup>, A. Sbrana<sup>1</sup>, E. Rofi<sup>1</sup>, F. Paolieri<sup>1</sup>, L. Galli<sup>1</sup>, A. Falcone<sup>1</sup>, R. van Schaik<sup>2</sup>, G. Jenster<sup>2</sup>, R. Morganti<sup>1</sup>, S. Pignata<sup>1</sup>, R. Danesi<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>NL
- 12:30 - 12:30 89P - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases  
Y. Zheng, Y. Ding, C. Xiao, W. Zhong, X. Teng, Q. Gao, Q. Wang, Y. Sun, C. Chen, L. Chen, J. Zhu, Q. Xu, N. Xu; CN
- 12:30 - 12:30 90P - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types  
J. Bacher<sup>1</sup>, R. Halberg<sup>1</sup>, P. Ward<sup>1</sup>, E. Udho<sup>1</sup>, K. Murphy<sup>2</sup>, M. Uhr<sup>1</sup>, L. Dubeau<sup>1</sup>, J. Pettersson<sup>1</sup>, D. Storts<sup>1</sup>, S. Gallinger<sup>3</sup>, D. Buchanan<sup>4</sup>, M. Jenkins<sup>4</sup>, N. Lindor<sup>1</sup>, J. Eshleman<sup>5</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>CA, <sup>4</sup>AU, <sup>5</sup>MD/US
- 12:30 - 12:30 91P - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients

Z. Wang, H. Qin, M. Wang, J. Gong, X. Wang, J. Li, J. Gao, Z. Li, D. Wang, S. Cai, Y. Bai, L. Xiong, F. Li, L. Shen; CN

- 12:30 - 12:30 92P - Vall d'Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).  
C. Hierro<sup>1</sup>, I. Matos<sup>1</sup>, J. Martin-Liberal<sup>1</sup>, M. Ochoa De Olza Amat<sup>1</sup>, E. Felip<sup>1</sup>, M. Costa Rivas<sup>1</sup>, M. Vieito Villar<sup>2</sup>, I. Brana<sup>1</sup>, A. Azaro<sup>1</sup>, M.C. Perez-Gago<sup>1</sup>, A. Gros<sup>1</sup>, J. Carles<sup>1</sup>, A. Oaknin<sup>1</sup>, T. Macarulla<sup>1</sup>, C. Saura<sup>1</sup>, N. pardo<sup>1</sup>, E. Muñoz-Couselo<sup>1</sup>, J. Tabernero<sup>1</sup>, R. Dienstmann<sup>1</sup>, E. Garralda<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>La Coruña/ES
- 12:30 - 12:30 93P - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients  
N. Brieu<sup>1</sup>, C. Gavriel<sup>2</sup>, D. Harrison<sup>2</sup>, G. Schmidt<sup>1</sup>, P. Caie<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>GB
- 12:30 - 12:30 94P - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma  
A. Bernard-Tessier<sup>1</sup>, E. Jeannot<sup>1</sup>, D. Guenat<sup>1</sup>, M. Michel<sup>1</sup>, C. Proudhon<sup>1</sup>, A. Vincent-Salomon<sup>1</sup>, I. Bièche<sup>1</sup>, J.-Y. Pierga<sup>2</sup>, B. Buecher<sup>2</sup>, E. Francois<sup>3</sup>, S. Kim<sup>4</sup>, T. André<sup>5</sup>, M. Jary<sup>4</sup>, V. Vendrely<sup>1</sup>, E. Samalin<sup>1</sup>, F. El Hajbi<sup>4</sup>, N. Baba-Hamed<sup>1</sup>, A. Meurisse<sup>1</sup>, F.-C. Bidard<sup>1</sup>, C. Borg<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>CEDEX 2/FR, <sup>4</sup>CEDEX/FR, <sup>5</sup>CEDEX 12/FR
- 12:30 - 12:30 95P - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis  
M. Iafolla<sup>1</sup>, C. Yang<sup>2</sup>, V. Chandran<sup>1</sup>, M. Pintilie<sup>1</sup>, A. Hansen<sup>3</sup>, P. Bedard<sup>3</sup>, S. Lheureux<sup>3</sup>, A. Spreafico<sup>2</sup>, A. Razak<sup>2</sup>, P. Ohashi<sup>1</sup>, S. Hakgor<sup>2</sup>, A. Giesler<sup>2</sup>, T. Pugh<sup>1</sup>, L. Siu<sup>3</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA, <sup>3</sup>Ontario/CA
- 12:30 - 12:30 96P - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)  
C. Cardone<sup>1</sup>, B. Blauensteiner<sup>2</sup>, V. Moreno-Viedma<sup>2</sup>, M. Paul<sup>2</sup>, G. Martini<sup>3</sup>, P.P. Vitiello<sup>1</sup>, D. Ciardiello<sup>1</sup>, C. Borrelli<sup>1</sup>, L. Poliero<sup>1</sup>, P. Vitale<sup>1</sup>, N. Zanaletti<sup>1</sup>, V. Famiglietti<sup>1</sup>, A.M. Rachiglio<sup>1</sup>, D. Rizzi<sup>1</sup>, E. Maiello<sup>1</sup>, T. Latiano<sup>1</sup>, N. Normanno<sup>1</sup>, M. Sibilia<sup>2</sup>, F. Ciardiello<sup>1</sup>, E. Martinelli<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>AT, <sup>3</sup>ES
- 12:30 - 12:30 97P - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)  
T. Carr<sup>1</sup>, C. Adelman<sup>1</sup>, A. Barnicle<sup>1</sup>, I. Kozarewa<sup>1</sup>, S. Luke<sup>1</sup>, Z. Lai<sup>1</sup>, S. Menon<sup>1</sup>, S. Hollis<sup>1</sup>, B. Dougherty<sup>2</sup>, E. Harrington<sup>1</sup>, J.C. Barrett<sup>2</sup>, C. Goessl<sup>2</sup>, F. Saad<sup>3</sup>, N. Sala<sup>4</sup>, N. Clarke<sup>1</sup>, D. Hodgson<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>US, <sup>3</sup>CA, <sup>4</sup>ES
- 12:30 - 12:30 98P - Identification of a highly suppressive Treg subset associated to immunotherapy response  
E. Giunta, S. Romano, P. D'Arrigo, A. Rea, M. Tufano, G. Matarese, C. Procaccini, N. Novizio, V. Vigorito, D. Faicchia, G. Argenziano, V. De Falco, F. Ciardiello, M.F. Romano, T. Troiani; IT
- 12:30 - 12:30 99P - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)

J. Evelhoch<sup>1</sup>, R. Mogg<sup>2</sup>, R. Cristescu<sup>2</sup>, D. Aurora-Garg<sup>2</sup>, L. Chow<sup>3</sup>, S. Loi<sup>4</sup>, D. Catenacci<sup>5</sup>, U. Matulonis<sup>6</sup>, P. Ott<sup>6</sup>, E. Antonarakis<sup>7</sup>, C. Poehlein<sup>8</sup>, A. Joe<sup>9</sup>, S. Keefe<sup>9</sup>, P. Kang<sup>2</sup>, V. Karantza<sup>2</sup>, J. Cheng<sup>10</sup>, E. Rubin<sup>11</sup>; <sup>1</sup>AR, <sup>2</sup>NJ/US, <sup>3</sup>WA/US, <sup>4</sup>VIC/AU, <sup>5</sup>IL/US, <sup>6</sup>MA/US, <sup>7</sup>MD/US, <sup>8</sup>New Jersey/US, <sup>9</sup>US, <sup>10</sup>PA/US, <sup>11</sup>Pennsylvania/US

12:30 - 12:30 100P - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC

J. Garcia<sup>1</sup>, A. Delherme<sup>1</sup>, F. Geiguer<sup>1</sup>, P. Merle<sup>1</sup>, C. Tissot<sup>1</sup>, F. Jones<sup>2</sup>, D. Edelstein<sup>3</sup>, P.-J. Souquet<sup>4</sup>, C. Rodriguez-Lafrasse<sup>1</sup>, S. Couraud<sup>4</sup>, L. PAYEN<sup>1</sup>, Z. Xu<sup>5</sup>; <sup>1</sup>FR, <sup>2</sup>California/US, <sup>3</sup>MD/US, <sup>4</sup>CEDEX/FR, <sup>5</sup>CH

12:30 - 12:30 101P - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer

O. Hamid<sup>1</sup>, A. Vanderwalde<sup>1</sup>, C. Szeto<sup>1</sup>, S. Reddy<sup>1</sup>, S. Pal<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US

12:30 - 12:30 102P - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study

Q. Zhang, C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song; CN

12:30 - 12:30 103P - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples

D. Moran<sup>1</sup>, D. Maurus<sup>2</sup>, C. Rohde<sup>2</sup>, A. Arozullah<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>DE

12:30 - 12:30 104P - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer

Y. Liu, C.K. Tham, S. Ong, C.L. Tang, Y. Zhao; SG

12:30 - 12:30 105P - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292

B. Besse<sup>1</sup>, V. Subbiah<sup>2</sup>, A. Drilon<sup>3</sup>, M. Shah<sup>4</sup>, L. Wirth<sup>5</sup>, T. Bauer<sup>6</sup>, V. Velcheti<sup>7</sup>, N. Lakhani<sup>7</sup>, V. Boni<sup>8</sup>, B. Solomon<sup>9</sup>, M. Johnson<sup>6</sup>, K. Park<sup>10</sup>, J. Patel<sup>11</sup>, M. Cabanillas<sup>2</sup>, E. Sherman<sup>3</sup>, E. Zhu<sup>7</sup>, K. Gordon<sup>7</sup>, K. Ebata<sup>12</sup>, B. Tuch<sup>7</sup>, G. Oxnard<sup>5</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>TX/US, <sup>3</sup>NY/US, <sup>4</sup>OH/US, <sup>5</sup>MA/US, <sup>6</sup>TN/US, <sup>7</sup>US, <sup>8</sup>ES, <sup>9</sup>VIC/AU, <sup>10</sup>KR, <sup>11</sup>IL/US, <sup>12</sup>CA/US

12:30 - 12:30 106P - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma

N. Shen<sup>1</sup>, Y. Pan<sup>2</sup>, X. Mo<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>DE

12:30 - 12:30 107P - Novel genomic classifier for early stage colorectal cancer patients

E. Letellier, M. Schmitz, A. Ginolhac, E. Koncina, M. Marchese, L. Antunes, S. Rauh, S. Haan; LU

12:30 - 12:30 108P - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer

E. Romano<sup>1</sup>, T. Le Bourgeois<sup>2</sup>, S. Lopez-Lastra<sup>2</sup>, V. Servois<sup>2</sup>, S. Beaucaire-Danel<sup>2</sup>, C. Daniel<sup>2</sup>, J.-Y. Pierga<sup>1</sup>, F.-C. Bidard<sup>2</sup>, O. Lantz<sup>2</sup>; <sup>1</sup>CEDEX 5/FR, <sup>2</sup>FR



- 12:30 - 12:30 109P - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.  
J. Cohen<sup>1</sup>, B. Rousseau<sup>2</sup>, R. Bourgoin<sup>1</sup>, C. Tournigand<sup>2</sup>, L. Larnaudie<sup>1</sup>, A. Dupuy<sup>1</sup>, M. Ollier<sup>1</sup>, A. PUJALS<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 110P - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?  
I. Matos Garcia<sup>1</sup>, A. Azaro<sup>1</sup>, C. Viaplana<sup>1</sup>, C. Hierro<sup>1</sup>, J. Martin-Liberal<sup>1</sup>, I. Brana<sup>1</sup>, I. Gardeazabal<sup>1</sup>, P. Gomila<sup>1</sup>, M. Vieito Villar<sup>2</sup>, M. Ochoa De Olza Amat<sup>1</sup>, E. Elez Fernandez<sup>1</sup>, M. Oliveira<sup>1</sup>, A. Oaknin<sup>1</sup>, H. Verdaguer<sup>1</sup>, A. Navarro Mendivil<sup>1</sup>, M. Alsina<sup>1</sup>, J. Taberero<sup>1</sup>, T. Macarulla Mercade<sup>1</sup>, R. Dienstmann<sup>1</sup>, E. Garralda<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>La Coruña/ES
- 12:30 - 12:30 111P - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies  
M.S. Cona, M. Lecchi, S. Damian, M. Del Vecchio, C. Cimminiello, S. Cresta, M. Duca, A. Necchi, D. Signorelli, M. Poggi, D. Raggi, R. Ratta, P. Verderio, F.G. de Braud, M. Di Nicola; IT
- 12:30 - 12:30 112P - Effects of concomitant genetic alterations on cancer patient overall survival  
Y. Wang, P. Peng, L. Shang, Y.-A. Dong, Z. Yang, H. Zhong; CN
- 12:30 - 12:30 113P - Circulating Exosomal Integrin  $\alpha\beta 5$  Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer  
D. Chu, CN
- 12:30 - 12:30 114P - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?  
R. Sorrentino, M. Terlizzi, C. Colarusso, A. Saccomanno, R. Salvi, R. Aquino, A. Pinto; IT
- 12:30 - 12:30 115P - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?  
M. Terlizzi, R. Sorrentino, C. Colarusso, A. Molino, A. Saccomanno, R. Aquino, A. Pinto; IT
- 12:30 - 12:30 116P - Genomic characteristics of standardized uptake value of 18F-fluorodeoxy-glucose positron emission tomography in breast cancer  
S.-K. Kim, S.G. Ahn, S.-H. Leem, J. Jeong, I.-S. Chu; KR
- 12:30 - 12:30 117P - Characterization of PD-L1, CD8, CD3, CD68 and PanCK in Tumor Microenvironment of GI Tract Tumors with respect to Patients' Mismatch Repair Status and Anti-PD-1 Treatment Outcome using 5Plex IHC and Whole Slide Image Analysis  
W. Zhang<sup>1</sup>, M. Khojasteh<sup>1</sup>, A. Hubbard<sup>1</sup>, J. Martin<sup>1</sup>, X. Wang<sup>1</sup>, S. Kamthamraju<sup>1</sup>, J. Munoz-Rodriguez<sup>2</sup>, D. Jiang<sup>1</sup>, Z. Cai<sup>1</sup>, J. Li<sup>1</sup>, R. Anders<sup>1</sup>, L. Diaz<sup>1</sup>, L. Pestic-Dragovich<sup>1</sup>, L. Tang<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>AZ/US
- 12:30 - 12:30 118P - Exhaustion of Platelet Kinetics and its Implication in Post-resection HCC Recurrence  
B. Aryal, T. Shimizu, J. Kadono, A. Furoi, T. Komokata, K. Gejima, M. Yamakuchi, T. Hashiguchi, Y. Imoto; JP

- 12:30 - 12:30 119P - Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project.  
B. You<sup>1</sup>, V. Kepenekian<sup>2</sup>, A. Prieur<sup>3</sup>, M. Caceres<sup>2</sup>, L. Payen-Gay<sup>2</sup>, P. Liaud<sup>3</sup>, M. Flaceliere<sup>3</sup>, M. Tod<sup>2</sup>, L. Villeneuve<sup>2</sup>, F. Bibeau<sup>4</sup>, L. Bernard<sup>2</sup>, P. Jourdan-Enfer<sup>2</sup>, N. Medeghri<sup>2</sup>, D. Dayde<sup>2</sup>, S. Calattini<sup>2</sup>, G. Freyer<sup>1</sup>, D. Maucort-Boulch<sup>2</sup>, D. Joubert<sup>3</sup>, O. Glehen<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CH, <sup>4</sup>CEDEX 5/FR
- 12:30 - 12:30 120P - A new biomarker of breast cancer stage and patient response to neoadjuvant chemotherapy: HLA-DR expression in cytotoxic and regulatory T cells  
D. Saraiva, A. Jacinto, S. Braga, M. Cabral; PT
- 12:30 - 12:30 121P - LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in Stage IV NSCLC patients  
P. Garrido Lopez<sup>1</sup>, E. Felip Font<sup>1</sup>, L. Paz-Ares<sup>1</sup>, M. Majem<sup>1</sup>, T. Moran<sup>1</sup>, J. Gonzalez-Larriba<sup>1</sup>, J. Bosch Barrera<sup>1</sup>, J. Trigo Perez<sup>1</sup>, M.R. Garcia Campelo<sup>1</sup>, J.M. Sanchez Torres<sup>1</sup>, D. Isla<sup>1</sup>, N. Vinolas Segarra<sup>1</sup>, C. Camps<sup>1</sup>, A. Insa Molla<sup>2</sup>, O.J. Juan Vidal<sup>1</sup>, B. Massuti<sup>1</sup>, A. Paredes Lario<sup>1</sup>, A. Artal-Cortes<sup>1</sup>, M. Lopez-Brea Piqueras<sup>1</sup>, J. Palacios Calvo<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Valencia/ES
- 12:30 - 12:30 122P - Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with colorectal liver metastases  
S. Stremitzer, A. Graf, B. Neudert, M. Herac, A. Beer, C. Schwarz, F. Wrba, K. Kaczirek, J. Stiff; AT
- 12:30 - 12:30 123P - Gene expression (GE)-based biomarkers associated with nivolumab response in a real-life cohort of patients with metastatic non-small cell lung cancer (mNSCLC)  
N. Radosevic-Robin<sup>1</sup>, S. Ong<sup>2</sup>, S. Warren<sup>2</sup>, M. Kossai<sup>1</sup>, C. Godfraind<sup>1</sup>, M. Masson<sup>1</sup>, H. Janicot<sup>1</sup>, P. Merle<sup>1</sup>, P. Dubray-Longueras<sup>1</sup>, X. Durando<sup>1</sup>, P. Morel<sup>2</sup>, A. Cesano<sup>2</sup>, F. Penault-Llorca<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>US
- 12:30 - 12:30 124P - Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)  
L. Miller-Phillips<sup>1</sup>, L. Fischer von Weikersthal<sup>1</sup>, F. Kaiser<sup>1</sup>, S.-E. Al-Batran<sup>1</sup>, T. Heintges<sup>1</sup>, D. Neureiter<sup>2</sup>, C. Kahl<sup>1</sup>, F. Kullmann<sup>1</sup>, M. Moehler<sup>1</sup>, W. Scheithauer<sup>2</sup>, C. Vazart<sup>3</sup>, K. Fontaine<sup>3</sup>, S. Held<sup>1</sup>, D. Modest<sup>1</sup>, J. Neumann<sup>1</sup>, A. Jung<sup>1</sup>, T. Kirchner<sup>1</sup>, V. Heinemann<sup>1</sup>, S. Stintzing<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>AT, <sup>3</sup>FR
- 12:30 - 12:30 125P - Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study.  
H. Blons<sup>1</sup>, J.-B. Oudart<sup>1</sup>, J.-P. Merlio<sup>1</sup>, S. Hominal<sup>2</sup>, F. de Fraipont<sup>1</sup>, D. Debievre<sup>1</sup>, F. Escande<sup>1</sup>, C. Audigier Valette<sup>2</sup>, P.-P. Bringuier<sup>1</sup>, S. Moreau Fraboulet<sup>1</sup>, L. Ouafik<sup>1</sup>, D. Moro-Sibilot<sup>1</sup>, A. Lemoine<sup>1</sup>, A. Langlais<sup>1</sup>, P. Missy<sup>1</sup>, F. Morin<sup>1</sup>, P.-J. Souquet<sup>2</sup>, F. Barlesi<sup>3</sup>, J. Cadranet<sup>1</sup>, M. Beau-Faller<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 20/FR
- 12:30 - 12:30 126P - Simultaneous identification and profiling of tumor-specific T cells by mass cytometry  
M. Fehlings, E. Newell; SG
- 12:30 - 12:30 127P - Over-expression of S100B protein as a serum marker of brain metastasis in non-small cell lung cancer and its prognostic value  
L. Chen, Y. Zhao, X. Hu, H. Wu, J. Liu, X. Mu; CN

- 12:30 - 12:30 128P - Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02)  
J.L. Ramirez<sup>1</sup>, A. Font Pous<sup>2</sup>, J. Garcia-Donas<sup>1</sup>, B. Perez Valderrama<sup>1</sup>, I. Aguirre Egaña<sup>1</sup>, L. Nonell<sup>1</sup>, V. Ruiz de Porras Fontdevila<sup>1</sup>, M. Mallo<sup>1</sup>, D. Balañá<sup>1</sup>, J.A. Virizuela<sup>1</sup>, U. Anido<sup>1</sup>, M.M. Llorente Ostiategui<sup>1</sup>, M.A. Gonzalez del Alba Baamonde<sup>1</sup>, N. Lainez<sup>1</sup>, B. Mellado<sup>1</sup>, M.A. Climent Duran<sup>1</sup>, J. Bellmunt<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 12:30 - 12:30 129P - Pre-diagnostic measurements of high-sensitive C - reactive protein and risk of Prostate Cancer. The PROCA-life study  
E. Stikbakke, H. Haugnes, I. Thune, T. Wilsgaard, T. Knutsen, E. Richardsen; NO
- 12:30 - 12:30 130P - Training and validation of a gene expression signature for microsatellite instability  
S. Warren<sup>1</sup>, P. Danaher<sup>2</sup>, S. Ong<sup>1</sup>, N. Elliott<sup>1</sup>, A. Cesano<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>WA/US
- 12:30 - 12:30 131P - Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels  
K. Quinn<sup>1</sup>, E. Helman<sup>1</sup>, T. Nance<sup>1</sup>, C. Artieri<sup>1</sup>, J. Yen<sup>2</sup>, J. Zhao<sup>1</sup>, S. Fairclough<sup>1</sup>, M. Sikora<sup>1</sup>, D. Chudova<sup>1</sup>, R. Lanman<sup>1</sup>, A. Talasz<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 12:30 - 12:30 132P - Carbohydrate antigen 19-9 and apolipoprotein A2 isoform as early detection biomarkers for pancreatic cancer: a prospective evaluation by the EPIC study  
K. Honda<sup>1</sup>, V. Katzke<sup>2</sup>, A. Hüsing<sup>2</sup>, S. Okaya<sup>1</sup>, H. Shoji<sup>1</sup>, K. Onidani<sup>1</sup>, F. Canzian<sup>2</sup>, R. Kaaks<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>DE
- 12:30 - 12:30 133P - Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)  
M. Bilen<sup>1</sup>, D. Martini<sup>2</sup>, J. Shabto<sup>2</sup>, Y. Liu<sup>2</sup>, A. Khan<sup>2</sup>, M. Williams<sup>2</sup>, C. Lewis<sup>1</sup>, H. Collins<sup>1</sup>, H. Kissick<sup>2</sup>, B. Carthon<sup>1</sup>, M. Akce<sup>1</sup>, W. Shaib<sup>1</sup>, O. Alese<sup>1</sup>, D. Lawson<sup>1</sup>, R. Kudchadkar<sup>1</sup>, B. El-Rayes<sup>1</sup>, S. Ramalingam<sup>2</sup>, T. Owonikoko<sup>2</sup>, R. Harvey<sup>1</sup>, V. Master<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GA/US
- 12:30 - 12:30 134P - Prediction of irAEs in Ipilimumab-treated melanoma patients based on serum autoantibodies  
J. Hassel<sup>1</sup>, J. Mangana<sup>2</sup>, R. Dummer<sup>2</sup>, C. Pföhler<sup>1</sup>, K. Wistuba-Hamprecht<sup>1</sup>, B. Weide<sup>1</sup>, L. Hakim-Meibodi<sup>1</sup>, F. Meier<sup>1</sup>, J. Roth<sup>1</sup>, H.-D. Zucht<sup>1</sup>, P. Budde<sup>1</sup>, M. Tuschen<sup>1</sup>, P. Schulz-Knappe<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>CH
- 12:30 - 12:30 135P - Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer  
B. Edith<sup>1</sup>, A. Leary<sup>1</sup>, P. Pautier<sup>2</sup>, E. Santana<sup>1</sup>, L. Lacroix<sup>1</sup>, O. Cabaret<sup>1</sup>, M. Guillaud-Bataille<sup>1</sup>, J. Michels<sup>1</sup>, A. Auguste<sup>1</sup>, C. Genestie<sup>1</sup>, E. Rouleau<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 5/FR
- 12:30 - 12:30 136P - EML4-ALK fusion variants associate with gender and age in Chinese NSCLC patients  
W. Zhao, G. Liang, L. Wang, L. Dai, D. Wu, K. Wang, A. Wang, H. Chen, Y.-A. Dong, M. Wang; CN
- 12:30 - 12:30 137P - Multi-Dimensional Immuno-Oncology Assays for Understanding the Immune System and Tumor Microenvironment

F. Hyland<sup>1</sup>, T. Looney<sup>2</sup>, R. Chaudhury<sup>3</sup>, A. Kamat<sup>3</sup>, A. Pankov<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>SG, <sup>3</sup>CA/US

- 12:30 - 12:30 138P - Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma  
N. Keegan, S. Toomey, A. Farrelly, A. Carr, G. Calzaferri, J. Walshe, G. Gullo, J. Crown, K. Egan, A. Hernando, A. Teiserskiene, L. Grogan, O. Breathnach, P. Morris, B. Hennessy; IE
- 12:30 - 12:30 139P - Analysis of circulating biomarkers in A randomized phase II trial of maintenance oral metronomic vinorelbine in advanced NSCLC following platinum-based chemotherapy: A correlative MA.NI.LA. trial study  
M. Boeri<sup>1</sup>, F. Nichetti<sup>1</sup>, L. Porcu<sup>1</sup>, V. Torri<sup>2</sup>, A. Del Conte<sup>1</sup>, A. Martinetti<sup>1</sup>, E. Sottotetti<sup>1</sup>, E. Vattemi<sup>1</sup>, F. Verderame<sup>1</sup>, M.C. Garassino<sup>1</sup>, L. Cavanna<sup>1</sup>, A. Tuzi<sup>1</sup>, L. Irtelli<sup>1</sup>, F.G. de Braud<sup>1</sup>, M. Platania<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>NA
- 12:30 - 12:30 140P - Oral cavity immune response in pancreatic ductal adenocarcinoma (PDAC)  
J. Marquez<sup>1</sup>, P. Lucero-Diaz<sup>2</sup>, J.A. Matute-Briseno<sup>2</sup>, M. Rosas-Delgado<sup>2</sup>, A. CAMACHO-HERNANDEZ<sup>2</sup>, Y. Cortez-Vargas<sup>2</sup>, I. Nava-Sanchez<sup>2</sup>, G. MONTANO<sup>2</sup>, L. MONTIJO-FERNANDEZ<sup>2</sup>, M. PEREZ-ASTORGA<sup>2</sup>; <sup>1</sup>Washington/MX, <sup>2</sup>MX
- 12:30 - 12:30 141P - Tumor Mutational Burden (TMB) Standardization Initiative: Establishing a Consistent Methodology for TMB Measurement in Clinical Samples  
A. Stenzinger<sup>1</sup>, J. Allen<sup>2</sup>, J. Maas<sup>1</sup>, M. Stewart<sup>2</sup>, D. Merino<sup>2</sup>, M. Dietel<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>DC/US
- 12:30 - 12:30 142P - DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?  
C.M. Della Corte<sup>1</sup>, K. Ramkumar<sup>2</sup>, T. Sen<sup>2</sup>, P. Tong<sup>2</sup>, D. Gibbons<sup>2</sup>, J. Heymach<sup>2</sup>, J. Wang<sup>2</sup>, Y.-H. Fan<sup>2</sup>, R. Cardnell<sup>2</sup>, L. Byers<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>TX/US
- 12:30 - 12:30 143P - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)  
J. Martin-Liberal<sup>1</sup>, F. Pagliuca<sup>2</sup>, C. Hierro<sup>1</sup>, C. Viaplana<sup>1</sup>, E. Muñoz Couselo<sup>1</sup>, J. Capdevila<sup>1</sup>, I. Matos<sup>1</sup>, L. Fariñas Madrid<sup>1</sup>, E. Zamora<sup>1</sup>, I. Braña Garcia<sup>1</sup>, E. Elez Fernandez<sup>1</sup>, M. Ochoa De Olza Amat<sup>1</sup>, A. Azaro<sup>1</sup>, M. Alsina<sup>1</sup>, M. Vieito Villar<sup>3</sup>, R. Fasani<sup>1</sup>, J. Tabernero<sup>1</sup>, E. Garralda<sup>1</sup>, R. Dienstmann<sup>1</sup>, P. Nuciforo<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>IT, <sup>3</sup>La Coruña/ES
- 12:30 - 12:30 144P - Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab.  
G. Mountzios<sup>1</sup>, V. Kotoula<sup>2</sup>, G.-A. Koliou<sup>3</sup>, K. Papadopoulou<sup>3</sup>, G. Lazaridis<sup>3</sup>, C. Christodoulou<sup>4</sup>, G. Pentheroudakis<sup>3</sup>, M. Skondra<sup>3</sup>, A. Koutras<sup>5</sup>, H. Linardou<sup>4</sup>, E. Razis<sup>3</sup>, P. Papakostas<sup>3</sup>, S. Chrisafi<sup>3</sup>, G. Aravantinos<sup>6</sup>, I. Nicolaou<sup>3</sup>, A. Goussia<sup>3</sup>, K. Kalogeras<sup>3</sup>, D. Pectasides<sup>3</sup>, G. Fountzilias<sup>3</sup>; <sup>1</sup>Neo Psychiko/GR, <sup>2</sup>Central Macedonia/GR, <sup>3</sup>GR, <sup>4</sup>N. Faliro/GR, <sup>5</sup>Rion/GR, <sup>6</sup>Attica/GR
- 12:30 - 12:30 145P - Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer  
S. Crucitta, M. Del Re, A. Fontana, I. Bertolini, E. Rofi, C. De Angelis, L. Diodati, D. Cavallero, B. Salvadori, A. Falcone, R. Morganti, R. Danesi; IT
- 12:30 - 12:30 146P - HER2 amplification is associated with higher tumor mutation burden in breast cancer

Y. Yin, W. Li, X. Huang, H. Wu, Y. Zhang, S. Cai, S. Zhou; CN

- 12:30 - 12:30 147P - Application of CRISPR/Cas9 system for identification of genes involved in the regulation of pancreatic cancer cells platinum sensitivity  
V. Skripova<sup>1</sup>, I. Serebriiskii<sup>1</sup>, R. Kiyamova<sup>1</sup>, I. Astsaturov<sup>2</sup>; <sup>1</sup>RU, <sup>2</sup>PA/US
- 12:30 - 12:30 148P - Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass  
A. athanasiou<sup>1</sup>, T. Orfanelli<sup>2</sup>, D. Lapolla<sup>3</sup>, E. Andreopoulou<sup>3</sup>, T.A. Moo<sup>3</sup>, J. Marti<sup>3</sup>, T. Cigler<sup>3</sup>, A.M. Bongiovanni<sup>3</sup>, S. Witkin<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>NJ/US, <sup>3</sup>NY/US
- 12:30 - 12:30 149P - Only estrogen receptor "Positive" is not enough to predict the prognosis of breast cancer Running head: Revisiting estrogen positive tumors in 8th AJCC staging era  
J.M. Ryu, S.K. Lee, J.E. Lee, S.J. Nam, J. Yu, H.J. Choi, I. Kim, S.W. Kim; KR
- 12:30 - 12:30 150P - Adjuvant radiation therapy leads to an up-regulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) which might contribute to radioresistance in primary breast cancer patients  
D. Schott, M. Pizon, U. Pachmann, K. Pachmann, M. Mäurer; DE
- 12:30 - 12:30 151P - Recurrent and Metastatic Carcinomas of the Lacrimal Gland: High Frequency of ERBB2 Driven Disease  
N. Girard<sup>1</sup>, R. Corona<sup>2</sup>, J. Chung<sup>3</sup>, S. Millis<sup>3</sup>, L. Gay<sup>4</sup>, J. Elvin<sup>3</sup>, J.-A. Vergilio<sup>3</sup>, S. Ramkissoon<sup>3</sup>, E. Severson<sup>3</sup>, S. Daniel<sup>3</sup>, J. Killian<sup>3</sup>, S. Ali<sup>3</sup>, A. Schrock<sup>4</sup>, V. Miller<sup>3</sup>, J. Ross<sup>4</sup>; <sup>1</sup>FR, <sup>2</sup>NY/US, <sup>3</sup>MA/US, <sup>4</sup>US
- 12:30 - 12:30 152P - Circulating tumour DNA experience in patients with Cancer of Unknown Primary  
H. Winter<sup>1</sup>, I. Faull<sup>2</sup>, P. Bains<sup>1</sup>, C. Murias<sup>1</sup>, M. Kushnir<sup>1</sup>, M. Forster<sup>3</sup>, A. Kulkarni<sup>1</sup>, D. Moore<sup>1</sup>, C. Swanton<sup>1</sup>, K. Shiu<sup>1</sup>, H.-T. Arkenau<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>ES, <sup>3</sup>London/GB
- 12:30 - 12:30 153P - Reproducibility of the mRECIST criteria for the assessment of HCC treated by anti- VEGFR therapy: Impact of readers' expertise  
H. Beaumont<sup>1</sup>, S. Egels<sup>1</sup>, N. Faye<sup>1</sup>, C. Klifa<sup>1</sup>, A. Iannessi<sup>1</sup>, E. Bonnard<sup>1</sup>, O. Lucidarme<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 13/FR
- 12:30 - 12:30 154P - PD-L1 expression pattern in large cell neuroendocrine carcinoma of the lung.  
D. damotte<sup>1</sup>, M.C. Charpentier<sup>1</sup>, M. Bernardi<sup>1</sup>, E. Watkin<sup>1</sup>, I. Goubin Versini<sup>1</sup>, R. Lamy<sup>1</sup>, N. Piton<sup>1</sup>, L. Geriniere<sup>1</sup>, F. Forest<sup>1</sup>, R. Gervais<sup>2</sup>, I. Monnet<sup>1</sup>, A. Madrosyk<sup>1</sup>, F. Guisier<sup>1</sup>, C. Serrand<sup>1</sup>, C. Locher Genty<sup>3</sup>, C. Decroisette<sup>4</sup>, J.B. Auliac<sup>1</sup>, T. Jeanfaivre<sup>1</sup>, H. Doubre<sup>1</sup>, D. Arpin<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>Cedex/FR, <sup>4</sup>CEDEX/FR
- 12:30 - 12:30 155P - Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)  
G. Williams<sup>1</sup>, A.G. Nicholson<sup>1</sup>, D. Snead<sup>1</sup>, E. Thunnissen<sup>2</sup>, S. Lantuejoul<sup>3</sup>, P. Cane<sup>1</sup>, K. Kerr<sup>1</sup>, M. Loddo<sup>1</sup>, M. Scott<sup>1</sup>, P. Scorer<sup>1</sup>, C. Barker<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>NL, <sup>3</sup>CEDEX 9/FR

- 12:30 - 12:30 156P - Relationship between ring-type dedicated breast PET and tumor-infiltrating lymphocytes in early breast cancer  
S. Sasada<sup>1</sup>, N. Shiroma<sup>2</sup>, E. Suzuki<sup>2</sup>, S. Sueoka<sup>2</sup>, N. Goda<sup>2</sup>, K. Kajitani<sup>2</sup>, A. Emi<sup>2</sup>, N. Masumoto<sup>2</sup>, T. Kadoya<sup>2</sup>, R. Haruta<sup>2</sup>, T. Kataoka<sup>2</sup>, K. Arihiro<sup>2</sup>, M. Okada<sup>2</sup>; <sup>1</sup>Hiroshima/JP, <sup>2</sup>JP
- 12:30 - 12:30 157P - Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms  
Y. Fan<sup>1</sup>, Y. Xu<sup>2</sup>, X. Tong<sup>3</sup>, J. Yan<sup>1</sup>, X. Wu<sup>3</sup>, Y.W. Shao<sup>3</sup>; <sup>1</sup>CN, <sup>2</sup>Zhejiang/CN, <sup>3</sup>CA
- 12:30 - 12:30 158P - Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy  
L. Angus<sup>1</sup>, E. van Helden<sup>2</sup>, S. van Es<sup>1</sup>, E. Boon<sup>1</sup>, C. van Herpen<sup>1</sup>, D.J. de Groot<sup>1</sup>, E.G.E. de Vries<sup>1</sup>, C.W. Menke-van der Houven van Oordt<sup>1</sup>, S. Sleijfer<sup>1</sup>, H. Verheul<sup>1</sup>, M. Jansen<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>AN
- 12:30 - 12:30 159P - Quantifying circulating cell-free DNA as clinical biomarker  
M. Romain, Z. Dache, A. Otandault, R. Tanos, B. Pastor, C. Sanchez, J. Azzi, G. Tusch, S. Azan, C. Mollevi, S. Thezenas, P. Blache, A. Thierry; FR
- 12:30 - 12:30 160P - Gene Expression Profile (GEP) and Survival Among Patients With Advanced Ovarian Cancer  
E. Høgdall<sup>1</sup>, C. Høgdall<sup>1</sup>, P.-T. Vo<sup>2</sup>, W. Zhou<sup>2</sup>, L. Huang<sup>2</sup>, M. Marton<sup>2</sup>, S. Keefe<sup>2</sup>, M. Busch-Sørensen<sup>2</sup>, S. Sørensen<sup>1</sup>, J. Georgsen<sup>1</sup>, E. Mejlgaard<sup>1</sup>, L. Nedergaard<sup>1</sup>, T. Steiniche<sup>1</sup>; <sup>1</sup>DK, <sup>2</sup>US
- 12:30 - 12:30 161P - Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics.  
D. Yan<sup>1</sup>, M.-H. Ryu<sup>2</sup>, E. An<sup>3</sup>, Y.S. Park<sup>2</sup>, H. Na<sup>2</sup>, J. Ma<sup>2</sup>, Y. Tian<sup>1</sup>, F. Cecchi<sup>1</sup>, T. Hembrough<sup>1</sup>, Y.-K. Kang<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>KR, <sup>3</sup>MD/US, <sup>4</sup>Songpa-gu/KR
- 12:30 - 12:30 162P - Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study  
B. De Craene<sup>1</sup>, J. Van de Velde<sup>1</sup>, E. Bellon<sup>1</sup>, M. Gazin<sup>1</sup>, E. Rondelez<sup>1</sup>, L. Vandenbroeck<sup>1</sup>, T. Vanhoey<sup>1</sup>, N. Elsen<sup>1</sup>, L. Melchior<sup>2</sup>, G.L. Willemoes<sup>2</sup>, E. Watkin<sup>3</sup>, N. Arens<sup>4</sup>, C. Altmann<sup>4</sup>, K. Decanniere<sup>1</sup>, E. Sablon<sup>1</sup>, G. Maertens<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>DK, <sup>3</sup>FR, <sup>4</sup>DE
- 12:30 - 12:30 163P - Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel  
T. Jiang<sup>1</sup>, S. Zhang<sup>2</sup>, A. Jager<sup>2</sup>, S. Katz<sup>2</sup>, J. Lococo<sup>2</sup>, P. Le<sup>2</sup>, B. Andrian<sup>2</sup>, C. Zhao<sup>2</sup>, D. Baker<sup>2</sup>, T. Pawlowski<sup>2</sup>, S. Bilke<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 12:30 - 12:30 164P - Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a Phase I/II clinical trial in mCRPC patients  
M. Tan<sup>1</sup>, S. Zhang<sup>1</sup>, Z. Zhao<sup>1</sup>, A. Wang<sup>1</sup>, D. Cheung<sup>1</sup>, P. Du<sup>1</sup>, J. Yu<sup>1</sup>, S. Jia<sup>2</sup>, C. Guo<sup>3</sup>, Y. Tong<sup>3</sup>, K. Zhou<sup>3</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>CN
- 12:30 - 12:30 165P - The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type

J. Dvorak<sup>1</sup>, B. Rosova<sup>2</sup>, A. Filipova<sup>2</sup>, D. Hadzi Nikolov<sup>2</sup>, L. Dusek<sup>2</sup>, A. Rozsypalova<sup>2</sup>, J. Proks<sup>2</sup>, I. Richter<sup>2</sup>, B. Melichar<sup>2</sup>, T. Buchler<sup>1</sup>, R. Zacheval<sup>2</sup>, R. Matej<sup>2</sup>; <sup>1</sup>4/CZ, <sup>2</sup>CZ

- 12:30 - 12:30 166P - Association of MMR protein expression and MMR gene mutations in Chinese colorectal cancer patients  
S. Wang, S. Zhang, Z. Zeng, Y. Ou, M. Han, J. Guo, D. Chen, X. Dong, J. Hu, G. Chirn, W. Shi, M. Yao; CN
- 12:30 - 12:30 167P - Somatic and germline mutations of Chinese gastric cancer patients  
Y. Wang, W. Gu, Y. Zhang, K. Li, Z. Niu, Y. Zheng, Q. Cui, A. Wang, H. Chen, W. Shi, K. Wang, M. Yao; CN
- 12:30 - 12:30 168P - Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)  
P.A. Fasching<sup>1</sup>, M. Laible<sup>1</sup>, K. Weber<sup>1</sup>, R.M. Wirtz<sup>1</sup>, C. Denkert<sup>1</sup>, K. Schlombs<sup>1</sup>, S. Schmatloch<sup>1</sup>, O. Camara<sup>1</sup>, H.J. Lück<sup>1</sup>, J. Huober<sup>1</sup>, T. Karn<sup>1</sup>, M. van Mackelenbergh<sup>1</sup>, F. Marme<sup>1</sup>, V. Müller<sup>1</sup>, C. Schem<sup>2</sup>, E. Stickeler<sup>1</sup>, U. Sahin<sup>1</sup>, S. Loibl<sup>1</sup>, M. Untch<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>Schleswig-Holstein/DE
- 12:30 - 12:30 169P - Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer  
E. Rofi, M. Del Re, C. Vivaldi, S. Crucitta, E. Arrigoni, G. Pasquini, S. Catanese, I. Pecora, G. Musettini, E. Vasile, A. Falcone, R. Danesi; IT
- 12:30 - 12:30 170P - Ecological diversity indices as measurements of tumor heterogeneity correlates with clinical outcomes in late stage small cell lung cancer (SCLC)  
S. Yaung<sup>1</sup>, L. Xi<sup>2</sup>, C. Woestmann<sup>3</sup>, S. McNamara<sup>3</sup>, B. Hinzmann<sup>3</sup>, S. Froehler<sup>3</sup>, N. Tikoo<sup>2</sup>, C. Ju<sup>2</sup>, A. Balasubramanyam<sup>2</sup>, H.-P. Adams<sup>3</sup>, M. Thomas<sup>3</sup>, F. Lasitschka<sup>3</sup>, M. Meister<sup>3</sup>, M. Schneider<sup>3</sup>, F. Herth<sup>3</sup>, T. Muley<sup>3</sup>, B. Wehnl<sup>3</sup>, J. Palma<sup>2</sup>, X.M. Ma<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>DE
- 12:30 - 12:30 171P - MET exon 14 splicing mutation and its correlation with clinopathological features in subjects with non-small cell lung cancer  
D. Katalinic, I. Aleric, A. Vcev; HR
- 12:30 - 12:30 172P - Cancer Stem Cell Markers in Pancreatic Ductal Adenocarcinoma  
F. Aksoy, E. Kaya, U. Egeli, H.Z. Dundar, P. Tasar, S. aksoy, Y. Ozen, B. Tunca, G. Cecener, O. Yerci; TR
- 12:30 - 12:30 173P - Tumor mutation burden assessment on FFPE samples using a targeted next-generation sequencing assay  
R. Chaudhary<sup>1</sup>, D. Cyanam<sup>2</sup>, V. Mittal<sup>3</sup>, W. Tom<sup>3</sup>, J. Au-Young<sup>3</sup>, C. Allen<sup>4</sup>, S. Sadis<sup>2</sup>, F. Hyland<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>MI/US, <sup>3</sup>CA/US, <sup>4</sup>GB
- 12:30 - 12:30 174P - Microsatellite instability-high (MSI-H) colorectal cancers with elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) signature represent a target population for immune checkpoint and DNA damaging therapies  
K.T. Tan, P.-N. Yu, S.-J. Chen, Y.-T. Liu, S.-C. Chang, M.-H. Chen; TW

- 12:30 - 12:30 175P - Levels of circulating fibroblast growth factor (FGF) 23 and prognosis of cancer patients with bone metastasis  
A. Mansinho, A. Ferreira, S. Casimiro, I. Alho, I. Vendrell, A.L. Costa, R. Sousa, C. Abreu, C. Pulido, D. Macedo, T. Pacheco, L. Correia, L. Costa; PT
- 12:30 - 12:30 176P - Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era  
N. Tsoukalas<sup>1</sup>, E. Aravantinou<sup>1</sup>, K. Tsapakidis<sup>1</sup>, C. Giaginis<sup>1</sup>, M. Tolia<sup>1</sup>, I. Binas<sup>1</sup>, P. Baxevasos<sup>1</sup>, M. Galanopoulos<sup>1</sup>, M. Kiakou<sup>1</sup>, I. Zerdes<sup>1</sup>, I. Kostakis<sup>1</sup>, C. Nikolaou<sup>1</sup>, I. Litos<sup>1</sup>, M. Lontos<sup>2</sup>, E. Tsiambas<sup>1</sup>, I. Gioulbasanis<sup>1</sup>, I. Sfiniadakis<sup>1</sup>, A. Karameris<sup>1</sup>, G. Kyrgias<sup>1</sup>, S. Theocharis<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>Attiki/GR
- 12:30 - 12:30 177P - Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung  
S. Wang, H. Chen, J. Zhao, J. Zhong, J. Wang; CN
- 12:30 - 12:30 178P - Xmal-RRBS DNA methylation screening resolves breast cancer epigenetic heterogeneity  
A. Tanas, T. Kekeeva, V. Sigin, E. Kuznetsova, E. Poddubskaya, I. Trotsenko, D. Zaletaev, V. Strelnikov; RU
- 12:30 - 12:30 179P - Prognostic value of change in neutrophil-lymphocyte ratio during treatment with first-line anti-PD1 therapy in metastatic melanoma  
J. Soon<sup>1</sup>, E. Blackley<sup>1</sup>, M. Moore<sup>1</sup>, L. Lim<sup>1</sup>, H.L. Yeoh<sup>1</sup>, M. Voskoboynik<sup>2</sup>, A. Haydon<sup>1</sup>; <sup>1</sup>VIC/AU, <sup>2</sup>AU
- 12:30 - 12:30 180P - A serum microRNA expression signature for radiosensitivity of non-small cell lung cancer  
L. Fan, B. Li; CN
- 12:30 - 12:30 181P - Anti-tNASP antibodies as a diagnostic marker for malignant tumors  
O. Alekseev<sup>1</sup>, K. Admire<sup>2</sup>, J. Brogdon<sup>2</sup>, B. Gorman<sup>2</sup>, C. Davis<sup>2</sup>, Z. Vaskalis<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NC/US
- 12:30 - 12:30 182TiP - EXPRESS study - A Multicenter, Prospective Trial In Progress Exploring The Association Between Low Level Of Genomic Alteration And Exceptional And Unexpected Response To Targeted Therapies In Patients With Solid Tumors  
A. Italiano<sup>1</sup>, O. Le Saux<sup>1</sup>, F. André<sup>1</sup>, T. Filleron<sup>2</sup>, D. Spaeth<sup>3</sup>, P.-E. Heudel<sup>4</sup>, L. Albiges<sup>1</sup>, T. Bachelot<sup>1</sup>, A. Gonçalves<sup>3</sup>, J.-Y. Pierga<sup>5</sup>, F. Barlesi<sup>6</sup>, V. Boige<sup>3</sup>, C. Lebbe<sup>7</sup>, L. Mortier<sup>3</sup>, J.-S. Frenel<sup>1</sup>, O. Tredan<sup>1</sup>, M. Jimenez<sup>3</sup>, F. Legrand<sup>3</sup>, C. Ferté<sup>3</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>CEDEX 3/FR, <sup>3</sup>FR, <sup>4</sup>Cedex 08/FR, <sup>5</sup>CEDEX 5/FR, <sup>6</sup>CEDEX 20/FR, <sup>7</sup>CEDEX 10/FR
- 12:30 - 12:30 183TiP - Neoadjuvant Biomarker Research Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast Cancer – the phase II NeorHEA trial  
M. Ignatiadis<sup>1</sup>, M. Brandao<sup>1</sup>, M. Maetens<sup>1</sup>, N. Ponde<sup>1</sup>, S. Martel<sup>2</sup>, S. Drisis<sup>1</sup>, I. Veys<sup>1</sup>, S. Mazy<sup>1</sup>, E. Bollue<sup>1</sup>, P. Neven<sup>1</sup>, F. Duhoux<sup>1</sup>, J. Chapiro<sup>3</sup>, A. Awada<sup>1</sup>, T. Besse-Hammer<sup>1</sup>, M. Paesmans<sup>1</sup>, M. Piccart<sup>1</sup>, P. Vuylsteke<sup>1</sup>, C. Sotiriou<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>CA, <sup>3</sup>Cedex/FR
- 12:30 - 12:30 944P - QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAMut subset



K. Moore<sup>1</sup>, A. Secord<sup>2</sup>, M. Geller<sup>2</sup>, D. Miller<sup>3</sup>, N. Cloven<sup>2</sup>, G. Fleming<sup>4</sup>, A. Wahner Hendrickson<sup>2</sup>, M. Azodi<sup>2</sup>, P. DiSilvestro<sup>2</sup>, A. Oza<sup>5</sup>, M. Cristea<sup>2</sup>, J. Berek<sup>6</sup>, J. Chan<sup>2</sup>, B. Rimel<sup>2</sup>, Y. Li<sup>2</sup>, K. Luptakova<sup>2</sup>, R. Clark<sup>2</sup>, U. Matulonis<sup>7</sup>, B. Monk<sup>2</sup>; <sup>1</sup>Oklahoma/US, <sup>2</sup>US, <sup>3</sup>TX/US, <sup>4</sup>IL/US, <sup>5</sup>CA, <sup>6</sup>CA/US, <sup>7</sup>MA/US

12:30 - 12:30

945P - A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

R. O'Ceirbhail<sup>1</sup>, A. Wolfer<sup>2</sup>, P. Disilvestro<sup>3</sup>, D. O'Malley<sup>3</sup>, P. Sabbatini<sup>1</sup>, L. Shohara<sup>1</sup>, P. Schwarzenberger<sup>4</sup>, T. Ricciardi<sup>1</sup>, M. Macri<sup>1</sup>, A. Ryan<sup>1</sup>, R. Venhaus<sup>1</sup>, J. Bryan<sup>3</sup>, P. Wong<sup>1</sup>, K. Homicsko<sup>5</sup>, L. Kandalaft<sup>2</sup>, S. Rusakiewicz<sup>2</sup>, A. Harari<sup>2</sup>, B. Monk<sup>3</sup>, G. Coukos<sup>2</sup>; <sup>1</sup>NY/US, <sup>2</sup>CH, <sup>3</sup>US, <sup>4</sup>LA/US, <sup>5</sup>Vaud/CH

12:30 - 12:30

946P - Brain metastases in primary ovarian cancer: real-world data

E. Ratner<sup>1</sup>, M. Bala<sup>2</sup>, M. Louie-Gao<sup>2</sup>, S. Hazard<sup>2</sup>, P. Brastianos<sup>2</sup>; <sup>1</sup>CT/US, <sup>2</sup>US

12:30 - 12:30

947P - Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: effect of prior chemotherapy regimens in ARIEL3

D. Lorusso<sup>1</sup>, R. Coleman<sup>2</sup>, A. Oza<sup>3</sup>, C. Aghajanian<sup>4</sup>, A. Oaknin<sup>5</sup>, A. Dean<sup>6</sup>, N. Colombo<sup>1</sup>, J. Weberpals<sup>3</sup>, A. Clamp<sup>7</sup>, G. Scambia<sup>1</sup>, A. Leary<sup>8</sup>, R. Holloway<sup>9</sup>, M. Amenedo Gancedo<sup>5</sup>, P. Fong<sup>10</sup>, J. Goh<sup>11</sup>, D. O'Malley<sup>12</sup>, S. Banerjee<sup>7</sup>, S. Goble<sup>12</sup>, T. Cameron<sup>7</sup>, J. Ledermann<sup>13</sup>; <sup>1</sup>IT, <sup>2</sup>TX/US, <sup>3</sup>Ontario/CA, <sup>4</sup>NY/US, <sup>5</sup>ES, <sup>6</sup>WA/AU, <sup>7</sup>GB, <sup>8</sup>FR, <sup>9</sup>FL/US, <sup>10</sup>NZ, <sup>11</sup>QLD/AU, <sup>12</sup>US, <sup>13</sup>London/GB

12:30 - 12:30

948P - Intraperitoneal Chemotherapy (IP CT) after cytoreductive surgery benefits survival in epithelial ovarian cancer (EOC): Results of a pooled meta-analysis including 9 randomized clinical trials (RCT)

M. Jimenez-Heredia<sup>1</sup>, J.A. Perez Fidalgo<sup>2</sup>, M. Morales Suarez-Varela<sup>1</sup>, J. Sanchis<sup>1</sup>, M. Aranda<sup>1</sup>, A. Cervantes<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>Valencia/ES

12:30 - 12:30

949P - Mirvetuximab soravtansine, a folate receptor alpha (FR $\alpha$ )-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a Phase Ib study

U. Matulonis<sup>1</sup>, K. Moore<sup>2</sup>, L. Martin<sup>3</sup>, I. Vergote<sup>4</sup>, C. Castro<sup>1</sup>, L. Gilbert<sup>5</sup>, K. Malek<sup>6</sup>, M. Birrer<sup>1</sup>, D. O'Malley<sup>6</sup>; <sup>1</sup>MA/US, <sup>2</sup>Oklahoma/US, <sup>3</sup>PA/US, <sup>4</sup>BE, <sup>5</sup>CA, <sup>6</sup>US

12:30 - 12:30

950P - Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

A. Oza<sup>1</sup>, D. Cibula<sup>2</sup>, A. Oaknin<sup>3</sup>, C. Poole<sup>4</sup>, R. Mathijssen<sup>5</sup>, G. Sonke<sup>5</sup>, N. Colombo<sup>6</sup>, J. Špaček<sup>2</sup>, P. Vuylsteke<sup>7</sup>, H. Hirte<sup>1</sup>, J. Pfisterer<sup>8</sup>, M. Plante<sup>9</sup>, L. Harker<sup>8</sup>, A. Fielding<sup>10</sup>, V. Haddad<sup>10</sup>, J. Chmielecki<sup>11</sup>, M. Friedlander<sup>12</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CZ, <sup>3</sup>ES, <sup>4</sup>West Midlands/GB, <sup>5</sup>NL, <sup>6</sup>IT, <sup>7</sup>BE, <sup>8</sup>DE, <sup>9</sup>CA, <sup>10</sup>GB, <sup>11</sup>US, <sup>12</sup>NSW/AU

12:30 - 12:30

951P - A Phase 1b Study of Navicixizumab & Weekly Paclitaxel in Heavily Pre-Treated Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer.

S. Fu<sup>1</sup>, B. Corr<sup>2</sup>, E. Hamilton<sup>3</sup>, R. Burger<sup>4</sup>, R. Wenham<sup>5</sup>, R. Naumann<sup>6</sup>, R. Stagg<sup>7</sup>, K. Moore<sup>8</sup>; <sup>1</sup>TX/US, <sup>2</sup>CO/US, <sup>3</sup>TN/US, <sup>4</sup>PA/US, <sup>5</sup>FL/US, <sup>6</sup>NC/US, <sup>7</sup>CA/US, <sup>8</sup>Oklahoma/US

- 12:30 - 12:30 952P - Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial  
J. KORACH<sup>1</sup>, G. Freyer<sup>2</sup>, S. Banerjee<sup>3</sup>, R. Asher<sup>4</sup>, J. Cosin<sup>5</sup>, A. Oza<sup>6</sup>, A. Poveda<sup>7</sup>, M. Di Napoli<sup>8</sup>, C. Scott<sup>4</sup>, M. Lapresa<sup>8</sup>, F. Heitz<sup>9</sup>, K. Takehara<sup>10</sup>, G. Sonke<sup>11</sup>, S. Tjulandin<sup>12</sup>, J.-W. Kim<sup>13</sup>, R. Hegg<sup>14</sup>, I. Vergote<sup>15</sup>, S. Turner<sup>3</sup>, E. Pujade-Lauraine<sup>16</sup>; <sup>1</sup>IL, <sup>2</sup>CEDEX/FR, <sup>3</sup>GB, <sup>4</sup>AU, <sup>5</sup>CT/US, <sup>6</sup>Ontario/CA, <sup>7</sup>ES, <sup>8</sup>IT, <sup>9</sup>DE, <sup>10</sup>JP, <sup>11</sup>NL, <sup>12</sup>RU, <sup>13</sup>KP, <sup>14</sup>SP/BR, <sup>15</sup>BE, <sup>16</sup>CEDEX 4/FR
- 12:30 - 12:30 953P - the impact of lymph node dissection on high risk versus low risk endometrial cancer  
C. ZHANG, A. Soochit, J. Liu; CN
- 12:30 - 12:30 954P - HOXA9 methylation in circulating tumor DNA as a prognostic biomarker in BRCA-mutated ovarian cancer patients treated with PARP inhibitor  
M. Rusan, R. Fredslund Andersen, A. Jakobsen, K. Steffensen; DK
- 12:30 - 12:30 955P - Prevalence and clinical implications of Mismatch Repair (MMR) deficiency in unselected endometrial cancer (EC) patients  
C. Orbegoso Aguilar, K. Vroobel, S. Lalondrelle, A. Taylor, M. Nobbenhuis, A. Attygalle, S. Banerjee, A. George; GB
- 12:30 - 12:30 956P - A Phase Ib and Randomised Phase II Trial of Pazopanib with or without Fosbretabulin in Advanced Recurrent Ovarian Cancer  
R. Morgan<sup>1</sup>, G. Jayson<sup>1</sup>, S. Banerjee<sup>1</sup>, A. Clamp<sup>1</sup>, A. Lyon<sup>1</sup>, W.D. Ryder<sup>1</sup>, R. Hutson<sup>1</sup>, N. Mescallado<sup>1</sup>, C. Orbegoso Aguilar<sup>1</sup>, S. Taylor<sup>1</sup>, J. Tugwood<sup>1</sup>, M. Hall<sup>2</sup>, C. Dive<sup>1</sup>, G. Rustin<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>Middlesex/GB
- 12:30 - 12:30 957P - Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy  
J.-Y. Lee, S. Paik; KR
- 12:30 - 12:30 958P - Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from Phase 1 cohorts  
D. Rischin<sup>1</sup>, M. Gil-Martin<sup>2</sup>, A. González-Martín<sup>2</sup>, I. Brana<sup>2</sup>, J. Hou<sup>3</sup>, D. Cho<sup>3</sup>, G. Falchook<sup>4</sup>, S. Formenti<sup>4</sup>, S. Jabbour<sup>5</sup>, K. Moore<sup>6</sup>, A. Naing<sup>7</sup>, K. Papadopoulos<sup>7</sup>, J. Baranda<sup>8</sup>, A. Weise<sup>9</sup>, M. Fury<sup>4</sup>, M. Feng<sup>4</sup>, J. Li<sup>4</sup>, I. Lowy<sup>4</sup>, M. Mathias<sup>4</sup>; <sup>1</sup>AU, <sup>2</sup>ES, <sup>3</sup>NY/US, <sup>4</sup>US, <sup>5</sup>NJ/US, <sup>6</sup>OK/US, <sup>7</sup>TX/US, <sup>8</sup>KS/US, <sup>9</sup>MI/US
- 12:30 - 12:30 959P - Molecular profiles as a function of treatment response/progression free survival in a prospective cervical cancer study (RAIDs)  
S. Scholl<sup>1</sup>, L. De Koning<sup>2</sup>, M. Popovic<sup>3</sup>, D.L.R. Anne<sup>1</sup>, A. Floquet<sup>4</sup>, E. Berns<sup>5</sup>, G. Kenter<sup>5</sup>, A. Kereszt<sup>6</sup>, E. Girard<sup>1</sup>, H. von der Leyen<sup>7</sup>, S. Dureau<sup>1</sup>, V. Fouchotte<sup>1</sup>, R. Rouzier<sup>1</sup>, M. Kamal<sup>1</sup>, R. Consortium<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 10/FR, <sup>3</sup>RS, <sup>4</sup>CEDEX/FR, <sup>5</sup>NL, <sup>6</sup>HU, <sup>7</sup>DE
- 12:30 - 12:30 960P - Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma: safety, clinical activity, and immunologic correlates  
C.H. Choi, H.J. Choi, J.-W. Lee, E.-S. Kang, D. Cho, Y.-M. Kim, D. Kim, H. Seo, M. Park, W. Kim, T. Oh, C.-Y. Kang, B.-G. Kim; KR

- 12:30 - 12:30 961P - Risk of secondary hematological malignancies and hematological toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance  
K. Thein<sup>1</sup>, A. Sultan<sup>2</sup>, M. Zaw<sup>3</sup>, M. Han<sup>2</sup>, R. Yendala<sup>2</sup>, M. Zin<sup>3</sup>, S. Awasthi<sup>2</sup>, N. D'Cunha<sup>2</sup>, F. Hardwicke<sup>2</sup>, C. Jones<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>NY/US
- 12:30 - 12:30 962P - Indicators of non-participation in cervical cancer screening: results from the EDIFICE 6 survey  
T. de La Motte Rouge<sup>1</sup>, S. Couraud<sup>2</sup>, F. Eisinger<sup>3</sup>, M. Roupret<sup>1</sup>, L. Brignoli-Guibaudet<sup>1</sup>, C. Lhomel<sup>1</sup>, L. Greillier<sup>1</sup>, J. Viguier<sup>1</sup>, J.F. Morère<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR
- 12:30 - 12:30 963P - A Phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: updated analysis of full cervical expansion cohort  
N. Concin<sup>1</sup>, I. Vergote<sup>2</sup>, U. Lassen<sup>3</sup>, Y. Drew<sup>4</sup>, J.-P. Machiels<sup>2</sup>, H.-T. Arkenau<sup>4</sup>, M. Forster<sup>5</sup>, R. Jones<sup>4</sup>, M. Johnson<sup>6</sup>, B. Slomovitz<sup>7</sup>, J. Spicer<sup>4</sup>, N. Cornez<sup>2</sup>, C. Gennigens<sup>2</sup>, R. Coleman<sup>8</sup>, K. Windfeld<sup>3</sup>, S. Ghatta<sup>1</sup>, R. Rangwala<sup>9</sup>, D. Hong<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>BE, <sup>3</sup>DK, <sup>4</sup>GB, <sup>5</sup>London/GB, <sup>6</sup>TN/US, <sup>7</sup>FL/US, <sup>8</sup>TX/US, <sup>9</sup>NJ/US
- 12:30 - 12:30 964P - Preoperative C-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer  
E.I. Braicu<sup>1</sup>, J. Sehouli<sup>1</sup>, R. Richter<sup>1</sup>, I. Vergote<sup>2</sup>, N. Concin<sup>2</sup>, E. van Nieuwenhuysen<sup>2</sup>, P. Achimas<sup>3</sup>, A. Berger<sup>4</sup>, B. Fetica<sup>3</sup>, S. Mahner<sup>1</sup>, J. Glajzer<sup>1</sup>, P. Andrea<sup>5</sup>, L. Woelber<sup>1</sup>, G. Maria Luisa<sup>5</sup>, A. Vanderstichele<sup>2</sup>, P. Benedetti Panici<sup>6</sup>, M. Mueller<sup>5</sup>, I. Ruscito<sup>1</sup>, J. Zimmer<sup>1</sup>, H. Wopen<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>BE, <sup>3</sup>RO, <sup>4</sup>AT, <sup>5</sup>CH, <sup>6</sup>IT
- 12:30 - 12:30 965P - Prognostic factors in patients with uterine leiomyosarcoma: A multiinstitutional retrospective study from the Japanese Gynecologic Oncology Group  
K. Takehara<sup>1</sup>, N. Yamashita<sup>1</sup>, T. Motohashi<sup>1</sup>, K. Harano<sup>2</sup>, T. Nakanishi<sup>1</sup>, H. Tokunaga<sup>1</sup>, N. Susumu<sup>1</sup>, Y. Ueda<sup>1</sup>, Y. Yokoyama<sup>1</sup>, Y. Watanabe<sup>1</sup>, R. Watanabe<sup>1</sup>, N. Teramoto<sup>1</sup>, H. Tsuda<sup>1</sup>, T. Saito<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Kanagawa/JP
- 12:30 - 12:30 966P - Screening for inherited cancer syndromes in Chinese patients with endometrial cancer  
H. Wang<sup>1</sup>, W. Tian<sup>1</sup>, R. Bi<sup>1</sup>, Y. Ren<sup>1</sup>, H. He<sup>1</sup>, S. Shi<sup>1</sup>, B. Shan<sup>1</sup>, Q. Wang<sup>2</sup>; <sup>1</sup>CN, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 967P - Clinical relevance of circulating MACC1 and S100A4 transcripts in serum of ovarian cancer patients  
P. Wimberger, T. Link, P. Herrmann, D. Kobelt, Y. Vassileva, F. Kerstin, J. Kuhlmann, U. Stein; DE
- 12:30 - 12:30 968P - Outcomes of Ovarian Clear Cell Carcinoma (OCCC) of the Vall d'Hebron Hospital/Vall d'Hebron Institute of Oncology (VHIO)  
F. Amair Pinedo, L. Fariñas-Madrid, V. Rodriguez Freixinos, F.J. Ros Montañá, G. Villacampa, R. Dienstmann, A. Oaknin; ES
- 12:30 - 12:30 969P - A systematic review and meta- analysis of randomized controlled trials to evaluate the risk of gastrointestinal and hepatic toxicities in patients with recurrent ovarian cancer treated with poly adenosine diphosphate ribose polymerase inhibitors maintenance  
K. Thein<sup>1</sup>, A. Sultan<sup>2</sup>, M. Zaw<sup>3</sup>, M. Han<sup>2</sup>, A. Hein<sup>3</sup>, H. Aung<sup>3</sup>, S. Awasthi<sup>2</sup>, C. Jones<sup>2</sup>, F. Hardwicke<sup>2</sup>, N. D'Cunha<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>NY/US

- 12:30 - 12:30 970P - Evaluation of Chemotherapy Response Score and lymphocytic infiltration as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.  
M. Liontos<sup>1</sup>, M. Sotiropoulou<sup>2</sup>, M. Kaparelou<sup>2</sup>, K. Tzannis<sup>2</sup>, G. Tsironis<sup>1</sup>, A. Kyriazoglou<sup>3</sup>, A. Tsiara<sup>2</sup>, R. Zakopoulou<sup>4</sup>, K. Koutsoukos<sup>1</sup>, F. Zagouri<sup>2</sup>, D. Vlachos<sup>2</sup>, N. Thomakos<sup>2</sup>, D. Haidopoulos<sup>2</sup>, A. Rodolakis<sup>2</sup>, M. Dimopoulos<sup>1</sup>, A. Bamias<sup>1</sup>; <sup>1</sup>Attiki/GR, <sup>2</sup>GR, <sup>3</sup>Athens/GR, <sup>4</sup>Attica/GR
- 12:30 - 12:30 971P - Embryonic protein Nodal as a novel marker of progression and drug resistance in ovarian cancer  
O. Bilyk<sup>1</sup>, L. Lee<sup>2</sup>, N. Le<sup>3</sup>, L. Cook<sup>4</sup>, M. Koebel<sup>1</sup>, L. Postovit<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>AB/CA, <sup>3</sup>BC/CA, <sup>4</sup>NM/US
- 12:30 - 12:30 972P - Bcl-2 proteins expression and response to Navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)  
P.E. Brachet<sup>1</sup>, F. Joly Lobbedez<sup>2</sup>, M. Fabbro<sup>2</sup>, A. Leary<sup>1</sup>, J. Medioni<sup>1</sup>, P. Follana<sup>3</sup>, A.F. Lesoin<sup>4</sup>, J.-S. Frenel<sup>4</sup>, S. Abadie Lacourtoisie<sup>1</sup>, A. Floquet<sup>4</sup>, L. Gladieff<sup>5</sup>, B. You<sup>4</sup>, C. Gavoille<sup>4</sup>, E. Kalbacher<sup>4</sup>, M. Briand<sup>1</sup>, P.A. Just<sup>1</sup>, C. Blanc-Fournier<sup>1</sup>, F. Giffard<sup>1</sup>, B. Clarisse<sup>2</sup>, L. Poulain<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>CEDEX 2/FR, <sup>4</sup>CEDEX/FR, <sup>5</sup>CEDEX 3/FR
- 12:30 - 12:30 973P - Expression of CD4, CD8 and Foxp3 and its clinical significance in neoadjuvant chemotherapy for locally advanced cervical cancer  
X. Yin, CN
- 12:30 - 12:30 974P - Clinical study on the efficacy of apatinib treatment for advanced ovarian cancer after second-line chemotherapy failure  
S. Sun, D. Zhai, C. Yu; CN
- 12:30 - 12:30 975P - Clear Cell Ovarian Cancer (CCOC): Predicting Risk of Relapse (ROR)  
M.-J. Devlin<sup>1</sup>, J. Ledermann<sup>2</sup>, M. Lockley<sup>1</sup>, N. Wilkinson<sup>1</sup>, J. McDermott<sup>1</sup>, R. Kristeleit<sup>1</sup>, R. Miller<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>London/GB
- 12:30 - 12:30 976P - Comparison of PARPi with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: a network meta-analysis  
Y. Feng, J. Liu, H. Huang, C. ZHANG, T. Wan, C. Tong, T. Deng, H. Tu, Y. Huang, G. Liu, Q. Huang, Z. Liu; CN
- 12:30 - 12:30 977P - The role of Bevacizumab plus Front-line Chemotherapy in patients with malignant ascites of Ovarian cancer  
M. Nikolaou, N. Ziras, I. Athanasiadis, A. Ardavanis, M. Vaslamatzis, N. Kentepozidis, P. Makrantonakis, A. Christopoulou, V. Michalaki, A. Polizos, C. Emmanouilidis, V. Georgoulas; GR
- 12:30 - 12:30 978P - Quality of life in newly diagnosed patients with cervical cancer in Brazil: results of EVITA study (EVA/LACOG 0215).  
A. Nogueira-Rodrigues, A. de Melo, A. Calabrich, E. Cronenberger, K. Torres, F. Damian, R. Cossetti, C. De Azevedo, A. da Fonseca, Y. Nerón, J. Nunes, A. Lopes, F. Thomé, R. Leal, G. Borges, P.R. Nunes Filho, F. Zaffaroni Caorsi, R. Freitas, G. Werutsky, F. Maluf; BR
- 12:30 - 12:30 979P - Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort  
J. Chan, S.H. Tan, T.W. Lim, T. Tan, W.Y. Chay, E. Lim, L.T. Soh, S.L. Lim, J. Chia; SG

- 12:30 - 12:30 980P - Genomic characterization of vulvar squamous cell carcinoma  
K. Prieske, M. Alawi, S.A. Joosse, K. Eylmann, E. Burandt, B. Schmalfeldt, L. Oliveira-Ferrer, L. Woelber; DE
- 12:30 - 12:30 981P - Economic and Humanistic Burden of Cervical Cancer in the United States  
C. Nwankwo, R. Shah, Y. Kwon, S. Corman; US
- 12:30 - 12:30 982P - Risk of fatigue and neuropathy in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials  
V. Ruiz-Schutz<sup>1</sup>, L. Gomes<sup>1</sup>, C. Oliveira<sup>1</sup>, R. Mariano<sup>1</sup>, D. Almeida<sup>1</sup>, J. Pimenta<sup>1</sup>, G. Dal Molin<sup>2</sup>, F. Kater<sup>3</sup>, R. Yamamura<sup>3</sup>, F. Maluf<sup>1</sup>, F. Schutz<sup>3</sup>; <sup>1</sup>BR, <sup>2</sup>TX/US, <sup>3</sup>SP/BR
- 12:30 - 12:30 983P - Risk of cancer associated death in younger vs. older patients with FIGO stage I endometrial cancer  
J. Ko<sup>1</sup>, B. Lester<sup>2</sup>, G. Bowering<sup>3</sup>, C. Rugayan<sup>3</sup>, I. Ghement<sup>2</sup>, K. Aalok<sup>3</sup>; <sup>1</sup>British Columbia/CA, <sup>2</sup>CA, <sup>3</sup>BC/CA
- 12:30 - 12:30 984P - Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)  
M. Hall<sup>1</sup>, G. Bertelli<sup>2</sup>, L. Li<sup>2</sup>, C. Green<sup>2</sup>, S. Chan<sup>2</sup>, C.C. Yeoh<sup>2</sup>, J. Hasan<sup>2</sup>, A. Ograbek<sup>2</sup>, T. Perren<sup>3</sup>; <sup>1</sup>Middlesex/GB, <sup>2</sup>GB, <sup>3</sup>Yorkshire/GB
- 12:30 - 12:30 985P - Prolonged Survival (SV) Associated with Pulmonary Metastasectomy (PM) for Carcinomas of the Cervix (CC)  
J. Corona-Cruz<sup>1</sup>, A. Castillo-Castañón<sup>1</sup>, C. Deneken<sup>2</sup>, L. Ramirez-Tirado<sup>1</sup>, A. Gonzalez-Enciso<sup>1</sup>, D. Gallardo-Rincon<sup>1</sup>, E. Jimenez-Fuentes<sup>1</sup>, O. Arrieta<sup>2</sup>; <sup>1</sup>MX, <sup>2</sup>Tlalpan. D.F./MX
- 12:30 - 12:30 986P - Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort  
J. Gallagher<sup>1</sup>, K. Heap<sup>2</sup>, S. Carroll<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>SC/US
- 12:30 - 12:30 987P - Trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First results of an observational, prospective study  
S. Pignata<sup>1</sup>, G. Scambia<sup>1</sup>, T. Mazzei<sup>1</sup>, M. Arruti Barbia<sup>2</sup>, E. Naglieri<sup>1</sup>, L.M. de Sande<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>ES
- 12:30 - 12:30 988P - Benefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM).  
F.J. Ros Montañá, V. Rodriguez Freixinos, L. Fariñas Madrid, F. Amair Pinedo, F. Ruiz-Pace, E. Garralda, R. Dienstmann, A. Oaknin; ES
- 12:30 - 12:30 989P - Identification research and application for protein phosphorylation modification sites in human ovarian carcinoma  
X. Zhan, N. Li; CN

- 12:30 - 12:30 990P - Enhancing prognosis prediction using nodal SUVmax and HPV status in cervical squamous cell carcinoma  
S.Y. Jeong, G.O. Chong, C.M. Hong; KR
- 12:30 - 12:30 991P - Clinical characteristics of ovarian cancer relapse in BRCA1/2 germ-line mutation carriers and non-carriers  
A. Sokolenko, T. Gorodnova, A. Ivantsov, I. Berlev, E. Imyanitov; RU
- 12:30 - 12:30 992P - Phase Ib study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.  
K. Broekman, A. Reyners, D. Touw, M. Hof, M. Jalving; NL
- 12:30 - 12:30 993P - Individual and Familial Phenotype in Hereditary Ovarian Cancer  
M.B. Mira, I. Miguel, S. Fragoso, A. Opinião, A.C. Luís, A. Clara, S. Bento, P. Machado, S. Santos, P. Rodrigues, J. Parreira, F. Vaz; PT
- 12:30 - 12:30 Gynaecological cancers
- 12:30 - 12:30 994P - Role of FGFR2 amplification in prognosis of patients with ovarian cancer  
A. Tyulyandina, I. Demidova, M. Gikalo, S. Tjulandin, I. Tsimafeyeu; RU
- 12:30 - 12:30 995P - MONITOR VII – Treatment Strategies of Low grade Ovarian Carcinomas – A German survey of the Charité – Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO  
S. Alavi, P. Harter, R. Richter, M. Keller, G. Oskay-Özcelik, A. Mustea, B. Schmalfeldt, P. Wimberger, F. Trillsch, S. Mahner, M. Klar, U. Wagner, R. Chekerov, A. du Bois, J. Sehouli; DE
- 12:30 - 12:30 996P - The ability of whole body SUVmax on F-FDG PET/CT in predicting suboptimal cytoreduction at primary debulking surgery in advanced ovarian cancer  
G.O. Chong, S.Y. Jeong, S.-W. Lee; KR
- 12:30 - 12:30 997P - Brain metastasis in ovarian cancer patients  
A.A. da Costa<sup>1</sup>, E. Dos Santos<sup>2</sup>, L. de Brot<sup>1</sup>, A. Ribeiro<sup>1</sup>, D. Cotrim<sup>1</sup>, N. Carvalho Pandolfi<sup>1</sup>, M. Cesca<sup>1</sup>, M. Chen<sup>1</sup>, G. Baiocchi<sup>1</sup>; <sup>1</sup>BR, <sup>2</sup>SP/BR
- 12:30 - 12:30 998TiP - Pamiparib, a Novel PARP 1/2 Inhibitor, Monotherapy for gBRCAm Patients with Recurrent Ovarian, Fallopian, and Primary Peritoneal Cancer: an Open-label, Multicenter, Phase 2 trial in China  
X. Wu<sup>1</sup>, J. Wang<sup>1</sup>, Q. Zhou<sup>1</sup>, T. Gu<sup>1</sup>, K. Zhang<sup>2</sup>, J. Liang<sup>1</sup>, S. Mu<sup>3</sup>, R. Ge<sup>1</sup>, H. Yang<sup>1</sup>, V. Huang<sup>2</sup>, R. Brachmann<sup>2</sup>, L. Wang<sup>1</sup>, M. Li<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>CA/US, <sup>3</sup>NJ/US
- 12:30 - 12:30 999TiP - OVARIO: A single-arm, open-label phase 2 study of maintenance therapy with niraparib + bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo)  
M. Hardisty<sup>1</sup>, J. Hope<sup>1</sup>, T. Krivak<sup>2</sup>, J. Chen<sup>2</sup>, M. Wainszelbaum<sup>2</sup>, D. Gupta<sup>2</sup>, D. Richardson<sup>2</sup>; <sup>1</sup>AK/US, <sup>2</sup>US

- 12:30 - 12:30 1000TiP - OPINION: A single-arm, open-label, phase 3b study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm)  
A. Poveda<sup>1</sup>, R. Davidson<sup>2</sup>, C. Blakeley<sup>2</sup>, A. Milner<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>GB
- 12:30 - 12:30 1001TiP - A phase 2 clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer  
A. Wahner Hendrickson<sup>1</sup>, B. Costello<sup>1</sup>, A. Jewell<sup>2</sup>, V. Kennedy<sup>3</sup>, G. Fleming<sup>4</sup>, B. Corr<sup>5</sup>, S. Taylor<sup>6</sup>, J. Lea<sup>7</sup>, J. Reid<sup>1</sup>, E. Swisher<sup>1</sup>, D. Satele<sup>1</sup>, J. Allred<sup>1</sup>, J. Lensing<sup>1</sup>, S.P. Ivy<sup>8</sup>, C. Erlichman<sup>1</sup>, A.A. Adjei<sup>9</sup>, S. Kaufmann<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>KS/US, <sup>3</sup>CA/US, <sup>4</sup>IL/US, <sup>5</sup>CO/US, <sup>6</sup>PA/US, <sup>7</sup>TX/US, <sup>8</sup>MD/US, <sup>9</sup>MN/US
- 12:30 - 12:30 1002TiP - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib with continuous schedule vs. cediranib-olaparib with intermittent schedule in advanced platinum resistant ovarian cancer  
N. Colombo<sup>1</sup>, O. Nicoletto<sup>1</sup>, P. Benedetti Panici<sup>1</sup>, G. Tognon<sup>1</sup>, A.A. Lissoni<sup>1</sup>, A. Bologna<sup>1</sup>, F. Tomao<sup>1</sup>, R. Fossati<sup>1</sup>, F. Tettamanzi<sup>1</sup>, E. Rulli<sup>1</sup>, F. Galli<sup>1</sup>, M.F. Alvisi<sup>1</sup>, V. Torri<sup>2</sup>, E. Biagioli<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>NA
- 12:30 - 12:30 1003TiP - Neoadjuvant chemotherapy and radical surgery versus chemorradiation for stage IB2, IIA2 e IIB cervical cancer: a randomized controlled trial  
P. Reis Filho<sup>1</sup>, J. Andrade<sup>1</sup>, M. Batista<sup>1</sup>, C. Sousa<sup>1</sup>, T. Oliveira<sup>1</sup>, G. Arruda<sup>1</sup>, T. Oliveira<sup>1</sup>, F. Gabrielli<sup>1</sup>, M.L. Genta<sup>1</sup>, A. Poveda<sup>2</sup>, M. Estevez Diz<sup>1</sup>, F.J. Candido Dos Reis<sup>1</sup>; <sup>1</sup>BR, <sup>2</sup>ES
- 12:30 - 12:30 Haematological malignancies
- 12:30 - 12:30 1017P - Estimating the Incidence of Cryptogenic Organising Pneumonia in Chronic Lymphocytic Leukaemia Patients: A Real-World Cohort Study  
I. Faghmous, H. Ramroth, C. Aguilar, A. Van Troostenburg, P. Badyal; GB
- 12:30 - 12:30 1018P - Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death  
S. Clara<sup>1</sup>, A. Lok<sup>1</sup>, T. Gastinne<sup>1</sup>, B. Mahé<sup>1</sup>, V. Dubruille<sup>1</sup>, N. Blin<sup>1</sup>, S. Howlett<sup>2</sup>, A. Tabah<sup>2</sup>, P. Arnaud<sup>3</sup>, A. Moreau<sup>1</sup>, P. Moreau<sup>1</sup>, C. Leux<sup>1</sup>, S. Le Gouil<sup>4</sup>; <sup>1</sup>FR, <sup>2</sup>NJ/US, <sup>3</sup>CEDEX 18/FR, <sup>4</sup>CEDEX 1/FR
- 12:30 - 12:30 1019P - Impact of genetic polymorphisms on prognosis and survival of diffuse large B-cell lymphoma  
O. Novosad, I. Pastushenko, T. Skrypets, I. Tytorenko, T. Kadnikova, O. Skachkova, O. Gorbach, N. Svergun, N. Khranovska, I. Kriachok; UA
- 12:30 - 12:30 Clinical-radiological features of Methotrexate induced sub-acute leukoencephalopathy in patients with Acute lymphoblastic leukemia: Incremental value of diffusion weighted magnetic resonance imaging.  
T. Vaidya, A. Mahajan, H. Jain, V. Simha, M. Sengar, S. Kumar; IN
- 12:30 - 12:30 1021P - Long term treatment outcome of patients with refractory or relapsed Hodgkin's lymphoma in the anthracycline era: a single-center intention-to-treat analysis  
T. Bogatyreva<sup>1</sup>, A. Terekhova<sup>2</sup>, S. Shklyayev<sup>2</sup>, V. Pavlov<sup>2</sup>, N. Falaleeva<sup>2</sup>; <sup>1</sup>Kalujskaya oblast/RU, <sup>2</sup>RU

- 12:30 - 12:30 1022P - Population-based use of intravenous bisphosphonates in patients newly diagnosed with symptomatic multiple myeloma in Denmark in 2005-2015: impact of patient characteristics  
V. Ehrenstein<sup>1</sup>, A. Ording<sup>1</sup>, S. Ulrichsen<sup>1</sup>, I. Andersen<sup>1</sup>, A. Seesagur<sup>2</sup>, C. Helleberg<sup>1</sup>, T. Silkjær<sup>1</sup>, R. Hernandez<sup>3</sup>, D. Niepel<sup>4</sup>, N. Abildgaard<sup>1</sup>; <sup>1</sup>DK, <sup>2</sup>GB, <sup>3</sup>CA/US, <sup>4</sup>CH
- 12:30 - 12:30 1023P - Role of Liposomal Doxorubicin as a first line agent with VTd regimen in newly diagnosed Multiple Myeloma  
M. Khanderia, G. Badarkhe, S. Bj, R. Naik; IN
- 12:30 - 12:30 1024P - The  $\beta$ 2-microgloulin Is Associated with the Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified  
B.S. Sohn, S.-N. Lim, J. Kim, D.H. Yoon, S. Kim, J. Huh, S.-E. Park, Y.J. Yuh, C. Suh; KR
- 12:30 - 12:30 1026P - Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.  
S. dote, K. Ito, S. Itakura, T. Yasu, D. Hira, S. Noda, S. Yamada, Y. Kobayashi, T. Terada; JP
- 12:30 - 12:30 1027P - The significance of FMS-Like Tyrosine Kinase 3 surface receptor expression in acute myeloblastic leukemia and precursor B-acute lymphoblastic leukemia patients  
S. Al Hassanin<sup>1</sup>, I. Ahmedy<sup>2</sup>; <sup>1</sup>Menoufia Governorate/EG, <sup>2</sup>EG
- 12:30 - 12:30 1028P - Prognostic factors of clinical use in acute myeloid leukemia  
P. Chorão, N. Tavares, E. Aguiar, M. Amorim, P. Gomes, F. Príncipe, J. Guimarães; PT
- 12:30 - 12:30 1029P - Frequency and clinical impact of compound mutation in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitor  
S. BONECKER, M. Carneiro, M. Bonamino, I. Zalberg; BR
- 12:30 - 12:30 1030P - Poor outcome of double-protein expressor diffuse large B-cell lymphoma  
E. Kharchenko, T. Semiglavova, A. Artemeva, V. Kushnarev, P. Shilo; RU
- 12:30 - 12:30 1031P - Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil.  
S.-N. Lim, B.S. Sohn, H.-J. Shin, C. Suh, W.S. Kim, W.S. Lee, J.S. Kim; KR
- 12:30 - 12:30 1032P - The impact of serum microRNA-21 on outcome of diffuse large B-cell lymphoma patients  
S. Gohar<sup>1</sup>, S. Kamal Eldin<sup>2</sup>, F. El-Bassal<sup>2</sup>, A. Shehata<sup>2</sup>, A. Azzam<sup>2</sup>, E. Tawfik<sup>2</sup>, S. Al Hassanin<sup>1</sup>; <sup>1</sup>Menoufia Governorate/EG, <sup>2</sup>EG
- 12:30 - 12:30 1033P - Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: subgroup analysis from the BELA trial  
H. Malhotra<sup>1</sup>, A. Maru<sup>1</sup>, N. Khattry<sup>1</sup>, M. Ramanan<sup>1</sup>, E. Leip<sup>2</sup>, R. Crescenzo<sup>3</sup>, C. Gambacorti-Passerini<sup>4</sup>, J. Cortes<sup>2</sup>; <sup>1</sup>IN, <sup>2</sup>US, <sup>3</sup>PA/US, <sup>4</sup>IT
- 12:30 - 12:30 1034P - A Prospective Multicenter Study of Primary Breast Lymphoma in the rituximab era: prognostic implication of beta 2 microglobulin and interleukin-6 & interleukin-10



L. Ezz Elarab<sup>1</sup>, E. Hamada<sup>1</sup>, A. Mostafa<sup>1</sup>, A. Saber<sup>1</sup>, M. Abdel-Gawad<sup>1</sup>, R. Haggag<sup>2</sup>, H. Darwish<sup>1</sup>, S. Elhassanin<sup>1</sup>, M. Swellam<sup>1</sup>; <sup>1</sup>EG, <sup>2</sup>EI Sharkia/EG

- 12:30 - 12:30 1035P - Experience in treatment of newly diagnosed multiple myeloma patients with renal failure required dialysis  
S. Semochkin, E. Zhelnova, E. Misyurina, T. Tolstykh, N. Arkhipova, E. Baryakh, E. Grishina, E. Karimova, O. Kochneva, E. Mavrina, Y. Polyakov, E. Yaskova; RU
- 12:30 - 12:30 1036P - Immunohistochemical (IHC) classification of DLBCL into CGB and non-CGB subtypes to predict survival after chemoimmunotherapy, at the Virgen de la Victoria University Hospital  
L. Galvez Carvajal, C. Quero Blanco, M. Robles Lasarte, I. Moreno Perez, L. Vicioso, I. Ramos Garcia, C. Bandera Lopez, J. Baena Espinar, C. Ithurbisquy, E. Alba; ES
- 12:30 - 12:30 1037P - Quality of life evaluation in acute leukemia patients receiving induction chemotherapy  
T. Lymanets, I. Skrypnik, G. Maslova, I. Gusachenko; UA
- 12:30 - 12:30 1038P - PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin Lymphoma.  
T. Skrypets<sup>1</sup>, O. Novosad<sup>1</sup>, I. Pastushenko<sup>1</sup>, T. Kadnikova<sup>1</sup>, O. Gorbach<sup>1</sup>, Y. Kmetiyuk<sup>1</sup>, O. Karpova<sup>1</sup>, L. Mykhalska<sup>1</sup>, E. Lukjanec<sup>1</sup>, V. Kozlov<sup>1</sup>, N. Novikov<sup>1</sup>, O. Oliinichenko<sup>1</sup>, N. Kostiukova<sup>1</sup>, O. Tkachenko<sup>1</sup>, O. Karnabeda<sup>2</sup>, V. Stratienco<sup>1</sup>, I. Kriachok<sup>1</sup>; <sup>1</sup>UA, <sup>2</sup>Kiev region/UA
- 12:30 - 12:30 1039P - Assessment to predict survival and risk of progression in patients with newly multiple myeloma in different age groups.  
I. Kriachok, O. Novosad, K. Ulianchenko, T. Skrypets, T. Kadnikova; UA
- 12:30 - 12:30 1040P - Impact of Bisphosphonate and Anti-myeloma therapy on Bone Turnover Markers in Multiple Myeloma  
A. JANDIAL, S. H J, K. Mishra, S. Bhadada, A. Sood, M. Prakash, A. Meshram, R. Sandal, D. Lad, R. Aggarwal, G. Prakash, S. Vikas, A. Khadwal, S. Kumari, N. Varma, S. Varma, P. Malhotra; IN
- 12:30 - 12:30 1041P - Assesment of bleeding risk by Sonoclot in Acute Lymphoblastic Leukemia  
K. Mishra, A. JANDIAL, A. Meshram, R. Sandal, D. Lad, G. Prakash, A. Khadwal, R. Dhiman, N. Varma, S. Varma, P. Malhotra; IN
- 12:30 - 12:30 1042P - Clinically Actionable Mutations Identified in Korean Patients with High-Risk Acute Lymphoblastic Leukemia  
K.-J. Park, I.-S. Kim; KR
- 12:30 - 12:30 1043TiP - A phase IIA dose optimization study of ASLAN003 in acute myeloid leukemia (AML)  
C.H. Ng<sup>1</sup>, S. Ting<sup>2</sup>, W. Hwang<sup>1</sup>, A. Bajel<sup>3</sup>, R. Eek<sup>3</sup>, M. McHale<sup>1</sup>, H.-J. Shih<sup>4</sup>, N. McIntyre<sup>1</sup>, J. Kwek<sup>1</sup>, B. Lindmark<sup>1</sup>; <sup>1</sup>SG, <sup>2</sup>AT, <sup>3</sup>AU, <sup>4</sup>TW
- 12:30 - 12:30 Immunotherapy of cancer
- 12:30 - 12:30 1143P - Responses and Durability of Clinical Benefit in Pancreatic Ductal Adenocarcinoma (PDAC) Patients Treated With Pegilodecakin (AM0010) in Combination With 5-FU/LV and Oxaliplatin (FOLFOX)

J.R. Hecht<sup>1</sup>, A. Naing<sup>2</sup>, G. Falchook<sup>3</sup>, M. Patel<sup>4</sup>, R. Aljumaily<sup>5</sup>, D. Wong<sup>3</sup>, K. Autio<sup>6</sup>, Z. Wainberg<sup>3</sup>, M. Javle<sup>2</sup>, J. Bendell<sup>7</sup>, S. Pant<sup>5</sup>, A. Hung<sup>1</sup>, M. Oft<sup>1</sup>, J. Leveque<sup>1</sup>, K. Papadopoulos<sup>2</sup>; <sup>1</sup>CA/US, <sup>2</sup>TX/US, <sup>3</sup>US, <sup>4</sup>MN/US, <sup>5</sup>OK/US, <sup>6</sup>NY/US, <sup>7</sup>TN/US

- 12:30 - 12:30 1144P - Responses and Durability of Clinical Benefit in Non-Small Cell Lung Cancer Treated with Pegilodecakin in Combination With Anti-PD-1 Inhibitors  
E. Garon<sup>1</sup>, D. Wong<sup>2</sup>, J. Schneider<sup>3</sup>, R. Aljumaily<sup>4</sup>, W.M. Korn<sup>2</sup>, M. Patel<sup>5</sup>, K. Autio<sup>3</sup>, K. Papadopoulos<sup>6</sup>, A. Naing<sup>6</sup>, N. Gabrail<sup>7</sup>, P. Munster<sup>2</sup>, J. Goldman<sup>1</sup>, A. Hung<sup>1</sup>, M. Oft<sup>1</sup>, J. Leveque<sup>1</sup>, D. Spigel<sup>8</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>NY/US, <sup>4</sup>OK/US, <sup>5</sup>MN/US, <sup>6</sup>TX/US, <sup>7</sup>OH/US, <sup>8</sup>TN/US
- 12:30 - 12:30 1145P - Responses and Durability of Clinical Benefit in Triple Negative Breast Cancer Patients Treated with Pegilodecakin Monotherapy or in Combination With Platinum Plus Taxane-Based Chemotherapy  
A. Naing<sup>1</sup>, K. Autio<sup>2</sup>, G. Falchook<sup>3</sup>, F. Meric-Bernstam<sup>1</sup>, J. Litton<sup>3</sup>, N. Ibrahim<sup>1</sup>, A. Hung<sup>4</sup>, M. Oft<sup>4</sup>, J. Leveque<sup>4</sup>, M. Patel<sup>5</sup>; <sup>1</sup>TX/US, <sup>2</sup>NY/US, <sup>3</sup>US, <sup>4</sup>CA/US, <sup>5</sup>MN/US
- 12:30 - 12:30 1146P - Durability of Clinical Benefit in Metastatic Epithelial Ovarian Cancer Patients Treated With Pegilodecakin Monotherapy or in Combination With Platinum Plus Taxane-Based Chemotherapy  
K. Autio<sup>1</sup>, A. Naing<sup>2</sup>, A. Hung<sup>3</sup>, M. Oft<sup>3</sup>, J. Leveque<sup>3</sup>, G. Falchook<sup>4</sup>; <sup>1</sup>NY/US, <sup>2</sup>TX/US, <sup>3</sup>CA/US, <sup>4</sup>US
- 12:30 - 12:30 1147P - Preliminary Results from a Phase 1 Study of GBR 1302, A Bispecific Antibody T-Cell Engager, in HER2 Positive Cancers  
M. Wermke<sup>1</sup>, J. Alt<sup>1</sup>, J. Kauh<sup>2</sup>, J. Back<sup>3</sup>, Y. Salhi<sup>2</sup>, V. Reddy<sup>2</sup>, M. Barve<sup>4</sup>, S. Ochsenreither<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>NJ/US, <sup>3</sup>CH, <sup>4</sup>TX/US
- 12:30 - 12:30 1148P - A phase Ia study of a personalized TSA-CTL (tumor specific antigen-induced cytotoxic T lymphocytes) therapy in metastatic melanoma  
B. Li, S. Qiu; CN
- 12:30 - 12:30 1149P - Safety, Tolerability, and Pharmacokinetics of the OX40 Agonist ABBV-368 in Patients With Advanced Solid Tumors  
A. Spira<sup>1</sup>, K. Chung<sup>2</sup>, A. Patnaik<sup>1</sup>, A. Tolcher<sup>3</sup>, M. Blaney<sup>4</sup>, A. Parikh<sup>4</sup>, A. Reddy<sup>4</sup>, W. Henner<sup>4</sup>, M. McDevitt<sup>4</sup>, D. Afar<sup>4</sup>, J. Powderly<sup>5</sup>; <sup>1</sup>US, <sup>2</sup>SC/US, <sup>3</sup>TX/US, <sup>4</sup>CA/US, <sup>5</sup>NC/US
- 12:30 - 12:30 1150P - Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study  
R. Xu<sup>1</sup>, F.H. Wang<sup>2</sup>, F.J. Feng<sup>2</sup>, Q. Li<sup>2</sup>, N. Xu<sup>2</sup>, X.C. Hu<sup>2</sup>, W.J. Liao<sup>2</sup>, Y. Jiang<sup>2</sup>, X. Lin<sup>2</sup>, Q.Y. Zhang<sup>2</sup>, X.L. Yuan<sup>2</sup>, H.X. Huang<sup>2</sup>, Y. Chen<sup>2</sup>, G.H. Dai<sup>2</sup>, J.H. Shi<sup>2</sup>, L. Shen<sup>2</sup>, C. Ren<sup>2</sup>, H. Wu<sup>2</sup>, H. Feng<sup>2</sup>, S. Yao<sup>2</sup>; <sup>1</sup>Guangdong/CN, <sup>2</sup>CN
- 12:30 - 12:30 1151P - Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a Phase 1 study  
M. Pishvaian<sup>1</sup>, G. Weiss<sup>1</sup>, G. Falchook<sup>1</sup>, N. Yee<sup>1</sup>, M. Gil-Martin<sup>2</sup>, S. Shahda<sup>1</sup>, V. Moreno<sup>2</sup>, I. Brana<sup>2</sup>, M. Crittenden<sup>1</sup>, S. Formenti<sup>1</sup>, R. Al-Rajabi<sup>1</sup>, K. Papadopoulos<sup>3</sup>, E. Stankevich<sup>1</sup>, M. Feng<sup>1</sup>, J. Li<sup>1</sup>, M. Mathias<sup>1</sup>, G. Kroog<sup>1</sup>, I. Lowy<sup>1</sup>, M. Fury<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>ES, <sup>3</sup>TX/US

- 12:30 - 12:30 1152P - Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors  
B. Glisson<sup>1</sup>, R. Leidner<sup>1</sup>, R. Ferris<sup>2</sup>, J. Powderly<sup>3</sup>, N. Rizvi<sup>4</sup>, B. Keam<sup>5</sup>, R. Schneider<sup>6</sup>, S. Goel<sup>1</sup>, J. Ohr<sup>2</sup>, Y. Zheng<sup>7</sup>, S. Eck<sup>7</sup>, M. Gribbin<sup>7</sup>, D. Townsley<sup>7</sup>, V. Chiou<sup>7</sup>, S. Patel<sup>8</sup>; <sup>1</sup>US, <sup>2</sup>PA/US, <sup>3</sup>NC/US, <sup>4</sup>NY/US, <sup>5</sup>KR, <sup>6</sup>TX/US, <sup>7</sup>MD/US, <sup>8</sup>CA/US
- 12:30 - 12:30 1153P - Autologous dendritic-cell vaccine based on cancer-testis antigens "CaTeVac" in the treatment of soft tissue sarcoma  
N. Pipia, I. Baldueva, T. Nekhaeva, A. Novik, A. Danilova, N. Avdonkina, S. Protsenko, Y. Komarov, D. Girduyk, A. Oganessian, A. Belyaev; RU
- 12:30 - 12:30 1154P - A Phase 1 study of MEDI1873, a novel GITR agonist, in advanced solid tumors  
C. Denlinger<sup>1</sup>, J. Infante<sup>2</sup>, R. Aljumaily<sup>3</sup>, A. Naing<sup>4</sup>, A. Chintakuntlawar<sup>5</sup>, N. Rizvi<sup>6</sup>, H. Ross<sup>7</sup>, M. Gordon<sup>7</sup>, R. Kumar<sup>8</sup>, M. Ma<sup>8</sup>, L. Yan<sup>9</sup>, P. Vicini<sup>10</sup>, N. Standifer<sup>9</sup>, J. Cann<sup>8</sup>, A. Perera<sup>10</sup>, N. Durham<sup>8</sup>, S. Krishnan<sup>8</sup>, A. Balmanoukian<sup>9</sup>; <sup>1</sup>US, <sup>2</sup>TN/US, <sup>3</sup>OK/US, <sup>4</sup>TX/US, <sup>5</sup>MN/US, <sup>6</sup>NY/US, <sup>7</sup>AZ/US, <sup>8</sup>MD/US, <sup>9</sup>CA/US, <sup>10</sup>GB
- 12:30 - 12:30 1155P - Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers  
A.-M. Tsimberidou<sup>1</sup>, H. Ma<sup>1</sup>, C. Stewart<sup>2</sup>, O. Schoor<sup>3</sup>, D. Maurer<sup>3</sup>, R. Mendrzyk<sup>3</sup>, A. Satelli<sup>2</sup>, J. Fritsche<sup>3</sup>, G. Stephens<sup>1</sup>, A. Mohamed<sup>1</sup>, P. Hwu<sup>1</sup>, C. Yee<sup>2</sup>, C. Reinhardt<sup>3</sup>, T. Weinschenk<sup>3</sup>, K. Gharpure<sup>1</sup>, A. Stungis<sup>1</sup>, D. Vining<sup>1</sup>, H. Singh<sup>1</sup>, S. Walter<sup>1</sup>, B. Andersson<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>DE
- 12:30 - 12:30 1156P - Initial Safety Assessment of MAGE-A4 SPEAR T-cells  
D. Hong<sup>1</sup>, M. Butler<sup>2</sup>, M. Johnson<sup>3</sup>, A. Olszanski<sup>1</sup>, E. Norry<sup>4</sup>, E. Van Winkle<sup>4</sup>, K. Chagin<sup>1</sup>, R. Amado<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>CA, <sup>3</sup>TN/US, <sup>4</sup>PA/US
- 12:30 - 12:30 1157P - Phase 1 trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms  
J. Spicer, V. Kwatra, C. Verma, K. Ioannou, R. Goldstein, T. Brier, J. Eremin, N. Zareian, L. Walker, D. Lobo, F. Farzaneh, O. Eremin; GB
- 12:30 - 12:30 1158P - Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer  
C. Drescher<sup>1</sup>, K. Moore<sup>2</sup>, J. Liu<sup>3</sup>, D. O'Malley<sup>4</sup>, E. Wang<sup>4</sup>, J. Wang<sup>4</sup>, V. Subbiah<sup>5</sup>, B. Wilky<sup>4</sup>, G. Yuan<sup>4</sup>, C. Dupont<sup>4</sup>, A. Gonzalez<sup>4</sup>, D. Savitsky<sup>4</sup>, S. Coulter<sup>4</sup>, O. Shebanova<sup>4</sup>, E. Dow<sup>4</sup>, W. Ortuzar<sup>3</sup>, J. Buell<sup>4</sup>, R. Stein<sup>4</sup>, H. Youssoufian<sup>4</sup>; <sup>1</sup>WA/US, <sup>2</sup>Oklahoma/US, <sup>3</sup>MA/US, <sup>4</sup>US, <sup>5</sup>TX/US
- 12:30 - 12:30 1159P - Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer  
C.-C. Lin<sup>1</sup>, M. Taylor<sup>2</sup>, V. Boni<sup>3</sup>, P. Brunsvig<sup>4</sup>, S. Geater<sup>5</sup>, S. Salvagni<sup>6</sup>, P. Garrido Lopez<sup>3</sup>, M. Özgüroğlu<sup>7</sup>, V. Sriuranpong<sup>5</sup>, S. Ponce Aix<sup>3</sup>, P. Ascierto<sup>6</sup>, A. Fasolo<sup>6</sup>, A. Sezer<sup>7</sup>, D. Kowalski<sup>8</sup>, J. Faris<sup>9</sup>, S. Cameron<sup>9</sup>, J. Mataraza<sup>9</sup>, H. Wu<sup>2</sup>, V. Antona<sup>10</sup>, M. Ochoa de Olza<sup>3</sup>; <sup>1</sup>TW, <sup>2</sup>US, <sup>3</sup>ES, <sup>4</sup>NO, <sup>5</sup>TH, <sup>6</sup>IT, <sup>7</sup>TR, <sup>8</sup>PL, <sup>9</sup>MA/US, <sup>10</sup>CH

- 12:30 - 12:30 1160P - Phase 1/2 evaluation of intratumoral INT230-6 for the treatment of solid tumors  
A. El-Khoeiry<sup>1</sup>, L. Siu<sup>2</sup>, N. Azad<sup>3</sup>, I. Walters<sup>3</sup>, L. Bender<sup>4</sup>, L. Kamen<sup>4</sup>, A. Olszanski<sup>3</sup>; <sup>1</sup>CA/US, <sup>2</sup>Ontario/CA, <sup>3</sup>US, <sup>4</sup>CT/US
- 12:30 - 12:30 1161P - OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments  
M. Fabre<sup>1</sup>, C. Ferrer<sup>1</sup>, S. Dominguez-Hormaetxe<sup>1</sup>, R. Kontermann<sup>2</sup>, K. Pfizenmaier<sup>2</sup>, O. Seifert<sup>2</sup>, P.P. López-Casas<sup>1</sup>, M. Abbas<sup>3</sup>, W. Richter<sup>3</sup>, L. Simon<sup>1</sup>, M. Hidalgo<sup>4</sup>; <sup>1</sup>ES, <sup>2</sup>DE, <sup>3</sup>AT, <sup>4</sup>MA/US
- 12:30 - 12:30 1162P - Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small-cell lung cancer (NSCLC): Results from a Phase 1 expansion cohort (EC 2)  
V. Moreno<sup>1</sup>, M. Gil-Martin<sup>1</sup>, M. Johnson<sup>2</sup>, R. Aljumaily<sup>3</sup>, P. Lopez Criado<sup>1</sup>, D. Northfelt<sup>4</sup>, M. Crittenden<sup>5</sup>, S. Jabbour<sup>6</sup>, L. Rosen<sup>7</sup>, P. Garrido Lopez<sup>1</sup>, A. Hervás Morón<sup>1</sup>, P. Rietschel<sup>6</sup>, K.K. Mohan<sup>8</sup>, J. Li<sup>5</sup>, E. Stankevich<sup>5</sup>, T. Rowlands<sup>6</sup>, M. Feng<sup>5</sup>, I. Lowy<sup>5</sup>, M. Fury<sup>5</sup>; <sup>1</sup>ES, <sup>2</sup>TN/US, <sup>3</sup>OK/US, <sup>4</sup>AZ/US, <sup>5</sup>US, <sup>6</sup>NJ/US, <sup>7</sup>CA/US, <sup>8</sup>NY/US
- 12:30 - 12:30 1163P - Study on Treatment of Stage IV Solid Tumors with Mutant Neoantigen Specific T Cells  
Q. Song, J. Song, H. Sun, W. Du, L. Wu, L. Wang, Z. Wei, Y. Wang, Y. Guan, X. Xia, X. Yi, S. Jiao; CN
- 12:30 - 12:30 1164P - Efficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients  
M. Hernandez, E. Neningen, E. Santiesteban, K. Camacho, N. Hernandez, R. Amador, S. Acosta, Y. Gonzalez, Y. Jimenez, M. Corella, R.A. Ortiz, L. Bello, A. Calana, G. Pichs, M. Cala, Y. Flores, C. Viada, M. Robaina, T. Crombet; CU
- 12:30 - 12:30 1165P - Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors  
L. Shen<sup>1</sup>, J. Cao<sup>1</sup>, J. Gong<sup>1</sup>, D. Ji<sup>1</sup>, Z. Qin<sup>2</sup>, H. Dai<sup>1</sup>, K. Wu<sup>1</sup>, J. Xu<sup>1</sup>, J. Yang<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>Beijing/CN
- 12:30 - 12:30 1166P - An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune checkpoint blockade  
C. Kim, N.K. Lee, J.S. Kim, W.R. Kim, D.H. Kim, D.J. Kim, J.S. Oh, S.K. Chang, J.W. Kim, H.J. Chon; KR
- 12:30 - 12:30 1167P - Phase 1, Open-Label Ascending Dose Trial of Anti-CTLA-4 Monoclonal Antibody AGEN1884 in Advanced Solid Malignancies, With Expansion to Patients Refractory to Recent Anti-PD-1/PD-L1 Therapy  
B. Wilky<sup>1</sup>, P. Kumthekar<sup>2</sup>, R. Wesolowski<sup>2</sup>, J. Hwang<sup>2</sup>, S. Park<sup>2</sup>, G. Yuan<sup>2</sup>, C. Dupont<sup>2</sup>, M. Lim<sup>3</sup>, O. Shebanova<sup>2</sup>, J.-M. Cuillerot<sup>3</sup>, E. Dow<sup>2</sup>, W. Ortuzar<sup>2</sup>, J. Raizer<sup>3</sup>, E. Drouin<sup>3</sup>, N. Wilson<sup>3</sup>, A. Gonzalez<sup>2</sup>, J. Goldberg<sup>3</sup>, J. Buell<sup>2</sup>, R. Stein<sup>2</sup>, H. Youssoufian<sup>2</sup>; <sup>1</sup>FL/US, <sup>2</sup>US, <sup>3</sup>MA/US
- 12:30 - 12:30 1168P - Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into 2L Cervical Cancer and Solid Tumors  
J. Coward<sup>1</sup>, C. Lemech<sup>1</sup>, T. Meniawy<sup>2</sup>, C. Dupont<sup>3</sup>, A. Gonzalez<sup>3</sup>, M. Lim<sup>4</sup>, D. Savitsky<sup>3</sup>, M. Carini<sup>3</sup>, S. Hu<sup>3</sup>, O. Shebanova<sup>3</sup>, E. Dow<sup>3</sup>, W. Ortuzar<sup>3</sup>, J. Buell<sup>3</sup>, R. Stein<sup>3</sup>, H. Youssoufian<sup>3</sup>; <sup>1</sup>AU, <sup>2</sup>WA/AU, <sup>3</sup>US, <sup>4</sup>MA/US

- 12:30 - 12:30 1169P - RORy agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: an open-label, multicenter Phase 1b trial  
D. Camidge<sup>1</sup>, S. Gadgeel<sup>2</sup>, H. Wilkins<sup>2</sup>, G. Weems<sup>2</sup>, R. Santana-Davila<sup>2</sup>, M. Johnson<sup>3</sup>; <sup>1</sup>CO/US, <sup>2</sup>US, <sup>3</sup>TN/US
- 12:30 - 12:30 1170P - ABP-100: A Tetravalent Bispecific T-cell Engaging Antibody for HER2+ Solid Tumors  
A. Boudot<sup>1</sup>, X. Huang<sup>2</sup>, S. Murphy<sup>2</sup>, V. Appleman<sup>2</sup>, H. Xu<sup>1</sup>, N.-K. Cheung<sup>1</sup>, G. Macbeath<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 12:30 - 12:30 1171P - Phase 1 expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)  
H. Babiker<sup>1</sup>, I. Brana<sup>2</sup>, D. Mahadevan<sup>3</sup>, T. Owonikoko<sup>4</sup>, E. Calvo<sup>2</sup>, D. Rischin<sup>5</sup>, V. Moreno<sup>2</sup>, K. Papadopoulos<sup>6</sup>, M. Crittenden<sup>1</sup>, S. Formenti<sup>1</sup>, J. Giralt<sup>2</sup>, P. Garrido Lopez<sup>2</sup>, A. Hervás Morón<sup>2</sup>, K.K. Mohan<sup>7</sup>, M. Fury<sup>1</sup>, I. Lowy<sup>1</sup>, E. Stankevich<sup>1</sup>, M. Feng<sup>1</sup>, J. Li<sup>1</sup>, M. Mathias<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>ES, <sup>3</sup>TN/US, <sup>4</sup>GA/US, <sup>5</sup>AU, <sup>6</sup>TX/US, <sup>7</sup>NY/US
- 12:30 - 12:30 1172P - A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors  
A. Awada<sup>1</sup>, F. Eskens<sup>2</sup>, D. Robbrecht<sup>2</sup>, U. Lassen<sup>3</sup>, M. Sorensen<sup>3</sup>, J. Schellens<sup>2</sup>, J. de Groot<sup>2</sup>, C. Jungels<sup>1</sup>, P. Aftimos<sup>1</sup>, S. Fretland<sup>4</sup>, L. Thorsson<sup>5</sup>, T.K. Guren<sup>4</sup>; <sup>1</sup>BE, <sup>2</sup>NL, <sup>3</sup>DK, <sup>4</sup>NO, <sup>5</sup>SE
- 12:30 - 12:30 1173P - Immunostimulatory AdCD40L gene therapy in patients with advanced solid tumours  
S. Irenaeus, J. Wenthe, E. Eriksson, J. Krause, A. Sundin, H. Ahlström, T. Tötterman, A. Loskog, G. Ullenhag; SE
- 12:30 - 12:30 1174P - Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials  
A. Bernard-Tessier<sup>1</sup>, C. Baldini<sup>2</sup>, E. Castanon Alvarez<sup>3</sup>, S. Ammari<sup>1</sup>, P. Martin Romano<sup>1</sup>, S. Champiat<sup>2</sup>, A. Hollebecque<sup>1</sup>, S. Postel-Vinay<sup>1</sup>, A. Varga<sup>2</sup>, R. Bahleda<sup>2</sup>, A. Gazzah<sup>1</sup>, J.-M. Michot<sup>1</sup>, V. Ribrag<sup>1</sup>, J.-P. Armand<sup>1</sup>, A. Marabelle<sup>1</sup>, J.-C. Soria<sup>4</sup>, C. Massard<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>ES, <sup>4</sup>CEDEX/US
- 12:30 - 12:30 1175P - Prognostic value of response according to tumour growth rate in a phase I trial on vaccine therapy  
A. Bellucci<sup>1</sup>, C. Nevoret<sup>1</sup>, C. De Bazelaire<sup>1</sup>, S. Oudard<sup>1</sup>, L. Teixeira<sup>2</sup>, R. Defrance<sup>1</sup>, T. Huet<sup>1</sup>, L.D. Pierre<sup>1</sup>, V. Doppler<sup>1</sup>, J. Medioni<sup>1</sup>, S. Culine<sup>2</sup>, L. Fournier<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 10/FR
- 12:30 - 12:30 1176P - Oncolytic Virotherapy For Multiple Myeloma Targeting CD40, 41BB and/or IL6R  
J. Wenthe, S. Naseri, A.-C. Hellström, E. Eriksson, A. Loskog; SE
- 12:30 - 12:30 1177P - Humanized knock-in mouse models for evaluating in vivo efficacy of immune-oncology drugs targeting stimulatory immune checkpoint molecules  
T. Gan<sup>1</sup>, J. Xiang<sup>2</sup>, C. Guo<sup>1</sup>, Y. Guo<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>MA/US
- 12:30 - 12:30 1178P - Tackling fratricide to manufacture clinical grade NKG2D-CAR T cells for cancer therapy  
B. Demoulin, B. Eytan, D. Gilham; BE

- 12:30 - 12:30 1179P - The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer .  
S. Agaoglu<sup>1</sup>, A. Hargreaves<sup>2</sup>, P. De Sousa<sup>3</sup>, P. De Waele<sup>3</sup>, D. Gilham<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>GB, <sup>3</sup>BE
- 12:30 - 12:30 1180P - Combination of Pegilodocakin and Docetaxel Shows Synergy in Tumor Rejection in Immune Resistant TNBC model  
N. Ratti<sup>1</sup>, N. Shifrin<sup>1</sup>, S. McCauley<sup>2</sup>, R. Verma<sup>2</sup>, P. Van Vlasselaer<sup>2</sup>, M. Ott<sup>2</sup>, J. Leveque<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 12:30 - 12:30 1181P - Mutations in Interferon Gamma and Antigen Presentation Pathways are frequent in Hiper/Ultra-Mutated (HiMut) Tumors and could be result of Immune-editing processes in HiMut tumors.  
J.M. Piulats Rodriguez<sup>1</sup>, S. Garcia-Mulero<sup>2</sup>, L. Valle<sup>2</sup>, V. Moreno<sup>2</sup>, X. Matias-Guiu<sup>2</sup>, R. Sanz-Pamplona<sup>2</sup>; <sup>1</sup>Barcelona/ES, <sup>2</sup>ES
- 12:30 - 12:30 1182P - Anti-CTLA4 toxicity associates with genetic variation correlating with serum antibody diversity.  
D. Simpson<sup>1</sup>, R. Ferguson<sup>2</sup>, M. Gowen<sup>2</sup>, K. Giles<sup>2</sup>, J. Tchack<sup>2</sup>, H. Zhou<sup>1</sup>, U. Moran<sup>1</sup>, Z. Dawood<sup>2</sup>, A. Pavlick<sup>1</sup>, S. Hu<sup>2</sup>, M. Wilson<sup>1</sup>, H. Zhong<sup>2</sup>, M. Krogsgaard<sup>2</sup>, J. Weber<sup>2</sup>, I. Osman<sup>2</sup>, T. Kirchhoff<sup>2</sup>; <sup>1</sup>NY/US, <sup>2</sup>US
- 12:30 - 12:30 1183P - PD-L1 expression is strongly associated with TIGIT, FOXP3 and LAG3 across advanced cancers, but not OX40, TIM3 and IDO  
S. Pal<sup>1</sup>, A. Vanderwalde<sup>2</sup>, C. Szeto<sup>2</sup>, S. Reddy<sup>2</sup>, O. Hamid<sup>2</sup>; <sup>1</sup>CA/US, <sup>2</sup>US
- 12:30 - 12:30 1184P - Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)  
O. Hamid<sup>1</sup>, S. Hu-Lieskovan<sup>1</sup>, W. Ros<sup>2</sup>, A. Diab<sup>3</sup>, A. El-Khoueiry<sup>3</sup>, J. Thompson<sup>4</sup>, F. Eskens<sup>2</sup>, J.-P. Spano<sup>5</sup>, E. Angevin<sup>6</sup>, N. Rizvi<sup>7</sup>, J. Wasser<sup>8</sup>, P. Ott<sup>9</sup>, A. Chiappori<sup>10</sup>, T. Joh<sup>7</sup>, H. Krupka<sup>7</sup>, S. Potluri<sup>7</sup>, X. Wang<sup>7</sup>, B. Ganguli<sup>7</sup>, J. Chou<sup>7</sup>, T. Doi<sup>11</sup>; <sup>1</sup>CA/US, <sup>2</sup>NL, <sup>3</sup>US, <sup>4</sup>WA/US, <sup>5</sup>CEDEX 13/FR, <sup>6</sup>CEDEX/FR, <sup>7</sup>NY/US, <sup>8</sup>CT/US, <sup>9</sup>MA/US, <sup>10</sup>FL/US, <sup>11</sup>Chiba/JP
- 12:30 - 12:30 1185P - Using MultiOmyx™ to analyze correlations between immunosuppressive cells and tumor-infiltrating lymphocytes in the pancreatic tumor microenvironment  
A. Juncker-Jensen<sup>1</sup>, J. Fang<sup>1</sup>, J. Kuo<sup>2</sup>, M. Nagy<sup>1</sup>, R.K. Padmanabhan<sup>2</sup>, E. Leones<sup>1</sup>, F. Sahafi<sup>1</sup>, S. Zhu<sup>1</sup>, Q. Au<sup>2</sup>, N. Hoe<sup>2</sup>, J. William<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 12:30 - 12:30 1186P - Interim results from exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.  
T. Kojima<sup>1</sup>, T. Marafioti<sup>2</sup>, T. Fujiwara<sup>3</sup>, Y. Shirakawa<sup>3</sup>, T. Nakatsura<sup>3</sup>, K. Kato<sup>3</sup>, I. Puccio<sup>2</sup>, M. Nagira<sup>3</sup>, N. Ide<sup>3</sup>, K. Stoeber<sup>2</sup>, A. Arimura<sup>3</sup>, H. Daiko<sup>3</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>GB, <sup>3</sup>JP
- 12:30 - 12:30 1187P - Clinical implication of PDL1 expression and TILs in male breast cancer: More Hype or New Hope? Results from the UMBREAC trial (NCT03240510)  
S. Abdeljaoued, I. Bettaieb, A. Goucha, O. Adouni, H. El Mokh, H. Bouzaïene, J. Ben Hassouna, H. Boussen, K. Rahal, A. Gamoudi; TN

- 12:30 - 12:30 1188P - Identification of Prognostic and Predictive Factors for Durvalumab Efficacy by Modeling of Tumor Response and Overall Survival (OS) in Patients with Non-Small-Cell Lung Cancer (NSCLC)  
Y. Zheng<sup>1</sup>, R. Narwal<sup>1</sup>, C. Jin<sup>1</sup>, P. Baverel<sup>2</sup>, A. Gupta<sup>2</sup>, P. Mukhopadhyay<sup>1</sup>, B. Higgs<sup>1</sup>, L. Roskos<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GB
- 12:30 - 12:30 1189P - Intrinsic and Extrinsic regulation of PD-L2 Expression by transcription factor STAT3 or c-FOS in Oncogene-Driven Non-Small Cell Lung Cancer  
D. Shibahara<sup>1</sup>, K. Tanaka<sup>1</sup>, E. Iwama<sup>2</sup>, N. Kubo<sup>1</sup>, K. Ota<sup>2</sup>, K. Azuma<sup>1</sup>, T. Harada<sup>1</sup>, J. Fujita<sup>1</sup>, Y. Nakanishi<sup>2</sup>, I. Okamoto<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Fukuoka/JP
- 12:30 - 12:30 1190P - Microsatellite instability detection by targeted sequencing of cell-free DNA  
A. Artyomenko<sup>1</sup>, M. Sikora<sup>1</sup>, M. Lefterova<sup>1</sup>, V. Raymond<sup>1</sup>, D. Gavino<sup>1</sup>, C. Barbacioru<sup>1</sup>, C. Artieri<sup>1</sup>, E. Helman<sup>1</sup>, D. Chudova<sup>1</sup>, R. Lanman<sup>1</sup>, J. Odegaard<sup>2</sup>, J. Willis<sup>1</sup>, M. Fakhri<sup>2</sup>, S. Kopetz<sup>3</sup>, A. Talasz<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>TX/US
- 12:30 - 12:30 1191P - Immune Checkpoints and T-Lymphocytes as Immunotherapeutic Target in the Treatment of Sebaceous Gland Carcinoma  
L. Singh<sup>1</sup>, M. Singh<sup>2</sup>, N. Pushker<sup>2</sup>, S. Bakhshi<sup>2</sup>, M. Rizvi<sup>2</sup>, S. Sen<sup>2</sup>, S. Kashyap<sup>2</sup>; <sup>1</sup>Delhi/IN, <sup>2</sup>IN
- 12:30 - 12:30 1192P - Evaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade  
H. Jackson<sup>1</sup>, S. Bhattacharya<sup>1</sup>, P. Bojczuk<sup>1</sup>, D. Kilian<sup>1</sup>, L. Seestaller Wehr<sup>1</sup>, A. Hahn<sup>1</sup>, H. Shi<sup>1</sup>, M. Bi<sup>1</sup>, M. Adam<sup>1</sup>, J. Jing<sup>1</sup>, P. Morley<sup>2</sup>, C. Hopson<sup>1</sup>, E. Paul<sup>1</sup>, A. Hoos<sup>1</sup>, J. Smothers<sup>1</sup>, R. Srinivasan<sup>1</sup>, N. yanamandra<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GB
- 12:30 - 12:30 1193P - Impact of tissue processing and interferents on the reproducibility and robustness of a multi-plex gene expression assay measuring tumor inflammation.  
B. Wallden<sup>1</sup>, S. Church<sup>1</sup>, I. Pekker<sup>1</sup>, S. Zimmerman<sup>1</sup>, S. Popa<sup>1</sup>, A. Sullivan<sup>1</sup>, C. Ngouenet<sup>1</sup>, E. Harris<sup>1</sup>, N. Dowidar<sup>1</sup>, A. Bergdahl<sup>1</sup>, C. Schaper<sup>1</sup>, P. Danaher<sup>2</sup>, S. Ferree<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>WA/US
- 12:30 - 12:30 1194P - Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A)  
J. Diamond<sup>1</sup>, N. Standifer<sup>2</sup>, M. Ascierto<sup>3</sup>, C. Morehouse<sup>4</sup>, H. Ghadially<sup>5</sup>, J. Rodriguez Canales<sup>3</sup>, M. Rebelatto<sup>4</sup>, J. Naidoo<sup>3</sup>, L. Mazarella<sup>6</sup>, S. Patel<sup>4</sup>, M.J. Flor Oncala<sup>7</sup>, T. Alonso Gordo<sup>7</sup>, D. Wang<sup>8</sup>, X. Song<sup>3</sup>, D. Jones<sup>5</sup>, X. Li<sup>3</sup>, S. Marshall<sup>3</sup>, S. Abdullah<sup>3</sup>, M. Jure-Kunkel<sup>3</sup>, M. Hellmann<sup>9</sup>; <sup>1</sup>CO/US, <sup>2</sup>CA/US, <sup>3</sup>MD/US, <sup>4</sup>US, <sup>5</sup>GB, <sup>6</sup>IT, <sup>7</sup>ES, <sup>8</sup>MI/US, <sup>9</sup>NJ/US
- 12:30 - 12:30 1195P - Alterations in peripheral T cell subsets, T cell Activation Markers and Immune Checkpoint Molecules in advanced Pancreatic Cancer Patients Receiving FOLFIRINOX or Gemcitabine + Nab-Paclitaxel  
L. Sams, S. Kruger, V. Heinemann, D. Bararia, S. Haebe, S. Alig, B. Westphalen, M. Haas, T. Kirchner, S. Ormanns, S. Endres, O. Weigert, M. von Bergwelt-Baildon, S. Kobold, F. Rataj, S. Boeck; DE
- 12:30 - 12:30 1196P - Resistance to anti-PD-1 therapy is associated with the retention of CXCR3+ CD4+ CD8- T cells in blood

X. Han, T. Tan, J. Sun, X. Chen, X. Cai, P. Lin, Y. Tan, B. Wang, Y. Wang, J. Wang, Z. Yu, X. Wu, Q. Xu, Y. Gu; CN

- 12:30 - 12:30 1197P - Cerebrospinal fluid lymphocytosis: a hallmark of neurological immune related adverse events (irAEs) during checkpoint inhibitor treatment  
K. Suijkerbuijk, F. De Vos, J. Koldenhof, T. Snijders; NL
- 12:30 - 12:30 1198P - Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real world scenario  
D. Iacono, M.G. Vitale, F. Cortiula, M. Cinausero, A. Tullio, F. Valent, M. Macerelli, A. Follador, A. Vogrig, A. Minisini, F. Puglisi, G. Fasola; IT
- 12:30 - 12:30 1199P - Clinical and molecular characteristics associated with efficacy of PD-1/PD-L1 inhibitors for solid tumors: A Meta-analysis  
M. Peng, Y. Weng, Y. Yao, Q. Song; CN
- 12:30 - 12:30 1200P - Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer  
T. Ota<sup>1</sup>, T. Takeda<sup>1</sup>, T. Fukui<sup>1</sup>, Y. Nakahara<sup>1</sup>, K. Kudo<sup>1</sup>, T. Okabe<sup>1</sup>, H. Hayashi<sup>1</sup>, S. Otani<sup>1</sup>, Y. Hiyoshi<sup>1</sup>, K. Yonesaka<sup>1</sup>, T. Sugiura<sup>1</sup>, T. Suzumura<sup>1</sup>, M. Terashima<sup>1</sup>, Y. Nakano<sup>1</sup>, Y. Hasegawa<sup>1</sup>, H. Tsukuda<sup>1</sup>, K. Matsui<sup>1</sup>, N. Masuda<sup>2</sup>, M. Fukuoka<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Minami-Ii, Sagamihara/JP
- 12:30 - 12:30 1201P - Association of immune-related adverse (irAEs) with immune-checkpoint inhibitors (ICIs) efficacy in solid tumors  
M. Riudavets Melia, L. del Carpio, I. Gabriela Sullivan, A. Barba Joaquín, P. Maroto Rey, G. Anguera Palacios, D. Páez López-Bravo, A. Callejo Pérez, C. González Blanco, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, I. Genua Trullos, A. López Pousa, A. Sebio García, C. Martín Lorente, A.C. Virgili Manrique, O. Gallego Rubio, A. Barnadas Molins, M. Majem Tarruella; ES
- 12:30 - 12:30 1202P - Use of Immune Checkpoint Inhibitors (CPI) in Patients with Cancer and Concomitant Myasthenia Gravis (MG)  
H. Safa<sup>1</sup>, N. Abdel-Wahab<sup>1</sup>, V.A. Trinh<sup>1</sup>, D. Johnson<sup>2</sup>, T.E. Rodgers<sup>1</sup>, M. Suarez-Almazor<sup>1</sup>, A. Diab<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>TX/US
- 12:30 - 12:30 1203P - Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events.  
A. Simonaggio<sup>1</sup>, J.-M. Michot<sup>1</sup>, S. Champiat<sup>2</sup>, A. Vozy<sup>1</sup>, A. Lopera<sup>1</sup>, A. Marabelle<sup>1</sup>, J. Le Pavec<sup>1</sup>, A.-L. Voisin<sup>1</sup>, A. Lallart<sup>1</sup>, G. Cengizalp<sup>1</sup>, O. Lambotte<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 1204P - Long term disease control and abscopal effects by stereotactic radiotherapy for growing metastases during anti-PD1.  
K. Suijkerbuijk, S. El Sharouni, P. Damen, A. Lindert, G. Groenewegen, J. Verhoeff; NL
- 12:30 - 12:30 1205P - Clinical impact of hypothyroidism and PD-L1 SNPs in patients with non-small cell lung cancer treated with nivolumab.  
T. Yamamoto, T. Nomizo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, T. Hirai, Y. Kim; JP
- 12:30 - 12:30 1206P - Incidence of Immune Related Adverse Events in patients 70 years old treated with anti-PD-(L)1 therapy



C. Baldini<sup>1</sup>, P. Martin-Romano<sup>2</sup>, A.-L. Voisin<sup>2</sup>, F.X. Danlos<sup>2</sup>, S. Champiat<sup>1</sup>, S. Laghouati<sup>2</sup>, M. Kfoury<sup>2</sup>, H. Vincent<sup>2</sup>, C. Nagera<sup>2</sup>, S. Postel-Vinay<sup>2</sup>, A. Varga<sup>1</sup>, V. Ribrag<sup>2</sup>, B. Besse<sup>1</sup>, A. Hollebecque<sup>2</sup>, O. Lambotte<sup>2</sup>, J.-M. Michot<sup>2</sup>, J.-C. Soria<sup>3</sup>, C. Massard<sup>1</sup>, A. Marabelle<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/US

- 12:30 - 12:30 1207P - PD-1 inhibitor-related pneumonitis in patients with minimal interstitial lung shadows before treatment  
K. Takahashi<sup>1</sup>, C. Kondo<sup>1</sup>, A. Inukai<sup>1</sup>, G. Asai<sup>2</sup>, M. Okuno<sup>1</sup>, H. Saito<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Aichi/JP
- 12:30 - 12:30 1208P - PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques – a safety study  
R. Carroll<sup>1</sup>, J. Zalcborg<sup>2</sup>, H. Tang<sup>3</sup>; <sup>1</sup>AU, <sup>2</sup>VIC/AU, <sup>3</sup>SA/AU
- 12:30 - 12:30 1209P - Immunotherapy In The Immunodeficient– A Treatment Paradox?  
N. Campbell, J. Longley, A. Pascalis, J. Bennett, M. Remer, R. Stone, D. Muller, I. Karydis, O. Donnelly, M. Wheeler, C. Ottensmeier; GB
- 12:30 - 12:30 1211P - Hyperprogression during immuno-checkpoint inhibitors (ICIs): a clinically significant problem?  
E. Farè, S. Sdao, S. Damian, S. Cresta, M. Del Vecchio, M. Di Bartolomeo, L. Di Guardo, M. Duca, A. Indini, A. Necchi, M. Niger, M. Prisciandaro, G. Procopio, D. Raggi, E. Verzoni, G. Pruneri, M. Di Nicola, F.G. de Braud; IT
- 12:30 - 12:30 1212P - Pathogenesis, clinical evolution, and outcomes of patients with immune checkpoint inhibitor induced acute liver injury: a multicentre study.  
L. Au, R. Nathwani, L. Possamai, C. Barlow, T. Tillett, R. Bowen, L. Spain, J. Thomas, M. Backhouse, A. Gurung, R. Morrison, T. Cross, C. Herbert, R. Goldin, M. Gore, J. Larkin, C. Antoniades, S. Turajlic; GB
- 12:30 - 12:30 1213P - Tolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV)  
A. Gobert<sup>1</sup>, M. Veyri<sup>1</sup>, A. Lavolé<sup>1</sup>, H. Montaudié<sup>1</sup>, N. Cloarec<sup>1</sup>, L. Doucet<sup>1</sup>, V. Gounant<sup>2</sup>, M.-A. Massiani<sup>1</sup>, C. Helissey<sup>1</sup>, S. Bregigeon<sup>1</sup>, C. Chouaid<sup>1</sup>, C.-H. Poulet<sup>1</sup>, M. Dewolf<sup>1</sup>, M. Kerjouan<sup>1</sup>, S. Beaucaire-Danel<sup>1</sup>, S. Brosseau<sup>1</sup>, G. Le Garff<sup>1</sup>, V. Garrait<sup>1</sup>, A.-G. Marcelin<sup>1</sup>, J.-P. Spano<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 18/FR, <sup>3</sup>CEDEX 13/FR
- 12:30 - 12:30 1214P - Establishing the Need for Immuno-oncology (IO) Therapy (tx) in Second-Line (2L) Small Cell Lung Cancer (SCLC)  
L. Schwartzberg<sup>1</sup>, J. Penrod<sup>2</sup>, Y. Yuan<sup>2</sup>, T. Gu<sup>2</sup>, T.K. Le<sup>3</sup>, P. Abraham<sup>2</sup>, B. Korytowsky<sup>2</sup>, G. Selvaggi<sup>2</sup>; <sup>1</sup>TN/US, <sup>2</sup>NJ/US, <sup>3</sup>US
- 12:30 - 12:30 1215P - Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity – from Case Report to Mice Model Validation  
Y.-J. Chen, W.-C. Huang, S.-Y. Liu, C.-C. Ko; TW
- 12:30 - 12:30 1216P - Impact of anti-infectious and corticosteroids on immunotherapy : Nivolumab and Pembrolizumab follow-up in a French study.  
J.-P. Metges<sup>1</sup>, E. Michaud<sup>2</sup>, D. Deniel Lagadec<sup>2</sup>, F. Marhuenda<sup>2</sup>, A. Chaslerie<sup>2</sup>, F. Grude<sup>2</sup>; <sup>1</sup>Cedex 2/FR, <sup>2</sup>FR

- 12:30 - 12:30 1217P - Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance  
Y. Ohe<sup>1</sup>, A. Gemma<sup>1</sup>, K. Nakagawa<sup>1</sup>, N. Yamamoto<sup>1</sup>, T. Saito<sup>1</sup>, A. Akamatsu<sup>1</sup>, K. Kuwano<sup>1</sup>, Y. Nakanishi<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Fukuoka/JP
- 12:30 - 12:30 1218P - Immune-related adverse events: comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy.  
N. Duma<sup>1</sup>, A.-G. Azzouqa<sup>1</sup>, S. Yadav<sup>1</sup>, K. Hoversten<sup>1</sup>, C. Reed<sup>1</sup>, A. Sitek<sup>1</sup>, Y. Lou<sup>1</sup>, J. Molina<sup>1</sup>, T. Halfdanarson<sup>1</sup>, K. Leventakos<sup>2</sup>, R. Joseph<sup>1</sup>, R. Manochakian<sup>1</sup>, R. Dronca<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MN/US
- 12:30 - 12:30 1219P - Evaluation of a possible link between immunotherapy (IO) and acute vascular events.  
J. Bar, K. Shulman, T. Kuznetsov, G. Markel, S. Daher, R. Berger, T. Golan, D. Urban, T. Sela, E. Shacham Shmueli, R. Klempfner, A. Talianski, A. Onn, E. Dudnik; IL
- 12:30 - 12:30 1220P - Real-World Experience of Pembrolizumab in Patients with Advanced Melanoma: A Large Retrospective Observational Study  
F.X. Liu<sup>1</sup>, W. Ou<sup>2</sup>, S. Diede<sup>2</sup>, E. Whitman<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NJ/US
- 12:30 - 12:30 1221P - Sites of Metastasis and Association with Clinical Outcome (CO) in Advanced Stage Cancer Patients (Pts) Treated with Immunotherapy (IO)  
M. Bilen<sup>1</sup>, J. Shabto<sup>2</sup>, D. Martini<sup>2</sup>, Y. Liu<sup>2</sup>, C. Lewis<sup>1</sup>, H. Collins<sup>1</sup>, M. Akce<sup>1</sup>, H. Kissick<sup>2</sup>, B. Carthon<sup>1</sup>, W. Shaib<sup>1</sup>, O. Alese<sup>1</sup>, C. Steuer<sup>1</sup>, C. Wu<sup>1</sup>, D. Lawson<sup>1</sup>, R. Kudchadkar<sup>1</sup>, V. Master<sup>1</sup>, B. El-Rayes<sup>1</sup>, S. Ramalingam<sup>2</sup>, T. Owonikoko<sup>2</sup>, R. Harvey<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GA/US
- 12:30 - 12:30 1222P - Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs).  
N. Shah, J. Puthiamadathil, M. Serzan, A. Belouali, W. Kelly, B. MA, M. Blackburn, A. Knoedler, S. OchoaGonzalez, M. Janni, S. Madhavan, G. Gibney, M. Atkins; US
- 12:30 - 12:30 1223P - Potential Drug Cost Impact of Dual Agent Immunotherapy (DAIO) with Nivolumab (N) plus Ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada.  
K. Virik<sup>1</sup>, R. Wilson<sup>2</sup>; <sup>1</sup>NS/CA, <sup>2</sup>NSW/AU
- 12:30 - 12:30 1224P - Q-TWiST Analysis to Assess Benefit-risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic NSCLC  
M. Huang<sup>1</sup>, M.C. Pietanza<sup>2</sup>, A. Samkari<sup>1</sup>, J. Pellissier<sup>1</sup>, T. Burke<sup>1</sup>, S. Chandwani<sup>1</sup>, F. Kong<sup>1</sup>, A.S. Pickard<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>NJ/US, <sup>3</sup>IL/US
- 12:30 - 12:30 1225P - Impact of immune-checkpoint inhibitors (ICPIs) as treatment of patients (pts) with metastatic primary uveal melanoma (UM): results of a single-institution database.  
C.L. Lee, G. Gullo, N. Horgan, D. Smith, M. Moran, J. Crown; IE
- 12:30 - 12:30 1226P - Anti-PD1 inhibitors: assessment of proper use, efficacy and economic impact in daily practice  
M. VALERY, FR

- 12:30 - 12:30 1227P - Immune-Related Adverse Events (irAEs) predict therapeutic efficacy of an anti-PD-1 antibody in cancer patients  
J. Rogado<sup>1</sup>, N. Romero Laorden<sup>2</sup>, J.M. Sanchez Torres<sup>1</sup>, A.I. Ballesteros Garcia<sup>1</sup>, V. Pacheco-Barcia<sup>1</sup>, R. Arranz<sup>1</sup>, R. Mondéjar Solís<sup>1</sup>, P. Gullón<sup>1</sup>, A. Lorenzo<sup>1</sup>, R. Colomer Bosch<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Madrid/ES
- 12:30 - 12:30 1228P - Previous immunotherapy treatments may improve tumor responses with subsequent chemotherapy regimens  
I. Baraibar Argota<sup>1</sup>, P. Martin-Romano<sup>2</sup>, M. Sanmamed<sup>3</sup>, M. Rodriguez-Ruiz<sup>1</sup>, J.L. Pérez-Gracia<sup>1</sup>, I. Gil-Bazo<sup>1</sup>, I. Melero<sup>1</sup>, L. Resano<sup>1</sup>, A. Chopitea Ortega<sup>1</sup>, J. Rodriguez<sup>1</sup>, J. Aramendia<sup>1</sup>, I. Gardezabal<sup>1</sup>, L. Cenicerós<sup>1</sup>, P. Sala Elarre<sup>1</sup>, M. Ponz-Sarvisé<sup>1</sup>, E. Castanon Alvarez<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>FR, <sup>3</sup>US
- 12:30 - 12:30 1229P - Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)  
M. Gutierrez<sup>1</sup>, A. Norden<sup>2</sup>, D. Lane<sup>3</sup>, B. Canavan<sup>3</sup>, E. Nwokeji<sup>3</sup>, Y. Xu<sup>3</sup>, S. Kaur<sup>2</sup>, S. Goldberg<sup>1</sup>, L. Noh<sup>2</sup>, L. Siegartel<sup>3</sup>, J. Whittington<sup>3</sup>, K. Tuell<sup>3</sup>, B. Korytowsky<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>NY/US, <sup>3</sup>NJ/US
- 12:30 - 12:30 1230P - Anti-PD-1 therapy combined with chemotherapy or target therapy in patients with advanced biliary tract cancer in real-world clinical setting  
D. Sun, J. Ma, C. Han, J. Wang, Y. Qian, G. Chen, X. Li, J. Zhang, J. Song, X. Zhao, S. Cai, Y. Hu; CN
- 12:30 - 12:30 1231P - The efficacy and safety of solid tumors combination therapy with immune checkpoint inhibitor: a systematic review and meta-analysis  
M. Peng, Y. Weng, Y. Yao, Q. Song; CN
- 12:30 - 12:30 1232P - Model-Based Assessment of Benefit-Risk Profile of Nivolumab (NIVO) Flat Dosing Schedules (Q2W and Q4W) Across Multiple Tumor Types  
X. Zhao<sup>1</sup>, J. Shen<sup>1</sup>, M. Gopalakrishnan<sup>2</sup>, Y. Feng<sup>1</sup>, B. Schmidt<sup>1</sup>, P. Statkevich<sup>1</sup>, T. Kelleher<sup>3</sup>, M. Rashford<sup>1</sup>, V. Ivaturi<sup>2</sup>, J. Gobburu<sup>2</sup>, S. Agrawal<sup>1</sup>, A. Bello<sup>1</sup>, A. Roy<sup>1</sup>; <sup>1</sup>NJ/US, <sup>2</sup>MD/US, <sup>3</sup>CT/US
- 12:30 - 12:30 1233P - Immunotherapy in Clinical Practice: Real World Multicentric Brazilian Experience.  
J. Cé Coelho, A.C. Zimmer Gelatti, E. Mascarenhas, C. Dutra, T. Rebelato, R. D'Avila, F. Zaffaroni Caorsi, B. Rocha Garcia, A.C. de Miranda e Figueiredo, M. Souto, A. Baldasso Zanon, N. Balzan, G. Werutsky, S. Jobim de Azevedo; BR
- 12:30 - 12:30 1234P - Correlation, in a real-world setting, between clinical-disease characteristics and compliance with immunotherapy in solid metastatic tumors. First results of an Italian CORE-IMMUNO Study  
C. Masini, A. Berselli, M. Banzi, C. Bonelli, A. Romagnani, M. Pagano, A. Damato, G. Prati, E. Gasparini, G. Moretti, I.T. Lorenzetti, F. Zanelli, F. Iachetta, C. Pinto; IT
- 12:30 - 12:30 1235P - Safety of immunotherapy in elderly patients: a retrospective analysis of a phase I Unit  
E. Ferraro<sup>1</sup>, G. Viale<sup>2</sup>, B. Achutti Duso<sup>2</sup>, C. Belli<sup>2</sup>, C. Criscitiello<sup>2</sup>, L. Mazzarella<sup>2</sup>, A. Esposito<sup>2</sup>, S. Morganti<sup>2</sup>, D. Trapani<sup>2</sup>, P. Tarantino<sup>2</sup>, P. D'Amico<sup>2</sup>, C. Busacca<sup>2</sup>, M.A. Massaro<sup>2</sup>, G. Curigliano<sup>2</sup>; <sup>1</sup>(MI)/IT, <sup>2</sup>IT
- 12:30 - 12:30 1236TiP - The Safety and Efficacy of Durvalumab in Combination with Paclitaxel for the treatment of Metastatic Triple Negative Breast Cancer

H. Ghebeh, A. Alsayed, K. Suleman, T. Al-Tweigeri; SA

- 12:30 - 12:30 1237TiP - VSV-IFN $\beta$ -NIS intratumoral (IT) injection: a first-in-human (FIH), phase 1 study of an innovative oncolytic virotherapy, alone and with an anti-PD-L1 antibody, in patients with refractory solid tumors  
S. Powell<sup>1</sup>, M. Patel<sup>2</sup>, J. Merchan<sup>1</sup>, J. Strauss<sup>3</sup>, T. Cripe<sup>4</sup>, M. Old<sup>1</sup>, R. Diaz<sup>2</sup>, M. Reckner<sup>1</sup>, B. Brunton<sup>1</sup>, N. Packiriswamy<sup>1</sup>, D. Upreti<sup>1</sup>, L. Suksanpaisan<sup>1</sup>, R. Vandergaast<sup>1</sup>, R. Khan<sup>1</sup>, S. Russell<sup>1</sup>, K.W. Peng<sup>1</sup>, A. Bexon<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MN/US, <sup>3</sup>TX/US, <sup>4</sup>OH/US
- 12:30 - 12:30 1238TiP - A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma  
R. Jabulowsky, C. Loquai, E. Derhovanessian, H. Mitzel-Rink, J. Utikal, J. Hassel, R. Kaufmann, A. Pinter, M. Diken, M. Gold, L. Heesen, K. Schreeb, D. Schwarck-Kokarakis, S. Kreiter, M. Gaiser, D. Jäger, S. Grabbe, Ö. Türeci, U. Sahin; DE
- 12:30 - 12:30 1239TiP - MORPHEUS: a Phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types  
I. Chau<sup>1</sup>, G. Haag<sup>2</sup>, O. Rahma<sup>3</sup>, T. Macarulla<sup>4</sup>, S. McCune<sup>5</sup>, D. Yardley<sup>6</sup>, B. Solomon<sup>7</sup>, M. Johnson<sup>6</sup>, G. Vidal<sup>6</sup>, P. Schmid<sup>8</sup>, G. Argiles<sup>4</sup>, K. Dimick<sup>9</sup>, S. Mahrus<sup>9</sup>, H. Abdullah<sup>9</sup>, X. He<sup>9</sup>, P. Sayyed<sup>9</sup>, H. Barak<sup>9</sup>, C. Bleul<sup>10</sup>, E. Cha<sup>9</sup>, A. Drakaki<sup>9</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>DE, <sup>3</sup>MA/US, <sup>4</sup>ES, <sup>5</sup>GA/US, <sup>6</sup>TN/US, <sup>7</sup>VIC/AU, <sup>8</sup>GB, <sup>9</sup>CA/US, <sup>10</sup>CH
- 12:30 - 12:30 1240TiP - Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy  
K. Lewis<sup>1</sup>, M. Fury<sup>2</sup>, E. Stankevich<sup>2</sup>, M. Mathias<sup>2</sup>, K.K. Mohan<sup>3</sup>, S. Li<sup>4</sup>, K. Nunnink<sup>3</sup>, C. Perry<sup>3</sup>, A. Narwal<sup>4</sup>; <sup>1</sup>CO/US, <sup>2</sup>US, <sup>3</sup>NY/US, <sup>4</sup>NJ/US
- 12:30 - 12:30 1241TiP - JAVELIN PARP Medley: a phase 1b/2 study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors  
T. Yap<sup>1</sup>, J. Beck<sup>2</sup>, R. Stewart<sup>3</sup>, S. Dahm<sup>3</sup>, C. Chappay<sup>3</sup>, R. Cesari<sup>4</sup>, A. Scheuber<sup>5</sup>, M. Galsky<sup>3</sup>, D. Wise<sup>6</sup>; <sup>1</sup>Surrey/US, <sup>2</sup>AZ/US, <sup>3</sup>US, <sup>4</sup>IT, <sup>5</sup>PA/US, <sup>6</sup>NY/US
- 12:30 - 12:30 1242TiP - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients with Solid Tumors  
M. Butler<sup>1</sup>, H. Majeed<sup>2</sup>, M. Nelles<sup>2</sup>, S. Saibil<sup>2</sup>, L. Bonilla<sup>2</sup>, S. Boross-Harmer<sup>2</sup>, V. Sotov<sup>2</sup>, S. Elston<sup>2</sup>, K. Ross<sup>2</sup>, B. van As<sup>2</sup>, M. Le<sup>2</sup>, M. Fyrsta<sup>2</sup>, C. Lo<sup>2</sup>, J. Yam<sup>2</sup>, J. Nie<sup>2</sup>, L. Scheid<sup>2</sup>, P. Ohashi<sup>2</sup>, L. Nguyen<sup>2</sup>, S. Tanaka<sup>3</sup>, N. Hirano<sup>2</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA, <sup>3</sup>JP
- 12:30 - 12:30 1243TiP - Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small-cell lung cancer (NSCLC) and other solid tumors  
M. Johnson<sup>1</sup>, M. Patel<sup>2</sup>, S. Ulahannan<sup>3</sup>, A. Hansen<sup>4</sup>, B. George<sup>3</sup>, Q.S.-C. Chu<sup>5</sup>, M. Elgadi<sup>5</sup>, M. Ge<sup>6</sup>, C. Duffy<sup>6</sup>, R. Graeser<sup>7</sup>, S. Khedkar<sup>1</sup>, S. Jones<sup>1</sup>, H. Burris<sup>1</sup>; <sup>1</sup>TN/US, <sup>2</sup>MN/US, <sup>3</sup>US, <sup>4</sup>Ontario/CA, <sup>5</sup>CA, <sup>6</sup>CT/US, <sup>7</sup>DE
- 12:30 - 12:30 1337P - Predictive models for CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?

L. Jun, Q. Chen, L. Tang, L. Yang, E. Han, Y. Chen, L. Yuan; CN

- 12:30 - 12:30 1338P - Tracking VSV-IFN $\beta$ -NIS oncolytic virus (OV) activity in patients (pts) with advanced solid tumors: the iodide symporter gene (NIS) as a pharmacodynamic (PD) marker using SPECT/CT imaging of OV therapy  
J. Merchan<sup>1</sup>, M. Patel<sup>2</sup>, S. Powell<sup>1</sup>, J. Strauss<sup>3</sup>, T. Cripe<sup>4</sup>, M. Old<sup>1</sup>, R. Diaz<sup>2</sup>, S. Russell<sup>1</sup>, A. Bexon<sup>1</sup>, L. Suksanpaisan<sup>1</sup>, M. O'Connor<sup>2</sup>, K.W. Peng<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MN/US, <sup>3</sup>TX/US, <sup>4</sup>OH/US
- 12:30 - 12:30 1339P - mRNA Expression of ER, PR, HER2 and Ki67 are Concordant to Central IHC and Predict Clinical Outcome: a Validation Study from the ABCSG-6 Biomarker Cohort  
M. Filipits<sup>1</sup>, M. Rudas<sup>1</sup>, C. Singer<sup>1</sup>, Z. Bago-Horvath<sup>1</sup>, R. Greil<sup>1</sup>, M. Balic<sup>1</sup>, S.F. Lax<sup>1</sup>, N. Wu<sup>2</sup>, S. Zhao<sup>2</sup>, J. Weidler<sup>2</sup>, M. Bates<sup>2</sup>, D. Hlauschek<sup>1</sup>, M. Gnant<sup>1</sup>, P. Dubsky<sup>1</sup>; <sup>1</sup>AT, <sup>2</sup>US
- 12:30 - 12:30 1340P - Clinical utility of complex multi-platform profiling in metastatic cancer patients  
J. Garcia Foncillas<sup>1</sup>, P. Aftimos<sup>2</sup>, P. Barthelemy<sup>3</sup>, J. Bellmunt<sup>1</sup>, G. Berchem<sup>4</sup>, C. Camps<sup>1</sup>, R. de las Peñas<sup>1</sup>, A. Finzel<sup>2</sup>, J.P. Hervonen<sup>5</sup>, T. Joensuu<sup>5</sup>, A. Kong<sup>6</sup>, J. Mackay<sup>7</sup>, C. Mikropoulos<sup>6</sup>, K. Mokbel<sup>6</sup>, J.-L. Mouysset<sup>8</sup>, T. Perren<sup>9</sup>, G. Guitti<sup>2</sup>, J.-F. Laes<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>BE, <sup>3</sup>CEDEX/FR, <sup>4</sup>LU, <sup>5</sup>FI, <sup>6</sup>GB, <sup>7</sup>London/GB, <sup>8</sup>FR, <sup>9</sup>Yorkshire/GB
- 12:30 - 12:30 1341P - Comparison of Tissue-Based and Liquid Biopsy Genomic Tests to Guide Lung Cancer Therapy – Asian Experience  
M.-L. Nairismägi<sup>1</sup>, K.-C. Tung<sup>2</sup>, Y.-T. Yang<sup>2</sup>, Y.-J. Lu<sup>2</sup>, R.-S. Jhou<sup>2</sup>, P.-N. Yu<sup>2</sup>, Y.-T. Liu<sup>2</sup>, Y.-L. Hsieh<sup>2</sup>, S.L. Poon<sup>1</sup>, S.-J. Chen<sup>2</sup>, K.T. Tan<sup>2</sup>; <sup>1</sup>SG, <sup>2</sup>TW
- 12:30 - 12:30 1342P - 68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma  
W. van Boxtel, S. Lütje, I. van Engen- van Grunsven, G. Verhaegh, J. Schalken, M. Janssen, J. Nagarajah, M. Gotthardt, C. van Herpen; NL
- 12:30 - 12:30 1343P - Histology and detectability on ring-type dedicated breast PET in breast cancer  
Y. Kimura<sup>1</sup>, S. Sasada<sup>2</sup>, N. Goda<sup>1</sup>, K. Kajitani<sup>1</sup>, A. Emi<sup>1</sup>, N. Masumoto<sup>1</sup>, T. Kadoya<sup>1</sup>, R. Haruta<sup>1</sup>, T. Kataoka<sup>1</sup>, M. Okada<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hiroshima/JP
- 12:30 - 12:30 1344P - Thermal Liquid Biopsy as a new tool for Lung Cancer patients diagnostic: pilot study  
A. Rodrigo, O. Abian, A. Velazquez-Campoy, A. Callejo, S. Vega, A. Fernandez, O. Sánchez-Gracia, P. Iranzo Gomez, M. Cruellas, E. Quilez Bielsa, D. Isla; ES
- 12:30 - 12:30 1345P - Data-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center  
P. Heudel<sup>1</sup>, T. Durand<sup>2</sup>, B. Fervers<sup>2</sup>, F. Gomez<sup>2</sup>, M. Rivoire<sup>2</sup>, T. Bachelot<sup>1</sup>, L. Claude<sup>2</sup>, C. Chassagne-Clement<sup>2</sup>, F. Pilleul<sup>2</sup>, T. Mognetti<sup>2</sup>, Y. Devaux<sup>2</sup>, J.-L. Soubirou<sup>2</sup>, C. Lasset<sup>2</sup>, D. Perol<sup>2</sup>, G. Chvetzoff<sup>2</sup>, C. Pezet<sup>2</sup>, S. Beaupere<sup>2</sup>, P. Zrounba<sup>2</sup>, J. Blay<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR
- 12:30 - 12:30 1346P - Real world cfDNA collection in EGFR-mutant NSCLC  
N. Marcoux<sup>1</sup>, L. Sequist<sup>2</sup>, A. Hata<sup>1</sup>, M. Banwait<sup>1</sup>, I. Dagogo-Jack<sup>1</sup>, R. Nagy<sup>1</sup>, R. Lanman<sup>1</sup>, A. Muzikansky<sup>1</sup>, S.R. Digumarthy<sup>2</sup>, Z. Piotrowska<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MA/US

- 12:30 - 12:30 1347TiP - Proof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice  
C. Mastier, C. de la Fouchardière, J. Fayette, M. Sarabi, P. Heudel, A. Coulon, N. Banaste, E. Mercier-Bischoff, M. Barma, M. Brahmi, P. Cassier, S. Couchon Thauinat, L. Eberst, G. Fournier-Garin, P. Metral, F. Pilleul, J.-Y. Blay; FR
- 12:30 - 12:30 1351P - Impact of the 8th edition AJCC classification in early stage lung cancer  
A.S. Cortegoso Mosquera<sup>1</sup>, M. Vieito Villar<sup>1</sup>, C. Rodriguez Lopez<sup>1</sup>, V. Varela Pose<sup>1</sup>, V. Cebey Lopez<sup>2</sup>, J. Alvarez Fernandez<sup>2</sup>, M. Perez Martelo<sup>2</sup>, S. Aguin Losada<sup>2</sup>, U. Anido Herranz<sup>1</sup>, L. Leon Mateos<sup>2</sup>, F.J. Baron Duarte<sup>2</sup>, J.J. Garcia Gonzalez<sup>2</sup>; <sup>1</sup>La Coruña/ES, <sup>2</sup>ES
- 12:30 - 12:30 1352P - A Serum miRNA Biomarker Panel for the Detection of Early Stage Non-Small Cell Lung Cancer  
L. Ying<sup>1</sup>, R. Zou<sup>1</sup>, L. Du<sup>1</sup>, L. Shi<sup>1</sup>, N. Zhang<sup>1</sup>, J. Jin<sup>1</sup>, J. Wu<sup>1</sup>, F. Zhang<sup>1</sup>, K. Chen<sup>1</sup>, M. Huang<sup>1</sup>, Y. Zhang<sup>1</sup>, A. Lin<sup>1</sup>, H. Yu<sup>2</sup>, L. Zhou<sup>1</sup>, W. Mao<sup>1</sup>, D. Su<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>US
- 12:30 - 12:30 1353P - Split-lobe resections versus lobectomy for stage IA-IB peripheral non-small cell lung cancer.  
A. Levitckij, D. Chichevatov, M. Ter-Ovanesov, E. Sinev; RU
- 12:30 - 12:30 1354P - Patient reported outcomes after the treatment of early stage non-small cell lung cancer by stereotactic body radiotherapy compared to surgery.  
L. Alberts, H. Wolff, E.A. Kastelijn, F.J. Lagerwaard, S. Senan, S.Y. El Sharouni, F. Schramel, V. Coupe; NL
- 12:30 - 12:30 1355P - miR-200s in operated NSCLC: main drivers of epithelial to mesenchymal transition and independent prognostic factors  
A. Legras, FR
- 12:30 - 12:30 1356P - The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small-cell-lung-cancer  
E. Picard<sup>1</sup>, Y. Godet<sup>1</sup>, C. Laheurte<sup>1</sup>, L. Boullerot<sup>1</sup>, E. Lauret Marie Joseph<sup>1</sup>, M. Jacquin<sup>1</sup>, V. Kaulek<sup>1</sup>, G. Eberst<sup>1</sup>, B. Gaugler<sup>1</sup>, P. Jacoulet<sup>1</sup>, M. Gainet-Brun<sup>1</sup>, J. Lahoucarde<sup>1</sup>, H. Almotlak<sup>2</sup>, F. Le Pimpec-Barthes<sup>1</sup>, E. Fabre-Guillevin<sup>1</sup>, C. Borg<sup>1</sup>, V. Westeel<sup>2</sup>, O. Adotevi<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 1357P - A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma  
G. Toyokawa<sup>1</sup>, K. Takada<sup>2</sup>, R. Hamamoto<sup>2</sup>, Y. Yamada<sup>2</sup>, T. Tagawa<sup>2</sup>, F. Shoji<sup>2</sup>, K. Yamazaki<sup>2</sup>, Y. Oda<sup>2</sup>, S. Takeo<sup>2</sup>; <sup>1</sup>Fukuoka/JP, <sup>2</sup>JP
- 12:30 - 12:30 1358P - Comprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules  
K. Takamochi, M. Hosoya, K. Mogushi, T. Hayashi, M. Ito, H. Kawaji, Y. Hayashizaki, K. Suzuki; JP
- 12:30 - 12:30 1359P - Association between PD-L1 expression and survival in early-stage non-small cell carcinoma  
E. Gálvez, C. Gálvez Muñoz, A. Cotes Sanchís, A. Gonzaga López, M.M. Llorente Ostiategui, M. Montero Gómez, I. Aranda López, C. Llorca Ferrandiz; ES

- 12:30 - 12:30 1360P - Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC) – initial report of a phase I study, MK3475-223  
A. Ben Nun, N. Golan, E. Ofek, D. Urban, I. Kamer, D. Simansky, A. Onn, A. Ackerstein, S. Raskin, T. Shulimzon, N. Zeitlin, I. Redinsky, S. Halperin, M. Jurkowicz, J. Bar; IL
- 12:30 - 12:30 1361P - Neoadjuvant chemotherapy with bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer: survival results from a phase II feasibility study (NAVAL)  
Y. Tsutani<sup>1</sup>, Y. Miyata<sup>2</sup>, K. Suzuki<sup>2</sup>, K. Takamochi<sup>2</sup>, F. Tanaka<sup>2</sup>, H. Nakayama<sup>2</sup>, Y. Yamashita<sup>2</sup>, M. Oda<sup>2</sup>, M. Tsuboi<sup>3</sup>, M. Okada<sup>2</sup>; <sup>1</sup>Hiroshima/JP, <sup>2</sup>JP, <sup>3</sup>Chiba/JP
- 12:30 - 12:30 1362P - Clinical outcomes and treatment strategies of sarcomatoid carcinoma of the lung  
Y. Wang, CN
- 12:30 - 12:30 1366P - The impact of the new TNM classification on survival of patients in stage III non-small cell lung cancer  
M. Vrankar, K. Stanic; SI
- 12:30 - 12:30 1367P - Survival in never-smokers with non-small cell lung cancer: A population-based study from Sweden  
L. Löfling, S. Bahmanyar, A. Karimi, H. Kieler, M. Lambe, K. Lamberg Lundström, F. Sandin, G. Wagenius; SE
- 12:30 - 12:30 1368P - Clinical Features and Prognosis of Eighty-five Patients with Primary Pulmonary Lymphoepithelioma-like Carcinoma  
Q. Yin, G. Gao, C. Zhou, Z. Zhu, Y. Liu, X. Xie, X. Lin, Z. Xie, J. Zhang, O. Ming, S. li, R. Chen; CN
- 12:30 - 12:30 1369P - Meta-analysis of prognostic factors of completely resected pathologic N2 stage IIIA non-small cell lung cancer: including 11,384 patients.  
X. Zhan, N. Li; CN
- 12:30 - 12:30 1370P - The results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy  
E. Rodionov, S. Miller, S. Tuzikov, M. Tsyganov, N. Litviakov, L. Efteev, I. Deriusheva; RU
- 12:30 - 12:30 1371P - Final results of RENO study: randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC. SLCG 10/02  
M. Provencio Pulla<sup>1</sup>, R. de las Peñas<sup>2</sup>, N. Martinez Banaclocha<sup>3</sup>, R. MarsÉ Fabregat<sup>2</sup>, A. Insa Molla<sup>4</sup>, T. Moran<sup>2</sup>, M.A. Sala Gonzalez<sup>2</sup>, B. Massuti Sureda<sup>2</sup>, P. Mut Sanchis<sup>2</sup>, A.L. Ortega Granados<sup>5</sup>, J.M. Jurado<sup>2</sup>, J. Gomez Codina<sup>2</sup>, A. Artal-Cortes<sup>2</sup>, F. Vazquez<sup>6</sup>, V. Gutierrez Calderon<sup>2</sup>, P. Diz Tain<sup>2</sup>, N. Vinolas Segarra<sup>2</sup>, I. Maestu Maiques<sup>2</sup>, C. Camps<sup>2</sup>, M.D. Isla Casado<sup>2</sup>; <sup>1</sup>Madrid/ES, <sup>2</sup>ES, <sup>3</sup>Alicante/ES, <sup>4</sup>Valencia/ES, <sup>5</sup>Jaen/ES, <sup>6</sup>La Coruña/ES
- 12:30 - 12:30 1372P - Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018  
Y. Takiguchi<sup>1</sup>, K. Yamada<sup>2</sup>, H. Tanaka<sup>3</sup>, K. Kubota<sup>2</sup>, K. Kishi<sup>2</sup>, T. Shimokawa<sup>4</sup>, H. Saito<sup>2</sup>, Y. Hosomi<sup>2</sup>, T. Kato<sup>2</sup>, N. Nogami<sup>2</sup>, S. Igawa<sup>5</sup>, T. Kasai<sup>2</sup>, Y. Nakamura<sup>2</sup>, T. Yamanaka<sup>2</sup>, H. Okamoto<sup>4</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>JP, <sup>3</sup>NA, <sup>4</sup>Kanagawa/JP, <sup>5</sup>Minami-Ii, Sagami-hara/JP

- 12:30 - 12:30 1373P - Identification of subjects with locally advanced lung cancer who are likely to respond to standard-of-care chemoradiotherapy by a longitudinal monitoring of circulating tumor DNA (ctDNA) using a comprehensive ultra-sensitive NGS assay  
P. Vitazka<sup>1</sup>, N. Tikoo<sup>2</sup>, A. Balasubramanyam<sup>2</sup>, L. Xi<sup>2</sup>, S. Yaung<sup>2</sup>, E. Kwok<sup>2</sup>, A. Lovejoy<sup>2</sup>, D. Klass<sup>2</sup>, M. Heibeck<sup>3</sup>, K. Probst<sup>3</sup>, A. Rehfeldt<sup>3</sup>, E. Meldgaard<sup>4</sup>, A. Madsen<sup>4</sup>, M. Clement<sup>4</sup>, J. Palma<sup>2</sup>, B. Sorensen<sup>4</sup>, P. Meldgaard<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>DE, <sup>4</sup>DK
- 12:30 - 12:30 1374P - Correlations between Ape1/Ref-1, ICAM-1 and IL-17A Levels in Serum and Radiation Pneumonitis for Local Advanced Non-small Cell Lung Cancer Patients  
L. Guo, CN
- 12:30 - 12:30 1375P - Programmed cell death ligand 1 expression and CD8 positive lymphocytes in stage III non-small cell lung cancer after neo adjuvant concurrent chemoradiotherapy and their relation with prognosis  
E. Choe, C. Yoon-Jin, H.-S. Shim, C.-Y. Lee, B.C. Cho, H.-R. Kim; KR
- 12:30 - 12:30 1376P - The standard of care for stage III NSCLC in the era of Immunotherapy: an Italian National Survey on the current pattern of care among Italian Thoracic Oncologists  
A. Bruni<sup>1</sup>, F. Grossi<sup>1</sup>, F. Katia<sup>1</sup>, E. Capelletto<sup>2</sup>, L. Buffoni<sup>1</sup>, S. Badellino<sup>1</sup>, V. Poletti<sup>1</sup>, R. Chiari<sup>1</sup>, N. Giaj Levra<sup>1</sup>, G.L. Banna<sup>1</sup>, S. Vagge<sup>1</sup>, P. Borghetti<sup>1</sup>, E. Baldini<sup>1</sup>, E. Bria<sup>1</sup>, M. Tiseo<sup>1</sup>, M. Paci<sup>1</sup>, P. Ciammella<sup>1</sup>, M. Taraborrelli<sup>1</sup>, U. Ricardi<sup>1</sup>, V. Scotti<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>TO/IT
- 12:30 - 12:30 1387P - Randomized, double-blind, placebo (P)-controlled phase 3 noninferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: an ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) ≤10.0 g/dL  
D. Henry<sup>1</sup>, V. Hirsh<sup>2</sup>, K. Kubota<sup>3</sup>, T. Steinmetz<sup>4</sup>, G. Thomas<sup>1</sup>, J.-H. Kang<sup>5</sup>, D. Gordon<sup>1</sup>, S. Orlov<sup>6</sup>, A. Fleishman<sup>1</sup>, C. De Oliveira Brandao<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>Quebec/CA, <sup>3</sup>JP, <sup>4</sup>DE, <sup>5</sup>KR, <sup>6</sup>RU
- 12:30 - 12:30 1388P - Incidence of cardiac toxicities in patients with advanced non-small-cell lung cancer treated with osimertinib: a combined analysis of two phase III randomized controlled trials  
K. Thein<sup>1</sup>, S. Swarup<sup>2</sup>, S. Ball<sup>2</sup>, M. Quirch<sup>2</sup>, Y. Vorakunthada<sup>2</sup>, K. Htwe<sup>3</sup>, N. D'Cunha<sup>2</sup>, F. Hardwicke<sup>2</sup>, S. Awasthi<sup>2</sup>, L. Tijani<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>NY/US
- 12:30 - 12:30 1389P - Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors  
G. Fucà, M. Poggi, G. Galli, M. Imbimbo, G. Lo Russo, D. Signorelli, M. Vitali, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, C. Proto; IT
- 12:30 - 12:30 1390P - Dose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: data from ALTER0303  
L. Zhang, X. Si, H. Wang, X. Zhang, M. Wang, B. Han, K. Li, Q. Wang, J. Shi, Z. Wang, Y. Cheng, J. He, Y. Shi, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, B. Li, Y. Chen; CN
- 12:30 - 12:30 1391P - Immune-Related Adverse Events (irAEs) and Survival (OS) in Metastatic Non-small Cell Lung Cancer (mNSCLC) Patients (pts) Treated With Immunotherapy  
M. Melià Sosa<sup>1</sup>, C. Puchades<sup>1</sup>, J. Mendez<sup>1</sup>, A. Torres<sup>1</sup>, C. Rodrigo<sup>1</sup>, G. Gimeno<sup>1</sup>, E. Rama<sup>1</sup>, A. Martínez-Castillo<sup>1</sup>, J. Caballero Daroqui<sup>1</sup>, J. Gomez Codina<sup>1</sup>, O. Juan-Vidal<sup>1</sup>, D. Lorente<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>Surrey/GB



- 12:30 - 12:30 1392P - Dose-determination results from a Phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)  
A. Santoro<sup>1</sup>, W.-C. Su<sup>2</sup>, A. Navarro<sup>3</sup>, M. Simonelli<sup>1</sup>, J.C.-H. Yang<sup>2</sup>, A. Ardizzoni<sup>4</sup>, F. Barlesi<sup>5</sup>, J.H. Kang<sup>6</sup>, S. Didominick<sup>7</sup>, A. Abdelhady<sup>8</sup>, B. Goswami<sup>7</sup>, A. Crystal<sup>7</sup>, E. Felip Font<sup>3</sup>; <sup>1</sup>(MI)/IT, <sup>2</sup>TW, <sup>3</sup>ES, <sup>4</sup>IT, <sup>5</sup>CEDEX 20/FR, <sup>6</sup>KP, <sup>7</sup>MA/US, <sup>8</sup>IN
- 12:30 - 12:30 1393P - Safety profile and effectiveness of alectinib in the real world surveillance study of 1251 Japanese patients with ALK-positive non-small cell lung cancer  
Y. Ohe<sup>1</sup>, N. Yamamoto<sup>1</sup>, A. Gemma<sup>1</sup>, M. Kusumoto<sup>1</sup>, I. Yamada<sup>1</sup>, T. Ishii<sup>1</sup>, N. Masuda<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Minami-Ii, Sagamihara/JP
- 12:30 - 12:30 1394P - A multicenter study of mutational profiling of Chinese ALK+ non-small cell lung cancer patients with required resistant to crizotinib using next generation sequencing  
C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, G. Chen, M. Fang, T. Lv, Y. Song; CN
- 12:30 - 12:30 1395P - Lung cancers carrying distinct ALK fusion variants demonstrate similar responsiveness to ALK tyrosine kinase inhibitors  
E. Imyanitov, N. Mitiushkina, V. Tiurin, A. Iyevleva, M. Holmatov, E. Filippova, F. Moiseyenko, N. Levchenko, S. Odintsova, A. Lozhkina, A. Togo, N. Karaseva, V. Moiseyenko, S. Orlov; RU
- 12:30 - 12:30 1396P - Efficacy and Safety of Crizotinib in Previously Treated Patients (Pts) with ALK+ Advanced Non-Small-Cell Lung Cancer (NSCLC) aged ≥65 years (y)  
D. Moro-Sibilot<sup>1</sup>, M.-J. Ahn<sup>2</sup>, B. Halmos<sup>3</sup>, D.-W. Kim<sup>2</sup>, G. Riely<sup>4</sup>, A. Shaw<sup>5</sup>, P.-C. Yang<sup>6</sup>, S. Lanzalone<sup>7</sup>, A. Polli<sup>7</sup>, K. Wilner<sup>8</sup>, J. De Castro Carpeño<sup>9</sup>; <sup>1</sup>FR, <sup>2</sup>KR, <sup>3</sup>NY/US, <sup>4</sup>US, <sup>5</sup>MA/US, <sup>6</sup>TW, <sup>7</sup>IT, <sup>8</sup>CA/US, <sup>9</sup>ES
- 12:30 - 12:30 1397P - Long-Term Safety of Crizotinib in Previously Treated Patients (Pts) with ALK-positive Advanced/Metastatic Non-Small-Cell Lung Cancer (NSCLC)  
L. Crinò<sup>1</sup>, M.-J. Ahn<sup>2</sup>, J.-Y. Han<sup>2</sup>, X. Liu<sup>3</sup>, S.-H. Ou<sup>4</sup>, A. Shaw<sup>5</sup>, P.-C. Yang<sup>6</sup>, Y.-K. Shi<sup>3</sup>, S. Lanzalone<sup>1</sup>, A. Polli<sup>1</sup>, K. Wilner<sup>4</sup>, D.-W. Kim<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>KR, <sup>3</sup>CN, <sup>4</sup>CA/US, <sup>5</sup>MA/US, <sup>6</sup>TW
- 12:30 - 12:30 1398P - Real-World Progression-Free Survival of Patients on Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) for ALK+ Non-Small Cell Lung Cancer (NSCLC)  
M. Jahanzeb<sup>1</sup>, H. Lin<sup>2</sup>, X. Pan<sup>2</sup>, Y. Yin<sup>2</sup>, P. Hou<sup>2</sup>, B. Nordstrom<sup>2</sup>, A. Desai<sup>2</sup>, M. Socinski<sup>3</sup>; <sup>1</sup>FL/US, <sup>2</sup>MA/US, <sup>3</sup>PA/US
- 12:30 - 12:30 1399P - Impact of Lorlatinib on Patient-Reported Outcomes (PROs) in Patients (Pts) With Advanced ALK+ or ROS1+ Non-Small Cell Lung Cancer (NSCLC)  
S. Peters<sup>1</sup>, A. Shaw<sup>2</sup>, B. Besse<sup>3</sup>, E. Felip Font<sup>4</sup>, B. Solomon<sup>5</sup>, R. Soo<sup>6</sup>, A. Bearz<sup>7</sup>, S. Gadgeel<sup>8</sup>, C.-C. Lin<sup>9</sup>, S. Kao<sup>10</sup>, T. Seto<sup>11</sup>, E. Masters<sup>12</sup>, A. Abbattista<sup>7</sup>, J. Clancy<sup>2</sup>, H. Thurm<sup>13</sup>, A. Reisman<sup>12</sup>, D.R. Camidge<sup>8</sup>; <sup>1</sup>CH, <sup>2</sup>MA/US, <sup>3</sup>CEDEX/FR, <sup>4</sup>ES, <sup>5</sup>VIC/AU, <sup>6</sup>SG, <sup>7</sup>IT, <sup>8</sup>US, <sup>9</sup>TW, <sup>10</sup>AU, <sup>11</sup>JP, <sup>12</sup>NY/US, <sup>13</sup>CA/US
- 12:30 - 12:30 1401P - The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey  
S. Kilickap, Ö. Ölmez, I. Cicin, U. Demirci, O. Alan, D. Cabuk, T. Şakalar, A. Tatlı, F. Başol Buğdaycı, Y. Eralp, M. Uysal, A. Demirkazık, B. Bilgin, B. Yıldız, M. Karaağaç, K. Okutur, A. Sakin; TR

- 12:30 - 12:30 1402P - Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer  
D. Harada<sup>1</sup>, A. Hata<sup>2</sup>, C. Okuda<sup>1</sup>, R. Kaji<sup>1</sup>, Y. Masuda<sup>1</sup>, Y. Takechi<sup>1</sup>, T. Kozuki<sup>1</sup>, N. Nogami<sup>1</sup>, N. Katakami<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hyogo/JP
- 12:30 - 12:30 1403P - Open-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (≥75 years old) patients (pts) with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC): TORG1323  
T. Honda, T. Kouzuki, Y. Tsunozuka, N. Seki, T. Shibayama, T. Okimoto, H. Taniguchi, Y. Takeda, N. Hata, K. Sugimoto, N. Takahashi, K. Sakai, T. Nishimura, S. Ikeda, S. Watanabe, K. Mori, T. Shinkai; JP
- 12:30 - 12:30 1404P - Safety of Nintedanib plus Docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: the preliminary results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial  
A.M. Morelli<sup>1</sup>, M.R. Migliorino<sup>1</sup>, A. Morabito<sup>1</sup>, R. Chiari<sup>1</sup>, F. Grossi<sup>1</sup>, P. Bordi<sup>1</sup>, F. Di Costanzo<sup>1</sup>, A. Delmonte<sup>2</sup>, G. Romano<sup>1</sup>, A. Misino<sup>1</sup>, V. Scotti<sup>1</sup>, V. Gregorc<sup>1</sup>, S. Pisconti<sup>1</sup>, G.L. Ceresoli<sup>1</sup>, A. Del Conte<sup>1</sup>, I. Colantonio<sup>1</sup>, L. Ciuffreda<sup>1</sup>, E. Capelletto<sup>1</sup>, I. Stura<sup>1</sup>, S. Novello<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Forlì-Cesena/IT
- 12:30 - 12:30 1405P - Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): results from phase II trial (IFCT-1001 CHIVA)  
M. Wislez<sup>1</sup>, H. Blons<sup>1</sup>, C. Domblides<sup>1</sup>, F. Barlesi<sup>2</sup>, J. Mazieres<sup>1</sup>, I. Monnet<sup>1</sup>, L. Kiakouama Maleka<sup>3</sup>, X. Quantin<sup>4</sup>, L. Taillade<sup>1</sup>, H. Lena<sup>5</sup>, P. Fraisse<sup>1</sup>, H. Janicot<sup>1</sup>, C. Audigier Valette<sup>5</sup>, E. Amour<sup>1</sup>, A. Langlais<sup>1</sup>, N. Rabbe<sup>1</sup>, J. Cadranet<sup>1</sup>, P. Laurent puig<sup>1</sup>, A. Lavolé<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 20/FR, <sup>3</sup>CEDEX 4/FR, <sup>4</sup>CEDEX 5/FR, <sup>5</sup>CEDEX/FR
- 12:30 - 12:30 1406P - Final results of the concordance analysis of PD-L1 immunohistochemistry (IHC) assays and polymerase chain reaction (PCR) in non-small lung cancer (NSCLC) patients  
I. Tsimafeyeu, E. Imyanitov, L. Zavalishina, G. Raskin, P. Povilaitite, N. Savelov, E. Kharitonova, A. Romyantsev, I. Pugach, Y. Andreeva, A. Petrov, G. Frank, S. Tjulandin; RU
- 12:30 - 12:30 1407P - Derived Neutrophil-to Lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during Immune checkpoint inhibitors (ICI) in advanced Non-small Cell Lung Cancer (NSCLC) patients  
L. Mezquita<sup>1</sup>, K. Arbour<sup>2</sup>, E. Auclin<sup>1</sup>, D. Saravia<sup>2</sup>, H. Rizvi<sup>2</sup>, L. Hendriks<sup>3</sup>, D. Planchard<sup>1</sup>, W. Park<sup>2</sup>, E. Nadal<sup>4</sup>, J.C. Ruffinelli Rodriguez<sup>5</sup>, S. Ponce<sup>5</sup>, C. Audigier-Valette<sup>1</sup>, A.P. Mariniello<sup>6</sup>, G. Zalcman<sup>1</sup>, M. Majem<sup>5</sup>, G. Schiavone<sup>6</sup>, A.-M. Dingemans<sup>3</sup>, G. Lopes<sup>7</sup>, M.D. Hellmann<sup>2</sup>, B. Besse<sup>8</sup>; <sup>1</sup>FR, <sup>2</sup>US, <sup>3</sup>NL, <sup>4</sup>Barcelona/ES, <sup>5</sup>ES, <sup>6</sup>IT, <sup>7</sup>FL/US, <sup>8</sup>CEDEX/FR
- 12:30 - 12:30 1408P - Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)  
L. Hendriks<sup>1</sup>, C. Henon<sup>2</sup>, E. Auclin<sup>2</sup>, L. Mezquita<sup>2</sup>, R. Ferrara<sup>2</sup>, C. Audigier Valette<sup>3</sup>, J. Mazieres<sup>2</sup>, C. Lefebvre<sup>2</sup>, S. Le Moulec<sup>4</sup>, B. Duchemann<sup>3</sup>, C. Le Pechoux<sup>3</sup>, A. Botticella<sup>5</sup>, S. Ammari<sup>2</sup>, A. Gazzah<sup>2</sup>, C. Caramella<sup>2</sup>, J. Adam<sup>2</sup>, D. Planchard<sup>2</sup>, D. De Ruyscher<sup>1</sup>, A.-M. Dingemans<sup>1</sup>, B. Besse<sup>3</sup>; <sup>1</sup>NL, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 5/FR, <sup>5</sup>BE

- 12:30 - 12:30 1409P - Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)  
M. Riudavets Melia, I. Gabriela Sullivan, A. Barba Joaquín, G. Anguera Palacios, L. del Carpio, C. Molto Valiente, S.D. Camacho Arellano, S. Moron Asensio, P. Gomila Pons, M. Andres Granyó, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, C. González Blanco, A. Barnadas Molins, I. Gich Saladich, M. Majem Tarruella; ES
- 12:30 - 12:30 1410P - Tumor mutation burden (TMB) estimation using small-sized targeted next-generation sequencing (NGS) to predict efficacy of immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)  
T. Ikeda<sup>1</sup>, K. Ohashi<sup>1</sup>, A. Sekine<sup>1</sup>, Y. Ohe<sup>1</sup>, T. Tsuda<sup>1</sup>, Y. Kataoka<sup>1</sup>, S. Hara<sup>1</sup>, N. Okamoto<sup>1</sup>, M. Kodani<sup>1</sup>, S. Matsumoto<sup>1</sup>, K. Goto<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP
- 12:30 - 12:30 1411P - Identification of genomic markers of sensitivity and resistance to checkpoint inhibitors in non-small cell lung cancer in a real world clinico-genomic database  
K. Murugesan<sup>1</sup>, G. Li<sup>2</sup>, G. Kaushik<sup>2</sup>, G. Singal<sup>2</sup>, V. Miller<sup>2</sup>, G. Frampton<sup>2</sup>, L. Albacker<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 12:30 - 12:30 1412P - HLA-DrbB1 heterozygosis and early auto-antibody rise predict prolonged survival in metastatic NSCLC patients undergone PD-1 blockade.  
P. Correale<sup>1</sup>, R. Giannicola<sup>1</sup>, C. Botta<sup>1</sup>, P.S. Tagliaferri<sup>1</sup>, P. Pastina<sup>1</sup>, M. Monoriti<sup>1</sup>, R. Saladino<sup>1</sup>, A. Falzea<sup>1</sup>, V. Barbieri<sup>1</sup>, G. D'Arrigo<sup>1</sup>, G. Tripepi<sup>1</sup>, P. Tassone<sup>2</sup>, L. Pirtoli<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Calabria/IT
- 12:30 - 12:30 1413P - Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small-cell lung cancer (NSCLC) patients  
X. Mielgo Rubio<sup>1</sup>, M. Sereno Moyano<sup>2</sup>, L. Chara<sup>2</sup>, R. López-Castro<sup>2</sup>, J. Rubio-Martínez<sup>2</sup>, A. Velastegui<sup>2</sup>, C. Olier-Garate<sup>2</sup>, S. Falagán<sup>2</sup>, I. Gómez-Barreda<sup>2</sup>, A. Riquelme<sup>2</sup>, J. Silva-Ruiz<sup>2</sup>, J. Moreno-Rubio<sup>2</sup>, C. López<sup>2</sup>, C. Bueno<sup>2</sup>, A. Cardeña<sup>2</sup>, E. Pérez-Fernández<sup>2</sup>, M.P. Martí-Castelló<sup>2</sup>, M. Sotelo-Lezama<sup>2</sup>; <sup>1</sup>Madrid/ES, <sup>2</sup>ES
- 12:30 - 12:30 1414P - Prediction of PD-1 immunotherapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model  
H. Wakelee<sup>1</sup>, J. Aredo<sup>1</sup>, S. Vali<sup>1</sup>, N. Singh<sup>2</sup>, S. Vasista<sup>2</sup>, U. Mitra<sup>2</sup>, T. Abbasi<sup>1</sup>, S. Padda<sup>1</sup>; <sup>1</sup>CA/US, <sup>2</sup>IN
- 12:30 - 12:30 1415P - Association between Early Immune-Related Adverse Events and Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab as First-line Therapy: A Retrospective Multicenter Cohort Study  
K. Hosoya, D. Fujimoto, M. Tamiya, A. Tamiya, H. Suzuki, K. Hirano, T. Yokoyama, M. Morita, Y. Fukuda, M. Kanazu, T. Makio; JP
- 12:30 - 12:30 1416P - Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO).  
R. Ferrara<sup>1</sup>, M. Naigeon<sup>1</sup>, E. Auclin<sup>1</sup>, B. Duchemann<sup>2</sup>, L. Cassard<sup>1</sup>, J. Medhi<sup>1</sup>, L. Boselli<sup>1</sup>, J. Grivel<sup>1</sup>, A. Desnoyer<sup>1</sup>, L. Mezquita<sup>1</sup>, F. Aboubakar<sup>3</sup>, L. Hendriks<sup>4</sup>, D. Planchard<sup>1</sup>, C. Caramella<sup>1</sup>, J. Remon<sup>5</sup>, M. Ngocamus<sup>1</sup>, C. Nicotra<sup>1</sup>, B. Besse<sup>2</sup>, N. Chaput<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>BE, <sup>4</sup>NL, <sup>5</sup>Barcelona/ES
- 12:30 - 12:30 1417P - Preliminary results of PRINCiPe (Predictors of Resistance to Immunotherapy with Nivolumab [NIV]) study in advanced pretreated non-small-cell lung cancer (APNSCLC), investigating the role of an Immune Genomic Signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations.

S. Pilotto, G. Grizzi, I. Sperduti, M. Simbolo, C. Vicentini, A. Caliò, M. Caccese, A. Mafficini, L. Carbognin, V. Corbo, A. Gkountakos, A. Santo, M. Infante, M. Brunelli, A. Scarpa, G. Tortora, E. Bria; IT

- 12:30 - 12:30 1418P - The need of re-biopsy: increase in PD-L1 expression from initial stage to recurrence of non-small cell lung cancer  
M. Lacour, S.Y. Lee, U. Rulle, A. Soltermann, E.J. Rushing, D. Soldini, S. Hiltbrunner, W. Weder, A. Curioni-Fontecedro; CH
- 12:30 - 12:30 1419P - Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer  
G. Galli, M. Poggi, G. Fucà, G. Lo Russo, C. Proto, D. Signorelli, M. Vitali, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino, M. Imbimbo; IT
- 12:30 - 12:30 1420P - Soluble immune biomarkers to anti-PD1 treatment in Non-Small-Cell Lung Cancer (NSCLC)  
J. Garde-Noguera, E. Jantus-Lewintre, B. Honrubia Peris, S. Gallach Garcia, F. ZHANG, J. García Sánchez, S. Calabuig Fariñas, A. Blasco Cordellat, N. Piera Molons, J. Vidal-Martinez, J. Murado-Pardo, L.D. Condori Farfan, R. Gisbert-Criado, E. Escorihuela, C. Camps; ES
- 12:30 - 12:30 1421P - Clinical characterization of rare EGFR mutations in non-small cell lung cancer and in silico prediction of drug sensitivity  
S. Ikemura<sup>1</sup>, H. Yasuda<sup>1</sup>, S. Matsumoto<sup>1</sup>, M. Kamada<sup>1</sup>, T. Betsuyaku<sup>1</sup>, Y. Okuno<sup>1</sup>, K. Goto<sup>2</sup>, K. Tsuchihara<sup>1</sup>, K. Soejima<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP
- 12:30 - 12:30 1422P - Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial  
A. Curioni<sup>1</sup>, E. Felip Font<sup>2</sup>, U. Dafni<sup>3</sup>, M.-A. Molina<sup>2</sup>, O. Gautschi<sup>1</sup>, S. Peters<sup>1</sup>, B. Massuti<sup>2</sup>, R. Palmero<sup>2</sup>, S. Ponce<sup>2</sup>, E. Carcereny<sup>2</sup>, M. Früh<sup>1</sup>, M. Pless<sup>1</sup>, S. Popat<sup>4</sup>, S. Cuffe<sup>5</sup>, N. Karachaliou<sup>2</sup>, R. Kammler<sup>1</sup>, M. Kassapian<sup>6</sup>, H. Roschitzki-Voser<sup>7</sup>, R. Stahel<sup>1</sup>, R. Rosell<sup>2</sup>; <sup>1</sup>CH, <sup>2</sup>ES, <sup>3</sup>Attica/GR, <sup>4</sup>GB, <sup>5</sup>IE, <sup>6</sup>GR, <sup>7</sup>Bern/CH
- 12:30 - 12:30 1423P - Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival?  
I. Prediletto, E. Vasile, R. Bruno, E. Macerola, G. Pasquini, G. Fontanini, A. Falcone; IT
- 12:30 - 12:30 1424P - The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)  
K. Usui, T. Yokoyama, A. Kishihara, Y. Mori, Y. Takeda, H. Ishida, N. Kusano, K. Kishi, U. Katsushima, T. Kuwako, H. Aono, Y. Shikama, K. Minato, H. Matsushima, K. Uemura, Y. Ohashi, H. Kunitoh; JP
- 12:30 - 12:30 1425P - ABCB1 Genetic Polymorphism and Pharmacokinetic Analysis of Low Dose Erlotinib in Frail Patients with EGFR Mutation (mt) -positive, Non-small Cell Lung Cancer: TORG1425  
S. Miyamoto<sup>1</sup>, T. Tokkito<sup>1</sup>, A. Bessho<sup>2</sup>, N. Fukamatsu<sup>1</sup>, H. Kunitoh<sup>1</sup>, M. Ishii<sup>1</sup>, H. Tanaka<sup>1</sup>, H. Aono<sup>1</sup>, T. Fukui<sup>1</sup>, K. Kusaka<sup>1</sup>, Y. Hosomi<sup>1</sup>, A. Hamada<sup>3</sup>, K. Yamada<sup>1</sup>, H. Okamoto<sup>4</sup>; <sup>1</sup>JP, <sup>2</sup>Okayama Prefecture/JJ, <sup>3</sup>JO, <sup>4</sup>Kanagawa/JJ
- 12:30 - 12:30 1426P - Longitudinal plasma monitoring of subjects treated with EGFR-TKIs allows better understanding of evolution of acquired resistance and can inform optimal treatment strategies

J. Palma<sup>1</sup>, P. Vitazka<sup>2</sup>, N. Tikoo<sup>1</sup>, A. Balasubramanyam<sup>1</sup>, L. Xi<sup>1</sup>, S. Yaung<sup>1</sup>, E. Kwok<sup>1</sup>, A. Lovejoy<sup>1</sup>, D. Klass<sup>1</sup>, M. Heibeck<sup>3</sup>, K. Probst<sup>3</sup>, A. Rehfeldt<sup>3</sup>, E. Meldgaard<sup>4</sup>, A. Madsen<sup>4</sup>, M. Clement<sup>4</sup>, B. Sorensen<sup>4</sup>, P. Meldgaard<sup>4</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>DE, <sup>4</sup>DK

- 12:30 - 12:30 1427P - Applicability of Lung-molGPA Index in Non-Small Cell Lung Cancer Patients with Various Gene Alterations and Brain Metastases  
K. Chen<sup>1</sup>, Y. Fan<sup>1</sup>, Z. Huang<sup>1</sup>, Y. Xu<sup>2</sup>, X. Yu<sup>1</sup>, H. Wang<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>Zhejiang/CN
- 12:30 - 12:30 1428P - Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)  
F. Griesinger, W. Eberhardt, A. Nusch, M. Reiser, C. Bernhardt, N. Marschner, M. Jaenicke, A. Fleitz, L. Spring, J. Sahlmann, A. Karatas, A. Hipper, W. Weichert, A. Rittmeyer, H. Bischoff, C. Waller, M. Thomas; DE
- 12:30 - 12:30 1429P - Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients.  
M.H. Hong<sup>1</sup>, M.H. Kim<sup>1</sup>, S.-Y. Kim<sup>1</sup>, S.G. Heo<sup>1</sup>, H.-N. Kang<sup>1</sup>, C.-W. Park<sup>1</sup>, J.C. Barrett<sup>2</sup>, D. Stetson<sup>2</sup>, J. Chmielecki<sup>2</sup>, A. Markovets<sup>2</sup>, H.R. Kim<sup>1</sup>, B.C. Cho<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>US
- 12:30 - 12:30 1430P - Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC).  
M. Kushnir<sup>1</sup>, H. Winter<sup>1</sup>, C. Murias<sup>1</sup>, P. Bains<sup>1</sup>, C. Abbosh<sup>2</sup>, D. Papadatos-Pastos<sup>1</sup>, T. Newsome-Davis<sup>1</sup>, T. Ahmed<sup>1</sup>, C. Swanton<sup>1</sup>, M. Forster<sup>3</sup>, D. Moore<sup>1</sup>, P. Bennett<sup>1</sup>, I. Faull<sup>4</sup>, R. Lanman<sup>5</sup>, H.-T. Arkenau<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Yorkshire/GB, <sup>3</sup>London/GB, <sup>4</sup>ES, <sup>5</sup>US
- 12:30 - 12:30 1431P - TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC  
P. Christopoulos, M. Kirchner, F. Bozorgmehr, V. Endris, M. Elsayed, N. Magios, A.-L. Volckmar, R. Penzel, F. Herth, C. Heussel, H. Winter, T. Muley, M. Meister, J. Fischer, S. Rieken, F. Lasitschka, H. Bischoff, P. Schirmacher, M. Thomas, A. Stenzinger; DE
- 12:30 - 12:30 1432P - Hybrid capture NGS reliably detects a spectrum of clinically significant genetic aberrations in both, primary diagnostics and the relapse scenario.  
S. Schatz<sup>1</sup>, M. Falk<sup>2</sup>, R. Menon<sup>1</sup>, L. Heukamp<sup>1</sup>, J. Roeper<sup>1</sup>, F. Griesinger<sup>1</sup>, M. Tiemann<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>Hamburg/DE
- 12:30 - 12:30 1433P - Prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in advanced non-small cell lung cancer.  
K. Adamowicz, A. Romanowska, R. Zaucha; PL
- 12:30 - 12:30 1434P - A Phase II Study of Nedaplatin and nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer (KRSG1302)  
T. Sugiyama, T. Kasai, N. Koyama, K. Kobayashi, E. Hoshi, M. Nakayama, K. Mori; JP
- 12:30 - 12:30 1435P - Bevacizumab as first-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC) in patients aged over 65 years in France. Final results of the AVANTAGE study.  
F. Lionel<sup>1</sup>, D. Perol<sup>1</sup>, P.-J. Souquet<sup>2</sup>, H. Le Caer<sup>1</sup>, E. Dansin<sup>2</sup>, C. Audigier Valette<sup>2</sup>, J.-L. Mouysset<sup>1</sup>, M.L. Uffredi<sup>1</sup>, M. Ionescu-Goga<sup>1</sup>, K. Veerabudun<sup>1</sup>, Y. Lelarge<sup>1</sup>, E. Fabre-Guillevin<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR

- 12:30 - 12:30 1436P - Randomized phase 2 study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small-cell lung cancer (CLEAR study)  
R. Koyama<sup>1</sup>, H. Udagawa<sup>1</sup>, E. Sugiyama<sup>2</sup>, K. Komuta<sup>1</sup>, M. Mori<sup>1</sup>, T. Yokoyama<sup>1</sup>, T. Sasaki<sup>1</sup>, H. Saito<sup>1</sup>, H. Ishida<sup>1</sup>, H. Nakagawa<sup>1</sup>, A. Sekine<sup>1</sup>, A. Tamura<sup>1</sup>, M. Shingyoji<sup>1</sup>, K. Mizuno<sup>1</sup>, A. Nakamura<sup>1</sup>, A. Kinoshita<sup>3</sup>, T. Yamanaka<sup>1</sup>, K. Goto<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP, <sup>3</sup>Nagasaki/JP
- 12:30 - 12:30 1437P - Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)  
R. Plummer<sup>1</sup>, N. Cook<sup>2</sup>, T. Arkenau<sup>3</sup>, J. Melear<sup>4</sup>, C. Redfern<sup>4</sup>, A. Spira<sup>5</sup>, K. Chung<sup>6</sup>, T. Haddad<sup>7</sup>, S. Ramalingam<sup>8</sup>, R. Wesolowski<sup>4</sup>, E. Dean<sup>3</sup>, T. Goddemeier<sup>9</sup>, M. Falk<sup>9</sup>, G. Shapiro<sup>4</sup>; <sup>1</sup>Tyne and Wear/GB, <sup>2</sup>Cambridgeshire/GB, <sup>3</sup>GB, <sup>4</sup>US, <sup>5</sup>VA/US, <sup>6</sup>SC/US, <sup>7</sup>MN/US, <sup>8</sup>GA/US, <sup>9</sup>DE
- 12:30 - 12:30 1438P - A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease  
Y. Usui<sup>1</sup>, H. Kenmotsu<sup>2</sup>, K. Mori<sup>1</sup>, A. Ono<sup>2</sup>, K. Yoh<sup>3</sup>, T. Baba<sup>1</sup>, Y. Fujiwara<sup>1</sup>, O. Yamaguchi<sup>1</sup>, R. Ko<sup>1</sup>, H. Okamoto<sup>4</sup>, N. Yamamoto<sup>1</sup>, T. Ninomiya<sup>1</sup>, T. Ogura<sup>1</sup>, T. Kato<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/JP, <sup>3</sup>Chiba/JP, <sup>4</sup>Kanagawa/JP
- 12:30 - 12:30 1439P - HALO 107-201: A Phase 1b, open-label, multicenter study of pegvorhialuronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small-cell lung cancer (NSCLC)  
M. Baumgart<sup>1</sup>, M. Muhsin<sup>2</sup>, W. Wu<sup>3</sup>, N. Gabrail<sup>4</sup>; <sup>1</sup>NY/US, <sup>2</sup>US, <sup>3</sup>CA/US, <sup>4</sup>OH/US
- 12:30 - 12:30 1440P - Randomised phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with OV versus gemcitabine (GEM) and P followed by maintenance with GEM as first-line chemotherapy in advanced Non-Small-Cell Lung Cancer (NSCLC) patients (pts) with squamous (sq) histological type.  
F. Grossi<sup>1</sup>, P. Jaskiewicz<sup>2</sup>, E. Pichon<sup>3</sup>, G. Czyzewicz<sup>4</sup>, D. Kowalski<sup>2</sup>, L. Ciuffreda<sup>1</sup>, R. Garcia Gomez<sup>5</sup>, S. Caruso<sup>6</sup>, J. Bosch Barrera<sup>5</sup>, C. Ta Thanh Minh<sup>6</sup>, S. Gautier<sup>6</sup>, H. Hervieu<sup>6</sup>, S. Henriët<sup>6</sup>, G. De Castro Jr.<sup>7</sup>; <sup>1</sup>IT, <sup>2</sup>PL, <sup>3</sup>CEDEX 9/FR, <sup>4</sup>Krakow/PL, <sup>5</sup>ES, <sup>6</sup>FR, <sup>7</sup>SP/BR
- 12:30 - 12:30 1441P - Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026  
Y. Kawashima, T. Fukuhara, N. Furuya, H. Saito, K. Watanabe, S. Iwasawa, Y. Tsunozuka, O. Yamaguchi, M. Okada, K. Yoshimori, I. Nakachi, A. Gemma, K. Azuma, K. Hagiwara, T. Nukiwa, S. Morita, K. Kobayashi, M. Maemondo; JP
- 12:30 - 12:30 1442P - Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): final analysis of the global Phase III LUX-Lung 8 (LL8) trial  
G. Goss<sup>1</sup>, M. Cobo<sup>2</sup>, S. Lu<sup>3</sup>, K. Syrigos<sup>4</sup>, K.H. Lee<sup>5</sup>, E. Göker<sup>6</sup>, V. Georgoulas<sup>4</sup>, D. Isla<sup>2</sup>, A. Morabito<sup>7</sup>, Y.J. Min<sup>5</sup>, A. Ardizzoni<sup>7</sup>, A. Cseh<sup>8</sup>, S. Bender<sup>9</sup>, E. Felip<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>ES, <sup>3</sup>CN, <sup>4</sup>GR, <sup>5</sup>KR, <sup>6</sup>TR, <sup>7</sup>IT, <sup>8</sup>AT, <sup>9</sup>CT/US
- 12:30 - 12:30 1443P - Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset.  
J.H. Kang, B.C. Cho, D.-W. Kim, K. Park, J.-S. Lee, S.S. Yoo, S.Y. Lee, C.H. Kim, S.H. Jang, Y.-C. Kim, H.-K. Yoon, S.-W. Kim; KR

- 12:30 - 12:30 1444P - A randomized phase 2 trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)  
T. Stinchcombe<sup>1</sup>, P. Janne<sup>1</sup>, X. Wang<sup>1</sup>, E. Bertino<sup>2</sup>, J. Weiss<sup>1</sup>, L. Bazhenova<sup>3</sup>, L. Gu<sup>1</sup>, C. Lau<sup>1</sup>, C. Paweletz<sup>1</sup>, A. Jaslawski<sup>4</sup>, G. Gerstner<sup>1</sup>, M. Baggstrom<sup>1</sup>, S. Graziano<sup>5</sup>, J. Bearden, III<sup>1</sup>, E. Vokes<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>OH/US, <sup>3</sup>CA/US, <sup>4</sup>WI/US, <sup>5</sup>NY/US, <sup>6</sup>IL/US
- 12:30 - 12:30 1445P - A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group Trial NEJ027.  
T. aiba, Y. Minegishi, O. Yamaguchi, S. Kuyama, S. Watanabe, K. Usui, M. Mori, O. Hataji, T. Nukiwa, S. Morita, K. Kobayashi, A. Gemma; JP
- 12:30 - 12:30 1446P - Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: analysis of tyrosine kinase inhibitors sequence.  
R. Flippot<sup>1</sup>, E. Auclin<sup>1</sup>, P. Biondani<sup>1</sup>, E. Le Rhun<sup>2</sup>, J. Adam<sup>1</sup>, D. Planchard<sup>1</sup>, C. Caramella<sup>1</sup>, C. Le Pechoux<sup>2</sup>, L. Lacroix<sup>1</sup>, A. Gazzah<sup>1</sup>, L. Mezquita<sup>1</sup>, B. Besse<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 1447P - Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts  
J. Roeper<sup>1</sup>, M. Falk<sup>2</sup>, S. Schatz<sup>1</sup>, M. Tiemann<sup>1</sup>, C. Wessler<sup>1</sup>, G. Wiest<sup>1</sup>, S. Sackmann<sup>1</sup>, D. Ukena<sup>1</sup>, L. Heukamp<sup>1</sup>, F. Griesinger<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>Hamburg/DE
- 12:30 - 12:30 1448P - Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss Cohort Study  
S. Schmid, D. Klingbiel, S. Aeppli, C. Britschgi, O. Gautschi, M. Pless, S. Rothschild, L. Wannesson De Nicola, W.-D. Janthur, D. Foerbs, I. Demmer, W. Jochum, M. Früh; CH
- 12:30 - 12:30 1449P - Efficacy of Afatinib in the clinical practice - First results of the GIDEON trial: a prospective non-interventional study (NIS) in EGFR mutated NSCLC in Germany  
W. Brueckl, E. Laack, M. Reck, F. Griesinger, H. Schäfer, C. Kortsik, T. Gaska, J. Rawluk, S. Krüger, K. Kokowski, S. Budweiser, A. Schueler, S. Kiessling; DE
- 12:30 - 12:30 1450P - Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small-cell lung cancer  
B. van Veggel, A. van der Wekken, S. Hashemi, R. Cornelissen, K. Monkhorst, D. Heideman, T. Radonic, E. Smit, E. Schuurin, J. De Langen; NL
- 12:30 - 12:30 1451P - The characteristics and clinical outcome of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's tertiary referral center.  
J. Chantharasamee, N. Pongvarin, P. Danchaivijitr, S. Techawatanawanna; TH
- 12:30 - 12:30 1452P - Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation  
S. Viteri<sup>1</sup>, G.-C. Chang<sup>2</sup>, R. Chiari<sup>3</sup>, B.C. Cho<sup>4</sup>, F. Ciardiello<sup>3</sup>, G. Curigliano<sup>3</sup>, T. Hida<sup>5</sup>, D.H. Lee<sup>4</sup>, W. Lim<sup>6</sup>, C.-C. Lin<sup>2</sup>, A. Martinez<sup>1</sup>, H. Murakami<sup>5</sup>, I. Natsume<sup>5</sup>, M. Nishio<sup>5</sup>, L. Paz-Ares<sup>1</sup>, R. Soo<sup>6</sup>, V. Cattan<sup>7</sup>, E. Gandossi<sup>7</sup>, H. Heck<sup>7</sup>, K. Park<sup>4</sup>; <sup>1</sup>ES, <sup>2</sup>TW, <sup>3</sup>IT, <sup>4</sup>KR, <sup>5</sup>JP, <sup>6</sup>SG, <sup>7</sup>FR
- 12:30 - 12:30 1453P - Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data

C. Escriu<sup>1</sup>, M. Sallam<sup>2</sup>, L. del Carpio<sup>3</sup>, N. Tokaca<sup>2</sup>, L. Solway<sup>2</sup>, R. Shah<sup>2</sup>, A. Fouzia<sup>2</sup>, Q. Ghafoor<sup>2</sup>, S. Popat<sup>2</sup>, P. Postmus<sup>4</sup>; <sup>1</sup>Merseyside/GB, <sup>2</sup>GB, <sup>3</sup>ES, <sup>4</sup>Merseyside/NL

- 12:30 - 12:30 1454P - EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Nationwide register-based cohort study in Sweden  
S. Bergström, H. Nordahl Christensen, F. Wiklund, M. Bergqvist; SE
- 12:30 - 12:30 1455P - Comparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real World Data of 1354 patients with EGFR mutant NSCLC  
K. Ito<sup>1</sup>, K. Murotani<sup>1</sup>, A. Kubo<sup>1</sup>, E. Kunii<sup>1</sup>, H. Taniguchi<sup>1</sup>, J. Shindo<sup>1</sup>, K. Asada<sup>1</sup>, K. Imaizumi<sup>1</sup>, K. Tanaka<sup>1</sup>, N. Inui<sup>1</sup>, M. Okuno<sup>1</sup>, O. Hataji<sup>1</sup>, S. Hayai<sup>1</sup>, T. Abe<sup>1</sup>, T. Kimura<sup>1</sup>, T. Tsuda<sup>1</sup>, T. Yamaguchi<sup>1</sup>, Y. Oya<sup>1</sup>, T. Yoshida<sup>2</sup>, T. Hida<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>US
- 12:30 - 12:30 1456P - Phase IV, open-label, multicentre trial of afatinib in patients (pts) aged ≥70 yrs with NSCLC harbouring common (Del19/L858R) EGFR mutations: preliminary results  
K. Reckamp<sup>1</sup>, P. Gilman<sup>2</sup>, B. Halmos<sup>3</sup>, M. Jahanzeb<sup>4</sup>, J. McCann<sup>5</sup>, H. Paripati<sup>6</sup>, L. Seneviratne<sup>7</sup>, J. Wallace<sup>8</sup>, B. Rueter<sup>9</sup>, A. Esler<sup>1</sup>, E. Dowling<sup>1</sup>, M. Koczywas<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>PA/US, <sup>3</sup>NY/US, <sup>4</sup>FL/US, <sup>5</sup>MA/US, <sup>6</sup>AZ/US, <sup>7</sup>CA/US, <sup>8</sup>IL/US, <sup>9</sup>CT/US
- 12:30 - 12:30 1457P - Is There a Difference in PFS or OS of T790M-Mutated NSCLC Patients Treated with Osimertinib either after Chemotherapy or Immediately after Previous Target Therapy?  
C.H. Lai, M.-C. Lin, Y.-H. Tsai, C.-C. Wang; TW
- 12:30 - 12:30 1458P - Bone metastasis reduces responsiveness to EGFR-TKIs in patients with EGFR-mutated advanced lung adenocarcinoma  
X. Zheng, C. Huang, G. Lin; CN
- 12:30 - 12:30 1459P - Which is better EGFR-TKI followed by osimertinib between afatinib and gefitinib/erlotinib?  
M. Tamiya<sup>1</sup>, A. Tamiya<sup>2</sup>, H. Suzuki<sup>2</sup>, K. Nakahama<sup>2</sup>, Y. Taniguchi<sup>2</sup>, K. Kunimasa<sup>2</sup>, M. Kimura<sup>2</sup>, T. Inoue<sup>2</sup>, K. Nishino<sup>2</sup>, T. Hirashima<sup>2</sup>, S. Atagi<sup>2</sup>, F. Imamura<sup>2</sup>, T. Kumagai<sup>2</sup>; <sup>1</sup>Osaka/JP, <sup>2</sup>JP
- 12:30 - 12:30 1460P - Biopsy on Progression in EGFR Mutation Positive (EGFRm) Advanced Non-Small Cell Lung Cancer (aNSCLC) patients (pts) - A Canadian Experience.  
Q.S.-C. Chu<sup>1</sup>, A. Agha<sup>1</sup>, N. Devost<sup>1</sup>, R. Walton<sup>1</sup>, S. Ghosh<sup>1</sup>, C. Ho<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>British Columbia/CA
- 12:30 - 12:30 1461P - ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC); European subset  
M. Tiseo<sup>1</sup>, A. Santo<sup>1</sup>, M. Hochmair<sup>2</sup>, T. Geldart<sup>3</sup>, G. Metro<sup>4</sup>, E. Hanrahan<sup>5</sup>, K. Lamberg<sup>6</sup>, T. Moran<sup>7</sup>, C. Nyhus<sup>8</sup>, A. Paredes<sup>9</sup>, J. Vansteenkiste<sup>10</sup>, D. Vicente<sup>7</sup>, M. Miranda<sup>3</sup>, J. Rigas<sup>11</sup>, F. de Marinis<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>AT, <sup>3</sup>GB, <sup>4</sup>(PG)/IT, <sup>5</sup>IE, <sup>6</sup>SE, <sup>7</sup>ES, <sup>8</sup>DK, <sup>9</sup>OH/US, <sup>10</sup>BE, <sup>11</sup>MD/US
- 12:30 - 12:30 1462P - Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts).  
R. Tay<sup>1</sup>, J. Chiramel<sup>2</sup>, E. Montague<sup>2</sup>, F. Wilson<sup>2</sup>, Y. Summers<sup>2</sup>, F. Blackhall<sup>2</sup>, R. Califano<sup>2</sup>; <sup>1</sup>VIC/AU, <sup>2</sup>GB



- 12:30 - 12:30 1463P - Updated results of M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF- $\beta$  and PD-L1, in second-line (2L) NSCLC  
L. Paz-Ares<sup>1</sup>, T.M. Kim<sup>2</sup>, D. Vincente<sup>1</sup>, E. Felip Font<sup>1</sup>, D.H. Lee<sup>2</sup>, K. Lee<sup>2</sup>, C.-C. Lin<sup>3</sup>, M. Oncala<sup>1</sup>, M. Di Nicola<sup>4</sup>, R.M. Alvarez<sup>1</sup>, I. Dussault<sup>5</sup>, C. Helwig<sup>6</sup>, L. Ojalvo<sup>5</sup>, J. Gulley<sup>7</sup>, B.C. Cho<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>KR, <sup>3</sup>TW, <sup>4</sup>IT, <sup>5</sup>MA/US, <sup>6</sup>DE, <sup>7</sup>MD/US
- 12:30 - 12:30 1464P - KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?  
D. Rodriguez Abreu<sup>1</sup>, M.C. Garassino<sup>2</sup>, E. Esteban<sup>3</sup>, G. Speranza<sup>4</sup>, E. Felip Font<sup>3</sup>, M. Domine<sup>3</sup>, M. Hochmair<sup>5</sup>, S. Powell<sup>6</sup>, S. Cheng<sup>7</sup>, H. Bischoff<sup>8</sup>, N. Peled<sup>9</sup>, R. Hui<sup>10</sup>, M. Reck<sup>8</sup>, E. Garon<sup>11</sup>, M. Boyer<sup>12</sup>, F. Grossi<sup>2</sup>, R. Jennens<sup>13</sup>, J. Yang<sup>6</sup>, M.C. Pietanza<sup>14</sup>, S. Gadgeel<sup>6</sup>; <sup>1</sup>Canary Islands/ES, <sup>2</sup>IT, <sup>3</sup>ES, <sup>4</sup>QC/CA, <sup>5</sup>AT, <sup>6</sup>US, <sup>7</sup>CA, <sup>8</sup>DE, <sup>9</sup>IL, <sup>10</sup>NSW/AU, <sup>11</sup>CA/US, <sup>12</sup>AU, <sup>13</sup>VIC/AU, <sup>14</sup>NJ/US
- 12:30 - 12:30 1465P - Phase 1 Dose Escalation of Pembrolizumab Given Concurrently with Palliative Thoracic Radiotherapy (RT) for NSCLC  
R. Kumar<sup>1</sup>, D. Walder<sup>2</sup>, A. Pejanaute<sup>2</sup>, R. Gunapala<sup>2</sup>, J. Bhosle<sup>2</sup>, N. Yousef<sup>2</sup>, S. Popat<sup>2</sup>, F. McDonald<sup>2</sup>, I. Locke<sup>2</sup>, K. Harrington<sup>2</sup>, A. Tree<sup>2</sup>, S. Lalondrelle<sup>2</sup>, R. Huddart<sup>2</sup>, M. O'Brien<sup>2</sup>, M. Ahmed<sup>2</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>GB
- 12:30 - 12:30 1466P - Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer  
G. Galli, M. Poggi, G. Fucà, M. Imbimbo, C. Proto, D. Signorelli, M. Vitali, N. Zilembo, M. Ganzinelli, F. de Braud, M.C. Garassino, G. Lo Russo; IT
- 12:30 - 12:30 1467P - Efficacy and safety of nivolumab for cytotoxic chemotherapy unfit patients with advanced non-small cell lung cancer: A phase II study  
Y. Okuma<sup>1</sup>, S. Kitano<sup>1</sup>, K. Watanabe<sup>1</sup>, M. Yomota<sup>1</sup>, Y. Hosomi<sup>1</sup>, Y. Zenke<sup>2</sup>, N. Yamamoto<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP
- 12:30 - 12:30 1468P - GECP 1605/NIVEX TRIAL. Nivolumab in the real world: the SPANISH expanded access program experience in pretreated advanced NSCLC  
M. Majem Tarruella<sup>1</sup>, J. Campillo<sup>1</sup>, J.F. Grau Béjar<sup>1</sup>, E. Carcereny<sup>1</sup>, R. Bernabe Caro<sup>1</sup>, Y. Garcia<sup>1</sup>, A. Artal-Cortes<sup>1</sup>, M. González Cao<sup>1</sup>, P. Lianes<sup>1</sup>, A. Paredes Lario<sup>1</sup>, M. Sereno Moyano<sup>1</sup>, X. Mielgo Rubio<sup>2</sup>, J.A. Macias<sup>1</sup>, M. Provencio Pulla<sup>2</sup>, D. Rodriguez-Abreu<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Madrid/ES
- 12:30 - 12:30 1469P - EVIDENS: An observational study of Nivolumab-treated patients in Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-world Setting: initial results on 1394 Patients (NCT03382496, BMS sponsored)  
A. Dixmier<sup>1</sup>, D. Debieuvre<sup>1</sup>, C. Raspaud<sup>1</sup>, J.B. Auliac<sup>1</sup>, N. Benoit<sup>1</sup>, P. Bombaron<sup>2</sup>, B. Asselain<sup>1</sup>, A. Dumont<sup>1</sup>, P. Lamoureux<sup>1</sup>, N. Goyard<sup>1</sup>, D. Moro-Sibilot<sup>1</sup>, M. Perol<sup>3</sup>, F. Barlesi<sup>4</sup>, C. Audigier Valette<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 8/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 20/FR
- 12:30 - 12:30 1470P - Fractional polynomial network meta-analysis: a different approach to indirectly assess the comparative efficacy of 2L+ cancer immunotherapy (CIT) treatments for metastatic NSCLC  
C. Schulz<sup>1</sup>, P. Chu<sup>2</sup>, C. Berardo<sup>2</sup>, B. Karthuria<sup>2</sup>, J. Foo<sup>3</sup>, C. Morel<sup>3</sup>, C. Watkins<sup>4</sup>, M. Ballinger<sup>5</sup>, D. Gandara<sup>6</sup>; <sup>1</sup>DE, <sup>2</sup>CH, <sup>3</sup>NL, <sup>4</sup>GB, <sup>5</sup>US, <sup>6</sup>CA/US

- 12:30 - 12:30 1471P - Prior or Concurrent Radiotherapy and Nivolumab Immunotherapy in Non-Small Cell Lung Cancer  
G. Ratnayake<sup>1</sup>, M. Shankar<sup>2</sup>, K. Roberts<sup>1</sup>, R. Mason<sup>2</sup>, B. Hughes<sup>1</sup>, Z. Lwin<sup>2</sup>, V. Jain<sup>1</sup>, K. O'Byrne<sup>2</sup>, B. Chua<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>QLD/AU
- 12:30 - 12:30 1472P - Immunotherapy in elderly patients (≥ 75 yrs) with advanced Non-Small-Cell Lung Cancer (NSCLC): a multicenter Italian experience.  
A. Luciani<sup>1</sup>, L. Toschi<sup>2</sup>, S. Fava<sup>1</sup>, D. Cortinovis<sup>1</sup>, V. Filipazzi<sup>1</sup>, A. Tuzi<sup>1</sup>, A. Marra<sup>1</sup>, S. Rossi<sup>1</sup>, A. Rossi<sup>1</sup>, M. Blasi<sup>1</sup>, M. Violati<sup>1</sup>, L. Sala<sup>1</sup>, F. Agustoni<sup>1</sup>, P. Bidoli<sup>1</sup>, S. Zonato<sup>1</sup>, D. Ferrari<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(MI)/IT
- 12:30 - 12:30 1473P - Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients  
T. Kubo, H. Watanabe, K. Ninomiya, K. Kudo, D. Minami, E. Murakami, N. Ochi, T. Ninomiya, D. Harada, M. Yasugi, E. Ichihara, K. Ohashi, K. Fujiwara, K. Hotta, M. Tabata, Y. Maeda, K. Kiura; JP
- 12:30 - 12:30 1474P - Nivolumab in Non Small Cell Lung Cancer: French evaluation of use, current practices and medico economic approach  
F. GRUDE<sup>1</sup>, R. Corre<sup>2</sup>, T. Urban<sup>3</sup>, J. Bennouna<sup>2</sup>, G. De Chabot<sup>1</sup>, T. Chatellier<sup>1</sup>, F. Denis<sup>1</sup>, R. Descourt<sup>1</sup>, J.-Y. Douillard<sup>4</sup>, C. Ricordel<sup>1</sup>, O. Molinier<sup>1</sup>, F. Pinquie<sup>1</sup>, G. Robinet<sup>5</sup>, M. Travers<sup>1</sup>, B. Moiteaux<sup>1</sup>, D. Deniel Lagadec<sup>1</sup>, F. Marhuenda<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR, <sup>4</sup>CEDEX/CH, <sup>5</sup>Cedex 2/FR
- 12:30 - 12:30 1475P - Radiological identification of rapid progressions in advanced NSCLC patients treated with Nivolumab.  
P. Simões da Rocha, E. Ripoll, A. Corbera, M. Hardy-Werbin, A.F. Fernandez-Alarza, M. Orrillo, Á. Taus, E. Arriola; ES
- 12:30 - 12:30 1476P - Role of Immunotherapy (I) for advanced. pre-treated, non-squamous NSCLC (APNS-NSCLC). Preliminary data of a pooled analysis with network meta-analysis.  
C. Cherubini, M. Papi, L. Gianni, C. Gianni, S.V.L. Nicoletti, M. Fantini, L.A. Lazzari Agli, D. Tassinari; IT
- 12:30 - 12:30 1477P - Evaluation of Progression-Free Survival (PFS) and One-Year (1y) Survival as Surrogate Endpoints (SE) in Previously Treated Advanced Non-Small Cell Lung Cancer (adNSCLC) in the Era of Immuno-Oncology (IO)  
S. Zhao, Z. Zhang, T. Zhou, Y. Zhang, L. Zhang; CN
- 12:30 - 12:30 1478P - Efficacy of second-line nivolumab after early time to progression on first-line cytotoxic chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).  
T. Ota<sup>1</sup>, K. Kirita<sup>2</sup>, H. Udagawa<sup>1</sup>, S. Umemura<sup>1</sup>, S. Matsumoto<sup>1</sup>, K. Yoh<sup>2</sup>, S. Niho<sup>1</sup>, K. Goto<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP
- 12:30 - 12:30 1479P - First analysis of patients (p) with stage IV Non-Small Cell Lung Cancer (NSCLC) of the Thoracic Tumor Registry (RTT) of the Spanish Lung Cancer Group (SLCG)  
E. Carcereny Costa<sup>1</sup>, D. Rodriguez-Abreu<sup>2</sup>, M. Guirado<sup>3</sup>, R. López-Castro<sup>2</sup>, B. Massutí<sup>2</sup>, J. Bosch Barrera<sup>2</sup>, E. Nogueron Martinez<sup>2</sup>, M.A. Sala Gonzalez<sup>2</sup>, M. Domine Gomez<sup>2</sup>, E. Del Barco Morillo<sup>2</sup>, S. Cerezo Gonzalez<sup>2</sup>, M. Dorta Suarez<sup>2</sup>, J. Casal Rubio<sup>4</sup>, C. Camps<sup>2</sup>, M.A. Muñoz<sup>2</sup>, R. de las Peñas<sup>2</sup>, J.A. Ortega dominguez<sup>2</sup>, J. Gonzalez-Larriba<sup>2</sup>, R. Bernabe Caro<sup>2</sup>, M. Provencio Pulla<sup>5</sup>; <sup>1</sup>Barcelona/ES, <sup>2</sup>ES, <sup>3</sup>Alicante/ES, <sup>4</sup>Pontevedra/ES, <sup>5</sup>Madrid/ES

- 12:30 - 12:30 1480P - Effects of Physical Exercise in non-operable lung cancer patients undergoing palliative treatment  
J. Wiskemann<sup>1</sup>, C. Titz<sup>1</sup>, M. Schmidt<sup>1</sup>, K. Steindorf<sup>1</sup>, C. Ulrich<sup>2</sup>, F. Herth<sup>1</sup>, C. Heussel<sup>1</sup>, H. Winter<sup>1</sup>, M. Steins<sup>1</sup>, S. Hummler<sup>1</sup>, M. Thomas<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>US
- 12:30 - 12:30 1481P - Extra-cost of brain metastases in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis  
N. Girard, D. Cozzone, L. de Léotoing, C. Tournier, A. Vainchtock, B. Tehard, A. Cortot; FR
- 12:30 - 12:30 1482P - Localablative treatment for synchronous oligometastatic lung cancer – a propensity score analysis of 180 patients  
N. Frost, A. Tessmer, A. Schmittl, V. van Laak, S. Ochsenreither, B. Temmesfeld-Wollbrück, B. Schmidt, N. Suttorp, M. Witzernath, C. Grohe; DE
- 12:30 - 12:30 1483P - Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005-2015: The SCAN-LEAF study  
J. Sørensen<sup>1</sup>, S. Ekman<sup>2</sup>, P. Horvat<sup>3</sup>, D. Layton<sup>3</sup>, J. Kim<sup>3</sup>, M. Rosenlund<sup>3</sup>, A. Juarez-Garcia<sup>3</sup>, M. Daumont<sup>4</sup>, H. Jacobs<sup>3</sup>, L. Lacoïn<sup>5</sup>, O.T. Brustugun<sup>6</sup>, M. Planck<sup>2</sup>; <sup>1</sup>DK, <sup>2</sup>SE, <sup>3</sup>GB, <sup>4</sup>BE, <sup>5</sup>NJ/US, <sup>6</sup>NO
- 12:30 - 12:30 1484P - Treatment patterns in patients (pts) with stage IIIB-IV non-small cell lung cancer (NSCLC) in Sweden: The SCAN-LEAF study  
S. Ekman<sup>1</sup>, M. Planck<sup>1</sup>, J. Sørensen<sup>2</sup>, P. Horvat<sup>3</sup>, D. Layton<sup>3</sup>, J. Kim<sup>3</sup>, M. Rosenlund<sup>3</sup>, A. Juarez-Garcia<sup>3</sup>, M. Daumont<sup>4</sup>, H. Jacobs<sup>3</sup>, L. Lacoïn<sup>5</sup>, O.T. Brustugun<sup>6</sup>; <sup>1</sup>SE, <sup>2</sup>DK, <sup>3</sup>GB, <sup>4</sup>BE, <sup>5</sup>NJ/US, <sup>6</sup>NO
- 12:30 - 12:30 1485P - NSCLC with well controlled extra-cranial disease but uncontrolled brain metastases  
H.A. Jung<sup>1</sup>, K. Park<sup>2</sup>, J.-M. Sun<sup>2</sup>, S.H. Lee<sup>2</sup>, J.S. Ahn<sup>2</sup>, M.-J. Ahn<sup>2</sup>, S. Park<sup>2</sup>; <sup>1</sup>Gyeong-Ki-Do/KR, <sup>2</sup>KR
- 12:30 - 12:30 1486P - Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): recursive partitioning analysis (RPA) model modification  
C. Salvador Coloma, D. Lorente, C. Escoin, J. Mendez, O. Juan-Vidal; ES
- 12:30 - 12:30 1487P - LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer  
K. Yoh<sup>1</sup>, T. Seto<sup>2</sup>, M. Satouchi<sup>2</sup>, M. Nishio<sup>2</sup>, N. Yamamoto<sup>2</sup>, H. Murakami<sup>2</sup>, N. Nogami<sup>2</sup>, S. Kuroda<sup>2</sup>, S. Nomura<sup>2</sup>, A. Sato<sup>2</sup>, K. Tsuchihara<sup>2</sup>, T. Kohno<sup>2</sup>, S. Matsumoto<sup>2</sup>, K. Goto<sup>1</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>JP
- 12:30 - 12:30 1488P - Vemurafenib in patients (pts) harboring BRAF V600 mutation. Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial.  
J. Mazières<sup>1</sup>, L. Montané<sup>1</sup>, F. Barlesi<sup>2</sup>, X. Quantin<sup>3</sup>, J. Trédaniel<sup>1</sup>, J. Le Treut<sup>1</sup>, V. Avrillon<sup>4</sup>, A. Lavolé<sup>1</sup>, V. Westeel<sup>5</sup>, F. Orsini Piocelle<sup>1</sup>, E. Pichon<sup>6</sup>, L. Thiberville<sup>1</sup>, C. Borel<sup>5</sup>, P. Renault<sup>1</sup>, M. Jaffro<sup>1</sup>, S. Collot<sup>1</sup>, G. Ferretti<sup>1</sup>, F. Legrand<sup>1</sup>, C. Mahier Ait Oukhatar<sup>1</sup>, J. Blay<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 20/FR, <sup>3</sup>CEDEX 5/FR, <sup>4</sup>Cedex 08/FR, <sup>5</sup>CEDEX/FR, <sup>6</sup>CEDEX 9/FR
- 12:30 - 12:30 1489P - Treatment Patterns and Overall Survival in Patients With BRAF-Mutated Metastatic Non-Small Cell Lung Cancer

R. Goyal<sup>1</sup>, A. Kron<sup>2</sup>, J. Wolf<sup>2</sup>, J. Mazieres<sup>3</sup>, C. Chouaid<sup>3</sup>, K. Davis<sup>4</sup>, M. Perrinjaquet<sup>5</sup>, S. Knoll<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>DE, <sup>3</sup>FR, <sup>4</sup>NC/US, <sup>5</sup>GB, <sup>6</sup>NJ/US

- 12:30 - 12:30 1490P - A prospective observational study of HER2 alterations in NSCLCs: HOT1303-A  
T. Goda<sup>1</sup>, I. Kinoshita<sup>1</sup>, S. Oizumi<sup>2</sup>, K. Nakano<sup>1</sup>, T. Harada<sup>1</sup>, Y. Kawai<sup>1</sup>, J. Sakakibara-Konishi<sup>1</sup>, H. Yokouchi<sup>3</sup>, N. Morikawa<sup>1</sup>, N. Yamada<sup>1</sup>, S. Yamazaki<sup>1</sup>, S. Sugawara<sup>4</sup>, H. Asahina<sup>2</sup>, T. Amano<sup>2</sup>, Y. Hatanaka<sup>1</sup>, Y. Matsuno<sup>1</sup>, H. Nishihara<sup>1</sup>, H. Isobe<sup>1</sup>, M. Nishimura<sup>1</sup>, H. Dosaka-Akita<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hokkaido/JP, <sup>3</sup>Fukushima/JP, <sup>4</sup>Miyagi/JP
- 12:30 - 12:30 1491P - A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial  
I. Kinoshita<sup>1</sup>, T. Goda<sup>1</sup>, K. Watanabe<sup>1</sup>, M. Maemondo<sup>1</sup>, S. Oizumi<sup>2</sup>, T. Amano<sup>2</sup>, Y. Hatanaka<sup>1</sup>, Y. Matsuno<sup>1</sup>, H. Nishihara<sup>1</sup>, H. Asahina<sup>2</sup>, T. Harada<sup>1</sup>, K. Goto<sup>3</sup>, H. Isobe<sup>1</sup>, M. Nishimura<sup>1</sup>, H. Dosaka-Akita<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hokkaido/JP, <sup>3</sup>Chiba/JP
- 12:30 - 12:30 1492P - BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: results from a first-in-human, phase 1, dose-escalation study  
X. Hu, X. Zheng, H. Mo, X. Cui, L. Ding, F. Tan, P. Hu, Y. Shi; CN
- 12:30 - 12:30 1493P - Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations.  
P. JAMME<sup>1</sup>, F. Escande<sup>1</sup>, C. Descarpentries<sup>1</sup>, M.C. Copin<sup>1</sup>, E. Dansin<sup>2</sup>, T. Vanparis<sup>1</sup>, D. Tulasne<sup>1</sup>, S. Baldacci<sup>1</sup>, Z. Kherrouche<sup>1</sup>, A. Cortot<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 1494P - Risk of lung cancer following pulmonary tuberculosis: A nationwide population-based cohort study, South Korea  
S.-S. Han, J. Heo, S.-J. Lee; KR
- 12:30 - 12:30 1495P - Analysis of the relationship between heading N / L and survival in patients treated with Immunotherapy in lung cancer  
N. De Dios Alvare, M. Costa Rivas, S. Agraso Busto, A. Alonso Herrero, M.J. Villanueva Silva, D. Pereiro Corbacho, C. García Benito; ES
- 12:30 - 12:30 1496P - Intracranial Activity of Ensartinib in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)  
H. Wakelee<sup>1</sup>, K. Reckamp<sup>2</sup>, T. Leal<sup>2</sup>, S. Patel<sup>1</sup>, G. Blumenschein<sup>2</sup>, E. Shum<sup>2</sup>, J. Nieva<sup>2</sup>, G. Oxnard<sup>3</sup>, R. Sanborn<sup>4</sup>, S. Waqar<sup>2</sup>, K. Zeman<sup>2</sup>, G. Dukart<sup>2</sup>, K. Harrow<sup>5</sup>, C. Liang<sup>2</sup>, A. Holzhausen<sup>2</sup>, L. Horn<sup>6</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>MA/US, <sup>4</sup>OR/US, <sup>5</sup>FL/US, <sup>6</sup>TN/US
- 12:30 - 12:30 1497P - JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non-Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results  
B.C. Cho<sup>1</sup>, J.-S. Lee<sup>1</sup>, J.-Y. Han<sup>1</sup>, E.K. Cho<sup>1</sup>, E. Haura<sup>2</sup>, K.H. Lee<sup>1</sup>, J. Bauml<sup>3</sup>, R. Sanborn<sup>4</sup>, M. Curtis<sup>5</sup>, E. Attiyeh<sup>5</sup>, N. Haddish-Berhane<sup>5</sup>, K. Bae<sup>5</sup>, R. Knoblauch<sup>5</sup>, L. Sherman<sup>5</sup>, M. Lorenzi<sup>5</sup>, K. Park<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>US, <sup>3</sup>PA/US, <sup>4</sup>OR/US, <sup>5</sup>NJ/US

- 12:30 - 12:30 1498P - Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC)  
H. Horinouchi, Y. Matsumoto, S. Murakami, Y. Goto, S. Kanda, Y. Fujiwara, N. Yamamoto, Y. Nakayama, Y. Ohe; JP
- 12:30 - 12:30 1499TiP - Tumor Treating Fields concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study  
U. Weinberg<sup>1</sup>, O. Farber<sup>2</sup>, M. Giladi<sup>2</sup>, Z. Bomzon<sup>2</sup>, E. Kirson<sup>2</sup>; <sup>1</sup>CH, <sup>2</sup>IL
- 12:30 - 12:30 1500TiP - eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients  
L. Horn<sup>1</sup>, Y.-L. Wu<sup>2</sup>, M. Reck<sup>3</sup>, H. Wakelee<sup>4</sup>, C. Liang<sup>5</sup>, K. Harrow<sup>6</sup>, V. Oertel<sup>5</sup>, T. Mok<sup>7</sup>; <sup>1</sup>TN/US, <sup>2</sup>Guangdong/CN, <sup>3</sup>DE, <sup>4</sup>CA/US, <sup>5</sup>US, <sup>6</sup>FL/US, <sup>7</sup>CN
- 12:30 - 12:30 1501TiP - Afatinib (AFA) plus Bevacizumab (BEV) Combination after Osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): a multicenter prospective single arm phase II study (ABCD-study)  
A. Hata<sup>1</sup>, N. Katakami<sup>2</sup>, K. Nishino<sup>2</sup>, M. Mori<sup>2</sup>, T. Yokoyama<sup>2</sup>, T. Kurata<sup>2</sup>, M. Tachihara<sup>2</sup>, N. Takase<sup>2</sup>, H. Daga<sup>2</sup>, T. Kijima<sup>2</sup>, S. Morita<sup>2</sup>, K. Sakai<sup>2</sup>, K. Nishio<sup>2</sup>, M. Satouchi<sup>2</sup>, S. Negoro<sup>2</sup>; <sup>1</sup>Hyogo/Jp, <sup>2</sup>Jp
- 12:30 - 12:30 1502TiP - FOstering efficacy of anti-PD-1-treatment: nivolumab plus Radiotherapy in advanCED non-small cell lung cancer - the FORCE trial  
F. Bozorgmehr, A. Hommertgen, F. Lasitschka, J. Krisam, J. Debus, J. Fischer, M. Bischof, A. Atmaca, S. Wetzel, M. Faehling, D. Bottke, C. Grohe, W. Engel-Riedel, E. Ingenhoff, D. Heigener, N. Reinmuth, C. Schumann, M. Wermke, M. Thomas, S. Rieken; DE
- 12:30 - 12:30 1503TiP - CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC  
S. Gettinger<sup>1</sup>, T. Beck<sup>2</sup>, X. Yang<sup>2</sup>, B. Telivala<sup>2</sup>, D. Morgensztern<sup>2</sup>, V. Velcheti<sup>2</sup>, S. Ramalingam<sup>3</sup>, K. Schalper<sup>1</sup>, M. Dajee<sup>2</sup>, A. Ranck<sup>2</sup>, R. Yang<sup>2</sup>, D. Spigel<sup>4</sup>; <sup>1</sup>CT/US, <sup>2</sup>US, <sup>3</sup>GA/US, <sup>4</sup>TN/US
- 12:30 - 12:30 1504TiP - Nintedanib plus docetaxel in routine clinical practice: VARGADO - a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape  
C. Grohe, I. Zander, K. Lüdtke-Heckenkamp, W. Blau, S. Krüger, C. Franke, H. Mueller-Huesmann, W. Brückl, N. Basara, D. Ukena, S. Lang, J. Atz, R. Kaiser; DE
- 12:30 - 12:30 1505TiP - A Phase III, Randomized, Open-Label, Multicenter Study of SHR-1210(Anti-PD-1 Antibody) in Combination with Pemetrexed and Carboplatin as First Line Therapy in Subjects with Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer  
F. Wu, G. Gao, C. Zhou, X. Kang, Y. Zhou; CN
- 12:30 - 12:30 1506TiP - Phase 1 study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC  
C. Yu, H. Yu, P. Janne, M. Vigliotti, T. Goldberg, J. Li, J. McGill, H. Zhang; US
- 12:30 - 12:30 1507TiP - Ultra-early response capturing in the treatment of non-squamous NSCLC using diffusion-weighted MRI: a prospective multicenter study.

G. Heussel, N. Batora, M. Schneider, P. Flechsig, J. Krisam, C. Wiedemann, O. Sedlacek, I. Fellhauer, H.-U. Kauczor, M. Thomas, H. Golpon, J. Vogel-Claussen, A. Tufman, J. Dinkel, A. Guenther, S. Janciauskiene, H. Sueltmann, M. Meister, C. Heussel, F. Bozorgmehr; DE

- 12:30 - 12:30 1508TiP - Durvalumab in frail and elder patients with stage four NSCLC- the DURATION trial  
J. Kuon, F. Bozorgmehr, M. Schneider, J. Krisam, F. Lasitschka, M. Serke, W. Schuette, N. Moosmann, W. Gleiber, M. Faehling, M. Wermke, P. Schuett, M. Boesche, V. van Laak, L. Fischer von Weikersthal, M. Ulmer, C. Meyer zum Büschenfelde, J. Fischer, M. Thomas; DE
- 12:30 - 12:30 1509TiP - Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)  
Y. Elamin<sup>1</sup>, M. Antonoff<sup>2</sup>, C. Blakely<sup>3</sup>, M. Baggstorm<sup>1</sup>, T. Bivona<sup>1</sup>, X. Le<sup>1</sup>, A. Louie<sup>4</sup>, R. Doebele<sup>1</sup>, C. Rusthoven<sup>1</sup>, P. Lee<sup>3</sup>, R. Govindan<sup>1</sup>, S. Swisher<sup>2</sup>, V. Papadimitrakopoulou<sup>1</sup>, J. Heymach<sup>2</sup>, D. Gomez<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>CA/US, <sup>4</sup>CA
- 12:30 - 12:30 1510TiP - The GATTO study: A phase I of the anti-EGFR Tomuzotuximab (TO) in combination with the anti-MUC1 Gatipotuzumab (GAT) in patients with EGFR positive solid tumors.  
E. Garralda<sup>1</sup>, M. van Hoer<sup>2</sup>, S. Ochsenreither<sup>3</sup>, L. Gianni<sup>4</sup>, D. Lorusso<sup>4</sup>, W. Fiedler<sup>3</sup>, U. Keilholz<sup>3</sup>, K. Klinghammer<sup>3</sup>, C. Dicke<sup>3</sup>, M. Kebenko<sup>3</sup>, I. Matos<sup>1</sup>, J. Tabernero<sup>1</sup>, F. Raspagliesi<sup>4</sup>, G. Del Conte<sup>4</sup>, B. Habel<sup>3</sup>, H. Baumeister<sup>3</sup>, A. Zurlo<sup>3</sup>; <sup>1</sup>ES, <sup>2</sup>CH, <sup>3</sup>DE, <sup>4</sup>IT
- 12:30 - 12:30 1668P - A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who in participated US National Cancer Institute Cooperative Group studies  
T. Stinchcombe<sup>1</sup>, W. Fan<sup>2</sup>, S. Schild<sup>3</sup>, E. Vokes<sup>4</sup>, J. Bogart<sup>5</sup>, Q.-T. Le<sup>6</sup>, C. Thomas, Jr.<sup>1</sup>, M. Edelman<sup>1</sup>, L. Horn<sup>7</sup>, R. Komaki<sup>8</sup>, H. Cohen<sup>2</sup>, A. Ganti<sup>9</sup>, H. Pang<sup>10</sup>, X. Wang<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NC/US, <sup>3</sup>AZ/US, <sup>4</sup>IL/US, <sup>5</sup>NY/US, <sup>6</sup>CA/US, <sup>7</sup>TN/US, <sup>8</sup>TX/US, <sup>9</sup>NE/US, <sup>10</sup>CN
- 12:30 - 12:30 1669P - Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: A Retrospective Study of the Merseyside and Cheshire Cancer Network  
M. Sallam<sup>1</sup>, H. Wong<sup>1</sup>, C. Escriu<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>Merseyside/GB
- 12:30 - 12:30 1670P - Timing of treatment in Small Cell Lung Cancer  
S. Bhandari<sup>1</sup>, D. Pham<sup>2</sup>, C. Pinkston<sup>2</sup>, M. Oechsli<sup>2</sup>, G. Kloecker<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>KY/US
- 12:30 - 12:30 1671P - Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy  
J. Sorrentino<sup>1</sup>, A. Lai<sup>1</sup>, J. Weiss<sup>1</sup>, K. Dragnev<sup>1</sup>, T. Owonikoko<sup>2</sup>, S. Adler<sup>3</sup>, J. Antal<sup>1</sup>, R. Malik<sup>1</sup>, P. Roberts<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GA/US, <sup>3</sup>NC/US
- 12:30 - 12:30 1672P - Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase 2 IMPULSE study  
M. Thomas<sup>1</sup>, S. Ponce Aix<sup>2</sup>, A. Navarro Mendivil<sup>2</sup>, J. Riera Knorrenschild<sup>1</sup>, M. Schmidt<sup>1</sup>, E. Wiegert<sup>1</sup>, K. Kapp<sup>1</sup>, C. Mauri<sup>3</sup>, M. Domine Gomez<sup>2</sup>, J. Kollmeier<sup>1</sup>, P. Sadjadian<sup>1</sup>, K.-P. Fröhling<sup>1</sup>, R. Huber<sup>1</sup>, M. Wolf<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>ES, <sup>3</sup>GB

- 12:30 - 12:30 1673P - Phase II study of NAB-paclitaxel in SensiTIVE and Refractory relapsed SCLC (NABSTER TRIAL)  
F. Gelsomino, M. Tiseo, F. Barbieri, F. Riccardi, L. Cavanna, A. Frassoldati, A. Delmonte, L. Longo, C. Dazzi, S. Cinieri, I. Colantonio, M. Tognetto, D. Baldari, L. Tofani, A. Ardizzoni; IT
- 12:30 - 12:30 1674P - Safety of belotecan as second-line treatment for recurrent small cell lung cancer: a phase IIb randomized multicenter study  
J.H. Kang<sup>1</sup>, H.T. Kim<sup>2</sup>, K.H. Lee<sup>3</sup>, D.-W. Kim<sup>3</sup>, S.-W. Kim<sup>3</sup>, H.R. Kim<sup>3</sup>, J.-H. Kim<sup>3</sup>, J.H. Chol<sup>3</sup>, H.J. An<sup>3</sup>, J.-S. Kim<sup>3</sup>, J.S. Jang<sup>3</sup>, B.-S. Kim<sup>3</sup>; <sup>1</sup>KP, <sup>2</sup>KR/KR, <sup>3</sup>KR
- 12:30 - 12:30 1675P - Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC  
D. von Eiff, F. Bozorgmehr, P. Christopoulos, I. Chung, D. Bernhardt, S. Rieken, S. Liersch, T. Muley, S. Kobinger, M. Thomas, M. Steins; DE
- 12:30 - 12:30 1676P - Over-expression of Shh is prognostic marker in patients with extensive stage small cell lung cancer.  
S. Lim, J. Kim, S.Y. Park; KR
- 12:30 - 12:30 1677P - UCHL1 has prognostic relevance and is a therapeutic target in high-grade neuroendocrine lung cancers  
Y. Shimada, T. Okano, T. Ohira, N. Ikeda; JP
- 12:30 - 12:30 1678P - Robustness of DLL3 (SP347) Immunohistochemistry Assay for Detection of DLL3 Protein in Small Cell Lung Cancer  
C. Powell, E. Elgabry, B. Holmes, D. Tyree, R. Marati, B. Admire, T. Birdi, A. Hanlon Newell, B. Damadzadeh, D. Dalvi, R. Huang; US
- 12:30 - 12:30 1679P - Residential radon and small cell lung cancer. A systematic review.  
Á. Rodríguez Martínez, A. Ruano Ravina, M. Torres Duran; ES
- 12:30 - 12:30 1680P - Nomogram for predicting the benefit of surgery for Stage IA-IIB Small-Cell Lung Cancer  
Y. Wang, Z. Wang, Q. Zheng; CN
- 12:30 - 12:30 1807P - STELLAR – Final results of a phase 2 trial of TTFIELDS with chemotherapy for first line treatment of pleural mesothelioma  
F. Grosso<sup>1</sup>, J. Aerts<sup>2</sup>, J. Madrzak<sup>3</sup>, R. Dziadziuszko<sup>3</sup>, R. Ramlau<sup>3</sup>, S. Cedres<sup>4</sup>, B. Hiddinga<sup>5</sup>, J. van Meerbeeck<sup>5</sup>, M. Mencoboni<sup>1</sup>, D. Planchard<sup>6</sup>, A. Chella<sup>1</sup>, L. Crino<sup>1</sup>, M. Krzakowski<sup>3</sup>, G.L. Ceresoli<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Noord Brabant/NL, <sup>3</sup>PL, <sup>4</sup>ES, <sup>5</sup>BE, <sup>6</sup>FR
- 12:30 - 12:30 1808P - Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and MisMatchRepair proteins expression in malignant mesothelioma  
L. Losi, F. Bertolini, L. Scurani, G. Guaitoli, C. Baldessari, A. Ambrosini Spaltro, L. Botticelli, A. Maiorana, F. Barbieri, S. Cascinu; IT
- 12:30 - 12:30 1809P - Development and Validation of a Deep Learning Model using Biomarkers in Pleural Effusion for Prediction of Malignant Pleural Mesothelioma  
S. Ikegaki, Y. Kataoka, T. Otoshi, T. Takemura, M. Shimada; JP

- 12:30 - 12:30 1810P - Elective nodal irradiation as adjuvant radiotherapy for advanced thymomas and thymic carcinomas  
Y.J. Kim, S.S. Kim, S.Y. Song, E.K. Choi; KR
- 12:30 - 12:30 1811P - Clinicopathological Features of Thymoma with the Expression of Programmed Death-Ligand 1  
S. Hakiri<sup>1</sup>, T. Fukui<sup>1</sup>, S. Mori<sup>1</sup>, K. Kawaguchi<sup>1</sup>, S. Nakamura<sup>1</sup>, N. Ozeki<sup>1</sup>, T. Kato<sup>1</sup>, M. Goto<sup>1</sup>, Y. Yatabe<sup>2</sup>, K. Yokoi<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Aichi/JP
- 12:30 - 12:30 1812P - The impact of PD-L1, TGF- $\beta$  expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors  
J. Duan, X. Liu, H. Chen, H. Bai, T. Xu, S. Cai, J. Wang; CN
- 12:30 - 12:30 1813P - Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic Large Cell Neuroendocrine Carcinoma (LCNEC)  
B. Hermans<sup>1</sup>, J. Derks<sup>1</sup>, E. Thunissen<sup>1</sup>, R. van Suylen<sup>1</sup>, M. den Bakker<sup>1</sup>, H. Groen<sup>1</sup>, E. Smit<sup>2</sup>, R. Damhuis<sup>1</sup>, E. van den Broek<sup>1</sup>, P. PALGA-group<sup>1</sup>, C. Stallinga<sup>1</sup>, G. Roemen<sup>1</sup>, E. Speel<sup>1</sup>, A.-M. Dingemans<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>ES
- 12:30 - 12:30 1814P - Computed tomography features of resected lung adenocarcinomas with spread through air spaces  
Y. Yamada<sup>1</sup>, G. Toyokawa<sup>2</sup>, T. Tagawa<sup>1</sup>, T. Kamitani<sup>1</sup>, Y. Yamasaki<sup>1</sup>, F. Shoji<sup>1</sup>, K. Yamazaki<sup>1</sup>, S. Takeo<sup>1</sup>, Y. Oda<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Fukuoka/JP
- 12:30 - 12:30 1815P - Comparative Proteomic Analysis of Acetylation Profiles in Esophageal Squamous Carcinoma Cells  
Y. Dai, J. Li; CN
- 12:30 - 12:30 1816P - Survival Outcomes for Patients with Lobectomy and Wedge Resection in Lung Cancer  
S. Alshafie, S. Ahmed; EG
- 12:30 - 12:30 1817TiP - SAKK 17/16: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial.  
Y. Metaxas<sup>1</sup>, A. Xyrafas<sup>1</sup>, M. Mark<sup>1</sup>, M. Pless<sup>1</sup>, M. Frueh<sup>1</sup>, P. Froesch<sup>1</sup>, M. Schneider<sup>1</sup>, C. Biaggi Rudolf<sup>1</sup>, F. Grosso<sup>2</sup>, R. von Moos<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>IT
- 12:30 - 12:30 1818TiP - Multicentre, double-blind, randomised Phase II study evaluating gemcitabine with or without Ramucirumab as II line treatment for MPM  
M. Pagano<sup>1</sup>, F. Zanelli<sup>2</sup>, R. Gnoni<sup>2</sup>, C. Bonelli<sup>2</sup>, M. Tiseo<sup>2</sup>, L. Boni<sup>2</sup>, G.L. Ceresoli<sup>2</sup>, P.A. Zucali<sup>2</sup>, F. Grosso<sup>2</sup>, G. Pasello<sup>2</sup>, F. Cappuzzo<sup>2</sup>, C. Pinto<sup>2</sup>; <sup>1</sup>RE/IT, <sup>2</sup>IT
- 12:30 - 12:30 1838P - CANscript™ as a Patient-Derived Predictive Platform for individualizing Treatment in Lung Cancer  
G. Babu<sup>1</sup>, K. Deepak<sup>1</sup>, B. Balakrishnan<sup>1</sup>, M. Biswas<sup>1</sup>, A. Prasath<sup>1</sup>, P. Radhakrishnan<sup>2</sup>, A. Chatterjee<sup>1</sup>, S. Thiyagarajan<sup>1</sup>, P. Chaudhuri<sup>1</sup>, P. Majumder<sup>2</sup>; <sup>1</sup>IN, <sup>2</sup>US



- 12:30 - 12:30 1839P - Whole-exome cfDNA profiling captures the mutational signatures of metastatic breast cancer for monitoring disease evolution  
R. Hastings<sup>1</sup>, M. Openshaw<sup>1</sup>, M. Vazquez<sup>2</sup>, D. Fernandez-Garcia<sup>1</sup>, D. Guttery<sup>1</sup>, K. Page<sup>1</sup>, B. Toghil<sup>1</sup>, A. Thomas<sup>1</sup>, S. Ahmed<sup>1</sup>, R. Toledo<sup>2</sup>, J. Shaw<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>ES
- 12:30 - 12:30 1840P - Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody  
S. Brett<sup>1</sup>, S. Yadavilli<sup>2</sup>, L. Seestaller-Wehr<sup>3</sup>, S. Bhattacharya<sup>2</sup>, H. Jackson<sup>2</sup>, M. Bi<sup>2</sup>, J. Willoughby<sup>1</sup>, T. Zhang<sup>2</sup>, Y.-B. Liu<sup>2</sup>, Y.K. Katlinskaya<sup>2</sup>, H. Shi<sup>2</sup>, J. Jing<sup>2</sup>, A. Hahn<sup>2</sup>, S. Speller<sup>1</sup>, D. David Figueroa<sup>2</sup>, J. Yu<sup>2</sup>, D. Olive<sup>4</sup>, M. Cragg<sup>1</sup>, P. Mayes<sup>2</sup>, A. Hoos<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>US, <sup>3</sup>PA/US, <sup>4</sup>FR
- 12:30 - 12:30 1841P - Refining criteria of Hyperprogression (HPD) with Immune Checkpoint Inhibitors (ICIs) to improve clinical applicability.  
I. Matos Garcia<sup>1</sup>, A. García Ruiz<sup>1</sup>, J. Martin-Liberal<sup>1</sup>, C. Hierro<sup>1</sup>, M. Ochoa De Olza Amat<sup>1</sup>, C. Viaplana<sup>1</sup>, G. Mur<sup>1</sup>, M. Vieito Villar<sup>2</sup>, I. Brana<sup>1</sup>, A. Azaro<sup>1</sup>, C. Perez<sup>1</sup>, V. Rodriguez Freixinos<sup>1</sup>, G. Argiles<sup>1</sup>, M. Oliveira<sup>1</sup>, E. Felip Font<sup>1</sup>, E. Muñoz-Couselo<sup>1</sup>, J. Tabernero<sup>1</sup>, R. Dienstmann<sup>1</sup>, E. Garralda<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>La Coruña/ES
- 12:30 - 12:30 1842P - Foretinib circumvents the NTRK1 G667C mutation-associated entrectinib-resistance in the brain and liver metastases produced by NTRK1 fusion-positive tumor cells  
S. Yano<sup>1</sup>, A. Nishiyama<sup>2</sup>, K. Kita<sup>2</sup>, S. Takeuchi<sup>2</sup>; <sup>1</sup>Ishikawa/JP, <sup>2</sup>JP
- 12:30 - 12:30 1843P - Molecular alterations and matched treatment in older patients: results from the MOSCATO 01 trial.  
P. Vuagnat<sup>1</sup>, C. Baldini<sup>2</sup>, L. Verlingue<sup>1</sup>, P. Martin Romano<sup>1</sup>, A. Varga<sup>2</sup>, A. Hollebecque<sup>1</sup>, S. Postel-Vinay<sup>1</sup>, A. Gazzah<sup>1</sup>, R. Bahleda<sup>2</sup>, A. Marabelle<sup>1</sup>, V. Ribrag<sup>1</sup>, S. Champiat<sup>2</sup>, J.-M. Michot<sup>1</sup>, J.-C. Soria<sup>3</sup>, C. Massard<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX/US
- 12:30 - 12:30 1844P - Prognostic implications of mismatch repair deficiency in patients with early-stage colorectal and endometrial cancer  
E. Fountzila<sup>1</sup>, V. Kotoula<sup>2</sup>, G. Pentherdoudakis<sup>1</sup>, K. Manousou<sup>1</sup>, E. Vrettou<sup>1</sup>, C. Poullos<sup>1</sup>, C. Papadimitriou<sup>3</sup>, G. Raptou<sup>1</sup>, E. Pectasides<sup>4</sup>, G. Polychronidou<sup>1</sup>, G. Karayannopoulou<sup>1</sup>, S. Chrisafi<sup>1</sup>, P. Papakostas<sup>1</sup>, T. Makatsoris<sup>5</sup>, A. Psyri<sup>1</sup>, E. Samantas<sup>6</sup>, M. Bobos<sup>1</sup>, C. Christodoulou<sup>7</sup>, D. Pectasides<sup>1</sup>, G. Fountzilias<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>Central Macedonia/GR, <sup>3</sup>Attiki/GR, <sup>4</sup>MA/US, <sup>5</sup>Rion/GR, <sup>6</sup>Attica/GR, <sup>7</sup>N. Faliro/GR
- 12:30 - 12:30 1845P - Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: results from two phase I trials  
M. Mau-Sorensen<sup>1</sup>, M. van Bussel<sup>2</sup>, M. Kuipers<sup>3</sup>, D. Nielsen<sup>1</sup>, H. Verheul<sup>2</sup>, P. Aftimos<sup>4</sup>, M. de Jonge<sup>2</sup>, B. van Triest<sup>2</sup>, J. Falkenius<sup>5</sup>, J. Debus<sup>3</sup>, E. Troost<sup>3</sup>, M. Samuels<sup>6</sup>, B. Sarholz<sup>3</sup>, V. Budach<sup>3</sup>, S. Goel<sup>6</sup>, G. Locatelli<sup>3</sup>, P. Geertsen<sup>1</sup>; <sup>1</sup>DK, <sup>2</sup>NL, <sup>3</sup>DE, <sup>4</sup>BE, <sup>5</sup>SE, <sup>6</sup>US
- 12:30 - 12:30 1846P - Role of TP53 mutations in relation to response to anti-ALK agents in EML4-ALK-translocated NSCLC patients  
M. Canale<sup>1</sup>, A. Delmonte<sup>2</sup>, C. Dazzi<sup>1</sup>, A. Gamboni<sup>1</sup>, C. Casanova<sup>1</sup>, M. Papi<sup>1</sup>, M. Mariotti<sup>1</sup>, N. De Luigi<sup>1</sup>, M. Burgio<sup>1</sup>, G. Minuti<sup>1</sup>, D. Calistri<sup>1</sup>, M. Bonafè<sup>1</sup>, L. Crinò<sup>1</sup>, P. Ulivi<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Forlì-Cesena/IT

- 12:30 - 12:30 1847P - Meta-enrichment analysis to identify a higher response patient population to S-1/Cisplatin for advanced gastric cancer  
M. Takeuchi<sup>1</sup>, M. Takeuchi<sup>1</sup>, H. van Laarhoven<sup>2</sup>, X. Fang<sup>1</sup>, P. Pfeiffer<sup>3</sup>, J. Ajani<sup>4</sup>; <sup>1</sup>JP, <sup>2</sup>NL, <sup>3</sup>DK, <sup>4</sup>US
- 12:30 - 12:30 1848P - Predictive significance of tumour angiogenic and anti-angiogenic VEGF-A splice variants in patients with metastatic colorectal cancer  
G. Pentheroudakis<sup>1</sup>, V. Kotoula<sup>2</sup>, G.-A. Koliou<sup>1</sup>, K. Papadopoulou<sup>1</sup>, E. Samantas<sup>3</sup>, T. Makatsoris<sup>4</sup>, V. Karavasiliis<sup>2</sup>, D. Mauri<sup>1</sup>, I. Efstratiou<sup>1</sup>, D. Bafaloukos<sup>5</sup>, P. Papakostas<sup>1</sup>, A. Psyri<sup>1</sup>, G. Papatsibas<sup>1</sup>, G. Zarkavelis<sup>1</sup>, A. Goussia<sup>1</sup>, I. Bompolaki<sup>1</sup>, G. Oikonomopoulos<sup>6</sup>, A. Christopoulou<sup>1</sup>, D. Pectasides<sup>1</sup>, G. Fountzilias<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>Central Macedonia/GR, <sup>3</sup>Attica/GR, <sup>4</sup>Rion/GR, <sup>5</sup>N. Faliro/GR, <sup>6</sup>Athens/GR
- 12:30 - 12:30 1849P - ATR inhibition with radiation creates an inflammatory tumour microenvironment.  
M. Dillon, K. Bergerhoff, M. Pedersen, H. Whittock, E. Patin, H. Smith, J. Paget, R. Patel, G. Bozhanova, S. Foo, J. Campbell, C. Ragulan, E. Fontana, A. Wilkins, A. Sadanandam, A. Melcher, M. McLaughlin, K. Harrington; GB
- 12:30 - 12:30 1850P - RNA-based analysis of anaplastic lymphoma kinase (ALK) fusions in non-small cell lung cancer (NSCLC) cases showing immunohistochemistry/fluorescence in-situ hybridisation (IHC/FISH) discordance  
C. Vollbrecht, D. Lenze, M. Hummel, A. Lehmann, M. Moebs, N. Frost, P. Jurmeister, L. Schweizer, U. Kellner, M. Dietel, M. von Laffert; DE
- 12:30 - 12:30 1851P - The combination of MEK inhibitor and anti PD-L1: effects on organoid models from NSCLC biopsies  
C.M. Della Corte, G. Barra, V. Ciaramella, R. Di Liello, M. Fasano, F. Ciardiello, F. Morgillo; IT
- 12:30 - 12:30 1852P - Intraoperative Fluorescent Image-Guided Detection of Esophageal Cancer in Rabbit and Patient Specimens  
J. Rho, Y.H. Quan, B.H. Choi, B.-M. Kim, K.N. Han, Y.H. Choi, H.K. Kim; KR
- 12:30 - 12:30 1853P - Interaction Between Cancer Associated Fibroblasts and Cancer Cells Influence Immune Infiltrate and Is Modulated by Therapeutic Agents  
A. Rullan Iriarte<sup>1</sup>, E. Arwert<sup>2</sup>, E. Milford<sup>2</sup>, P. Chakravarty<sup>2</sup>, A. Melcher<sup>2</sup>, K. Harrington<sup>2</sup>, E. Sahai<sup>2</sup>; <sup>1</sup>Barcelona/ES, <sup>2</sup>GB
- 12:30 - 12:30 1854P - Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer  
T. Mizukami, Y. Sunakawa, H. Arai, M. Chosokabe, A. Doi, Y. Horie, M. Hirakawa, O. Saji, S. Naruki, N. Izawa, T. Ogura, T. Tsuda, T. Enomoto, S. Mikami, T. Fujino, T. Otsubo, T. Nakajima; JP
- 12:30 - 12:30 1855P - CD5 and CD6: evaluation of their role as prognostic biomarkers in resectable non-small cell lung cancer  
A. Moreno<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, S. Gallach Garcia<sup>1</sup>, A. Fernando<sup>1</sup>, I. Simoes<sup>1</sup>, E. Carreras<sup>1</sup>, M. Consuegra-Fernández<sup>1</sup>, A. Blasco Cordellat<sup>1</sup>, A. Cunqueiro Tomas<sup>1</sup>, M. Martorell<sup>1</sup>, C. Camps<sup>1</sup>, F. Lozano<sup>1</sup>, R. Sirera Perez<sup>2</sup>, E. Jantus-Lewintre<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>NA

- 12:30 - 12:30 1856P - Identification of the rational combination of two epigenetic inhibitors therapy in refractory AML using patient tumor derived ex vivo platform.  
P. Majumder<sup>1</sup>, G. Babu<sup>2</sup>, C. Rajagowda<sup>2</sup>, S. Thiyagarajan<sup>2</sup>, M. Biswas<sup>2</sup>, P. Radhakrishnan<sup>1</sup>, P. Chaudhuri<sup>2</sup>, A. Chatterjee<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>IN
- 12:30 - 12:30 1857P - Tyrosine Kinase Inhibitors and acid-inhibitory drugs : strong concomitant dispensing and drug-drug interaction risk.  
F. GRUDE, C. Vigneau-Victorri, D. Deniel Lagadec, E. Michaud, H. Bourgeois, B. Forestier, F. Marhuenda; FR
- 12:30 - 12:30 1858P - Intraoperative Detection of Resection Margin by Inhalation of ICG in Lung Cancer Preclinical Study  
Y.H. Quan, C.H. Oh, D. Jung, J.-Y. Lim, B.H. Choi, J. Rho, Y. Choi, K.N. Han, J.-H. Park, H.K. Kim, Y.H. Choi; KR
- 12:30 - 12:30 1859P - Proteomic-based machine learning computational analysis discovered biomarkers of aberrant vesicle-exosomal trafficking to determine chemotherapeutic responses in breast cancer  
H. Ryu, D.H. Han, K.-M. Lee, K. Kim; KR
- 12:30 - 12:30 1860P - CARCINOMA OF UNKNOWN ORIGIN: Deep Genomic profile helps to achieve an accurate diagnosis.  
A. Fernandez Díaz<sup>1</sup>, V. Iranzo Gonzalez-Cruz<sup>1</sup>, A.J. Cunqueiro Tomas<sup>1</sup>, C. Avila Andrade<sup>1</sup>, E. Jantus-Lewintre<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, J.E. Ales<sup>1</sup>, M. Valero<sup>1</sup>, G. D'Errico<sup>1</sup>, R. Pazo Cid<sup>1</sup>, A. Gallego Martínez<sup>1</sup>, A. Viana<sup>1</sup>, S. Ponce Aix<sup>1</sup>, J.A. Pérez-Fidalgo<sup>1</sup>, A. Terradez<sup>2</sup>, A. Rodrigo<sup>2</sup>, L. Alvarez<sup>2</sup>, G. Beniuga<sup>2</sup>, M. Martorell<sup>1</sup>, C. Camps<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>BE
- 12:30 - 12:30 1861P - Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy.  
J. Lee<sup>1</sup>, S.Y. Lim<sup>2</sup>, A. Menzies<sup>1</sup>, M. Carlino<sup>2</sup>, A. Guminski<sup>2</sup>, K. Nahar<sup>1</sup>, D. Palmieri<sup>2</sup>, E. Breen<sup>2</sup>, R. Kefford<sup>1</sup>, R. Scolyer<sup>1</sup>, G. Long<sup>2</sup>, H. Rizos<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU
- 12:30 - 12:30 1862P - A Phase 1 Trial of Vorelanib (X-82), a Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitor, in Patients (pts) with Advanced Solid Tumors  
J. Bendell<sup>1</sup>, K. Moore<sup>2</sup>, M. Patel<sup>3</sup>, C. Chua<sup>4</sup>, H.-T. Arkenau<sup>5</sup>, G. Dukart<sup>4</sup>, K. Harrow<sup>6</sup>, C. Liang<sup>4</sup>; <sup>1</sup>TN/US, <sup>2</sup>Oklahoma/US, <sup>3</sup>MN/US, <sup>4</sup>US, <sup>5</sup>GB, <sup>6</sup>FL/US
- 12:30 - 12:30 1863P - Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR+) non-small cell lung cancer (NSCLC)  
P.N. Ding<sup>1</sup>, T. Becker<sup>2</sup>, V. Bray<sup>1</sup>, W. Chua<sup>1</sup>, Y.F. Ma<sup>2</sup>, A. Luk<sup>2</sup>, J. Po<sup>2</sup>, D. Lynch<sup>2</sup>, N. Caixeiro<sup>2</sup>, P. de Souza<sup>2</sup>, T. Roberts<sup>2</sup>; <sup>1</sup>NSW/AU, <sup>2</sup>AU
- 12:30 - 12:30 1864P - Genotyping of circulating tumor DNA in biliary tract cancer reveals diagnostic and prognostic information  
T. Ettrich, D. Schwerdel, A. Dolnik, F. Beuter, T. Blätte, S. Schmidt, N. Stanescu-Siegmund, J. Steinacker, R. Marienfeld, A. Kleger, L. Bullinger, T. Seufferlein, A. Berger; DE

- 12:30 - 12:30 1865P - Interactions of cancer stem cell and immune microenvironment in non-small cell lung cancer (NSCLC)  
F. ZHANG<sup>1</sup>, N. Dong<sup>1</sup>, S. Torres<sup>1</sup>, S. Calabuig Fariñas<sup>1</sup>, R. Sirera Perez<sup>2</sup>, M. Mosqueda<sup>1</sup>, E. Escorihuela<sup>1</sup>, E. Jantus-Lewintre<sup>1</sup>, C. Camps<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>NA
- 12:30 - 12:30 1866P - Association of the rs1883832 variant of CD40 with NSCLC risk and overall survival  
F.-I. Dimitrakopoulos<sup>1</sup>, A. Antonacopoulou<sup>2</sup>, A. Kottorou<sup>1</sup>, S. Marousi<sup>2</sup>, I. Koukourikou<sup>2</sup>, C. Scopa<sup>2</sup>, D. Dougenis<sup>2</sup>, V. Tzelepi<sup>2</sup>, H. Kalofonos<sup>2</sup>; <sup>1</sup>Rion/GR, <sup>2</sup>GR
- 12:30 - 12:30 1867P - Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer  
S. Khakoo<sup>1</sup>, P. Carter<sup>2</sup>, N. Valeri<sup>2</sup>, R. Shaikh<sup>2</sup>, T. Jones<sup>2</sup>, R. Begum<sup>2</sup>, I. Rana<sup>2</sup>, S. Picchia<sup>2</sup>, M. Bali<sup>2</sup>, G. Brown<sup>2</sup>, A. Wotherspoon<sup>2</sup>, M. Terlizzo<sup>2</sup>, K. von Loga<sup>2</sup>, I. Ahmed<sup>2</sup>, D. Watkins<sup>2</sup>, I. Chau<sup>1</sup>, N. Starling<sup>2</sup>, D. Tait<sup>2</sup>, M. Hubank<sup>2</sup>, D. Cunningham<sup>2</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>GB
- 12:30 - 12:30 1868P - A Genetic Analysis of Gemcitabine-Induced High-Grade Neutropenia in Pancreatic Cancer Patients  
F. Innocenti<sup>1</sup>, C. Jiang<sup>2</sup>, A. Sibley<sup>2</sup>, S. Denning<sup>2</sup>, A. Etheridge<sup>2</sup>, D. Watson<sup>2</sup>, D. Niedzwiecki<sup>3</sup>, A. Hatch<sup>2</sup>, H. Hurwitz<sup>2</sup>, A. Nixon<sup>3</sup>, Y. Furukawa<sup>2</sup>, M. Kubo<sup>4</sup>, D. Crona<sup>2</sup>, H. Kindler<sup>5</sup>, H. McLeod<sup>2</sup>, M. Ratain<sup>5</sup>, K. Owzar<sup>2</sup>; <sup>1</sup>US/US, <sup>2</sup>US, <sup>3</sup>NC/US, <sup>4</sup>JP, <sup>5</sup>IL/US
- 12:30 - 12:30 1869P - Effect of a combined treatment with iPS cells derived dendritic cells and proton beam irradiation in a murine subcutaneous melanoma model  
Y. Wang, L. Sun, X. Li, K. Tsuboi; JP
- 12:30 - 12:30 1870P - Developing the liquid biopsy in gastroesophageal adenocarcinoma: Disease monitoring and detection of minimal residual disease  
M. Openshaw, B. Ottolini, C. Richards, D. Guttery, J. Shaw, A. Thomas; GB
- 12:30 - 12:30 1871P - Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>C]) polymorphisms.  
J. Huszno, Z. Kolosza; PL
- 12:30 - 12:30 1872P - Phase I pharmacological study of continuous chronomodulated capecitabine treatment  
J. Roosendaal, B. Jacobs, D. Pluim, H. Rosing, B. Nuijen, J. Beijnen, A. Huitema, J. Schellens, S. Marchetti; NL
- 12:30 - 12:30 1873P - Head and Neck (HN) Primary Sarcomatoid Carcinoma (PSC) profile by High-throughput somatic mutation profiling.  
V. Fallet<sup>1</sup>, R. Taouachi<sup>1</sup>, R. Saffroy<sup>1</sup>, A. Ben Lakhdar<sup>1</sup>, N. Rabbe<sup>1</sup>, F. André<sup>2</sup>, S. Temam<sup>1</sup>, A. Lemoine<sup>1</sup>, M. Wislez<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 1874P - A composite liquid biomarker for non-invasive diagnosis of resectable pancreatic ductal adenocarcinoma  
A. Berger, T. Ettrich, D. Schwerdel, A. Reinacher-Schick, H. Algül, A.-O. König, E. Gallmeier, K. Wille, S. Daum, M. Geissler, A. Tannapfel, W. Uhl, T. Seufferlein; DE

- 12:30 - 12:30 1875P - Acquired chemoresistance of colorectal cancer (CRC) cells is accompanied by pro-invasive VEGF-signaling that can be attenuated by aflibercept (Zaltrap®).  
A. LARSEN, P. van Dreden, B. Chibaudel, A. de Gramont, G. Gerotziafas, S. Thouroude; FR
- 12:30 - 12:30 1876P - Actionable Mutations and Overall Survival in 3,211 Patients with Cancer: The Hellenic Cooperative Oncology Group Precision Medicine Initiative  
E. Fountzila<sup>1</sup>, V. Kotoula<sup>2</sup>, G.-A. Koliou<sup>1</sup>, E. Giannoulatou<sup>3</sup>, H. Gogas<sup>4</sup>, C. Papadimitriou<sup>4</sup>, I. Tikas<sup>1</sup>, K. Papadopoulou<sup>1</sup>, F. Zagouri<sup>1</sup>, C. Christodoulou<sup>5</sup>, A. Koutras<sup>6</sup>, E. Razis<sup>1</sup>, P. Papakostas<sup>1</sup>, E. Samantas<sup>7</sup>, G. Aravantinos<sup>7</sup>, A. Psyrri<sup>1</sup>, D. Pectasides<sup>1</sup>, A. Futreal<sup>8</sup>, A.-M. Tsimberidou<sup>9</sup>, G. Fountzilas<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>Central Macedonia/GR, <sup>3</sup>AU, <sup>4</sup>Attiki/GR, <sup>5</sup>N. Faliro/GR, <sup>6</sup>Rion/GR, <sup>7</sup>Attica/GR, <sup>8</sup>TX/US, <sup>9</sup>US
- 12:30 - 12:30 1877P - DNA Repair genetic profiling in epithelial ovarian cancer: an opportunity for clinical improvement?  
J. Assis<sup>1</sup>, S. Coelho<sup>1</sup>, A. Nogueira<sup>1</sup>, R. Pinto<sup>1</sup>, M. Brandao<sup>2</sup>, J. Dias<sup>1</sup>, S. Alves<sup>1</sup>, D. Pereira<sup>1</sup>, R. Medeiros<sup>1</sup>; <sup>1</sup>PT, <sup>2</sup>BE
- 12:30 - 12:30 1878P - Strategy to improve the antitumor efficacy of dendritic cell-based nanovaccine under magnetic field control  
O. Gorbach, N. Khranovska, O. Skachkova, M. Inomistova, I. Shumeiko, V. Orel; UA
- 12:30 - 12:30 1879P - Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in Squamous Cell Lung Cancer (SQLC) models.  
A. Gkoutakos, S. Pilotto, M. Simbolo, C. Vicentini, A. Mafficini, A. del Curatolo, A. Scarpa, G. Tortora, V. Corbo, E. Bria; IT
- 12:30 - 12:30 1880P - Final results of the Phase 1 study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response.  
L. Seitz<sup>1</sup>, D. Ashok<sup>2</sup>, M. Leleti<sup>2</sup>, J. Powers<sup>2</sup>, B. Rosen<sup>2</sup>, D. Miles<sup>2</sup>, E. Sharif<sup>2</sup>, L. Jin<sup>2</sup>, A. Park<sup>2</sup>, S. Young<sup>2</sup>, A. Rieger<sup>2</sup>, U. Schindler<sup>2</sup>, J. Karakunnel<sup>1</sup>, M. Walters<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 12:30 - 12:30 1881P - An expression signature characterizes cancer stem cells from lung adenocarcinoma patients  
A. Herreros-Pomares, S. Calabuig Fariñas, J.D. de Maya, E. Escorihuela, E. Durendez-Saez, A. Blasco Cordellat, A. Navarro, E. García-Del-Olmo, R. Lucas, R. Farràs, E. Jantus-Lewintre, C. Camps; ES
- 12:30 - 12:30 1882P - Development of primary human NSCLC patient derived xenograft and organoids models as a precision approach to tumor treatment  
O.J. Juan Vidal, C. Gandia, J. Pardo-Sánchez, M. Benet, S. Aparisi, S. Palanca, E. Ansotegui, C. Jordá, J. Cerón, N. Mancheño, M. Sánchez-Céspedes, A. Lahoz, J. Carretero, R. Farràs; ES
- 12:30 - 12:30 1883P - PBRM1 is a novel candidate low-penetrance familial cancer predisposition gene  
I. Volodin, V. Kozlova, K. Anoshkin, A. Tanas, D. Zaletaev, V. Strelnikov; RU
- 12:30 - 12:30 1884P - Liprin-alpha4 contributes to increased proliferation and decreased chemosensitivity under hypoxia for small cell lung cancer as a downstream mediator of HIF-1alpha  
H. Onishi<sup>1</sup>, A. Yamasaki<sup>2</sup>, M. Kawamoto<sup>2</sup>; <sup>1</sup>Fukuoka/JP, <sup>2</sup>JP
- 12:30 - 12:30 1885P - Precision Medicine for patients with rare cancers: an effective strategy within the prospective MOSCATO trial

M. Abdelshafy<sup>1</sup>, Y. El Dakdouki<sup>2</sup>, L. Verlingue<sup>2</sup>, A. Hollebecque<sup>2</sup>, L. Lacroix<sup>2</sup>, S. Postel-Vinay<sup>2</sup>, A. Varga<sup>1</sup>, R. Balheda<sup>2</sup>, J.-M. Michot<sup>2</sup>, A. Marabelle<sup>2</sup>, E. Rouleau<sup>3</sup>, E. Solary<sup>2</sup>, T. de Baere<sup>2</sup>, E. Angevin<sup>1</sup>, V. Ribrag<sup>2</sup>, S. Michiels<sup>2</sup>, F. André<sup>1</sup>, J.-Y. Scoazec<sup>2</sup>, J.-C. Soria<sup>4</sup>, C. Massard<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX 5/FR, <sup>4</sup>CEDEX/US

- 12:30 - 12:30 1886P - Streamlining Multi-omic and Artificial Intelligence Analysis Through Interrogative Biology and BALcis for Translational Precision Medicine Applications in Clinical Oncology  
L. Rodrigues<sup>1</sup>, M. Kiebish<sup>2</sup>, G. Miller<sup>2</sup>, L. Zhang<sup>2</sup>, V. Vemulapalli<sup>2</sup>, V. Vishnudas<sup>2</sup>, R. Sarangarajan<sup>1</sup>, N. Narain<sup>1</sup>, V. Akmaev<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 12:30 - 12:30 1887P - Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach  
R. Falcone, P. Paci, A. Verrienti, G. Fiscon, M. Sponziello, F. Conte, V. Pecce, F. Rosignolo, G. Grani, L. Lamartina, V. Ramundo, C. Durante, L. Farina, S. Filetti; IT
- 12:30 - 12:30 1888P - Improving value for cancer patients: A European study of outcomes in practice  
R. Hazarika<sup>1</sup>, T. Albrecht<sup>2</sup>, B. Berger<sup>1</sup>, D. Duplay<sup>1</sup>, L. Makaroff<sup>1</sup>, Z. Maravic<sup>1</sup>, R. Mortuza<sup>1</sup>, V. Muthu<sup>1</sup>, K. Oliver<sup>1</sup>, R. Price<sup>1</sup>, M.V.M. van Meerveld<sup>1</sup>, K. Steinmann<sup>1</sup>, A. Krukowsk<sup>1</sup>, R. Catena<sup>1</sup>, S. Wait<sup>1</sup>, V. Zilli<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>SI
- 12:30 - 12:30 1889P - High-throughput screening of new drugs targeting lung CSCs  
H. Amado Labrador, E. Jantus-Lewintre, S. Calabuig Fariñas, C. Aguilar-Gallardo, J. Murga, E. Munera-Maravilla, E. Durendez-Saez, M. Mosqueda, E. Escorihuela, F. ZHANG, E. Masiá, N. Dong, R. Guijarro, C. Camps; ES
- 12:30 - 12:30 1890TiP - RING observational trial to compare T790M mutation testing in blood by different methodologies  
B. Garcia-Pelaez<sup>1</sup>, E. Jantus<sup>1</sup>, A. Romero<sup>1</sup>, M.-A. Molina<sup>1</sup>, A. Blasco Cordellat<sup>1</sup>, C. Perez-Barrios<sup>1</sup>, R. Rosell<sup>2</sup>, C. Camps<sup>1</sup>, M. Provencio Pulla<sup>3</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES, <sup>3</sup>Madrid/ES

12:30 - 14:30 Type: Patient Advocacy Track ICM - Room 5  
 Title: Pillars of an effective healthcare system in Europe  
 Chair(s): A. Plate, BE; V. Voiculescu, RO

12:30 - 12:45 Key components of a well-functioning healthcare system  
J. Figueras, BE

12:45 - 13:00 Measuring performance of healthcare systems: The Euro Health Consumer Index  
B. Cebolla Garrofé, FR

13:00 - 13:15 Special focus on healthcare in CEE  
V. Voiculescu, RO

13:15 - 13:30 Civic participation: How citizens shape the society they live in  
G. Moro, IT

13:30 - 14:00 Discussion

13:00 - 14:30 Type: ESMO Colloquium ICM - Room 1  
 Title: ESMO COLLOQUIUM - HepatoCellular Carcinoma treatment: Now, next and beyond  
 Chair(s): J.-L. Raoul, FR

13:00 - 13:05 Introduction  
J.-L. Raoul, CEDEX/FR

13:05 - 13:30 Pros and cons of loco-regional therapy options  
C. Gomez Martin, ES

13:30 - 13:55 Transitioning to first line systemic treatment; Pros and Cons of initiating early systemic treatment?  
M. Scartozzi, IT

13:55 - 14:20 Moving beyond monotherapy in first line HCC: What will be the new standard for the expected clinical and patient outcomes?  
A. Vogel, DE

14:20 - 14:30 Summary and conclusion  
J.-L. Raoul, CEDEX/FR

13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 14b  
 Title: Industry satellite symposium 14 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 13  
 Title: Industry satellite symposium 15 (TBC)

13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 16 (TBC)	Hall A1 - Room 15
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 17 (TBC)	Hall A1 - Room 16
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 18 (TBC)	Hall B3 - Room 20
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 19 (TBC)	Hall B3 - Room 22
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 20 (TBC)	Hall B4 - Room 19
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium (TBC)	Hall B4 - Room 24
14:45 - 16:30	Type: Educational session Title: Novel therapies for small cell lung cancer Chair(s): C. Faivre-Finn, GB; N. Reguart Aransay, ES	Hall A1 - Room 17
14:45 - 15:10	Genetic background of SCLC <u>C. Rudin</u> , US	
15:10 - 15:35	Radiotherapy in SCLC: Lessons to learn <u>C. Faivre-Finn</u> , GB	
15:35 - 16:00	Targeted therapies in SCLC: What might we expect? <u>N. Reguart Aransay</u> , ES	
16:00 - 16:25	Immunotherapy in SCLC: Current status and future perspectives <u>S. Novello</u> , IT	



14:45 - 16:15	Type: Educational session Title: Adjuvant treatment in colon cancer: Standards and next steps Chair(s): J. Taieb, FR	Hall A2 - Room 18
14:45 - 15:07	Using the standards but when, for what, and for how long? <u>R. Labianca</u> , IT	
15:07 - 15:29	Tumour biology: What have we learned from the preceding trials (and what is “ready for daily use”)? <u>J. Taieb</u> , FR	
15:29 - 15:51	What are we doing with rare subtypes: Is the time right for treatment stratification? <u>C. Montagut</u> , ES	
15:51 - 16:13	Monitoring “molecular residual disease” in colon cancer: Implications for the future <u>L. Diaz</u> , US	
14:45 - 16:05	Type: Poster Discussion session Title: Poster Discussion session - Genitourinary tumours, non prostate Chair(s): R. Jones, GB; I. Duran, ES; C. Suarez, ES	ICM - Room 1
14:45 - 14:45	One LBA TBC	
14:45 - 14:45	One LBA TBC	
14:45 - 14:45	865PD - RANGE, a phase 3, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): overall survival results <u>D. Petrylak</u> <sup>1</sup> , <u>C. Sternberg</u> <sup>2</sup> , <u>A. Drakaki</u> <sup>3</sup> , <u>R. de Wit</u> <sup>4</sup> , <u>H. Nishiyama</u> <sup>5</sup> , <u>A. Necchi</u> <sup>2</sup> , <u>D. Castellano</u> <sup>6</sup> , <u>A. Bamias</u> <sup>7</sup> , <u>K. Chi</u> <sup>8</sup> , <u>M. van der Heijden</u> <sup>4</sup> , <u>N. Matsubara</u> <sup>9</sup> , <u>S. Hussain</u> <sup>10</sup> , <u>A. Flechon</u> <sup>11</sup> , <u>B. Alekseev</u> <sup>12</sup> , <u>E. Yu</u> <sup>13</sup> , <u>R. Walgren</u> <sup>14</sup> , <u>F. Russo</u> <sup>14</sup> , <u>A. Zimmermann</u> <sup>14</sup> , <u>K. Bell-Mcguinn</u> <sup>15</sup> , <u>T. Powles</u> <sup>10</sup> ; <sup>1</sup> CT/US, <sup>2</sup> IT, <sup>3</sup> CA/US, <sup>4</sup> NL, <sup>5</sup> JP, <sup>6</sup> ES, <sup>7</sup> Attiki/GR, <sup>8</sup> British Columbia/CA, <sup>9</sup> Chiba/JP, <sup>10</sup> GB, <sup>11</sup> CEDEX/FR, <sup>12</sup> RU, <sup>13</sup> WA/US, <sup>14</sup> US, <sup>15</sup> IN/US	
14:45 - 15:00	Invited Discussant two LBAs TBC and 865PD <u>R. Jones</u> , GB	
15:00 - 15:10	Q&A led by Discussant	
15:10 - 15:10	One LBA TBC	
15:10 - 15:10	866PD - Comprehensive biomarker analyses and updated results of PURE-01 study: neoadjuvant pembrolizumab (Pembro) in muscle-invasive urothelial bladder carcinoma (MIBC).	

A. Necchi<sup>1</sup>, A. Briganti<sup>1</sup>, D. Raggi<sup>1</sup>, R. Luciano<sup>1</sup>, M. Colecchia<sup>1</sup>, S. Massa<sup>1</sup>, P. Giannatempo<sup>1</sup>, R. Colombo<sup>1</sup>, A. Gallina<sup>1</sup>, R. Salvioni<sup>1</sup>, R. Mortarini<sup>1</sup>, F. Montorsi<sup>1</sup>, R. Madison<sup>2</sup>, S. Ali<sup>3</sup>, J. Ross<sup>2</sup>, J. Chung<sup>3</sup>, A. Anichini<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>US, <sup>3</sup>MA/US

15:10 - 15:10 867PD - Comprehensive genomic profiling (CGP) of chemotherapy-resistant, primary mediastinal nonseminomatous germ cell tumors (PMNSGCT)  
A. Necchi<sup>1</sup>, G. Bratslavsky<sup>2</sup>, R. Corona<sup>2</sup>, J. Chung<sup>3</sup>, S. Millis<sup>3</sup>, L. Gay<sup>4</sup>, J. Elvin<sup>3</sup>, J.-A. Vergilio<sup>3</sup>, S. Ramkissoon<sup>3</sup>, E. Severson<sup>3</sup>, S. Daniel<sup>3</sup>, J. Killian<sup>3</sup>, S. Ali<sup>3</sup>, A. Schrock<sup>4</sup>, V. Miller<sup>3</sup>, J. Ross<sup>4</sup>; <sup>1</sup>IT, <sup>2</sup>NY/US, <sup>3</sup>MA/US, <sup>4</sup>US

15:10 - 15:25 Invited Discussant One LBA TBC, 866PD and 867PD  
I. Duran, ES

15:25 - 15:35 Q&A led by Discussant

15:35 - 15:35 One LBA TBC

15:35 - 15:35 868PD - Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): prospective analysis from the GETUG-AFU 26 (NIVOREN) trial  
R. Flippot<sup>1</sup>, C. Dalban<sup>1</sup>, B. Laguerre<sup>2</sup>, D. Borchiellini<sup>1</sup>, G. Gravis<sup>3</sup>, S. Negrier<sup>2</sup>, C. Chevreau<sup>4</sup>, F. Joly<sup>1</sup>, L. Geoffrois<sup>2</sup>, S. Ladoire<sup>5</sup>, H. Mahammedi<sup>6</sup>, F. Tantot<sup>1</sup>, B. Escudier<sup>2</sup>, L. Albiges<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR, <sup>4</sup>Haute-Garonne/FR, <sup>5</sup>Cedex/FR, <sup>6</sup>CEDEX 1/FR

15:35 - 15:35 869PD - Tumor molecular characteristics in patients (pts) with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) good (G) and intermediate/poor (I/P) risk  
B. Beuselinck<sup>1</sup>, A. Verbiest<sup>1</sup>, G. Couchy<sup>2</sup>, S. Job<sup>2</sup>, A. de Reyniès<sup>2</sup>, S. Caruso<sup>2</sup>, V. Verkarre<sup>2</sup>, N. Rioux-Leclercq<sup>2</sup>, P. Schöffski<sup>1</sup>, Y. Vano<sup>2</sup>, R.-T. Elaidi<sup>2</sup>, E. Lerut<sup>1</sup>, M. Albersen<sup>1</sup>, S. Oudard<sup>2</sup>, J. Zucman-Rossi<sup>2</sup>; <sup>1</sup>BE, <sup>2</sup>FR

15:35 - 15:35 870PD - Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): results of a GETUG multicenter phase II trial (Axipap)  
S. Negrier<sup>1</sup>, N. Rioux-Leclercq<sup>2</sup>, A. Ravaud<sup>2</sup>, G. Gravis<sup>3</sup>, L. Geoffrois<sup>1</sup>, C. Chevreau<sup>4</sup>, F. Rolland<sup>1</sup>, E. Blanc<sup>1</sup>, C. Segura-Ferlay<sup>2</sup>, D. Perol<sup>1</sup>, M. Gross Goupil<sup>2</sup>, S. Dermeche<sup>3</sup>, A. Flechon<sup>1</sup>, L. Albiges<sup>1</sup>, B. Escudier<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX 9/FR, <sup>4</sup>Haute-Garonne/FR

15:35 - 15:50 Invited Discussant One LBA TBC, 868PD, 869PD and 870PD  
C. Suarez, ES

15:50 - 16:00 Q&A led by Discussant

14:45 - 16:05	Type: Poster Discussion session Title: Poster Discussion session - Melanoma Chair(s): G. Long, AU; J.J. Grob, FR	ICM - Room 14b
14:45 - 14:45	One LBA TBC	
14:45 - 14:45	1245PD - Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a Multicenter, Phase 1/2 study  <u>A. Diab</u> <sup>1</sup> , C. Haymaker <sup>2</sup> , C. Bernatchez <sup>2</sup> , R. Andtbacka <sup>3</sup> , M. Shaheen <sup>1</sup> , D. Johnson <sup>1</sup> , J. Markowitz <sup>1</sup> , I. Puzanov <sup>4</sup> , R. Murthy <sup>1</sup> , D. Johnson <sup>2</sup> , M. James <sup>2</sup> , S. Chunduru <sup>1</sup> , J. Geib <sup>1</sup> , S. Swann <sup>5</sup> , S. Rahimian <sup>1</sup> , P. Hwu <sup>1</sup> ; <sup>1</sup> US, <sup>2</sup> TX/US, <sup>3</sup> UT/US, <sup>4</sup> NY/US, <sup>5</sup> PA/US	
14:45 - 14:45	1246PD - Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: evidence for systemic effects in a phase 2, single-arm study  <u>H. Gogas</u> <sup>1</sup> , I. Samoylenko <sup>2</sup> , D. Schadendorf <sup>3</sup> , R. Gutzmer <sup>3</sup> , J.J. Grob <sup>4</sup> , J. Sacco <sup>5</sup> , K. Gorski <sup>6</sup> , A. Anderson <sup>6</sup> , C. Liu <sup>6</sup> , J. Malvey <sup>7</sup> ; <sup>1</sup> Attiki/GR, <sup>2</sup> RU, <sup>3</sup> DE, <sup>4</sup> FR, <sup>5</sup> GB, <sup>6</sup> US, <sup>7</sup> ES	
14:45 - 14:45	One LBA TBC	
14:45 - 15:05	Invited Discussant two LBAs TBC, 1245PD and 1246PD	
15:05 - 15:15	Q&A led by Discussant	
15:15 - 15:15	One LBA TBC	
15:15 - 15:15	1247PD - Phase II multicenter, single arm, open label study of Nivolumab in combination with Ipilimumab in untreated patients with metastatic uveal melanoma. GEM1402.NCT02626962  <u>J.M. Piulats Rodriguez</u> <sup>1</sup> , L. De La Cruz Merino <sup>2</sup> , E. Espinosa <sup>2</sup> , L. Alonso Carrión <sup>2</sup> , S. Martin Algarra <sup>2</sup> , R. López-Castro <sup>2</sup> , M.T. Curiel García <sup>2</sup> , D. Rodriguez Abreu <sup>2</sup> , A. Rullan Iriarte <sup>1</sup> , A. Berrocal Jaime <sup>2</sup> ; <sup>1</sup> Barcelona/ES, <sup>2</sup> ES	
15:15 - 15:25	Invited Discussant One LBA TBC and 1247PD  <u>G. Long</u> , NSW/AU	
15:25 - 15:35	Q&A led by Discussant	
15:35 - 15:35	1248PD - Efficacy of Pembrolizumab (Pembro) in Patients (Pts) With Advanced Melanoma with Stable Brain Metastases (BM) at Baseline: A Pooled Retrospective Analysis	

O. Hamid<sup>1</sup>, A. Ribas<sup>1</sup>, A. Daud<sup>1</sup>, M. Butler<sup>2</sup>, M. Carlino<sup>3</sup>, W.-J. Hwu<sup>4</sup>, G. Long<sup>3</sup>, K. Ansell<sup>5</sup>, F.S. Hodi<sup>6</sup>, N. Khushalani<sup>7</sup>, C. Blank<sup>8</sup>, C. Loquai<sup>9</sup>, J. Lin<sup>10</sup>, S. Diede<sup>10</sup>, C. Robert<sup>11</sup>; <sup>1</sup>CA/US, <sup>2</sup>CA, <sup>3</sup>NSW/AU, <sup>4</sup>TX/US, <sup>5</sup>TN/US, <sup>6</sup>MA/US, <sup>7</sup>FL/US, <sup>8</sup>NL, <sup>9</sup>DE, <sup>10</sup>NJ/US, <sup>11</sup>FR

15:35 - 15:35 1249PD - Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase.

C. Allayous<sup>1</sup>, B. Oriano<sup>1</sup>, S. Dalle<sup>2</sup>, L. Mortier<sup>2</sup>, M.-T. Leccia<sup>3</sup>, B. Guillot<sup>1</sup>, G. Jeudy<sup>1</sup>, C. Dutriaux<sup>1</sup>, J.-P. Lacour<sup>1</sup>, P. Saiag<sup>1</sup>, F. Brunet-Possenti<sup>1</sup>, J. De Quatrebarbes<sup>1</sup>, P.-E. Stoeber<sup>1</sup>, D. Legoupil<sup>1</sup>, M. Beylot-Barry<sup>1</sup>, T. Lesimple<sup>1</sup>, F. Aubin<sup>1</sup>, A. Ballon<sup>1</sup>, R. Porcher<sup>1</sup>, C. Lebbe<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR

15:35 - 15:45 Invited Discussant 1248PD and 1249PD  
J.J. Grob, FR

15:45 - 15:55 Q&A led by Discussant

14:45 - 16:15 Type: Special session  
Title: Technologies of the future  
Chair(s): A.A. Adjei, US Hall A1 - Room 16

14:45 - 15:15 CRISPR  
R. Bernards, NL

15:15 - 15:45 CAR T cells  
M. Sadelain, US

15:45 - 16:15 Oncolytic viruses  
E. Galanis, MN/US

14:45 - 16:15 Type: Educational session Hall B3 - Room 20  
 Title: Precision medicine with chemotherapy  
 Chair(s): S. Taylor, GB

14:45 - 15:10 Precision medicine with conventional therapies in ovarian cancer  
S. Taylor, GB

15:10 - 15:35 Functional selection assays for precision therapy in breast cancer  
R. Kanaar, NL

15:35 - 16:00 Therapy, response and resistance in breast cancer  
J. Jonkers, NL

16:00 - 16:15 Discussion

14:45 - 16:15 Type: EONS session Hall B4 - Room 24  
 Title: Patient safety  
 Chair(s): C. de Lacerda, BE

14:45 - 15:00 Patient safety as a current concern for health systems in Europe  
D. Schwappach, CH

15:00 - 15:15 Risk assessment (in broad)  
J. Richmond, IE

15:15 - 15:30 Safety in the era of oral chemotherapy  
L. Iacorossi, IT

15:30 - 15:45 Safety outside of cancer centres: The rise of oral chemotherapy and the safety needs of patients  
C. Oakley, GB

15:45 - 16:15 Discussion

14:45 - 16:15 Type: Special session ICM - Room  
 Title: The way to assure sustainable, accessible and affordable cancer care within National 14a  
 Cancer Control Plans (NCCP)  
 Chair(s): G. Curigliano, IT; L. Stevens, US

14:45 - 14:50 Introduction  
L. Stevens, US

14:50 - 15:05 To have an NCCP or not: That is issue and where should we begin?  
A. Eniu, RO

15:05 - 15:20 Profile from Central Europe – Czech Republic  
T. Svoboda, Plzen/CZ

15:20 - 15:35 Kazakhstan: National Cancer Control Plan update on progress made in 2017 – 2018  
D. Kaidarova, KZ

15:35 - 15:50 Belarus: National Cancer Control Plan update on progress made in 2017 – 2018  
S. Krasny, BY

15:50 - 16:15 Interactive Q&A/Wrap up  
G. Curigliano, IT

15:00 - 16:00 Type: Multidisciplinary interactive sessions ICM - Room 13  
 Title: Prevention and management in long term chronic cancer care  
 Chair(s): A. Young, GB

15:00 - 15:10 Case presentation on venous thromboembolism and pain  
M. Ozturk, TR

15:10 - 15:25 VTE  
A. Young, GB

15:25 - 15:40 Pain  
A. Caraceni, IT

15:40 - 16:00 Discussion

15:00 - 16:15 Type: Poster Discussion session Hall A1 - Room 15  
 Title: Poster Discussion session - Breast cancer early stage  
 Chair(s): H. Bonnefoi, FR; V. Dieras, FR

15:00 - 15:00 One LBA TBC

- 15:00 - 15:00 One LBA TBC
- 15:00 - 15:00 188PD - Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)  
M. Untch<sup>1</sup>, C. Jackisch<sup>1</sup>, A. Schneeweiss<sup>1</sup>, S. Schmatloch<sup>1</sup>, B. Aktas<sup>1</sup>, C. Denkert<sup>1</sup>, C. Schem<sup>2</sup>, H. Wiebringhaus<sup>1</sup>, S. Kümmel<sup>1</sup>, K. Rhiem<sup>1</sup>, M. Warm<sup>1</sup>, P.A. Fasching<sup>1</sup>, M. Just<sup>1</sup>, C. Hanusch<sup>1</sup>, J. Hackmann<sup>1</sup>, J.-U. Blohmer<sup>1</sup>, J. Furlanetto<sup>1</sup>, V. Nekljudova<sup>1</sup>, G. von Minckwitz<sup>1</sup>, S. Loibl<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>Schleswig-Holstein/DE
- 15:00 - 15:15 Invited Discussant two LBAs TBC and 188PD  
H. Bonnefoi, CEDEX/FR
- 15:15 - 15:25 Q&A led by Discussant
- 15:25 - 15:25 189PD - Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04)  
A. van Rossum, M. Hoogstraat, M. Opdam, H. Horlings, L. Wessels, R. Kerkhoven, A. van Leeuwen - Stok, H. Oosterkamp, M. Kok, S. Linn; NL
- 15:25 - 15:25 190PD - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies  
G. Bianchini<sup>1</sup>, J. Parker<sup>2</sup>, L. Carey<sup>2</sup>, C. Perou<sup>2</sup>, L. Sica<sup>1</sup>, A. Prat<sup>3</sup>, T. Pieńkowski<sup>4</sup>, Y.-H. Im<sup>5</sup>, G. Bianchi<sup>1</sup>, T. Ling-Ming<sup>6</sup>, M.-C. Liu<sup>6</sup>, A. Lluch<sup>7</sup>, V. Semiglazov<sup>8</sup>, J. de la Haba-Rodriguez<sup>3</sup>, D.-Y. Oh<sup>5</sup>, B. Poirier<sup>9</sup>, J. Pedrini<sup>10</sup>, P. Valagussa<sup>1</sup>, L. Gianni<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>NC/US, <sup>3</sup>ES, <sup>4</sup>PL, <sup>5</sup>KR, <sup>6</sup>TW, <sup>7</sup>Valencia/ES, <sup>8</sup>RU, <sup>9</sup>CA, <sup>10</sup>BR
- 15:25 - 15:40 Invited Discussant 189PD and 190PD
- 15:40 - 15:50 Q&A led by Discussant
- 15:50 - 15:50 191PD - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio  
P.F. Conte<sup>1</sup>, V. Guarneri<sup>1</sup>, G. Bisagni<sup>1</sup>, F. Piacentini<sup>1</sup>, A. Brandes<sup>1</sup>, L. Cavanna<sup>1</sup>, F. Giotta<sup>1</sup>, M. Aieta<sup>2</sup>, V. Gebbia<sup>1</sup>, A. Frassoldati<sup>1</sup>, A. Musolino<sup>1</sup>, O. Garrone<sup>1</sup>, C. Taverniti<sup>1</sup>, A. Rimanti<sup>1</sup>, S. Sarti<sup>3</sup>, D. Rubino<sup>1</sup>, A. Bologna<sup>1</sup>, R. Vicini<sup>1</sup>, S. Balduzzi<sup>1</sup>, R. D'Amico<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(PZ)/IT, <sup>3</sup>Forlì-Cesena/IT
- 15:50 - 15:50 192PD - Randomized Trial of Lisinopril or Carvedilol for the Prevention of Cardiotoxicity in Patients with Early Stage HER2-Positive Breast Cancer Receiving Trastuzumab  
P. Munster<sup>1</sup>, J. Krischer<sup>2</sup>, R. Tamura<sup>2</sup>, L. Bello-Matricaria<sup>2</sup>, A. Fink<sup>2</sup>, W. McCaskill-Stevens<sup>3</sup>, M. Guglin<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>FL/US, <sup>3</sup>MD/US, <sup>4</sup>KY/US

15:50 - 16:05 Invited Discussant 191PD and 192PD

V. Dieras, CEDEX 5/FR

16:05 - 16:15 Q&A led by Discussant

15:00 - 16:15 Type: Poster Discussion session Hall B3 - Room 23  
 Title: Poster Discussion session - Head and neck  
 Chair(s): M. Merlano, IT; H. Mehanna, GB; E.M. Ozsahin, CH

15:00 - 15:00 1047PD - Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC): Post Hoc Analyses of Treatment Options From the Phase 3 KEYNOTE-040 Trial

C. Le Tourneau<sup>1</sup>, E. Cohen<sup>2</sup>, K. Harrington<sup>3</sup>, J. Dinis<sup>4</sup>, L. Licitra<sup>5</sup>, M.-J. Ahn<sup>6</sup>, J.-P. Machiels<sup>7</sup>, N. Mach<sup>8</sup>, R. Mehra<sup>2</sup>, B. Burtness<sup>2</sup>, P. Zhang<sup>9</sup>, J. Cheng<sup>10</sup>, R. Swaby<sup>9</sup>, D. Soulières<sup>11</sup>; <sup>1</sup>FR, <sup>2</sup>US, <sup>3</sup>GB, <sup>4</sup>PT, <sup>5</sup>IT, <sup>6</sup>KR, <sup>7</sup>BE, <sup>8</sup>CH, <sup>9</sup>NJ/US, <sup>10</sup>PA/US, <sup>11</sup>QC/CA

15:00 - 15:00 1048PD - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ , in patients (pts) with advanced SCCHN: results from a phase 1 cohort

B.C. Cho<sup>1</sup>, A. Daste<sup>2</sup>, A. Ravaud<sup>2</sup>, S. Salas<sup>2</sup>, N. Isambert<sup>3</sup>, E. McClay<sup>4</sup>, A. Awada<sup>5</sup>, C. Borel<sup>6</sup>, J. Gullely<sup>7</sup>, L. Ojalvo<sup>8</sup>, C. Helwig<sup>9</sup>, P.A. Rolfe<sup>8</sup>, N. Penel<sup>6</sup>; <sup>1</sup>KR, <sup>2</sup>FR, <sup>3</sup>Cedex/FR, <sup>4</sup>CA/US, <sup>5</sup>BE, <sup>6</sup>CEDEX/FR, <sup>7</sup>MD/US, <sup>8</sup>MA/US, <sup>9</sup>DE

15:00 - 15:00 1049PD - Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

J. Fayette<sup>1</sup>, G. Lefebvre<sup>1</sup>, M. Posner<sup>2</sup>, J. Bauman<sup>3</sup>, S. Salas<sup>4</sup>, C. Even<sup>4</sup>, E. Saada-Bouzi<sup>4</sup>, T. Seiwert<sup>5</sup>, D. Colevas<sup>3</sup>, F. Calmels<sup>4</sup>, R. Zerbib<sup>4</sup>, A. Boyer Chammard<sup>4</sup>, R. Cohen<sup>3</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>NY/US, <sup>3</sup>US, <sup>4</sup>FR, <sup>5</sup>IL/US

15:00 - 15:00 1050PD - Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

E. Cohen<sup>1</sup>, A. Algazi<sup>2</sup>, D. Laux<sup>3</sup>, D. Wong<sup>2</sup>, A. Amin<sup>4</sup>, L. Nabel<sup>2</sup>, M. Chisamore<sup>2</sup>, E. Gamelin<sup>5</sup>, R. Janssen<sup>2</sup>, S. Bishnoi<sup>6</sup>; <sup>1</sup>IL/US, <sup>2</sup>US, <sup>3</sup>IA/US, <sup>4</sup>NC/US, <sup>5</sup>CA/US, <sup>6</sup>AU

15:00 - 15:15 Invited Discussant 1047PD, 1048PD, 1049PD and 1050PD

M. Merlano, IT

15:15 - 15:25 Q&A led by Discussant

15:25 - 15:25 1051PD - Comparison of Patient Populations Identified by Different PD-L1 Assays in Head and Neck Squamous Cell Carcinoma (HNSCC)

M. Scott<sup>1</sup>, S. Wildsmith<sup>1</sup>, M. Ratcliffe<sup>1</sup>, H. Al-Masri<sup>2</sup>, P. Scorer<sup>1</sup>, C. Barker<sup>1</sup>, M. Rebelatto<sup>3</sup>, J. Walker<sup>4</sup>; <sup>1</sup>GB, <sup>2</sup>IL/US, <sup>3</sup>US, <sup>4</sup>NL



- 15:25 - 15:25 1052PD - Predictor of Effectiveness of Treatment Intensification on Overall Survival in Head and Neck Cancer (HNC)  
K. Zakeri<sup>1</sup>, F. Rotolo<sup>2</sup>, B. Lacas<sup>2</sup>, L. Vitzthum<sup>3</sup>, Q.-T. Le<sup>3</sup>, V. Gregoire<sup>2</sup>, J. Overgaard<sup>4</sup>, J. Tobias<sup>5</sup>, B. Zackrisson<sup>6</sup>, M. Parmar<sup>7</sup>, B. Burtress<sup>1</sup>, M.G. Ghi<sup>8</sup>, G. Sanguineti<sup>9</sup>, B. O'Sullivan<sup>10</sup>, C. Fortpie<sup>11</sup>, J. Bourhis<sup>12</sup>, H. Shen<sup>3</sup>, J. Harris<sup>13</sup>, J.-P. Pignon<sup>14</sup>, L. Mell<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>FR, <sup>3</sup>CA/US, <sup>4</sup>DK, <sup>5</sup>GB, <sup>6</sup>SE, <sup>7</sup>London/GB, <sup>8</sup>Mestre-VE/IT, <sup>9</sup>IT, <sup>10</sup>CA, <sup>11</sup>BE, <sup>12</sup>CH, <sup>13</sup>PA/US, <sup>14</sup>CEDEX/FR
- 15:25 - 15:25 1053PD - Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)  
S. Cavalieri<sup>1</sup>, L. De Cecco<sup>1</sup>, G. Calareso<sup>1</sup>, M. Silva<sup>1</sup>, S. Gazzani<sup>1</sup>, M. Bologna<sup>1</sup>, I. Nauta<sup>2</sup>, F. Wesseling<sup>2</sup>, L. Lopez Perez<sup>3</sup>, R. Shefi<sup>4</sup>, V. Tountopoulos<sup>5</sup>, G. Fico<sup>3</sup>, K. Scheckenbach<sup>6</sup>, R. Brakenhoff<sup>2</sup>, F. Hoebbers<sup>2</sup>, S. Canevari<sup>1</sup>, T. Poli<sup>1</sup>, L. Licitra<sup>1</sup>, L. Mainardi<sup>1</sup>, B. BD2Decide Consortium<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>NL, <sup>3</sup>ES, <sup>4</sup>IL, <sup>5</sup>GR, <sup>6</sup>DE
- 15:25 - 15:40 Invited Discussant 1051PD, 1052PD and 1053PD  
H. Mehanna, West Midlands/GB
- 15:40 - 15:50 Q&A led by Discussant
- 15:50 - 15:50 1054PD - Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT) versus conventional chemo-radiotherapy for locally advanced (LA) head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial  
Y. Tao<sup>1</sup>, A. Auperin<sup>1</sup>, P. Blanchard<sup>1</sup>, M. Alfonsi<sup>1</sup>, X.-S. Sun<sup>1</sup>, M. Rives<sup>1</sup>, Y. Pointreau<sup>1</sup>, J. Castelli<sup>1</sup>, P. Graff<sup>1</sup>, S. Wong Hee Kam<sup>1</sup>, J. Thariat<sup>1</sup>, O. Veresezan<sup>1</sup>, A. Cornely<sup>1</sup>, O. Casiraghi<sup>1</sup>, M. Lapeyre<sup>1</sup>, J. Bourhis<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CH
- 15:50 - 15:50 1055PD - Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).  
G. Koutsodontis<sup>1</sup>, G. Papaxoinis<sup>2</sup>, I. Kotsantis<sup>1</sup>, P. Economopoulou<sup>1</sup>, A. Strati<sup>1</sup>, C. Avgerinou<sup>1</sup>, N. Spathas<sup>1</sup>, E. Kirodimos<sup>1</sup>, O. Tsavaris<sup>1</sup>, E. Maratou<sup>1</sup>, L. Hoxhallari<sup>1</sup>, M. Anastasiou<sup>1</sup>, M. Prevezanou<sup>1</sup>, E. Lianidou<sup>1</sup>, A. Psyri<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>GB
- 15:50 - 15:50 1056PD - Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression  
M. Joerger<sup>1</sup>, S. Takahashi<sup>2</sup>, C.M. Sayehli<sup>3</sup>, S. Slosarczyk<sup>3</sup>, A. Navarro Mendivil<sup>4</sup>, P. Cassier<sup>5</sup>, H. Nogai<sup>3</sup>, C. Zhang<sup>2</sup>, F. Sei<sup>2</sup>, S. Bender<sup>3</sup>, P. Ellinghaus<sup>3</sup>, M. Tahara<sup>6</sup>; <sup>1</sup>CH, <sup>2</sup>JP, <sup>3</sup>DE, <sup>4</sup>ES, <sup>5</sup>FR, <sup>6</sup>Chiba/JP
- 15:50 - 16:05 Invited Discussant 1054PD, 1055PD and 1056PD  
E.M. Ozsahin, CH
- 16:05 - 16:15 Q&A led by Discussant

15:00 - 16:15	Type: Poster Discussion session Title: Poster Discussion session - Developmental therapeutics Chair(s): M.G. Daidone, IT; B.-C. Goh, SG; C. Dittrich, AT	Hall B3 - Room 22
15:00 - 15:00	One LBA TBC	
15:00 - 15:00	ONE LBA TBC	
15:00 - 15:00	412PD - Clinical activity, safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)  <u>I. Melero</u> <sup>1</sup> , E. Castanon Alvarez <sup>1</sup> , M. Mau-Sorensen <sup>2</sup> , U. Lassen <sup>2</sup> , M. Lolkema <sup>3</sup> , D. Robbrecht <sup>3</sup> , C. Gomez-Roca <sup>4</sup> , J. Martin-Liberal <sup>1</sup> , J. Tabernero <sup>1</sup> , W. Ros <sup>3</sup> , S. Ahmed <sup>5</sup> , N. Isambert <sup>6</sup> , H. Piper Lepoutre <sup>7</sup> , C. Boetsch <sup>7</sup> , J. Charo <sup>7</sup> , S. Evers <sup>7</sup> , V. Teichgräber <sup>7</sup> , J. Schellens <sup>3</sup> ; <sup>1</sup> ES, <sup>2</sup> DK, <sup>3</sup> NL, <sup>4</sup> Haute-Garonne/FR, <sup>5</sup> GB, <sup>6</sup> Cedex/FR, <sup>7</sup> CH	
15:00 - 15:00	413PD - Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma  <u>M. Krebs</u> <sup>1</sup> , J. Lopez <sup>1</sup> , A. El-Khoueiry <sup>2</sup> , Y.-J. Bang <sup>3</sup> , S. Postel-Vinay <sup>4</sup> , W. Abidah <sup>2</sup> , S.-A. Im <sup>3</sup> , L. Khoja <sup>5</sup> , N. Standifer <sup>2</sup> , G. Jones <sup>1</sup> , P. Marco-Casanova <sup>1</sup> , P. Frewer <sup>1</sup> , A. Berges <sup>1</sup> , A. Cheung <sup>1</sup> , C. Stephens <sup>1</sup> , B. Felicetti <sup>1</sup> , E. Dean <sup>1</sup> , A. Pierce <sup>1</sup> , S. Hollingsworth <sup>1</sup> ; <sup>1</sup> GB, <sup>2</sup> US, <sup>3</sup> KR, <sup>4</sup> FR, <sup>5</sup> Hertfordshire/GB	
15:00 - 15:20	Invited Discussant two LBAs, 412PD nad 413PD  <u>M.G. Daidone</u> , IT	
15:20 - 15:30	Q&A led by Discussant	
15:30 - 15:30	414PD - Phase 1 Study of the CTLA-4 Inhibitor MK-1308 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors  <u>B.C. Cho</u> <sup>1</sup> , R. Perets <sup>2</sup> , J. Bar <sup>2</sup> , M.-J. Ahn <sup>1</sup> , D.-W. Kim <sup>1</sup> , K. Yoh <sup>3</sup> , A. Nagrial <sup>4</sup> , D. Spigel <sup>5</sup> , D.H. Lee <sup>1</sup> , M. Gutierrez <sup>6</sup> , D. Kotasek <sup>7</sup> , S. Siddiqi <sup>6</sup> , A. Chain <sup>6</sup> , B. Butts <sup>6</sup> , Y. Zhang <sup>6</sup> , X. Li <sup>6</sup> , J. Cyrus <sup>6</sup> , A. Tse <sup>6</sup> , R. Altura <sup>6</sup> , D. Rasco <sup>8</sup> ; <sup>1</sup> KR, <sup>2</sup> IL, <sup>3</sup> Chiba/JP, <sup>4</sup> NSW/AU, <sup>5</sup> TN/US, <sup>6</sup> NJ/US, <sup>7</sup> SA/AU, <sup>8</sup> TX/US	
15:30 - 15:30	415PD - Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients with advanced solid tumors.  <u>J. Medioni</u> <sup>1</sup> , M. Brizard <sup>1</sup> , L. Teixeira <sup>2</sup> , L. Doucet <sup>1</sup> , Z. Ghrieb <sup>1</sup> , A. Angelergues <sup>1</sup> , S. Oudard <sup>1</sup> , S. Culine <sup>2</sup> , O. Adotevi <sup>3</sup> , C. Laheurte <sup>1</sup> , M.-A. Dragon-Durey <sup>1</sup> , P. Laurent-Puig <sup>1</sup> , J.-J. Kiladjian <sup>1</sup> , V. Doppler <sup>1</sup> , B. Souttou <sup>1</sup> , S. Wain-Hobson <sup>1</sup> , R. Defrance <sup>1</sup> , T. Huet <sup>1</sup> , P. Langlade-Demoyen <sup>1</sup> ; <sup>1</sup> FR, <sup>2</sup> CEDEX 10/FR, <sup>3</sup> CEDEX/FR	
15:30 - 15:30	416PD - Final Results from a Phase I Clinical Trial Evaluating the Safety, Immunogenicity, and Anti-Tumor Activity of SNS-301 in Men with Biochemically Relapsed Prostate Cancer	

L. Nordquist<sup>1</sup>, H. Ghanbari<sup>2</sup>, J. Elist<sup>3</sup>, J. Oliver<sup>4</sup>, W. Gannon<sup>5</sup>, A. Shahlaee<sup>2</sup>, S. Fuller<sup>2</sup>, N. Shore<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MD/US, <sup>3</sup>CA/US, <sup>4</sup>MA/US, <sup>5</sup>DC/US

15:30 - 15:45 Invited Discussant 414PD, 415PD and 416PD

B.-C. Goh, SG

15:45 - 15:55 Q&A led by Discussant

15:55 - 15:55 417PD - Combination Therapy Optimization in Gastrointestinal Cancers using Multi-omic Molecular Profiling

M.C. Monge Bonilla<sup>1</sup>, E. Blais<sup>2</sup>, W. Chen<sup>3</sup>, M. Pishvain<sup>4</sup>, E. Petricoin<sup>2</sup>, J. Marshall<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>VA/US, <sup>3</sup>TX/US, <sup>4</sup>DC/US

15:55 - 15:55 418PD - NCI-MATCH Arms N & P: phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss

F. Janku<sup>1</sup>, O. Jegede<sup>2</sup>, S. Puhalla<sup>3</sup>, P. Konstantinopoulos<sup>4</sup>, F. Meric-Bernstam<sup>1</sup>, E. Mitchell<sup>3</sup>, J. Zwiebel<sup>4</sup>, L. McShane<sup>4</sup>, S. Li<sup>2</sup>, L. Rubinstein<sup>4</sup>, L. Doyle<sup>4</sup>, D. Patton<sup>4</sup>, B. Conley<sup>4</sup>, P. O'Dwyer<sup>4</sup>, L. Harris<sup>4</sup>, C. Arteaga<sup>4</sup>, P. Williams<sup>4</sup>, S. Hamilton<sup>1</sup>, A. Chen<sup>4</sup>, K. Flaherty<sup>2</sup>; <sup>1</sup>TX/US, <sup>2</sup>MA/US, <sup>3</sup>PA/US, <sup>4</sup>US

15:55 - 16:05 Invited Discussant 417PD and 418PD

C. Ditttrich, AT

16:05 - 16:15 Q&A led by Discussant

15:00 - 16:00 Type: Poster Discussion session

Hall B4 - Room 19

Title: Poster Discussion session - Translational research 1

Chair(s): R. Dienstmann, ES; S. Quezada, GB

15:00 - 15:00 53PD - Association of PD-L1 expression with prognosis among patients with 10 select cancers

T. Steiniche<sup>1</sup>, M. Ladekar<sup>1</sup>, J. Bæhr Georgsen<sup>1</sup>, S. Andreassen<sup>1</sup>, M. Busch-Sørensen<sup>1</sup>, W. Zhou<sup>2</sup>, S. Pruitt<sup>3</sup>, A. Joe<sup>3</sup>, K.-L. Liaw<sup>3</sup>; <sup>1</sup>DK, <sup>2</sup>US, <sup>3</sup>NJ/US

15:00 - 15:00 54PD - Pre-treatment CD4 senescent T cells accurately predicts lack of response to PD-L1/PD-1 immune checkpoint blockade in non small cell lung cancer, and correlates with risk of hyperprogression

M. Zuazo, H. Arasan, M. Gato-Cañas, G. Fernández-Hinojal, B. Hernández-Marín, M. Martínez-Aguillo, M. Ibáñez-Vea, M.J. Lecumberri Biurrun, Á. Fernández de Lascoiti, G. Kochan, D. Escors; ES

15:00 - 15:00 55PD - Identification of biological axes associated with stage II/III CRC recurrence risk and outcome after adjuvant therapy revealed a T-effector-independent prognostic role for granzyme B.

M. Das Thakur<sup>1</sup>, A. Udyavar<sup>1</sup>, T. Sandmann<sup>1</sup>, C. Li<sup>1</sup>, L. Bosch<sup>2</sup>, W. O'Gorman<sup>1</sup>, Y. Li<sup>1</sup>, A. Au-Yeung<sup>1</sup>, C. Takahashi<sup>1</sup>, R. Bourgon<sup>1</sup>, A. Daemen<sup>1</sup>, P. Hegde<sup>1</sup>, C. Bais<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NL

- 15:00 - 15:00 56PD - Analytic Validation of Tumor Mutational Burden as a Companion Diagnostic for Combination Immunotherapy in Non-Small Cell Lung Cancer  
D. Fabrizio<sup>1</sup>, C. Milbury<sup>1</sup>, W.-K. Yip<sup>1</sup>, L. Ramamurthy<sup>1</sup>, X. Bai<sup>1</sup>, V. Pattani<sup>1</sup>, P. Maness<sup>1</sup>, A. Cowen<sup>1</sup>, K. Fedorchak<sup>1</sup>, P. Ma<sup>1</sup>, G. Frampton<sup>2</sup>, C. Connelly<sup>1</sup>, Y. Li<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 15:00 - 15:00 57PD - Tumor mutational burden and prognosis across pan-cancers  
H. Ding, J. Zhao, Y. Zhang, G. Wang, S. Cai, F. Qiu; CN
- 15:00 - 15:20 Invited Discussant 53PD, 54PD, 55PD, 56PD and 57PD  
S. Quezada, London/GB
- 15:20 - 15:30 Q&A led by Discussant
- 15:30 - 15:30 58PD - Pan-Cancer Analysis of RET Fusions (FN) and Rearrangements (RE) By Genomic Profiling of 158,360 Tumors  
L. Gay<sup>1</sup>, D. Pavlick<sup>1</sup>, S. Ramkissoon<sup>2</sup>, S. Daniel<sup>2</sup>, J. Killian<sup>2</sup>, J.-A. Vergilio<sup>2</sup>, E. Severson<sup>2</sup>, G. Frampton<sup>2</sup>, J. Elvin<sup>2</sup>, J. Ross<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 15:30 - 15:30 59PD - Final analysis of serum biomarkers in patients (pts) from the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]  
R. Finn<sup>1</sup>, M. Kudo<sup>2</sup>, A.-L. Cheng<sup>3</sup>, L. Wyrwicz<sup>4</sup>, R. Ngan<sup>5</sup>, J.F. Blanc<sup>6</sup>, A. Baron<sup>1</sup>, A. Vogel<sup>7</sup>, M. Ikeda<sup>8</sup>, F. Piscaglia<sup>9</sup>, K.-H. Han<sup>10</sup>, S. Qin<sup>11</sup>, Y. Minoshima<sup>2</sup>, M. Kanekiyo<sup>2</sup>, M. Ren<sup>12</sup>, R. Dairiki<sup>2</sup>, T. Tamai<sup>12</sup>, C. Dutcus<sup>13</sup>, Y. Funahashi<sup>14</sup>, T.R.J. Evans<sup>15</sup>; <sup>1</sup>CA/US, <sup>2</sup>JP, <sup>3</sup>TW, <sup>4</sup>PL, <sup>5</sup>HK, <sup>6</sup>FR, <sup>7</sup>DE/US, <sup>8</sup>Chiba/JP, <sup>9</sup>IT, <sup>10</sup>KP, <sup>11</sup>CN, <sup>12</sup>NJ/US, <sup>13</sup>New Jersey/US, <sup>14</sup>US, <sup>15</sup>GB
- 15:30 - 15:30 60PD - Colon Cancer Molecular Subtype IntraTumoral Heterogeneity and its prognostic impact : An Extensive Molecular Analysis of the PETACC-8  
P. Laurent-Puig<sup>1</sup>, L. Marisa<sup>1</sup>, M. Ayadi<sup>1</sup>, Y. Blum<sup>1</sup>, R. Balogoun<sup>1</sup>, C. Pilati<sup>1</sup>, K. Le Malicot<sup>1</sup>, C. Lepage<sup>2</sup>, J.F. Emile<sup>1</sup>, R. Salazar<sup>3</sup>, D. Aust<sup>4</sup>, A. Duval<sup>1</sup>, J. Selves<sup>1</sup>, D. Guenot<sup>1</sup>, G. Milano<sup>1</sup>, J.-F. Seitz<sup>5</sup>, J. Taieb<sup>1</sup>, V. Boige<sup>1</sup>, A. de Reyniès<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>Cedex/FR, <sup>3</sup>ES, <sup>4</sup>DE, <sup>5</sup>CEDEX 5/FR
- 15:30 - 15:30 61PD - Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3  
M. Berger<sup>1</sup>, S. Stintzing<sup>2</sup>, V. Heinemann<sup>2</sup>, S. Cao<sup>1</sup>, D. Yang<sup>1</sup>, Y. Miyamoto<sup>1</sup>, M. Suenaga<sup>3</sup>, D.L. Hanna<sup>1</sup>, S. Soni<sup>1</sup>, A. Puccini<sup>4</sup>, R. Tokunaga<sup>1</sup>, M. Naseem<sup>1</sup>, F. Battaglin<sup>1</sup>, M. McSkane<sup>1</sup>, W. Zhang<sup>1</sup>, H.-J. Lenz<sup>1</sup>; <sup>1</sup>CA/US, <sup>2</sup>DE, <sup>3</sup>JP, <sup>4</sup>IT
- 15:30 - 15:30 1831PD - Molecular differences between colorectal cancers with mutations in histone modifiers genes vs wild-type (WT) tumors.  
A. Puccini<sup>1</sup>, K. Poorman<sup>2</sup>, R. Goldberg<sup>3</sup>, A. Shields<sup>4</sup>, M. Winerip<sup>2</sup>, W.M. Korn<sup>4</sup>, M. Berger<sup>5</sup>, R. Tokunaga<sup>5</sup>, M. Naseem<sup>5</sup>, F. Battaglin<sup>5</sup>, W. Zhang<sup>5</sup>, S. Soni<sup>5</sup>, J. Hwang<sup>4</sup>, P. Philip<sup>4</sup>, J. Marshall<sup>6</sup>, H.-J. Lenz<sup>5</sup>; <sup>1</sup>IT, <sup>2</sup>AZ/US, <sup>3</sup>SG, <sup>4</sup>US, <sup>5</sup>CA/US, <sup>6</sup>DC/US
- 15:30 - 15:50 Invited Discussant 58PD, 59PD, 60PD, 61PD and 1831PD

R. Dienstmann, ES

15:50 - 16:00 Q&A led by Discussant

15:00 - 16:00 Type: Young Oncologist session ICM - Room 14c  
Title: YO Medical students: ESMO for medical students and young physicians

15:00 - 15:20 ESMO-ESO Medical Students Course  
A. Cervantes, Valencia/ES

15:20 - 15:40 How to prepare and present your first poster at a congress  
A.S. Berghoff, AT

15:40 - 16:00 Guided poster walk

16:30 - 18:00 Type: Proffered Paper session Hall A1 - Room 17  
Title: Proffered paper session 6

16:30 - 18:00 Type: Educational session ICM - Room 1  
Title: Multimodality approaches to hepatobiliary cancers  
Chair(s): E. O'Reilly, US

16:30 - 16:55 Locoregional treatment of HCC  
J. Ricke, DE

16:55 - 17:20 Systemic treatment of HCC in the era of immunotherapy  
B. Daniele, IT

17:20 - 17:45 Targeted therapy for biliary cancer  
E. O'Reilly, NY/US

17:45 - 18:00 Discussion

16:30 - 18:00	Type: Special Symposium Title: Epigenetic alterations and potential clinical implications in sarcomas and other rare tumours Chair(s): O. Mir, FR; S. Chi, US	Hall A1 - Room 15
16:30 - 16:35	Introduction <u>O. Mir</u> , FR	
16:35 - 16:55	Epigenetic insights into Ewing sarcoma <u>O. Delattre</u> , FR	
16:55 - 17:15	Epigenetic insights into midline carcinoma <u>C. French</u> , US	
17:15 - 17:35	Epigenetic insights into rhabdoid tumours <u>S. Chi</u> , US	
17:35 - 17:55	Epigenetic insights into epithelioid sarcomas <u>O. Mir</u> , FR	
17:55 - 18:00	Conclusions and clinical perspectives <u>S. Chi</u> , US	
16:30 - 18:00	Type: Proffered Paper session Title: Presidential Symposium 1	Hall A2 - Room 18
16:30 - 17:45	Type: Poster Discussion session Title: Poster Discussion session - CNS tumours Chair(s): M. Weller, CH; P. Brastianos, US	Hall B3 - Room 23
16:30 - 16:30	376PD - Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors. <u>J.C. Benítez Montañez</u> <sup>1</sup> , M. Vieito Villar <sup>2</sup> , C. Hierro <sup>1</sup> , M. Gonzalez Rodriguez <sup>1</sup> , I. Matos <sup>1</sup> , I. Braña Garcia <sup>1</sup> , C. Suarez Rodriguez <sup>1</sup> , E.A. Martinez Saez <sup>1</sup> , M.C. Perez-Gago <sup>1</sup> , R. Morales-Barrera <sup>1</sup> , C. Ortiz <sup>1</sup> , C. Suarez <sup>1</sup> , X. Maldonado <sup>1</sup> , F. Martinez-Ricarte <sup>1</sup> , C. Auger <sup>1</sup> , A. Azaro <sup>1</sup> , R. Dienstmann <sup>1</sup> , J. Carles <sup>1</sup> , E. Garralda <sup>1</sup> ; <sup>1</sup> ES, <sup>2</sup> La Coruña/ES	
16:30 - 16:30	377PD - Multiplex digital PCR for the diagnostic of pilocytic astrocytoma and glioneuronal tumors <u>F. Fina</u> , D. HENAFF, A. Bresson, V. Juline, A. Romain, C. Carole, D. Figarella-Branger; FR	
16:30 - 16:40	Invited Discussant 376PD and 377PD <u>M. Weller</u> , CH	
16:40 - 16:50	Q&A led by Discussant	

- 16:50 - 16:50 378PD - Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases  
C. Wippel, A. Starzer, A.S. Berghoff, E. Bergen, P. Wolf, G. Widhalm, J. Frischer, B. Gatterbauer, C. Marosi, K. Dieckmann, R. Bartsch, M. Preusser; AT
- 16:50 - 16:50 379PD - Androgen receptor expression in breast cancer brain metastases  
E. Bergen, A.S. Berghoff, U. Rajky, M. Rudas, Z. Bago-Horvath, R. Exner, K. Dieckmann, G. Widhalm, M. Gnant, C. Zielinski, G. Steger, M. Preusser, R. Bartsch; AT
- 16:50 - 17:00 Invited Discussant 378PD and 379PD  
P. Brastianos, US
- 17:00 - 17:10 Q&A led by Discussant
- 17:10 - 17:10 380PD - Understanding Biological Activity, Tumor Response and Pseudoprogression in a Phase-2b Study of MDNA55 in Adults with Recurrent or Progressive Glioblastoma (GB)  
M. Bexon<sup>1</sup>, A. Achrol<sup>2</sup>, K. Bankiewicz<sup>2</sup>, A. Brenner<sup>3</sup>, N. Butowski<sup>2</sup>, S. Kesari<sup>2</sup>, F. Merchant<sup>3</sup>, R. Merchant<sup>3</sup>, D. Randazzo<sup>4</sup>, M. Vogelbaum<sup>5</sup>, M. Zabek<sup>6</sup>, J. Sampson<sup>4</sup>; <sup>1</sup>CH, <sup>2</sup>CA/US, <sup>3</sup>TX/US, <sup>4</sup>NC/US, <sup>5</sup>OH/US, <sup>6</sup>PL
- 17:10 - 17:10 381PD - Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): a mono-institutional experience  
G. Lombardi, E. Bergo, L. Bellu, M. Caccese, A. Lettiero, G. Tierno, A. Pambuku, A. Brunello, V. Zagonel; IT
- 17:10 - 17:10 382PD - Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma  
J. Simões<sup>1</sup>, N. Tavares<sup>2</sup>, C. Borges<sup>2</sup>, S. Meireles<sup>2</sup>, C. Fernandes<sup>2</sup>, A. Costa<sup>2</sup>, C. Caeiro<sup>2</sup>, M. Damasceno<sup>2</sup>; <sup>1</sup>Porto/PT, <sup>2</sup>PT
- 17:10 - 17:25 Invited Discussant 380PD, 381PD and 382PD
- 17:25 - 17:35 Q&A led by Discussant

16:30 - 18:00	Type: EONS session Title: EONS-ESO: How to stay resilient and lead cancer services successfully Chair(s): D. Kelly, GB	Hall B4 - Room 24
16:30 - 16:45	Leading the multiprofessional team	
16:45 - 17:00	Leadership from research to an organisational level <u>T. Wiseman</u> , GB	
17:00 - 17:15	Safe staffing	
17:15 - 17:30	Proffered paper 1	
17:30 - 17:45	Proffered paper 2	
17:45 - 18:00	Discussion	



16:45 - 17:45	Type: Poster Discussion session Title: Poster discussion session - Immuno 1 Chair(s): U. Keilholz, DE; J. Haanen, NL	ICM - Room 14b
16:45 - 16:45	1131PD - Preliminary results of Phase 1/2 study of SENL-B19 chimeric antigen receptor T cell therapy in pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r-ALL) <u>F. Ma</u> , J. Li, J. Ren, X. Zhang, F. Wang, X. Guo, J. Zhang, D. Wang, Q. Liu, J. Luo; CN	
16:45 - 16:45	One LBA TBC	
16:45 - 16:45	1132PD - Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients <u>T. Borch</u> , R. Andersen, M.A. Rana, P. Kongsted, M. Pedersen, M. Nielsen, J. Kjeldsen, A. Kverneland, C. Lorentzen, Ö. Met, M. Donia, I.-M. Svane; DK	
16:45 - 17:05	Invited Discussant 1131PD, One LBA TBC and 1132PD <u>J. Haanen</u> , NL	
17:05 - 17:15	Q&A led by Discussant	
17:15 - 17:15	One LBA TBC	
17:15 - 17:15	One LBA TBC	
17:15 - 17:15	1133PD - A Phase 2a Trial to Assess the Safety and Efficacy of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC) <u>M. Hidalgo</u> <sup>1</sup> , R. Epelbaum <sup>2</sup> , B. Wolpin <sup>3</sup> , S. Stemmer <sup>2</sup> , R. Geva <sup>2</sup> , T. Golan <sup>2</sup> , E. Borazanci <sup>4</sup> , M. Borad <sup>4</sup> , K. Pedersen <sup>5</sup> , J.O. Park <sup>6</sup> , R. Ramirez <sup>7</sup> , A. Peled <sup>2</sup> , T. Lustig <sup>2</sup> , O. Bohana Kashtan <sup>2</sup> , O. Rosenfeld <sup>2</sup> , E. Sorani <sup>2</sup> , K. Schlienger <sup>1</sup> , A. Vainstein Haras <sup>8</sup> , D. Von Hoff <sup>4</sup> ; <sup>1</sup> US, <sup>2</sup> IL, <sup>3</sup> MA/US, <sup>4</sup> AZ/US, <sup>5</sup> MO/US, <sup>6</sup> KR, <sup>7</sup> LA/US, <sup>8</sup> NA	
17:15 - 17:15	1134PD - A Phase 1a/2b Trial of the CXCR4 Inhibitor X4P-001 and Nivolumab for Advanced Renal Cell Carcinoma (RCC) that is Unresponsive to Nivolumab Monotherapy <u>T. Choueiri</u> <sup>1</sup> , M. Atkins <sup>2</sup> , T. Rose <sup>3</sup> , R. Alter <sup>4</sup> , E. Tsiroyannis <sup>5</sup> , K. Niland <sup>5</sup> , Y. Wang <sup>5</sup> , S. Parasuraman <sup>5</sup> , L. Gan <sup>5</sup> , D. McDermott <sup>5</sup> ; <sup>1</sup> US, <sup>2</sup> DC/US, <sup>3</sup> NC/US, <sup>4</sup> NJ/US, <sup>5</sup> MA/US	
17:15 - 17:35	Invited Discussant two LBAs TBC, 1133PD and 1134PD <u>U. Keilholz</u> , DE	
17:35 - 17:45	Q&A led by Discussant	

16:45 - 17:45 Type: Multidisciplinary interactive sessions ICM - Room 13  
 Title: Management of brain metastases in patients with oncogene drivers  
 Chair(s): D. Tan, SG

16:45 - 16:50 Case 1: ALK positive patient with brain oligo-metastasis  
D. Tan, SG

16:50 - 17:00 Neurosurgeons' perspective on patient selection  
C. Watts, GB

17:00 - 17:10 Discussion

17:10 - 17:15 Case 2: First presentation of multiple brain mets EGFR mutant NSCLC

17:15 - 17:25 Key considerations from the viewpoint of radiation oncologist  
D. De Ruyscher, NL

17:25 - 17:35 Emerging TKI strategies to tackle brain mets  
D. Tan, SG

17:35 - 17:45 Discussion

16:45 - 17:45 Type: Special session Hall A1 - Room 16  
 Title: Molecular tumour board and drug access  
 Chair(s): T. Troiani, IT

16:45 - 16:55 How to select targeted agents for molecular aberrations  
R. Dienstmann, ES

16:55 - 17:05 Integration of new technology in the identification of molecular targets  
I. Wistuba, TX/US

17:05 - 17:15 Identifying actionable targets  
Y. Shyr, US

17:15 - 17:25 Industry reaction to new scientific insights  
S. Galbraith, GB

17:25 - 17:45 Discussion

18:00 - 19:30	Type: Patient Advocacy Track Title: Cancer prevention Chair(s): F. Johansson, SE	ICM - Room 5
18:00 - 18:15	Why we are losing the war on cancer <u>C. Leaf</u> , US	
18:15 - 18:30	Tobacco control: Saving lives and driving development <u>G. Morgan</u> , SE	
18:30 - 18:45	Behavioural aspects of health-related prevention measures	
18:45 - 19:00	Cancer awareness and screening: The challenges <u>J. Gore-Booth</u> , Wiltshire/GB	
19:00 - 19:30	Discussion	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 21 (TBC)	ICM - Room 1
18:30 - 20:00	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Systemic therapies in unresectable Hepato-Cellular Carcinoma (HCC): 1st and later lines Chair(s): P. Galle, DE	ICM - Room 14b
18:30 - 18:35	Introduction <u>P. Galle</u> , DE	
18:35 - 18:55	Targets Biology in HCC <u>J.-L. Raoul</u> , CEDEX/FR	
18:55 - 19:15	Targeted agents in unresectable HCC: a review of results in 1st and 2nd line <u>L. Rimassa</u> , IT	
19:15 - 19:35	Emerging Immunotherapy in unresectable HCC <u>B. Sangro</u> , ES	
19:35 - 19:55	Future systemic treatments: new agents, targeted drug-combination, immune-drug combination? <u>J. Bruix</u> , ES	
19:55 - 20:00	Conclusion <u>P. Galle</u> , DE	

18:30 - 20:00 Type: Industry Satellite Symposium ICM - Room 13  
Title: Industry satellite symposium 23 (TBC)

18:30 - 20:00 Type: Industry Satellite Symposium Hall A1 - Room 15  
Title: Industry satellite symposium 24 (TBC)

18:30 - 20:00 Type: Industry Satellite Symposium Hall A1 - Room 16  
Title: Industry satellite symposium 25 (TBC)

18:30 - 20:00 Type: Industry Satellite Symposium Hall B3 - Room 20  
Title: Industry satellite symposium 26 (TBC)

18:30 - 20:00 Type: Industry Satellite Symposium Hall B4 - Room 19  
Title: Industry satellite symposium 27 (TBC)

## 21.10.2018

08:00 - 09:00 Type: Controversy Session Hall A1 - Room 15  
Title: Should oligosymtomatic brain metastasis patients without oncogene addiction receive upfront systemic therapy?  
Chair(s): M. Preusser, AT

08:00 - 08:10 Introduction and 1st vote  
M. Preusser, AT

08:10 - 08:30 Pro  
P. Brastianos, US

08:30 - 08:50 Contra

08:50 - 09:00 2nd vote and conclusions  
M. Preusser, AT

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall A1 - Room 16  
Title: The right time for discontinuing immunotherapy  
Chair(s): J.-C. Soria, US

08:00 - 08:10 The right time for discontinuing immunotherapy  
J. Weber, US

08:10 - 09:00 Discussion led by  
J.-C. Soria, CEDEX/US

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall A2 - Room 18  
Title: Self-care for young cancer nurses

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 21  
Title: Challenging germ cell tumour patients  
Chair(s): K.G. Daugaard, DK

08:00 - 08:10 Challenging germ cell tumour patients  
J. Gietema, NL

08:10 - 09:00 Discussion led by  
K.G. Daugaard, DK

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 23  
Title: Multiscale tumor heterogeneity: Clinical implications  
Chair(s): N. Normanno, IT

08:00 - 08:10 Multiscale tumor heterogeneity: Clinical implications  
E. Mardis, Missouri/US

08:10 - 09:00 Discussion led by  
N. Normanno, IT

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 20  
Title: Personalised breast cancer medicine: Should all patients have whole genome sequencing?  
Chair(s): F. André, FR

08:00 - 08:10 Personalised breast cancer medicine: Should all patients have whole genome sequencing?  
C. Caldas, Cambridgeshire/GB

08:10 - 09:00 Discussion led by  
F. André, CEDEX/FR

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 22  
Title: Small bowel adenocarcinomas  
Chair(s): S. Cascinu, IT

08:00 - 08:10 Small bowel adenocarcinomas  
T. Aparicio, CEDEX/FR

08:10 - 09:00 Discussion led by  
S. Cascinu, IT

08:00 - 09:00 Type: Special session Hall B4 - Room 19  
Title: Special session: Guidelines in ovarian

08:00 - 08:20 Title to be defined

08:20 - 08:40 Title to be defined

08:40 - 09:00 Q&A

08:00 - 09:00 Type: EONS session Hall B4 - Room 24  
Title: Self-care for young cancer nurses  
Chair(s): S. Parreira, PT

08:00 - 08:20 Compassion fatigue, burn-out, resilience and balance: What does it entail?  
S. Parreira, PT

08:20 - 08:40 Compassion fatigue, burn-out, resilience and balance: How can cancer nurses support each other?  
L.-L. Aruväli, EE

08:40 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session ICM - Room 14a  
Title: Follicular and other indolent lymphomas  
Chair(s): M. Dreyling, DE

08:00 - 08:10 Follicular and other indolent lymphomas  
M. Ghelmini, CH

08:10 - 09:00 Discussion led by  
M. Dreyling, DE

08:15 - 09:00 Type: Keynote lecture Hall A1 - Room 17  
Title: How do we manipulate the tumour microenvironment for immunotherapy?

08:15 - 09:00 How do we manipulate the tumour microenvironment for immunotherapy?  
T. Gajewski, US

09:10 - 10:45	Type: Special session Title: Practicing oncologists and rare tumours Chair(s): G. Pentheroudakis, GR; S. Rauh, LU	ICM - Room 14a
09:10 - 09:10	Is there still a Cancer of Unknown Primary (CUP) in 2018? Who will mostly guide your decision: Your genetician, pathologist, radiologist, or your “gut feeling”? <u>G. Lakatos</u> , HU	
09:10 - 09:15	Clinical case presentation <u>G. Lakatos</u> , HU	
09:15 - 09:38	Do clinical and “standard” pathological decision parameters dominate the treatment algorithms, or do we rely on the genetic signature? <u>G. Pentheroudakis</u> , GR	
09:38 - 09:38	Adjuvant treatment of GIST: Who should benefit? Is there a need for referral?	
09:38 - 09:43	Clinical case presentation <u>M. Karamouzis</u> , Athens/GR	
09:43 - 10:06	State of Art: Recommendation for adjuvant treatment in GIST <u>A. Le Cesne</u> , CEDEX/FR	
10:06 - 10:06	Rare tumours with recent treatment progresses	
10:06 - 10:11	New treatment options in NET (incl combined radio nuclides) <u>S. Rauh</u> , LU	
10:11 - 10:34	Should nuclear medicine be a mandatory treatment option for NET’s in 2018? <u>A. Beer</u> , DE	
10:34 - 10:40	Closing remarks: The role of the PO in rare tumor management / Management issues of rare cancer from a community oncology point of view <u>S. Rauh</u> , LU	

09:15 - 10:45	Type: Proffered Paper session Title: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies Chair(s): P. Postmus, NL; E. Felip, ES	Hall A1 - Room 17
09:15 - 09:27	One LBA TBC	
09:27 - 09:39	Invited Discussant One LBA TBC	
09:39 - 09:51	1664O - A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial  <u>J.-L. Pujol</u> <sup>1</sup> , L. Greillier <sup>2</sup> , C. Audigier Valette <sup>3</sup> , D. Moro-Sibilot <sup>2</sup> , L. Uwer <sup>3</sup> , J. Hureauux <sup>4</sup> , L. Thiberville <sup>2</sup> , D. Carmier <sup>2</sup> , J. Madelaine <sup>2</sup> , J. Otto <sup>2</sup> , V. Gounant <sup>5</sup> , P. Merle <sup>2</sup> , P. Mourlanette <sup>2</sup> , O. Molinier <sup>2</sup> , P. Renault <sup>2</sup> , J. Mazieres <sup>2</sup> , M. Antoine <sup>2</sup> , A. Langlais <sup>2</sup> , F. Morin <sup>2</sup> , P.-J. Souquet <sup>3</sup> ; <sup>1</sup> CEDEX 5/FR, <sup>2</sup> FR, <sup>3</sup> CEDEX/FR, <sup>4</sup> CEDEX 9/FR, <sup>5</sup> CEDEX 18/FR	
09:51 - 10:03	1363O - Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC  <u>C. Faivre-Finn</u> <sup>1</sup> , D. Spigel <sup>2</sup> , S. Senan <sup>3</sup> , C. Langer <sup>4</sup> , D. Raben <sup>5</sup> , B. Perez <sup>5</sup> , M. Özgüroğlu <sup>6</sup> , D. Daniel <sup>2</sup> , A. Villegas <sup>7</sup> , D. Vicente <sup>8</sup> , R. Hui <sup>9</sup> , S. Murakami <sup>10</sup> , L. Paz-Ares <sup>8</sup> , L. Poole <sup>1</sup> , C. Wadsworth <sup>1</sup> , P. Dennis <sup>11</sup> , S. Antonia <sup>7</sup> ; <sup>1</sup> GB, <sup>2</sup> TN/US, <sup>3</sup> NL, <sup>4</sup> PA/US, <sup>5</sup> US, <sup>6</sup> TR, <sup>7</sup> FL/US, <sup>8</sup> ES, <sup>9</sup> NSW/AU, <sup>10</sup> JP, <sup>11</sup> MD/US	
10:03 - 10:15	Invited Discussant 1664O and 1363O <u>J. Vansteenkiste</u> , BE	
10:15 - 10:27	One LBA TBC	
10:27 - 10:39	Invited Discussant One LBA TBC <u>E. Felip</u> , ES	



09:15 - 10:45 Type: Special Symposium Hall A2 - Room 18  
 Title: Precision cancer medicine in metastatic colorectal cancer  
 Chair(s): T. Maughan, GB; A. Marabelle, FR

09:15 - 09:20 Introduction  
A. Marabelle, FR

09:20 - 09:40 Pathological subgroups and molecular characterisation  
S. Tejpar, BE

09:40 - 10:00 Cell free tumour DNA: Yet a role in treatment monitoring of mCRC?  
K.-L. Spindler, DK

10:00 - 10:20 Novel therapeutic approaches for specific (rare) subtypes  
T. Maughan, GB

10:20 - 10:40 Immunotherapy: Checkpoint inhibitors and beyond  
A. Marabelle, FR

10:40 - 10:45 Conclusions and perspectives  
T. Maughan, GB

09:15 - 10:30 Type: Poster Discussion session ICM - Room 14b  
 Title: Poster Discussion session - Genitourinary tumours, prostate  
 Chair(s): J. Mateo, ES; J. O'Sullivan, GB; A. Bamias, GR

09:15 - 09:15 793PD - Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations  
W. Abida<sup>1</sup>, A. Bryce<sup>1</sup>, N. Vogelzang<sup>2</sup>, R. Amato<sup>3</sup>, I. Percent<sup>1</sup>, J. Shapiro<sup>4</sup>, R. McDermott<sup>5</sup>, A. Hussain<sup>1</sup>, A. Patnaik<sup>1</sup>, D. Petrylak<sup>1</sup>, C. Ryan<sup>6</sup>, T. Stanton<sup>1</sup>, J. Zhang<sup>1</sup>, A. Simmons<sup>6</sup>, D. Despain<sup>1</sup>, M. Collins<sup>1</sup>, T. Golsorski<sup>1</sup>, H. Scher<sup>7</sup>, S. Chowdhury<sup>8</sup>; <sup>1</sup>US, <sup>2</sup>NV/US, <sup>3</sup>TX/US, <sup>4</sup>VIC/AU, <sup>5</sup>Belgard Square North/IE, <sup>6</sup>CA/US, <sup>7</sup>NY/US, <sup>8</sup>GB

09:15 - 09:15 794PD - Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors  
S. Ali<sup>1</sup>, J. Chung<sup>2</sup>, N. Dewal<sup>1</sup>, L. Gay<sup>2</sup>, Y. He<sup>1</sup>, E. Sokol<sup>1</sup>, S. Millis<sup>1</sup>, J. Killian<sup>1</sup>, A. Schrock<sup>2</sup>, S. Pal<sup>3</sup>, V. Miller<sup>1</sup>, J. Ross<sup>2</sup>, N. Agarwal<sup>2</sup>; <sup>1</sup>MA/US, <sup>2</sup>US, <sup>3</sup>CA/US

09:15 - 09:15 795PD - Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)  
S. Chowdhury<sup>1</sup>, R. McDermott<sup>2</sup>, J.M. Piulats<sup>3</sup>, J. Shapiro<sup>4</sup>, I. Mejlholm<sup>5</sup>, D. Morris<sup>6</sup>, P. Ostler<sup>1</sup>, A. Hussain<sup>7</sup>, I. Dumbadze<sup>7</sup>, E. Goldfischer<sup>7</sup>, E. Pintus<sup>1</sup>, A. Benjelloun<sup>8</sup>, M. Gross<sup>7</sup>, S. Tejwani<sup>9</sup>, G. Chatta<sup>7</sup>, A. Font<sup>3</sup>, A. Loehr<sup>7</sup>, A. Simmons<sup>10</sup>, S. Watkins<sup>1</sup>, W. Abida<sup>7</sup>; <sup>1</sup>GB, <sup>2</sup>Belgard Square North/IE, <sup>3</sup>ES, <sup>4</sup>VIC/AU, <sup>5</sup>DK, <sup>6</sup>TN/US, <sup>7</sup>US, <sup>8</sup>CA, <sup>9</sup>MI/US, <sup>10</sup>CA/US

- 09:15 - 09:30 Invited Discussant 793PD, 794PD and 795PD  
J. Mateo, ES
- 09:30 - 09:40 Q&A led by Discussant
- 09:40 - 09:40 796PD - Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer  
W. Struss<sup>1</sup>, G. Vandekerkhove<sup>2</sup>, M. Annala<sup>2</sup>, K. Chi<sup>3</sup>, M. Gleave<sup>1</sup>, A. Wyatt<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>BC/CA, <sup>3</sup>British Columbia/CA
- 09:40 - 09:40 797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)  
N. Matsubara<sup>1</sup>, K. Chi<sup>2</sup>, M. Ozguroglu<sup>3</sup>, A. Rodriguez Antolin<sup>4</sup>, S. Feyerabend<sup>5</sup>, L. Fein<sup>6</sup>, B. Alekseev<sup>7</sup>, G. Sultur<sup>8</sup>, A. Protheroe<sup>9</sup>, S. Li<sup>10</sup>, S. Mundle<sup>10</sup>, P. De Porre<sup>11</sup>, N. Tran<sup>10</sup>, K. Fazazi<sup>12</sup>; <sup>1</sup>JP, <sup>2</sup>British Columbia/CA, <sup>3</sup>TR, <sup>4</sup>ES, <sup>5</sup>DE, <sup>6</sup>AR, <sup>7</sup>RU, <sup>8</sup>California/CN, <sup>9</sup>Oxfordshire/GB, <sup>10</sup>US, <sup>11</sup>BE, <sup>12</sup>FR
- 09:40 - 09:55 Invited Discussant 796PD and 797PD  
J. O'Sullivan, GB
- 09:55 - 10:05 Q&A led by Discussant
- 10:05 - 10:05 798PD - In-depth assessment of metastatic prostate cancer with high tumour mutational burden  
N. Mehra<sup>1</sup>, J. van Riet<sup>2</sup>, M. Smits<sup>2</sup>, H. Westdorp<sup>2</sup>, M. Gorris<sup>2</sup>, T. van Ee<sup>2</sup>, M. van der Doelen<sup>2</sup>, I. van Oort<sup>2</sup>, M. Sedelaar<sup>2</sup>, J. Textor<sup>2</sup>, E. Cuppen<sup>2</sup>, K. Grunberg<sup>2</sup>, M. Ligtenberg<sup>2</sup>, W. Zwart<sup>2</sup>, A. Bergman<sup>2</sup>, H. van de Werken<sup>2</sup>, J. Schalken<sup>2</sup>, I. de Vries<sup>2</sup>, M. Lolkema<sup>2</sup>, W. Gerritsen<sup>2</sup>; <sup>1</sup>Surrey/NL, <sup>2</sup>NL
- 10:05 - 10:05 One LBA TBC
- 10:05 - 10:05 799PD - Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)  
S. Tagawa<sup>1</sup>, S. Vallabhajosula<sup>2</sup>, Y. Jhanwar<sup>2</sup>, A. Hackett<sup>2</sup>, C. Oromendia<sup>2</sup>, M. Naiz<sup>2</sup>, S. Goldsmith<sup>2</sup>, D.M. Nanus<sup>2</sup>, H. Beltran<sup>2</sup>, A. Molina<sup>2</sup>, B. Faltas<sup>2</sup>, J. Sreekumar<sup>2</sup>, J. Babich<sup>2</sup>, K. Ballman<sup>2</sup>, N. Bander<sup>2</sup>; <sup>1</sup>US/US, <sup>2</sup>US
- 10:05 - 10:20 Invited Discussant 798PD, One LBA TBC and 799PD  
A. Bamias, Attiki/GR
- 10:20 - 10:30 Q&A led by Discussant

09:15 - 10:45 Type: Special Symposium ICM - Room 13  
 Title: Modern tools to optimise therapy for patients with head and neck cancer  
 Chair(s): A. Psyrri, GR

09:15 - 09:20 Introduction  
A. Psyrri, GR

09:20 - 09:40 Biomarkers and next generation sequencing  
B. Solomon, VIC/AU

09:40 - 10:00 Optimising response to immunotherapy using combinations in the recurrent/metastatic setting  
A. Psyrri, GR

10:00 - 10:20 Taking the next step – immunotherapy in the curative setting  
E. Cohen, IL/US

10:20 - 10:40 Response assessment and endpoint selection for immunotherapy studies  
S. Faivre, FR

10:40 - 10:45 Conclusions and perspectives

09:15 - 10:45 Type: Educational session Hall B3 - Room 21  
 Title: Opportunities in clinic trial design in the era of genomics and immuno-oncology  
 Chair(s): C. Rolfo, US; A. Jordan, GB

09:15 - 09:40 Integration of biomarkers into drug development  
C. Rolfo, US

09:40 - 10:05 Novel pre-clinical models to design drug combinations  
J. Hoffmann, DE

10:05 - 10:30 Role of artificial intelligence in drug development  
M. Kris, NY/US

10:30 - 10:45 Discussion

09:15 - 10:45 Type: EONS session Hall B4 - Room 24  
 Title: Symptom management: Clinical aspects and implementation  
 Chair(s): K. Jordan, DE; W. Oldenmenger, NL

09:15 - 09:35 Guidelines on peripheral neuropathy  
K. Jordan, DE

09:35 - 09:55 Patient-centered care and self-management  
M. Piredda, IT

09:55 - 10:15 Essentials of optimal pain management  
J. Wood, GB

10:15 - 10:35 Oral cryotherapy for the prevention of oral mucositis

10:35 - 10:45 Discussion

09:30 - 10:30 Type: Poster Discussion session ICM - Room 1  
 Title: Poster Discussion session - Breast cancer metastatic  
 Chair(s): L. Carey, US

09:30 - 09:30 285PD - Balixafortide (a novel CXCR4 inhibitor) and Eribulin in HER2-neg Metastatic Breast Cancer (MBC) patients (pts): a Phase I trial  
J. Cortes Castan<sup>1</sup>, M. Martín<sup>1</sup>, S. Pernas Simon<sup>1</sup>, P. Gomez Pardo<sup>1</sup>, S. Lopez-Tarruella<sup>1</sup>, M. Gil Martin<sup>1</sup>, L. Manso<sup>1</sup>, E. Ciruelos<sup>1</sup>, J.A. Perez Fidalgo<sup>2</sup>, C. Hernando<sup>1</sup>, F. Ademuyiwa<sup>3</sup>, K. Weillbaeher<sup>3</sup>, I. Mayer<sup>4</sup>, T. Pluard<sup>3</sup>, M. Martinez Garcia<sup>1</sup>, L. Vahdat<sup>5</sup>, A. Wach<sup>6</sup>, D. Barker<sup>6</sup>, B. Romagnoli<sup>6</sup>, P. Kaufman<sup>7</sup>; <sup>1</sup>ES, <sup>2</sup>Valencia/ES, <sup>3</sup>MO/US, <sup>4</sup>TN/US, <sup>5</sup>NY/US, <sup>6</sup>CH, <sup>7</sup>NH/US

09:30 - 09:30 286PD - Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratumzumab vedotin-treated advanced breast cancer patients  
J. Specht<sup>1</sup>, L. Pusztai<sup>2</sup>, A. Forero-Torres<sup>3</sup>, M. Mita<sup>4</sup>, A. Weise<sup>5</sup>, I. Krop<sup>3</sup>, A. Grosse-Wilde<sup>3</sup>, Z. Wang<sup>3</sup>, M. Li<sup>3</sup>, S. Hengel<sup>3</sup>, P. Garfin<sup>3</sup>, G. Means<sup>3</sup>, M. Onsum<sup>3</sup>, S. Modi<sup>3</sup>; <sup>1</sup>WA/US, <sup>2</sup>CT/US, <sup>3</sup>US, <sup>4</sup>CA/US, <sup>5</sup>MI/US

09:30 - 09:30 287PD - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients  
M.-S. DAI<sup>1</sup>, T.-Y. Chao<sup>1</sup>, T.-C. Chao<sup>1</sup>, C.-F. Chiu<sup>1</sup>, Y.-S. Lu<sup>1</sup>, H.-S. Shiah<sup>1</sup>, Y.-Y. Wu<sup>1</sup>, G. Gerald Fetterly<sup>2</sup>, N. Hung<sup>2</sup>, D.L. Cutler<sup>2</sup>, R. Kwan<sup>2</sup>, D. Douglas Kramer<sup>2</sup>, W.-K. Chan<sup>2</sup>, T. Hung<sup>3</sup>; <sup>1</sup>TW, <sup>2</sup>US, <sup>3</sup>NZ

09:30 - 09:45 Invited Discussant 285PD, 286PD and 287PD

- 09:45 - 09:55 Q&A led by Discussant
- 09:55 - 09:55 One LBA TBC
- 09:55 - 09:55 288PD - PERNETTA – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)  
J. Huober<sup>1</sup>, P. Weder<sup>2</sup>, C. Veyret<sup>3</sup>, B. Thürlimann<sup>2</sup>, A. Xyrafas<sup>2</sup>, L. Vanlemmens<sup>4</sup>, S. Guiu<sup>5</sup>, E. Brain<sup>5</sup>, J. Grenier<sup>6</sup>, F. Dalenc<sup>7</sup>, C. Levy<sup>8</sup>, A.M. Savoye<sup>4</sup>, A. Müller<sup>2</sup>, V. Membrez-Antonioli<sup>2</sup>, M.A. Gerard<sup>2</sup>, J. Lemonnier<sup>5</sup>, H. Hawle<sup>2</sup>, E. Boven<sup>9</sup>, H. Bonnefoi<sup>4</sup>; <sup>1</sup>DE, <sup>2</sup>CH, <sup>3</sup>CEDEX 1/FR, <sup>4</sup>CEDEX/FR, <sup>5</sup>FR, <sup>6</sup>CEDEX 2/FR, <sup>7</sup>CEDEX 3/FR, <sup>8</sup>CEDEX 5/FR, <sup>9</sup>NL
- 09:55 - 09:55 289PD - Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): results from the multicohort phase II FINESSE trial  
R. Hui<sup>1</sup>, A. Pearson<sup>2</sup>, J. Cortes Castan<sup>3</sup>, C. Campbell<sup>2</sup>, C. Poirot<sup>4</sup>, H. Azim Jr.<sup>5</sup>, D. Fumagalli<sup>6</sup>, M. Lambertini<sup>6</sup>, F. Daly<sup>2</sup>, A. Arahmani<sup>6</sup>, J. Perez-Garcia<sup>3</sup>, P. Aftimos<sup>6</sup>, P. Bedard<sup>7</sup>, L. Xuereb<sup>4</sup>, S. Loibl<sup>8</sup>, S. Loi<sup>9</sup>, M.-J. Pierrat<sup>4</sup>, N. Turner<sup>2</sup>, F. André<sup>10</sup>, G. Curigliano<sup>11</sup>; <sup>1</sup>NSW/AU, <sup>2</sup>GB, <sup>3</sup>ES, <sup>4</sup>FR, <sup>5</sup>LB, <sup>6</sup>BE, <sup>7</sup>Ontario/CA, <sup>8</sup>DE, <sup>9</sup>VIC/AU, <sup>10</sup>CEDEX/FR, <sup>11</sup>IT
- 09:55 - 10:10 Invited Discussant 288PD, 289PD and one LBA TBC  
L. Carey, NC/US
- 10:10 - 10:20 Q&A led by Discussant
- 09:30 - 10:30 Type: Controversy Session  
Title: Identification of ultra-rare, life-saving molecular subtypes of cancer – NGS for everyone, some or none?  
Chair(s): G. Demetri, US  
Hall A1 - Room 15
- 09:30 - 09:40 Introduction and 1st vote  
G. Demetri, US
- 09:40 - 10:00 Yes  
E. Wardelmann, DE
- 10:00 - 10:20 No
- 10:20 - 10:30 2nd vote and conclusions  
G. Demetri, US

09:30 - 10:30 Type: Special session Hall A1 - Room 16  
 Title: Integration of immunotherapy with disease entities  
 Chair(s): U. Keilholz, DE

09:30 - 09:50 Head and neck  
U. Keilholz, DE

09:50 - 10:10 Lung cancer  
S. Peters, CH

10:10 - 10:30 Lymphoma  
C. Arber Barth, TX/CH

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Hall B3 - Room 23  
 Title: Challenges in the treatment of early stage ovarian cancer  
 Chair(s): J. Ledermann, GB

09:30 - 09:40 Challenges in the treatment of early stage ovarian cancer  
C. Marth, AT

09:40 - 10:30 Discussion led by  
J. Ledermann, London/GB

09:30 - 10:30 Type: Special session Hall B3 - Room 20  
 Title: Using population data evidence to support policy decisions in cancer  
 Chair(s): A. Briggs, GB

09:30 - 09:45 The role of evidence in alternative frameworks for the valuation of oncology treatments

09:45 - 10:00 Using real world data for decision-making in R&D and health technology assessment  
S. Khozin, US

10:00 - 10:15 Using RWE to identify gaps in the provision of effective – and cost-effective – care  
A. Briggs, GB

10:15 - 10:30 Discussion

09:30 - 10:35	Type: Multidisciplinary interactive sessions Title: Dissecting mediastinal grey zone lymphomas Chair(s): M. Martelli, IT	Hall B3 - Room 22
09:30 - 09:35	Case presentation <u>M. Martelli</u> , IT	
09:35 - 09:45	The pathologist's perspective <u>T. Molina</u> , FR	
09:45 - 09:55	The haematologist's perspective <u>M. Martelli</u> , IT	
09:55 - 10:05	The radiation oncologist's perspective	
10:05 - 10:35	Discussion	

10:45 - 12:45    Type: Clinical Practice Guidelines    Hall A1 - Room 15  
 Title: ESMO Clinical Practice Guidelines 1

10:45 - 10:55    Introduction to the ESMO Clinical Practice Guidelines  
G. Pentheroudakis, GR

10:55 - 11:05    Questionnaire  
C. Sessa, CH

11:05 - 11:15    GEP NETs

11:15 - 11:25    Discussant  
A. Berruti, IT

11:25 - 11:30    Q&A

11:30 - 11:40    Mantle cell lymphoma  
M. Jerkeman, SE

11:40 - 11:50    Discussant  
M. Dreyling, DE

11:50 - 11:55    Q&A

11:55 - 12:05    Rectal cancer

12:05 - 12:15    Discussant

12:15 - 12:20    Q&A

12:20 - 12:30    Metastatic NSCLC

12:30 - 12:40    Discussant

12:40 - 12:45    Q&A



11:00 - 12:30	Type: Proffered Paper session Title: Proffered paper session - Gastrointestinal tumours, non colorectal Chair(s): Y.-K. Kang, KR; F. Lordick, DE	Hall A1 - Room 17
11:00 - 11:15	One LBA TBC	
11:15 - 11:30	One LBA TBC	
11:30 - 11:45	Invited Discussant two LBAs TBC <u>Y.-K. Kang</u> , Songpa-gu/KR	
11:45 - 12:00	One LBA TBC	
12:00 - 12:15	6150 - Randomized phase III study of Gemcitabine, Cisplatin plus S-1 (GCS) versus Gemcitabine, Cisplatin (GC) for Advanced Biliary Tract Cancer (KHBO1401-MITSUBA) <u>D. Sakai</u> <sup>1</sup> , M. Kanai <sup>2</sup> , S. Kobayashi <sup>2</sup> , H. Eguchi <sup>2</sup> , H. Baba <sup>2</sup> , S. Seo <sup>2</sup> , A. Taketomi <sup>2</sup> , T. Takayama <sup>2</sup> , H. Yamaue <sup>2</sup> , C. Ishioka <sup>3</sup> , M. Sho <sup>2</sup> , Y. Takeyama <sup>2</sup> , J. Fujimoto <sup>2</sup> , M. Toyoda <sup>4</sup> , J. Shimizu <sup>2</sup> , T. Goto <sup>2</sup> , K. Yoshimura <sup>5</sup> , E. Hatano <sup>2</sup> , H. Nagano <sup>2</sup> , T. Ioka <sup>2</sup> ; <sup>1</sup> Osaka/JP, <sup>2</sup> JP, <sup>3</sup> Miyagi/JP, <sup>4</sup> Hyogo/JP, <sup>5</sup> Ishikawa/JP	
12:15 - 12:30	Invited Discussant one LBA TBC and 6150	

11:00 - 12:30 Type: Special session Hall A1 - Room 16  
 Title: Integrating radiation in immunotherapy schemes  
 Chair(s): F. Herrera, CH

11:00 - 11:05 Introduction

11:05 - 11:25 Checkpoint inhibitors plus radiotherapy to increase cure rates in head and neck cancer  
K. Harrington, GB

11:25 - 11:45 Abscopal effect of radiotherapy with checkpoint inhibitors  
E. Deutsch, CEDEX/FR

11:45 - 12:05 Radiation dose to harness the immune system  
F. Herrera, CH

12:05 - 12:25 Manipulating the tumour microenvironment through radiation  
S. Demaria, US

12:25 - 12:30 Conclusions and perspectives

11:00 - 12:30 Type: Special Symposium Hall A2 - Room 18  
 Title: Safe de-escalation of therapy in the management of early breast cancer  
 Chair(s): C. Coles, GB; E. Rutgers, NL

11:00 - 11:05 Introduction  
C. Coles, GB

11:05 - 11:25 Chemotherapy or not: How do you decide?  
S. Delaloge, FR

11:25 - 11:45 Duration of targeted therapy for HER2 and for hormone therapy  
H. Earl, Cambridgeshire/GB

11:45 - 12:05 Minimising surgical management of early breast cancer  
E. Rutgers, NL

12:05 - 12:25 Biomarker-guided radiotherapy in the management of early breast cancer  
T. Whelan, CA

12:25 - 12:30 Conclusions and perspectives  
E. Rutgers, NL

11:00 - 12:30 Type: Educational session ICM - Room 1  
 Title: The critical need of a multidisciplinary approach for the treatment of prostate cancer  
 Chair(s): S. Gillessen, CH

11:00 - 11:25 Update on diagnosis and treatment of localised prostate cancer  
M. Emberton, GB

11:25 - 11:50 Oligometastatic disease  
A. Bossi, FR

11:50 - 12:15 What is new in metastatic castration resistant prostate cancer (CRPC)?  
R. de Wit, NL

12:15 - 12:30 Discussion

11:00 - 12:30 Type: Educational session ICM - Room 14b  
 Title: Optimal antineoplastic therapy and supportive care of elderly cancer patients  
 Chair(s): J. Herrstedt, DK; S. Kaasa, NO

11:00 - 11:02 Introduction  
J. Herrstedt, DK

11:02 - 11:27 Anticancer therapy-induced dose-limiting toxicity in elderly cancer patients  
K. Jordan, DE

11:27 - 11:52 Importance of maintaining dose density and dose intensity  
J. Herrstedt, DK

11:52 - 12:17 Immunotherapy in the elderly  
M. Apro, CH

12:17 - 12:30 Discussion

11:00 - 12:30 Type: Special Symposium ICM - Room 13  
 Title: Novel therapies for brain tumors  
 Chair(s): M. Weller, CH; J.-C. Tonn, DE

11:00 - 11:05 Introduction  
J.-C. Tonn, DE

11:05 - 11:20 Immunotoxins for gliomas  
M. van den Bent, NL

11:20 - 11:35 Update on vaccination strategies for gliomas  
M. Weller, CH

11:35 - 11:50 Immune check-point inhibitors in brain tumors  
A.S. Berghoff, AT

11:50 - 12:05 Genomically targeted therapies in neuro-oncology  
W. Wick, DE

12:05 - 12:20 Targeted therapies of pediatric brain tumors  
D. Hargrave, GB

12:20 - 12:30 Conclusions and clinical perspectives  
M. Weller, CH

11:00 - 12:00 Type: Poster Discussion session Hall B3 - Room 21  
 Title: Poster Discussion session - Translational research 2  
 Chair(s): G. Tortora, IT; G. Attard, GB

11:00 - 11:00 62PD - Could plasma EBV DNA kinetics predict long-term disease-free survival in metastatic nasopharyngeal carcinoma?  
L. guoying, H. Liang, W.-X. Xia, Y.-Q. Xiang, X. Lv, X. Guo, Y.-H. Yu, S.-H. Lv, K.-Y. Liu, W.-Z. Qiu, X.-J. Huang, W.-Z. Li; CN

11:00 - 11:00 63PD - Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials  
B. Holt<sup>1</sup>, D. Micklem<sup>1</sup>, A. Brown<sup>2</sup>, M. Yule<sup>2</sup>, J. Lorens<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>NO

11:00 - 11:00 64PD - Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma  
Q. Xu, Q. Wang, J. Chen, C. Chen, Y. Sun, L. Chen, Q. Ye, X. Du; CN

11:00 - 11:00 1832PD - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

A. Hollebecque<sup>1</sup>, J. de Bono<sup>2</sup>, R. Plummer<sup>3</sup>, N. Isambert<sup>4</sup>, P. Martin-Romano<sup>1</sup>, E. Baudin<sup>1</sup>, S. Mora<sup>5</sup>, A. Harding<sup>2</sup>, A. Nguyen<sup>6</sup>, E. Filvaroff<sup>6</sup>, M. Lamba<sup>7</sup>, K. Liu<sup>7</sup>, J. De Alvaro<sup>5</sup>, J. DiMartino<sup>6</sup>, M. Zuraek<sup>6</sup>, Z. Nikolova<sup>5</sup>; <sup>1</sup>FR, <sup>2</sup>GB, <sup>3</sup>Tyne and Wear/GB, <sup>4</sup>Cedex/FR, <sup>5</sup>ES, <sup>6</sup>CA/US, <sup>7</sup>US

- 11:00 - 11:00 1833PD - Lack of efficiency of Precision Oncology with target-based investigational treatments for patients in Early Phase clinical trials based on pre-screened molecular alterations  
B. Doger de Spéville, V. Moreno, T. Hernandez, V. Boni, M.J. de Miguel, F. Rojo, F. Lopez-Rios, E. Calvo; ES
- 11:00 - 11:20 Invited Discussant 62PD, 63PD, 64PD, 1832PD and 1833PD  
G. Tortora, IT
- 11:20 - 11:30 Q&A led by Discussant
- 11:30 - 11:30 65PD - High tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4  
B. Higgs, US
- 11:30 - 11:30 1834PD - Genomic profile and T cell receptor repertoire of lung adenosquamous carcinomas  
G. Lin, C. Li, W.-Z. Fang, W. Chen, C. Huang; CN
- 11:30 - 11:30 1835PD - Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low  
M. Salem<sup>1</sup>, A. Puccini<sup>2</sup>, A. Grothey<sup>3</sup>, J. Xiu<sup>4</sup>, R. Goldberg<sup>5</sup>, E. Kim<sup>6</sup>, W.M. Korn<sup>4</sup>, H.-J. Lenz<sup>7</sup>, D. Raghavan<sup>8</sup>, J. Marshall<sup>1</sup>, M. Hall<sup>9</sup>; <sup>1</sup>DC/US, <sup>2</sup>IT, <sup>3</sup>MN/US, <sup>4</sup>US, <sup>5</sup>SG, <sup>6</sup>NC/US, <sup>7</sup>CA/US, <sup>8</sup>North Carolina/US, <sup>9</sup>PA/US
- 11:30 - 11:30 1837PD - Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)  
J.L. Perez Gracia<sup>1</sup>, M.J. Pajares<sup>1</sup>, J.P. Fusco<sup>1</sup>, M. Andueza<sup>1</sup>, V. Segura<sup>1</sup>, M.I. Mora<sup>1</sup>, E. Guruceaga<sup>1</sup>, R. Sanchez Bayona<sup>1</sup>, A. Gurrpide<sup>1</sup>, J.M. Lopez-Picazo<sup>1</sup>, I. Gil-Bazo<sup>1</sup>, J.P. de Torres<sup>1</sup>, J. Zulueta<sup>1</sup>, R. Pio<sup>1</sup>, I. Melero<sup>1</sup>, M. Sanmamed<sup>2</sup>, M. Rodriguez-Ruiz<sup>1</sup>, A. Gonzalez Neira<sup>1</sup>, L. Montuenga<sup>1</sup>, A. Patiño-Garcia<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>US
- 11:30 - 11:50 Invited Discussant 1834PD, 1835PD, 1836PD and 1837PD  
G. Attard, GB
- 11:50 - 12:00 Q&A led by Discussant

11:00 - 12:05 Type: Multidisciplinary interactive sessions Hall B3 - Room 23  
 Title: Multidisciplinary perspectives in stage I-II NSCLC management  
 Chair(s): E. Felip Font, ES

11:00 - 11:05 Case presentation on stage  
E. Felip Font, ES

11:05 - 11:15 The role of medical oncology  
E. Felip Font, ES

11:15 - 11:25 The role of radiotherapy  
S. Senan, NL

11:25 - 11:35 The role of surgery  
D.A. Waller, GB

11:35 - 12:05 Discussion

11:00 - 12:05 Type: Multidisciplinary interactive sessions Hall B3 - Room 20  
 Title: Pre-op/neoadjuvant treatments in sarcomas: "Think twice before you open it"  
 Chair(s): P.G. Casali, IT

11:00 - 11:05 Case presentation  
P.G. Casali, IT

11:05 - 11:15 The surgeon's perspective  
P. Rutkowski, PL

11:15 - 11:25 The radiation oncologist's perspective  
A. Miah, GB

11:25 - 11:35 The medical oncologist's perspective  
A. Le Cesne, CEDEX/FR

11:35 - 12:05 Discussion

11:00 - 12:15	Type: Proffered Paper session Title: Proffered paper session - Developmental therapeutics Chair(s): A.A. Adjei, US; A. Jordan, GB	Hall B3 - Room 22
11:00 - 11:12	408O - Sitravatinib demonstrates activity in patients with novel genetic alterations that inactivate CBL <u>L. Bazhenova</u> <sup>1</sup> , R. Carvajal <sup>2</sup> , B.C. Cho <sup>3</sup> , K. Eaton <sup>4</sup> , S. Goel <sup>2</sup> , R. Heist <sup>2</sup> , M. Ingham <sup>2</sup> , D. Wang <sup>5</sup> , T. Werner <sup>6</sup> , S. Neuteboom <sup>2</sup> , D. Potvin <sup>2</sup> , I. Chen <sup>1</sup> , J. Christensen <sup>1</sup> , R. Chao <sup>1</sup> , A. Alva <sup>5</sup> ; <sup>1</sup> CA/US, <sup>2</sup> US, <sup>3</sup> KR, <sup>4</sup> WA/US, <sup>5</sup> MI/US, <sup>6</sup> UT/US	
11:12 - 11:24	409O - Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach <u>U. Lassen</u> <sup>1</sup> , C. Albert <sup>2</sup> , S. Kummar <sup>3</sup> , C. van Tilburg <sup>4</sup> , S. Dubois <sup>5</sup> , B. Geoerger <sup>6</sup> , L. Mascarenhas <sup>7</sup> , N. Federman <sup>7</sup> , R. Schilder <sup>8</sup> , F. Doz <sup>6</sup> , J. Berlin <sup>9</sup> , D.-Y. Oh <sup>10</sup> , S. Bielack <sup>4</sup> , R. McDermott <sup>11</sup> , D. Tan <sup>12</sup> , S. Cruickshank <sup>7</sup> , N. Ku <sup>7</sup> , M. Cox <sup>7</sup> , A. Drilon <sup>13</sup> , D. Hong <sup>3</sup> ; <sup>1</sup> DK, <sup>2</sup> WA/US, <sup>3</sup> US, <sup>4</sup> DE, <sup>5</sup> MA/US, <sup>6</sup> FR, <sup>7</sup> CA/US, <sup>8</sup> PA/US, <sup>9</sup> TN/US, <sup>10</sup> KR, <sup>11</sup> Belgard Square North/IE, <sup>12</sup> SG, <sup>13</sup> NY/US	
11:24 - 11:39	Invited Discussant 408O and 409O <u>A. Jordan</u> , GB	
11:39 - 11:51	410O - First-in-Human, First-in-Class study of the CD44v6 inhibitor AMC303 as monotherapy in patients with advanced epithelial tumors <u>E. Calvo</u> <sup>1</sup> , P. Aftimos <sup>2</sup> , A. Azaro <sup>1</sup> , M.J. de Miguel <sup>1</sup> , C. Jungels <sup>2</sup> , J. Zeron-Medina Cuairan <sup>1</sup> , P. Nuciforo <sup>1</sup> , P. Ehmer <sup>3</sup> , A. Martin <sup>3</sup> , H. Bender <sup>3</sup> , K. Dembowski <sup>3</sup> ; <sup>1</sup> ES, <sup>2</sup> BE, <sup>3</sup> DE	
11:51 - 12:03	411O - Initial results from a phase 1/2a trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer <u>J. Hilton</u> <sup>1</sup> , M. Cristea <sup>2</sup> , M. Voskoboynik <sup>3</sup> , S. Postel-Vinay <sup>4</sup> , W. Edenfield <sup>5</sup> , A. Gavai <sup>6</sup> , S. Wee <sup>6</sup> , N. Srivastava <sup>6</sup> , A. Klippel <sup>7</sup> , D. Jackson <sup>6</sup> , A. Apfel <sup>6</sup> , S. Chasalow <sup>8</sup> , D. Williams <sup>6</sup> , M. Donovan <sup>6</sup> , B. Fischer <sup>7</sup> , S. Khaldoyanidi <sup>6</sup> , J. Diamond <sup>7</sup> ; <sup>1</sup> CA, <sup>2</sup> CA/US, <sup>3</sup> VIC/AU, <sup>4</sup> FR, <sup>5</sup> SC/US, <sup>6</sup> NJ/US, <sup>7</sup> US, <sup>8</sup> New Jersey/US	
12:03 - 12:18	Invited Discussant 410O and 411O <u>U. Banerji</u> , Surrey/GB	

11:00 - 12:30	Type: Proffered Paper session Title: Proffered paper session - Haematological malignancies Chair(s): M. Ladetto, IT; M.-V. Mateos, ES	Hall B4 - Room 19
11:00 - 11:15	1004O - Final Overall Survival Results of Frontline Bortezomib plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) vs R-CHOP in Transplantation-ineligible Patients (Pts) with Newly Diagnosed Mantle-Cell Lymphoma (MCL): A Randomized, Open-Label, Phase 3 (LYM-3002) Study  <u>F. Cavalli</u> <sup>1</sup> , J. Jin <sup>2</sup> , H. Pylypenko <sup>3</sup> , G. Verhoef <sup>4</sup> , N. Siritanaratkul <sup>5</sup> , J. Drach <sup>6</sup> , M. Raderer <sup>6</sup> , J. Mayer <sup>7</sup> , J. Pereira <sup>8</sup> , G. Tumyan <sup>9</sup> , R. Okamoto <sup>10</sup> , S. Nakahara <sup>10</sup> , P. Hu <sup>11</sup> , C. Appiani <sup>11</sup> , S. Nemat <sup>12</sup> , T. Robak <sup>13</sup> ; <sup>1</sup> CH, <sup>2</sup> CN, <sup>3</sup> UA, <sup>4</sup> BE, <sup>5</sup> TH, <sup>6</sup> AT, <sup>7</sup> CZ, <sup>8</sup> BR, <sup>9</sup> RU, <sup>10</sup> JP, <sup>11</sup> NJ/US, <sup>12</sup> GB, <sup>13</sup> PL	
11:15 - 11:30	1005O - A Revised International Prognostic Score System for Waldenström's Macroglobulinemia  <u>M. Gavriatopoulou</u> <sup>1</sup> , E. Kastritis <sup>1</sup> , P. Morel <sup>2</sup> , A. Duhamel <sup>3</sup> , M. Kyrtonis <sup>1</sup> , E. Durot <sup>3</sup> , A. Symeonidis <sup>1</sup> , K. Laribi <sup>3</sup> , E. Hatjiharisi <sup>1</sup> , L. Ysebaert <sup>3</sup> , A. Vassou <sup>1</sup> , N. Giannakoulas <sup>1</sup> , G. Merlini <sup>4</sup> , P. Repousis <sup>1</sup> , M. Varettoni <sup>3</sup> , E. Michalis <sup>1</sup> , B. Hivert <sup>3</sup> , M. Michalis <sup>5</sup> , V. Leblond <sup>3</sup> , M. Dimopoulos <sup>6</sup> ; <sup>1</sup> GR, <sup>2</sup> Pas de Calais/FR, <sup>3</sup> FR, <sup>4</sup> IT, <sup>5</sup> CY, <sup>6</sup> Attiki/GR	
11:30 - 11:45	1006O - Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: combined analysis from phase I and II studies  <u>P. Zinzani</u> <sup>1</sup> , A. Santoro <sup>2</sup> , L. Mollica <sup>3</sup> , G. Follows <sup>4</sup> , K. Bouabdallah <sup>5</sup> , F. Morschhauser <sup>5</sup> , A. Patnaik <sup>6</sup> , L. Huang <sup>6</sup> , F. Hiemeyer <sup>7</sup> , A. Benson <sup>8</sup> , I. Genvresse <sup>7</sup> , J. Garcia-Vargas <sup>8</sup> , B. Childs <sup>9</sup> , M. Dreyling <sup>7</sup> ; <sup>1</sup> IT, <sup>2</sup> (MI)/IT, <sup>3</sup> CA, <sup>4</sup> GB, <sup>5</sup> FR, <sup>6</sup> US, <sup>7</sup> DE, <sup>8</sup> NJ/US, <sup>9</sup> New York/US	
11:45 - 12:05	Invited Discussant 1004O, 1005O and 1006O  <u>C. Buske</u> , DE	
12:05 - 12:20	1007O - Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry  <u>R. Abonour</u> <sup>1</sup> , R. Rifkin <sup>2</sup> , C. Gasparetto <sup>2</sup> , K. Toomey <sup>2</sup> , B. Durie <sup>2</sup> , J. Hardin <sup>2</sup> , H. Terebelo <sup>2</sup> , S. Jagannath <sup>2</sup> , M. Narang <sup>2</sup> , S. Ailawadhi <sup>2</sup> , S. Srinivasan <sup>2</sup> , A. Kitali <sup>2</sup> , A. Agarwal <sup>2</sup> , L. Wagner <sup>2</sup> ; <sup>1</sup> IN/US, <sup>2</sup> US	
12:20 - 12:30	Invited Discussant 1007O  <u>M.-V. Mateos</u> , ES	



11:00 - 12:00 Type: EONS session Hall B4 - Room 24  
Title: Symptom management

11:00 - 11:15 CN26 - The Cost of Survival: A Mixed-Method Exploration of Healthcare-Related Factors Predicting Colorectal Cancer Survivors' Quality of Life  
A. Drury<sup>1</sup>, S. Payne<sup>2</sup>, A.-M. Brady<sup>1</sup>; <sup>1</sup>IE, <sup>2</sup>GB

11:15 - 11:30 CN53 - Rectal cancer survivorship: the struggle of the low anterior resection syndrome (LARS)  
E. Pape, P. Pattyn, A. van Hecke, N. Somers, D. Van De Putte, W. Ceelen, E. van Daele, W. Willaert, Y. van Nieuwenhove; BE

11:30 - 11:45 CN54 - Nurse-led approaches to self-management of symptoms in routine Swiss outpatient care: a qualitative exploration  
K. Ribj, M. Bana, S. Peters, S. Kropf-Straub, E. Näf, S. Zürcher, M. Eicher; CH

11:45 - 12:00 CN27 - The influence of social networks on cancer survivors' self-management support: A survey analysis  
G. Howard-Jones, A. Richardson, I. Vassilev, D. Fenlon, S. Ewings; GB

11:00 - 11:45 Type: Young Oncologist session ICM - Room 14a  
Title: YO Brunch 2: Breaking bad news: How to deal with end-of-life discussions

11:00 - 11:15 Breaking bad news: How to deal with end-of-life discussions  
E. Mase<sup>1</sup>, M. Petrova<sup>2</sup>, M.A. Ozturk<sup>3</sup>; <sup>1</sup>AT, <sup>2</sup>BG, <sup>3</sup>TR

12:00 - 13:00 Type: Poster Display session Hall B4 - Room 24  
Title: EONS Poster display

12:00 - 12:00 CN5 - Patients - power sources for cancer nurses  
C. Beisel, DE

12:00 - 12:00 CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care  
J. Koldenhof, S. Vervoort, C. Nierop, K. Suijkerbuijk; NL

12:00 - 12:00 CN7 - Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy  
Q. Alnasser<sup>1</sup>, K. Cameron<sup>1</sup>, J. Prouse<sup>2</sup>; <sup>1</sup>SA, <sup>2</sup>AU

12:00 - 12:00 CN8 - AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.  
S. Smith, DK

12:00 - 12:00 CN9 - Nurse led follow-up for CML patients on oral cancer treatment  
S. De Wilde, J. De Munter, M. Quaghebeur, D. Mazure, A. De Pauw, B. Casteels; BE

12:00 - 12:00 CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses – patient-reported evaluation.

B. Westman, H. Ullgren, L. Sharp; SE

- 12:00 - 12:00 CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.  
E. Mahía, G. Simó, E. Heras, M. Pascual, F. Cobo, J. Pujadas, S. Albiol; AD
- 12:00 - 12:00 CN12 - Systemic Anticancer Therapy Administration Safety  
S. Toland, A. Simons; GB
- 12:00 - 12:00 CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: the role of the nurse practitioner for early recognition and management  
C. Roth, M. Labots, A. Eertwegh; NL
- 12:00 - 12:00 CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method  
H. Ullgren, SE
- 12:00 - 12:00 CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study  
S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR
- 12:00 - 12:00 CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease  
J. De Munter, S. De Wilde, M. Quaghebeur; BE
- 12:00 - 12:00 CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital  
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES
- 12:00 - 12:00 CN18 - Are there differences between nurses' and patients' perceptions of cancer patients' quality of life in Greece?  
M. LAVDANITI, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. ZIOGA, K. MARMARA, E. Fradelos; GR
- 12:00 - 12:00 CN19 - How an empowerment program can touch cancer survivor's life by improving posttraumatic growth?  
Y.S. UZAR OZCETIN, TR
- 12:00 - 12:00 CN20 - Organising a general oncology nursing outpatient clinic  
C. Lundgren, A. Lagerquist, M. Högman, U. Östlund; SE
- 12:00 - 12:00 CN21 - Job content of advanced practice nurses in Flanders  
E. Decoene, A. Van Hecke; BE
- 12:00 - 12:00 CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professionals self-efficacy when supporting parents newly diagnosed with cancer who have dependent children  
C. Semple, E. McCaughan; GB

- 12:00 - 12:00 CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals  
J. Bird, M. Nolan, S. Danson; GB
- 12:00 - 12:00 CN24 - Assessing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona  
C. PUIGMARTI, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher; ES
- 12:00 - 12:00 CN28 - Transmural collaborative care in oncology: Experiences of general practitioners  
M. daem, E. van Roekeghem, M. Grypdonck, P. Pype; BE
- 12:00 - 12:00 CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review  
S. Colomer-Lahiguera<sup>1</sup>, D. Bryant-Lukosius<sup>2</sup>, S. Rietkoetter<sup>2</sup>, L. Martelli<sup>2</sup>, K. Ribi<sup>1</sup>, A. Orcurto<sup>1</sup>, R. Juergens<sup>2</sup>, M. Eicher<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>ON/CA
- 12:00 - 12:00 CN30 - Laryngectomized patients caregivers' life experience: a phenomenological study  
V. Bressan, E. Dri, S. Stevanin, L. Cadorin, A. Rizzuto, G. Bulfone, L. Ghirotto; IT
- 12:00 - 12:00 CN31 - Comparing nurses' and patients' research priorities in cancer care: A mixed methods systematic review  
L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT
- 12:00 - 12:00 CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy  
A. Psychogyiou, S. KATSARAGAKIS, C. Lemonidou, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network  
K. Dieperink, M. Kjerholt, P. Riis Olsen; DK
- 12:00 - 12:00 CN34 - Individual network meetings in cancer care - From young people with cancer to adults with brain tumours  
P. Riis Olsen, DK
- 12:00 - 12:00 CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?  
G. Bagcivan, N. Ozen, D. Bayrak, F.I. Cinar; TR
- 12:00 - 12:00 CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment  
C. Johnston, M. Tanay; GB
- 12:00 - 12:00 CN37 - Evaluation of support and information needs for patients with cancer in a Phase I trials unit.  
S. Stapleton, L. O'Leary, M. van Zyl, J. Hanwell, T. Wiseman; GB
- 12:00 - 12:00 CN38 - Dignity of Greek patients with advanced cancer: a cross-sectional study  
S. KATSARAGAKIS, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki; GR

- 12:00 - 12:00 CN39 - Development and implementation of national guidelines on lifestyle issues and cancer -Report from an on-going quality improvement project  
K. Vuollet Karlsson, C. Landegren, B. Westman; SE
- 12:00 - 12:00 CN40 - Developing a Patient Reported Experience Measure (PREM) in Secondary Breast Cancer (SBC)  
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke; GB
- 12:00 - 12:00 CN41 - Cancer situation in sub-Saharan Countries: development of educational, diagnosis and treatment plans.  
J. de la Torre-Montero, N. Gil-Gómez, J. RIBES BERNAL, N. Domenech Climent, A. OJER PEREA, P. BEORLEGUI MURILLO, J.M. GAVALA ARJONA, R. CUMPLIDO CORBACHO, I. MAGALLON PEDRERA, M.A. PEÑUELAS SAIZ; ES
- 12:00 - 12:00 CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital.  
J. Duncan<sup>1</sup>, V. Michalarea<sup>2</sup>, T. Coyne<sup>1</sup>, J. Thomas<sup>1</sup>, D. Cunningham<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Surrey/GB
- 12:00 - 12:00 CN43 - Patients' learning and participation in their breast cancer care  
L. Boman, K. Sandelin, Y. Wengström, C. Silén; SE
- 12:00 - 12:00 CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration.  
S.Y. Oh, J.M. Lee, J.W. Kim, S.H. Kim, J.M. Park, G.Y. Yeo, J.E. Hyun, J.-H. Park; KR
- 12:00 - 12:00 CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy  
A. Frade, S. Miguel; PT
- 12:00 - 12:00 CN46 - Safe navigation of CARs in a changing landscape  
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite; GB
- 12:00 - 12:00 CN47 - Patients' interpretations and experiences of participation in cancer care  
J. Jackson, J. Rundgren; SE
- 12:00 - 12:00 CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab  
M. Qiu, Y. Chen, B.-L. Zhang, X.-Y. Wang; CN
- 12:00 - 12:00 CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care  
J. De Munter, P. Crombez; BE
- 12:00 - 12:00 CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre  
M. Foulkes, GB
- 12:00 - 12:00 CN51 - The development and evaluation of an online oncology portal  
J. De Munter, E. Decoene, A. Van Hecke; BE

- 12:00 - 12:00 CN52 - Pilot Study – Nurses' Role in Management of Cutaneous Toxicity in Patients with Targeted Therapies Anti EGFR-Is' Treatment.  
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso; IT
- 12:00 - 12:00 CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?  
D. Oliva, F. Lewin, N. Lewin, M. Nilsson, M. Strandéus, B.-Å. Andersson, L. Sharp; SE
- 12:00 - 12:00 CN58 - Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain and Fatigue in Patients Receiving Oxaliplatin  
N. Izgu, L. Ozdemir, F. Bugdayci Basal; TR
- 12:00 - 12:00 CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital  
C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protogiros, E. Patiraki; GR
- 12:00 - 12:00 CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: a qualitative study  
D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT
- 12:00 - 12:00 CN61 - "It may not affect you" -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.  
M. Tanay, J. Armes; GB
- 12:00 - 12:00 CN62 - App about chemotherapy - helping the patient with cancer  
B. Espersen, DK
- 12:00 - 12:00 CN63 - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing  
P. Fernández- Ortega, Y. Escobar, E. Trigo, R. Blat, M. Cantero, A. Alvarez; ES
- 12:00 - 12:00 CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the Memorial Symptom Assessment Scale  
D. PALITZIKA, E. Fradelos, V. ALIKARI, P. CHARITOUPOULOS, E. ZIOGA, S. ZYGA, M. LAVDANITI; GR
- 12:00 - 12:00 CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®"  
M. Belhadj<sup>1</sup>, E. Kempf<sup>1</sup>, A. Lebel<sup>1</sup>, A. Guillemin<sup>1</sup>, H. BouSSION<sup>1</sup>, C. Joly<sup>1</sup>, I. Baumgaertner<sup>2</sup>, E. Assaf<sup>2</sup>, C. Saldana<sup>2</sup>, B. Rousseau<sup>2</sup>, C. Tournigand<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:00 - 12:00 CN66 - Medical makeup in cancer patients and its impact in their quality of life  
R. LECHOU, GR
- 12:45 - 13:45 Type: Poster Display session  
Title: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal &&  
Hall A3 - Poster Area  
Networking Hub

- 12:45 - 13:05 Basic science
- 13:05 - 13:05 6P - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome  
E. Llabres Valenti, A. Sanchez de Abajo, J. Brenes Castro, A. Ramchandani Vaswani, A. Gómez de Liaño, A. Hernández, M. Cejuela, J. Rodriguez Garcia, E. González, E. Vicente; ES
- 13:05 - 13:05 7P - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender  
J.B. Ramirez Sabio, J.V. Sorlí, I. González-Monje, C. Ortega-Azorín, Ó. Coltell, D. Corella; ES
- 13:05 - 13:05 8P - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population  
J.B. Ramirez Sabio, J.V. Sorlí, C. Ortega-Azorín, J.A. Pérez-Fidalgo, E.M. Asensio, D. Corella; ES
- 13:05 - 13:05 9P - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer  
S. Shahid Sales<sup>1</sup>, M. Mehramiz<sup>2</sup>, S.A. Aledavood<sup>2</sup>, M. Joudi Mashhad<sup>2</sup>, S. Ahmadi Simab<sup>2</sup>, A. avan<sup>2</sup>; <sup>1</sup>Khorasan Razavi/IR, <sup>2</sup>IR
- 13:05 - 13:05 10P - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR  
K. BAKSHI, IN
- 13:05 - 13:05 11P - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma  
H. Jo, S. Hwang, M. Lee; KR
- 13:05 - 13:05 12P - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System  
Y. Ge<sup>1</sup>, C. Ma<sup>2</sup>, L. Tao<sup>1</sup>, M.F. Han<sup>1</sup>, L. Ma<sup>3</sup>, G. Li<sup>4</sup>, L.M. Ma<sup>4</sup>, Q. Lu<sup>2</sup>, Z. Wu<sup>4</sup>, P.F. Yu<sup>4</sup>, Y.F. Yang<sup>4</sup>, Y.Y. Ma<sup>2</sup>, B.B. Song<sup>4</sup>, W. Gao<sup>4</sup>; <sup>1</sup>Ahnui/CN, <sup>2</sup>WA/US, <sup>3</sup>Beijing/CN, <sup>4</sup>CN
- 13:05 - 13:05 13P - Measuring the Efficiency of Cancer Care in Europe  
R. Althin<sup>1</sup>, R. Färe<sup>2</sup>, S. Grosskopf<sup>2</sup>, B. Jönsson<sup>1</sup>, N. Wilking<sup>1</sup>; <sup>1</sup>SE, <sup>2</sup>OR/US
- 13:05 - 13:05 14P - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients  
C.-Y. Yang, C.-H. Lin, J.-K. Jiang; TW
- 13:05 - 13:05 15P - Clonality of uterine carcinosarcoma as a factor of clinical prognosis.  
N. Levitskaya, O. Vostriukhina, I. Poddubnaia; RU
- 13:05 - 13:05 16P - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer  
A. Moilanen<sup>1</sup>, J. Lindqvist<sup>1</sup>, M. Björkman<sup>1</sup>, R. Riikonen<sup>1</sup>, D. Nicorici<sup>1</sup>, E. Mattila<sup>1</sup>, C. Abbineni<sup>2</sup>, M. Jaleel<sup>2</sup>, J. Eriksson<sup>1</sup>, P. Kallio<sup>1</sup>; <sup>1</sup>FI, <sup>2</sup>IN

- 13:05 - 13:05 17P - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.  
R. Dubianski, E. Sarnowska, M. Leszczynski, S. Kubala, W. Olszewski, N. Rusetska, A. Jagiello-Gruszfeld, R. Konopinski, T. Sarnowski, J. Siedlecki, Z. Nowecki; PL
- 13:05 - 13:05 18P - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.  
P.P. Vitiello, C. Cardone, D. Ciardiello, V. Belli, N. Matrone, C. Borrelli, L. Poliero, V. De Falco, E. Giunta, P. Vitale, N. Zanaletti, G. Tirino, T. Troiani, F. Ciardiello, E. Martinelli; IT
- 13:05 - 13:05 19P - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.  
X. Fu, M. Liu, S. Qu, J. Ma, Y. Zhang, T. Shi, H. Wen, Y. Yang, S. Wang, J. Wang, K. Nan, Y. Yao, T. Tian; CN
- 13:05 - 13:05 20P - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women  
J.B. Ramirez Sabio, J.V. Sorlí, R. Barragán, F.-C. Rebeca, E.M. Asensio, D. Corella; ES
- 13:05 - 13:05 21P - Cisplatin in NIPEC or HIPEC?  
I. Alvovsky, V. Bespalov, G. Kireeva; RU
- 13:05 - 13:05 22P - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment  
M. HIRAI, Y. Kobayashi, M. Miyazawa, H. Kitahara, S. Kawashiri, H. Nakamura; JP
- 13:05 - 13:05 24P - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis  
P. Sriskandarajah, K. Macleod, N. Carragher, M. Kaiser, S. Whittaker; GB
- 13:05 - 13:05 25P - Functional inhibition of TGF- $\beta$  in colorectal cancer cells and its interaction with AXL receptor  
D. Ciardiello<sup>1</sup>, G. Martini<sup>2</sup>, N. Matrone<sup>1</sup>, V. Belli<sup>1</sup>, P.P. Vitiello<sup>1</sup>, C. Cardone<sup>1</sup>, V. Ciaramella<sup>1</sup>, G. Barra<sup>1</sup>, L. Poliero<sup>1</sup>, C. Borrelli<sup>1</sup>, T. Troiani<sup>1</sup>, D. Melisi<sup>1</sup>, F. Morgillo<sup>1</sup>, E. Giunta<sup>1</sup>, V. De Falco<sup>1</sup>, F. Ciardiello<sup>1</sup>, E. Martinelli<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>ES
- 13:05 - 13:05 26P - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma  
H. Arasan, M. Gato-Cañas, M. Zuazo, M. Ibáñez-Vea, G. Fernández-Hinojal, J. Fernandez-Irigoyen, E. Santamaria, G. Kochan, R. Vera, D. Escors; ES
- 13:05 - 13:05 27P - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors  
I. Tsimafeyeu, M. Volkova, A. Olshanskaia, G. Raskin, S. Aschuba, Y. Khochenkova, A. Bondarenko, D. Khochenkov; RU
- 13:05 - 13:05 28P - Oncogenes analysis using GO-based clustering  
D. Babenko, Y. Babenko; KZ
- 13:05 - 13:05 29P - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt Pathway

S. Shahid Sales<sup>1</sup>, A. avan<sup>2</sup>, F. Rahmani<sup>2</sup>, S.M. Hassanian<sup>2</sup>, M. Hashemzahi<sup>2</sup>, F. Amerizadeh<sup>2</sup>, G. A. Ferns<sup>3</sup>, M. Khazaei<sup>2</sup>; <sup>1</sup>Khorasan Razavi/IR, <sup>2</sup>IR, <sup>3</sup>GB

- 13:05 - 13:05 30P - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer  
M. Iida, M. Nakamura, E. Tokuda, T. Niwa, T. Ishida, S.-I. Hayashi; JP
- 13:05 - 13:05 31P - Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo  
T. Kozako, T. Ohsugi, M. Yoshimitsu, Y.-I. Uchida, K. Ishitsuka, K. Naho, A. Aikawa, S.-I. Honda; JP
- 13:05 - 13:05 32P - 9-ING-41, a clinically relevant inhibitor of Glycogen Synthase Kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers  
H. KUROKI<sup>1</sup>, T. Anraku<sup>1</sup>, V. Bilim<sup>1</sup>, M. Tasaki<sup>1</sup>, D. Schmitt<sup>2</sup>, A. Mazar<sup>3</sup>, A. Ugolkov<sup>3</sup>, Y. Tomita<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>TX/US, <sup>3</sup>IL/US
- 13:05 - 13:05 33P - A new natural compound identified with metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab  
V. De Falco, E. Giunta, V. Belli, N. Matrone, S. Napolitano, E. Martinelli, P. Vitale, N. Zanaletti, M. Terminiello, P.P. Vitiello, F. Ciardiello, T. Troiani; IT
- 13:05 - 13:05 34P - Multiple Myeloma Metal Levels and Proteasome Activity  
K.U. Stumpf, H. Einsele, T. Nekova; DE
- 13:05 - 13:05 35P - A translational drug-screening tool for interrogating the effect of anti-TGF- $\beta$  therapy on fibroblast activity and the desmoplastic reaction  
N. Nissen, N. Willumsen, N. Gudmann, S. Rønnow, M. Karsdal, D. Leeming, J. Sand; DK
- 13:05 - 13:05 36P - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors  
H. Kitahara, Y. Kobayashi, M. Hirai, S. Kawashiri, H. Nakamura; JP
- 13:05 - 13:05 37P - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.  
K. Takahashi, S. Nishikawa, R. Miyata, M. Noguchi, H. Ishikawa, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, T. Menju, F. Chen-Yoshikawa, T. Sato, M. Sonobe, H. Date; JP
- 13:05 - 13:05 38P - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro  
A. Cortez, K. Kujawa, P. Tudrej, K. Lisowska; PL
- 13:05 - 13:05 39P - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1  
L. Qiu, CN
- 13:05 - 13:05 40P - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1  
X. Wang, X. Che, Y. Fan, M. Bai, X. Qu; CN
- 13:05 - 13:05 41P - Risk prediction of metastasis through study of circulating tumor cells



P. Apostolou, I. Papatotiriou; GR

- 13:05 - 13:05 42P - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells  
V. Halytskiy, UA
- 13:05 - 13:05 43P - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment  
A. Tsidulko<sup>1</sup>, C. Bezier<sup>2</sup>, G. de La Bourdonnaye<sup>2</sup>, A. Suhovskih<sup>1</sup>, G. Kazanskaya<sup>1</sup>, S. Aidagulova<sup>1</sup>, E. Grigorieva<sup>1</sup>; <sup>1</sup>RU, <sup>2</sup>FR
- 13:05 - 13:05 44P - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro  
D. Albert Bellver, R. Gil-Benso, A. Martínez, T. San-Miguel, L. Muñoz-Hidalgo, A. Carratalá, D. Gozalbo, C. López-Ginés, M. Cerdá-Nicolás, M.L. Gil, J. Megías; ES
- 13:05 - 13:05 45P - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients  
Z. Min, F. Yibo, C. Xiaofang, H. Kezuo, Q. Xiujuan; CN
- 13:05 - 13:05 46P - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?  
F. Kohutek, B. Bystricky, M. Kohutekova; SK
- 13:05 - 13:05 47P - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)  
S. Wanandi, G. Wideani, M. Zainuri, R. Putri, E. Bachtiar, S. Jusman; ID
- 13:05 - 13:05 48P - Estrogen-related receptor  $\alpha$  as a potential molecular target for endometrial cancer therapy  
T. KOKABU, T. Mori, H. Matsushima, Y. Tarumi, K. Yoriki, H. Kuroboshi, M. Sawada, S. Umemura, J. Kitawaki; JP
- 13:05 - 13:05 49P - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies  
J. Gaudreault<sup>1</sup>, A. Schmidt<sup>1</sup>, P. Altevogt<sup>2</sup>, G. Spohn<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>DE
- 13:05 - 13:05 451P - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma  
A. Jouinot<sup>1</sup>, B. Royer<sup>1</sup>, S. Moeung<sup>1</sup>, E. Chatelut<sup>1</sup>, A. Bellesoeur<sup>2</sup>, G. Assié<sup>1</sup>, A. Thomas-Schoemann<sup>1</sup>, J. Bertherat<sup>1</sup>, F. Goldwasser<sup>2</sup>, B. Blanchet<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 14/FR
- 13:05 - 13:05 463P - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study  
J.M. O'Connor<sup>1</sup>, M. Ducreux<sup>2</sup>, L.N. Petersen<sup>3</sup>, L. Öhler<sup>4</sup>, F. Bergamo<sup>5</sup>, J.-P. Metges<sup>2</sup>, J.W. de Groot<sup>6</sup>, J.-Y. Wang<sup>7</sup>, B. García Paredes<sup>8</sup>, E. Dochy<sup>9</sup>, S. Fiala-Buskies<sup>10</sup>, A. Cervantes<sup>8</sup>, A. Falcone<sup>5</sup>; <sup>1</sup>AR, <sup>2</sup>FR, <sup>3</sup>DK, <sup>4</sup>AT, <sup>5</sup>IT, <sup>6</sup>NL, <sup>7</sup>TW, <sup>8</sup>ES, <sup>9</sup>US, <sup>10</sup>DE

- 13:05 - 13:05 464P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study  
J. Taieb<sup>1</sup>, A. Falcone<sup>2</sup>, S. Lonardi<sup>2</sup>, T. Price<sup>3</sup>, J.-B. Bachet<sup>4</sup>, L. Wyrwicz<sup>5</sup>, F. Ciardiello<sup>2</sup>, M. Becquart<sup>1</sup>, N. Mounedji<sup>1</sup>, E. van Cutsem<sup>6</sup>; <sup>1</sup>FR, <sup>2</sup>IT, <sup>3</sup>SA/AU, <sup>4</sup>CEDEX 13/FR, <sup>5</sup>PL, <sup>6</sup>BE
- 13:05 - 13:05 465P - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study  
T. Kawakami<sup>1</sup>, K. Yamazaki<sup>2</sup>, E. Oki<sup>3</sup>, M. Shimokawa<sup>3</sup>, N. Takahashi<sup>1</sup>, M. Yokota<sup>1</sup>, S. Tokunaga<sup>1</sup>, T. Esaki<sup>1</sup>, M. Gamoh<sup>4</sup>, A. Maeda<sup>1</sup>, Y. Tsuji<sup>5</sup>, A. Sakai<sup>1</sup>, K. Hatanaka<sup>1</sup>, Y. Shimada<sup>1</sup>, M. Shiozawa<sup>1</sup>, Y. Komatsu<sup>1</sup>, H. Okuda<sup>1</sup>, M. Ohue<sup>1</sup>, Y. Maehara<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/JP, <sup>3</sup>Fukuoka/JP, <sup>4</sup>Miyagi/JP, <sup>5</sup>Hokkaido/JP
- 13:05 - 13:05 466P - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD  
T. Aparicio<sup>1</sup>, A. Darut Jouve<sup>1</sup>, F. Khemissa<sup>1</sup>, C. Montérymard<sup>1</sup>, P. Artru<sup>2</sup>, L. Cany<sup>1</sup>, O. Romano<sup>3</sup>, B. Valenza<sup>4</sup>, C. Le Foll<sup>1</sup>, C. Delbaldo<sup>1</sup>, C. Falandry<sup>3</sup>, M. Duluc<sup>5</sup>, Y. Rinaldi<sup>1</sup>, J.L. Legoux<sup>1</sup>, M. Ben Abdelghani<sup>1</sup>, E. Assenat<sup>1</sup>, M. Dhooge<sup>1</sup>, D. Smith<sup>1</sup>, G. Des Guetz<sup>3</sup>, C. Lepage<sup>4</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 8/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>Cedex/FR, <sup>5</sup>CEDEX 5/FR
- 13:05 - 13:05 467P - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer  
T. Masuishi<sup>1</sup>, T. Suzuki<sup>2</sup>, Y. Sukawa<sup>2</sup>, C. Imamura<sup>2</sup>, H. Satake<sup>3</sup>, Y. Kumezawa<sup>2</sup>, S. Funakoshi<sup>2</sup>, M. Kotaka<sup>3</sup>, Y. Horie<sup>2</sup>, S. Kawai<sup>2</sup>, H. Okuda<sup>2</sup>, T. Terazawa<sup>4</sup>, C. Kondoh<sup>2</sup>, K. Kato<sup>2</sup>, K. Yoshimura<sup>5</sup>, H. Ishikawa<sup>2</sup>, Y. Hamamoto<sup>2</sup>, N. Boku<sup>6</sup>, T. Kanai<sup>2</sup>, H. Takaishi<sup>2</sup>; <sup>1</sup>Aichi/JP, <sup>2</sup>JP, <sup>3</sup>Hyogo/JP, <sup>4</sup>Osaka/JP, <sup>5</sup>Ishikawa/JP, <sup>6</sup>Kanagawa/JP
- 13:05 - 13:05 468P - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis  
K. Kopeckova<sup>1</sup>, R. Chloupkova<sup>2</sup>, B. Melichar<sup>2</sup>, Z. Linke<sup>2</sup>, L. Petruzela<sup>3</sup>, J. Finek<sup>4</sup>, O. Fiala<sup>4</sup>, J. Tomasek<sup>2</sup>, I. Kiss<sup>5</sup>, J. Prausova<sup>1</sup>, T. Buchler<sup>6</sup>; <sup>1</sup>5/CZ, <sup>2</sup>CZ, <sup>3</sup>2/CZ, <sup>4</sup>Plzen/CZ, <sup>5</sup>South Moravian/CZ, <sup>6</sup>4/CZ
- 13:05 - 13:05 469P - The Combination of TAS-102 and Bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)  
H. Kamiyama<sup>1</sup>, Y. Yoshida<sup>1</sup>, H. Yoshida<sup>1</sup>, C. Kosugi<sup>2</sup>, K. Ishibashi<sup>1</sup>, K. Ihara<sup>1</sup>, M. Takahashi<sup>1</sup>, H. Kuramochi<sup>1</sup>, A. Fukazawa<sup>1</sup>, H. Sonoda<sup>3</sup>, K. Yoshimatsu<sup>1</sup>, A. Matsuda<sup>2</sup>, S. Yamaguchi<sup>1</sup>, H. Ishida<sup>1</sup>, S. Hasegawa<sup>1</sup>, T. Yamada<sup>1</sup>, K. Sakamoto<sup>1</sup>, K. Koda<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP, <sup>3</sup>Higashiyama-ku/JP
- 13:05 - 13:05 470P - Safety run-in evaluation of the phase I trial of trifluridine/tipiracil (FTD/TPI) in combination with oxaliplatin and a monoclonal antibody (bevacizumab or nivolumab) in patients (pts) with metastatic colorectal cancer (mCRC)  
A. Calvo Ferrandiz<sup>1</sup>, L. Dahan<sup>2</sup>, A. Hollebecque<sup>2</sup>, G. Prager<sup>3</sup>, T. Andre<sup>2</sup>, G. Argiles Martinez<sup>1</sup>, R. Bordonaro<sup>4</sup>, A. Stein<sup>5</sup>, G. Tortora<sup>4</sup>, C. Leger<sup>2</sup>, N. Amella<sup>6</sup>, J. Taberno<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>FR, <sup>3</sup>AT, <sup>4</sup>IT, <sup>5</sup>DE, <sup>6</sup>CEDEX/FR

- 13:05 - 13:05 471P - A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study  
M. Suenaga, T. Wakatsuki, M. Ogura, T. Ichimura, E. Shinozaki, I. Nakayama, H. Osumi, Y. Ota, K. Chin, T. Mashima, H. Seimiya, D. Takahari, K. Yamaguchi; JP
- 13:05 - 13:05 472P - Sidedness of the Primary Tumor on the Effect of TAS-102 for Refractory metastatic colorectal cancer  
S. Ueda<sup>1</sup>, Y. Tsuboguchi<sup>1</sup>, Y. Nakatani<sup>1</sup>, A. Tsuya<sup>1</sup>, S.-I. Nishina<sup>1</sup>, K. Akiyoshi<sup>1</sup>, S. Okazaki<sup>2</sup>, S. Tokunaga<sup>1</sup>, H. Daga<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Fushimi-ku/JP
- 13:05 - 13:05 473P - Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib  
F. de Man, K. Husaarts, M. de With, E. Oomen-De Hoop, H. van Halteren, N. van der Burg-De Graauw, F. Eskens, T. van Gelder, R. van Leeuwen, R. Mathijssen; NL
- 13:05 - 13:05 474P - A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.  
T. Seufferlein<sup>1</sup>, L. Lausser<sup>1</sup>, A. Stein<sup>1</sup>, G. Prager<sup>2</sup>, S. Kasper<sup>1</sup>, M. Niedermeier<sup>1</sup>, L. Müller<sup>1</sup>, S. Kubicka<sup>1</sup>, A.-O. König<sup>1</sup>, P. Büchner-Stedel<sup>1</sup>, K. Wille<sup>1</sup>, L. Perkhofer<sup>1</sup>, A. Hann<sup>1</sup>, A. Berger<sup>1</sup>, D. Arnold<sup>1</sup>, H. Kestler<sup>1</sup>, T. Ettrich<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>AT
- 13:05 - 13:05 475P - Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer  
M. Nakamura<sup>1</sup>, A. Takashima<sup>1</sup>, T. Denda<sup>2</sup>, M. Gamoh<sup>3</sup>, I. Iwanaga<sup>4</sup>, Y. Komatsu<sup>5</sup>, M. Takahashi<sup>1</sup>, H. Ohori<sup>3</sup>, T. Sekikawa<sup>1</sup>, M. Tsuda<sup>1</sup>, Y. Kobayashi<sup>5</sup>, Y. Miyamoto<sup>1</sup>, M. Kotake<sup>1</sup>, C. Ishioka<sup>3</sup>, K. Shimada<sup>1</sup>, A. Sato<sup>1</sup>, S. Yuki<sup>5</sup>, S. Morita<sup>1</sup>, S. Takahashi<sup>3</sup>, T. Yamaguchi<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP, <sup>3</sup>Miyagi/JP, <sup>4</sup>Hokkaido Prefecture/JP, <sup>5</sup>Hokkaido/JP
- 13:05 - 13:05 476P - Aflibercept in combination with Irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients : a phase II multicentric study.  
A. Lapeyre-Prost<sup>1</sup>, S. Pernot<sup>1</sup>, J. Sigrand<sup>1</sup>, F. Mary<sup>2</sup>, K. Le Malicot<sup>1</sup>, T. Aparicio<sup>1</sup>, L. Dahan<sup>1</sup>, F.-X. Caroli-Bosc<sup>1</sup>, T. Lecomte<sup>1</sup>, S. Racine Doat<sup>3</sup>, L. Marthey<sup>1</sup>, J. Desrame<sup>4</sup>, C. Lepage<sup>5</sup>, J. Taieb<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 13/FR, <sup>4</sup>CEDEX 8/FR, <sup>5</sup>Cedex/FR
- 13:05 - 13:05 477P - Folfiri-Aflibercept vs Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.  
A. Ottaiano, M. Capozzi, C. De Divitiis, A. Cassata, A. De Stefano, S. Tafuto, A. Avallone, G. Nasti; IT
- 13:05 - 13:05 478P - In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?  
E. Mata Velasco, E. González-Flores, I. Juez Martel, V. Alonso, P. Iranzo Gomez, N. Martinez Lago, C. Lopez, J. Cabrera Romero, M.J. Safont Aguilera, A. Ruiz Casado, M. Salgado Fernandez, B. González Astorga, P. Escudero, F. Rivera Herrero, C. Pericay Pijaume, R. Vera; ES
- 13:05 - 13:05 479P - A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer. The AIRS study

M. Honda<sup>1</sup>, C. Matsuda<sup>1</sup>, C. Tanaka<sup>1</sup>, K. Kondo<sup>2</sup>, T. Takahashi<sup>1</sup>, C. Kosugi<sup>3</sup>, Y. Tokunaga<sup>1</sup>, H. Takemoto<sup>1</sup>, H. Kim<sup>1</sup>, J. Sakamoto<sup>4</sup>, K. Oba<sup>1</sup>, H. Mishima<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Aichi/JP, <sup>3</sup>Chiba/JP, <sup>4</sup>Gifu/JP

- 13:05 - 13:05 480P - The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study  
T. Ogata<sup>1</sup>, H. Satake<sup>2</sup>, M. Ogata<sup>1</sup>, Y. Hatachi<sup>1</sup>, M. Hamada<sup>1</sup>, H. Yasui<sup>3</sup>; <sup>1</sup>JP, <sup>2</sup>Hyogo/JP, <sup>3</sup>Fushimi-ku/JP
- 13:05 - 13:05 481P - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial  
H. Osawa<sup>1</sup>, E. Shinozaki<sup>1</sup>, M. Nakamura<sup>1</sup>, Y. Ohhara<sup>1</sup>, Y. Shindo<sup>1</sup>, M. Shiozawa<sup>1</sup>, H. Uetake<sup>1</sup>, H. Matsumoto<sup>1</sup>, N. Ureshino<sup>1</sup>, H. Satake<sup>2</sup>, T. Kobayashi<sup>1</sup>, T. Suto<sup>1</sup>, S. Kitano<sup>1</sup>, Y. Ohashi<sup>1</sup>, K. Uemura<sup>1</sup>, K. Yamaguchi<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hyogo/JP
- 13:05 - 13:05 482P - RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer  
T. Rich<sup>1</sup>, K. Clifton<sup>1</sup>, A. Grothey<sup>2</sup>, A. Hendifar<sup>3</sup>, D. Henry<sup>1</sup>, Y. Kagawa<sup>4</sup>, Y. Nakamura<sup>5</sup>, W. Okamoto<sup>4</sup>, B. Tan<sup>1</sup>, G. Sherrill<sup>1</sup>, T. Yoshino<sup>4</sup>, V. Raymond<sup>1</sup>, Y. Shiotsu<sup>3</sup>, R. Lanman<sup>1</sup>, V. Morris<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MN/US, <sup>3</sup>CA/US, <sup>4</sup>JP, <sup>5</sup>Chiba/JP
- 13:05 - 13:05 483P - A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3  
Y. Sunakawa<sup>1</sup>, S. Stintzing<sup>2</sup>, S. Cao<sup>3</sup>, J. Luecke<sup>4</sup>, D. Thompson<sup>4</sup>, M. Moran<sup>3</sup>, S. Astrow<sup>3</sup>, J. Hsiang<sup>3</sup>, C. Stephens<sup>3</sup>, W. Zhang<sup>3</sup>, A. Tsuji<sup>1</sup>, T. Takahashi<sup>1</sup>, T. Denda<sup>5</sup>, K. Shimada<sup>1</sup>, M. Kochi<sup>1</sup>, M. Takeuchi<sup>1</sup>, M. Fujii<sup>1</sup>, W. Ichikawa<sup>1</sup>, V. Heinemann<sup>2</sup>, H.-J. Lenz<sup>3</sup>; <sup>1</sup>JP, <sup>2</sup>DE, <sup>3</sup>CA/US, <sup>4</sup>AZ/US, <sup>5</sup>Chiba/JP
- 13:05 - 13:05 484P - Retrospective RAS Analysis of the EPIC Trial: Cetuximab Plus Irinotecan vs Irinotecan in Patients (pts) With Second-Line Metastatic Colorectal Cancer (mCRC)  
A. Sobrero<sup>1</sup>, H.-J. Lenz<sup>2</sup>, C. Eng<sup>3</sup>, W. Scheithauer<sup>4</sup>, G. Middleton<sup>5</sup>, W. Chen<sup>6</sup>, R. Esser<sup>7</sup>, J. Nippgen<sup>7</sup>, H. Burris<sup>8</sup>; <sup>1</sup>IT, <sup>2</sup>CA/US, <sup>3</sup>TX/US, <sup>4</sup>AT, <sup>5</sup>GB, <sup>6</sup>CN, <sup>7</sup>DE, <sup>8</sup>TN/US
- 13:05 - 13:05 485P - Withholding Anti-EGFR: ImpacT on Outcome of RAS wild-type metastatic Colorectal Tumors (WAIT OR ACT): a multicentric AGEO study  
L.-J. Palmieri<sup>1</sup>, L. Mineur<sup>2</sup>, D. Tougeron<sup>3</sup>, B. Rousseau<sup>3</sup>, V. Granger<sup>1</sup>, J.-M. Gornet<sup>4</sup>, D. Smith<sup>1</sup>, A. Lievre<sup>1</sup>, M.P. Galais<sup>5</sup>, S. Racine Doat<sup>6</sup>, S. Pernot<sup>1</sup>, A.L. Bignon Bretagne<sup>7</sup>, J.-P. Metges<sup>8</sup>, N. Baba-Hamed<sup>1</sup>, M. Hassine<sup>1</sup>, S. Obled<sup>1</sup>, C. Vitellius<sup>7</sup>, O. Bouche<sup>1</sup>, D. Vernerey<sup>1</sup>, R. Coriat<sup>9</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 2/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 10/FR, <sup>5</sup>CEDEX 5/FR, <sup>6</sup>CEDEX 13/FR, <sup>7</sup>CEDEX 9/FR, <sup>8</sup>Cedex 2/FR, <sup>9</sup>CEDEX 14/FR
- 13:05 - 13:05 486P - Prospective biomarker study in advanced RAS wild-type colorectal cancer. POSIBA trial.  
X. García Albéniz<sup>1</sup>, V. Alonso<sup>2</sup>, P. Escudero<sup>2</sup>, M. Méndez<sup>2</sup>, J. Gallego Plazas<sup>3</sup>, J.R. Rodríguez<sup>2</sup>, A. Salud Salvia<sup>2</sup>, J. Fernández-Plana<sup>2</sup>, H. Manzano Alemany<sup>2</sup>, M. Zanui<sup>2</sup>, E. Falcó<sup>2</sup>, J. Feliu Battle<sup>2</sup>, M. Gil-Raga<sup>2</sup>, C. Fernández-Martos<sup>2</sup>, U. Bohn Sarmiento<sup>4</sup>, M.C. Alonso López<sup>2</sup>, V. Calderero Aragón<sup>2</sup>, F. Rojo<sup>2</sup>, M. Cuatrecasas<sup>2</sup>, J. Maurel<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>ES, <sup>3</sup>Alicante/ES, <sup>4</sup>Canary Island/ES

- 13:05 - 13:05 487P - Patient selection for targeting integrin with abtuzumab in patients with metastatic colorectal cancer (mCRC). A retrospective analysis of the randomized phase I/II Poseidon study.  
R. Laeufle<sup>1</sup>, D. Arnold<sup>2</sup>, S. Kopetz<sup>3</sup>, J. Straub<sup>2</sup>, R. Bruns<sup>2</sup>, G. Massimini<sup>2</sup>, R. Debenedetto<sup>4</sup>, R. Linke<sup>1</sup>, E. Elez Fernandez<sup>5</sup>, J. Taberero<sup>5</sup>; <sup>1</sup>CA/US, <sup>2</sup>DE, <sup>3</sup>TX/US, <sup>4</sup>US, <sup>5</sup>ES
- 13:05 - 13:05 488P - Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial.  
Y. Emi<sup>1</sup>, T. Yamanaka<sup>1</sup>, K. Muro<sup>2</sup>, H. Uetake<sup>1</sup>, E. Oki<sup>3</sup>, T. Takahashi<sup>1</sup>, Y. Katayose<sup>4</sup>, K. Yoshida<sup>1</sup>, M. Sakamoto<sup>1</sup>, S. Aishima<sup>1</sup>, K. Ishida<sup>1</sup>, J. Imura<sup>1</sup>, M. Unno<sup>4</sup>, I. Hyodo<sup>5</sup>, N. Tomita<sup>6</sup>, K. Sugihara<sup>1</sup>, Y. Maehara<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Aichi/JP, <sup>3</sup>Fukuoka/JP, <sup>4</sup>Miyagi/JP, <sup>5</sup>Ibaraki/JP, <sup>6</sup>Hyogo/JP
- 13:05 - 13:05 489P - Verification of guideline conform mCRC treatment with EGFR inhibitors with real-world evidence data from EU5 countries  
L. Hoyer, N. Schmidt; DE
- 13:05 - 13:05 490P - Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.  
G. Bruera, S. Massacese, F. Pepe, U. Malapelle, A. Dal Mas, E. Ciacco, G. Calvisi, G. Troncone, M. Simmaco, E. Ricevuto; IT
- 13:05 - 13:05 491P - Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: a retrospective registry-based analysis  
T. Buchler<sup>1</sup>, O. Fiala<sup>2</sup>, V. Veskrnova<sup>3</sup>, R. Chloupkova<sup>3</sup>, A. Poprach<sup>4</sup>, I. Kiss<sup>4</sup>, K. Kopeckova<sup>5</sup>, L. Dusek<sup>3</sup>, L. Slavicek<sup>6</sup>, M. Kohoutek<sup>7</sup>, J. Finek<sup>2</sup>, M. Svoboda<sup>4</sup>, J. Dvorak<sup>1</sup>, L. Petruzelka<sup>8</sup>, B. Melichar<sup>3</sup>; <sup>1</sup>4/CZ, <sup>2</sup>Plzen/CZ, <sup>3</sup>CZ, <sup>4</sup>South Moravian/CZ, <sup>5</sup>5/CZ, <sup>6</sup>Vysocina/CZ, <sup>7</sup>Zlin/CZ, <sup>8</sup>2/CZ
- 13:05 - 13:05 492P - A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)  
Y. NISHIOKA, K. Hasegawa, A. Saiura, M. Oba, J. Yamamoto, Y. Nomura, T. Takayama, Y. Hashiguchi, M. Shibasaki, H. Sakamoto, S. Yamagata, N. Aoyanagi, H. Kaneko, H. Koyama, S. Miyagawa, Y. Mise, E. Shinozaki, S. Yoshida, H. Nozawa, N. Kokudo; JP
- 13:05 - 13:05 493P - Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer  
E. Oki<sup>1</sup>, H. Samura<sup>1</sup>, H. Okumura<sup>1</sup>, T. Ohchi<sup>1</sup>, H. Orita<sup>1</sup>, K. Kobayashi<sup>1</sup>, T. Kinjo<sup>1</sup>, S. Mori<sup>1</sup>, T. Touyama<sup>1</sup>, K. Ohgaki<sup>1</sup>, H. Kawanaka<sup>1</sup>, A. Makiyama<sup>2</sup>, N. Ureshino<sup>1</sup>, M. Kotaka<sup>3</sup>, T. Shimose<sup>1</sup>, H. Saeki<sup>1</sup>, T. Nishimaki<sup>1</sup>, H. Baba<sup>1</sup>, Y. Maehara<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Fukuoka/JP, <sup>3</sup>Hyogo/JP
- 13:05 - 13:05 494P - A multi-institutional randomized phase II study on the timing of Oxaliplatin plus 5-Fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR Study.  
P. Kavan, I. Barrera, L. Azoulay, A.-G. Martin, C. Vasilevsky, M. Boutros, E. Ferland, G. Batist, T. Vuong; QC/CA
- 13:05 - 13:05 495P - Tumor Regression Grading After Preoperative Hyperfractionated Radiotherapy/Chemoradiotherapy for Locally Advanced Rectal Cancers: A Phase III Clinical Study  
A. IDASIAK, K. Galwas-Kliber, K. Behrendt, I. Wziętek, M. Zeman, E. Stobiecka, E. Chmielik, T. Dworzecki, R. Suwiński; PL

- 13:05 - 13:05 496P - Short-Term radiotherapy plus chemotherapy versus Long-term chemoradiotherapy in Locally Advanced Rectal cancer (STELLAR): a planned interim analysis  
J. Jin, Y. Tang, S. Liu, Y. Zhu, W. Wang, G. Li, X. Wang, J. Wang, J. Yang, S. Li, N. Li, W. Liu, Y. Li, Y. Chi, A. Zhou, J. Huang, X. Wang, L. Jiang, J. Jiang, S. Zou; CN
- 13:05 - 13:05 497P - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Analysis from two prospective trials  
J. Zhang, Y. Deng, Z. Wu, H. Hu, Y. Cai, J. Ling; CN
- 13:05 - 13:05 498P - Phase 1/2 study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3).  
A. Budillon, P. Delrio, B. Pecori, F. Tatangelo, E. Di Gennaro, C. Romano, V. D'Angelo, P. Marone, C. Granata, E. Cavalacanti, A. De Stefano, U. Pace, F. Bianco, A. Petrillo, S. Lastoria, G. Botti, P. Muto, F. Perrone, M.C. Piccirillo, A. Avallone; IT
- 13:05 - 13:05 499P - A classifier of 53BP1, immune score and texture analysis of MRI images can predict pathological response to chemoradiotherapy in locally advanced rectal cancer  
H. Ma, J. Yao, A. Huang, Y. Xiao, L. Fan; CN
- 13:05 - 13:05 500P - Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy  
A. Cercek<sup>1</sup>, G. Dos Santos Fernandes<sup>1</sup>, C. Roxburgh<sup>1</sup>, S. Ng<sup>1</sup>, R. Yaeger<sup>1</sup>, N. Segal<sup>1</sup>, K. Ganesh<sup>1</sup>, D. Reidy<sup>1</sup>, J.J. Smith<sup>1</sup>, G. Nash<sup>1</sup>, J. Guillem<sup>1</sup>, P. Paty<sup>1</sup>, J. Shia<sup>2</sup>, J. Garcia-Aguilar<sup>1</sup>, L. Diaz<sup>1</sup>, C. Crane<sup>1</sup>, K. Goodman<sup>1</sup>, L. Saltz<sup>1</sup>, M. Weiser<sup>1</sup>, Z. Stadler<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NY/US
- 13:05 - 13:05 501P - Outcomes of Chemoradiotherapy plus Local Excision in Patients with Clinical T1 or T2, N0 Rectal Cancer  
T. Suzuki<sup>1</sup>, S. Sadahiro<sup>2</sup>, T. Ogimi<sup>2</sup>, H. Miyakita<sup>2</sup>, G. Saito<sup>2</sup>, K. Okada<sup>2</sup>, A. Tanaka<sup>2</sup>; <sup>1</sup>Kanagawa/JP, <sup>2</sup>JP
- 13:05 - 13:05 502P - Comparison of Immune Microenvironment between Different Neoadjuvant Radiotherapy Regimens for Rectal Cancer  
J. Wu, Q. Peng, J. Li, L. Tang, Y. Huang, X. Zhang; CN
- 13:05 - 13:05 503P - Prognostic factors of chemo-radiotherapy efficacy in patients with locally-advanced rectal cancer  
M. Fedyanin<sup>1</sup>, A. Tryakin<sup>1</sup>, I. Pokataev<sup>1</sup>, A. Bulanov<sup>2</sup>, O. Sekhina<sup>1</sup>, D. Chekini<sup>1</sup>, S. Gordeev<sup>1</sup>, V. Aliev<sup>1</sup>, D. Kuzmichev<sup>1</sup>, Z. Mamedli<sup>1</sup>, Y. Barsukov<sup>1</sup>, V. Glebovskaya<sup>1</sup>, S. Tkachev<sup>1</sup>, M. Chernykh<sup>1</sup>, N. Kozlov<sup>1</sup>, S. Tjulandin<sup>1</sup>; <sup>1</sup>RU, <sup>2</sup>IR
- 13:05 - 13:05 504P - Association of Systemic and Local Inflammation with Prognosis in Rectal Cancer Treated with Neoadjuvant Radiotherapy  
J. Li, X. Zhang, Y. Huang, L. Tang, Q. Peng, J. Wu; CN
- 13:05 - 13:05 505P - Early prediction of histopathological response by PET/CT after two weeks of neoadjuvant chemoradiotherapy for rectal cancer: wishful thinking or reality?  
Y. Kundel, G. Natalia, H. Berenshtain, J. Prus, B. Brenner; IL
- 13:05 - 13:05 506P - Association between obesity and efficacy of chemoradiotherapy in rectal cancer patients

C. Diaz Romero, R. Calderillo, M. Herrera-Martínez, R. Erika, J.M. Flores Castro; MX

- 13:05 - 13:05 507P - Treatment Outcomes of Patients with Localized Anal Squamous Cell Carcinoma and HIV Infection: Systematic Review and Meta-Analysis  
M. Camandaroba, R. Riechelmann, V. Silva, C. Mello, R. Araujo; BR
- 13:05 - 13:05 508P - p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal – A single center retrospective analysis in Japan  
R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi; JP
- 13:05 - 13:05 509P - Factors influencing conversion to resectability and survival after resection of metastases in RAS WT metastatic colorectal cancer (mCRC): a FIRE-3 analysis  
D. Modest<sup>1</sup>, V. Heinemann<sup>1</sup>, G. Folprecht<sup>1</sup>, T. Denecke<sup>1</sup>, J. Pratschke<sup>1</sup>, H. Lang<sup>1</sup>, M. Bemelmans<sup>2</sup>, T. Becker<sup>1</sup>, M. Rentsch<sup>1</sup>, D. Seehofer<sup>1</sup>, C. Bruns<sup>1</sup>, B. Gebauer<sup>1</sup>, S. Held<sup>1</sup>, U. Neumann<sup>1</sup>, I. Ricard<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>NL
- 13:05 - 13:05 510P - Targeted therapies in conversion therapy in mCRC: A systematic review and meta-analysis  
B. Xing<sup>1</sup>, B. Cui<sup>1</sup>, Z. Gu<sup>2</sup>, H. Peng<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>DE
- 13:05 - 13:05 511P - Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM): a post hoc analysis of the WJOG4407G phase III study  
A. Hosokawa<sup>1</sup>, K. Yamazaki<sup>2</sup>, C. Matsuda<sup>1</sup>, S. Ueda<sup>1</sup>, H. Fujii<sup>1</sup>, E. Baba<sup>1</sup>, S. Okamura<sup>1</sup>, M. Tsuda<sup>1</sup>, T. Tamura<sup>1</sup>, K. Shinozaki<sup>1</sup>, T. Tsushima<sup>2</sup>, T. Tsuda<sup>1</sup>, T. Shirakawa<sup>1</sup>, H. Yamashita<sup>1</sup>, S. Morita<sup>1</sup>, K. Muro<sup>3</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/JP, <sup>3</sup>Aichi/JP
- 13:05 - 13:05 512P - KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients  
M. Domenech Viñolas<sup>1</sup>, C. Santos<sup>1</sup>, J. Pérez<sup>1</sup>, M. Varela<sup>1</sup>, M. Martinez Villacampa<sup>1</sup>, A. Teule<sup>1</sup>, J. Ruffinelli Rodriguez<sup>1</sup>, N. Mulet Margalef<sup>1</sup>, G. Soler<sup>1</sup>, A. Ortega<sup>1</sup>, M. Bergamino<sup>2</sup>, X. SanJuan<sup>1</sup>, J. Torras<sup>1</sup>, E. Ramos<sup>1</sup>, R. Salazar<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 13:05 - 13:05 513P - Impact of response to preoperative chemotherapy on the outcome of pulmonary metastasectomy for colorectal cancer: Results of a retrospective multicenter study  
T. Okumura<sup>1</sup>, N. Boku<sup>2</sup>, T. Hishida<sup>1</sup>, Y. Ohde<sup>1</sup>, Y. Sakao<sup>1</sup>, K. Yoshiya<sup>1</sup>, M. Higashiyama<sup>1</sup>, K. Kameyama<sup>1</sup>, H. Adachi<sup>1</sup>, K. Shiomi<sup>1</sup>, M. Kanzaki<sup>1</sup>, M. Yoshimura<sup>1</sup>, M. Matsuura<sup>1</sup>, Y. Hata<sup>1</sup>, F. Chen<sup>1</sup>, K. Yoshida<sup>1</sup>, H. Sasaki<sup>1</sup>, I. Hyodo<sup>3</sup>, K. Mori<sup>1</sup>, H. Kondo<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Kanagawa/JP, <sup>3</sup>Ibaraki/JP
- 13:05 - 13:05 514P - Long-term Outcomes with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis: 10-Year Experience in a Developing Country  
F. Arias, E. Londoño-Schimmer, J. Otero, C.E. Cétaires, G.E. Herrera, M. Mora, P. Rodriguez, M. Mejía, J.D. Guerra, A. Ruiz-Patiño, A. Cardona Zorrilla; CO
- 13:05 - 13:05 515P - Clinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section.

J.J. Garcia-Mosquera<sup>1</sup>, L. Layos Romero<sup>1</sup>, C. Buges<sup>1</sup>, S. España Fernandez<sup>2</sup>, S. Chen<sup>2</sup>, J.M. Velarde<sup>2</sup>, E. Felip<sup>2</sup>, C. Erasan Lecuona<sup>2</sup>, L. Angelats<sup>2</sup>, M. Cucurull Salamero<sup>2</sup>, J.L. Manzano<sup>2</sup>; <sup>1</sup>Barcelona/ES, <sup>2</sup>ES

- 13:05 - 13:05 516P - Simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis  
Y. Xu, CN
- 13:05 - 13:05 517P - Clinical factors are unable to accurately predict the absence of benefit of surgery in patients operated for resection of colorectal liver metastasis  
A. Bohlok, H. Tessely, E. Naets, F. Bouazza, D. Germanova, J.L. Van Laethem, A. Hendlisz, V. Lucidi, V. Donckier; BE
- 13:05 - 13:05 518P - Hepatic arterial infusion (HAI) of oxaliplatin with capecitabine in first line treatment of patients (pts) with liver limited metastases from colorectal cancer (LLmCRC).  
B. Vittrup, H. Nørgaard, M. Bergenfeldt, F.O. Larsen, E. Høgdall, J. Johansen, J. Sidenius Johansen, H. Hermann, D. Nielsen; DK
- 13:05 - 13:05 519P - Microsatellite instability is associated with distinct clinical and molecular characteristics in early colon cancer: Analysis of a molecular registry of the AIO colorectal study group - Colopredict Plus  
A. Reinacher-Schick, H. Juette, S. Noepel-Duenebacke, D. Arnold, N. Basara, H. Boehner, T. Dahm, I. Feder, T. Herzog, W. Hiller, L. Mueller, L. Engel, M. Senkal, C. Teschendorf, G. Trenn, B. Verdoodt, H. Wolters, W. Uhl, A. Tannapfel; DE
- 13:05 - 13:05 520P - Prognostic impact of MSI and 18qLOH in stage II colon cancer: A prospective biomarker study in the SACURA trial  
T. Ishikawa, M. Ishiguro, E. Nakatani, H. Ueno, H. Uetake, K. Murotani, S. Matsui, N. Tomita, Y. Shimada, K. Takahashi, K. Kotake, M. Watanabe, H. Mochizuki, S. Teramukai, K. Sugihara; JP
- 13:05 - 13:05 521P - miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: a retrospective analysis of the PETACC-8 trial.  
Y. Gaston Mathe<sup>1</sup>, S. Martin-Lannerée<sup>1</sup>, C. Vazart<sup>1</sup>, K. Fontaine<sup>1</sup>, C. Mulo<sup>1</sup>, A. Caumont<sup>1</sup>, F. Montestruc<sup>1</sup>, K. Le Malicot<sup>1</sup>, C. Lepage<sup>2</sup>, J. Taieb<sup>1</sup>, P. Laurent-Puig<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>Cedex/FR
- 13:05 - 13:05 522P - Prognostic value of neutrophil-lymphocyte ratio in resected high risk colorectal cancer: an analysis of adjuvant TOSCA trial  
F. Petrelli<sup>1</sup>, G. Rosati<sup>2</sup>, M. Banzi<sup>2</sup>, M.G. Zampino<sup>2</sup>, N. Pella<sup>2</sup>, M. Di Bartolomeo<sup>2</sup>, E. Maiello<sup>2</sup>, P. Bidoli<sup>2</sup>, D. Ferrari<sup>2</sup>, L. Rimassa<sup>2</sup>, R. Labianca<sup>2</sup>, M. Scartozzi<sup>2</sup>, S. Lonardi<sup>2</sup>, S. de Placido<sup>2</sup>, A. Zaniboni<sup>2</sup>, A. Sobrero<sup>2</sup>, L. Frassinetti<sup>3</sup>, N. Silvestris<sup>2</sup>, D. Corsi<sup>2</sup>, F. Galli<sup>2</sup>, S. Barni<sup>2</sup>; <sup>1</sup>(BG)/IT, <sup>2</sup>IT, <sup>3</sup>Forlì-Cesena/IT
- 13:05 - 13:05 523P - Distribution of lymph node metastases can have an impact on survival benefit of oxaliplatin-containing chemotherapy in stage III colon cancer  
Y. Chae, J.G. Kim, J.H. Baek, S.J. Lee, D.W. Baek, B.W. Kang; KR
- 13:05 - 13:05 524P - Implications of Thymidylate Synthase gene polymorphisms, KRAS and BRAF mutations in the survival of patients with colorectal cancer treated with adjuvant chemotherapy  
A. Ntavatzikos, A. Spathis, P. Patapis, G. Peros, I. Panayiotides, I. Papadopoulos, A. Koumariou; GR
- 13:05 - 13:05 525P - Profile of individuals who never undergo colorectal cancer screening



J. Viguier<sup>1</sup>, J.F. Morère<sup>1</sup>, S. Couraud<sup>2</sup>, M. Roupret<sup>1</sup>, C. Touboul<sup>1</sup>, C. Lhomel<sup>1</sup>, L. Greillier<sup>1</sup>, T. de La Motte Rouge<sup>1</sup>, F. Eisinger<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR

- 13:05 - 13:05 526P - Results of the national organised colorectal cancer screening program with FIT in Paris  
A. Pellat<sup>1</sup>, R. Coriat<sup>2</sup>, S. Chaussade<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 14/FR
- 13:05 - 13:05 527P - Screening strategy of Lynch syndrome for Chinese colorectal cancer patients with MLH1-immunoloss  
W. Wang, L. Dong, S. Zou, N. Lu; CN
- 13:05 - 13:05 528P - Early Detection of Colorectal Cancer Using Breath Biomarkers- Preliminary Study  
G. Woodfield, I. Belluomo, H. Panesar, G.P. Lin, P. Boshier, A. Romano, J. Martin, C. Groves, B. Saunders, W. Atkin, G. Hanna; GB
- 13:05 - 13:05 529P - Survival of stage IV colorectal cancer: interaction of cancer location, microsatellite instability and KRAS mutation.  
J. Uhlig<sup>1</sup>, S. Stein<sup>2</sup>, J. Lacy<sup>2</sup>, C. Fuchs<sup>2</sup>, H. Kim<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CT/US
- 13:05 - 13:05 530P - Influence of primary tumour sidedness on survival after upfront primary tumour resection (PTR) in synchronous metastatic colon cancer (mCC)  
K. van Rooijen<sup>1</sup>, S. Kurk<sup>1</sup>, D. van der Kruijssen<sup>1</sup>, S. Elias<sup>1</sup>, A. May<sup>1</sup>, A. Cats<sup>1</sup>, G.-J. Creemers<sup>1</sup>, F. Erdkamp<sup>1</sup>, O. Loosveld<sup>2</sup>, C. Rodenburg<sup>1</sup>, P. Tanis<sup>1</sup>, G. Vink<sup>1</sup>, J. de Wilt<sup>1</sup>, C. Punt<sup>1</sup>, M. Koopman<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>Noord Brabant/NL
- 13:05 - 13:05 531P - The Clinical Features and Genomic Landscape of Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Patients with Colorectal Cancer  
M.-H. Chen, S.-C. Chang, P.-C. Lin, S.-H. Yang, C.-C. Lin, Y.-T. Lan, H.-H. Lin, C.-H. Lin, W.-Y. Liang, W.-S. Chen, J.-K. Jiang, J.-K. Lin; TW
- 13:05 - 13:05 532P - Identification of positively and negatively selected driver gene mutations associated with colorectal cancer with microsatellite instability  
V. Jonchere, L. Marisa, M. Greene, A. Guilloux, A. Collura, A. De Reynies, A. Duval; FR
- 13:05 - 13:05 533P - Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients  
T. Nagasaka, A. Nyuya, H. Tanioka, Y. Katata, M. Yokota, F. Taniguchi, T. Kawai, Y. Mori, K. Shigeyasu, M. Okawaki, M. Yamamura, Y. Umeda, A. Tsuruta, T. Ueno, Y. Yamaguchi; JP
- 13:05 - 13:05 534P - Patterns of Germline and Somatic Mutations in 16 Mismatch Repair associated genes analyzed with Next Generation Sequencing(NGS) in Colorectal Cancer with EMAST(+) and/or MSI-high  
S.-C. Chang, P.-C. Lin, C.-C. Lin, J.-K. Lin, Y.-T. Lan, J.-K. Jiang, S.-H. Yang, C.-H. Lin, W.-S. Chen; TW
- 13:05 - 13:05 535P - Lower Tumor Mutational Burden (TMB) and Hepatic Metastases May Predict for Lack of Response to PD-1 Blockade in MSI-H Metastatic Colorectal Cancer (MCRG)  
I. Amanam<sup>1</sup>, J. Chao<sup>1</sup>, D. Lim<sup>1</sup>, S. Rahmanuddin<sup>1</sup>, A. Schrock<sup>1</sup>, S. Ali<sup>2</sup>, C. Lau<sup>1</sup>, D. Chevalier<sup>1</sup>, E. Harris<sup>1</sup>, J. Saluja<sup>1</sup>, C. Wang<sup>1</sup>, M. Fakh<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>MA/US, <sup>3</sup>CA/US

- 13:05 - 13:05 536P - Comparison of microsatellite status detections in colorectal carcinoma  
M. Chen, L. Yu, B. Liu, X. Qian, M. Yang; CN
- 13:05 - 13:05 537P - Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy  
R. Cohen<sup>1</sup>, E. Hain<sup>1</sup>, O. Buhard<sup>1</sup>, A. Guilloux<sup>1</sup>, A. Bardier<sup>1</sup>, R. Kaci<sup>1</sup>, P. Bertheau<sup>1</sup>, F. Renaud<sup>1</sup>, F. Bibeau<sup>2</sup>, J.-F. Fléjou<sup>1</sup>, T. André<sup>3</sup>, M. Svrcek<sup>1</sup>, A. Duval<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>CEDEX 12/FR
- 13:05 - 13:05 538P - The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection  
S.-H. Cho<sup>1</sup>, H.-J. Shim<sup>2</sup>, J.E. Hwang<sup>2</sup>, W.-K. Bae<sup>2</sup>, I.J. Chung<sup>3</sup>; <sup>1</sup>Jeollanam-do/KR, <sup>2</sup>KR, <sup>3</sup>Jeonnam/KR
- 13:05 - 13:05 539P - Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor-infiltrating immune cell composition  
J. Bertsson, J. Eberhard, B. Nodin, A. Larsson, K. Jirstrom; SE
- 13:05 - 13:05 540P - Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: prognostic role evaluation and cut-off definition  
D. Basile, S. Garattini, G. Pelizzari, F. Cortiula, L. Gerratana, M. Cattaneo, C. Corvaja, A. Parnofiello, V. Andreotti, E. Bertoli, C. Lisanti, D. Iacono, M. Casagrande, G. Cardellino, G. Miolo, N. Pella, G. Aprile, A. Buonadonna, G. Fasola, F. Puglisi; IT
- 13:05 - 13:05 541P - Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis  
H. Osumi, E. Shinozaki, H. Zembutsu, Y. Takeda, T. Wakatsuki, T. Ichimura, Y. Ota, I. Nakayama, M. Ogura, M. Suenaga, D. Takahari, K. Chin, A. Saiura, S. Takahashi, T. Noda, K. Yamaguchi; JP
- 13:05 - 13:05 542P - Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer  
E. van Cutsem<sup>1</sup>, K. Lesniewski-Kmak<sup>2</sup>, M. Saunders<sup>3</sup>, H. Wasan<sup>3</sup>, G. Argiles<sup>4</sup>, C. Borg<sup>5</sup>, G.-J. Creemers<sup>6</sup>, M. Fedyanin<sup>7</sup>, R. Glynne-Jones<sup>8</sup>, P. Pfeiffer<sup>9</sup>, C. Punt<sup>6</sup>, D. Stroyakovskiy<sup>10</sup>, A. Ten Tije<sup>11</sup>, A. van de Wouw<sup>6</sup>, V. Cattan<sup>5</sup>, G. Desachy<sup>5</sup>, N. Amellal<sup>12</sup>, V. Moiseyenko<sup>7</sup>; <sup>1</sup>BE, <sup>2</sup>PL, <sup>3</sup>GB, <sup>4</sup>ES, <sup>5</sup>FR, <sup>6</sup>NL, <sup>7</sup>RU, <sup>8</sup>Middlesex/GB, <sup>9</sup>DK, <sup>10</sup>Krasnogorski District/RU, <sup>11</sup>Noord Brabant/NL, <sup>12</sup>CEDEX/FR
- 13:05 - 13:05 543P - Gene mutation status in circulating tumor DNA (ctDNA) and 1st-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation  
Y. Sunakawa<sup>1</sup>, J. Usher<sup>2</sup>, H. Satake<sup>3</sup>, Y. Jaimes<sup>2</sup>, Y. Miyamoto<sup>1</sup>, M. Nakamura<sup>1</sup>, M. Kataoka<sup>1</sup>, M. Shiozawa<sup>1</sup>, A. Takagane<sup>1</sup>, T. Terazawa<sup>4</sup>, T. Watanabe<sup>1</sup>, K. Ishigure<sup>1</sup>, C. Tanaka<sup>1</sup>, T. Sekikawa<sup>1</sup>, M. Takeuchi<sup>1</sup>, M. Fujii<sup>1</sup>, K. Danenberg<sup>2</sup>, P. Danenberg<sup>2</sup>, H.-J. Lenz<sup>2</sup>, W. Ichikawa<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>CA/US, <sup>3</sup>Hyogo/JP, <sup>4</sup>Osaka/JP
- 13:05 - 13:05 544P - ctDNA assays identify alterations in RAS, EGFR, and cMET that are unique to RAS-WT patients progressing on anti-EGFR therapy  
R. Gupta<sup>1</sup>, D. Chevalier<sup>1</sup>, J. Saluja<sup>1</sup>, C. Lau<sup>1</sup>, C. Wang<sup>2</sup>, M. Fakih<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US

- 13:05 - 13:05 545P - Clinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy. Combined analysis of two prospective clinical trials  
C. Montagut<sup>1</sup>, V. Alonso<sup>1</sup>, P. Escudero<sup>1</sup>, C. Fernández-Martos<sup>1</sup>, A. Salud Salvia<sup>1</sup>, M. Méndez<sup>1</sup>, J. Gallego Plazas<sup>2</sup>, J.R. Rodríguez<sup>1</sup>, M. Martín-Richard<sup>1</sup>, J. Fernández-Plana<sup>1</sup>, J. Aparicio<sup>1</sup>, J. Feliu Battle<sup>1</sup>, X. García de Albéniz<sup>3</sup>, F. Rojo<sup>1</sup>, V. Fernández<sup>1</sup>, B. Claes<sup>4</sup>, G. Maertens<sup>4</sup>, E. Sablon<sup>4</sup>, B. Jacobs<sup>5</sup>, J. Maurel<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Alicante/ES, <sup>3</sup>MA/US, <sup>4</sup>BE, <sup>5</sup>NL
- 13:05 - 13:05 546P - First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts). PERSEIDA study  
P. García Alfonso, M. Valladares-Ayerbes, J. Muñoz Luengo, P. Pimentel, J.M. Viéitez, J.J. Cruz Hernandez, M. Llanos, C. Garcia Girón, A. Salud Salvia, A. Lloansí Vila; ES
- 13:05 - 13:05 547P - Serial monitoring of circulating tumor DNA in patients with metastatic colorectal cancer to predict the therapeutic response  
J. Zhou, C. Bai, Z. Sun, Y. Cheng, N. JIA, Y. Zhou; CN
- 13:05 - 13:05 548P - Cross-Platform Comparison of NGS and MALDI-TOF for Detecting RAS/RAF/PIK3CA Mutations in Circulating Tumor DNA from metastatic Colorectal Cancer Patient Plasma  
L. Liang, B.-L. Wang, Q. Yu, T.-S. Liu, W. GUO; CN
- 13:05 - 13:05 549P - Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: the plasma RAS wild type "window of opportunity"  
P. Gazzaniga, C. Raimondi, F. Urbano, E. Cortesi; IT
- 13:05 - 13:05 550P - Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay  
A. Vivancos, E. Aranda Aguilar, M. Benavides, E. Elez Fernandez, M. Toledano, M. Alvarez, E. Diaz Rubio, A. Gómez-España, V. Garcia-Barberan, M. Chica-Parrao; ES
- 13:05 - 13:05 551P - Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer (LARC) patients using circulating tumor DNA (ctDNA)  
S. Toomey<sup>1</sup>, A. Sartori<sup>2</sup>, D. Irwin<sup>3</sup>, S. Hummel<sup>4</sup>, A. Carr<sup>1</sup>, C.L. Lee<sup>1</sup>, P. Armstrong<sup>1</sup>, A. Farrelly<sup>1</sup>, S. El-Masry<sup>1</sup>, D. McNamara<sup>1</sup>, P. Morris<sup>1</sup>, L. Grogan<sup>1</sup>, O. Breathnach<sup>1</sup>, L. O'Sullivan<sup>1</sup>, S. Bradshaw<sup>1</sup>, A. Rashed<sup>5</sup>, R. Smyth<sup>1</sup>, J. Workman<sup>1</sup>, B. O'Neill<sup>1</sup>, B. Hennessy<sup>1</sup>; <sup>1</sup>IE, <sup>2</sup>DE, <sup>3</sup>QLD/AU, <sup>4</sup>CA/US, <sup>5</sup>Co. Louth/IE
- 13:05 - 13:05 552P - Circulating tumor DNA by next generation sequencing as a prognostic and predictive biomarker in metastatic colorectal cancer  
N. JIA, L. Chang, X. Dou, M. Guan, Y. Shao, N. Li, Y. Cheng, H. Ying, Z. Sun, Y. Zhou, L. Zhao, J. Zhou, C. Bai; CN
- 13:05 - 13:05 553P - Dynamic monitoring of KRAS, NRAS, BRAF and PIK3CA mutations in circulating cell-free DNA for metastatic colorectal cancer patients treated with cetuximab  
L. Liu, Z. Tong, C. Yan, H. Zhang, W. Jiang, Y. Zheng, P. Zhao, W. Fang; CN
- 13:05 - 13:05 554P - KRAS-dependent and independent mechanisms of progressive disease (PD) in colorectal cancer (CRC) patients (pts) with liver metastases (LM) while monitoring on circulating cell free DNA (cfDNA)  
A. Kirov, Z. Mihaylova, V. Petrova, T. Todorov, D. Petkova, A. Garev, A. Todorova-Georgieva; BG

- 13:05 - 13:05 555P - Correlation between ctDNA methylation and CEA in colorectal cancer  
W. Tang, H.-X. An, D. Zhou, L. Chen, M. Cai, F. Ye, Y. Zhang; CN
- 13:05 - 13:05 556P - Cell free DNA and Hepatic Arterial Infusion of oxaliplatin plus systemic capecitabine for patients with colorectal cancer liver metastases.  
A. Boysen, J. Schou, B. Jensen, D. Nielsen, B. Sørensen, J. Johansen, K.-L. Spindler; DK
- 13:05 - 13:05 557P - Metastatic colorectal signet-ring cell carcinoma : clinical, histological and molecular description from an AGEO French multicenter retrospective cohort  
M. ALLART-SAVA<sup>1</sup>, F. Le Roy<sup>1</sup>, S. Kim<sup>2</sup>, D. Sefrioui<sup>1</sup>, C. Mariette<sup>2</sup>, A. Zaanani<sup>1</sup>, B. Rousseau<sup>2</sup>, M. Ben Abdelghani<sup>2</sup>, C. De La Fouchardière<sup>1</sup>, W. Cacheux<sup>1</sup>, R. Legros<sup>1</sup>, S. Louafi<sup>2</sup>, D. Tougeron<sup>2</sup>, N. Fares<sup>1</sup>, G. Roquin<sup>1</sup>, A.L. Bignon Bretagne<sup>3</sup>, M. Mailet<sup>1</sup>, B. Tchoundjeu<sup>1</sup>, A. Pozet<sup>1</sup>, V. Hautefeuille<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR
- 13:05 - 13:05 558P - The combination of trifluridine/tipiracil and oxaliplatin induces immunogenic cell death in microsatellite stable colorectal cancer  
F. Ghiringhelli<sup>1</sup>, E. Limagne<sup>2</sup>, M. Thibaudin<sup>2</sup>, L. Nuttin<sup>2</sup>, A. Spill<sup>2</sup>, V. Derangere<sup>2</sup>, V. Cattan<sup>2</sup>, E. Peranzoni<sup>2</sup>, N. Amellal<sup>3</sup>; <sup>1</sup>Cedex/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR
- 13:05 - 13:05 559P - Distribution of Endocrine Tumor Marker-positive Cells in Adenocarcinoma Tissue Between Right-sided and Left-sided Colon Cancer  
T. Ogimi<sup>1</sup>, S. Sadahiro<sup>2</sup>, H. miyakita<sup>1</sup>, G. Saito<sup>1</sup>, K. Okada<sup>1</sup>, A. Tanaka<sup>1</sup>, T. Suzuki<sup>2</sup>, H. Kajiwara<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Kanagawa/JP
- 13:05 - 13:05 560P - Prospective DPYD testing in colorectal cancer patients in a realworld UK population  
B. Eccles, A. Harle, S. Pullinger, C. Holling, A. Ingram, S. Stark, M. Bunce, G. Melville, J. Gibbins, N. Calcutt, T. Hickish, M. Flubacher, T. Marinaki; GB
- 13:05 - 13:05 561P - Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers  
C. Lunenburg<sup>1</sup>, L. Henricks<sup>1</sup>, E. Dreussi<sup>2</sup>, F. Peters<sup>1</sup>, M. Fiocco<sup>1</sup>, D. Meulendijks<sup>1</sup>, G. Toffoli<sup>2</sup>, H.-J. Guchelaar<sup>1</sup>, J. Swen<sup>1</sup>, E. Cecchin<sup>2</sup>, J. Schellens<sup>1</sup>, H. Gelderblom<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>IT
- 13:05 - 13:05 562P - Determination of DPYD polymorphisms before treatment with chemotherapy with a pyrimidine. Should we continue doing it?  
C. Avila Andrade<sup>1</sup>, A.J. Cunqueiro Tomas<sup>1</sup>, A.B. Fernandez Diaz<sup>1</sup>, M. Meri Abad<sup>1</sup>, L.D. Condori Farfan<sup>1</sup>, I. Shaheen<sup>1</sup>, S. Cervantes Garcia<sup>1</sup>, M.J. Safont Aguilera<sup>1</sup>, V. Iranzo Gonzalez-Cruz<sup>1</sup>, V. Sforza<sup>2</sup>, C. Caballero<sup>1</sup>, M.C. Godes de Bremond<sup>1</sup>, M. Gil<sup>1</sup>, F.D.A. Aparisi Aparisi<sup>1</sup>, A. Blasco Cordellat<sup>1</sup>, A. Berrocal Jaime<sup>1</sup>, I. Ferrer Bolufer<sup>1</sup>, M. Lobo de Mena<sup>1</sup>, G. Marcaida Benito<sup>1</sup>, C. Camps<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>IT
- 13:05 - 13:05 563P - Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer  
T. Yoshino<sup>1</sup>, H. Iwata<sup>2</sup>, K. Tamura<sup>1</sup>, S. Takahashi<sup>1</sup>, C. Redfern<sup>3</sup>, S. Modi<sup>3</sup>, T. Doi<sup>4</sup>, H. Kawakami<sup>1</sup>, H. Taniguchi<sup>2</sup>, A. Takashima<sup>1</sup>, K. Yamaguchi<sup>1</sup>, J. Fisher<sup>3</sup>, B. Li<sup>3</sup>, K. Saito<sup>1</sup>, Y. Fujisaki<sup>1</sup>, M. Sugihara<sup>1</sup>, J. Tsurutani<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Aichi/JP, <sup>3</sup>US, <sup>4</sup>Chiba/JP

- 13:05 - 13:05 564P - TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer – final results from the randomized phase II trial of the AIO  
T. Ettrich, A. Berger, T. Decker, R.D. Hofheinz, V. Heinemann, T. Hoffmann, H. Hebart, T. Herrmann, C.-V. Hannig, P. Büchner-Steudel, H. Bartholomäus, M. Güthle, L. Perkhofer, T. Seufferlein; DE
- 13:05 - 13:05 565P - Dose finding and safety study of Reovirus (Reo) with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final results  
S. Goel<sup>1</sup>, A. Ocean<sup>2</sup>, R. Parakrama<sup>2</sup>, M. Ghalib<sup>2</sup>, I. Chaudhary<sup>2</sup>, U. Shah<sup>2</sup>, M. Coffey<sup>3</sup>, E. Kaledzi<sup>2</sup>, R. Maitra<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NY/US, <sup>3</sup>AB/CA
- 13:05 - 13:05 566P - A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with colorectal cancer and gastric/GEJ cancer  
D.-Y. Oh<sup>1</sup>, K.-W. Lee<sup>2</sup>, S.-W. Han<sup>1</sup>, J.W. Kim<sup>1</sup>, J.-W. Shin<sup>1</sup>, S.-J. Jo<sup>1</sup>, N.H. Kim<sup>1</sup>, A. Woo<sup>1</sup>, J. Won<sup>1</sup>, S. Hahn<sup>1</sup>, H. Lee<sup>1</sup>, W.H. Kim<sup>1</sup>, Y.-J. Bang<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>Gyeonggi-do/KR
- 13:05 - 13:05 567P - Results of a phase I study of andeciximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer  
H.-J. Lenz<sup>1</sup>, H. Park<sup>2</sup>, M. Shah<sup>3</sup>, J. Berlin<sup>4</sup>, D. Bruetman<sup>5</sup>, J. Chaves<sup>6</sup>, M. Gordon<sup>7</sup>, R. Patel<sup>1</sup>, A. Starodub<sup>5</sup>, J. Liu<sup>1</sup>, C. Baker Brachmann<sup>1</sup>, P. Bhargava<sup>1</sup>, Z. Wainberg<sup>1</sup>, J. Bendell<sup>4</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>NY/US, <sup>4</sup>TN/US, <sup>5</sup>IN/US, <sup>6</sup>WA/US, <sup>7</sup>AZ/US
- 13:05 - 13:05 568P - A Phase 2 study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy  
S.-H. Beom<sup>1</sup>, K.-W. Lee<sup>1</sup>, S.-H. Cho<sup>2</sup>, Y.S. Park<sup>1</sup>, T.W. Kim<sup>1</sup>, K.H. Lee<sup>1</sup>, M. Jung<sup>1</sup>, S.J. Shin<sup>1</sup>, J.B. Ahn<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>Jeollanam-do/KR
- 13:05 - 13:05 569P - ISO-CC-005; a phase I/II study of arfolitoxin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer  
G. Carlsson<sup>1</sup>, T.K. Guren<sup>2</sup>, J. Haux<sup>1</sup>, P. Pfeiffer<sup>3</sup>, H. Taflin<sup>1</sup>, D. Mavroudis<sup>4</sup>, V. Georgoulis<sup>4</sup>, C. Papadimitriou<sup>5</sup>, N. Kentepozidis<sup>4</sup>, D. Boumpas<sup>4</sup>, L. Skintemo<sup>1</sup>, K. Ganlöv<sup>1</sup>, B. Gustavsson<sup>1</sup>; <sup>1</sup>SE, <sup>2</sup>NO, <sup>3</sup>DK, <sup>4</sup>GR, <sup>5</sup>Attiki/GR
- 13:05 - 13:05 570P - Detection of frailty in elderly colorectal cancer patients: is G8 a good screening tool?  
J. Ruffinelli Rodriguez<sup>1</sup>, G. Soler<sup>1</sup>, R. Legido<sup>1</sup>, M. Martinez Villacampa<sup>1</sup>, F. Perez<sup>1</sup>, B. Pardo-Burdalo<sup>1</sup>, J. Marín<sup>1</sup>, I. Morilla Ruiz<sup>2</sup>, L. Heras Lopez<sup>1</sup>, S. Vazquez<sup>1</sup>, S. Recalde<sup>1</sup>, M. Plana Serrahima<sup>2</sup>, C. Santos<sup>1</sup>, N. Mulet Margalef<sup>1</sup>, A. Teule<sup>1</sup>, R. Salazar<sup>1</sup>, M. Galan<sup>1</sup>, J. Saldaña<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 13:05 - 13:05 571P - Interim Results from a Real World European Survey on the Unmet Needs of Patients Living with Metastatic Colorectal Cancer (mCRC)  
Z. Maravic<sup>1</sup>, J. Borrás<sup>2</sup>, E. Espin Basany<sup>2</sup>, Á. Petrányi<sup>3</sup>, Z. Kapitány<sup>3</sup>, P. Rakonczai<sup>3</sup>, A. Benedict<sup>3</sup>, N. Muszbek<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>ES, <sup>3</sup>HU
- 13:05 - 13:05 572P - Socioeconomic discrepancies in survival of stage IV colorectal cancer.  
H. Kim<sup>1</sup>, J. Uhlig<sup>1</sup>, S. Stein<sup>2</sup>, L. Jill<sup>2</sup>, C. Fuchs<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CT/US

- 13:05 - 13:05 573P - Influence of not having children on mortality in patients with metastatic (mCRC) colorectal cancer.  
S. Ahmed<sup>1</sup>, T. Baig<sup>1</sup>, A. Zaidi<sup>2</sup>, H. Chalchal<sup>1</sup>, K. Haider<sup>2</sup>, T. Asif<sup>2</sup>, N. Iqbal<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>SK/CA
- 13:05 - 13:05 574P - Interim Quality of Life Results from a Real World European Survey on the Unmet Needs of Patients Living with Metastatic Colorectal Cancer (mCRC)  
Z. Maravic<sup>1</sup>, L. Wyrwicz<sup>2</sup>, B. Karczmarek-Borowska<sup>2</sup>, A. Horvath<sup>3</sup>, A. Ruiz Casado<sup>4</sup>, A. Carrato Mena<sup>4</sup>, N. Muszbek<sup>1</sup>, P. Rakonczal<sup>3</sup>; <sup>1</sup>GB, <sup>2</sup>PL, <sup>3</sup>HU, <sup>4</sup>ES
- 13:05 - 13:05 575P - Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI – Efficacy according to age group ≤65 and >65 years  
R.D. Hofheinz<sup>1</sup>, H.-G. Derigs<sup>1</sup>, G. Piringer<sup>2</sup>, R. von Moos<sup>3</sup>; <sup>1</sup>DE, <sup>2</sup>AT, <sup>3</sup>CH
- 13:05 - 13:05 576P - Inhibitory Effect of a Synthetic Bioresorbable Adhesion Membrane (Seprafilm®) on Small Bowel Obstruction (SBO) in Patients Undergoing Elective Surgery for Colon Cancer :a Randomized Controlled Trial  
G. Saito<sup>1</sup>, S. Sadahiro<sup>2</sup>, H. miyakita<sup>1</sup>, K. Okada<sup>1</sup>, A. Tanaka<sup>1</sup>, T. Suzuki<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Kanagawa/JP
- 13:05 - 13:05 577P - Short- and Long-term Outcomes of High Tie versus Low Tie with Lymph Node Dissection around the Inferior Mesenteric Artery in Sigmoid Colon or Rectal Cancer Surgery  
X. Li, CN
- 13:05 - 13:05 578P - Mesenteric Vs. Antimesenteric Colorectal Cancer. A Single Center Study.  
K.H. Lee, W.R. Kim, J.W. Kim; KR
- 13:05 - 13:05 579P - The SLICE study: the prognostic role of viSceraL fat In metastatic Colorectal canCEr  
D. Basile, C. Lisanti, M. Borghi, M. Bartoletti, L. Gerratana, L. Bortot, G. Pelizzari, C. Corvaja, E. Ongaro, S. Garattini, V. Fanotto, A. Parnofiello, F. Cortiula, M. Cattaneo, V. Andreotti, E. Bertoli, M. Guardascione, G. Miolo, F. Puglisi, A. Buonadonna; IT
- 13:05 - 13:05 580P - Safety and Outcomes of Self-expandable Metal Stents (SEMS) versus Emergency Surgery for Acute Colonic Obstruction in Metastatic Colon Cancer patients treated with Bevacizumab (BV)  
V. Pacheco-Barcia, R. Mondéjar Solís, O. Martínez-Sáez, F. Longo, E. Bermejo, J.A. Moreno, C. Marin, A. Correa, R. maqueda, J. Rogado, A. García de Paredes, E. Rodriguez de Santiago, V. Pachón Olmos, R. Ferreira Monteagudo, M. Rodriguez Garrote, A. Carrato Mena, O. Donnay, E. Martin Perez, C. Santander, R. Colomer Bosch; ES
- 13:05 - 13:05 581P - Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed Pseudomyxoma Peritonei  
A. RAIMONDI, S. Corallo, M. Niger, M. Antista, G. Randon, F. Morano, C. Cremolini, M. Di Bartolomeo, F.G. de Braud, F. Pietrantonio; IT
- 13:05 - 13:05 582P - Utility of Carcinoembryonic Antigen (CEA) in Appendiceal carcinoma  
A. KARIPPOT<sup>1</sup>, S. Groover<sup>2</sup>, J. Ai<sup>1</sup>, S. NAMBIAR<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>OK/US
- 13:05 - 13:05 583P - Thromboembolic risk and survival with Khorana score in resected colorectal cancer patients. Subgroup analysis from the adjuvant TOSCA trial

S. Barni<sup>1</sup>, G. Rosati<sup>1</sup>, V. Zagonel<sup>1</sup>, N. Pella<sup>1</sup>, M. Banzi<sup>1</sup>, M.G. Zampino<sup>1</sup>, M. Di Bartolomeo<sup>1</sup>, L. Rimassa<sup>2</sup>, P. Marchetti<sup>1</sup>, E. Maiello<sup>1</sup>, F. Artioli<sup>1</sup>, D. Ferrari<sup>1</sup>, R. Labianca<sup>1</sup>, P. Bidoli<sup>1</sup>, A. Zaniboni<sup>1</sup>, A. Sobrero<sup>1</sup>, V. Iaffaioli<sup>1</sup>, S. de Placido<sup>1</sup>, L. Frassinetti<sup>3</sup>, F. Galli<sup>1</sup>, F. Petrelli<sup>4</sup>; <sup>1</sup>IT, <sup>2</sup>(MI)/IT, <sup>3</sup>Forli-Cesena/IT, <sup>4</sup>(BG)/IT

- 13:05 - 13:05 584P - The clinical utility of early follow-up computed tomography in patients with stage II-III colorectal cancer receiving oxaliplatin-based chemotherapy  
Y. Lee<sup>1</sup>, S.Y. Kim<sup>2</sup>, J.E. Kim<sup>1</sup>, Y.S. Hong<sup>1</sup>, T.W. Kim<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR
- 13:05 - 13:05 585P - Clinical Benefit of Whole Genome and Transcriptome Analysis (WGTA) in Metastatic Colorectal Cancer (MCRC): Results from the Personalized Oncogenomics Program (POG)  
S. Liu<sup>1</sup>, J. Loree<sup>2</sup>, D. Renouf<sup>1</sup>, M. Jones<sup>3</sup>, S. Yip<sup>3</sup>, M. Marra<sup>3</sup>, S. Jones<sup>3</sup>, J. Nelson<sup>3</sup>, J. Laskin<sup>2</sup>, H. Lim<sup>2</sup>, S. Gill<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>British Columbia/CA, <sup>3</sup>BC/CA
- 13:05 - 13:05 586P - Sequencing of KRAS and NRAS in 1501 colorectal carcinomas reveals significant share of mutations, which are not included in common diagnostic kits  
E. Imyanitov, N. Mitiushkina, E. Kuligina, M. Holmatov, G. Yanus, I. Demidova, T. Kekeeva, M. Gordiev, E. Kharitonova, I. Tsimafeyeu, S. Tjulandin; RU
- 13:05 - 13:05 587P - Patterns of care and of biomolecular characterization of Right, Transverse, and Left Colorectal Cancer from real-life evidence in Asia Pacific and European countries  
E. Mari<sup>1</sup>, S. Mpima<sup>2</sup>, F. Guglielmetti<sup>3</sup>, P. Nasuti<sup>2</sup>; <sup>1</sup>MI/IT, <sup>2</sup>GB, <sup>3</sup>(MI)/IT
- 13:05 - 13:05 588P - The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer  
M. Rimini, C. Bardasi, F. Gelsomino, K. Andrikou, C. Santini, G. Orsi, M. Salati, M.L. Riggi, S. Pipitone, S. Cascinu, A. Spallanzani; IT
- 13:05 - 13:05 589P - The prognostic value of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status in left- and right-sided metastatic colorectal cancer (mCRC): a Belgian population-based study.  
K. Janssens, G. van Camp, K. Op de Beeck, E. Fransen, F. Calay, N. van Damme, M. Peeters; BE
- 13:05 - 13:05 590P - Increase in tumor-infiltrating FoxP3-positive regulatory T cells in left-sided colorectal cancer tissues after preoperative oral uracil and tegafur/leucovorin chemotherapy  
S. Sadahiro<sup>1</sup>, T. Suzuki<sup>1</sup>, A. Tanaka<sup>2</sup>, K. Okada<sup>2</sup>, G. Saito<sup>2</sup>, H. Miyakita<sup>2</sup>, H. Kajiwara<sup>2</sup>, H. Nagase<sup>2</sup>; <sup>1</sup>Kanagawa/JP, <sup>2</sup>JP
- 13:05 - 13:05 591P - Comparing Metastatic (M) Young Onset (YO) Colorectal Cancer (CRC) with Average Onset (AO): Are They Do They Differ Clinical and Genetically?  
G. Dos Santos Fernandes<sup>1</sup>, W. Chatila<sup>2</sup>, R. Yaeger<sup>2</sup>, R. Mendelsohn<sup>2</sup>, Z. Stadler<sup>2</sup>, N. Segal<sup>1</sup>, A. Varghese<sup>1</sup>, D. Reidy<sup>1</sup>, L. Diaz<sup>1</sup>, J. Shia<sup>2</sup>, E. Vakiani<sup>2</sup>, J. Hechtman<sup>2</sup>, N. Schultz<sup>2</sup>, M. Berger<sup>2</sup>, D. Hyman<sup>1</sup>, D. Solit<sup>2</sup>, L. Saltz<sup>1</sup>, J. Garcia Aguilar<sup>2</sup>, A. Cercek<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NY/US
- 13:05 - 13:05 592P - Impact of Charlson comorbidity index on survival of octogenarian patients with colorectal cancer.  
E. Inga Saavedra, J.R. Rodriguez, E. Casaut Lora, A. Gonzalez-Haba, V. Serrano Pecos, M.F. Martinez Barragan, E. Blanco, J. Gomez-Ulla; ES

- 13:05 - 13:05 593P - The SENECA study: prognostic role of Serum biomarkers in Elderly metastatic Colorectal cancer patients.  
C. Lisanti, D. Basile, S. Garattini, G. Pelizzari, A. Parnofiello, F. Cortiula, E. Ongaro, M. Cattaneo, C. Corvaja, V. Andreotti, M. Bartoletti, M. Casagrande, D. Iacono, M. Bonotto, P. Ermacora, N. Pella, A. Buonadonna, F. Puglisi, G. Fasola, G. Miolo; IT
- 13:05 - 13:05 594P - Determinants of oncologist's choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer  
S.K. Garattini, M. Bonotto, L. Porcu, E. Ongaro, D. Basile, F. Cortiula, G. Pelizzari, M. Cattaneo, A. Parnofiello, V. Andreotti, C. Corvaja, G. Cardellino, P. Ermacora, M. Casagrande, D. Iacono, N. Pella, A. Buonadonna, A. Minisini, F. Puglisi, G. Fasola; IT
- 13:05 - 13:05 596P - Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models  
V. Belli<sup>1</sup>, N. Matrone<sup>1</sup>, S. Napolitano<sup>1</sup>, E. Martinelli<sup>1</sup>, M. Castellone<sup>1</sup>, L. Trusolino<sup>2</sup>, E. Giunta<sup>1</sup>, V. De Falco<sup>1</sup>, N. Zanaletti<sup>1</sup>, P.P. Vitiello<sup>1</sup>, D. Ciardiello<sup>1</sup>, M. Terminiello<sup>1</sup>, F. Ciardiello<sup>1</sup>, T. Troiani<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(TO)/IT
- 13:05 - 13:05 597P - Predictive value of in-vitro testing anti-cancer therapy sensitivity on 3D micro-tumors (tumoroids) from patients with metastatic colorectal cancer – a feasibility study  
L.H. Jensen, C. Dam, G. Hagel, C. Hansen, H. Harling, B. Havelund, A. Jakobsen, J. Lindebjerg, S. Rafaelsen, O. Thastrup, T. Hansen; DK
- 13:05 - 13:05 598P - Macrophage Migration Inhibitory Factor Overexpression is a mechanisms of Acquired Resistance to anti-EGFR Inhibitor Cetuximab in Human Colorectal Cancer Cell Line.  
N. Matrone, A. Chambery, R. Russo, P.V. Pedone, V. Belli, S. Napolitano, E. Martinelli, E. Giunta, V. De Falco, N. Zanaletti, P. Vitale, M. Terminiello, C. Cardone, F. Ciardiello, T. Troiani; IT
- 13:05 - 13:05 599P - Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): results of a placebo-controlled, randomized, double-blind phase 2 study  
T. Kato<sup>1</sup>, M. Kotaka<sup>1</sup>, H. Satake<sup>1</sup>, A. Makiyama<sup>2</sup>, Y. Tsuji<sup>3</sup>, K. Shinozaki<sup>4</sup>, T. Fujiwara<sup>4</sup>, T. Mizushima<sup>5</sup>, Y. Harihara<sup>4</sup>, N. Nagata<sup>6</sup>, N. Kurihara<sup>4</sup>, Y. Kagawa<sup>4</sup>, G. Kusakawa<sup>4</sup>, T. Sakai<sup>4</sup>, Y. Uchida<sup>4</sup>, M. Takamoto<sup>4</sup>, S. Asami<sup>4</sup>, M. Ando<sup>4</sup>, Y. Saito<sup>4</sup>, I. Hyodo<sup>7</sup>; <sup>1</sup>Hyogo/JP, <sup>2</sup>Fukuoka/JP, <sup>3</sup>Hokkaido/JP, <sup>4</sup>JP, <sup>5</sup>Osaka/JP, <sup>6</sup>Hukuoka/JP, <sup>7</sup>Ibaraki/JP
- 13:05 - 13:05 600P - Development of a Nomogram for Predicting Survival in Microsatellite Stable Patients with Resected Colorectal Cancer  
Y. Li, J. Peng, T. Hou, H. Han-Zhang, H. Liu, J. Xiang, L. Zhang, X. Ma, D. Huang, S. Cai; CN
- 13:05 - 13:05 601P - Germline mutations in Chinese colorectal cancer patients with mismatch repair deficiency  
Y. Yuan<sup>1</sup>, L. Zhu<sup>2</sup>, D. Xu<sup>1</sup>, C. Liu<sup>2</sup>, X. Mao<sup>2</sup>; <sup>1</sup>Zhejiang/CN, <sup>2</sup>CN
- 13:05 - 13:05 602P - Kynurenine 3-monooxygenase as a potential biomarker for colorectal cancer  
C.-Y. Liu, C.-H. Lee, J.-L. Chen, T.-T. Huang, S.-H. Yang, J.-K. Jiang, W.-S. Chen, K.-D. Lee, H.-W. Teng; TW
- 13:05 - 13:05 603TiP - Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer (ICAR)



J. Souza, R. Araujo, M. Valadão, C. Carrara, M. Barbosa, R. Guimarães, J. Carvalho, G. Kovalski, I. Small, A. Marins, A.P. Victorino, R. Gil, J.P. Jesus, L.H. de Araujo, A. de Melo; BR

- 13:05 - 13:05 604TiP - Phase II study of surgery after S-1 + oxaliplatin +bevacizumab therapy for unresectable rectal cancer by organ-preserved TME  
T. Yoshida, T. Miura, Y. Sakamoto, H. Morohashi, H. Fujita, K. Sato, K. Hakamada; JP
- 13:05 - 13:05 605TiP - Phase II study of resection of primary colorectal cancer and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy  
T. Miura, H. Morohashi, Y. Sakamoto, T. Yoshida, K. Sato, K. Ishido, D. Kudo, N. Kimura, K. Hakamada; JP
- 13:05 - 13:05 606TiP - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G  
Y. Kito<sup>1</sup>, T. Yamada<sup>1</sup>, T. Matsumoto<sup>1</sup>, H. Yasui<sup>2</sup>, K. Murata<sup>1</sup>, A. Makiyama<sup>3</sup>, H. Hara<sup>1</sup>, E. Baba<sup>3</sup>, K. Nishio<sup>1</sup>, K. Yoshimura<sup>4</sup>, S. Hironaka<sup>5</sup>, K. Muro<sup>6</sup>, K. Yamazaki<sup>7</sup>; <sup>1</sup>JP, <sup>2</sup>Fushimi-ku/JP, <sup>3</sup>Fukuoka/JP, <sup>4</sup>Ishikawa/JP, <sup>5</sup>Chiba/JP, <sup>6</sup>Aichi/JP, <sup>7</sup>Shizuoka/JP
- 13:05 - 13:05 607TiP - BIG BANG study: A Multicenter Phase II Study of the MEK Inhibitor Binimetinib + BRAF Inhibitor Encorafenib + Anti-EGFR Antibody Cetuximab in Patients with BRAF Non-V600E Mutated Metastatic Colorectal Cancer (EPOC 1703)  
D. Kotani<sup>1</sup>, H. Bando<sup>2</sup>, T. Masuishi<sup>3</sup>, Y. Komatsu<sup>2</sup>, K. Yamaguchi<sup>2</sup>, T. Nakajima<sup>2</sup>, T. Satoh<sup>4</sup>, T. Nishina<sup>2</sup>, T. Esaki<sup>2</sup>, S. Nomura<sup>2</sup>, S. Sakamoto<sup>2</sup>, S. Iida<sup>2</sup>, S. Matsuda<sup>2</sup>, M. Yonemura<sup>2</sup>, N. Fuse<sup>2</sup>, A. Sato<sup>2</sup>, S. Fujii<sup>2</sup>, H. Ebi<sup>2</sup>, A. Ohtsu<sup>2</sup>, T. Yoshino<sup>2</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>JP, <sup>3</sup>Aichi/JP, <sup>4</sup>Osaka/JP
- 13:05 - 13:05 608TiP - BRAVERY study: A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer (EPOC1701).  
T. Masuishi<sup>1</sup>, H. Taniguchi<sup>1</sup>, D. Kotani<sup>2</sup>, H. Bando<sup>3</sup>, Y. Komatsu<sup>4</sup>, K. Yamaguchi<sup>3</sup>, T. Nakajima<sup>3</sup>, T. Satoh<sup>5</sup>, T. Nishina<sup>3</sup>, T. Esaki<sup>3</sup>, M. Wakabayashi<sup>3</sup>, S. Nomura<sup>3</sup>, S. Sakamoto<sup>3</sup>, H. Ono<sup>3</sup>, N. Hirano<sup>3</sup>, N. Fujishiro<sup>3</sup>, N. Fuse<sup>3</sup>, A. Sato<sup>3</sup>, A. Ohtsu<sup>3</sup>, T. Yoshino<sup>3</sup>; <sup>1</sup>Aichi/JP, <sup>2</sup>Chiba/JP, <sup>3</sup>JP, <sup>4</sup>Hokkaido/JP, <sup>5</sup>Osaka/JP
- 13:05 - 13:05 609TiP - Intermittent or continuous Panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): a randomized phase 2 trial (IMPROVE)  
A. De Stefano, G. Nasti, A. Febbraro, G. Rosati, F. Giuliani, D. Santini, G. Aprile, M. Scartozzi, F. Silvestris, G. Luppi, I. Lolli, C. Mastroianni, S. Leo, V. Montesarchio, C. Gridelli, C. Pozzo, E. Sperti, D. Giannarelli, A. Budillon, A. Avallone; IT
- 13:05 - 13:05 610TiP - Preoperative Nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): a window-of-opportunity study (NICOLE)  
A. Avallone<sup>1</sup>, P. Delrio<sup>1</sup>, G. Nasti<sup>1</sup>, A. Cassata<sup>1</sup>, L. Silvestro<sup>1</sup>, A. De Stefano<sup>1</sup>, S. Lastoria<sup>1</sup>, R. Casaretti<sup>1</sup>, C. Romano<sup>1</sup>, A. Ottaiano<sup>1</sup>, E. Di gennaro<sup>1</sup>, A. Nappi<sup>1</sup>, P. Maiolino<sup>1</sup>, E. Cavalcanti<sup>1</sup>, A. Petrillo<sup>1</sup>, F. Tatangelo<sup>1</sup>, D. Giannarelli<sup>1</sup>, J. Galon<sup>2</sup>, P. Ascierto<sup>1</sup>, A. Budillon<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>FR
- 13:05 - 13:05 611TiP - AVEVAC. A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients. (GEMCAD 16-02)

M. Español Rego<sup>1</sup>, V. Alonso<sup>1</sup>, J. Aparicio<sup>1</sup>, E. Elez Fernandez<sup>1</sup>, P. Escudero<sup>1</sup>, C. Fernández-Martos<sup>1</sup>, N. Rodríguez<sup>1</sup>, A. Ruiz Casado<sup>1</sup>, J. Cid<sup>1</sup>, R. Cabezón<sup>1</sup>, M. Lozano<sup>1</sup>, A. Ginés<sup>1</sup>, L. Bianchi<sup>1</sup>, J. Garcia-Corbacho<sup>1</sup>, X. García de Albéniz<sup>2</sup>, J. Maurel<sup>1</sup>, D. Benitez Ribas<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>MA/US

- 13:05 - 13:05 612TiP - Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer  
A. Flament, A. Hendlisz, L. Shaza, S. Aspeslagh, M. Vouche, V. Donckier, A. Awada, J.-P. Machiels, M. van den Eynde, J.-L. Canon, J. Carrasco, C. Lonez, F. Lehmann; BE
- 13:05 - 13:05 613TiP - Serum levels of interleukin 8 (IL-8) and other cytokines as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic colo-rectal cancer patients: the FLIBER study  
C. Buonerba, S. Vecchiarelli, F. Cappuzzo; IT
- 13:05 - 13:05 614TiP - UCGI 28 Panirinox : a randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis.  
T. Mazard<sup>1</sup>, F. Ghiringhelli<sup>2</sup>, C. Mollevi<sup>1</sup>, E. Assenat<sup>1</sup>, C. Gavoille<sup>3</sup>, D. Smith<sup>1</sup>, V. Pezzella<sup>1</sup>, R. Meddeb<sup>1</sup>, B. Pastor<sup>1</sup>, M. Ychou<sup>4</sup>, A. Thierry<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>Cedex/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 5/FR
- 13:05 - 13:05 627P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer.  
K. Kato, T. Kojima, H. Saeki, H. Hara, T. Kajiwara, S. Hironaka, H. Nakatsumi, S. Kadowaki, Y. Kagawa, T. Esaki, T. Moriwaki, T. Kobayashi, N. Izawa, S. Nomura, T. Kuwata, S. Fujii, W. Okamoto, K. Shitara, A. Ohtsu, T. Yoshino; JP
- 13:05 - 13:05 628P - Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas  
A. Creemers, S. Meijer, M. Stoffels, G. Hooijer, L. Holtzer, H. van Ooijen, A. Van Brussel, E. Aussems-Custers, M. van Berge Henegouwen, M. Hulshof, K. Krishnadath, A. van de Stolpe, M. Bijlsma, H. van Laarhoven; NL
- 13:05 - 13:05 629P - Hypoxia Gene Expression Defines a Poor Prognostic Sub-group in Oesophageal Adenocarcinoma  
R. Douglas, C. McKinney, L. Stevenson, L. Cairns, R. Kennedy, J. Blayney, R. Turkington; GB
- 13:05 - 13:05 630P - Neoadjuvant radio-chemotherapy for esophageal cancer: a multicenter european study comparing PACLITAXEL/CARBOPLATIN , 5FU/CISPLATIN and FOLFOX.  
P. Allemann<sup>1</sup>, S. Mantziari<sup>1</sup>, M. Winiker<sup>1</sup>, A. Wagner<sup>1</sup>, A. Digkila<sup>1</sup>, M. van Berge Henegouwen<sup>2</sup>, S. Gisbertz<sup>2</sup>, A. Slaman<sup>2</sup>, R. van Hillegersberg<sup>2</sup>, J. Ruurda<sup>2</sup>, H. Brenkman<sup>2</sup>, M. Nilsson<sup>3</sup>, K. Satoshi<sup>3</sup>, G. Piessen<sup>4</sup>, D. Collet<sup>4</sup>, C. Gronnier<sup>4</sup>, N. Carrere<sup>4</sup>, A. Marinho<sup>4</sup>, N. Demartines<sup>1</sup>, M. Schafer<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>NL, <sup>3</sup>SE, <sup>4</sup>FR
- 13:05 - 13:05 631P - Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy  
A. Barbour<sup>1</sup>, S. Brosda<sup>2</sup>, B. Wijnhoven<sup>3</sup>, S. van Hootgem<sup>3</sup>, J. Lanschoot<sup>3</sup>, S. Barbour<sup>1</sup>, S. Lagarde<sup>3</sup>, L. Krause<sup>2</sup>, D. Pryor<sup>2</sup>, J. Thomas<sup>2</sup>, E. Walpole<sup>2</sup>, A. van der Gaast<sup>3</sup>, M. Smithers<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>QLD/AU, <sup>3</sup>NL

- 13:05 - 13:05 632P - induction chemotherapy for locally advanced esophageal cancer  
G. Harada, R. Bonadio, F. de Araújo, C. Victor, F. Takeda, R. Sallum, U. Junior, I. Cecconello, T. de Castria; BR
- 13:05 - 13:05 633P - The role of comprehensive evaluation for clinical complete response in predicting pathologic complete response in patients treated with neoadjuvant chemoradiation for esophageal squamous cell carcinoma (ESCC)  
H.-S. Im, J. Kang, Y.-H. Kim, H.R. Kim, J.H. Kim, H.-Y. Jung, G.-H. Lee, H.J. Song, D.H. Kim, K.D. Choi, J.H. Lee, J.Y. Ahn, J.-S. Ryu, K.-J. Cho, S.-B. Kim, S.R. Park; KR
- 13:05 - 13:05 634P - Prognostic impact of inflammation-based scores in esophageal cancer patients achieving pathologic complete response after neoadjuvant chemoradiotherapy followed by surgery  
J. Kang, H.-S. Im, Y.-H. Kim, H.R. Kim, J.H. Kim, H.-Y. Jung, G.-H. Lee, H.J. Song, D.H. Kim, K.D. Choi, J.H. Lee, J.Y. Ahn, J.-S. Ryu, K.-J. Cho, S.-B. Kim, S.R. Park; KR
- 13:05 - 13:05 635P - Association of sarcopenia with dose-limiting toxicities and survival in oesophageal adenocarcinoma treated with neoadjuvant chemotherapy  
J. Weaver, C. Cipriano, A. McWilliam, Z. Kordatou, M. Abraham, T. Germetaki, G. Papaxoinis, W. Mansoor; GB
- 13:05 - 13:05 636P - Survival Benefit of Re-irradiation in Esophageal Cancer Patients with Locoregional Recurrence: A Propensity Score Matched Analysis  
K. Xiangquan, Y. Huang, B. Zheng, Q. Zhuang, X. Zhang, L. Tang, J. Li, J. Wu; CN
- 13:05 - 13:05 637P - Magnetic resonance imaging in oesophageal (oes) cancer: results from the STO3 MRI substudy  
M. Davidson, M. Nankivell, D. Cunningham, N. Starling, D.-M. Koh, G. Brown, W. Allum, A. Wotherspoon, E. Smyth, L. Ly, N. Kleovoulou, R. Langley, A. Riddell; GB
- 13:05 - 13:05 638P - Prognostic Value of Pretreatment Diffusion Weighted Magnetic Resonance Imaging based Texture in Concurrent Chemo-radiotherapy of Esophageal Squamous Cell Cancer  
B. li, Z. li, C. Han; CN
- 13:05 - 13:05 639P - Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?  
S. Nagasawa, T. Ogata, K. Hara, Y. Shimoda, M. Nakazono, Y. Kumazu, T. Hayashi, T. Yamada, Y. Rino, M. Masuda, T. Yoshikawa, T. Oshima; JP
- 13:05 - 13:05 640P - A model using computed tomography-based compactness to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma  
Q. Wang, B. Cao, J. Chen, T. Li, J. Lang, Z. Xiao; CN
- 13:05 - 13:05 641P - Clinical significance of 18F-fluorodeoxyglucose-positron emission tomography-positive lymph nodes to outcomes of trimodal therapy for esophageal squamous cell carcinoma  
Y. Hamai, M. Emi, Y. Ibuki, M. Okada; JP
- 13:05 - 13:05 642P - Phase 1 study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor  $\beta$  (TGF- $\beta$ ) and PD-L1

C.-C. Lin<sup>1</sup>, T. Doi<sup>2</sup>, K. Muro<sup>3</sup>, M.-M. Hou<sup>1</sup>, T. Esaki<sup>4</sup>, H. Hara<sup>4</sup>, H.-C. Chung<sup>5</sup>, M. Osada<sup>4</sup>, C. Helwig<sup>6</sup>, S. Kondo<sup>4</sup>; <sup>1</sup>TW, <sup>2</sup>Chiba/Jp, <sup>3</sup>Aichi/Jp, <sup>4</sup>Jp, <sup>5</sup>KR, <sup>6</sup>DE

- 13:05 - 13:05 643P - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ , in patients with post-platinum esophageal adenocarcinoma (EAC): preliminary results from a phase 1 cohort  
B. Tan<sup>1</sup>, A. Khattak<sup>2</sup>, E. Felip Font<sup>3</sup>, K. Kelly<sup>4</sup>, P. Rich<sup>5</sup>, D. Wang<sup>6</sup>, C. Helwig<sup>7</sup>, I. Dussault<sup>8</sup>, L. Ojalvo<sup>8</sup>, N. Isambert<sup>9</sup>; <sup>1</sup>MO/US, <sup>2</sup>AU, <sup>3</sup>ES, <sup>4</sup>US, <sup>5</sup>GA/US, <sup>6</sup>MI/US, <sup>7</sup>DE, <sup>8</sup>MA/US, <sup>9</sup>FR
- 13:05 - 13:05 644P - The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient Identification of Cancer Genome Alterations in Advanced Pancreatic Cancer.  
N. Izawa<sup>1</sup>, C. Morizane<sup>1</sup>, H. Takahashi<sup>2</sup>, M. Ueno<sup>1</sup>, Y. Kawamoto<sup>3</sup>, N. Okano<sup>4</sup>, S. Shimizu<sup>1</sup>, K. Sudo<sup>1</sup>, S. Itoh<sup>1</sup>, A. Asagi<sup>1</sup>, Y. Kagawa<sup>1</sup>, K. Kamata<sup>1</sup>, T. Kudo<sup>5</sup>, S. Nomura<sup>1</sup>, T. Kuwata<sup>1</sup>, S. Fujii<sup>1</sup>, W. Okamoto<sup>1</sup>, K. Shitara<sup>1</sup>, A. Ohtsu<sup>1</sup>, T. Yoshino<sup>1</sup>; <sup>1</sup>Jp, <sup>2</sup>Chiba/Jp, <sup>3</sup>Hokkaido/Jp, <sup>4</sup>Tokyo/Jp, <sup>5</sup>Osaka/Jp
- 13:05 - 13:05 645P - Spatial Genomic Heterogeneity from Multi-Region Endoscopic Biopsies in Primary Gastric Cancer: Implications for Precision Therapy  
S. Klempner<sup>1</sup>, J. Chao<sup>2</sup>, K. Kim<sup>3</sup>, K.-M. Kim<sup>3</sup>, S.-T. Kim<sup>3</sup>, J. Lee<sup>3</sup>, H. Lee<sup>3</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>KR
- 13:05 - 13:05 646P - EGFR amplification (amp) and survival in the REAL-3 trial  
E. Smyth<sup>1</sup>, K. Kouvelakis<sup>1</sup>, D. Cunningham<sup>1</sup>, J.C. Hahne<sup>1</sup>, C. Peckitt<sup>1</sup>, G. Vlachogiannis<sup>1</sup>, D. Watkins<sup>1</sup>, S. Rao<sup>1</sup>, N. Starling<sup>1</sup>, S.H. Wilson<sup>1</sup>, T. Waddell<sup>1</sup>, A. Okines<sup>1</sup>, T. Crosby<sup>1</sup>, W. Mansoor<sup>1</sup>, J. Wadsley<sup>2</sup>, G. Middleton<sup>1</sup>, A. Wotherspoon<sup>1</sup>, I. Chau<sup>3</sup>, N. Valeri<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>South Yorkshire/GB, <sup>3</sup>Surrey/GB
- 13:05 - 13:05 647P - The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine-based chemotherapy  
M. Skupinska, M. Jesiotr, P. Chrom, A. Mroz, S. Cierniak, M. Winiarek, L. Wyrwicz, J. Pieczykolan, M. Wieczorek, A. Stanczak, L. Bodnar; PL
- 13:05 - 13:05 648P - Changes in CpG methylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A in gastric adenocarcinoma  
N. Timoshkina, O. Kit, D. Vodolazhskiy, N. Soldatkina, Y. Gevorkyan, N. Samoylenko, D. Kharagezov, M. Duritskiy, A. Dashkov, D. Kaymakchi, D. Petrov, S. Ilchenko, V. Sustretov, L. Vladimirova; RU
- 13:05 - 13:05 649P - The level of somatic mutations as an indicator of overall survival in gastric cancer  
T. Kekeeva, A. Tanas, L. Khashimov, V. Lyadov, Y. Andreeva, G. Frank, L. Zavalishina, D. Zaletaev, V. Strelnikov; RU
- 13:05 - 13:05 650P - mechanisms of G9a on promoting tumor invasion and metastasis of gastric cancer  
B. Liu, L. Hu; CN
- 13:05 - 13:05 651P - Prospective Observation: Clinicopathological Features and Clinical Utility of Plasma Epstein-Barr Virus DNA Load of Epstein-Barr Virus-associated Gastric Carcinoma  
M.-Z. Qiu, CN
- 13:05 - 13:05 652P - Is standard adjuvant chemotherapy effective in patients with Epstein-Barr virus associated gastric cancer?  
J.G. Kim, Y. Chae, J.H. Baek, B.W. Kang; KR

- 13:05 - 13:05 653P - PD-L1 Expression and T-Cell Inflamed Gene Expression Profile (GEP) in Korean and US Patients (pts) With Advanced Gastric Cancer (GC)  
S.Y. Rha<sup>1</sup>, G. Ku<sup>2</sup>, H.S. Kim<sup>1</sup>, H.C. Chung<sup>1</sup>, F.G. Amlashi<sup>2</sup>, D. Maru<sup>2</sup>, C. Fein<sup>2</sup>, L. Tang<sup>2</sup>, M. Savage<sup>2</sup>, W. Zhou<sup>2</sup>, T. Wu<sup>2</sup>, S. Peter<sup>2</sup>, D. Kelsen<sup>2</sup>, J. Ajani<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>US
- 13:05 - 13:05 654P - Relationship between immune related molecules and chemosensitivity and prognosis in gastric cancer  
T. Hagi<sup>1</sup>, Y. Kurokawa<sup>2</sup>, T. Hashimoto<sup>1</sup>, Y. Miyazaki<sup>2</sup>, T. Takahashi<sup>1</sup>, K. Tanaka<sup>1</sup>, T. Makino<sup>1</sup>, M. Yamasaki<sup>1</sup>, K. Nakajima<sup>1</sup>, M. Mori<sup>1</sup>, Y. Doki<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Osaka/JP
- 13:05 - 13:05 655P - Prognostic significance of lymphocyte-activation gene-3 expression in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma  
C. Siesing, M. Svensson, C. Hedner, B. Nodin, D. Borg, K. Jirstrom; SE
- 13:05 - 13:05 656P - Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: an exploratory analysis of JCOG1302A  
Y. Sato<sup>1</sup>, J. Mizusawa<sup>1</sup>, K. Nakamura<sup>1</sup>, T. Fukagawa<sup>1</sup>, H. Katai<sup>1</sup>, S. Haruta<sup>1</sup>, M. Yamada<sup>1</sup>, M. Takagi<sup>1</sup>, S. Tamura<sup>1</sup>, T. Yoshimura<sup>1</sup>, T. Inada<sup>1</sup>, N. Hirabayashi<sup>1</sup>, I. Wada<sup>1</sup>, Y. Kodera<sup>1</sup>, M. Tokunaga<sup>1</sup>, T. Yoshikawa<sup>1</sup>, N. Boku<sup>2</sup>, T. Sano<sup>1</sup>, M. Sasako<sup>3</sup>, M. Terashima<sup>4</sup>; <sup>1</sup>JP, <sup>2</sup>Kanagawa/JP, <sup>3</sup>Hyogo/JP, <sup>4</sup>Shizuoka/JP
- 13:05 - 13:05 657P - Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?  
K. Hara, T. Hayashi, Y. Shimoda, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Oshima, T. Yoshikawa; JP
- 13:05 - 13:05 658P - Patient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA)  
R. Morlock<sup>1</sup>, M. Krukas-Hampel<sup>1</sup>, Ö. Türeci<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>DE
- 13:05 - 13:05 659P - Avelumab (anti-PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated results from the phase 1b JAVELIN Solid Tumor JPN trial  
T. Doi<sup>1</sup>, S. Iwasa<sup>2</sup>, K. Muro<sup>3</sup>, T. Satoh<sup>4</sup>, S. Hironaka<sup>2</sup>, T. Esaki<sup>2</sup>, T. Nishina<sup>2</sup>, H. Hara<sup>2</sup>, N. Machida<sup>2</sup>, Y. Komatsu<sup>5</sup>, Y. Shimada<sup>2</sup>, S. Otsu<sup>2</sup>, S. Shimizu<sup>2</sup>, V. Chand<sup>6</sup>, M. Watanabe<sup>2</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>JP, <sup>3</sup>Aichi/JP, <sup>4</sup>Osaka/JP, <sup>5</sup>Hokkaido/JP, <sup>6</sup>MA/US
- 13:05 - 13:05 660P - Safety and Efficacy of a DKK1 Inhibitor (DKN-01) in Combination with Pembrolizumab (P) in Patients (Pts) with Advanced Gastroesophageal (GE) Malignancies  
S. Klempner<sup>1</sup>, J. Bendell<sup>2</sup>, V. Meucci Villaflor<sup>3</sup>, L. Tenner<sup>4</sup>, S. Stein<sup>5</sup>, C. Sirard<sup>6</sup>, W. Newman<sup>3</sup>, M. Kagey<sup>3</sup>, K. Schlienger<sup>3</sup>, J. Strickler<sup>3</sup>; <sup>1</sup>CA/US, <sup>2</sup>TN/US, <sup>3</sup>US, <sup>4</sup>TX/US, <sup>5</sup>CT/US, <sup>6</sup>MA/US
- 13:05 - 13:05 661P - Updated results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer  
Y.-J. Bang<sup>1</sup>, T. Doi<sup>2</sup>, S. Kondo<sup>3</sup>, H.C. Chung<sup>1</sup>, K. Muro<sup>4</sup>, I. Dussault<sup>5</sup>, C. Helwig<sup>6</sup>, M. Osada<sup>3</sup>, Y.-K. Kang<sup>7</sup>; <sup>1</sup>KR, <sup>2</sup>Chiba/JP, <sup>3</sup>JP, <sup>4</sup>Aichi/JP, <sup>5</sup>MA/US, <sup>6</sup>DE, <sup>7</sup>Songpa-gu/KR

- 13:05 - 13:05 662P - Biomarker-Guided Enrichment of the Antitumor Activity of Margetuximab (M) plus Pembrolizumab (P) in Patients with Advanced HER2+ Gastric Adenocarcinoma (GEA)  
D. Catenacci<sup>1</sup>, H. Park<sup>2</sup>, H. Uronis<sup>2</sup>, Y.-K. Kang<sup>3</sup>, M. Ng<sup>4</sup>, P. Gold<sup>5</sup>, J. Lacy<sup>6</sup>, P. Enzinger<sup>7</sup>, S. Park<sup>8</sup>, K.-W. Lee<sup>8</sup>, J. Yen<sup>9</sup>, J. Odegaard<sup>9</sup>, A. Franovic<sup>9</sup>, J. Baughman<sup>9</sup>, J. Muth<sup>10</sup>, A. Wynter-Horton<sup>10</sup>, T. Wu<sup>10</sup>, J. Wigginton<sup>2</sup>, J. Davidson-Moncada<sup>11</sup>, Y.-J. Bang<sup>8</sup>; <sup>1</sup>IL/US, <sup>2</sup>US, <sup>3</sup>Songpa-gu/KR, <sup>4</sup>SG, <sup>5</sup>WA/US, <sup>6</sup>CT/US, <sup>7</sup>MA/US, <sup>8</sup>KR, <sup>9</sup>CA/US, <sup>10</sup>MD/US, <sup>11</sup>NY/US
- 13:05 - 13:05 663P - HER2 alterations is associated with higher tumor mutation burden in gastric cancer  
B. Wei, Z. Li, Q. Han, X. Xing, Y. Hao, J. Zhou, Y. Zhang, S. Cai, Y. Gu; CN
- 13:05 - 13:05 664P - Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)  
M. Alsina<sup>1</sup>, A. Varga<sup>2</sup>, A. Amatu<sup>3</sup>, J. Schellens<sup>4</sup>, P. Witteveen<sup>4</sup>, V. Boni<sup>1</sup>, V. Moreno<sup>1</sup>, K. Bol<sup>4</sup>, A. Loubakos<sup>4</sup>, M. Magin Ferrer<sup>4</sup>, E. Wasserman<sup>5</sup>; <sup>1</sup>ES, <sup>2</sup>FR, <sup>3</sup>IT, <sup>4</sup>NL, <sup>5</sup>US
- 13:05 - 13:05 665P - NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer  
V. Gambardella<sup>1</sup>, F. Gimeno-Valiente<sup>2</sup>, N. Tarazona<sup>1</sup>, T. Fleitas Kanonnikoff<sup>2</sup>, P. Tolosa<sup>2</sup>, M. Belda Moscardo<sup>2</sup>, B. Garcia-Mico<sup>2</sup>, M. Huerta<sup>2</sup>, S. Roselló<sup>2</sup>, D. Roda<sup>2</sup>, A. Cervantes<sup>1</sup>, J. Castillo<sup>2</sup>; <sup>1</sup>Valencia/ES, <sup>2</sup>ES
- 13:05 - 13:05 666P - Discordance between HER2 Expression status in Primary Tumor and Matched Malignant Ascites in Gastric Adenocarcinoma  
Y. Yang, H. Kim, S.-M. Son, H.S. Han; KR
- 13:05 - 13:05 667P - A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).  
K. Chin<sup>1</sup>, A. Takashima<sup>1</sup>, K. Minashi<sup>1</sup>, S. Kadowaki<sup>1</sup>, T. Nishina<sup>1</sup>, T. Nakajima<sup>1</sup>, K. Amagai<sup>2</sup>, N. Machida<sup>1</sup>, M. Gotoh<sup>3</sup>, K. Taku<sup>1</sup>, N. Ishizuka<sup>1</sup>, D. Takahari<sup>4</sup>; <sup>1</sup>JP, <sup>2</sup>Ibaraki/JP, <sup>3</sup>Osaka/JP, <sup>4</sup>Aichi/JP
- 13:05 - 13:05 668P - Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B  
S. Yuki<sup>1</sup>, K. Shinozaki<sup>2</sup>, T. Kashiwada<sup>2</sup>, T. Kusumoto<sup>2</sup>, M. Iwatsuki<sup>2</sup>, H. Satake<sup>3</sup>, S. Tokunaga<sup>2</sup>, Y. Emi<sup>2</sup>, A. Makiyama<sup>4</sup>, Y. Kawamoto<sup>1</sup>, Y. Komatsu<sup>1</sup>, M. Shimokawa<sup>2</sup>, H. Saeki<sup>2</sup>, E. Oki<sup>4</sup>, H. Baba<sup>2</sup>, Y. Maehara<sup>2</sup>; <sup>1</sup>Hokkaido/JP, <sup>2</sup>JP, <sup>3</sup>Hyogo/JP, <sup>4</sup>Fukuoka/JP
- 13:05 - 13:05 669P - Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ).  
N. Martinez Lago<sup>1</sup>, S. Candamio Folgar<sup>1</sup>, C. Grande Ventura<sup>1</sup>, M. Salgado Fernandez<sup>1</sup>, J. De la Camara Gomez<sup>1</sup>, J.C. Méndez Méndez<sup>1</sup>, D. Arias Ron<sup>1</sup>, F. Vazquez<sup>2</sup>, M. Reboredo Lopez<sup>1</sup>, Y. Vidal Ínsua<sup>1</sup>, B. Graña Suarez<sup>1</sup>, M. Jorge Fernandez<sup>1</sup>, M.E. Brozos Vazquez<sup>1</sup>, M.L. Pellon Augusto<sup>1</sup>, J. Prato Varela<sup>1</sup>, P. Gonzalez Villarroel<sup>1</sup>, A. Fernandez Montes<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>La Coruña/ES

- 13:05 - 13:05 670P - Phase II study of S-1 and Oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)  
K. Kobayashi<sup>1</sup>, M. Iwatsuki<sup>1</sup>, H. Orita<sup>1</sup>, S. Hidaka<sup>1</sup>, T. Arigami<sup>1</sup>, T. Kusumoto<sup>1</sup>, H. Satake<sup>2</sup>, E. Oki<sup>3</sup>, K. Satoshi<sup>4</sup>, K. Tobimatsu<sup>1</sup>, M. Shimokawa<sup>1</sup>, H. Saeki<sup>1</sup>, A. Makiyama<sup>3</sup>, Y. Kakeji<sup>1</sup>, S. Natsugoe<sup>1</sup>, H. Baba<sup>1</sup>, S. Eguchi<sup>1</sup>, Y. Maehara<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hyogo/Jp, <sup>3</sup>Fukuoka/Jp, <sup>4</sup>SE
- 13:05 - 13:05 671P - A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)  
R. Kawabata<sup>1</sup>, T. Terazawa<sup>2</sup>, J. Matsuyama<sup>3</sup>, S. Endo<sup>4</sup>, O. Shiraishi<sup>4</sup>, S. Fujita<sup>4</sup>, Y. Akamaru<sup>4</sup>, H. Taniguchi<sup>4</sup>, M. Tatsumi<sup>4</sup>, M. Gotoh<sup>2</sup>, S.-W. Lee<sup>4</sup>, Y. Kurokawa<sup>2</sup>, T. Shimokawa<sup>4</sup>, D. Sakai<sup>2</sup>, T. Kato<sup>5</sup>, K. Fujitani<sup>4</sup>, T. Satoh<sup>2</sup>; <sup>1</sup>Osaka Prefecture/Jp, <sup>2</sup>Osaka/Jp, <sup>3</sup>Osaka pref./Jp, <sup>4</sup>Jp, <sup>5</sup>Hyogo/Jp
- 13:05 - 13:05 672P - Comparison of preoperative neoadjuvant chemotherapy SOX with different courses of treatment on the patients with advanced gastric cancer  
X. Wang, CN
- 13:05 - 13:05 673P - Phase II trial of neoadjuvant therapy using apatinib plus SOX regimen in locally advanced gastric cancer: updated results  
Y. Zheng, X. Yang, H. Shi, Z. Yang, C. Yan, Z. Ni, M. Li, B.K. Sah, W. Liu, W. Xu, X. Yao, Z. Zhu, M. Yan, Z. Zhu, C. Li; CN
- 13:05 - 13:05 674P - The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis  
T. van den Ende, E. Ter Veer, M. Machiels, R. Mali, F. Abe Nijenhuis, L. Waal, M. Laarman, S. Gisbertz, M. Hulshof, M. van Oijen, H. van Laarhoven; NL
- 13:05 - 13:05 675P - Irinotecan, oxaliplatin, 5-fluorouracil/leucovorin (FOLFIRINOX) as first-line therapy in advanced HER2-negative gastric or gastroesophageal adenocarcinoma (G/GEA)  
E. Obarevich, N. Besova, E. Trusilova, V. Gorbunova; RU
- 13:05 - 13:05 676P - Efficacy and safety for apatinib combined with oxaliplatin and S1 in initially treated metastatic gastric cancer ----- a single-center observational study  
J. Peng<sup>1</sup>, L. Peng<sup>2</sup>, H. Wu<sup>2</sup>, K. Wu<sup>2</sup>, W. Chen<sup>2</sup>, C. Xie<sup>2</sup>, J. Xu<sup>2</sup>, X. Zhang<sup>2</sup>, D. Chen<sup>2</sup>, S. Cai<sup>2</sup>, Y. He<sup>2</sup>; <sup>1</sup>Guangdong/CN, <sup>2</sup>CN
- 13:05 - 13:05 677P - Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer. A phase II study by the Hellenic Cooperative Oncology Group.  
T. Makatsoris<sup>1</sup>, E. Samantas<sup>2</sup>, K. Manousou<sup>3</sup>, V. Karavasilis<sup>4</sup>, G. Aravantinos<sup>2</sup>, D. Tryfonopoulos<sup>3</sup>, A. Psyri<sup>3</sup>, D. Pectasides<sup>3</sup>, E. Pazarli<sup>3</sup>, C. Petraki<sup>3</sup>, A. Tsioura<sup>3</sup>, I. Kaklamanos<sup>3</sup>, G. Fountzilias<sup>3</sup>, G. Pentheroudakis<sup>3</sup>; <sup>1</sup>Rion/GR, <sup>2</sup>Attica/GR, <sup>3</sup>GR, <sup>4</sup>Central Macedonia/GR
- 13:05 - 13:05 678P - Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer  
K.-W. Lee<sup>1</sup>, J.W. Kim<sup>1</sup>, J.G. Kim<sup>1</sup>, B.W. Kang<sup>1</sup>, I.J. Chung<sup>2</sup>, Y.S. Hong<sup>1</sup>, T.-Y. Kim<sup>1</sup>, K.H. Lee<sup>1</sup>, D.Y. Zang<sup>1</sup>, Y.H. Ko<sup>1</sup>, E.-K. Song<sup>1</sup>, J.H. Baek<sup>1</sup>, D. Koo<sup>1</sup>, S.Y. Oh<sup>1</sup>, H. Cho<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>Jeonnam/KR

- 13:05 - 13:05 679P - Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer  
K. Nishikawa<sup>1</sup>, W. Koizumi<sup>2</sup>, A. Tsuburaya<sup>3</sup>, T. Yamanaka<sup>1</sup>, S. Morita<sup>1</sup>, K. Fujitani<sup>1</sup>, Y. Akamaru<sup>1</sup>, K. Shimada<sup>1</sup>, H. Hosaka<sup>1</sup>, N. Nakayama<sup>1</sup>, Y. Miyashita<sup>1</sup>, T. Tsujinaka<sup>4</sup>, J. Sakamoto<sup>5</sup>; <sup>1</sup>JP, <sup>2</sup>Minami-Ii, Sagamihara/Jp, <sup>3</sup>Minami-ku/Jp, <sup>4</sup>Osaka/Jp, <sup>5</sup>Gifu/Jp
- 13:05 - 13:05 680P - A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients With Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)  
K.-W. Lee, C.H. Maeng, T.-Y. Kim, D.Y. Zang, Y.H. Kim, I.G. Hwang, S.C. Oh, J.S. Chung, H.S. Song, J.W. Kim, S.J. Jeong, J.Y. Cho; KR
- 13:05 - 13:05 681P - Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study  
T. Masuishi<sup>1</sup>, S. Kadowaki<sup>2</sup>, H. Hirano<sup>2</sup>, S. Kawai<sup>2</sup>, T. Yamada<sup>2</sup>, T. Moriwaki<sup>2</sup>, N. Machida<sup>2</sup>, N. Boku<sup>3</sup>, K. Muro<sup>1</sup>; <sup>1</sup>Aichi/Jp, <sup>2</sup>Jp, <sup>3</sup>Kanagawa/Jp
- 13:05 - 13:05 682P - Identification of patients who benefit from apatinib in advanced gastric cancer: data derived from a real world study  
J. Feng, B. Shen, H. Jiang, L. Wang, J. Qian, Y. Shu, P. Chen, G. Mao, B. Liu, X. Zhang, C. Liu, J. Wu, X. Li, W. Cai, W. Shen, Q. Wang, J. He, D. Hua, Z. Zhang, Y. Zhang; CN
- 13:05 - 13:05 683P - A real world study of apatinib treatment in gastric cancer: current status and clinical benefit  
G. Sun, D. Li, Z. Ning, Y. He, J. Chang, F. Zhang, C. Jiang, Y. Cheng, L. Xia, B. Hu, C. Yu, Z. Wang, D. Wang, G. Wang, Y. Zhao, J. Wang, H. Liang, M. Xiong, W. Peng, H. Qian; CN
- 13:05 - 13:05 684P - An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake  
S. Kadowaki<sup>1</sup>, H. Ishigami<sup>1</sup>, K. Muro<sup>2</sup>, S. Yoshida<sup>1</sup>, Y. Hirono<sup>1</sup>, T. Tomita<sup>1</sup>, H. Yabusaki<sup>1</sup>, T. Kusumoto<sup>1</sup>, M. Ota<sup>1</sup>, Y. Kodera<sup>1</sup>, Y. Tsuji<sup>3</sup>, A. Hidemura<sup>1</sup>, O. Hachiya<sup>1</sup>, K. Oba<sup>1</sup>, J. Kitayama<sup>1</sup>; <sup>1</sup>Jp, <sup>2</sup>Aichi/Jp, <sup>3</sup>Hokkaido/Jp
- 13:05 - 13:05 685P - Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese Phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer.  
M. Takeuchi<sup>1</sup>, W. Ichikawa<sup>1</sup>, K. Shitara<sup>1</sup>, Y. Sunakawa<sup>1</sup>, K. Oba<sup>1</sup>, W. Koizumi<sup>2</sup>, Y. Sakata<sup>3</sup>, H. Furukawa<sup>1</sup>, M. Takeuchi<sup>1</sup>, M. Fujii<sup>1</sup>; <sup>1</sup>Jp, <sup>2</sup>Minami-Ii, Sagamihara/Jp, <sup>3</sup>Aomori/Jp
- 13:05 - 13:05 686P - Immune gene expression profiling (GEP) of resected gastric adenocarcinomas (GAs) to identify biomarkers associated with immune checkpoint inhibitor (ICPI) response in early stage disease  
J. Chao<sup>1</sup>, H. Yin<sup>1</sup>, J. Lee<sup>2</sup>, S. Klemperer<sup>3</sup>, R. Pillai<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>KR, <sup>3</sup>CA/US
- 13:05 - 13:05 687P - Significant prognostic markers related to lymphocytes in gastric cancer  
T. Hashimoto<sup>1</sup>, Y. Kurokawa<sup>2</sup>, T. Takahashi<sup>1</sup>, Y. Miyazaki<sup>2</sup>, K. Tanaka<sup>1</sup>, T. Makino<sup>1</sup>, M. Yamasaki<sup>1</sup>, K. Nakajima<sup>1</sup>, M. Mori<sup>1</sup>, Y. Doki<sup>1</sup>; <sup>1</sup>Jp, <sup>2</sup>Osaka/Jp
- 13:05 - 13:05 688P - Correlation between clinic-pathological features, MSI, PD-L1 and survival in resectable gastric cancer: looking for prognostic biomarkers



M. Ratti<sup>1</sup>, N. Valeri<sup>2</sup>, J.C. Hahne<sup>2</sup>, A. Lampis<sup>2</sup>, M. Ghidini<sup>3</sup>, G. Tomasello<sup>4</sup>, G. Tanzi<sup>1</sup>, L. Toppo<sup>1</sup>, C. Pizzo<sup>1</sup>, B. Donida<sup>1</sup>, C. Senti<sup>1</sup>, M. Salati<sup>1</sup>, M. Trombatore<sup>1</sup>, M. Fassan<sup>1</sup>, R. Passalacqua<sup>4</sup>; <sup>1</sup>IT, <sup>2</sup>GB, <sup>3</sup>(MI)/IT, <sup>4</sup>(CR)/IT

- 13:05 - 13:05 689P - Neutrophil-lymphocyte ratio (NLR) as an important prognostic factor for paclitaxel as a second line chemotherapy in advanced gastric cancer (AGC): Results from phase 3 DREAM study  
M.-H. Ryu<sup>1</sup>, J.H. Kim<sup>1</sup>, S.C. Oh<sup>1</sup>, S. Park<sup>1</sup>, J.G. Kim<sup>1</sup>, J.W. Kim<sup>1</sup>, S.-H. Cho<sup>1</sup>, K.-E. Yoon<sup>1</sup>, Y.-K. Kang<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR
- 13:05 - 13:05 690P - Combination versus single-agent as palliative chemotherapy for gastric cancer: significance of age and platelet-to-lymphocyte ratio  
M.S. Ahn, Y.W. Choi, H. Lee, S.Y. Kang, J.-H. Choi; KR
- 13:05 - 13:05 691P - Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial  
A. Slagter, K. Sikorska, C. Grootsholten, H. van Laarhoven, H. Boot, E. Meershoek-Klein Kranenbarg, C. van de Velde, N. van Grieken, E. Jansen, M. Verheij, A. Cats; NL
- 13:05 - 13:05 692P - The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients.  
T. Hayashi, T. Oshima, K. Hara, Y. Shimoda, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Yoshikawa; JP
- 13:05 - 13:05 693P - Gastric Cancer In Young Patients  
M.M. Seker, A. Bahceci, T. Kacan; TR
- 13:05 - 13:05 694P - Differences in presentation and outcomes among young and old patients with gastric cancer  
M. Al Otaibi, J. Al Barak, J. Al Abbad, A. Akbar; KW
- 13:05 - 13:05 695P - Prospective Observational Cohort study of Oesophagogastric cancer Patients (POCOP): a Dutch nationwide cohort  
J.J. van Kleef, L. van de Poll-Franse, R. Verhoeven, M. Slingerland, J. Ruurda, J. Heisterkamp, C. Rosman, J.W. de Groot, E. Kouwenhoven, M. van Dijk, E. de Graaf, T. van Voorthuizen, F. Daams, S. Lagarde, G. Nieuwenhuijzen, J. Vincent, M. van Berge Henegouwen, M. van Oijen, M. Sprangers, H. van Laarhoven; NL
- 13:05 - 13:05 696P - Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)  
M. Pishvaian<sup>1</sup>, M. Lee<sup>2</sup>, B.-Y. Ryoo<sup>3</sup>, S. Stein<sup>4</sup>, K.-H. Lee<sup>5</sup>, W. Verret<sup>1</sup>, A. Kwan<sup>1</sup>, B. Liu<sup>1</sup>, K. Iizuka<sup>1</sup>, C.-H. Hsu<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>NC/US, <sup>3</sup>Songpa-gu/KR, <sup>4</sup>CT/US, <sup>5</sup>KR, <sup>6</sup>TW
- 13:05 - 13:05 697P - A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma  
A.-L. Cheng<sup>1</sup>, C.-J. Yen<sup>1</sup>, T. Okusaka<sup>2</sup>, M. Ikeda<sup>3</sup>, C.-H. Hsu<sup>1</sup>, S.-Y. Wu<sup>1</sup>, C. Morizane<sup>2</sup>, Y. Hashimoto<sup>2</sup>, K. Ueshima<sup>2</sup>, T. Ohtomo<sup>2</sup>, T. Tanaka<sup>2</sup>, M. Kudo<sup>2</sup>; <sup>1</sup>TW, <sup>2</sup>JP, <sup>3</sup>Chiba/JP
- 13:05 - 13:05 698P - Phase 2 efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)

T. Decaens<sup>1</sup>, C. Barone<sup>2</sup>, E. Assenat<sup>1</sup>, M. Wermke<sup>3</sup>, A. Fasolo<sup>2</sup>, P. Merle<sup>1</sup>, J.F. Blanc<sup>1</sup>, V. Grando<sup>1</sup>, R. Bruns<sup>3</sup>, J. Straub<sup>3</sup>, C. Zhao<sup>4</sup>, S. Faivre<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>IT, <sup>3</sup>DE, <sup>4</sup>US

- 13:05 - 13:05 699P - Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma  
S.E. Yoon, J.Y. Hur, K.K. Lee, S.J. Lee, J. Lee, S. Paik, H.Y. Lim; KR
- 13:05 - 13:05 700P - Stemness in hepatocellular carcinoma reduced by inhibition of WEE1 expression  
K.U. Park, M.J. Ko, H.M. Ryoo, Y.-H. Lee; KR
- 13:05 - 13:05 701P - Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)  
K. Köchert<sup>1</sup>, G. Meinhardt<sup>2</sup>, J. Bruix<sup>3</sup>, M. Teufel<sup>2</sup>; <sup>1</sup>DE, <sup>2</sup>NJ/US, <sup>3</sup>ES
- 13:05 - 13:05 702P - Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)  
R. Kelley<sup>1</sup>, A. El-Khoueiry<sup>2</sup>, T. Meyer<sup>3</sup>, L. Rimassa<sup>4</sup>, P. Merle<sup>5</sup>, S. Chan<sup>6</sup>, A. Tran<sup>6</sup>, F. Parnis<sup>7</sup>, V. Tam<sup>8</sup>, S. Cattani<sup>5</sup>, D. Markby<sup>2</sup>, D. Clary<sup>2</sup>, A.-L. Cheng<sup>9</sup>, G. Abou-Alfa<sup>10</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>GB, <sup>4</sup>IT, <sup>5</sup>FR, <sup>6</sup>CN, <sup>7</sup>AU, <sup>8</sup>CA, <sup>9</sup>TW, <sup>10</sup>NY/US
- 13:05 - 13:05 703P - Assessment of disease burden in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)  
J.F. Blanc<sup>1</sup>, T. Meyer<sup>2</sup>, A.-L. Cheng<sup>3</sup>, A. El-Khoueiry<sup>4</sup>, I. Cicin<sup>5</sup>, Y. Chen<sup>3</sup>, L. Bolondi<sup>6</sup>, V. Dadduzio<sup>6</sup>, A. Baron<sup>4</sup>, Z.-Z. Lin<sup>3</sup>, J. Adriani<sup>4</sup>, R. Kelly<sup>4</sup>, G. Abou-Alfa<sup>7</sup>; <sup>1</sup>FR, <sup>2</sup>GB, <sup>3</sup>TW, <sup>4</sup>US, <sup>5</sup>TR, <sup>6</sup>IT, <sup>7</sup>NY/US
- 13:05 - 13:05 704P - Outcomes by prior transarterial chemoembolization (TACE) in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)  
T. Yau<sup>1</sup>, A.-L. Cheng<sup>2</sup>, T. Meyer<sup>3</sup>, B.-Y. Ryoo<sup>4</sup>, J.-W. Park<sup>5</sup>, H.-J. Klumpen<sup>6</sup>, H.Y. Lim<sup>5</sup>, S. Kim<sup>7</sup>, J. Knox<sup>8</sup>, M. Patel<sup>9</sup>, A. El-Khoueiry<sup>10</sup>, R. Kelley<sup>9</sup>, G. Abou-Alfa<sup>11</sup>; <sup>1</sup>CN, <sup>2</sup>TW, <sup>3</sup>GB, <sup>4</sup>Songpa-gu/KR, <sup>5</sup>KR, <sup>6</sup>NL, <sup>7</sup>CEDEX/FR, <sup>8</sup>ON/CA, <sup>9</sup>CA/US, <sup>10</sup>US, <sup>11</sup>NY/US
- 13:05 - 13:05 705P - Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib  
L. Fonseca<sup>1</sup>, A. Díaz<sup>2</sup>, V. Sapena<sup>2</sup>, Á. Díaz-González<sup>2</sup>, L. Boix<sup>2</sup>, M. Sanduzzi-Zamparelli<sup>2</sup>, C. Fuster<sup>2</sup>, N. Llarch<sup>2</sup>, G. Iserte<sup>2</sup>, F. Torres<sup>2</sup>, J. Bruix<sup>2</sup>, M. Reig<sup>2</sup>; <sup>1</sup>SP/BR, <sup>2</sup>ES
- 13:05 - 13:05 706P - Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database  
D. Meyers<sup>1</sup>, R. Lee-Ying<sup>1</sup>, M. Alghamdi<sup>1</sup>, H.-W. Sim<sup>2</sup>, V. Zaborska<sup>1</sup>, Y.-J. Ko<sup>1</sup>, T. Raycraft<sup>1</sup>, E. Batuyong<sup>1</sup>, W. Cheung<sup>3</sup>, H. Samawi<sup>1</sup>, J. Davies<sup>1</sup>, V. Tam<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>Ontario/CA, <sup>3</sup>AB/CA
- 13:05 - 13:05 707P - Efficacy and safety of sorafenib (SFN) in elderly patients with hepatocellular carcinoma (HCC)  
L. Gomes Da Fonseca, G. Nader Marta, M.I. Braghiroli, P. M. Hoff, J. Sabbaga; BR
- 13:05 - 13:05 708P - Relationship between change in  $\alpha$ -fetoprotein (AFP) and patient (pt) survival in hepatocellular carcinoma (HCC): a real-world electronic medical records (EMR) database study

L. Hess<sup>1</sup>, Z. Cui<sup>1</sup>, T. Sugihara<sup>1</sup>, Y. Fang<sup>1</sup>, A. Girvan<sup>2</sup>, P. Abada<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>IN/US

- 13:05 - 13:05 709P - Antiviral Therapy Improves Outcomes after Radiofrequency Ablation for HBV-related Hepatocellular Carcinoma: A Propensity Score Matching Analysis  
K. Wang, F. Shen, J. Liu, Z. Yan, J. Li, Y. Xia, L. Shi, G. Qian, Z. Lu, Y. Chen, X. Wan, M. Wu, Y. Zhang; CN
- 13:05 - 13:05 710P - Practice Patterns and Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): Final Analysis of OPTIMIS in Europe and Canada  
J.-L. Raoul<sup>1</sup>, T. Decaens<sup>1</sup>, K. Burak<sup>2</sup>, J. Koskinas<sup>3</sup>, G.E. Villadsen<sup>4</sup>, A. Heurgue-Berlot<sup>1</sup>, I. Bayh<sup>5</sup>, A.-L. Cheng<sup>6</sup>, M. Kudo<sup>7</sup>, H.C. Lee<sup>8</sup>, K. Nakajima<sup>9</sup>, M. Peck-Radosavljevic<sup>10</sup>; <sup>1</sup>FR, <sup>2</sup>AB/CA, <sup>3</sup>GR, <sup>4</sup>DK, <sup>5</sup>DE, <sup>6</sup>TW, <sup>7</sup>JP, <sup>8</sup>KR, <sup>9</sup>NJ/US, <sup>10</sup>AT
- 13:05 - 13:05 711P - Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy  
M. Pracht<sup>1</sup>, E. Chajon<sup>2</sup>, T. de Baere<sup>2</sup>, F. Nguyen<sup>2</sup>, J.-P. Bronowicki<sup>2</sup>, V. Vendrely<sup>2</sup>, A.-S. Baumann<sup>2</sup>, V. Croisé-Laurent<sup>2</sup>, E. Rio<sup>2</sup>, Y. Rolland<sup>2</sup>, S. Le Sourd<sup>1</sup>, P. Gustin<sup>2</sup>, C. Perret<sup>2</sup>, F. Mornex<sup>1</sup>, D. Peiffert<sup>2</sup>, P. Merle<sup>2</sup>, E. Deutsch<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR
- 13:05 - 13:05 712P - Molecular profiling of PDAC and response to chemotherapy: an update from the COMPASS trial  
G. O'Kane<sup>1</sup>, S. Fischer<sup>1</sup>, R. Denroche<sup>1</sup>, G.H. Jang<sup>1</sup>, A. Zhang<sup>1</sup>, A. Dodd<sup>1</sup>, H. Albaba<sup>1</sup>, S. Moura<sup>1</sup>, S. Holter<sup>2</sup>, K. Aung<sup>1</sup>, R. Grant<sup>1</sup>, P. Krzyzanowski<sup>1</sup>, E. Elimova<sup>1</sup>, N. Dhani<sup>1</sup>, D. Hedley<sup>1</sup>, F. Notta<sup>1</sup>, J. Wilson<sup>1</sup>, S. Gallinger<sup>1</sup>, J. Knox<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA
- 13:05 - 13:05 713P - Analysis of BRCAness with MLPA in pancreatic ductal adenocarcinoma patients using FFPE sample obtained via EUS-FNAB  
K. Okuwaki<sup>1</sup>, H. Imaizumi<sup>1</sup>, H. Masutani<sup>1</sup>, T. Yoshida<sup>1</sup>, M. Kida<sup>1</sup>, T. Iwai<sup>1</sup>, H. Yamauchi<sup>1</sup>, T. Kaneko<sup>1</sup>, R. Hasegawa<sup>1</sup>, E. Miyata<sup>1</sup>, K. Adachi<sup>1</sup>, M. Tadehara<sup>1</sup>, W. Koizumi<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Minami-Ii, Sagamihara/JP
- 13:05 - 13:05 714P - Repeated mutKRAS ctDNA measurements in patients with advanced pancreatic cancer patients: kinetics, response prediction and therapy monitoring in comparison to protein-based tumor markers  
S. Kruger, V. Heinemann, C. Ross, F. Diehl, S. Ormanns, S. Liebmann, C. Westphalen, M. Haas, A. Jung, T. Kirchner, M. von Bergwelt-Baildon, S. Holdenrieder, S. Boeck; DE
- 13:05 - 13:05 715P - Clinical utility of plasma cell-free DNA in patients with pancreatic cancer.  
I. Chen, K. Wind, C. Dehlendorff, B. Sørensen, B. Vittrup, A. Johansen, P. Pfeiffer, J. Bjerregaard, S. Bojesen, S. Nielsen, N. Holländer, M. Yilmaz, L. Rasmussen, N. Pallisgaard, J. Johansen, K.-L. Spindler; DK
- 13:05 - 13:05 716P - Cell free Tumor-DNA can predict treatment outcome in advanced PDAC  
S. Payr, J. Beck, U. König, M. Brunner, J. Gaedcke, A. Azizian, M. Ghadimi, V. Ellenrieder, E. Schütz, A.-O. König; DE
- 13:05 - 13:05 717P - Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Ductal Adenocarcinoma Patients Treated with FOLFIRINOX  
A. Sehdev<sup>1</sup>, O. Gbolahan<sup>2</sup>, B. Hancock<sup>2</sup>, M. Stanley<sup>2</sup>, S. Shahda<sup>1</sup>, J. Wan<sup>2</sup>, H. Wu<sup>2</sup>, M. Radovich<sup>2</sup>, B. O'Neil<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>IN/US

- 13:05 - 13:05 718P - A three-gene signature to predict lymph node metastasis of pancreatic cancer  
C. Liang, X. Yu; CN
- 13:05 - 13:05 719P - Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: an explorative randomized AIO phase II trial (ACCEPT)  
M. Haas, D. Waldschmidt, M. Stahl, A. Reinacher-Schick, J. Freiberg-Richter, F. Kaiser, S. Kanzler, N. Frickhofen, T. Seufferlein, T. Dechow, R. Mahlberg, P. Malfertheiner, G. Illerhaus, S. Kubicka, S. Held, C. Westphalen, S. Kruger, S. Boeck, V. Heinemann; DE
- 13:05 - 13:05 720P - SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): results of Stage 1 - the non-randomised dose-finding component  
S. Mukherjee<sup>1</sup>, P. Virdee<sup>1</sup>, R. Shaw<sup>1</sup>, J. Bridgewater<sup>1</sup>, G. Radhakrishna<sup>1</sup>, S. Falk<sup>1</sup>, M. Scott-Brown<sup>1</sup>, V. Strauss<sup>1</sup>, C. Brooks<sup>1</sup>, R. Gillmore<sup>1</sup>, N. Patel<sup>1</sup>, B. Tranter<sup>1</sup>, P. Parsons<sup>1</sup>, D. Sebag-Montefiore<sup>1</sup>, M. Hawkins<sup>1</sup>, P. Corrie<sup>2</sup>, T. Maughan<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Cambridgeshire/GB
- 13:05 - 13:05 721P - A phase 1 study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer.  
E. MIYATA<sup>1</sup>, K. Okuwaki<sup>1</sup>, H. Imaizumi<sup>1</sup>, M. Kida<sup>1</sup>, T. Iwai<sup>1</sup>, H. Yamauchi<sup>1</sup>, T. Kaneko<sup>1</sup>, R. Hasegawa<sup>1</sup>, K. Adachi<sup>1</sup>, M. Tadehara<sup>1</sup>, W. Koizumi<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Minami-Ii, Sagamihara/JP
- 13:05 - 13:05 722P - Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer  
J. Taieb<sup>1</sup>, J.M. Phelip<sup>2</sup>, Y. Rinaldi<sup>1</sup>, E. Barbier<sup>1</sup>, O. Bouche<sup>1</sup>, F. Khemissa Akouz<sup>1</sup>, A. Gratet<sup>1</sup>, C. Petorin<sup>3</sup>, L. Miglianico<sup>1</sup>, D. Malka<sup>1</sup>, H. Laharie Mineur<sup>1</sup>, C. Rebischung<sup>4</sup>, C. Lepage<sup>5</sup>, E. Francois<sup>6</sup>, L. Dahan<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>cédex 2/FR, <sup>3</sup>CEDEX 1/FR, <sup>4</sup>CEDEX 9/FR, <sup>5</sup>Cedex/FR, <sup>6</sup>CEDEX 2/FR
- 13:05 - 13:05 723P - First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe  
J. Taieb<sup>1</sup>, A. Carrato<sup>2</sup>, B. Westphalen<sup>3</sup>, D. Melisi<sup>4</sup>, G. Prager<sup>5</sup>, T. Macarulla Mercade<sup>2</sup>, Å. Mellbring<sup>6</sup>, N. d'Esquermes<sup>1</sup>, A. Ferreras<sup>1</sup>, F. de Jong<sup>7</sup>; <sup>1</sup>FR, <sup>2</sup>ES, <sup>3</sup>DE, <sup>4</sup>IT, <sup>5</sup>AT, <sup>6</sup>SE, <sup>7</sup>CH
- 13:05 - 13:05 724P - Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)  
E.G. Chiorean<sup>1</sup>, W. Cheung<sup>2</sup>, G. Giordano<sup>3</sup>, G. Kim<sup>4</sup>, S.-E. Al-Batran<sup>5</sup>; <sup>1</sup>WA/US, <sup>2</sup>AB/CA, <sup>3</sup>IT, <sup>4</sup>FL/US, <sup>5</sup>DE
- 13:05 - 13:05 725P - Efficacy and safety of Nab-Paclitaxel plus Gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis  
K. Lee<sup>1</sup>, I. Hwang<sup>1</sup>, J. Kang<sup>1</sup>, C. Yoo<sup>2</sup>, K.-P. Kim<sup>1</sup>, J.H. Jeong<sup>1</sup>, H.-M. Chang<sup>3</sup>, B.-Y. Ryoo<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR, <sup>3</sup>KP
- 13:05 - 13:05 726P - FOLFIRINOX for recurrent pancreatic cancer after resection: nationwide multicenter observational study by Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)

S. Morinaga<sup>1</sup>, M. Takita<sup>1</sup>, A. Yoshizawa<sup>1</sup>, K. Kamei<sup>1</sup>, S. Nakamori<sup>1</sup>, S. Ishihara<sup>1</sup>, H. Kuramochi<sup>1</sup>, Y. Yokoyama<sup>1</sup>, T. Uchiyama<sup>1</sup>, G. Murohisa<sup>1</sup>, M. Kobayashi<sup>1</sup>, A. Todaka<sup>1</sup>, A. Fukutomi<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/JP

- 13:05 - 13:05 727P - A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer  
S.J. Lee, D.-Y. Oh, J.-H. Kang, H.J. Choi, M.A. Lee, S.Y. Oh, S.-T. Kim, Y.S. Park, B.-Y. Ryu, J.O. Park; KR
- 13:05 - 13:05 728P - Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis  
Y. Zhang, S. Shi, X. Yu; CN
- 13:05 - 13:05 729P - Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)  
I. Hwang<sup>1</sup>, J. Kang<sup>1</sup>, C. Yoo<sup>2</sup>, J.H. Jeong<sup>1</sup>, K.-P. Kim<sup>1</sup>, H.-M. Chang<sup>3</sup>, B.-Y. Ryou<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR, <sup>3</sup>KP
- 13:05 - 13:05 730P - A Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 (PAG) and Rivaroxaban for Advanced Pancreatic Adenocarcinoma: Interim Safety and Efficacy Analysis  
K. Yu<sup>1</sup>, S. Mantha<sup>1</sup>, C. Tjan<sup>1</sup>, E. Kaufmann<sup>1</sup>, R. Brenner<sup>1</sup>, M. Lowery<sup>1</sup>, G. Ku<sup>1</sup>, N. Raj<sup>1</sup>, M. Shcherba<sup>1</sup>, Z. Goldberg<sup>1</sup>, J. Li<sup>1</sup>, A. Zervoudakis<sup>1</sup>, A. Hamilton<sup>1</sup>, E. Won<sup>1</sup>, R. Do<sup>1</sup>, E. O'Reilly<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NY/US
- 13:05 - 13:05 731P - Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)  
H. Takahashi<sup>1</sup>, C. Morizane<sup>2</sup>, S. Nomura<sup>2</sup>, N. Okano<sup>3</sup>, M. Tsuda<sup>2</sup>, N. Mizuno<sup>2</sup>, H. Satake<sup>4</sup>, K. Tsuji<sup>2</sup>, K. Shioji<sup>2</sup>, H. Ishii<sup>2</sup>, K. Yasui<sup>2</sup>, H. Miyakawa<sup>2</sup>, A. Ishiguro<sup>2</sup>, T. Ogura<sup>2</sup>, M. Ueno<sup>2</sup>, A. Ikeda<sup>2</sup>, T. Terashima<sup>5</sup>, M. Ikeda<sup>1</sup>, T. Okusaka<sup>2</sup>, J. Furuse<sup>3</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>JP, <sup>3</sup>Tokyo/JP, <sup>4</sup>Hyogo/JP, <sup>5</sup>Ishikawa/JP
- 13:05 - 13:05 732P - GEMOX plus hypofractionated radiotherapy for unresectable locally advanced pancreatic cancer: results from a phase 2 study.  
A. Passardi<sup>1</sup>, E. Scarpi<sup>2</sup>, E. Neri<sup>2</sup>, E. Parisi<sup>2</sup>, G. Ghigi<sup>2</sup>, G. Ercolani<sup>2</sup>, A. Gardini<sup>2</sup>, G. La Barba<sup>2</sup>, F. Pagan<sup>2</sup>, A. Casadei Gardini<sup>2</sup>, L. Frassinetti<sup>1</sup>, F. Ferroni<sup>2</sup>, M. Valgiusti<sup>2</sup>, S. Darwish<sup>3</sup>, A. Romeo<sup>2</sup>; <sup>1</sup>Forlì-Cesena/IT, <sup>2</sup>IT, <sup>3</sup>EG
- 13:05 - 13:05 733P - NAPOLI-1 phase 3 trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)  
T. Macarulla Mercade<sup>1</sup>, G. Bodoky<sup>2</sup>, J. Siveke<sup>3</sup>, K.-H. Lee<sup>4</sup>, J. Chen<sup>5</sup>, B. Mirakhor<sup>6</sup>, A. Dean<sup>7</sup>, L.-T. Chen<sup>8</sup>, F. de Jong<sup>9</sup>; <sup>1</sup>ES, <sup>2</sup>HU, <sup>3</sup>DE, <sup>4</sup>KR, <sup>5</sup>MA/US, <sup>6</sup>NJ/US, <sup>7</sup>WA/AU, <sup>8</sup>TW, <sup>9</sup>CH
- 13:05 - 13:05 734P - Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1  
L.-T. Chen<sup>1</sup>, T. Macarulla<sup>2</sup>, J. Blanc<sup>3</sup>, B. Mirakhor<sup>4</sup>, F. de Jong<sup>5</sup>, B. Belanger<sup>4</sup>, T. Bekaii-Saab<sup>6</sup>, J. Siveke<sup>7</sup>; <sup>1</sup>TW, <sup>2</sup>ES, <sup>3</sup>FR, <sup>4</sup>US, <sup>5</sup>CH, <sup>6</sup>AZ/US, <sup>7</sup>DE

- 13:05 - 13:05 735P - Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics  
D. Ahn<sup>1</sup>, A. Barzi<sup>2</sup>, R. Miksad<sup>3</sup>, A. Surinach<sup>4</sup>, F. Corvino<sup>4</sup>, A. Valderrama<sup>5</sup>, K. Mamlouk<sup>5</sup>, S. Pulgar<sup>5</sup>, T. Bekaii-Saab<sup>1</sup>; <sup>1</sup>AZ/US, <sup>2</sup>CA/US, <sup>3</sup>NY/US, <sup>4</sup>US, <sup>5</sup>NJ/US
- 13:05 - 13:05 736P - Multicenter, Phase II Trial of Biweekly S-1, Leucovorin (LV), Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma (mPDAC): Final Report of TCOG T1211 Study  
N.-J. Chiang, K.K. Tsai, J.-S. Chen, S.-H. Yang, H.-H. Hsiao, Y.-S. Shan, L.-T. Chen; TW
- 13:05 - 13:05 737P - A phase II trial of gemcitabine, S-1 and LV combination therapy in patients with advanced pancreatic cancer  
K. Saito, Y. Nakai, H. Isayama, K. Ishigaki, T. Saito, N. Takahara, S. Mizuno, H. Kogure, K. Koike; JP
- 13:05 - 13:05 738P - Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer  
Y. Sunakawa, H. Arai, N. Izawa, T. Mizukami, Y. Horie, A. Doi, M. Hirakawa, T. Ogura, T. Tsuda, T. Nakajima; JP
- 13:05 - 13:05 739P - Quality of Life (QoL) in patients with metastatic pancreatic cancer receiving first-line Nab-paclitaxel/gemcitabine chemotherapy: results of the large QoL study AIO-QoliXane/PARAGON  
C. Schönherr<sup>1</sup>, T. Götze<sup>1</sup>, G. zur Hausen<sup>1</sup>, A. Reichart<sup>1</sup>, C. Pauligk<sup>1</sup>, R. Schlag<sup>2</sup>, G. Siegler<sup>1</sup>, S. Dörfel<sup>1</sup>, A. Aldaoud<sup>1</sup>, L. Hahn<sup>1</sup>, J. Schubert<sup>1</sup>, M.-O. Zahn<sup>1</sup>, H.-G. Höffkes<sup>1</sup>, M. Reiser<sup>1</sup>, M. Koenigsmann<sup>1</sup>, W. Blau<sup>1</sup>, O. Waidmann<sup>1</sup>, N. Homann<sup>1</sup>, J. Trojan<sup>1</sup>, S.-E. Al-Batran<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>Bayern/DE
- 13:05 - 13:05 740P - Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC  
G. Chiritescu<sup>1</sup>, K. Dumon<sup>1</sup>, C. Verslype<sup>1</sup>, G. Houbiers<sup>1</sup>, M. Peeters<sup>1</sup>, J. Janssens<sup>1</sup>, D. van Daele<sup>1</sup>, S. Laurent<sup>1</sup>, J. Arts<sup>2</sup>, K. Hendrickx<sup>3</sup>, I. Borbath<sup>1</sup>, M. Ferrante<sup>1</sup>, F. Bastin<sup>1</sup>, J.-C. Goeminne<sup>1</sup>, J.-L. van Laethem<sup>1</sup>, E. Vanderstraeten<sup>1</sup>, J. Decaestecker<sup>1</sup>, W. van Vaerenbergh<sup>1</sup>, B. Delhougne<sup>1</sup>, E. van Cutsem<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>Assebroek/BE, <sup>3</sup>Oost VI/BE
- 13:05 - 13:05 741P - Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): a systematic literature review (SLR)  
T. Macarulla Mercade<sup>1</sup>, A. Hendifar<sup>2</sup>, C.-P. Li<sup>3</sup>, M. Reni<sup>4</sup>, H. Riess<sup>5</sup>, M. Tempero<sup>6</sup>, A. Dueck<sup>7</sup>, M. Botteman<sup>8</sup>, C. Deshpande<sup>8</sup>, E. Lucas<sup>8</sup>, D.-Y. Oh<sup>9</sup>; <sup>1</sup>ES, <sup>2</sup>CA/US, <sup>3</sup>TW, <sup>4</sup>IT, <sup>5</sup>DE, <sup>6</sup>US/US, <sup>7</sup>AZ/US, <sup>8</sup>US, <sup>9</sup>KR
- 13:05 - 13:05 742P - Outcome Following Centralisation of Pancreatic Cancer Care in Ireland  
R. Abdul Rahman<sup>1</sup>, M. Moriarty<sup>2</sup>, G. McVey<sup>2</sup>, P. Ridgway<sup>2</sup>, D. Maguire<sup>2</sup>, E. Hoti<sup>2</sup>, J. Geoghegan<sup>2</sup>, K. Conlon<sup>2</sup>, R. McDermott<sup>1</sup>; <sup>1</sup>Belgard Square North/IE, <sup>2</sup>IE
- 13:05 - 13:05 743P - Initial treatment and survival in a national unselected Danish cohort of 4161 patients with pancreatic cancer.  
L. Rasmussen, B. Vittrup, M. Ladekarl, P. Pfeiffer, M. Yilmaz, L. Poulsen, K. Østerlind, H. Skuladottir, C. Hansen, M. Mortensen, F. Mortensen, M. Sall, U. Falkmer, C. Frstrup; DK
- 13:05 - 13:05 744P - Trends of care of non-metastatic pancreas cancer patients in Ireland.

R. Abdul Rahman<sup>1</sup>, G. McVey<sup>2</sup>, M. Moriarty<sup>2</sup>, D. Maguire<sup>2</sup>, E. Hoti<sup>2</sup>, P. Ridgway<sup>2</sup>, K. Conlon<sup>2</sup>, J. Geoghegan<sup>2</sup>, R. McDermott<sup>1</sup>; <sup>1</sup>Belgard Square North/IE, <sup>2</sup>IE

- 13:05 - 13:05 745P - Anti-hypertensive medication, sRAGE, and risk of pancreatic cancer: results from the Women's Health Initiative Study  
Z. Wang, D. White, L. Chen, E. Whitsel, P. Richardson, J. Garcia, H. El-Serag, L. Jiao; US
- 13:05 - 13:05 746P - Usefulness of the first screening using apolipoprotein A2 isoforms as the enrichment strategy for pancreatic cancer and its risk diseases  
Y. Sato, T. Kobayashi, S. Nishiumi, S. Okaya, M. Yoshida, Y. Kodama, K. Nagashima, K. Honda; JP
- 13:05 - 13:05 747P - Survival-associated factors and a prognostic nomogram in resected pancreatic cancer: A large international population-based cohort study  
L. Huang<sup>1</sup>, Y. Balavarca<sup>1</sup>, L. van der Geest<sup>2</sup>, V. Lemmens<sup>2</sup>, L. van Eycken<sup>3</sup>, H. De Schutter<sup>3</sup>, T. Johannesen<sup>4</sup>, V. Zadnik<sup>5</sup>, M. Primic-Zakelj<sup>5</sup>, M. Mägi<sup>6</sup>, R. Grützmann<sup>1</sup>, M. Besselink<sup>2</sup>, P. Schrotz-King<sup>1</sup>, H. Brenner<sup>1</sup>, L. Jansen<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>NL, <sup>3</sup>BE, <sup>4</sup>NO, <sup>5</sup>SI, <sup>6</sup>EE
- 13:05 - 13:05 748P - Predicting Survival of Pancreatic Cancer Using Supervised Machine Learning  
M. Osman, EG
- 13:05 - 13:05 749P - The prognostic value of the Modified Glasgow Prognostic Score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)  
L.-T. Chen<sup>1</sup>, T. Macarulla<sup>2</sup>, B. Belanger<sup>3</sup>, B. Mirakhur<sup>4</sup>, F. de Jong<sup>5</sup>, J. Siveke<sup>6</sup>; <sup>1</sup>TW, <sup>2</sup>ES, <sup>3</sup>MA/US, <sup>4</sup>NJ/US, <sup>5</sup>CH, <sup>6</sup>DE
- 13:05 - 13:05 750P - Prognostic Value of the Neutrophil-Lymphocyte Ratio and CA 19-9 in Predicting Survival in Patients with Metastatic Pancreatic Cancer  
I. Dede, M. Cetin, S. Cetin; TR
- 13:05 - 13:05 751P - Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC)  
R. Pihlak<sup>1</sup>, R. Almond<sup>2</sup>, P. Srivastava<sup>2</sup>, H. Raja<sup>2</sup>, R. Broadbent<sup>2</sup>, L. Hopewell<sup>2</sup>, C. Higham<sup>2</sup>, A. Lamarca<sup>2</sup>, R. Hubner<sup>2</sup>, J. Valle<sup>2</sup>, M. McNamara<sup>2</sup>; <sup>1</sup>EE, <sup>2</sup>GB
- 13:05 - 13:05 752P - Clinical utility of serum type III collagen in patients with pancreatic carcinoma.  
I. Chen, N. Willumsen, C. Dehlendorff, A. Johansen, B. Vittrup, M. Krüger, P. Pfeiffer, J. Bjerregaard, S. Bojesen, S. Nielsen, N. Holländer, M. Yilmaz, L. Rasmussen, M. Karsdal, J. Johansen; DK
- 13:05 - 13:05 753P - Venous thromboembolism in Asian patients with pancreatic cancer who underwent palliative chemotherapy: low prevalence, but a poor prognostic factor for early onset  
W.-C. Chou<sup>1</sup>, J.-S. Chen<sup>1</sup>, Y.-Y. Chen<sup>1</sup>, C.-H. Lu<sup>2</sup>, P.-H. Chang<sup>1</sup>; <sup>1</sup>TW, <sup>2</sup>Chiayi County/TW
- 13:05 - 13:05 754P - Targeted Therapy based on the Genetic Alterations Prolongs the Progression-free Survival of Patients with Advanced Biliary Tract Cancer  
F. Feng, Q. Cheng, D. Zhang, B. Li, H. Qin, C. Xu, M. Han, Y. Yu, Z. Li, J.-Y. Li, Z. Qiu, L. Xiong, C. Liu, F. Li, B. Yi, X. Jiang; CN

- 13:05 - 13:05 755P - Evaluation of genetic alterations in biliary tract cancer using targeted exome sequencing.  
H. Chae<sup>1</sup>, C. Yoo<sup>2</sup>, D. Kim<sup>1</sup>, J.H. Jung<sup>1</sup>, H.-M. Chang<sup>3</sup>, B.-Y. Ryoo<sup>2</sup>, K.-P. Kim<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR, <sup>3</sup>KP
- 13:05 - 13:05 756P - Interim results of fight-202, a phase 2, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations  
A. Hollebecque<sup>1</sup>, M. Borad<sup>2</sup>, V. Sahai<sup>3</sup>, D. Catenacci<sup>4</sup>, A. Murphy<sup>3</sup>, G. Vaccaro<sup>3</sup>, A. Paulson<sup>3</sup>, D.-Y. Oh<sup>5</sup>, L. Féliz<sup>6</sup>, C. Lihou<sup>3</sup>, H. Zhen<sup>3</sup>, G. Abou-Alfa<sup>7</sup>; <sup>1</sup>FR, <sup>2</sup>AZ/US, <sup>3</sup>US, <sup>4</sup>IL/US, <sup>5</sup>KR, <sup>6</sup>CH, <sup>7</sup>NY/US
- 13:05 - 13:05 757P - M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- $\beta$ , in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase 1 trial  
C. Yoo<sup>1</sup>, D.-Y. Oh<sup>2</sup>, H.J. Choi<sup>2</sup>, M. Kudo<sup>3</sup>, M. Ueno<sup>3</sup>, S. Kondo<sup>3</sup>, L.-T. Chen<sup>4</sup>, M. Osada<sup>3</sup>, C. Helwig<sup>5</sup>, I. Dussault<sup>6</sup>, M. Ikeda<sup>7</sup>; <sup>1</sup>Songpa-gu/KR, <sup>2</sup>KR, <sup>3</sup>JP, <sup>4</sup>TW, <sup>5</sup>DE, <sup>6</sup>MA/US, <sup>7</sup>Chiba/JP
- 13:05 - 13:05 758P - A new ProTide, NUC-1031, combined with cisplatin for the first-line treatment of advanced biliary tract cancer (ABC-08)  
M. McNamara, J. Bridgewater, D. Palmer, H. Wasan, W.D. Ryder, C. Gnanaranjan, E. Ghazaly, T.R.J. Evans, J. Valle; GB
- 13:05 - 13:05 759P - Phase II Study of Evofosfamide (TH-302) monotherapy as a second-line treatment in advanced biliary tract cancer  
J.S. YOON, K.-H. Lee, G.J. Cheon, Y.-J. Bang, D.-Y. Oh; KR
- 13:05 - 13:05 760P - PhotoChemical Internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma – results from a phase I dose escalation trial  
J. Trojan<sup>1</sup>, R. Sturgess<sup>2</sup>, D. Harrison Palmer<sup>2</sup>, B. Neu<sup>1</sup>, S. Kasper<sup>1</sup>, A. Dechene<sup>1</sup>, C. Jürgensen<sup>1</sup>, J. Schirra<sup>1</sup>, R. Jakobs<sup>1</sup>, A. Högset<sup>3</sup>, L. Finnesand<sup>3</sup>, H. Olivecrona<sup>3</sup>; <sup>1</sup>DE, <sup>2</sup>GB, <sup>3</sup>NO
- 13:05 - 13:05 761P - FOLFIRINOX as a first-line chemotherapy for patients (pts) with advanced biliary tract cancer (BTC)  
A. Ulusakarya, W. Karray, J. Abdou, A. Karaboué, M. Haydar, S. Krimi, Y. Gumus, W. Almohamad, E. Goldschmidt, P. Biondani, J.F. Morère; FR
- 13:05 - 13:05 762P - A randomized phase II trial of adjuvant chemotherapy with gemcitabine versus S-1 after major hepatectomy for biliary tract cancer: Kansai Hepato-Biliary Oncology Group (KHBO1208)  
H. Terajima<sup>1</sup>, S. Kobayashi<sup>1</sup>, H. Nagano<sup>1</sup>, A. Tomokuni<sup>1</sup>, K. Gotoh<sup>1</sup>, D. Sakai<sup>2</sup>, E. Hatano<sup>1</sup>, S. Seo<sup>1</sup>, Y. Uchida<sup>1</sup>, T. Ajiki<sup>1</sup>, H. Satake<sup>3</sup>, K. Kamei<sup>1</sup>, T. Tohyama<sup>1</sup>, T. Hirose<sup>1</sup>, I. Ikai<sup>1</sup>, S. Morita<sup>1</sup>, T. Ioka<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Osaka/JP, <sup>3</sup>Hyogo/JP
- 13:05 - 13:05 763P - Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis  
S. Yadav<sup>1</sup>, H. Xie<sup>2</sup>, I. Riaz<sup>2</sup>, P. Sharma<sup>3</sup>, A. Mahipal<sup>4</sup>, R. McWilliams<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MN/US, <sup>3</sup>CT/US, <sup>4</sup>FL/US
- 13:05 - 13:05 764P - Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): outcomes and safety from a multicenter Italian experience



V. Dadduzio<sup>1</sup>, M. Rizzato<sup>1</sup>, G. Ramondo<sup>1</sup>, C. Vivaldi<sup>1</sup>, M. Milella<sup>1</sup>, G. Brandi<sup>1</sup>, S. Cereda<sup>1</sup>, S. Murgioni<sup>2</sup>, G. Cardellino<sup>1</sup>, R. Filippi<sup>3</sup>, D. Santini<sup>1</sup>, G. Pasquini<sup>1</sup>, R. Intini<sup>1</sup>, V. Vaccaro<sup>1</sup>, A. Palloni<sup>1</sup>, M. Reni<sup>1</sup>, G. Musettini<sup>1</sup>, E. Gringeri<sup>1</sup>, C. Aliberti<sup>1</sup>, V. Zagonel<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>OG/IT, <sup>3</sup>(TO)/IT

- 13:05 - 13:05 765P - Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations
- C. Neuzillet<sup>1</sup>, A. Casadei Gardini<sup>2</sup>, B. Brieau<sup>3</sup>, C. Vivaldi<sup>2</sup>, C. Smolenschi<sup>1</sup>, G. Brandi<sup>2</sup>, D. Tougeron<sup>4</sup>, R. Filippi<sup>5</sup>, A. Vienot<sup>1</sup>, N. Silvestris<sup>2</sup>, A.-L. Pointet<sup>1</sup>, S. Murgioni<sup>6</sup>, B. Rousseau<sup>4</sup>, M. Scartozzi<sup>2</sup>, L. Dahan<sup>1</sup>, T. Boussaha<sup>7</sup>, S. Cruz<sup>8</sup>, A. Meurisse<sup>1</sup>, A. Lievre<sup>1</sup>, D. Vernerey<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>IT, <sup>3</sup>CEDEX 14/FR, <sup>4</sup>CEDEX/FR, <sup>5</sup>(TO)/IT, <sup>6</sup>OG/IT, <sup>7</sup>Vaud/CH, <sup>8</sup>GB
- 13:05 - 13:05 766P - Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)
- J. Hyung<sup>1</sup>, C. Yoo<sup>2</sup>, K.-P. Kim<sup>1</sup>, B.J. Kim<sup>1</sup>, J.H. Jeong<sup>1</sup>, H.-M. Chang<sup>3</sup>, B.-Y. Ryoo<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR, <sup>3</sup>KP
- 13:05 - 13:05 767P - Predictive factors of outcome in patients with advanced biliary tract cancer receiving Gemcitabine plus Cisplatin as first-line chemotherapy
- Y. Suzuki<sup>1</sup>, M. Kan<sup>1</sup>, G. Kimura<sup>1</sup>, K. Umemoto<sup>1</sup>, K. Watanabe<sup>1</sup>, M. Sasaki<sup>1</sup>, H. Takahashi<sup>1</sup>, Y. Hashimoto<sup>1</sup>, H. Imaoka<sup>1</sup>, I. Ohno<sup>1</sup>, S. Mitsunaga<sup>1</sup>, M. Ikeda<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP
- 13:05 - 13:05 768P - Nomograms predicting survival of patients with advanced or recurrent biliary tract cancer receiving a first-line chemotherapy.
- N. Takahara, Y. Nakai, K. Saito, M. Sato, H. Ooyama, S. Kanai, T. Suzuki, T. Sato, R. Hakuta, K. Ishigaki, T. Takeda, S. Mizuno, H. Kogure, M. Tada, K. Koike; JP
- 13:05 - 13:05 769P - Stromal progesterone receptor expression and long-term survival in patients with resected periampullary adenocarcinoma
- G. Andersson, S. Olsson-Hau, S. Lundgren, M. Heby, B. Nodin, K. Jirstrom; SE
- 13:05 - 13:05 770P - A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (aBTC) receiving first-line chemotherapy (1-line cht).
- M. Salati, F. Caputo, A. Spallanzani, M. Rimini, F. Gelsomino, K. Andrikou, S. Cascinu; IT
- 13:05 - 13:05 771P - "The German- Registry" of Incidental gallbladder cancer and the GAIN- phase III trial—transformation from a registry to treatment platform due to a trial in trial concept
- T. Götze, V. Paolucci, S.-E. Al-Batran; DE
- 13:05 - 13:05 772P - ARCAD-NADEGE cohort: Result of a small bowel adenocarcinomas prospective cohort
- T. Aparicio<sup>1</sup>, S. Manfredi<sup>1</sup>, D. Tougeron<sup>1</sup>, J. Henriques<sup>2</sup>, O. Bouche<sup>2</sup>, D. Pezet<sup>2</sup>, G. Piessen<sup>2</sup>, R. Coriat<sup>3</sup>, A. Zaanan<sup>2</sup>, J.L. Legoux<sup>2</sup>, E. Terrebone<sup>2</sup>, M. Pocard<sup>2</sup>, J.-M. Gornet<sup>4</sup>, D. Vernerey<sup>2</sup>, P. Afchain<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX 14/FR, <sup>4</sup>CEDEX 10/FR
- 13:05 - 13:05 773P - Impact of the Number of Nodes Examined on Survival in Node Negative Small Bowel Adenocarcinoma – A SEER Database Analysis
- M. Thiessen, P. Tang, R. Lee-Ying, J. Monzon; CA

- 13:05 - 13:05 774P - The role of adjuvant therapy in resectable SBA: a different clinicians attitude with a relevant impact on outcome.  
G. Orsi<sup>1</sup>, K. Andrikou<sup>1</sup>, F. Bergamo<sup>1</sup>, F. Nappo<sup>1</sup>, C. Manai<sup>1</sup>, A. Passardi<sup>2</sup>, M. Puzzone<sup>1</sup>, S. Vallarelli<sup>1</sup>, M. Libertini<sup>1</sup>, M.L. Riggi<sup>1</sup>, G. Pugliese<sup>1</sup>, A. Zaniboni<sup>1</sup>, M. Schirripa<sup>1</sup>, L. Procaccio<sup>1</sup>, N. Silvestris<sup>1</sup>, M. Scartozzi<sup>1</sup>, A. Casadei Gardini<sup>1</sup>, V. Zagonel<sup>1</sup>, S. Cascinu<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Forlì-Cesena/IT
- 13:05 - 13:05 775TiP - A Phase 3, Randomized, Open-Label Study to Compare the Efficacy of Tislelizumab Versus Chemotherapy as Second-Line Therapy for Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)  
L. Shen<sup>1</sup>, J. Ajani<sup>2</sup>, S.-B. Kim<sup>3</sup>, E. van Cutsem<sup>4</sup>, B. Guo<sup>1</sup>, J. Song<sup>5</sup>, V. Paton<sup>6</sup>, K. Kato<sup>7</sup>; <sup>1</sup>CN, <sup>2</sup>TX/US, <sup>3</sup>KR, <sup>4</sup>BE, <sup>5</sup>NJ/US, <sup>6</sup>CA/US, <sup>7</sup>JP
- 13:05 - 13:05 776TiP - Global Phase 3 Study of Tislelizumab Versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC): A Trial-in-Progress  
S. Qin<sup>1</sup>, R. Finn<sup>2</sup>, M. Kudo<sup>3</sup>, T. Meyer<sup>4</sup>, A. Vogel<sup>5</sup>, M. Ducreux<sup>6</sup>, T. Macarulla<sup>7</sup>, G. Tomasello<sup>8</sup>, F. Boissier<sup>9</sup>, J. Hou<sup>2</sup>, C. Li<sup>1</sup>, J. Song<sup>9</sup>, A. Zhu<sup>10</sup>; <sup>1</sup>CN, <sup>2</sup>CA/US, <sup>3</sup>JP, <sup>4</sup>GB, <sup>5</sup>DE, <sup>6</sup>CEDEX/FR, <sup>7</sup>ES, <sup>8</sup>(CR)/IT, <sup>9</sup>NJ/US, <sup>10</sup>US
- 13:05 - 13:05 777TiP - A Phase 3, Double-Blind, Randomized Study of Pamiparib Versus Placebo as Maintenance Therapy in Patients With Inoperable, Locally Advanced, or Metastatic Gastric Cancer that Responded to Platinum-Based First-Line Chemotherapy  
F. Ciardiello<sup>1</sup>, Y.-J. Bang<sup>2</sup>, J. Bendell<sup>3</sup>, A. Cervantes<sup>4</sup>, R. Brachmann<sup>5</sup>, K. Zhang<sup>5</sup>, M. Raponi<sup>5</sup>, H. Farin<sup>6</sup>, L. Shen<sup>7</sup>; <sup>1</sup>IT, <sup>2</sup>KR, <sup>3</sup>TN/US, <sup>4</sup>ES, <sup>5</sup>CA/US, <sup>6</sup>MA/US, <sup>7</sup>CN
- 13:05 - 13:05 778TiP - Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastatic EsophagoGastric Adenocarcinoma (EGA) - the randomized phase 2 INTEGA trial (AIO STO 0217)  
E. Goekkurt, M. Binder, S. Lorenzen, P. Thuss-Patience, S.-E. Al-Batran, A. Hinke, S. Hegewisch-Becker, S. Nilsson, C. Bokemeyer, A. Stein; DE
- 13:05 - 13:05 779TiP - TRIANGLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus  
H. Daiko, H. Hara, H. Ogawa, K. Hori, J. Mizusawa, S. Ozawa, M. Takagi, M. Tanaka, H. Baba, Y. Shirakawa, M. Tsuda, S. Nakagawa, H. Takeuchi, T. Abe, Y. Ito, T. Kojima, T. Kadota, H. Fukuda, K. Kato, Y. Kitagawa; JP
- 13:05 - 13:05 780TiP - Phase II trial of perioperative PD-L1 inhibition with Avelumab and mDCF chemotherapy for Resectable Locally Advanced Gastric And Esophago-Gastric Adenocarcinoma  
T. Alcindor, A. Awan, T. Opu, J. Asselah, M. Vanhuyse, C. Mueller, L. Ferri; CA
- 13:05 - 13:05 781TiP - PRODIGE 29-UCGI 26(NEOPAN): A Randomised trial of chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC).  
M. Ducreux<sup>1</sup>, R. Desgrrippes<sup>2</sup>, M. Texier<sup>2</sup>, F. Di Fiore<sup>2</sup>, P. Vanelslander<sup>2</sup>, O. Capitain<sup>2</sup>, R. Guimbaud<sup>3</sup>, J. Forestier<sup>2</sup>, F. El Hajbi<sup>1</sup>, P. Follana<sup>4</sup>, A. Parzy<sup>2</sup>, N. Baba Hamed<sup>2</sup>, Y. Rinaldi<sup>2</sup>, T. Brotelle<sup>2</sup>, J.-P. Pignon<sup>1</sup>, C. Jouffroy<sup>2</sup>, L. Dahan<sup>2</sup>, O. Bouche<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX 3/FR, <sup>4</sup>CEDEX 2/FR

- 13:05 - 13:05 782TiP - Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: the randomised Phase III study IMbrave150  
M. Ducreux<sup>1</sup>, A.-L. Cheng<sup>2</sup>, S. Qin<sup>3</sup>, A. Zhu<sup>4</sup>, M. Ikeda<sup>5</sup>, T.-Y. Kim<sup>6</sup>, D.-Z. Xu<sup>3</sup>, W. Verret<sup>4</sup>, J. Liu<sup>3</sup>, R. Finn<sup>7</sup>, P. Galle<sup>8</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>TW, <sup>3</sup>CN, <sup>4</sup>US, <sup>5</sup>JP, <sup>6</sup>KR, <sup>7</sup>CA/US, <sup>8</sup>DE
- 13:05 - 13:05 783TiP - CA209-9DX: Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab vs Placebo for Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence after Curative Resection or Ablation  
M. Jimenez Exposito<sup>1</sup>, M. Akce<sup>1</sup>, J. Montero Alvarez<sup>2</sup>, E. Assenat<sup>3</sup>, L. Balart<sup>1</sup>, A. Baron<sup>4</sup>, T. Decaens<sup>3</sup>, A. Heurgue-Berlot<sup>3</sup>, A. Martin<sup>2</sup>, S. Paik<sup>5</sup>, V. Poulart<sup>6</sup>, A. Sehbai<sup>1</sup>, N. Takemura<sup>7</sup>, J.-H. Yoon<sup>5</sup>; <sup>1</sup>US, <sup>2</sup>ES, <sup>3</sup>FR, <sup>4</sup>CA/US, <sup>5</sup>KR, <sup>6</sup>BE, <sup>7</sup>JP
- 13:05 - 13:05 784TiP - Phase 3 KEYNOTE-585 Study of Chemotherapy (Chemo) + Pembrolizumab (Pembro) vs Chemo + Placebo as Neoadjuvant/Adjuvant Treatment for Patients (Pts) With Gastric or Gastroesophageal Junction (G/GEJ) Cancer  
Y.-J. Bang<sup>1</sup>, E. van Cutsem<sup>2</sup>, C. Fuchs<sup>3</sup>, A. Ohtsu<sup>4</sup>, J. Taberero<sup>5</sup>, D. Ilson<sup>6</sup>, W.J. Hyung<sup>1</sup>, V.E. Strong<sup>6</sup>, T.O. Goetze<sup>7</sup>, T. Yoshikawa<sup>4</sup>, L. Tang<sup>6</sup>, P.M.T. Hwang<sup>6</sup>, D. Adelberg<sup>8</sup>, K. Shitara<sup>4</sup>; <sup>1</sup>KR, <sup>2</sup>BE, <sup>3</sup>CT/US, <sup>4</sup>JP, <sup>5</sup>ES, <sup>6</sup>NY/US, <sup>7</sup>DE, <sup>8</sup>NJ/US
- 13:05 - 13:05 785TiP - Phase 3 KEYNOTE-590 Study of Chemotherapy + Pembrolizumab Versus Chemotherapy + Placebo as First-Line Therapy for Patients (Pts) With Advanced Esophageal or Esophagogastric Junction (E/EGJ) Cancer  
K. Kato<sup>1</sup>, M. Shah<sup>2</sup>, P. Enzinger<sup>3</sup>, J. Bennouna<sup>4</sup>, L. Shen<sup>5</sup>, A. Adenis<sup>4</sup>, J.-M. Sun<sup>6</sup>, B.C. Cho<sup>6</sup>, M. Ozguroglu<sup>7</sup>, T. Kojima<sup>1</sup>, V. Kostorov<sup>8</sup>, C. Hierro<sup>9</sup>, Y. Zhu<sup>10</sup>, S. Shah<sup>10</sup>, P. Bhagia<sup>10</sup>, T. Doi<sup>11</sup>; <sup>1</sup>JP, <sup>2</sup>NY/US, <sup>3</sup>MA/US, <sup>4</sup>FR, <sup>5</sup>CN, <sup>6</sup>KR, <sup>7</sup>TR, <sup>8</sup>RU, <sup>9</sup>ES, <sup>10</sup>NJ/US, <sup>11</sup>Chiba/JP
- 13:05 - 13:05 786TiP - Prospective multicenter feasibility study of laparoscopic sentinel basin dissection after endoscopic submucosal dissection for early gastric cancer.  
K.W. Ryu, B.W. Eom, H.M. Yoon, Y.-W. Kim, J.S. Min, G.S. Cho, I. Cho, Y.J. Lee, J.-H. Park, H. Hur, Y.K. Park, O. Jeong, M.R. Jung, J.H. Lee, J.Y. An; KR
- 13:05 - 13:05 787TiP - A phase III study of adjuvant docetaxel, capecitabine and oxaliplatin triplet vs capecitabine and oxaliplatin doublet in patients with curatively resected stage IIIB or IV(M0) (AJCC 6th ed) gastric adenocarcinoma (TRIUMPH, KCSG ST14-05)  
M.-H. Ryu<sup>1</sup>, D.Y. Zang<sup>1</sup>, K.-W. Lee<sup>1</sup>, B.Y. Shim<sup>1</sup>, M.H. Lee<sup>1</sup>, S.Y. Rha<sup>1</sup>, Y.-K. Kang<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR
- 13:05 - 13:05 788TiP - ACELARATE – A randomised Phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma  
D. Harrison Palmer<sup>1</sup>, P. Ross<sup>1</sup>, P. Silcocks<sup>1</sup>, W. Greenhalf<sup>1</sup>, O. Faluyi<sup>1</sup>, Y.T. Ma<sup>1</sup>, J. Wadsley<sup>1</sup>, C. Rawcliffe<sup>1</sup>, J. Neoptolemos<sup>2</sup>, J. Valle<sup>1</sup>, H. Wasan<sup>1</sup>, N. Starling<sup>1</sup>, K. Patel<sup>1</sup>, J. Bridgewater<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>DE
- 13:05 - 13:05 789TiP - HALO 109-301: Phase 3, randomized, double-blind, placebo-controlled study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan (HA)-high Stage IV pancreatic ductal adenocarcinoma (PDA)

E. van Cutsem<sup>1</sup>, P. Corrie<sup>2</sup>, M. Ducreux<sup>3</sup>, D. Sigal<sup>4</sup>, V. Sahai<sup>4</sup>, D.-Y. Oh<sup>5</sup>, A. Bullock<sup>6</sup>, Y.-J. Bang<sup>5</sup>, A. Baron<sup>7</sup>, A. Hendifar<sup>7</sup>, C.-P. Li<sup>8</sup>, P. Philip<sup>4</sup>, M. Reni<sup>9</sup>, M. Zalupski<sup>10</sup>, L. Zheng<sup>11</sup>, C. Berman<sup>4</sup>, D. Chondros<sup>7</sup>, M. Tempero<sup>12</sup>; <sup>1</sup>BE, <sup>2</sup>Cambridgeshire/GB, <sup>3</sup>CEDEX/FR, <sup>4</sup>US, <sup>5</sup>KR, <sup>6</sup>MA/US, <sup>7</sup>CA/US, <sup>8</sup>TW, <sup>9</sup>IT, <sup>10</sup>MI/US, <sup>11</sup>MD/US, <sup>12</sup>US/US

- 13:05 - 13:05 790TiP - A Phase 2 Clinical Investigation of BPM31510-IV (Ubidecarenone) in patients with advanced Pancreatic Cancer  
A. Niewiarowska<sup>1</sup>, D. Lucius<sup>2</sup>, R. Sarangarajan<sup>2</sup>, N. Narain<sup>2</sup>, R. Ramanathan<sup>3</sup>, P. Ritch<sup>4</sup>, J. Strauss<sup>5</sup>, M. Kundranda<sup>3</sup>, D. Propper<sup>6</sup>; <sup>1</sup>PA/US, <sup>2</sup>US, <sup>3</sup>AZ/US, <sup>4</sup>WI/US, <sup>5</sup>TX/US, <sup>6</sup>GB
- 13:05 - 13:05 1057P - Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): an observational study (ENCORE)  
C. Le Tourneau<sup>1</sup>, M. Ghiani<sup>2</sup>, M. Cau<sup>2</sup>, R. Depenni<sup>2</sup>, G. Ronzino<sup>2</sup>, P. Bonomo<sup>2</sup>, V. Montesarchio<sup>2</sup>, L. Leo<sup>2</sup>, J. Schulten<sup>3</sup>, D. Messinger<sup>3</sup>, A. Sbrana<sup>2</sup>, M.G. Ghi<sup>4</sup>; <sup>1</sup>FR, <sup>2</sup>IT, <sup>3</sup>DE, <sup>4</sup>Mestre-VE/IT
- 13:05 - 13:05 1058P - Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3 nanoparticles activated by radiotherapy: a phase I trial.  
C. Le Tourneau<sup>1</sup>, V. Calugaru<sup>1</sup>, V. Moreno<sup>2</sup>, X. Mirabel<sup>1</sup>, B. Dodger<sup>2</sup>, E. Calvo<sup>2</sup>, T. Jouffroy<sup>1</sup>, J. Rodriguez<sup>1</sup>, A. Chilles<sup>1</sup>, M. Yemi<sup>1</sup>, C. Hoffmann<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>ES
- 13:05 - 13:05 1059P - Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma  
S. Secondino, P. Bossi, A. Gurrado, S. Basso, I. Imarisio, A. Pagani, M. Zecca, I. Pisani, J. Bagnarino, M. Casanova, C. Bergamini, C. Perotti, L. Licitra, P. Comoli, P. Pedrazzoli; IT
- 13:05 - 13:05 1060P - Radiotherapy Alone for Human Papillomavirus-Related Locally Advanced Oropharyngeal Squamous Cell Carcinoma: a Single-Arm, Phase 2 Study  
N. Takemoto, M. Suzuki, Y. Seo, K. Ogawa, H. Inohara; JP
- 13:05 - 13:05 1061P - Molecular screening in advanced cancer patients with head and neck cancers: a retrospective analysis of MOSCATO-01 trial.  
A. Houesson<sup>1</sup>, L. Verlingue<sup>1</sup>, A. Hollebecque<sup>1</sup>, C. Even<sup>1</sup>, L. Lacroix<sup>1</sup>, S. Postel-Vinay<sup>1</sup>, A. Varga<sup>2</sup>, Y. El Dakdouki<sup>1</sup>, R. Balheda<sup>1</sup>, J.-M. Michot<sup>1</sup>, A. Gazzah<sup>1</sup>, A. Marabelle<sup>1</sup>, S. Michiels<sup>1</sup>, E. Rouleau<sup>3</sup>, I. Breuskin<sup>1</sup>, T. de Baere<sup>1</sup>, E. Angevin<sup>2</sup>, J.-Y. Scoazec<sup>1</sup>, J.-C. Soria<sup>4</sup>, C. Massard<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 5/FR, <sup>4</sup>CEDEX/US
- 13:05 - 13:05 1062P - Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma  
H.-F. Kao, R.-L. Hong; TW
- 13:05 - 13:05 1063P - A Multicenter Phase II Trial of Paclitaxel, Carboplatin and Cetuximab (PCE) followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck (SCCHN)  
T. Enokida<sup>1</sup>, T. Ogawa<sup>2</sup>, A. Homma<sup>2</sup>, K. Okami<sup>2</sup>, S. Minami<sup>2</sup>, S. Iwae<sup>2</sup>, A. Nakanome<sup>3</sup>, Y. Shimizu<sup>2</sup>, A. Motegi<sup>2</sup>, D. Maki<sup>2</sup>, Y. Ueda<sup>2</sup>, T. Fujisawa<sup>2</sup>, S. Nomura<sup>2</sup>, S. Okano<sup>1</sup>, M. Tahara<sup>1</sup>; <sup>1</sup>Chiba/JP, <sup>2</sup>JP, <sup>3</sup>Miyagi/JP

- 13:05 - 13:05 1064P - Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study  
M. Hecht, D. Hahn, P. Wolber, M. Hautmann, D. Reichert, J. Weniger, C. Belka, T. Bergmann, T. Göhler, M. Welslau, D. Hofmann, R. Fiektkau; DE
- 13:05 - 13:05 1065P - TOPNIVO - A safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): first results on behalf of the Unicancer Head&Neck Group and the GORTEC.  
C. Even<sup>1</sup>, A. Daste<sup>1</sup>, E. Saada-Bouزيد<sup>1</sup>, J. Fayette<sup>2</sup>, M.-C. Kaminsky-Forretti<sup>2</sup>, S. Zanetta<sup>3</sup>, A. Prevost<sup>1</sup>, G. Lefebvre<sup>2</sup>, C. Borel<sup>2</sup>, D. Cupissol<sup>4</sup>, F. Huguet<sup>1</sup>, J.-P. Delord<sup>5</sup>, N. Baste Rotllan<sup>6</sup>, J. Delaye<sup>1</sup>, I. Jallut<sup>1</sup>, N. Vintonenko<sup>1</sup>, J. Bourhis<sup>7</sup>, J. Guigay<sup>8</sup>, M. Texier<sup>1</sup>, A. Auperin<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>Cedex/FR, <sup>4</sup>CEDEX 5/FR, <sup>5</sup>Haute-Garonne/FR, <sup>6</sup>ES, <sup>7</sup>CH, <sup>8</sup>CEDEX 2/FR
- 13:05 - 13:05 1066P - A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck  
Y. Imamura<sup>1</sup>, N. Kiyota<sup>2</sup>, K. Tanaka<sup>2</sup>, H. Hayashi<sup>2</sup>, I. Ota<sup>2</sup>, K. Nario<sup>2</sup>, S. Hirano<sup>2</sup>, A. Arai<sup>2</sup>, S. Iwae<sup>2</sup>, T. Onoe<sup>2</sup>, S. Minami<sup>2</sup>, T. Shimada<sup>3</sup>, K. Yane<sup>2</sup>, T. Yamazaki<sup>2</sup>, Y. Nagatani<sup>2</sup>, M. Toyoda<sup>1</sup>, N. Otsuki<sup>2</sup>, K.-I. Nibu<sup>2</sup>, H. Minami<sup>1</sup>; <sup>1</sup>Hyogo/Jp, <sup>2</sup>Jp, <sup>3</sup>Tokyo/Jp
- 13:05 - 13:05 1067P - Multicenter Phase II Trial of nab-paclitaxel and Cisplatin (AP) followed by Chemoradiation Therapy (CRT) for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)  
D. Adkins<sup>1</sup>, J. Ley<sup>2</sup>, H. Gay<sup>1</sup>, M. Daly<sup>1</sup>, R. Jackson<sup>1</sup>, J. Rich<sup>1</sup>, P. Pipkorn<sup>1</sup>, R. Paniello<sup>1</sup>, K. Trinkaus<sup>1</sup>, P. Neupane<sup>3</sup>, J. Zevallos<sup>1</sup>, W. Thorstad<sup>1</sup>, P. Oppelt<sup>1</sup>; <sup>1</sup>MO/US, <sup>2</sup>US, <sup>3</sup>KS/US
- 13:05 - 13:05 1068P - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX.  
J. Ham<sup>1</sup>, E. Meerten<sup>1</sup>, E. Fiets<sup>1</sup>, F. Jeurissen Mc Haaglanden<sup>2</sup>, M. Slingerland<sup>1</sup>, W. van der Graaf<sup>3</sup>, C. van Herpen<sup>1</sup>, L. Beerepoot<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>VA/NL, <sup>3</sup>Surrey/GB
- 13:05 - 13:05 1069P - Phase II study of biweekly TPFL induction chemotherapy for locally advanced squamous cell carcinoma of head and neck  
C.Y. Hsieh, M.Y. Lein, C.-H. Hua; TW
- 13:05 - 13:05 1070P - Evaluate the Role of Induction Chemotherapy in the Treatment of Stage II Nasopharyngeal Carcinoma in Intensity Modulated Radiotherapy Era  
T. Jin, P.-J. Li; CN
- 13:05 - 13:05 1071P - Phase 2 study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): final results  
R. Mesia Nin<sup>1</sup>, P. Bossi<sup>2</sup>, A. Hansen<sup>3</sup>, C. Hsieh<sup>4</sup>, L. Licitra<sup>2</sup>, E.H. Tan<sup>5</sup>, P. Chen<sup>6</sup>, J. Miller<sup>7</sup>, L. Siu<sup>3</sup>, R. Haddad<sup>8</sup>; <sup>1</sup>Barcelona/ES, <sup>2</sup>IT, <sup>3</sup>Ontario/CA, <sup>4</sup>TW, <sup>5</sup>SG, <sup>6</sup>NJ/US, <sup>7</sup>US, <sup>8</sup>MA/US
- 13:05 - 13:05 1072P - Concurrent cisplatin-based chemoradiotherapy versus cetuximab-based bioradiotherapy for p16-positive, locally advanced oropharyngeal cancer: A meta-analysis  
P. Suton, M. Skelin, I. Luksic; HR

- 13:05 - 13:05 1073P - Survival benefit of adjuvant chemotherapy VS active surveillance in locally advanced nasopharyngeal carcinoma, a multicenter retrospective study  
P. Danchaivijitr, A. Dechaphunkul, C. Paoin, J. Setakornnukul, T. Dechaphunkul, R. Jiratrachu, S. Niyomnaitam, B. Suktitipat, C. Sookthon, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon; TH
- 13:05 - 13:05 1074P - Paclitaxel in combination with anti-EGFR therapy as induction chemotherapy for patients unfit for cisplatin with locally advanced head and neck squamous cell carcinoma (LA-HNSCC)  
J. Marín<sup>1</sup>, M. Oliva Bernal<sup>2</sup>, M. Plana Serrahima<sup>2</sup>, M. Ferrer<sup>1</sup>, N. Vilaríño Quintela<sup>1</sup>, S. Vazquez<sup>1</sup>, E. Vilajosana<sup>1</sup>, A. Lozano<sup>1</sup>, J. Nogués<sup>1</sup>, A. Mari<sup>1</sup>, O. Bermejo<sup>1</sup>, R. Mesia Nin<sup>2</sup>, M. Taberna Sanz<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 13:05 - 13:05 1075P - Safety and efficacy of nivolumab (nivo) in platinum-refractory recurrent/metastatic head and neck squamous cell (PR R/M HNSCC) patients (pts):real-life experience.  
G. Bruixola<sup>1</sup>, J. Caballero Daroqui<sup>2</sup>, A.J. Cunqueiro Tomas<sup>2</sup>, S. Sandiego<sup>2</sup>, J. García Sánchez<sup>2</sup>, S. Blasco<sup>2</sup>, S. Ochendusko<sup>2</sup>, A. Iranzo<sup>2</sup>, J. Lavernia<sup>2</sup>, A. Berrocal Jaime<sup>2</sup>, M. Pastor Borgoñón<sup>2</sup>; <sup>1</sup>Valencia/ES, <sup>2</sup>ES
- 13:05 - 13:05 1076P - Comparison of 3-weekly cisplatin versus 3-weekly carboplatin in patients with locally advanced nasopharyngeal carcinoma (LA-NPC) receiving concurrent chemoradiotherapy (CCRT) : A multicenter retrospective study  
A. Dechaphunkul, P. Danchaivijitr, R. Jiratrachu, T. Dechaphunkul, C. Sookthon, C. Jiarpinitnun, C. Paoin, J. Setakornnukul, S. Niyomnaitam, B. Suktitipat, P. Pattaranutaporn, N. Ngamphaiboon; TH
- 13:05 - 13:05 1077P - Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma.  
Z. Zeng, R. Yan, L. Tu, Y. Wang, P. Chen, F. Luo, L. Liu; CN
- 13:05 - 13:05 1078P - Genomic Profiling and Matched Therapy for recurrent or metastatic malignant salivary gland tumors  
E. Malone<sup>1</sup>, R. Jang<sup>2</sup>, A. Spreafico<sup>2</sup>, I. Weinreb<sup>2</sup>, S. Jennings<sup>2</sup>, L. Siu<sup>3</sup>, A. Hansen<sup>3</sup>; <sup>1</sup>IE, <sup>2</sup>ON/CA, <sup>3</sup>Ontario/CA
- 13:05 - 13:05 1079P - Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma  
W. van Boxtel, I. van Engen- van Grunsven, D. van Strijp, J.B.A. van Zon, M. Ligtenberg, G. Verhaegh, J. Schalken, S. Neerken, A. van de Stolpe, C. van Herpen; NL
- 13:05 - 13:05 1080P - Prognostics factors in Adenoid Cystic Carcinoma of the Head and Neck (ACCHN): retrospective study of 15 years  
P. Neji, R. Conde, S. Esteves, M.T. Alexandre, M. Ferreira, E. Netto, J. Santos, M. Magalhães, A. Moreira; PT
- 13:05 - 13:05 1081P - Molecular analysis of NRAS, BRAF, C-KIT, ROS1, ALK and RET alterations in serial biopsies in sinonasal mucosal melanoma  
G. Anguera Palacios, L. del Carpio, M.-A. Molina, C. Aguado, J.R. Gras-Cabrerizo, X. Leon, M. Gonzalez-Cao, N. Karachaliou, A. Mozos, A. Gonzalez, A. Barnadas, R. Rosell, M. Majem; ES

- 13:05 - 13:05 1082P - Programmed Death-Ligand 1 (PD-L1) Expression and HPV-associated p16 in Oropharyngeal Squamous Cell Carcinoma (OSCC) treated with primary curative radiotherapy (RT)  
T. Steiniche<sup>1</sup>, J. Eriksen<sup>1</sup>, J. Lilja-Fischer<sup>1</sup>, J. Georgsen<sup>1</sup>, P.-T. Vo<sup>2</sup>, M. Busch-Sørensen<sup>2</sup>, D. Chirovsky<sup>3</sup>, J. Cheng<sup>4</sup>, D. Aurora-Garg<sup>5</sup>, R. Swaby<sup>5</sup>, J. Overgaard<sup>1</sup>; <sup>1</sup>DK, <sup>2</sup>US, <sup>3</sup>New Jersey/US, <sup>4</sup>PA/US, <sup>5</sup>NJ/US
- 13:05 - 13:05 1083P - Dynamics of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC)  
A. Grages, S. Jeske, L. Puntigam, C. Brunner, J. Kraus, H. Kestler, J. Döscher, T. Hoffmann, P. Schuler, S. Laban; DE
- 13:05 - 13:05 1084P - Multiobjective optimization reveals distinct cancer-testis antigen patterns by primary site and Human Papilloma Virus status in head and neck squamous cell carcinoma  
S. Laban, G. Völkel, J. Ezic, T. Hoffmann, H.-G. Rammensee, J. Döscher, P. Schuler, C. Brunner, J. Kraus, H. Kestler; DE
- 13:05 - 13:05 1085P - The use of HPV16-E5, EGFR and pEGFR as prognostic biomarkers for oropharyngeal cancer patients  
M. Taberna<sup>1</sup>, M. Torres<sup>1</sup>, M. Alejo<sup>1</sup>, M. Mena<sup>1</sup>, S. Tous<sup>1</sup>, S. Marquez<sup>1</sup>, M.A. Pavon<sup>1</sup>, X. Leon<sup>1</sup>, J. Garcia<sup>1</sup>, M. Guix<sup>1</sup>, R. Hijano<sup>1</sup>, T. Bonfill<sup>1</sup>, A. Aguilà<sup>1</sup>, A. Lozano<sup>1</sup>, R. Mesia Nin<sup>2</sup>, L. Alemany<sup>1</sup>, I.G. Bravo<sup>3</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES, <sup>3</sup>FR
- 13:05 - 13:05 1086P - Combined analysis of gene expression profiles in 2 preoperative trials with afatinib and cetuximab in head and neck squamous cell carcinoma  
P. Bossi<sup>1</sup>, S. Schmitz<sup>2</sup>, J.-P. Machiels<sup>2</sup>, L. Licitra<sup>1</sup>, C. Fortpied Lefevre<sup>2</sup>, C. Caballero<sup>2</sup>, S. Canevari<sup>1</sup>, L. De Cecco<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>BE
- 13:05 - 13:05 1087P - Association of LIPI Score with Immune Checkpoint Inhibitors (ICI) outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck (R/M SCCHN) patients (pts).  
R.G. Herrera Gomez<sup>1</sup>, L. Mezquita<sup>1</sup>, E. Auclin<sup>1</sup>, K. Saleh<sup>1</sup>, N. Baste Rotllan<sup>2</sup>, M. Iacobs<sup>1</sup>, S. Bursuc<sup>3</sup>, L. Mayache Badis<sup>1</sup>, F.R. Ferrand<sup>4</sup>, O. Casiraghi<sup>1</sup>, S. Temam<sup>1</sup>, I. Breuskin<sup>1</sup>, Y. Tao<sup>1</sup>, B. Besse<sup>5</sup>, C. Even<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>ES, <sup>3</sup>RO, <sup>4</sup>CEDEX 5/FR, <sup>5</sup>CEDEX/FR
- 13:05 - 13:05 1088P - Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma(R/M HNSCC) treated with Pembrolizumab in the INSPIRE study  
M. Oliva Bernal<sup>1</sup>, S. Lien<sup>2</sup>, B. Wang<sup>2</sup>, S.C. Yang<sup>2</sup>, A. Spreafico<sup>2</sup>, R. Jang<sup>2</sup>, S. Elston<sup>2</sup>, S. Jennings<sup>2</sup>, H. Jiang<sup>3</sup>, B. Haibe-Kains<sup>2</sup>, T. Pugh<sup>3</sup>, P. Ohashi<sup>3</sup>, L. Siu<sup>4</sup>, A. Hansen<sup>4</sup>; <sup>1</sup>Barcelona/ES, <sup>2</sup>ON/CA, <sup>3</sup>CA, <sup>4</sup>Ontario/CA
- 13:05 - 13:05 1089P - C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer  
M.-C. Lin, P.-H. Chien, H.-Y. Wu, S.-T. Chen, H.-F. Juan, N.-Y. Lin, P.-J. Lou, M.-C. Huang; TW
- 13:05 - 13:05 1090P - Frequency of PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma (HNSCC) in Southern Thailand.  
P. Thongwatchara, P. Thongsuksai, T. Dechaphunkul, A. Dechaphunkul; TH

- 13:05 - 13:05 1091P - Comparison between the 7th and the proposed 8th editions of the UICC staging system for nasopharyngeal carcinoma patients without cervical lymph node metastasis: a retrospective analysis  
C. Hu, CN
- 13:05 - 13:05 1092P - Validation of the Clinical AJCC/UICC TNM 8th Edition for Human Papillomvirus Related Oropharyngeal Squamous Cell Carcinoma  
S. Deschuymer, R. Dok, A. Laenen, E. Hauben, S. Nuyts; BE
- 13:05 - 13:05 1093P - Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)  
K. Xu<sup>1</sup>, A. Lo<sup>1</sup>, V. Chin<sup>1</sup>, C. Gzell<sup>1</sup>, C. O'Connor<sup>1</sup>, D. Forstner<sup>1</sup>, R. Gallagher<sup>1</sup>, R. Bova<sup>1</sup>, J. Crawford<sup>1</sup>, R. Harvey<sup>1</sup>, A. Lochhead<sup>2</sup>, P. Earls<sup>2</sup>, M. Qiu<sup>2</sup>, E. Hsu<sup>1</sup>, G. Bigg-Wither<sup>1</sup>, L. Chan<sup>1</sup>, H. Bao<sup>1</sup>, P. Foltyn<sup>1</sup>, H.-W. Sim<sup>1</sup>, A. Prawira<sup>3</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU, <sup>3</sup>Ontario/CA
- 13:05 - 13:05 1094P - Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy.  
P. Bossi, R. Depenni, M. Cossu Rocca, D. Ferrari, G. Azzarello, M. Alù, F. Nolè, C. Codecà, G. Boscolo, M. Piccininni, S. Cavalieri, G. Pugliese, L. Licitra; IT
- 13:05 - 13:05 1095P - Prognostic value of MRI-derived residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma and a nomogram for the prediction of it  
W.-Z. Li, H. Liang, X. Lv, L.-R. Ke, Y.-F. Ye, Y.-H. Yu, W.-Z. Qiu, G.-Y. Liu, X.-J. Huang, K.-Y. Liu, S.-H. Lv, X. Guo, Y.-Q. Xiang, W.-X. Xia; CN
- 13:05 - 13:05 1096P - Proteomic Comparison Based on 18FDG-PET/CT Defined Metabolic Tumor Volume in Non-metastatic Nasopharyngeal Carcinoma  
C. Chen, L. Li, Z. Fei, J. Wang, T. Chen; CN
- 13:05 - 13:05 1097P - Prognostic value of metabolic tumor volume in recurrent and/or metastatic head and neck squamous cell carcinoma treated with platinum-based chemotherapy.  
M. Suzuki, N. Takemoto, T. Fukuzumi, M. Yamamoto, S. Otozai, T. Yoshii, T. Fujii, H. Inohara; JP
- 13:05 - 13:05 1098P - The prognostic value of early tumor response in metastatic nasopharyngeal carcinoma patients treated with first-line chemotherapy  
W.-X. Xia, L. Guoying, X. Lv, S.-H. Lv, X.-J. Huang, W.-Z. Qiu, H. Liang, W.-Z. Li, K.-Y. Liu, Y.-H. Yu, Y.-Q. Xiang, X. Guo; CN
- 13:05 - 13:05 1099P - Potential clinical management changes in patients harboring locally advanced squamous-cell carcinoma of head and neck by incorporating pre and post chemoradiotherapy 18.FDG PET/CT: A prospective trial.  
U. Nicolau, A.C. Queiroz, T. Felismino, E. Lima, V.H. Jesus, L. Cezana, M. Alves, A.C. Pellizzon, P. Pinto, G. Porto, G. Carvalho, C.A. Pinto, V. Silva, A. Guimarães, T. Oliveira, M. Ikeda, T. Paiva Jr, P. Bes, L.P. Kowalski; BR
- 13:05 - 13:05 1100P - Patterns of Local Failures and Suggestions for Reduction of Clinical Target Volume for Nasopharyngeal Carcinoma Patients Without Cervical Lymph Node Metastasis  
C. Hu, Y. Li; CN
- 13:05 - 13:05 1101P - Target delineation and dose prescription for adaptive replanned intensity-modulated radiotherapy in nasopharyngeal carcinoma.



X. Huan, CN

- 13:05 - 13:05 1102P - Significance of Pretreatment F-18 FDG PET/CT Parameters in Nasopharyngeal Carcinoma Treated with Intensity-modulated Radiation Therapy  
Y. Huang, C. Chen, Y. Li, X. Qiu, T. Chen; CN
- 13:05 - 13:05 1103P - Sentinel lymph node biopsy for clinically N0 oral squamous cell carcinoma  
H. Goda, K.-I. Nakashiro; JP
- 13:05 - 13:05 1104P - An insight on Head and neck cancer management in China  
Y. Xiaoshi, D. Weiyi; CN
- 13:05 - 13:05 1105P - Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck  
A. Lafuma, F.-E. Cotté, C. Le Tourneau, C. Emery, A.-F. Gaudin, E. Torreton, J. Gourmelen, J. Bonastre; FR
- 13:05 - 13:05 1106P - Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): results from an EORTC led survey  
S. Oosting<sup>1</sup>, I. Desideri<sup>2</sup>, D. Staelens<sup>3</sup>, C. Caballero<sup>3</sup>, S. Tribius<sup>4</sup>, C. Simon<sup>5</sup>, S. Singer<sup>4</sup>, V. Gregoire<sup>6</sup>, C. Fortpied<sup>3</sup>, A. Luciani<sup>2</sup>; <sup>1</sup>NL, <sup>2</sup>IT, <sup>3</sup>BE, <sup>4</sup>DE, <sup>5</sup>CH, <sup>6</sup>FR
- 13:05 - 13:05 1107P - The importance of comorbidity assessment in patients with oral squamous cell carcinoma (OSCC). Could the Adult Comorbidity Evaluation – 27 (ACE-27) provide an additional information?  
U. Jariod Ferrer, S. Blanco Sanfrutos, M. Gavin Clavero, T. Uson Bouthelier, B. Nadal Cristobal, I. Moral Saez, I. Pajares Bernad, A. Cisneros Gimeno, J. Martinez Trufero; ES
- 13:05 - 13:05 1108P - Can concomitant diseases predict the compliance with cisplatin plus RT in patients with LA SCCHN? An exploratory endpoint analysis of the COMPLY trial.  
J. Dunst<sup>1</sup>, G. Hildebrandt<sup>1</sup>, M. Becker-Schiebe<sup>1</sup>, T. Kuhnt<sup>1</sup>, F. Weykamp<sup>1</sup>, F. Martucci<sup>2</sup>, D. Vordermark<sup>1</sup>, M. Pless<sup>2</sup>, D. Hofmann<sup>1</sup>, V. Bühler<sup>2</sup>, S. Rothschild<sup>2</sup>; <sup>1</sup>DE, <sup>2</sup>CH
- 13:05 - 13:05 1109P - Comparison of acute hematologic and renal toxicities in two chemotherapy schedules of cisplatin for epithelial cell carcinoma of head and neck  
A. Ameri, S. Norouzi, A. Sourati, K. Novin, S. Azghandi; IR
- 13:05 - 13:05 1110P - Patient reports of mouth symptoms after radiotherapy treatment for head and neck cancer: an international survey.  
C. Curtis, A. Nicotera, C. Griseri, H. Roddam; GB
- 13:05 - 13:05 1111P - Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer.  
H. Shirasu<sup>1</sup>, T. Yokota<sup>2</sup>, K. Fushiki<sup>1</sup>, H. Inoue<sup>1</sup>, M. Shibata<sup>1</sup>, M. Furuta<sup>1</sup>, T. Kawakami<sup>1</sup>, S. Kawai<sup>1</sup>, S. Hamauchi<sup>1</sup>, A. Todaka<sup>1</sup>, T. Tsushima<sup>2</sup>, N. Machida<sup>1</sup>, K. Yamazaki<sup>2</sup>, A. Fukutomi<sup>2</sup>, Y. Onozawa<sup>2</sup>, H. Yasui<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/JP
- 13:05 - 13:05 1112P - Nutritional Support Dependence after Curative Chemoradiotherapy in Head and Neck Cancer: a Supplementary Analysis of a Phase II Trial (JCOG0706S1)

Y. Imamura<sup>1</sup>, N. Kiyota<sup>2</sup>, T. Akimoto<sup>2</sup>, G. Ogawa<sup>2</sup>, J. Eba<sup>2</sup>, S. Minami<sup>2</sup>, Y. Hasegawa<sup>2</sup>, S. Iwae<sup>2</sup>, N. Monden<sup>2</sup>, K. Matsuura<sup>2</sup>, H. Fujii<sup>2</sup>, Y. Onozawa<sup>3</sup>, A. Homma<sup>2</sup>, R. Hayashi<sup>2</sup>, M. Tahara<sup>4</sup>; <sup>1</sup>Hyogo/JP, <sup>2</sup>JP, <sup>3</sup>Shizuoka/JP, <sup>4</sup>Chiba/JP

13:05 - 13:05 1113P - The retrospective analysis of nephrotoxicity for cisplatin dose of CRT compared 100 mg/m<sup>2</sup> to 80 mg/m<sup>2</sup> for head and neck cancer (HNC) patients

T. Oguri<sup>1</sup>, K. Nakano<sup>2</sup>, N. Fukuda<sup>2</sup>, K. Kawaguchi<sup>2</sup>, T. Urasaki<sup>2</sup>, M. Nishizawa<sup>2</sup>, M. Yunokawa<sup>2</sup>, M. Ono<sup>2</sup>, S. Taira<sup>2</sup>, J. Tomomatsu<sup>2</sup>, T. Toshiyasu<sup>2</sup>, H. Mitani<sup>2</sup>, S. Takahashi<sup>2</sup>; <sup>1</sup>Aichi/JP, <sup>2</sup>JP

13:05 - 13:05 1114P - Comparison of Treatment Outcomes and Tolerability of Patients with Recurrent (R) Nasopharyngeal Carcinoma (NPC) and Metastatic Disease at Diagnosis (M1) : A Retrospective Analysis  
C. Sookthorn, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon; TH

13:05 - 13:05 1115P - Impact of the multidisciplinary approach on the survival of squamous head and neck cancer in our institution.

M.J. Martínez-Ortiz, Á. Martínez-Ortiz, G. Marín-Zafra, P. Cerezuela-Fuentes, J. Balsalobre, J.A. Díaz-Manzano, J. Trujillo-Santos, M.T. García-García; ES

13:05 - 13:05 1116TiP - A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)

N. Hanai, T. Asakage, N. Kiyota, A. Homma, N. Monden, H. Fukushima, T. Fujii, T. Ogawa, K. Tanaka, J. Mizusawa, J. Eba, R. Hayashi; JP

13:05 - 13:05 1117TiP - IMvoke010: Randomized Phase III Study of Atezolizumab (atezo) as Adjuvant Monotherapy After Definitive Therapy of Squamous Cell Carcinoma of the Head and Neck (SCCHN)

R. Haddad<sup>1</sup>, D. Wong<sup>2</sup>, Y. Guo<sup>3</sup>, J. Fayette<sup>4</sup>, E. Cohen<sup>2</sup>, M. Kowgier<sup>5</sup>, A. Sandler<sup>6</sup>, C. Matheny<sup>2</sup>, F. Kabbinavar<sup>2</sup>, D. Raben<sup>2</sup>; <sup>1</sup>MA/US, <sup>2</sup>US, <sup>3</sup>CN, <sup>4</sup>FR, <sup>5</sup>CA, <sup>6</sup>OR/US

13:05 - 13:05 1118TiP - A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

N. Ngamphaiboon, S. Lukerak, C. Jiarpinitnun, A. Jinawath, N. Jinawath, J. Juengsamarn, L. Arsa, J. Konmun, N. Kongsuphon, N. Sankaseam, E. Sirachainan, P. Witoonpanich, A. Kositwattanarerk, P. Pattaranutaporn; TH

13:05 - 13:05 1119TiP - Randomized phase II multicenter study comparing modified PFE regimen with modified TPEX regimen in recurrent or metastatic squamous cell carcinoma of the head and neck: TEMPER study

M. Shimokawa<sup>1</sup>, M. Suzuki<sup>1</sup>, M. Sugawara<sup>1</sup>, K. Shiga<sup>1</sup>, T. Satoh<sup>2</sup>, H. Inohara<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Osaka/JP

13:05 - 13:05 1120TiP - Randomized phase III study in EBV positive locally advanced nasopharyngeal carcinoma treated with concurrent chemo-radiotherapy with or without Anti-Viral drug.

K. Alsaleh, A. Elbasmi, A. Hussein, F. Alshaflan, M. El-Sherify; KW

13:05 - 13:05 1121TiP - KEYNOTE-412: Phase 3 Study of Pembrolizumab Plus Chemoradiation vs Chemoradiation Alone for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

J.-P. Machiels<sup>1</sup>, L. Licitra<sup>2</sup>, Y.G. Tao<sup>3</sup>, C.-J. Yen<sup>4</sup>, D. Rischin<sup>5</sup>, J. Waldron<sup>6</sup>, B. Burtness<sup>7</sup>, V. Gregoire<sup>1</sup>, S. Agarwala<sup>8</sup>, J. Yorio<sup>7</sup>, J.-P. Delord<sup>3</sup>, S. Aksoy<sup>9</sup>, S. Ikeda<sup>10</sup>, R.-L. Hong<sup>4</sup>, J.Y. Ge<sup>7</sup>, H. Brown<sup>7</sup>, B. Bidadi<sup>7</sup>, L. Siu<sup>11</sup>; <sup>1</sup>BE, <sup>2</sup>IT, <sup>3</sup>FR, <sup>4</sup>TW, <sup>5</sup>VIC/AU, <sup>6</sup>ON/CA, <sup>7</sup>US, <sup>8</sup>PA/US, <sup>9</sup>TR, <sup>10</sup>JP, <sup>11</sup>Ontario/CA

- 13:05 - 13:05 1122TiP - Pembrolizumab in Patients With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC): The Phase 2 KEYNOTE-629 Study  
L. Licitra<sup>1</sup>, L. Siu<sup>2</sup>, E. Cohen<sup>3</sup>, P. Zhang<sup>4</sup>, B. Gumuscu<sup>4</sup>, R. Swaby<sup>4</sup>, K. Harrington<sup>5</sup>; <sup>1</sup>IT, <sup>2</sup>Ontario/CA, <sup>3</sup>US, <sup>4</sup>NJ/US, <sup>5</sup>GB
- 13:05 - 13:05 1123TiP - A Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk, HPV-Positive, Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9)  
A. Spreafico<sup>1</sup>, K. Sultanem<sup>1</sup>, B. Chen<sup>1</sup>, S. Bratman<sup>1</sup>, J. Ringash<sup>1</sup>, A. Louie<sup>1</sup>, A. McNiven<sup>1</sup>, K. Whelan<sup>1</sup>, J. Hilton<sup>1</sup>, J. Yoo<sup>1</sup>, J.-P. Machiels<sup>2</sup>, L. Licitra<sup>3</sup>, S. Oosting<sup>4</sup>, J. Waldron<sup>5</sup>, L. Siu<sup>6</sup>, W. Parulekar<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>BE, <sup>3</sup>IT, <sup>4</sup>NL, <sup>5</sup>ON/CA, <sup>6</sup>Ontario/CA
- 13:05 - 13:05 1124TiP - Randomized, Phase II Study of Ficlatazumab with or without Cetuximab in Patients (pts) with Cetuximab-Resistant, Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)  
J. Bauman, PA/US
- 13:05 - 13:05 1125P - Prophylactic versus reactive enteral nutritional supplement in local advanced nasopharyngeal carcinoma patients receiving radical chemo-radiotherapy: A prospective, randomized, controlled clinical trial (NCT02948699)  
S. Huang, Y.-Y. Chen, X. Chen, Q. Hu; CN
- 13:05 - 13:05 1126TiP - Nivolumab and Ipilimumab in Combination with Radiotherapy in Patients with Locally Advanced Head and Neck Cancer  
J. Johnson<sup>1</sup>, V. Bar Ad<sup>1</sup>, E. Lorber<sup>2</sup>, A. Luginbuhl<sup>1</sup>, J. Curry<sup>1</sup>, D. Cognetti<sup>1</sup>, S. Keith<sup>2</sup>, R. Axelrod<sup>2</sup>, R. Zinner<sup>2</sup>, U. Rodeck<sup>2</sup>, L. Harshyne<sup>1</sup>, A. Argiris<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>PA/US, <sup>3</sup>GR
- 13:05 - 13:05 1250P - Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial  
R. Dummer<sup>1</sup>, D. Schadendorf<sup>2</sup>, A. Hauschild<sup>3</sup>, M. Santinami<sup>4</sup>, V. Atkinson<sup>5</sup>, M. Mandala<sup>4</sup>, V. Chiarion Sileni<sup>4</sup>, J. Larkin<sup>6</sup>, M. Nyakas<sup>7</sup>, C. Dutriaux<sup>8</sup>, A. Haydon<sup>9</sup>, L. Mortier<sup>8</sup>, C. Robert<sup>8</sup>, J. Schachter<sup>10</sup>, X. Feng<sup>11</sup>, E. de Jong<sup>11</sup>, B. Mookerjee<sup>12</sup>, R. Kefford<sup>5</sup>, J. Kirkwood<sup>13</sup>, G. Long<sup>14</sup>; <sup>1</sup>CH, <sup>2</sup>DE, <sup>3</sup>Schleswig-Holstein/DE, <sup>4</sup>IT, <sup>5</sup>AU, <sup>6</sup>GB, <sup>7</sup>NO, <sup>8</sup>FR, <sup>9</sup>VIC/AU, <sup>10</sup>IL, <sup>11</sup>US, <sup>12</sup>NJ/US, <sup>13</sup>PA/US, <sup>14</sup>NSW/AU
- 13:05 - 13:05 1251P - Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial  
V. Atkinson<sup>1</sup>, A. Hauschild<sup>2</sup>, M. Santinami<sup>3</sup>, M. Mandala<sup>3</sup>, V. Chiarion Sileni<sup>3</sup>, J. Larkin<sup>4</sup>, M. Nyakas<sup>5</sup>, C. Dutriaux<sup>6</sup>, A. Haydon<sup>7</sup>, L. Mortier<sup>6</sup>, C. Robert<sup>6</sup>, J. Schachter<sup>8</sup>, D. Schadendorf<sup>9</sup>, X. Feng<sup>10</sup>, E. de Jong<sup>10</sup>, B. Mookerjee<sup>11</sup>, R. Kefford<sup>1</sup>, R. Dummer<sup>12</sup>, J. Kirkwood<sup>13</sup>, G. Long<sup>14</sup>; <sup>1</sup>AU, <sup>2</sup>Schleswig-Holstein/DE, <sup>3</sup>IT, <sup>4</sup>GB, <sup>5</sup>NO, <sup>6</sup>FR, <sup>7</sup>VIC/AU, <sup>8</sup>IL, <sup>9</sup>DE, <sup>10</sup>US, <sup>11</sup>NJ/US, <sup>12</sup>CH, <sup>13</sup>PA/US, <sup>14</sup>NSW/AU
- 13:05 - 13:05 1252P - Management of melanoma recurrence following adjuvant anti-PD1 therapy  
C. Owen<sup>1</sup>, D. Palmieri<sup>2</sup>, A. Guminski<sup>2</sup>, M. Carlino<sup>2</sup>, A. Menzies<sup>1</sup>, G. Long<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU

- 13:05 - 13:05 1253P - High Response Rate with T-VEC in Early Metastatic Melanoma (Stage IIIB/C-IVM1a)  
V. Franke, D. Berger, W. Klop, B. van der Hiel, B. van de Wiel, S. Ter Meulen, M. Wouters, W. van Houdt, A. van Akkooi; NL
- 13:05 - 13:05 1254P - Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR trial  
S. Blankenstein, M. Rohaan, W. Klop, B. van der Hiel, B. van de Wiel, D. Peeper, A. van Akkooi, J. Haanen; NL
- 13:05 - 13:05 1255P - Impact of Intralesional Interleukin 2 (IL2) for In-transit Melanoma in two Canadian Centres  
D.S. Ernst<sup>1</sup>, V. Hayward<sup>2</sup>, H. McConkey<sup>3</sup>, X. Teng<sup>3</sup>, E. Saettler<sup>3</sup>, T. Cheng<sup>4</sup>, C. Temple-Oberle<sup>4</sup>, F. Gwadry-Sridhar<sup>3</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>BC/CA, <sup>3</sup>ON/CA, <sup>4</sup>AB/CA
- 13:05 - 13:05 1256P - Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients  
H. Dearden<sup>1</sup>, R. Mason<sup>2</sup>, B. Nguyen<sup>3</sup>, J. Soon<sup>4</sup>, J. Smith<sup>5</sup>, M. Randhawa<sup>6</sup>, A. Mant<sup>4</sup>, L. Warburton<sup>3</sup>, S. Lo<sup>1</sup>, T. Meniawy<sup>3</sup>, A. Guminski<sup>5</sup>, P. Parente<sup>4</sup>, S. Ali<sup>6</sup>, A. Haydon<sup>4</sup>, G. Long<sup>5</sup>, M. Carlino<sup>5</sup>, M. Millward<sup>3</sup>, V. Atkinson<sup>1</sup>, A. Menzies<sup>1</sup>; <sup>1</sup>AU, <sup>2</sup>QLD/AU, <sup>3</sup>WA/AU, <sup>4</sup>VIC/AU, <sup>5</sup>NSW/AU, <sup>6</sup>ACT/AU
- 13:05 - 13:05 1257P - KEYNOTE-151: a Phase 1b Study of Second-Line Pembrolizumab (Pembro) for Chinese Patients (Pts) With Advanced or Metastatic Melanoma  
L. Si<sup>1</sup>, X. Zhang<sup>1</sup>, Y. Shu<sup>1</sup>, H. Pan<sup>2</sup>, D. Wu<sup>1</sup>, J. Liu<sup>1</sup>, F. Lou<sup>1</sup>, X. Wang<sup>1</sup>, X. Wen<sup>1</sup>, Y. Gu<sup>1</sup>, L. Zhu<sup>1</sup>, S. Lan<sup>1</sup>, X. Cai<sup>1</sup>, Y. Zhou<sup>1</sup>, J. Ge<sup>1</sup>, J. Li<sup>1</sup>, H. Wu<sup>1</sup>, J. Guo<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>Zhejiang/CN
- 13:05 - 13:05 1258P - Baseline Predictive Factors for efficacy of AntiPD1 used in first line in Melanoma Patients: an Italian Melanoma Intergroup study  
R. Marconcini<sup>1</sup>, E. Tanda<sup>1</sup>, L. Di Guardo<sup>1</sup>, O. Nigro<sup>1</sup>, P. Fava<sup>1</sup>, A. Todisco<sup>1</sup>, F. Morgese<sup>1</sup>, A. Cortellini<sup>1</sup>, E. Stroppa<sup>1</sup>, G. Gallizzi<sup>1</sup>, L. Festino<sup>1</sup>, E. Grego<sup>1</sup>, S. Quadri<sup>2</sup>, C. Orlandini<sup>1</sup>, A. Nuzzo<sup>1</sup>, S. Manacorda<sup>1</sup>, F. Bloise<sup>1</sup>, A. Indini<sup>1</sup>, C. Astrua<sup>1</sup>, A. Falcone<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Frosinone/IT
- 13:05 - 13:05 1259P - Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: a retrospective analysis of patients with advanced BRAF mutated melanoma.  
I. Reijers, E. Rozeman, H. Mallo, W. Uytterlinde, S. Adriaansz, J. Lijnsvelt, S. Wilgenhof, J. van Thienen, J. Haanen, C. Blank; NL
- 13:05 - 13:05 1260P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma  
P. Saiag<sup>1</sup>, C. Robert<sup>1</sup>, J.J. Grob<sup>1</sup>, L. Mortier<sup>2</sup>, O. Deraure<sup>1</sup>, C. Lebbe<sup>3</sup>, S. Mansard<sup>4</sup>, F. Grange<sup>1</sup>, E.-M. Neidhardt<sup>2</sup>, T. Lesimple<sup>1</sup>, L. Machel<sup>1</sup>, C. Bedane<sup>2</sup>, G. Jeudy<sup>1</sup>, F. Aubin<sup>1</sup>, B. Dreno<sup>4</sup>, A. Szenik<sup>1</sup>, A. Denden<sup>1</sup>, C. Dutriaux<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 10/FR, <sup>4</sup>CEDEX 1/FR
- 13:05 - 13:05 1261P - Loss of HLA class I expression and T-cell infiltration or PD-L1 expression are associated with different response patterns to pembrolizumab in melanoma  
A. Degraeuwe, N. van Baren, F. Cornelis, P. van Eeckhout, J.-F. Baurain; BE
- 13:05 - 13:05 1262P - Soluble PD-L1 as a prognostic factor in advanced acral and mucosal melanoma  
X. Wang, C. Cui, J. Yu, Y. Kong, L. Si, Z. Chi, X. Sheng, L. Mao, B. Lian, B. Tang, X. Yan, J. Guo; CN

- 13:05 - 13:05 1263P - The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice.  
A. Czarnecka<sup>1</sup>, P. Teterycz<sup>1</sup>, I. Lugowska<sup>1</sup>, P. Rogala<sup>1</sup>, T. Switaj<sup>2</sup>, P. Rutkowski<sup>1</sup>; <sup>1</sup>PL, <sup>2</sup>IR
- 13:05 - 13:05 1264P - Long-term survivors among patients with metastatic melanoma treated with targeted agents and/or checkpoint inhibitors  
H. Linardou<sup>1</sup>, A. Laskarakis<sup>2</sup>, A. Molfeta<sup>2</sup>, K. Sakellariou<sup>2</sup>, A. Tarampikou<sup>1</sup>, E. Soroli<sup>2</sup>, K. Gkiati<sup>2</sup>, D. Bafaloukos<sup>1</sup>; <sup>1</sup>N. Falero/GR, <sup>2</sup>GR
- 13:05 - 13:05 1265P - Phase 1b/2 study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy  
A. Ribas<sup>1</sup>, I. Mehmi<sup>2</sup>, T. Medina<sup>2</sup>, C. Lao<sup>2</sup>, S. Kummer<sup>2</sup>, A. Amin<sup>3</sup>, S. Deva<sup>4</sup>, A. Salama<sup>3</sup>, T. Tueting<sup>5</sup>, M. Milhem<sup>2</sup>, C. Hoimes<sup>2</sup>, G. Daniels<sup>2</sup>, M. Shaheen<sup>2</sup>, S. Jang<sup>2</sup>, M. Barve<sup>6</sup>, A. Powell<sup>7</sup>, S. Chandra<sup>2</sup>, E. Schmidt<sup>2</sup>, R. Janssen<sup>2</sup>, G. Long<sup>8</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>NC/US, <sup>4</sup>NZ, <sup>5</sup>DE, <sup>6</sup>TX/US, <sup>7</sup>AU, <sup>8</sup>NSW/AU
- 13:05 - 13:05 1266P - Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma  
C. Schuster, G. Gausdal, B. Gjertsen, J. Lorens, O. Straume; NO
- 13:05 - 13:05 1267P - Topline Results from Phase II of Combination Treatment with Canerpaturev (HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Patients with Unresectable or Metastatic Melanoma after Anti-PD-1 Therapy  
N. Yamazaki<sup>1</sup>, K. Yokota<sup>1</sup>, H. Uhara<sup>1</sup>, Y. Fujisawa<sup>2</sup>, T. Takenouchi<sup>1</sup>, Y. Kiyohara<sup>1</sup>, H. Uchi<sup>1</sup>, H. Saruta<sup>1</sup>, H. Ihn<sup>1</sup>, T. Inozume<sup>1</sup>, D. Watanabe<sup>1</sup>, A. Takahashi<sup>1</sup>, S. Fukushima<sup>1</sup>, M. Tanaka<sup>3</sup>, T. Isei<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Ibaraki/JP, <sup>3</sup>Shiga/JP
- 13:05 - 13:05 1268P - NCI 9922: Phase 2 Study of Ibrutinib in Treatment-Refractory Distant Metastatic Cutaneous Melanoma (DMCM)  
S. Moschos<sup>1</sup>, Z. Eroglu<sup>2</sup>, N. Khushalani<sup>2</sup>, K. Kendra<sup>3</sup>, G. Ansstas<sup>4</sup>, G. In<sup>5</sup>, P. Wang<sup>6</sup>, G. Liu<sup>7</sup>, F. Collichio<sup>8</sup>, C. Arrowood<sup>8</sup>, J. Reed<sup>1</sup>, N. Garrett-Mead<sup>8</sup>, N. Thomas<sup>8</sup>, D. Ollila<sup>8</sup>, S.P. Ivy<sup>9</sup>, A. Ivanova<sup>8</sup>, E. Dees<sup>8</sup>, J. Abbruzzese<sup>8</sup>; <sup>1</sup>US, <sup>2</sup>FL/US, <sup>3</sup>OH/US, <sup>4</sup>MO/US, <sup>5</sup>CA/US, <sup>6</sup>KY/US, <sup>7</sup>WI/US, <sup>8</sup>NC/US, <sup>9</sup>MD/US
- 13:05 - 13:05 1269P - Initial cohort expansion results of sustained arginine depletion with Pegzilarginase in melanoma patients in a Phase 1 advanced solid tumor trial  
B. Chmielowski<sup>1</sup>, M. Gordon<sup>2</sup>, E. Buchbinder<sup>3</sup>, R. Sullivan<sup>3</sup>, J. Cohen<sup>3</sup>, B. Curti<sup>4</sup>, D. Davar<sup>5</sup>, J. Homsí<sup>6</sup>, K. Komatsubara<sup>7</sup>, H. Lara-Guerra<sup>8</sup>, S. Alters<sup>8</sup>, S. Ferrati<sup>6</sup>, S. Eckert<sup>6</sup>, S. Rowlinson<sup>6</sup>, J. Wooldridge<sup>8</sup>, A. Ribas<sup>1</sup>, R. Carvajal<sup>7</sup>; <sup>1</sup>CA/US, <sup>2</sup>AZ/US, <sup>3</sup>MA/US, <sup>4</sup>OR/US, <sup>5</sup>PA/US, <sup>6</sup>TX/US, <sup>7</sup>NY/US, <sup>8</sup>US
- 13:05 - 13:05 1270P - Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma  
C. Mignard, A. Deschamps-Huvier, A.-B. Duval-Modeste, C. Dutriaux, A. Khammari, M.-F. Avril, L. Mortier, T. Lesimple, C. Gaudy-Marqueste, C. Lesage, L. Machet, F. Aubin, N. Meyer, N. Beneton Benhard, G. Jeudy, H. Montaudié, J.-P. Arnault, M.-T. Leccia, P. Joly, S.F.D. Oncology Research Group Of The French Society Of Dermatology; FR

- 13:05 - 13:05 1271P - Retrospective analysis of the treatment of metastatic uveal melanoma comparing systemic chemotherapy and transarterial chemoembolization  
C.A. Peuker, L. Polzin, S. Ochsenreither, M. De Bucourt, S. Leyvraz, U. Keilholz, A. Joussem, J. Eucker; DE
- 13:05 - 13:05 1272P - Outcome of an active surveillance programme for patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): single-institution 10-year experience  
C.L. Lee, G. Gullo, N. Horgan, D. Smith, M. Moran, J. Crown; IE
- 13:05 - 13:05 1273P - Activation of Non-Canonical NFκB (NC-NFκB) Pathway in Inflammatory Environment of Uveal Melanoma  
M. Singh, R. Meel, N. Pushker, S. Sen, K. Chodsol, S. Bakhshi, S. Kashyap; IN
- 13:05 - 13:05 1274P - The use of PD-1 inhibitors for the advanced melanoma of esophagus  
L. Mao, X. Wang, L. Si, Y. Kong, Z. Chi, X. Sheng, C. Cui, B. Lian, B. Tang, X. Yan, J. Guo; CN
- 13:05 - 13:05 1275P - Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma.  
M. Nomura<sup>1</sup>, M. Andoh<sup>1</sup>, T. Yokota<sup>2</sup>, T. Miyazaki<sup>1</sup>, H. Satake<sup>3</sup>, S. Iwasawa<sup>1</sup>, A. Sonoda<sup>1</sup>, K. Kato<sup>1</sup>, M. Muto<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/JP, <sup>3</sup>Hyogo/JP
- 13:05 - 13:05 1276P - Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population  
M. van Zeijl<sup>1</sup>, M. Wouters<sup>1</sup>, A. van den Eertwegh<sup>1</sup>, M. Aarts<sup>1</sup>, A. van Akkooi<sup>1</sup>, F. van den Bergmortel<sup>1</sup>, M. Franken<sup>1</sup>, J.W. de Groot<sup>1</sup>, K. Herbschleb<sup>1</sup>, J. van der Hoeven<sup>1</sup>, G. Hospers<sup>1</sup>, E. Kapiteijn<sup>1</sup>, D. Piersma<sup>1</sup>, R. van Rijn<sup>1</sup>, K. Suijkerbuijk<sup>1</sup>, A. Ten Tije<sup>2</sup>, A. Van der Veldt<sup>1</sup>, G. Vreugdenhil<sup>1</sup>, J. Haanen<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>Noord Brabant/NL
- 13:05 - 13:05 1277P - Stereotactic radiation therapy in melanoma brain metastasis: a European, multicentric cohort  
A. paix<sup>1</sup>, F. Thillays<sup>1</sup>, F. Courtault-Deslandes<sup>1</sup>, I. Popp<sup>2</sup>, J. Biau<sup>1</sup>, O. Briard<sup>1</sup>, A.-L. Grosu<sup>2</sup>, G. Noël<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>DE
- 13:05 - 13:05 1278P - Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: an international randomized double-blind phase 3 trial.  
C. Coens<sup>1</sup>, A. Bottomley<sup>1</sup>, C. Blank<sup>2</sup>, M. Mandala<sup>3</sup>, G. Long<sup>4</sup>, V. Atkinson<sup>5</sup>, S. Dalle<sup>6</sup>, A. Haydon<sup>7</sup>, M. Lichinitser<sup>8</sup>, A. Khattak<sup>5</sup>, M. Carlino<sup>4</sup>, S. Sandhu<sup>7</sup>, J. Larkin<sup>9</sup>, S. Puig Sarda<sup>10</sup>, P. Ascierto<sup>3</sup>, D. Schadendorf<sup>11</sup>, N. Ibrahim<sup>12</sup>, S. Suci<sup>1</sup>, C. Robert<sup>13</sup>, A. Eggermont<sup>13</sup>; <sup>1</sup>BE, <sup>2</sup>NL, <sup>3</sup>IT, <sup>4</sup>NSW/AU, <sup>5</sup>AU, <sup>6</sup>CEDEX/FR, <sup>7</sup>VIC/AU, <sup>8</sup>RU, <sup>9</sup>GB, <sup>10</sup>ES, <sup>11</sup>DE, <sup>12</sup>NJ/US, <sup>13</sup>FR
- 13:05 - 13:05 1279P - The real-world impact of modern treatments on the survival of patients with metastatic melanoma  
M. Donia, E. Ellebaek, T. Øllegaard, L. Duval, J. Aaby, L. Højberg, U. Køhler, H. Schmidt, L. Bastholt, I.-M. Svane; DK
- 13:05 - 13:05 1280P - Treatment patterns of melanoma by BRAF mutation status in the US in 2011-2017: a retrospective cohort study  
L. Raskin, S. Shah, M. Braunlin, J. Buchanan, D. Cohan; US

- 13:05 - 13:05 1281P - Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: a retrospective cohort study  
M. Freeman, K. Gupte-Singh, M. You, T.K. Le, C. Ritchings, S. Rao, S. Jang; US
- 13:05 - 13:05 1282P - Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab  
S. D'Angelo<sup>1</sup>, F. Fofana<sup>2</sup>, M. Schlichting<sup>3</sup>, M. Henry-Szatkowski<sup>4</sup>, M. Hennessy<sup>5</sup>, M. Bharmal<sup>3</sup>; <sup>1</sup>NY/US, <sup>2</sup>NL, <sup>3</sup>DE, <sup>4</sup>FR, <sup>5</sup>US
- 13:05 - 13:05 1283P - Treatment Pattern and Clinical Outcomes of Patients With Locally Advanced and Metastatic Melanoma in a Real-World Setting in China  
C. Cui<sup>1</sup>, X. Yan<sup>1</sup>, S. Liu<sup>1</sup>, A. Deitz<sup>2</sup>, L. Si<sup>1</sup>, Z. Chi<sup>1</sup>, X. Sheng<sup>1</sup>, B. Lian<sup>1</sup>, J. Li<sup>1</sup>, J. Ge<sup>1</sup>, X. Wang<sup>1</sup>, L. Mao<sup>1</sup>, B. Tang<sup>1</sup>, L. Zhou<sup>1</sup>, X. Bai<sup>1</sup>, S. Li<sup>1</sup>, B. Li<sup>1</sup>, H. Wu<sup>1</sup>, J. Guo<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>NJ/US
- 13:05 - 13:05 1284P - Real life costs associated with the management of unresectable metastatic melanoma (uMM)  
D. Strens, M. Peeters, P. Specenier; BE
- 13:05 - 13:05 1285P - Drug treatment in melanoma: a real-world analysis across Europe and Japan  
A. Martinez de Pinillos, P. Nasuti, C. Anger; GB
- 13:05 - 13:05 1286P - EUMelaReg - a European platform for outcome research on real world treatment data of patients with advanced melanoma.  
M. Weichenthal<sup>1</sup>, A. van Akkooi<sup>2</sup>, P. Mohr<sup>1</sup>, E. Ellebaek<sup>3</sup>, I.-M. Svane<sup>3</sup>, S. Ugurel-Becker<sup>4</sup>, U. Leiter<sup>1</sup>, L. Hojbjerg<sup>3</sup>, J. Haanen<sup>2</sup>, H. Schmidt<sup>3</sup>, T.H. Oellegaard<sup>3</sup>, M. Wouters<sup>2</sup>, D. Schadendorf<sup>1</sup>, L. Bastholt<sup>3</sup>; <sup>1</sup>DE, <sup>2</sup>NL, <sup>3</sup>DK, <sup>4</sup>AT
- 13:05 - 13:05 1287P - Advanced melanoma treatment patterns in the modern era: United Kingdom (UK) real world retrospective chart review study  
J. Sacco<sup>1</sup>, P. Corrie<sup>2</sup>, O. Oladipo<sup>1</sup>, M. Payne<sup>1</sup>, J. Larkin<sup>1</sup>, T. Talbot<sup>1</sup>, J. Wagstaff<sup>1</sup>, S. Cheetham<sup>1</sup>, D. Stein<sup>1</sup>, M. Soni<sup>1</sup>, C. Coombs<sup>3</sup>, A. Amadi<sup>1</sup>, M. Wang<sup>1</sup>, J. Ellis<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Cambridgeshire/GB, <sup>3</sup>MD/US
- 13:05 - 13:05 1288P - The National Melanoma Research Registry: a fundamental for disease characterization and epidemiology  
F. Gwadry-Sridhar<sup>1</sup>, H. McConkey<sup>2</sup>, X. Teng<sup>2</sup>, D.S. Ernst<sup>3</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA, <sup>3</sup>Ontario/CA
- 13:05 - 13:05 1289P - assessment of quality of life in patients with metastatic melanoma in real clinical practice in france  
M. Kandel<sup>1</sup>, C. Allayous<sup>1</sup>, S. Dalle<sup>2</sup>, L. Mortier<sup>2</sup>, S. Dalac Rat<sup>3</sup>, C. Dutriaux<sup>1</sup>, M.-T. Leccia<sup>4</sup>, B. Guillot<sup>1</sup>, P. Saiag<sup>1</sup>, J.-P. Lacour<sup>1</sup>, D. Legoupil<sup>1</sup>, F. Brunet-Possenti<sup>1</sup>, B. Dreno<sup>5</sup>, A. Ballon<sup>1</sup>, A. Bardet<sup>1</sup>, S. Michiels<sup>1</sup>, C. Lebbe<sup>1</sup>, I. Borget<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>Cedex/FR, <sup>4</sup>CEDEX 9/FR, <sup>5</sup>CEDEX 1/FR
- 13:05 - 13:05 1290P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program (EAP)  
P. Nathan<sup>1</sup>, V. Kasturi<sup>2</sup>, L. Dirix<sup>3</sup>, E. Fenig<sup>4</sup>, P. Ascierto<sup>5</sup>, M. Hennessy<sup>2</sup>, J. Reed<sup>2</sup>, A. Engelsberg<sup>6</sup>, S. Hariharan<sup>2</sup>, C. Lebbe<sup>7</sup>; <sup>1</sup>Middlesex/GB, <sup>2</sup>US, <sup>3</sup>BE, <sup>4</sup>IL, <sup>5</sup>IT, <sup>6</sup>DE, <sup>7</sup>FR

- 13:05 - 13:05 1291P - Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)  
M. Bharmal<sup>1</sup>, A. Amin<sup>2</sup>, C. Stapelkamp<sup>2</sup>, C. Pescott<sup>1</sup>, A. Hatswell<sup>2</sup>, C. Lilley<sup>2</sup>, A. Bullement<sup>2</sup>, A. Willis<sup>2</sup>; <sup>1</sup>DE, <sup>2</sup>GB
- 13:05 - 13:05 1292P - Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): longer follow-up efficacy and safety data  
T. Owonikoko<sup>1</sup>, K. Papadopoulos<sup>2</sup>, M. Gil-Martin<sup>3</sup>, V. Moreno<sup>3</sup>, A. Salama<sup>4</sup>, E. Calvo<sup>3</sup>, H. Safran<sup>5</sup>, A. González-Martín<sup>3</sup>, R. Aljumaily<sup>6</sup>, D. Mahadevan<sup>7</sup>, J. Niu<sup>8</sup>, K. Kal Mohan<sup>9</sup>, J. Li<sup>10</sup>, E. Stankevich<sup>5</sup>, M. Mathias<sup>5</sup>, I. Lowy<sup>5</sup>, M. Fury<sup>5</sup>, H. Babiker<sup>5</sup>; <sup>1</sup>GA/US, <sup>2</sup>TX/US, <sup>3</sup>ES, <sup>4</sup>NC/US, <sup>5</sup>US, <sup>6</sup>OK/US, <sup>7</sup>TN/US, <sup>8</sup>AZ/US, <sup>9</sup>NY/US, <sup>10</sup>NJ/US
- 13:05 - 13:05 1293P - Cetuximab in patients with unresectable cutaneous squamous cell carcinoma is safe and effective - A real-life analysis.  
F. Peyrade<sup>1</sup>, M. Kogay<sup>2</sup>, J. Viotti<sup>2</sup>, P. Combemale<sup>2</sup>, C. Dutriaux<sup>2</sup>, N. Dupin<sup>2</sup>, C. Robert<sup>2</sup>, L. Mortier<sup>3</sup>, A.-B. Duval-Modeste<sup>2</sup>, S. Dalle<sup>3</sup>, J. De Quatrebarbes<sup>2</sup>, A. Stefan<sup>2</sup>, F. Brunet-Possenti<sup>2</sup>, A. Picard<sup>2</sup>, G. Poissonnet<sup>2</sup>, H. Montaudie<sup>2</sup>; <sup>1</sup>CEDEX 2/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR
- 13:05 - 13:05 1294P - Sonidegib Preplanned Subgroups Analyses of Objective Response Rates: Final 42-Month Results from the BOLT Study  
R. Dummer, CH
- 13:05 - 13:05 1295P - Treatment of Advanced Basal Cell Carcinoma With Sonidegib: Duration of Response and Quality of Life Evaluation From BOLT  
M. Migden, US
- 13:05 - 13:05 1296P - Discovery of novel germline genetic biomarkers of melanoma recurrence impacting exonic and long non-coding RNA (lncRNA) transcripts.  
T. Kirchhoff<sup>1</sup>, D. Simpson<sup>2</sup>, T. Hekal<sup>2</sup>, R. Ferguson<sup>1</sup>, E. Kazlow<sup>2</sup>, U. Moran<sup>2</sup>, Y. Lee<sup>1</sup>, A. Izsak<sup>1</sup>, M. Wilson<sup>2</sup>, R. Shapiro<sup>2</sup>, A. Pavlick<sup>2</sup>, I. Osman<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NY/US
- 13:05 - 13:05 1297P - Pilot Study: Localizing target lymph node using a magnetic marker allows reliable and representative judgement of pathological responses after neo-adjuvant Ipilimumab (IPI) + Nivolumab (NIVO) in macroscopic stage III melanoma  
A. van Akkooi, B. Schermers, V. Franke, M. Wouters, C. Zuur, W. Klop, E. Rozeman, B. van de Wiel, T. Ruers, C. Blank; NL
- 13:05 - 13:05 1298P - Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma  
S. Lundgren, H. Fagerström-Vahman, L. Ben-Dror, B. Nodin, K. Jirstrom; SE
- 13:05 - 13:05 1299P - BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation  
M. Wasylecka-Juszczynska, P. Górniak, M. Szydłowski, A. Polak, P. Juszczynski; PL
- 13:05 - 13:05 1300TiP - A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)



P. Corrie<sup>1</sup>, R. Matin<sup>2</sup>, A. Gupta<sup>2</sup>, W. Qian<sup>1</sup>, S. Wordsworth<sup>2</sup>, E. Gibbons<sup>2</sup>, A. Chhabra<sup>2</sup>, C. Harman<sup>2</sup>, C. Mather<sup>2</sup>, M. Middleton<sup>3</sup>; <sup>1</sup>Cambridgeshire/GB, <sup>2</sup>GB, <sup>3</sup>Oxfordshire/GB

- 13:05 - 13:05 1301TiP - A Phase I/Ib Study of Concurrent Intravenous (IV) and Intrathecal (IT) Nivolumab (Nivo) for Melanoma Patients (pts) with Leptomeningeal Disease (LMD)
- I. Glitza<sup>1</sup>, M. Rohlf<sup>1</sup>, M. Iqbal<sup>1</sup>, J. Richard<sup>1</sup>, E. Burton<sup>1</sup>, S. Duncan<sup>1</sup>, C. Brown<sup>1</sup>, J. Anderson<sup>1</sup>, P. Hwu<sup>2</sup>, W.-J. Hwu<sup>1</sup>, M. Wong<sup>1</sup>, C. Yee<sup>1</sup>, S. Patel<sup>1</sup>, S. Woodman<sup>1</sup>, R. Amaria<sup>1</sup>, A. Diab<sup>2</sup>, H. Tawbi<sup>1</sup>, M. Davies<sup>2</sup>; <sup>1</sup>TX/US, <sup>2</sup>US
- 13:05 - 13:05 1302TiP - CA224-047: A Randomized, Double-Blind, Phase 2/3 Study of Relatlimab (Anti-LAG-3) in Combination With Nivolumab (Anti-PD-1) Versus Nivolumab Alone in Previously Untreated Metastatic or Unresectable Melanoma
- E. Lipson<sup>1</sup>, G. Long<sup>2</sup>, H. Tawbi<sup>3</sup>, D. Schadendorf<sup>4</sup>, V. Atkinson<sup>5</sup>, M. Maurer<sup>6</sup>, K. Simonsen<sup>7</sup>, C. Harbison<sup>7</sup>, F.S. Hodi<sup>8</sup>; <sup>1</sup>MD/US, <sup>2</sup>NSW/AU, <sup>3</sup>TX/US, <sup>4</sup>DE, <sup>5</sup>QLD/AU, <sup>6</sup>US, <sup>7</sup>NJ/US, <sup>8</sup>MA/US
- 13:05 - 13:05 1303TiP - Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma
- M. Rohaan<sup>1</sup>, T. Borch<sup>2</sup>, J. van den Berg<sup>1</sup>, M. Geukes Foppen<sup>1</sup>, M. Donia<sup>2</sup>, Ö. Met<sup>2</sup>, B. Nuijen<sup>1</sup>, M. van Zon<sup>1</sup>, E. Bakker<sup>1</sup>, R. de Boer<sup>1</sup>, L. Pronk<sup>1</sup>, S. Wilgenhof<sup>1</sup>, C. Blank<sup>1</sup>, J. van Thienen<sup>1</sup>, A. van Akkooi<sup>1</sup>, I.-M. Svane<sup>2</sup>, J. Haanen<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>DK
- 13:05 - 13:05 1304TiP - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
- J. Weber<sup>1</sup>, G. Long<sup>2</sup>, J. Haanen<sup>3</sup>, A. Arance<sup>4</sup>, R. Dummer<sup>5</sup>, P. Nathan<sup>6</sup>, A. Ribas<sup>7</sup>, P. Ascierto<sup>8</sup>, C. Robert<sup>9</sup>, E. Gasal<sup>1</sup>, A. D'Amelio Jr<sup>1</sup>, S. Bettinger<sup>5</sup>, A. Boran<sup>1</sup>, D. Schadendorf<sup>10</sup>; <sup>1</sup>US, <sup>2</sup>NSW/AU, <sup>3</sup>NL, <sup>4</sup>ES, <sup>5</sup>CH, <sup>6</sup>Middlesex/GB, <sup>7</sup>CA/US, <sup>8</sup>IT, <sup>9</sup>FR, <sup>10</sup>DE
- 13:05 - 13:05 1305TiP - Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors
- P. Terheyden, C. Weishaupt, L. Heinzerling, U. Klinkhardt, J. Krauss, P. Mohr, F. Kiecker, J. Becker, A. Dähling (Submitter), F. Döner, R. Heidenreich, B. Scheel, O. Schönborn-Kellenberger, T. Seibel, U. Gnad-Vogt; DE
- 13:05 - 13:05 1306TiP - ILLUMINATE 301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab (ipi) versus Ipi Alone in Subjects with Anti PD 1 Refractory Melanoma
- P. Ascierto<sup>1</sup>, P. Arenberger<sup>2</sup>, V. Atkinson<sup>3</sup>, J. Hansson<sup>4</sup>, E. Kapiteijn<sup>5</sup>, C. Loquai<sup>6</sup>, S. Negrier<sup>7</sup>, H. Shaw<sup>8</sup>, A. Tarhini<sup>9</sup>, J. Walker<sup>10</sup>, J. Geib<sup>11</sup>, S. Rahimian<sup>12</sup>, S. Swann<sup>12</sup>, A. Diab<sup>11</sup>; <sup>1</sup>IT, <sup>2</sup>CZ, <sup>3</sup>QLD/AU, <sup>4</sup>SE, <sup>5</sup>NL, <sup>6</sup>DE, <sup>7</sup>CEDEX/FR, <sup>8</sup>GB, <sup>9</sup>OH/US, <sup>10</sup>CA, <sup>11</sup>US, <sup>12</sup>PA/US
- 13:05 - 13:05 1314P - Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase 3 double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies
- D. Hörsch<sup>1</sup>, R. Garcia-Carbonero<sup>2</sup>, J. Valle<sup>3</sup>, P. Perros<sup>3</sup>, S. Welin<sup>4</sup>, L. Keeber<sup>3</sup>, A. Houchard<sup>5</sup>, P. Lapuerta<sup>6</sup>; <sup>1</sup>DE, <sup>2</sup>ES, <sup>3</sup>GB, <sup>4</sup>SE, <sup>5</sup>FR, <sup>6</sup>US

- 13:05 - 13:05 1315P - Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study.  
R. Garcia-Carbonero<sup>1</sup>, V. Alonso<sup>1</sup>, J. Capdevila<sup>1</sup>, M. Sanchez Canovas<sup>1</sup>, T. Alonso<sup>1</sup>, M. Benavent<sup>1</sup>, A. Custodio<sup>1</sup>, G. Crespo Herrero<sup>1</sup>, C. Lopez<sup>1</sup>, J. Hernando<sup>1</sup>, M.C. Riesco Martinez<sup>2</sup>, P. Escudero<sup>1</sup>, J. Gallego Plazas<sup>3</sup>, M. Marazuela<sup>1</sup>, J.A. Diaz<sup>1</sup>, M. Llanos-Munoz<sup>4</sup>, A. La Casta<sup>1</sup>, J.C. Percovich<sup>1</sup>, P. Jimenez-Fonseca<sup>1</sup>, A. Carmona-Bayonas<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Ontario/ES, <sup>3</sup>Alicante/ES, <sup>4</sup>Santa Cruz de Tenerife, Canary Islands/ES
- 13:05 - 13:05 1316P - Impact of liver tumor burden on therapeutic effect of 177Lu-Dotatate treatment in NETTER-1 study  
J. Strosberg<sup>1</sup>, A. Hendifar<sup>2</sup>, J. Yao<sup>3</sup>, M. Kulke<sup>4</sup>, T. O'Doriso<sup>1</sup>, M. Caplin<sup>5</sup>, R. Baum<sup>6</sup>, P. Kunz<sup>2</sup>, T. Hobday<sup>1</sup>, E. Wolin<sup>1</sup>, E. Mittra<sup>1</sup>, K. Oberg<sup>7</sup>, P. Ruszniewski<sup>8</sup>, B. Polack<sup>1</sup>, B. He<sup>9</sup>, D. Barton<sup>1</sup>, P. Santaro<sup>1</sup>, E. Krenning<sup>10</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>TX/US, <sup>4</sup>MA/US, <sup>5</sup>GB, <sup>6</sup>DE, <sup>7</sup>SE, <sup>8</sup>FR, <sup>9</sup>CH, <sup>10</sup>NL
- 13:05 - 13:05 1317P - Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)  
L. Apostolidis, D. Jäger, E. Winkler; DE
- 13:05 - 13:05 1318P - Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); real-world findings from two European Neuroendocrine Tumour Society Centres of Excellence.  
M. Frizziero<sup>1</sup>, F. Spada<sup>2</sup>, A. Lamarca<sup>3</sup>, Z. Kordatou<sup>4</sup>, J. Barriuso<sup>3</sup>, C. Nuttall<sup>3</sup>, M. McNamara<sup>3</sup>, R. Hubner<sup>3</sup>, W. Mansoor<sup>3</sup>, P. Manoharan<sup>3</sup>, N. Fazio<sup>2</sup>, J. Valle<sup>3</sup>; <sup>1</sup>Bolzano/GB, <sup>2</sup>IT, <sup>3</sup>GB, <sup>4</sup>Nicosia/GB
- 13:05 - 13:05 1319P - Post-hoc analysis of CLARINET phase III study to investigate the influence of diabetic status on progression-free survival (PFS) of patients with neuroendocrine tumours (NETs) treated with lanreotide (LAN) or placebo (PBO)  
S. Pusceddu<sup>1</sup>, C. Vernieri<sup>1</sup>, M. Di Maio<sup>1</sup>, N. Prinzi<sup>1</sup>, M. Torchio<sup>2</sup>, R. Buzzoni<sup>1</sup>, X.-M. Truong-Thanh<sup>3</sup>, V. Mazzaferro<sup>1</sup>, F.G. de Braud<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Pavia/IT, <sup>3</sup>FR
- 13:05 - 13:05 1320P - The Prognostic Role of Morphology and Ki67 in Grade 3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NEN)  
A. Hayes, M. Furnace, C. Rundell, R. Shah, G. Muller, C. Thirlwell, T.V. Luong, C. Toumpanakis, M. Caplin, D. Mandair; GB
- 13:05 - 13:05 1321P - Surgical resection of primary tumor is prolonged survival in metastatic pancreatic neuroendocrine carcinoma  
T. Feng, CN
- 13:05 - 13:05 1322P - The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET)  
E. Segelov<sup>1</sup>, E. Bergsland<sup>2</sup>, C. Card<sup>3</sup>, T. Hope<sup>2</sup>, P. Kunz<sup>2</sup>, D. Laidley<sup>4</sup>, B. Lawrence<sup>5</sup>, S. Leyden<sup>6</sup>, M. Michael<sup>6</sup>, L. Modahl<sup>5</sup>, S. Myrehaug<sup>4</sup>, S. Padda<sup>2</sup>, R. Pommier<sup>7</sup>, R. Ramirez<sup>8</sup>, M. Soulen<sup>9</sup>, J. Strosberg<sup>10</sup>, A. Thawer<sup>11</sup>, B. Wei<sup>12</sup>, S. Singh<sup>4</sup>; <sup>1</sup>NSW/AU, <sup>2</sup>CA/US, <sup>3</sup>AB/CA, <sup>4</sup>ON/CA, <sup>5</sup>NZ, <sup>6</sup>VIC/AU, <sup>7</sup>OR/US, <sup>8</sup>LA/US, <sup>9</sup>PA/US, <sup>10</sup>US, <sup>11</sup>CA, <sup>12</sup>AL/US

- 13:05 - 13:05 1323P - Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) in Patients with Pulmonary Carcinoid Tumours: Prevalence and Prognosis of an Under-Recognised Disease  
A. Hayes<sup>1</sup>, J. Banks<sup>1</sup>, H. Shah<sup>1</sup>, T.V. Luong<sup>1</sup>, S. Navalkisoor<sup>1</sup>, A. Grossman<sup>2</sup>, D. Mandair<sup>1</sup>, C. Toumpanakis<sup>1</sup>, M. Caplin<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Oxfordshire/GB
- 13:05 - 13:05 1324P - The role of modulation of Somatostatin Analogues (SSAs) in association to Peptide Receptor Radionuclide Therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) Entero-Pancreatic Neuroendocrine Tumours (EP-NETs)  
N. Prinzi<sup>1</sup>, E. Seregini<sup>1</sup>, A. RAIMONDI<sup>1</sup>, M. Maccauro<sup>1</sup>, F. Corti<sup>1</sup>, G. Lo Russo<sup>1</sup>, F. Nichetti<sup>1</sup>, M. Torchio<sup>2</sup>, J. Coppa<sup>1</sup>, G. Peverelli<sup>1</sup>, F. Pagani<sup>1</sup>, M. Di Bartolomeo<sup>1</sup>, V. Mazzaferro<sup>1</sup>, F. de Braud<sup>1</sup>, S. Pusceddu<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>Pavia/IT
- 13:05 - 13:05 1325P - Prognostic Importance of Lymph Node (LN) yield after Curative Resection of GastroEnteroPancreatic NeuroEndocrineTumours (GEP NETs)  
J. Chiramel<sup>1</sup>, R. Almond<sup>1</sup>, A. Slagter<sup>2</sup>, A. Khan<sup>1</sup>, K.H.J. Lim<sup>1</sup>, B. Chakrabarty<sup>1</sup>, A. Minicozzi<sup>1</sup>, A. Lamarca<sup>1</sup>, W. Mansoor<sup>1</sup>, R. Hubner<sup>1</sup>, J. Valle<sup>1</sup>, M. McNamara<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>NL
- 13:05 - 13:05 1326P - Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors  
A. Koumariou<sup>1</sup>, D. Pectasides<sup>1</sup>, K. Manousou<sup>1</sup>, D. Dionysopoulos<sup>1</sup>, G. Kaltsas<sup>1</sup>, D. Kolomodi<sup>1</sup>, C. Poullos<sup>1</sup>, M. Skondra<sup>1</sup>, E. Samantas<sup>2</sup>, G. Pentheroudakis<sup>1</sup>, G. Fountzilias<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>Attica/GR
- 13:05 - 13:05 1327P - Improved Quality of Life in Patients with GEP-NETs Treated with 177Lu-DOTATATE  
B. Saravana-Bawan<sup>1</sup>, M. Wieler<sup>2</sup>, T. McMullen<sup>2</sup>, A. McEwan<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>AB/CA
- 13:05 - 13:05 1328P - Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals  
C. Bouvier<sup>1</sup>, M. Caplin<sup>1</sup>, S. Conroy<sup>2</sup>, P. Davies<sup>1</sup>, S. Dureja<sup>3</sup>, M. Falconi<sup>4</sup>, P. Ferolla<sup>4</sup>, G. Fisher<sup>5</sup>, G. Goldstein<sup>6</sup>, R. Hicks<sup>7</sup>, R. Hollander<sup>6</sup>, T. Kolarova<sup>6</sup>, B. Lawrence<sup>2</sup>, S. Leyden<sup>7</sup>, Y. Majima<sup>8</sup>, D. Metz<sup>6</sup>, D. O'Toole<sup>9</sup>, P. Ruzsiewicz<sup>10</sup>, B. Wiedenmann<sup>11</sup>; <sup>1</sup>GB, <sup>2</sup>NZ, <sup>3</sup>IN, <sup>4</sup>IT, <sup>5</sup>CA/US, <sup>6</sup>US, <sup>7</sup>VIC/AU, <sup>8</sup>JP, <sup>9</sup>IE, <sup>10</sup>FR, <sup>11</sup>DE
- 13:05 - 13:05 1329P - Efficacy and safety of Vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy.  
J. Hernando Cubero<sup>1</sup>, E. Grande<sup>1</sup>, P. Jimenez Fonseca<sup>1</sup>, C. Villabona<sup>1</sup>, J. Trigo Perez<sup>1</sup>, J. Martinez Trufero<sup>1</sup>, I. Pajares Bernad<sup>1</sup>, C. Lopez<sup>1</sup>, T. Alonso<sup>1</sup>, J. Biarnes<sup>1</sup>, T. Ramón Y Cajal<sup>1</sup>, M. Duran<sup>1</sup>, J. Grau<sup>1</sup>, S. Arevalo Lobera<sup>1</sup>, R. Mesia Nin<sup>2</sup>, M. Llanos<sup>1</sup>, E. Dalmau Portulas<sup>1</sup>, C. Alvarez<sup>1</sup>, C. Zafon<sup>1</sup>, J. Capdevila<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 13:05 - 13:05 1330P - Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry  
S. Thyparambil<sup>1</sup>, E. An<sup>2</sup>, S. Sellappan<sup>2</sup>, E. Wertheimer<sup>1</sup>, S. Landolfi<sup>3</sup>, J. Capdevila<sup>3</sup>, F. Cecchi<sup>1</sup>, P. Nuciforo<sup>3</sup>, R. Heaton<sup>2</sup>, T. Hembrough<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MD/US, <sup>3</sup>ES

- 13:05 - 13:05 1331P - Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)  
V. Prasad<sup>1</sup>, R. Srirajskanthan<sup>2</sup>, C. Grana<sup>3</sup>, S. Baldari<sup>3</sup>, T. Shah<sup>2</sup>, A. Lamarca<sup>2</sup>, F. Courbon<sup>4</sup>, K. Scheidhauer<sup>1</sup>, E. Baudin<sup>5</sup>, X.-M. Truong-Thanh<sup>4</sup>, A. Houchard<sup>4</sup>, L. Bodel<sup>6</sup>; <sup>1</sup>DE, <sup>2</sup>GB, <sup>3</sup>IT, <sup>4</sup>FR, <sup>5</sup>CEDEX/FR, <sup>6</sup>US
- 13:05 - 13:05 1332P - Detection of mutations and copy number alterations in circulating DNA from pancreatic neuroendocrine tumor patients  
G. Boons, K. Op de Beeck, T. Vandamme, M. Beyens, G. Roeyen, K. Janssens, K. Zwaenepoel, G. van Camp, M. Peeters; BE
- 13:05 - 13:05 1333TiP - CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)  
A. Bongiovanni<sup>1</sup>, S. Pusceddu<sup>2</sup>, S. Leo<sup>2</sup>, G. Di meglio<sup>2</sup>, F. Gelsomino<sup>2</sup>, F. Pucci<sup>2</sup>, R. Berardi<sup>2</sup>, S. Ricci<sup>2</sup>, I. Lollì<sup>2</sup>, F. Bergamo<sup>2</sup>, D. Campana<sup>2</sup>, D. Santini<sup>2</sup>, S. Tamperi<sup>3</sup>, D. Pastorelli<sup>2</sup>, M. Cives<sup>4</sup>, N. Silvestris<sup>2</sup>, A. Russo<sup>2</sup>, A. Buonadonna<sup>2</sup>, F. FOca<sup>2</sup>, T. Ibrahim<sup>1</sup>; <sup>1</sup>Forlì-Cesena/IT, <sup>2</sup>IT, <sup>3</sup>Ravenna/IT, <sup>4</sup>FL/IT
- 13:05 - 13:05 1334TiP - A Phase 1 Study of Oncolytic Immunotherapy of Metastatic Neuroendocrine Tumours using Intralesional Rose Bengal Disodium  
T. Price<sup>1</sup>, G. Cehic<sup>1</sup>, I. Kirkwood<sup>1</sup>, G. Maddern<sup>1</sup>, E. Wachter<sup>2</sup>, D. Sarson<sup>3</sup>, R. Sebben<sup>1</sup>, L. Leopardi<sup>1</sup>, J. Reid<sup>1</sup>, S. Neuhaus<sup>1</sup>; <sup>1</sup>SA/AU, <sup>2</sup>TN/US, <sup>3</sup>NSW/AU
- 13:05 - 13:05 1335TiP - COMPETE trial – Peptide Receptor Radionuclide Therapy (PRRT) with <sup>177</sup>Lu-Edotreotide vs. Everolimus in progressive GEP-NET  
M. Pavel, A. Rinke, R. Baum; DE
- 13:05 - 13:05 1823P - Synergistic anti-cancer effect of Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway  
S.Y. Kim, Y.S. Lee, H. Chang, H.-S. Chang, C.S. Park; KR
- 13:05 - 13:05 1824P - Lenvatinib and Pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)  
C. Dierks, C. Miething, O. Thomusch, N. von Bubnoff, J. Duyster; DE
- 13:05 - 13:05 1825P - Both HIF-1 $\alpha$  and GAB1 can regulate Pim-1 in the papillary thyroid carcinoma  
X. Zhu, Q. Wen, M. Ge; CN
- 13:05 - 13:05 1826P - Increase in Thyroid Cancer (TC) Incidence in Cyprus: Overdiagnosis or True Increase of clinically relevant TC?  
H. Charalambous<sup>1</sup>, A. Demetriou<sup>2</sup>, S. Frangos<sup>2</sup>, P. Pavlou<sup>2</sup>; <sup>1</sup>Nicosia/CY, <sup>2</sup>CY
- 13:05 - 13:05 1827P - Surgery for lymph node metastases of sporadic medullary thyroid carcinoma  
W. fan, H. Jiang; CN
- 13:05 - 13:05 1828P - Role of SPECT-CT somatostatin-receptor scintigraphy in the management of Medullary Thyroid Cancer (MTC)  
S. Sergieva, M. Atanasova, A. Fakirova, S. Velchova; BG

- 13:05 - 13:05 1829TiP - A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)  
J. Krajewska<sup>1</sup>, B. Robinson<sup>2</sup>, B. Keam<sup>3</sup>, J. Capdevila<sup>4</sup>, A. Klochikhin<sup>5</sup>, H. Gan<sup>2</sup>, E. Kapiteijn<sup>6</sup>, R. Elisei<sup>7</sup>, J. Partyka<sup>8</sup>, A. Borgman<sup>8</sup>, M. Schlumberger<sup>9</sup>; <sup>1</sup>PL, <sup>2</sup>AU, <sup>3</sup>KR, <sup>4</sup>ES, <sup>5</sup>RU, <sup>6</sup>NL, <sup>7</sup>IT, <sup>8</sup>US, <sup>9</sup>FR
- 13:05 - 13:05 1898P - The role of SWI/SNF chromatin remodelling complex ATPase subunit – BRM in TNBC  
I. Jancewicz, N. Rusetska, A. Armatowska, M. Stachowiak, K. Pogoda, A. Niwińska, W. Olszewski, Z. Nowecki, T. Sarnowski, E. Sarnowska, J. Siedlecki; PL
- 13:05 - 13:05 1899P - Fluoropyrimidine and Inflammatory Genes Promoter Methylation in Egyptian CRC patients  
M. Fouad, S. Salem, M. Hussein, A. Zekri, D. Badr, H. Hafez, E. Eldesouky, S. Shouman; EG
- 13:05 - 13:05 1900P - Realworld prospective data of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer  
K. Morikawa, A. Tsunoda, T. Inoue, M. Mineshita; JP
- 13:05 - 13:05 1901P - ATM as a DNA Damage Response Protein in Uveal Melanoma: Association with Clinicopathological Factors and Prognostic Outcome  
J. JHA, M. Singh, N. Pushker, S. Sen, S. Kashyap; IN
- 13:05 - 13:05 1902P - BRCA mutation and castration-resistant prostate cancer  
L. Spirina, RU
- 13:05 - 13:05 1903P - Prevalence of KRAS mutation subtypes and MSI status in Pancreatic Cancer.  
P. Gultawatvichai<sup>1</sup>, I. Puthawala<sup>1</sup>, K. Tomaszewicz<sup>1</sup>, V. Bathini<sup>2</sup>, L. Hutchinson<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 13:05 - 13:05 1904P - Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES Study  
F. Zanelli, M. Pagano, C. Bonelli, R. Gnani, L. Boni, G.L. Ceresoli, M. Larocca, M. Tiseo, P. Zucali, F. Grosso, F. Cappuzzo, A. CIARROCCI, F. TORRICELLI, C. Pinto; IT
- 13:05 - 13:05 1905P - N-Myc and STAT interactor (NMI) as a key determinant of chemosensitivity in breast cancer: proteomic-based computing network mapping and in vivo verification with a mouse model  
H. Lee, K.-M. Lee, D. Han, H. Ryu; KR
- 13:05 - 13:05 1906P - Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing  
F. Grossi, C. Genova, D. Cittaro, S. Bonfiglio, S. Boccardo, I. Vanni, M. Mora, M.G. Dal Bello, F. Biello, E. Rijavec, C. Sini, G. Rossi, M. Tagliamento, A. Alama, G. Burrafato, G. Barletta, A. Ballestrero, S. Coco; IT
- 13:05 - 13:05 1907P - Discordance of the PAM50 intrinsic subtypes compared with IHC-based surrogate in breast cancer patients: Potential implication of genomic alterations of discordance  
Y.H. Park, H.K. Kim, J.H. Cho; KR
- 13:05 - 13:05 1908P - Impact of Invasive Lobular Carcinoma in Latin American Breast Cancer Patients' Disease-Free Survival. The new paradox.

D. Flores-Díaz<sup>1</sup>, C. Arce Salinas<sup>2</sup>, L. Flores<sup>1</sup>, F. Lara<sup>1</sup>, J.A. Matus Santos<sup>1</sup>, J.E. Bargallo Rocha<sup>1</sup>, V. Perez<sup>1</sup>, N. Reynoso-Noveron<sup>1</sup>, P.A. Cabrera<sup>2</sup>, A. Mohar<sup>2</sup>; <sup>1</sup>MX, <sup>2</sup>Tlalpan. D.F./MX

- 13:05 - 13:05 1909P - Clinical validation of a NGS-based assay for the detection of BRCA1 and BRCA2 variants in Chinese patients with breast cancer or ovarian cancer  
G. Zhu, H. Ge, X. Li, L. Ruan; CN
- 13:05 - 13:05 1910P - Correlation between the expression of androgens receptor (RA) and histopathological characteristics and survival parameters of breast cancer  
I. Sillero, A. López González, L.F. Sanchez Cousido, M. López-Flores, E. Honrado Franco, L. Lopez Gonzalez, O. Sanz, C. Castañón López, A. García Palomo; ES
- 13:05 - 13:05 1911P - Metabolic Syndrome in Breast Cancer Patients: An Observational Study  
S. Khare, IN
- 13:05 - 13:05 1912P - The prognostic value of different molecular subtypes of breast cancer in relation to Enhancer-of-zeste homologue 2 expression  
Z. Sanaat<sup>1</sup>, R. Dolatkah<sup>2</sup>; <sup>1</sup>East Azarbaijan/IR, <sup>2</sup>IR
- 13:05 - 13:05 1913P - A guided and personnalized treatment in metastatic breast cancer: optimisation of gene and protein expression in tumor tissue.  
E. Seront, S. Lejeune, B. Petit, V. Samartzy, S. Sauvage, J.-F. Laes; BE
- 13:05 - 13:05 1914P - HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer  
H. Yi-Hsuan, L. Yen-Shu, H. Chih-Yi, T. Ling-Ming; TW
- 13:05 - 13:05 1915P - Does the minimal axillary approach lead to lose of prognostic factors in breast cancer?  
R. de Araujo<sup>1</sup>, C. Nascimento<sup>2</sup>, C. Da Cunha<sup>2</sup>, E. Marinho<sup>2</sup>, E. Mosca<sup>2</sup>, F. Da Luz<sup>2</sup>, P. Delfino<sup>2</sup>, R. Antonioli<sup>2</sup>, T. Mendes<sup>2</sup>, M. Silva<sup>2</sup>; <sup>1</sup>MG/BR, <sup>2</sup>BR
- 13:05 - 13:05 1916P - The influence of the surgical approach in women diagnosed with breast neoplasia  
R. de Araujo<sup>1</sup>, C. Nascimento<sup>2</sup>, C. Da Cunha<sup>2</sup>, E. Marinho<sup>2</sup>, E. Mosca<sup>2</sup>, F. Da Luz<sup>2</sup>, P. Delfino<sup>2</sup>, R. Antonioli<sup>2</sup>, T. Mendes<sup>2</sup>, M. Silva<sup>2</sup>; <sup>1</sup>MG/BR, <sup>2</sup>BR
- 13:05 - 13:05 1917P - Use of comparative proteomics to identify potential cisplatin resistance mechanisms in neuroblastoma  
M.A. Merlos Rodrigo, H. Buchtelova, V. Strmiska, Z. Heger, V. Adam; CZ
- 13:05 - 13:05 1918P - Acquired resistance mechanism of Osimertinib targeting EGFR in human lung cancer  
V. Ciaramella, C.M. Della Corte, G. Barra, R. Di Liello, G. Viscardi, M. Orditura, E. Martinelli, F. Ciardiello, F. Morgillo; IT
- 13:05 - 13:05 1919P - Interaction of Oncostatin M and its receptor OSMR promotes gastric cancer progression via STAT3/FAK/Src signaling  
L. Su, X. Wu, J. Li, Z. Yu, B. Liu; CN

- 13:05 - 13:05 1920P - Role of Pioglitazone on gene/protein expression profile, bioenergetics and TGFβ/SMAD signaling pathway in NSCLC  
R. Di Liello, G. Viscardi, V. Ciaramella, G. Barra, G. Esposito, M. Fasano, F. Ciardiello, F. Morgillo; IT
- 13:05 - 13:05 1921P - Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma  
S. Han, J. Yeong, C. Lim, M.-K. Ang, W. Lim, C.K. Toh, Q.S. Ng, D. Tan, T. Lim, J.H. Loh, A. Tanako, R. Kanesvaran, W.L. Tan, T. Rajasekaran, W. Nei, A. Jain; SG
- 13:05 - 13:05 1922P - The Role of Neurotrophic Factors in Nerve-Cancer Crosstalk  
A. Planken, L. Truu, K. Oselin, V. Valvere; EE
- 13:05 - 13:05 (Withdrawn)
- 13:05 - 13:05 1924P - Glutathione S-transferase M subfamily in TMZ-resistant glioblastoma cells  
S.Y. Cheng, W.-F. Chen, Z.-H. Wen; TW
- 13:05 - 13:05 1925P - Combining 2D angiogenesis and 3D Osteosarcoma microtissues to improve vascularization  
H. Chaddad, FR
- 13:05 - 13:05 1926P - Survival analysis of sorafenib in hepatocellular carcinoma patients with microvascular invasion after hepatectomy  
Z. Zhang, Y. Huang, Y. Zhou, J. Yang, K. Hu, Z. Wang; CN
- 13:05 - 13:05 1927P - FAM115c that upregulates proliferation and invasion under hypoxia could be a predictive biomarker for pancreatic cancer.  
K. Saeki<sup>1</sup>, H. Onishi<sup>2</sup>, Y. Oda<sup>1</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Fukuoka/JP
- 13:05 - 13:05 1928P - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC)  
A. Weissferdt<sup>1</sup>, B. Sepesi<sup>2</sup>, A. Pataer<sup>2</sup>, N. Kalhor<sup>1</sup>, C. Moran<sup>1</sup>, W. William<sup>1</sup>, X. Le<sup>1</sup>, B. Glisson<sup>1</sup>, F. Skoulidis<sup>2</sup>, G. Blumenschein<sup>1</sup>, J. Zhang<sup>1</sup>, M. Altan<sup>1</sup>, D. Rice<sup>2</sup>, R. Mehran<sup>2</sup>, J. Lee<sup>1</sup>, A. Vaporciyan<sup>2</sup>, D. Gibbons<sup>2</sup>, S. Swisher<sup>2</sup>, J. Heymach<sup>1</sup>, T. Cascone<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>MO/US
- 13:05 - 13:05 1929P - Tumor-infiltrating CD3+ lymphocytes and ICOS+ T-cells predict a favorable survival in resected esophageal squamous cell carcinoma  
M.H. Hong, S.-J. Shin, Y.-L. Choi, B.C. Cho, H.R. Kim; KR
- 13:05 - 13:05 1930P - Chemokine receptor CXCR7 expression, function and clinical implications in head and neck squamous cell carcinoma  
M.-W. Lee, N. Kim, S. Kim, M. Joo, H. Ryu, H.J. Lee; KR
- 13:05 - 13:05 1931P - Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis  
T. Mrowiec<sup>1</sup>, F. Wilm<sup>1</sup>, E. Frick-Krieger<sup>1</sup>, M. Silva<sup>1</sup>, L. Terracciano<sup>2</sup>, I. Dussault<sup>3</sup>, C. Ihling<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>CH, <sup>3</sup>MA/US

13:05 - 13:05	1932P - Pulmonary tumor thrombotic microangiopathy (PTTM): 24 case series and its criteria for pathological diagnosis. <u>N. Sato</u> , T. Tasaki, H. Noguchi, K. Irie, T. Nakayama; JP	
13:05 - 13:05	1933P - Autofluorescence: a new marker for identifying cancer stem cells (CSCs) in primary tumors <u>M. López Gómez</u> , E. Casado, M. Muñoz, S. Alcalá, J. Moreno-Rubio, S. Salinas, F. Zambrana, A.M. Jiménez-Gordo, B. Sainz Jr; ES	
13:05 - 13:05	1934P - NACC1 as a target of microRNA-331-3p regulates cell proliferation in urothelial carcinoma cells <u>K. Morita</u> <sup>1</sup> , T. Fujii <sup>2</sup> , K. Shimada <sup>1</sup> , H. Itami <sup>1</sup> , K. Hatakeyama <sup>1</sup> , M. Miyake <sup>1</sup> , K. Fujimoto <sup>1</sup> , C. Ohbayashi <sup>1</sup> ; <sup>1</sup> JP, <sup>2</sup> 634-8522/JP	
13:05 - 13:05	1935P - Somatic-stem transition of tumor cells is a key link in the metastasis <u>N. Litviakov</u> , M. Ibragimova, E. Slonimskaya, E. Skurikhin, M. Tsyganov, O. Pershina, I. Deriusheva, P. Kazantseva; RU	
13:05 - 13:05	1936P - Survival effect of lncRNA-X expression in EGFR-mutant adenocarcinoma <u>Y. Nakano</u> , K. Isobe, A. Kakimoto, H. Kobayashi, K. Kaburaki, G. Sano, S. Sakamoto, Y. Takai, N. Tochigi, T. Mikami, A. Iyoda, S. Homma; JP	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 28 (TBC)	ICM - Room 1
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 29 (TBC)	ICM - Room 14b
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 30 (TBC)	ICM - Room 13
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 31 (TBC)	Hall A1 - Room 16
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 32 (TBC)	Hall B3 - Room 20



13:00 - 14:30	Type: ESMO Colloquium Title: ESMO COLLOQUIUM - Immune Check Point Inhibitors: Are we ready for combination? Chair(s): J. Haanen, NL	Hall B3 - Room 22
13:00 - 13:05	Introduction <u>J. Haanen</u> , NL	
13:05 - 13:15	Mechanisms of chemotherapy-induced increased immune response <u>J. Vansteenkiste</u> , BE	
13:15 - 13:40	Achievements and present development in lung cancer <u>M.C. Garassino</u> , IT	
13:40 - 14:05	Where do we stand in TNBC breast cancer? <u>S. Loi</u> , VIC/AU	
14:05 - 14:25	Which patients do benefit? How to select and for which benefit? <u>J. Haanen</u> , NL	
14:25 - 14:30	Conclusion <u>J. Haanen</u> , NL	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium 34 (TBC)	Hall B4 - Room 19
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry satellite symposium (TBC)	Hall B4 - Room 24

13:00 - 14:30 Type: Patient Advocacy Track ICM - Room 5  
Title: The cancer drugs we need: Incentivising innovation in cancer  
Chair(s): B. Ryll, SE

13:00 - 13:15 The entrepreneurial state

13:15 - 13:30 Innovating for public health  
S. Garner, CH

13:30 - 13:45 Incentivising innovation  
J. Scannell, GB

13:45 - 14:00 Patient advocate driving innovation

14:00 - 14:30 Discussion

14:30 - 16:30 Type: Clinical Practice Guidelines Hall A1 - Room 15  
Title: ESMO Clinical Practice Guidelines 2

14:30 - 14:40 Introduction to the ESMO Clinical Practice Guidelines  
G. Pentheroudakis, GR

14:40 - 14:50 Questionnaire  
C. Sessa, CH

14:50 - 15:00 Early HER2-positive breast cancer  
S. Volovat, Iasi/RO

15:00 - 15:10 Discussant  
E. Senkus-Konefka, PL

15:10 - 15:15 Q&A

15:15 - 15:25 Soft tissue sarcoma  
B. Lopes David, BR

15:25 - 15:35 Discussant  
S. Stacchiotti, IT

15:35 - 15:40 Q&A

15:40 - 15:50 Cancer cachexia  
T. Solheim, NO

15:50 - 16:00 Discussant  
J. Arends, DE

16:00 - 16:05 Q&A

16:05 - 16:15 Prostate cancer

16:15 - 16:25 Discussant  
C. Parker, GB

16:25 - 16:30 Q&A

14:30 - 17:30	Type: Young Oncologist session Title: YO Masterclass: From genetic data to clinical trial design: Joint session EACR and ESMO YOC Chair(s): T. Sorlie, NO; G. Argiles, ES	ICM - Room 14c
14:30 - 15:10	Next generation sequencing of cancer <u>N. Normanno</u> , IT	
15:10 - 15:50	Fighting cancer with biomarker data analysis <u>S. Michiels</u> , FR	
15:50 - 16:10	Break	
16:10 - 16:50	Immuno genetics & immuno genomics	
16:50 - 17:30	Crystallising Knowledge, new trial designs in the molecular oncology era <u>J. Rodon</u> , ES	
14:45 - 16:15	Type: Special Symposium Title: Tumour heterogeneity in gynaecological cancers Chair(s): D. Huntsman, CA; S. Banerjee, GB	Hall A1 - Room 17
14:45 - 14:50	Introduction <u>D. Huntsman</u> , British Columbia/CA	
14:50 - 15:10	The molecular classification of endometrial cancer: Applications for treatment decisions <u>C. Creutzberg</u> , NL	
15:10 - 15:30	Intratumour heterogeneity in high grade serous ovarian cancer and beyond <u>B. Davidson</u> , NO	
15:30 - 15:50	The immune response and heterogeneity in gynaecological cancers: Treatment opportunities <u>A. González Martín</u> , ES	
15:50 - 16:10	Genomics of rare ovarian cancers: What have we learned and who how can it influence practice? <u>D. Huntsman</u> , British Columbia/CA	
16:10 - 16:15	Conclusions and perspectives <u>S. Banerjee</u> , GB	

14:45 - 16:15	Type: Special Symposium Title: Combination strategies of immunotherapy in breast cancer Chair(s): G. Curigliano, IT	Hall A2 - Room 18
14:45 - 14:50	Introduction	
14:50 - 15:10	Integrating genomic data and immuno-markers in breast cancer <u>G. Curigliano</u> , IT	
15:10 - 15:30	Combining chemotherapy and immunotherapy in TNBC <u>L. Carey</u> , NC/US	
15:30 - 15:50	Combining anti HER2 with immunotherapy in HER2+ patients <u>S. Loi</u> , VIC/AU	
15:50 - 16:10	Immunotherapy strategies for luminal breast cancer <u>M. Kok</u> , NL	
16:10 - 16:15	Conclusions and perspectives <u>G. Curigliano</u> , IT	
14:45 - 16:00	Type: Poster Discussion session Title: Poster Discussion session - Lung early Chair(s): W. Eberhardt, DE; P. Postmus, NL	ICM - Room 1
14:45 - 14:45	One LBA TBC	
14:45 - 14:45	1348PD - Genomic landscape and its correlation with TMB, CD8 TILs and PD-L1 expression in Chinese lung squamous cell carcinoma <u>C. Zhou</u> , T. Jiang; CN	
14:45 - 14:45	1349PD - Gene expression signature of DNA damage response to predict the prognosis of early stage lung adenocarcinoma <u>Z. Wang</u> , C. Xu, J. Zhao, X. Zhao, S. Cai, Y. Song, J. Wang; CN	
14:45 - 14:45	1350PD - Social and behavioral indicators of undergoing a screening test for lung cancer <u>S. Couraud</u> <sup>1</sup> , J.F. Morère <sup>2</sup> , J. Viguier <sup>2</sup> , M. Roupret <sup>2</sup> , L. Brignoli-Guibaudet <sup>2</sup> , C. Lhomel <sup>2</sup> , T. de La Motte Rouge <sup>2</sup> , F. Eisinger <sup>3</sup> , L. Greillier <sup>2</sup> ; <sup>1</sup> CEDEX/FR, <sup>2</sup> FR, <sup>3</sup> CEDEX 9/FR	
14:45 - 15:00	Invited Discussant One LBA TBC, 1348PD, 1349PD and 1350PD <u>W. Eberhardt</u> , DE	
15:00 - 15:10	Q&A led by Discussant	

- 15:10 - 15:10 1364PD - Cardiac events in stage III non-small cell lung cancer (NSCLC) treated in daily clinical practice: is it time for cardiovascular screening and follow-up?  
J. Degens, D. De Ruyscher, B. Kietselaer, G. Bootsma, A. Schols, A.-M. Dingemans; NL
- 15:10 - 15:10 1806PD - Multiple primary cancers (MPC) in a series of lung cancer (LC) patient: incidence and outcome  
S. Cedres Perez<sup>1</sup>, M. Sanso<sup>1</sup>, A. Hernando-Calvo<sup>1</sup>, A. Callejo<sup>1</sup>, N. Pardo Aranda<sup>1</sup>, A. Navarro Mendivil<sup>1</sup>, A. Martinez<sup>1</sup>, J. Remon<sup>2</sup>, J.M. Miquel<sup>1</sup>, G. Rodriguez<sup>1</sup>, V. Monton<sup>1</sup>, G. Villacampa<sup>1</sup>, R. Dienstmann<sup>1</sup>, A. Vivancos<sup>1</sup>, E. Felip Font<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 15:10 - 15:20 Invited Discussant 1364PD and 1806PD  
P. Postmus, Merseyside/NL
- 15:20 - 15:25 Q&A led by Discussant
- 15:25 - 15:25 1665PD - Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study  
I. Bondarenko<sup>1</sup>, O. Juan-Vidal<sup>2</sup>, G. Pajkos<sup>3</sup>, A. Kryzhanivska<sup>1</sup>, Z. Pápai Székely<sup>3</sup>, D. Vicente<sup>2</sup>, I. Vynnychenko<sup>1</sup>, S. Jones<sup>4</sup>, Y. Wang<sup>4</sup>, H. Jiang<sup>4</sup>, N. Reinmuth<sup>5</sup>; <sup>1</sup>UA, <sup>2</sup>ES, <sup>3</sup>HU, <sup>4</sup>MD/US, <sup>5</sup>DE
- 15:25 - 15:25 1666PD - Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy  
K. Dragnev<sup>1</sup>, T. Owonikoko<sup>2</sup>, T. Csozsi<sup>3</sup>, M. Maglakelidze<sup>4</sup>, J. Beck<sup>5</sup>, M. Domine Gomez<sup>6</sup>, A. Lowczak<sup>7</sup>, A. Fulop<sup>3</sup>, R. Hoyer<sup>1</sup>, W. Hanna<sup>1</sup>, P. Lowry<sup>1</sup>, R. Aljumaily<sup>8</sup>, V. Chiu<sup>1</sup>, I. Bulat<sup>9</sup>, Z. Yang<sup>1</sup>, P. Roberts<sup>1</sup>, J. Antal<sup>1</sup>, R. Malik<sup>1</sup>, S. Morris<sup>1</sup>, J. Weiss<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GA/US, <sup>3</sup>HU, <sup>4</sup>GE, <sup>5</sup>AZ/US, <sup>6</sup>ES, <sup>7</sup>PL, <sup>8</sup>OK/US, <sup>9</sup>MD
- 15:25 - 15:35 Invited Discussant 1665PD and 1666PD
- 15:35 - 15:40 Q&A led by Discussant
- 15:40 - 15:40 1667PD - Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small-cell lung cancer. A multicenter phase II trial (SAKK 15/12)  
H. Veas<sup>1</sup>, F. Caparrotti<sup>1</sup>, A. Xyrafas<sup>1</sup>, A. Fuhrer<sup>1</sup>, U. Meier<sup>1</sup>, M. Mark<sup>1</sup>, O. Elicin<sup>1</sup>, D. Aebersold<sup>1</sup>, D. Betticher<sup>2</sup>, C. Biaggi Rudolf<sup>1</sup>, K. Ribic<sup>1</sup>, T. Finazzi<sup>1</sup>, D. Zwahlen<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>CH/CH
- 15:40 - 15:40 1365PD - Screening for brain metastases (BM) in patients (pts) with stage III non-small cell lung cancer (NSCLC), magnetic resonance imaging (MRI) or dedicated contrast-enhanced computed tomography (dCE-CT)? A prospective observational study  
J. Schoenmaekers, L. Hendriks, A.-M. Dingemans, D. De Ruyscher, G. Bootsma, W. Schreurs, M. Westenend, R. Houben, P. Hofman, M. De Booi; NL
- 15:40 - 15:50 Invited Discussant 1667PD and 1365PD

15:50 - 15:55 Q&A led by Discussant

14:45 - 16:15 Type: Educational session ICM - Room 13  
 Title: Revisiting systemic therapy in HNSCC in the era of immunotherapy  
 Chair(s): E. Cohen, US; A. Castro, PT

14:45 - 15:10 New data from randomised studies in recurrent metastatic setting  
M. Merlano, IT

15:10 - 15:35 Management of toxicities  
A. Castro, PT

15:35 - 16:00 Patients selection  
I. Braña Garcia, ES

14:45 - 16:15 Type: Educational session Hall B3 - Room 21  
 Title: Sarcomas as a key foundation for molecular-targeted basket trials  
 Chair(s): G.D. Demetri, US; S. Bauer, DE

14:45 - 15:10 Targeting translocations in sarcomas: From EWS to NTRK-translocated sarcomas

15:10 - 15:35 A basket of epigenetic changes in sarcomas: EZH2 inhibitor development and targeting the SWI/SNF complex in synovial sarcomas  
R. Jones, WA/GB

15:35 - 16:00 Current and emerging spectra of kinase targeting: From PDGFRA in STS to mTOR in PEComas  
S. Bauer, DE

16:00 - 16:15 Discussion

14:45 - 16:15 Type: Special session Hall B3 - Room 23  
 Title: Precision medicine

- 14:45 - 16:15 Type: Proffered Paper session Hall B3 - Room 20  
 Title: Proffered paper session - Supportive and palliative care  
 Chair(s): K. Jordan, DE; J. Herrstedt, DK
- 14:45 - 14:57 1681O - Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data  
M. Aapro<sup>1</sup>, F. Scotté<sup>2</sup>, Y. Escobar<sup>3</sup>, L. Celio<sup>4</sup>, R. Berman<sup>5</sup>, A. Franceschetti<sup>5</sup>, D. Bell<sup>6</sup>, K. Jordan<sup>7</sup>; <sup>1</sup>CH, <sup>2</sup>FR, <sup>3</sup>ES, <sup>4</sup>IT, <sup>5</sup>GB, <sup>6</sup>US, <sup>7</sup>DE
- 14:57 - 15:09 1682O - Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced diarrhea in cancer patients receiving Fluoropyrimidines and/or Irinotecan based therapy  
A. Sharma, S. Chaudhary, V. Raina, N. Shukla, V. Sreenivas, S. Prakash, P. Priyatma, S. Bharti; IN
- 15:09 - 15:24 Invited Discussant 1681O and 1682O  
J. Herrstedt, DK
- 15:24 - 15:36 1511O - Training oncologists and preparing patients for shared decision making about palliative systemic treatment: results from the randomized controlled CHOICE study  
H. van Laarhoven, I. Henselmans, P. van Maarschalkerweerd, H. de Haes, D. Sommeijer, P.B. Ottevanger, H.-B. Fiebrich, S. Dohmen, G.-J. Creemers, F. De Vos, E. Smets; NL
- 15:36 - 15:48 1512O - Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data  
M. Gensheimer<sup>1</sup>, A. Henry<sup>2</sup>, D. Wood<sup>2</sup>, T. Hastie<sup>2</sup>, S. Aggarwal<sup>1</sup>, S. Dudley<sup>1</sup>, P. Pradhan<sup>1</sup>, I. Banerjee<sup>2</sup>, E. Cho<sup>1</sup>, K. Ramchandran<sup>1</sup>, E. Pollom<sup>1</sup>, A. Koong<sup>1</sup>, D. Rubin<sup>2</sup>, D. Chang<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 15:48 - 16:00 1539O - Posttraumatic Growth and Death anxiety in Caregivers of Cancer Patients: PHOENIX Study  
A. Alkan, E.B. Köksoy, E. Karçı, H. Burgaç, A. Arıkanoğlu Soğancı, D. Yaman, F. Çay Şenler; TR
- 16:00 - 16:15 Invited Discussant 1512O and 1539O



14:45 - 16:15	Type: Special Symposium Title: Emerging therapies in neuroendocrine and endocrine malignancies Chair(s): M. Pavel, DE; E. Baudin, FR	Hall B3 - Room 22
14:45 - 14:50	Introduction <u>M. Pavel</u> , DE	
14:50 - 15:05	Immunotherapy in NETs: Where are we now? <u>K. Oeberg</u> , SE	
15:05 - 15:20	Novel targeted therapies in NETs <u>R. Garcia-Carbonero</u> , ES	
15:20 - 15:35	Novel targeted therapies in thyroid carcinoma <u>S. Leboulleux</u> , FR	
15:35 - 15:50	Novel therapies in adrenal malignancies <u>M. Fassnacht</u> , DE	
15:50 - 16:05	Novel approaches in mixed adenoneuroendocrine carcinoma <u>A. Berruti</u> , IT	
16:05 - 16:15	Conclusions and clinical perspectives <u>E. Baudin</u> , CEDEX/FR	

14:45 - 16:15 Type: EONS session Hall B4 - Room 24  
Title: The essential elements of safety standards for systemic cancer therapies

14:45 - 15:00 The pharmacist's perspective  
K. Meier, DE

15:00 - 15:15 The oncologist's perspective

15:15 - 15:30 The nurse manager's perspective

15:30 - 15:45 The clinical nurse's perspective  
H. Titzer, AT

15:45 - 16:00 The patient's perspective

16:00 - 16:15 Discussion

14:45 - 16:15 Type: Special session ICM - Room 14a  
Title: Are there enough cancer services and oncologists in your country?  
Chair(s): A. Eniu, RO; A. Ilbawi, CH

14:45 - 14:50 Introduction  
A. Eniu, RO

14:50 - 15:10 Where does the world stand on global cancer control?  
A. Ilbawi, CH

15:10 - 15:30 Tools that show how investing in cancer care pays off

15:30 - 15:50 How many patients can one oncologist care for?  
D. Trapani, IT

15:50 - 16:10 WHO-ESMO Workforce Survey: How can your country assure enough oncologists for the future?  
G. Curigliano, IT

16:10 - 16:15 Conclusions

15:00 - 16:05 Type: Multidisciplinary interactive sessions ICM - Room 14b  
 Title: Locally advanced pancreatic cancer  
 Chair(s): M. Ducreux, FR

15:00 - 15:05 Case presentation

15:05 - 15:15 The surgical point of view: What is resectable?  
A. Sa Cunha, FR

15:15 - 15:25 The radiation oncologist's point of view  
M. Verheij, NL

15:25 - 15:35 The medical oncologist's point of view  
M. Ducreux, CEDEX/FR

15:35 - 16:05 Discussion

15:00 - 16:00 Type: Multidisciplinary interactive sessions Hall A1 - Room 16  
 Title: Management of toxicities of immunotherapy  
 Chair(s): J. Larkin, GB

15:00 - 15:10 GI toxicity  
H. Gogas, Attiki/GR

15:10 - 15:20 Neurotoxicity  
C. Robert, FR

15:20 - 15:30 How to treat beyond acute toxicity  
J. Larkin, GB

15:30 - 16:00 Discussion

16:30 - 17:30 Type: Multidisciplinary interactive sessions Hall A1 - Room 16  
Title: Molecular tumour boards in the practice of precision oncology

16:30 - 16:40 The clinician's perspective  
D. Planchard, FR

16:40 - 16:50 The bioinformatician's perspective  
A. Vivancos, ES

16:50 - 17:00 The germline genetician's perspective

17:00 - 17:20 Discussion

16:30 - 18:00 Type: Proffered Paper session Hall A2 - Room 18  
Title: Presidential Symposium 2

16:30 - 18:00 Type: Educational session ICM - Room 1  
Title: Unresolved questions in melanoma  
Chair(s): M. Soengas, ES

16:30 - 16:55 Emerging prognostic factors in primary melanoma  
P. Lorigan, GB

16:55 - 17:20 Treatment in advanced melanoma patients with a worse prognosis  
R. Dummer, CH

17:20 - 17:45 Patient treatment resistance in melanoma  
J. Haanen, NL

17:45 - 18:00 Discussion

16:30 - 17:45 Type: Poster Discussion session Hall B3 - Room 21  
Title: Poster Discussion session - Haematological malignancies  
Chair(s): A. Ferreri, IT; M. Ghilmini, CH

16:30 - 16:30 1008PD - CD13 and CD33 CAR-T cells for the treatment of myeloid malignancies.  
K. Lee<sup>1</sup>, K. Gowrishankar<sup>1</sup>, D. Gottlieb<sup>2</sup>, E. Blyth<sup>2</sup>, K. Micklethwaite<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU

16:30 - 16:30 1009PD - The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS  
H. Medyouf, I. Tirado-Gonzalez, A. Mies, A. Nevmerzhitskaya, A.-S. Kubasch, U. Platzbecker; DE

- 16:30 - 16:45 Invited Discussant 1008PD and 1009PD
- 16:45 - 16:55 Q&A led by Discussant
- 16:55 - 16:55 1010PD - ALK positive Anaplastic large cell lymphoma: molecular diagnosis and minimal residual disease monitoring  
M. Kalinova, L. Krskova, M. Mrhalova, E. Kabickova, P. Riha, R. Kodet; CZ
- 16:55 - 16:55 1011PD - Intensified 14 day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.  
J. Sandoval-Sus<sup>1</sup>, S. Dalia<sup>2</sup>, R. Mhaskar<sup>3</sup>, J. Chavez<sup>1</sup>, A. Ausekar<sup>4</sup>, K. Purnapatre<sup>4</sup>, J. Scheiber<sup>4</sup>, L. Sokol<sup>1</sup>; <sup>1</sup>FL/US, <sup>2</sup>MO/US, <sup>3</sup>US, <sup>4</sup>DE
- 16:55 - 16:55 1012PD - Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice  
M. Dreyling<sup>1</sup>, G. Hess<sup>1</sup>, M. Woike<sup>2</sup>, G. Krekeler<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>NA
- 16:55 - 16:55 1013PD - A comparative study of 18F-FDG PET/CT with bilateral bone marrow trephine biopsy for assessment of bone marrow infiltration by lymphoma  
D. Arjunan, G. Prakash, P. Malhotra, N. Varma, S. Varma, A. Das, B. Mittal, R. Basher, D. Lad, S. Kumari, A. Khadwal, S. Vikas, S. Naseem, A. Bal; IN
- 16:55 - 17:10 Invited Discussant 1010PD, 1011PD, 1012PD and 1013PD  
A. Ferreri, IT
- 17:10 - 17:20 Q&A led by Discussant
- 17:20 - 17:20 1014PD - Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies  
W. Jurczak<sup>1</sup>, S. Rule<sup>2</sup>, W. Townsend<sup>3</sup>, D. Tucker<sup>3</sup>, B. Sarholz<sup>4</sup>, J. Scheele<sup>4</sup>, J. Gribben<sup>3</sup>, P. Zinzani<sup>5</sup>; <sup>1</sup>PL, <sup>2</sup>Devon/GB, <sup>3</sup>GB, <sup>4</sup>DE, <sup>5</sup>IT
- 17:20 - 17:20 1015PD - A prospective study of first-line Helicobacter pylori eradication therapy in treating localized extragastric mucosa-associated lymphoid tissue lymphoma  
S.-H. Kuo, M. Yao, C.-H. Tsai, C.-W. Lin, J.-M. Liou, W.-L. Ma, A.-L. Cheng; TW
- 17:20 - 17:20 1016PD - Bendamustine and rituximab followed by 90Y-ibritumomab tiuxetan for relapsed follicular lymphoma; a preliminary analysis of a multicenter, prospective phase II study (BRIZ2012).  
M. Kanno<sup>1</sup>, K. Miura<sup>1</sup>, Y. Masaki<sup>1</sup>, H. Tsujimura<sup>2</sup>, M. Iino<sup>1</sup>, J. Takizawa<sup>1</sup>, Y. Maeda<sup>1</sup>, K. Yamamoto<sup>1</sup>, S. Tamura<sup>1</sup>, A. Yoshida<sup>1</sup>, H. Yagi<sup>1</sup>, I. Yoshida<sup>1</sup>, K. Kitazume<sup>1</sup>, T. Masunari<sup>1</sup>, I. Choi<sup>1</sup>, Y. Kakinoki<sup>1</sup>, T. Yoshino<sup>1</sup>, S. Nakamura<sup>1</sup>, T. Yoshida<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP

17:20 - 17:35 Invited Discussant 1014PD, 1015PD and 1016PD  
M. Ghielmini, CH

17:35 - 17:45 Q&A led by Discussant

16:30 - 18:00 Type: EONS session Hall B4 - Room 24  
Title: Improving communication in cancer nursing  
Chair(s): P. Crombez, BE

16:30 - 16:50 How to communicate well with people with advanced disease  
E. Patiraki, GR

16:50 - 17:10 Be silent, or say something better than silence  
E. Masel, AT

17:10 - 17:30 Dealing with impending death in young adult cancer patients: How to communicate and offer effective support in practice  
M. Bisset, GB

17:30 - 18:00 Discussion

16:45 - 17:45 Type: Poster Discussion session ICM - Room 14b  
Title: Poster Discussion session - Gastrointestinal, colorectal 2  
Chair(s): S. Marsoni, IT; R. Adams, GB

16:45 - 16:45 456PD - Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer  
T. Reinert<sup>1</sup>, T. Henriksen<sup>1</sup>, M. Rasmussen<sup>1</sup>, H. Sethi<sup>2</sup>, R. Salari<sup>2</sup>, S. Shchegrova<sup>2</sup>, R. Swenerton<sup>2</sup>, H.-T. Wu<sup>2</sup>, S. Sharma<sup>2</sup>, E. Christensen<sup>1</sup>, P. Natarajan<sup>2</sup>, S. Dashner<sup>2</sup>, T. Tin<sup>2</sup>, A. Olson<sup>3</sup>, H. Pawar<sup>3</sup>, B. Zimmermann<sup>3</sup>, L. Iversen<sup>1</sup>, M. Madsen<sup>1</sup>, J. Lin<sup>3</sup>, C. Andersen<sup>1</sup>; <sup>1</sup>DK, <sup>2</sup>CA/US, <sup>3</sup>US

16:45 - 16:45 457PD - Kinase Fusions in Colorectal Cancers: A Unique Biologic Subset  
R. Madison<sup>1</sup>, F. Pietrantonio<sup>2</sup>, L. Juckett<sup>1</sup>, C. Cremolini<sup>2</sup>, J. Chung<sup>3</sup>, V. Miller<sup>3</sup>, S. Klempner<sup>4</sup>, M. Resnick<sup>5</sup>, E. Yakirevich<sup>5</sup>, S.-H. Ou<sup>4</sup>, M. Fakih<sup>4</sup>, A. Schrock<sup>1</sup>, J. Ross<sup>3</sup>, S. Ali<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>IT, <sup>3</sup>MA/US, <sup>4</sup>CA/US, <sup>5</sup>RI/US

16:45 - 16:45 One LBA TBC

16:45 - 16:45 458PD - Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)

R. Das<sup>1</sup>, L. Furchtgott<sup>1</sup>, F.-S. Ou<sup>2</sup>, D. Swanson<sup>3</sup>, B. Hayete<sup>1</sup>, B. Harms<sup>1</sup>, D. Cunha<sup>1</sup>, J. Latourelle<sup>1</sup>, D. Wuest<sup>1</sup>, I. Khalil<sup>1</sup>, C. Washburn<sup>1</sup>, K. Rich<sup>1</sup>, C. Blanke<sup>4</sup>, J. Meyerhardt<sup>5</sup>, D. Niedzwiecki<sup>6</sup>, A. Nixon<sup>6</sup>, E. O'Reilly<sup>7</sup>, F. Innocenti<sup>8</sup>, H.-J. Lenz<sup>9</sup>, A. Venook<sup>9</sup>; <sup>1</sup>US, <sup>2</sup>MN/US, <sup>3</sup>NO, <sup>4</sup>OR/US, <sup>5</sup>MA/US, <sup>6</sup>NC/US, <sup>7</sup>NY/US, <sup>8</sup>US/US, <sup>9</sup>CA/US

16:45 - 17:00 Invited Discussant 56PD, 457PD, one LBA TBC and 458PD

S. Marsoni, (TO)/IT

17:00 - 17:15 Q&A led by Discussant

17:15 - 17:15 459PD - Long-term Results of Postoperative Chemoradiation Therapy With Capecitabine and Oxaliplatin Versus Capecitabine Alone for Locally Advanced Rectal Cancer: A Randomized, Multicenter, Phase 3 Trial

N. Li, J. Jin, Y. Li, Y. Zhu, W. Wang, J. Wang, Y. Feng, L. Liu, S. Wang, Y. Song, Y. Liu, Y. Tang, W. Liu, H. Ren, H. Fang; CN

17:15 - 17:15 460PD - The value of chemotherapy in Stage II colon cancer: much less than we thought

L. Wu<sup>1</sup>, J. Fu<sup>1</sup>, W. Fu<sup>2</sup>, J. Du<sup>1</sup>, L. Wang<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>US

17:15 - 17:15 461PD - Folfox and intra-arterial DEBIRI as front-line treatment in patients with non resectable colorectal cancer liver metastases (FFCD 1201 phase II trial)

S. Pernot<sup>1</sup>, P. Artru<sup>2</sup>, D. Tougeron<sup>3</sup>, C. Montérymard<sup>1</sup>, D. Smith<sup>1</sup>, C. De La Fouchardière<sup>1</sup>, J.-L. Raoul<sup>3</sup>, L. Dahan<sup>1</sup>, R. Guimbaud<sup>1</sup>, P. Michel<sup>1</sup>, J.-L. Jouve<sup>1</sup>, O. Pellerin<sup>1</sup>, J. Taieb<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 8/FR, <sup>3</sup>CEDEX/FR

17:15 - 17:15 462PD - Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): post hoc analysis of the MOSAIC trial.

E. Auclin<sup>1</sup>, T. Andre<sup>1</sup>, J. Taieb<sup>1</sup>, M. Banzi<sup>2</sup>, J.-L. van Laethem<sup>3</sup>, J. Tabernero<sup>4</sup>, T. Hickish<sup>5</sup>, A. De Gramont<sup>1</sup>, D. Vernerey<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>IT, <sup>3</sup>BE, <sup>4</sup>ES, <sup>5</sup>GB

17:15 - 17:30 Invited Discussant 459PD, 460PD, 461PD and 462PD

R. Adams, GB

17:30 - 17:45 Q&A led by Discussant

16:45 - 17:45 Type: Poster Discussion session

ICM - Room 13

Title: Poster Discussion session - Lung metastatic 2

Chair(s): S. Popat, GB; S. Ekman, SE

16:45 - 16:45 One LBA TBC

16:45 - 16:45 One LBA TBC

- 16:45 - 16:45 One LBA TBC
- 16:45 - 16:45 1384PD - Pembrolizumab in performance status 2 patients with non-small-cell lung cancer (NSCLC): results of the PePS2 trial  
G. Middleton, K. Brock, Y. Summers, J. Connibear, R. Shah, C. Ottensmeier, P. Shaw, S. Ming-Lee, S. Popat, C. Barrie, G. Barone, R. Mant, J. Savage, L. Billingham; GB
- 16:45 - 17:05 Invited Discussant three LBAs TBC and 1384PD  
S. Ekman, SE
- 17:05 - 17:15 Q&A led by Discussant
- 17:15 - 17:15 One LBA TBC
- 17:15 - 17:15 1385PD - A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial.  
S. Peters<sup>1</sup>, S. Danson<sup>2</sup>, B. Hasan<sup>3</sup>, N. Reinmuth<sup>4</sup>, M. Majem<sup>5</sup>, K. Tournoy<sup>3</sup>, M. Mark<sup>1</sup>, M. Pless<sup>1</sup>, M. Cobo<sup>5</sup>, D. Rodriguez-Abreu<sup>5</sup>, L. Falchero<sup>6</sup>, B. Massutí<sup>5</sup>, L. Coate<sup>7</sup>, R. von Moos<sup>1</sup>, C. Zielinski<sup>8</sup>, E. De Maio<sup>3</sup>, M. O'Brien<sup>2</sup>, H. Roschitzki-Voser<sup>9</sup>, U. Dafni<sup>10</sup>, R. Stahel<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>GB, <sup>3</sup>BE, <sup>4</sup>DE, <sup>5</sup>ES, <sup>6</sup>FR, <sup>7</sup>IE, <sup>8</sup>AT, <sup>9</sup>Bern/CH, <sup>10</sup>Attica/GR
- 17:15 - 17:15 One LBA TBC
- 17:15 - 17:15 One LBA TBC
- 17:15 - 17:15 One LBA TBC
- 17:15 - 17:15 1386PD - IMpower150: clinical safety, tolerability and immune-related adverse events in a Phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC  
M. Reck<sup>1</sup>, T. Wehler<sup>1</sup>, F. Orlandi<sup>2</sup>, N. Nogami<sup>3</sup>, C. Barone<sup>4</sup>, D. Moro-Sibilot<sup>5</sup>, M. Shtivelband<sup>6</sup>, J. González Larriba<sup>7</sup>, J. Rothenstein<sup>8</sup>, M. Frueh<sup>9</sup>, G. Shankar<sup>6</sup>, A. Lee<sup>6</sup>, Y. Deng<sup>6</sup>, H. Patel<sup>6</sup>, C. Kelsch<sup>6</sup>, W. Lin<sup>6</sup>, M. Socinski<sup>10</sup>; <sup>1</sup>DE, <sup>2</sup>CL, <sup>3</sup>JP, <sup>4</sup>IT, <sup>5</sup>FR, <sup>6</sup>US, <sup>7</sup>ES, <sup>8</sup>Ontario/CA, <sup>9</sup>CH, <sup>10</sup>PA/US
- 17:15 - 17:35 Invited Discussant four LBAs TBC, 1385PD and 1386PD  
S. Popat, GB
- 17:35 - 17:45 Q&A led by Discussant



16:45 - 17:45	Type: Controversy Session Title: Gene expression signatures should be used in luminal node negative breast cancer	Hall A1 - Room 15
16:45 - 16:55	Introduction and 1st vote	
16:55 - 17:15	Pro	
17:15 - 17:35	Contra	
17:35 - 17:45	2nd vote and conclusions	
18:00 - 19:30	Type: Patient Advocacy Track Title: Snake oil sold as science: How to protect patients from Pseudoscience Chair(s): G. Spurrier, FR	ICM - Room 5
18:00 - 18:15	Pseudoscience and having to destroy false hope: The oncologist's perspective <u>P. Wolter</u> , BE	
18:15 - 18:30	Tackling apart pseudoscience <u>E. Ernst</u> , GB	
18:30 - 18:45	The responsibility of journalism in science reporting <u>H. Scowcroft</u> , GB	
18:45 - 19:00	Preventing pseudoscience on patient forums <u>G. Spurrier</u> , FR	
19:00 - 19:30	Discussion	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 35 (TBC)	ICM - Room 1
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 36 (TBC)	ICM - Room 14b

18:30 - 20:00 Type: Industry Satellite Symposium ICM - Room 13  
Title: Industry satellite symposium 37 (TBC)

18:30 - 20:00 Type: ESMO Colloquium Hall A1 - Room 15  
Title: ESMO COLLOQUIUM - Acute Myeloid Leukemia – Focus on FLT3-ITD mutation  
Chair(s): J. Cortes Castan, ES

18:30 - 18:35 Introduction  
J. Cortes Castan, ES

18:35 - 18:55 Molecular profile of AML and prognostication/risk classification

18:55 - 19:10 Are present clinical practice GL for the management of AML obsolete?  
M. Fey, CH

19:10 - 19:25 FLT3-ITD mutated AML: A special entity?  
K. Metzeler, DE

19:25 - 19:45 New approaches on the management of refractory FLT3-ITD mutated AML  
J. Cortes Castan, ES

19:45 - 19:55 Q&A and discussion led by Chair and Speakers

19:55 - 20:00 Conclusion  
J. Cortes Castan, ES

18:30 - 20:00 Type: ESMO Colloquium Hall A1 - Room 16  
Title: ESMO COLLOQUIUM - Are biosimilars the key to access, in practice?

18:30 - 18:35 Introduction

18:35 - 18:45 Success story: How were oncology biosimilars in supportive care positively accepted and used?

18:45 - 18:55 Existing challenges for uptake of oncology biosimilars – ESMO survey results

18:55 - 19:05 In practice (UK): patients being switched from a biologic to a biosimilar - UK

19:05 - 19:15 One year on – state of play in the EU on oncology biosimilars  
M. Aitken, US

19:15 - 19:25 Supplementary Protection Certificates & their potential impact on availability of biosimilars

19:25 - 19:55 Panel with industry representatives

19:55 - 20:00 Conclusion

18:30 - 20:00 Type: Industry Satellite Symposium Hall B3 - Room 20  
Title: Industry satellite symposium 40 (TBC)

18:30 - 20:00 Type: Industry Satellite Symposium Hall B4 - Room 19  
Title: Industry satellite symposium 41 (TBC)

18:30 - 20:00 Type: Industry Satellite Symposium Hall B4 - Room 24  
Title: Industry satellite symposium (TBC)

22.10.2018

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall A1 -  
 Title: Optimal treatment of patients with metastatic colorectal cancer: Planned sequencing, Room 16  
 or just taking the next best option?  
 Chair(s): A. Falcone, IT

08:00 - 08:10 Optimal treatment of patients with metastatic colorectal cancer: Planned sequencing, or just taking the  
 next best option?  
A. Stein, DE

08:10 - 09:00 Discussion led by  
A. Falcone, IT

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 21  
 Title: Optimal management of luminal advanced breast cancer  
 Chair(s): N. Harbeck, DE

08:00 - 08:10 Optimal management of luminal advanced breast cancer  
F. Cardoso, PT

08:10 - 09:00 Discussion led by  
N. Harbeck, DE

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 23  
 Title: Clinical application of liquid biopsy in metastatic lung cancer  
 Chair(s): S. Popat, GB

08:00 - 08:10 Clinical application of liquid biopsy in metastatic lung cancer  
C. Rolfo, US

08:10 - 09:00 Discussion led by  
S. Popat, GB

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 20  
 Title: Salivary gland cancers  
 Chair(s): L. Licitra, IT

08:00 - 08:10 Salivary gland cancers  
A. Ho, US

08:10 - 09:00 Discussion led by  
L. Licitra, IT

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Hall B3 - Room 22  
 Title: What is the role of intratumour therapy?  
 Chair(s): C. Robert, FR

08:00 - 08:10 What is the role of intratumour therapy?  
O. Michielin, CH

08:10 - 09:00 Discussion led by  
C. Robert, FR

08:00 - 09:00 Type: EONS session Hall B4 - Room 24  
 Title: Assessments and monitoring in advanced cancer nursing  
 Chair(s): C. Wylegalla, DE

08:00 - 08:20 How to observe and manage the acutely ill patient  
C. Diez de los Rios, GB

08:20 - 08:40 Reflections on systematic symptom assessment and monitoring in advanced cancer patients in the late palliative phase/terminal phase in hospital, at home and/or hospice  
S. Teunissen, NL

08:40 - 09:00 Discussion

08:00 - 09:00 Type: Challenge Your Expert (CYE) session ICM - Room 14a  
 Title: Health care decision making and the international context  
 Chair(s): F. Perrone, IT

08:00 - 08:10 Health care decision making and the international context  
H. Severens, NL

08:10 - 09:00 Discussion led by  
F. Perrone, IT

08:15 - 09:00 Type: Keynote lecture Hall A1 - Room 17  
 Title: Beyond resistance in immuno-oncology

08:15 - 09:00 Beyond resistance in immuno-oncology  
A. Ribas, CA/US

09:15 - 11:00 Type: Proffered Paper session Hall A1 - Room 17  
Title: Proffered paper session- NSCLC, metastatic

09:15 - 09:27 One LBA TBC

09:27 - 09:39 One LBA TBC

09:39 - 09:51 One LBA TBC

09:51 - 10:06 Invited Discussant three LBAs TBC  
B. Besse, CEDEX/FR

10:06 - 10:18 1378O - ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥3L advanced NSCLC treatment  
D. Kowalski<sup>1</sup>, N. Reinmuth<sup>2</sup>, S. Orlov<sup>3</sup>, J. Fischer<sup>2</sup>, S. Sugawara<sup>4</sup>, S. Mandziuk<sup>1</sup>, D. Medine<sup>5</sup>, S. Novello<sup>6</sup>, Y. Takeda<sup>7</sup>, R. Soo<sup>8</sup>, K. Park<sup>9</sup>, M. McCleod<sup>10</sup>, S. Geater<sup>11</sup>, M. Powell<sup>10</sup>, R. May<sup>10</sup>, P. Stockman<sup>12</sup>, D. Planchard<sup>13</sup>; <sup>1</sup>PL, <sup>2</sup>DE, <sup>3</sup>RU, <sup>4</sup>Miyagi/JP, <sup>5</sup>ES, <sup>6</sup>IT, <sup>7</sup>JP, <sup>8</sup>SG, <sup>9</sup>KR, <sup>10</sup>US, <sup>11</sup>TH, <sup>12</sup>GB, <sup>13</sup>FR

10:18 - 10:30 One LBA TBC

10:30 - 10:45 Invited Discussant 1378O and One LBA TBC  
N. Rizvi, NY/US

09:15 - 11:00	Type: Proffered Paper session Title: Proffered paper session - Gastrointestinal tumours, colorectal Chair(s): D. Arnold, DE; A. Falcone, IT	Hall A2 - Room 18
09:15 - 09:27	One LBA TBC	
09:27 - 09:39	One LBA TBC	
09:39 - 09:51	One LBA TBC	
09:51 - 10:06	Invited Discussant three LBAs TBC <u>J. Taieb</u> , FR	
10:06 - 10:18	One LBA TBC	
10:18 - 10:30	452O - DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A <u>L. Henricks</u> , C. Lunenburg, F. de Man, D. Meulendijks, G. Frederix, E. Kienhuis, G.-J. Creemers, A. Baars, V. Dezentjé, H. Rosing, J. Beijnen, E. van Werkhoven, A. van Kuilenburg, R. van Schaik, R. Mathijssen, J. Swen, H. Gelderblom, A. Cats, H.-J. Guchelaar, J. Schellens; NL	
10:30 - 10:42	One LBA TBC	
10:42 - 10:57	Invited Discussant two LBAs TBC and 452O <u>C.-H. Koehne</u> , DE	

09:15 - 11:00	Type: Proffered Paper session Title: Proffered paper session - Melanoma and other skin tumour Chair(s): R. Dummer, CH; C. Robert, FR	ICM - Room 1
09:15 - 09:27	One LBA TBC	
09:27 - 09:39	One LBA TBC	
09:39 - 09:51	One LBA TBC	
09:51 - 10:06	Invited Discussant three LBA TBC <u>C. Robert</u> , FR	
10:06 - 10:18	One LBA TBC	
10:18 - 10:30	One LBA TBC	
10:30 - 10:42	1244O - KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF-Mutant Advanced Melanoma <u>P. Ascierto</u> <sup>1</sup> , P.F. Ferrucci <sup>1</sup> , R. Stephens <sup>2</sup> , M. Del Vecchio <sup>1</sup> , V. Atkinson <sup>3</sup> , H. Schmidt <sup>4</sup> , J. Schachter <sup>5</sup> , P. Queirolo <sup>1</sup> , G. Long <sup>6</sup> , A. Di Giacomo <sup>1</sup> , I. Svane <sup>4</sup> , M. Lotem <sup>5</sup> , G. Bar-Sela <sup>5</sup> , F. Couture <sup>7</sup> , B. Mookerjee <sup>8</sup> , R. Ghorri <sup>9</sup> , N. Ibrahim <sup>9</sup> , B. Homet Moreno <sup>9</sup> , A. Ribas <sup>10</sup> ; <sup>1</sup> IT, <sup>2</sup> NZ, <sup>3</sup> QLD/AU, <sup>4</sup> DK, <sup>5</sup> IL, <sup>6</sup> NSW/AU, <sup>7</sup> QC/CA, <sup>8</sup> US, <sup>9</sup> NJ/US, <sup>10</sup> CA/US	
10:42 - 10:57	Invited Discussant two LBA TBC and 1244O <u>R. Dummer</u> , CH	



09:15 - 10:45 Type: Special Symposium ICM - Room 14b  
 Title: Strategies to improve the outcome of advanced prostate cancer  
 Chair(s): J. de Bono, GB; S. Tomlins, US

09:15 - 09:20 Introduction  
J. de Bono, GB

09:20 - 09:40 Heterogeneity in prostate cancer  
S. Tomlins, US

09:40 - 10:00 Improving treatment outcome by dissecting heterogeneity  
J. de Bono, GB

10:00 - 10:20 Improving outcome by optimising combination and/or sequencing of treatments  
E. Efstathiou, TX/US

10:20 - 10:40 Improving treatment outcome by manipulating the immune system  
W. Gerritsen, NL

10:40 - 10:45 Conclusions and perspectives  
S. Tomlins, US

09:15 - 10:45 Type: Special Symposium ICM - Room 13  
 Title: Minimising potentially futile treatments in advanced disease  
 Chair(s): F. Scotté, FR; M. Apro, CH

09:15 - 09:20 Introduction  
M. Apro, CH

09:20 - 09:40 Monitoring toxicities  
C. Ruhlmann, DK

09:40 - 10:00 Prediction of relevant toxicities using the example of neuro toxicities  
G. Cavaletti, IT

10:00 - 10:20 Decisional processes (with patients) to minimise futility  
F. Strasser, CH

10:20 - 10:40 Integration of palliative care based on (ESMO) guidelines  
S. Kaasa, NO

10:40 - 10:45 Conclusions and perspectives  
F. Scotté, FR

09:15 - 10:45 Type: Educational session Hall A1 - Room 15  
 Title: Multiple myeloma  
 Chair(s): M. Dimopoulos, GR

09:15 - 09:40 Next generation diagnostics  
H. Avet-Loiseau, FR

09:40 - 10:05 Frontline treatment  
M.-V. Mateos, ES

10:05 - 10:30 Relapsed disease  
M. Dimopoulos, Attiki/GR

10:30 - 10:45 Discussion

09:15 - 10:45 Type: EONS session Hall B4 - Room 24  
 Title: Complex symptom burden and management related to multimodality cancer treatment

09:15 - 09:30 Effects of lavender oil on sleep quality of patients with cancer: A RCT of lavender oil versus sweet almond oil

09:30 - 09:45 Advanced care planning

09:45 - 10:00 Cancer pain and associated symptoms

10:00 - 10:15 CN55 - Evaluation of a nursing aftercare intervention for patients with head and neck cancer treated with chemoradiation  
C. Braat, G. Verduijn, H. van der Stege, M. Offerman, M. Peeters, A. van Staa, W. Oldenmenger; NL

10:15 - 10:30 CN56 - When symptom complexity is the norm: a mediation analysis between pain, anxiety, depression and fatigue  
A. Charalambous, CY

10:30 - 10:45 Discussion

09:30 - 10:30 Type: Poster Discussion session Hall A1 - Room 16  
 Title: Poster discussion session - Gynaecological cancers 2  
 Chair(s): N. Colombo, IT; C. Sessa, CH

- 09:30 - 09:30 938PD - Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group  
T. de La Motte Rouge<sup>1</sup>, F. Derquin<sup>1</sup>, A. Floquet<sup>2</sup>, J. Edeline<sup>2</sup>, J.-P. Lotz<sup>1</sup>, J. Alexandre<sup>3</sup>, P. Pautier<sup>2</sup>, G. Ferron<sup>4</sup>, E. Boissier<sup>1</sup>, C. Lefevre-Plesse<sup>1</sup>, H. Vegas<sup>5</sup>, A. Patsouris<sup>1</sup>, E. Kalbacher<sup>2</sup>, D. Berton-Rigaud<sup>2</sup>, A.-C. Hardy Bessard<sup>1</sup>, V. Lavoué<sup>1</sup>, I. Ray-Coquard<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 4/FR, <sup>4</sup>CEDEX 3/FR, <sup>5</sup>CEDEX 9/FR
- 09:30 - 09:30 939PD - Quality of life and symptoms in longterm survivors with ovarian cancer: It's still an issue. Expression VI – Carolin meets HANNA – Holistic Analysis of Long-term survival with Ovarian Cancer: the international NOGGO, ENGOT and GCIG survey  
H. Woopen<sup>1</sup>, I. Braicu<sup>1</sup>, R. Richter<sup>1</sup>, K. Schnuppe<sup>1</sup>, P. Krabisch<sup>1</sup>, T. Boxler<sup>1</sup>, G. Emons<sup>1</sup>, J. Glajzer<sup>1</sup>, M. Rose<sup>1</sup>, L. Erdur<sup>1</sup>, R. Lindhorst<sup>1</sup>, M. Endres<sup>1</sup>, P. Hühnchen<sup>1</sup>, I. Vergote<sup>2</sup>, R. Berger<sup>3</sup>, C. Marth<sup>3</sup>, J. Sehouli<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>BE, <sup>3</sup>AT
- 09:30 - 09:30 940PD - OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer  
S. Blagden<sup>1</sup>, G. Bertelli<sup>1</sup>, E. Frangou<sup>1</sup>, C. Butcher<sup>1</sup>, S. Love<sup>1</sup>, M. Mackean<sup>2</sup>, R. Glasspool<sup>1</sup>, A. Cook<sup>1</sup>, S. Nicum<sup>1</sup>, R. Lord<sup>3</sup>, M. Ferguson<sup>1</sup>, R. Roux<sup>4</sup>, M. Martinez<sup>1</sup>, S. Black<sup>1</sup>, A. James<sup>1</sup>, H. Palmer<sup>1</sup>, S. Hughes<sup>1</sup>, C. Marriott<sup>1</sup>, L. Howells<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Midlothian/GB, <sup>3</sup>Merseyside/GB, <sup>4</sup>Middlesex/GB
- 09:30 - 09:30 941PD - A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study  
A. Gonzalez<sup>1</sup>, M.R. Mirza<sup>2</sup>, I. Vergote<sup>3</sup>, Y. Li<sup>4</sup>, S. Hazard<sup>4</sup>, R. Clark<sup>4</sup>, W. Graybill<sup>4</sup>, B. Pothuri<sup>4</sup>, B. Monk<sup>4</sup>; <sup>1</sup>ES, <sup>2</sup>DK, <sup>3</sup>BE, <sup>4</sup>US
- 09:30 - 09:42 Invited Discussant 938PD, 939PD, 940PD and 941PD  
N. Colombo, IT
- 09:42 - 09:52 Q&A led by Discussant
- 09:52 - 09:52 One LBA TBC
- 09:52 - 09:52 943PD - Response to Neoadjuvant Chemotherapy in ICON8: A GCIG Phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment  
A. Clamp<sup>1</sup>, I. McNeish<sup>1</sup>, A. Dean<sup>2</sup>, D. Gallardo-Rincon<sup>3</sup>, J.-W. Kim<sup>4</sup>, D. O'Donnell<sup>5</sup>, J. Hook<sup>1</sup>, S. Blagden<sup>1</sup>, J. Brenton<sup>1</sup>, R. Naik<sup>1</sup>, T. Perren<sup>6</sup>, S. Sundar<sup>1</sup>, A. Cook<sup>1</sup>, E. James<sup>1</sup>, H. Gabra<sup>1</sup>, R. Lord<sup>7</sup>, M. Hall<sup>8</sup>, G. Dark<sup>1</sup>, R. Kaplan<sup>1</sup>, J. Ledermann<sup>9</sup>; <sup>1</sup>GB, <sup>2</sup>WA/AU, <sup>3</sup>MX, <sup>4</sup>KP, <sup>5</sup>IE, <sup>6</sup>Yorkshire/GB, <sup>7</sup>Merseyside/GB, <sup>8</sup>Middlesex/GB, <sup>9</sup>London/GB
- 09:52 - 10:04 Invited Discussant One LBA TBC and 943PD  
C. Sessa, CH

10:04 - 10:14 Q&A led by Discussant

09:30 - 10:30 Type: Poster Discussion session Hall B3 - Room 21  
Title: Poster Discussion session - Immuno 2  
Chair(s): I.-M. Svane, DK; A. Marabelle, FR

09:30 - 09:30 1135PD - Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations

J. Luke<sup>1</sup>, R. Edwards<sup>2</sup>, C. Hedvat<sup>2</sup>, D. Pandya<sup>2</sup>, S. Ely<sup>2</sup>, R. Meier<sup>1</sup>, D. McDonald<sup>1</sup>, C. Harbison<sup>3</sup>, V. Baxi<sup>2</sup>, G. Lee<sup>2</sup>, P. Szabo<sup>2</sup>, T. Garcia<sup>1</sup>, R. Bao<sup>1</sup>, T. Reilly<sup>1</sup>, E. Jaffee<sup>4</sup>, F. Hodi<sup>5</sup>; <sup>1</sup>US, <sup>2</sup>NJ/US, <sup>3</sup>New Jersey/US, <sup>4</sup>MD/US, <sup>5</sup>MA/US

09:30 - 09:30 1136PD - Discrepancy of tumor neoantigen burden between primary lesions and matched metastases in lung cancer

T. Jiang, C. Zhou; CN

09:30 - 09:30 1137PD - Identification of Adenosine Pathway Genes Associated with Response to Therapy with the Adenosine Receptor Antagonist CPI-444

S. Willingham<sup>1</sup>, A. Hotson<sup>2</sup>, G. Laport<sup>1</sup>, L. Kwei<sup>1</sup>, L. Fong<sup>2</sup>, M. Sznol<sup>1</sup>, J. Powderly<sup>3</sup>, R. Miller<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>NC/US

09:30 - 09:45 Invited Discussant 1135PD, 1136PD and 1137PD

09:45 - 09:55 Q&A led by Discussant

09:55 - 09:55 1138PD - First in Human Study with GSK3359609 [GSK609], Inducible T cell Co-stimulator (ICOS) Receptor Agonist in Patients [Pts] with Advanced, Solid Tumors: Preliminary Results from INDUCE-1

A. Hansen<sup>1</sup>, T. Bauer<sup>2</sup>, V. Moreno<sup>3</sup>, M. Maio<sup>4</sup>, S. Groenland<sup>5</sup>, J. Martin-Liberal<sup>3</sup>, H. Gan<sup>6</sup>, D. Rischin<sup>6</sup>, M. Millward<sup>7</sup>, A. Olszanski<sup>8</sup>, D. Cho<sup>9</sup>, E. Paul<sup>8</sup>, M. Ballas<sup>8</sup>, C. Ellis<sup>8</sup>, H. Zhou<sup>8</sup>, S. Yadavilli<sup>8</sup>, J. Sadik Shaik<sup>8</sup>, E. Schmidt<sup>8</sup>, A. Hoos<sup>8</sup>, E. Angevin<sup>10</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>TN/US, <sup>3</sup>ES, <sup>4</sup>IT, <sup>5</sup>NL, <sup>6</sup>AU, <sup>7</sup>WA/AU, <sup>8</sup>US, <sup>9</sup>NY/US, <sup>10</sup>CEDEX/FR

09:55 - 09:55 1139PD - Novel Small-Molecule RORγ Agonist Immuno-oncology Agent LYC-55716: Safety and Efficacy in a Phase 2A Open-Label, Multicenter Trial

J. Wang<sup>1</sup>, S. Liu<sup>2</sup>, H. Uronis<sup>2</sup>, C. Wu<sup>2</sup>, D. Mahalingam<sup>2</sup>, A. Spira<sup>3</sup>, L. Carter<sup>4</sup>, X. Hu<sup>4</sup>, G. Weems<sup>2</sup>, H. Wilkins<sup>2</sup>, L. Duska<sup>2</sup>, K. Kelly<sup>2</sup>; <sup>1</sup>FL/US, <sup>2</sup>US, <sup>3</sup>VA/US, <sup>4</sup>MI/US

09:55 - 09:55 1140PD - Phase I Study of KN035, a novel fusion Anti-PD-L1 Antibody administered subcutaneously in Patients with Advanced Solid Tumors in the USA

K. Papadopoulos<sup>1</sup>, W. Harb<sup>2</sup>, N. Lu<sup>3</sup>, X. Ma<sup>3</sup>, Y. He<sup>3</sup>, L. Yuan<sup>3</sup>, M. Fu<sup>3</sup>, Y. Lin<sup>3</sup>, W. Xu<sup>3</sup>, X. Wang<sup>3</sup>, P. Wang<sup>3</sup>, T. Xu<sup>3</sup>, R. Dong<sup>3</sup>, J. Gong<sup>3</sup>; <sup>1</sup>TX/US, <sup>2</sup>IN/US, <sup>3</sup>CN

- 09:55 - 10:10 Invited Discussant 1138PD, 1139PD and 1140PD  
A. Marabelle, FR
- 10:10 - 10:20 Q&A led by Discussant
- 10:20 - 10:20 1141PD - Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1  
M. Kfoury<sup>1</sup>, A.-L. Voisin<sup>1</sup>, M. Najean<sup>1</sup>, S. Champiat<sup>2</sup>, S. Laghouati<sup>1</sup>, J.-M. Michot<sup>1</sup>, C. Robert<sup>1</sup>, C. Mateus<sup>1</sup>, L. Albiges<sup>1</sup>, B. Besse<sup>2</sup>, C. Massard<sup>2</sup>, M. Texier<sup>1</sup>, O. Lambotte<sup>1</sup>, A. Marabelle<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 10:20 - 10:20 1142PD - Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: data from a French multicentric cohort  
C. Domblides<sup>1</sup>, I. Monnet<sup>1</sup>, J. Mazieres<sup>1</sup>, F. Barlesi<sup>2</sup>, V. Gounant<sup>3</sup>, S. Baldacci<sup>1</sup>, B. Mennecier<sup>4</sup>, A.C. Toffart<sup>1</sup>, C. Audigier Valette<sup>4</sup>, L. Doucet<sup>1</sup>, E. Giroux-Leprieur<sup>1</sup>, F. Guisier<sup>1</sup>, O. Molinier<sup>1</sup>, M. Perol<sup>4</sup>, E. Pichon<sup>5</sup>, G. Robinet<sup>6</sup>, D. Templement Grangerat<sup>4</sup>, A.-M. Ruppert<sup>1</sup>, M. Wislez<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 20/FR, <sup>3</sup>CEDEX 18/FR, <sup>4</sup>CEDEX/FR, <sup>5</sup>CEDEX 9/FR, <sup>6</sup>Cedex 2/FR
- 10:20 - 10:30 Invited Discussant 1041PD and 1042PD  
I.-M. Svane, DK
- 10:30 - 10:40 Q&A led by Discussant
- 09:30 - 10:30 Type: Multidisciplinary interactive sessions Hall B3 - Room 23  
Title: Managing early breast cancer during pregnancy  
Chair(s): S. Linn, NL
- 09:30 - 09:40 Pathology of breast cancer and pregnancy  
E. Provenzano, Cambridgeshire/GB
- 09:40 - 09:50 Chemotherapy during pregnancy  
F. Amant, BE
- 09:50 - 10:00 Her2-targeted therapy during pregnancy  
S. Linn, NL
- 10:00 - 10:30 Discussion

09:30 - 10:30 Type: Multidisciplinary interactive sessions Hall B3 - Room 20  
 Title: At the heyday of molecular classification of cancer  
 Chair(s): R. Fitzgerald, GB

09:30 - 09:35 Introduction  
R. Fitzgerald, GB

09:35 - 09:50 Pathology  
M. Sobrinho Simões, PT

09:50 - 10:05 Molecular classification  
R. Bristow, GB

10:05 - 10:30 Moderated panel discussion with Q&A by audience  
R. Fitzgerald, GB

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Hall B3 - Room 22  
 Title: Tumour sequencing in drug development  
 Chair(s): M. Krebs, GB

09:30 - 09:40 Tumour sequencing in drug development  
C. Le Tourneau, FR

09:40 - 10:30 Discussion led by  
M. Krebs, GB

09:30 - 10:30 Type: Challenge Your Expert (CYE) session ICM - Room 14a  
 Title: Neuroendocrine tumours: Role of theranostics and nuclear medicine  
 Chair(s): M. Pavel, DE

09:30 - 09:40 Neuroendocrine tumours: Role of theranostics and nuclear medicine

09:40 - 10:30 Discussion led by  
M. Pavel, DE

09:30 - 10:30 Type: Young Oncologist session ICM - Room 14c  
Title: YO Mentorship Session: Career paths in oncology

09:30 - 09:30 Clinical  
E. Martinelli<sup>1</sup>, C. Zielinski<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>AT

09:30 - 09:30 Basic science  
M. Sibilía, AT

09:30 - 09:30 Translational research  
M. Hegi<sup>1</sup>, R. Marais<sup>2</sup>; <sup>1</sup>CH, <sup>2</sup>GB

09:30 - 09:30 Industry  
E. Thalmann<sup>1</sup>, W. Pao<sup>2</sup>; <sup>1</sup>AT, <sup>2</sup>NY/CH

11:00 - 12:30 Type: Special session ICM - Room 13  
Title: Liquid biopsies in cancer management  
Chair(s): K. Pantel, DE

11:00 - 11:25 What are the limitations of liquid biopsies  
M. Speicher, AT

11:25 - 11:50 Circulating tumour cells  
K. Pantel, DE

11:50 - 12:15 Liquid biopsies in haematological malignancies  
G. Gaidano, IT

12:15 - 12:30 Discussion

11:00 - 12:30 Type: Educational session Hall A1 - Room 15  
 Title: Epigenetics  
 Chair(s): T. Helleday, GB

11:00 - 11:25 Defining new epigenetic modulators in cancer therapies  
S. Boulton, GB

11:25 - 11:50 Epigenetic reprogramming in paediatric malignancies  
S. Armstrong, US

11:50 - 12:15 Epigenetic regulation of cancer

12:15 - 12:30 Discussion

11:00 - 12:30 Type: Special session Hall B3 - Room 21  
 Title: The changing scenario of drug registration

11:00 - 12:15 Type: Poster Discussion session Hall B3 - Room 23  
 Title: Poster Discussion session - Sarcoma  
 Chair(s): M. Toulmonde, FR; E. Wardelmann, DE

11:00 - 11:00 1604PD - Health-related quality of life in patients with advanced soft tissue sarcoma (ASTS): Results from the TSAR randomized phase III trial of the French Sarcoma Group  
A. LE CESNE, R. KAPSO KAPNANG, S. FOULON, J. BONASTRE; FR

11:00 - 11:00 1605PD - Health-related Quality of Life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first line  
V. Grünwald<sup>1</sup>, M. Schuler<sup>1</sup>, P. Schöffski<sup>2</sup>, H.-G. Kopp<sup>1</sup>, S. Bauer<sup>1</sup>, B. Kasper<sup>1</sup>, L. Lindner<sup>1</sup>, J. Chemnitz<sup>1</sup>, M. Crysandt<sup>1</sup>, A. Stein<sup>1</sup>, B. Steffen<sup>1</sup>, S. Richter<sup>1</sup>, M. Kneba<sup>1</sup>, G. Egerer<sup>1</sup>, S. Zimmermann<sup>1</sup>, A. Karch<sup>1</sup>, A. Kunitz<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>BE

11:00 - 11:00 1606PD - Quality of Life in patients with soft tissue sarcoma undergoing palliative treatment - A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12)  
L. Hentschel, S. Richter, H.-G. Kopp, B. Kasper, A. Kunitz, V. Grünwald, T. Kessler, J.-M. Chemnitz, U. Pelzer, U. Schuler, J. Freitag, A. Schilling, B. Hornemann, K. Arndt, G. Ehninger, M. Bornhäuser, M. Schuler; DE

11:00 - 11:15 Invited Discussant 1604PD, 1605PD and 1606PD

11:15 - 11:25 Q&A led by Discussant



- 11:25 - 11:25 1607PD - Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy  
S. Chawla<sup>1</sup>, S. Pollack<sup>2</sup>, M. Block<sup>3</sup>, M. Druta<sup>4</sup>, K. Do<sup>3</sup>, J. Morris<sup>5</sup>, J. Kim<sup>6</sup>, C. Bohac<sup>7</sup>, H. Lu<sup>3</sup>, S. Gnjatic<sup>8</sup>, R. Jones<sup>9</sup>, P. Hwu<sup>3</sup>, N. Somaiah<sup>10</sup>; <sup>1</sup>CA/US, <sup>2</sup>WA/US, <sup>3</sup>US, <sup>4</sup>FL/US, <sup>5</sup>OH/US, <sup>6</sup>CT/US, <sup>7</sup>California/US, <sup>8</sup>NY/US, <sup>9</sup>WA/GB, <sup>10</sup>SC/US
- 11:25 - 11:25 1608PD - Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients.  
J.-B. Delhorme<sup>1</sup>, E. Nassif<sup>1</sup>, G. Ferron<sup>2</sup>, E. Bompas<sup>3</sup>, J. Adam<sup>1</sup>, O. Glehen<sup>1</sup>, A. Italiano<sup>3</sup>, F. Bertucci<sup>4</sup>, D. Orbach<sup>1</sup>, A. Le Cesne<sup>3</sup>, J. Blay<sup>1</sup>, C. Chevreau<sup>5</sup>, O. Mir<sup>1</sup>, C. Honoré<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 3/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 9/FR, <sup>5</sup>Haute-Garonne/FR
- 11:25 - 11:25 1609PD - Preoperative hypofractionated radiotherapy (RT) in patients with locally advanced myxoid liposarcomas: interim analysis of prospective phase II clinical trial  
H. Kosela Paterczyk<sup>1</sup>, M. Spalek<sup>1</sup>, M. Wagrodzki<sup>1</sup>, A. Borkowska<sup>1</sup>, A. Szumera-Cieckiewicz<sup>2</sup>, A. Cieszanowski<sup>1</sup>, T. Morynski<sup>1</sup>, J. Palucki<sup>1</sup>, P. Rutkowski<sup>1</sup>; <sup>1</sup>PL, <sup>2</sup>PL/PL
- 11:25 - 11:25 1610PD - A Phase II Study of pazopanib with Oral Topotecan in Patients with Metastatic Osteosarcoma  
B. van Tine<sup>1</sup>, N. Mohindra<sup>2</sup>, M. Milhem<sup>2</sup>, S. Attia<sup>2</sup>, S. Robinson<sup>3</sup>, A. Rademaker<sup>4</sup>, S. Okuno<sup>2</sup>, M. Agulnik<sup>2</sup>; <sup>1</sup>Missouri/US, <sup>2</sup>US, <sup>3</sup>MN/US, <sup>4</sup>IL/US
- 11:25 - 11:40 Invited Discussant 1607PD, 1608PD, 1609PD and 1610PD  
M. Toulmonde, CEDEX/FR
- 11:40 - 11:50 Q&A led by Discussant
- 11:50 - 11:50 1611PD - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)  
S. Stacchiotti<sup>1</sup>, J.-Y. Blay<sup>2</sup>, R. Jones<sup>3</sup>, G.D. Demetri<sup>4</sup>, O. Mir<sup>5</sup>, A. Italiano<sup>2</sup>, D. Thomas<sup>6</sup>, T.W.-W. Chen<sup>7</sup>, P. Schöffski<sup>8</sup>, T. Gil<sup>8</sup>, T. Jahan<sup>9</sup>, G. Cote<sup>9</sup>, R. Ratan<sup>9</sup>, S. Attia<sup>9</sup>, M. Roche<sup>9</sup>, S. Daigle<sup>9</sup>, I. Sapir<sup>9</sup>, A. Clawson<sup>9</sup>, M. Gounder<sup>10</sup>; <sup>1</sup>IT, <sup>2</sup>CEDEX/FR, <sup>3</sup>WA/GB, <sup>4</sup>MA/US, <sup>5</sup>FR, <sup>6</sup>AU, <sup>7</sup>TW, <sup>8</sup>BE, <sup>9</sup>US, <sup>10</sup>NY/US
- 11:50 - 11:50 1612PD - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)  
R. Jones<sup>1</sup>, J.-Y. Blay<sup>2</sup>, M. Agulnik<sup>3</sup>, R. Chugh<sup>3</sup>, O. Mir<sup>4</sup>, A. Italiano<sup>2</sup>, D. Thomas<sup>5</sup>, A. Gupta<sup>6</sup>, T. Jahan<sup>3</sup>, G. Cote<sup>3</sup>, V. Villalobos<sup>3</sup>, G.D. Demetri<sup>7</sup>, M. Roche<sup>3</sup>, I. Sapir<sup>3</sup>, S. Daigle<sup>3</sup>, A. Clawson<sup>3</sup>, M. Gounder<sup>8</sup>; <sup>1</sup>WA/GB, <sup>2</sup>CEDEX/FR, <sup>3</sup>US, <sup>4</sup>FR, <sup>5</sup>AU, <sup>6</sup>CA, <sup>7</sup>MA/US, <sup>8</sup>NY/US
- 11:50 - 11:50 1613PD - mTOR inhibitors in uterine and extra-uterine malignant PEComas: a multicenter international case series retrospective analysis.  
R. Sanfilippo<sup>1</sup>, R. Jones<sup>2</sup>, S. Provenzano<sup>1</sup>, G. Antoniou<sup>3</sup>, J.-Y. Blay<sup>4</sup>, E. Fumagalli<sup>1</sup>, S. Stacchiotti<sup>1</sup>, R.M. Bertulli<sup>1</sup>, O. Mir<sup>5</sup>, N. Hindi<sup>6</sup>, M. Brahmi<sup>5</sup>, A. Dufresne<sup>5</sup>, A.P. Dei Tos<sup>1</sup>, P.G. Casali<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>WA/GB, <sup>3</sup>GB, <sup>4</sup>CEDEX/FR, <sup>5</sup>FR, <sup>6</sup>ES

- 11:50 - 11:50 1614PD - A Phase II Study of Preoperative Chemoradiation plus Sorafenib (S) for High-Risk Extremity Soft Tissue Sarcomas (STS)  
C. Ryan, L. Davis, Y.-C. Doung, J. Davis, A. Hung, J. Hayden, K. Gundle, J. Vetto, A. Mansoor, B. Beckett, P. Norr, S. Bertolone-Smith, W. Huang; US
- 11:50 - 11:50 1615PD - A phase 2, multicenter study of the EZH2 inhibitor tazemetostat in adults: (epithelioid sarcoma cohort) (NCT02601950)  
M. Gounder<sup>1</sup>, P. Schöffski<sup>2</sup>, V. Villalobos<sup>1</sup>, G. Cote<sup>1</sup>, R. Chugh<sup>1</sup>, T.W.-W. Chen<sup>3</sup>, T. Jahan<sup>1</sup>, E. Loggers<sup>1</sup>, A. Italiano<sup>4</sup>, A. Gupta<sup>5</sup>, M. Agulnik<sup>1</sup>, S. Attia<sup>1</sup>, R. Jones<sup>6</sup>, B. van Tine<sup>7</sup>, G.D. Demetri<sup>8</sup>, M. Roche<sup>1</sup>, I. Sapir<sup>1</sup>, S. Daigle<sup>1</sup>, A. Clawson<sup>1</sup>, S. Stacchiotti<sup>9</sup>; <sup>1</sup>US, <sup>2</sup>BE, <sup>3</sup>TW, <sup>4</sup>CEDEX/FR, <sup>5</sup>CA, <sup>6</sup>WA/GB, <sup>7</sup>Missouri/US, <sup>8</sup>MA/US, <sup>9</sup>IT
- 11:50 - 12:05 Invited Discussant 1611PD, 1612PD, 1613PD and 1614PD  
E. Wardelmann, DE
- 12:05 - 12:15 Q&A led by Discussant
- 11:00 - 12:30 Type: Special Symposium Hall B3 - Room 20  
Title: Global surveillance of cancer survival: Impact on cancer control  
Chair(s): M. Coleman, GB
- 11:00 - 11:05 Introduction: Global surveillance of cancer survival will stimulate policy and improve equity  
M. Coleman, GB
- 11:05 - 11:25 Trends and inequalities in cancer survival world-wide: The latest results  
C. Allemani, GB
- 11:25 - 11:45 Information for cancer patients, their families and care-givers: Improving outcomes in low- and middle-income countries  
S. Cowal, US
- 11:45 - 12:05 Cancer survival comparisons as a tool to improve the quality of health care: The experience from OECD  
N. Klazinga, FR
- 12:05 - 12:25 Delivering affordable cancer care in developed and developing countries  
R. Sullivan, GB
- 12:25 - 12:30 Panel discussion
- 11:00 - 12:15 Type: Poster Discussion session Hall B3 - Room 22  
Title: Poster Discussion session - NETs  
Chair(s): E. Grande, ES

- 11:00 - 11:00 450PD - Potential Therapeutic Targets in Recurrent and Metastatic Parathyroid Carcinomas revealed by next-generation sequencing.  
M. Cui, Y. Hu, Q. Liao, Y. Zhao; CN
- 11:00 - 11:00 1310PD - Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms  
L. Apostolidis, S. Kreutzfeldt, M. Oles, L. Geldon, C. Heining, P. Horak, B. Hutter, M. Fröhlich, B. Klink, M. Lamping, S. Uhrig, A. Stenzinger, E. Winkler, B. Wiedenmann, D. Jäger, E. Schröck, U. Keilholz, M. Pavel, H. Glimm, S. Fröhling; DE
- 11:00 - 11:15 Invited Discussant 450PD and 1310PD
- 11:15 - 11:25 Q&A led by Discussant
- 11:25 - 11:25 1820PD - Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo  
Y.S. Lee, H. Chang, S.Y. Kim, H.-S. Chang, C.S. Park; KR
- 11:25 - 11:25 1821PD - Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E-mutated anaplastic thyroid cancer (ATC)  
B. Keam<sup>1</sup>, R. Kreitman<sup>2</sup>, Z. Wainberg<sup>3</sup>, M. Cabanillas<sup>4</sup>, D. Cho<sup>5</sup>, A. Italiano<sup>6</sup>, A. Stein<sup>7</sup>, J.Y. Cho<sup>1</sup>, J. Schellens<sup>8</sup>, P. Wen<sup>3</sup>, C. Zielinski<sup>9</sup>, A. Boran<sup>3</sup>, B. Mookerjee<sup>10</sup>, P. Burgess<sup>11</sup>, F. Rangwala<sup>12</sup>, V. Subbiah<sup>4</sup>; <sup>1</sup>KR, <sup>2</sup>MD/US, <sup>3</sup>US, <sup>4</sup>TX/US, <sup>5</sup>NY/US, <sup>6</sup>CEDEX/FR, <sup>7</sup>DE, <sup>8</sup>NL, <sup>9</sup>AT, <sup>10</sup>NJ/US, <sup>11</sup>CH, <sup>12</sup>NC/US
- 11:25 - 11:40 Invited Discussant 1820PD and 1821PD
- 11:40 - 11:50 Q&A led by Discussant
- 11:50 - 11:50 1311PD - Health-related quality of life (HRQoL) for octreotide long-acting (oct I-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial  
A. Rinke<sup>1</sup>, M. Neary<sup>2</sup>, J. Eriksson<sup>2</sup>, M. Hunger<sup>1</sup>, T. Doan<sup>3</sup>, D. Karli<sup>3</sup>, R. Arnold<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>SE, <sup>3</sup>IE
- 11:50 - 11:50 1312PD - Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: the FFCD 1104-EVACEL-GTE phase II study  
T. Walter<sup>1</sup>, C. Lepage<sup>2</sup>, R. Coriat<sup>3</sup>, E. Barbier<sup>1</sup>, G. Cadiot<sup>1</sup>, F.X. Caroli Bosc<sup>4</sup>, T. Aparicio<sup>1</sup>, K. Bouhier Leporrier<sup>4</sup>, O. Hentic Dhome<sup>1</sup>, A.-C. Dupont-Gossart<sup>5</sup>, M. Duluc<sup>6</sup>, C. Lepere<sup>1</sup>, T. Lecomte<sup>1</sup>, D. Smith<sup>1</sup>, C. Petorin<sup>7</sup>, I. Iwanicki Caron<sup>1</sup>, M. Ducreux<sup>5</sup>, C. Lombard Bohas<sup>8</sup>, T. de Baere<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>Cedex/FR, <sup>3</sup>CEDEX 14/FR, <sup>4</sup>CEDEX 9/FR, <sup>5</sup>CEDEX/FR, <sup>6</sup>CEDEX 5/FR, <sup>7</sup>CEDEX 1/FR, <sup>8</sup>CEDEX 3/FR
- 11:50 - 11:50 1313PD - A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy

H. Okuyama<sup>1</sup>, M. Ikeda<sup>2</sup>, T. Okusaka<sup>1</sup>, J. Furuse<sup>1</sup>, M. Furukawa<sup>1</sup>, S. Ohkawa<sup>1</sup>, A. Hosokawa<sup>1</sup>, Y. Kojima<sup>1</sup>, K. Yamaguchi<sup>1</sup>, G. Murohisa<sup>1</sup>, K. Shioji<sup>1</sup>, H. Ishii<sup>1</sup>, N. Mizuno<sup>1</sup>, M. Kojima<sup>1</sup>, T. Yamanaka<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP

11:50 - 12:05 Invited Discussant 1311PD, 1312PD and 1313PD

E. Grande, ES

12:05 - 12:15 Q&A led by Discussant

11:00 - 12:30 Type: EONS session Hall B4 - Room 24  
Title: Nurse-led cancer services  
Chair(s): D. Kelly, GB

11:00 - 11:20 Nurse led acute oncology service developments

M. Fowler, GB

11:20 - 11:40 Introduction of a new advanced cancer nursing role in Sweden

L. Sharp, SE

11:40 - 12:00 Towards implementation of an eHealth-powered integrated model of care in allogeneic hematopoietic stem cell transplantation: The SMILe project

L. Leppla, DE

12:00 - 12:20 Psychosexual support service development

I. White, GB

12:20 - 12:40 Discussion

11:00 - 11:45 Type: Young Oncologist session ICM - Room 14a  
Title: YO Brunch 3: Biosimilars: What they are and their use in oncology

11:00 - 11:45 Biosimilars: What they are and their use in oncology

R. Vidra<sup>1</sup>, I. Litos<sup>2</sup>; <sup>1</sup>RO, <sup>2</sup>GR

11:15 - 12:45	Type: Special Symposium Title: Changing landscape in renal and bladder cancer Chair(s): K. Fizazi, FR; M. Schmidinger, AT	Hall A1 - Room 17
11:15 - 11:20	Introduction <u>K. Fizazi</u> , FR	
11:20 - 11:40	Challenging established frontline therapies in renal cancer <u>L. Albiges</u> , CEDEX/FR	
11:40 - 12:00	Challenging established frontline therapies in bladder cancer <u>T. Powles</u> , GB	
12:00 - 12:20	Can biology help guide treatment decisions in renal cancer? <u>M. Schmidinger</u> , AT	
12:20 - 12:40	Can biology help guide treatment decisions in bladder cancer? <u>M. Galsky</u> , US	
12:40 - 12:45	Conclusion and perspectives <u>K. Fizazi</u> , FR	

11:15 - 12:45	Type: Proffered Paper session Title: Proffered paper session - Immunotherapy of Cancer Chair(s): G. Coukos, CH	Hall A2 - Room 18
11:15 - 11:27	One LBA TBC	
11:27 - 11:39	1127O - A Personal Neoantigen Vaccine, NEO-PV-01, with anti-PD1 Induces Broad De Novo Anti-Tumor Immunity in Patients with Metastatic Melanoma, NSCLC, and Bladder Cancer <u>P. Ott</u> <sup>1</sup> , R. Govindan <sup>2</sup> , A. Naing <sup>3</sup> , T. Friedlander <sup>2</sup> , K. Margolin <sup>2</sup> , J. Lin <sup>2</sup> , N. Bhardwaj <sup>2</sup> , M. Hellman <sup>2</sup> , L. Srinivasan <sup>2</sup> , J. Greshock <sup>2</sup> , M. Moles <sup>2</sup> , R. Gaynor <sup>2</sup> , M. Goldstein <sup>2</sup> , S. Hu-Lieskovan <sup>2</sup> ; <sup>1</sup> MA/US, <sup>2</sup> US, <sup>3</sup> TX/US	
11:39 - 11:54	Invited Discussant One LBA TBC and 1127O <u>G. Coukos</u> , CH	
11:54 - 12:06	1128O - Pre-specified interim analysis of a randomized phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients <u>D. Hale</u> <sup>1</sup> , E.A. Mittendorf <sup>2</sup> , T. Brown <sup>2</sup> , G. Clifton <sup>1</sup> , T. Vreeland <sup>2</sup> , J. Myers <sup>1</sup> , K. Peace <sup>1</sup> , D. Jackson <sup>1</sup> , J. Greene <sup>1</sup> , J. Holmes <sup>3</sup> , G. Peoples <sup>1</sup> ; <sup>1</sup> TX/US, <sup>2</sup> US, <sup>3</sup> CA/US	
12:06 - 12:18	1129O - Stage 2 enrollment complete: Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy <u>T. Leal</u> <sup>1</sup> , A. Spira <sup>2</sup> , C. Blakely <sup>3</sup> , K. He <sup>1</sup> , D. Berz <sup>3</sup> , D. Richards <sup>4</sup> , J. Uyeki <sup>1</sup> , A. Savage <sup>1</sup> , T. Roque <sup>1</sup> , E. Massarelli <sup>1</sup> , R. Jotte <sup>5</sup> , I. Chen <sup>1</sup> , J. Christensen <sup>3</sup> , P. Olson <sup>1</sup> , V. Tassell <sup>1</sup> , L. Horn <sup>6</sup> ; <sup>1</sup> US, <sup>2</sup> VA/US, <sup>3</sup> CA/US, <sup>4</sup> TX/US, <sup>5</sup> CO/US, <sup>6</sup> TN/US	
12:18 - 12:30	1130O - Responses and Durability of Clinical Benefit in Renal Cell Carcinoma Treated with Pegilodectakin in Combination With Anti-PD-1 Inhibitors <u>N. Tannir</u> <sup>1</sup> , A. Naing <sup>1</sup> , K. Papadopoulos <sup>1</sup> , D. Wong <sup>2</sup> , W.M. Korn <sup>2</sup> , R. Aljumaily <sup>3</sup> , K. Autio <sup>4</sup> , S. Pant <sup>3</sup> , T. Bauer <sup>5</sup> , A. Drakaki <sup>6</sup> , N. Daver <sup>1</sup> , A. Hung <sup>6</sup> , M. Oft <sup>6</sup> , J. Leveque <sup>6</sup> ; <sup>1</sup> TX/US, <sup>2</sup> US, <sup>3</sup> OK/US, <sup>4</sup> NY/US, <sup>5</sup> TN/US, <sup>6</sup> CA/US	
12:30 - 12:45	Invited Discussant 1128O, 1129O and 1130O	

11:15 - 12:15	Type: Multidisciplinary interactive sessions Title: The paradigm of oligometastatic disease and ablative treatment Chair(s): G. Prager, AT	ICM - Room 1
11:15 - 11:25	Choice of systemic therapy in oligometastatic disease <u>G. Prager</u> , AT	
11:25 - 11:35	Local ablative treatments: Which instruments – and why used? <u>T. Helmberger</u> , DE	
11:35 - 11:45	Surgery in mCRC: How invasive should our patients be treated in a non-curative setting? <u>P. Naredi</u> , SE	
11:45 - 12:15	Discussion	
11:15 - 12:15	Type: Poster Discussion session Title: Poster Discussion session - Breast cancer metastatic Chair(s): L. Fallowfield, GB	ICM - Room 14b
11:15 - 11:15	193PD - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23)- EORTC QLQ-BR45 <u>V. Bjelic-Radicic</u> <sup>1</sup> , A. Bottomley <sup>2</sup> , F. Cardoso <sup>3</sup> , D. Cameron <sup>4</sup> , E. Brain <sup>5</sup> , K. Kuljanic <sup>6</sup> , R. de Costa <sup>7</sup> , T. Conroy <sup>5</sup> , E. Inwald <sup>8</sup> , S. Serpentine <sup>9</sup> , M. Pinto <sup>9</sup> , J. Weis <sup>8</sup> , O. Morag <sup>10</sup> , G. Guro Lindviksmoen Astrup <sup>11</sup> , K. Tomaszewski <sup>12</sup> , K. Pogoda <sup>12</sup> , P. Sinai <sup>13</sup> , M. Sprangers <sup>14</sup> , N. Aaronson <sup>14</sup> , E. Greimel <sup>1</sup> ; <sup>1</sup> AT, <sup>2</sup> BE, <sup>3</sup> PT, <sup>4</sup> Midlothian/GB, <sup>5</sup> FR, <sup>6</sup> HR, <sup>7</sup> BR, <sup>8</sup> DE, <sup>9</sup> IT, <sup>10</sup> IL, <sup>11</sup> NO, <sup>12</sup> PL, <sup>13</sup> GB, <sup>14</sup> NL	
11:15 - 11:15	290PD - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 <u>P.A. Fasching</u> <sup>1</sup> , F. Esteva <sup>2</sup> , X. Pivot <sup>3</sup> , A. Nusch <sup>1</sup> , J. Beck <sup>4</sup> , A. Chan <sup>5</sup> , A. Pieris-Gunatilaka <sup>6</sup> , Y. Wang <sup>6</sup> , B. Lanoue <sup>6</sup> , D. Chandiwana <sup>6</sup> , P. Neven <sup>7</sup> ; <sup>1</sup> DE, <sup>2</sup> NY/US, <sup>3</sup> CEDEX/FR, <sup>4</sup> AZ/US, <sup>5</sup> AU, <sup>6</sup> NJ/US, <sup>7</sup> BE	
11:15 - 11:15	291PD - Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs) <u>N. Harbeck</u> <sup>1</sup> , R. Villanueva <sup>2</sup> , F. Franke <sup>3</sup> , G. Babu <sup>4</sup> , P. Wheatley-Price <sup>5</sup> , Y.-H. Im <sup>6</sup> , K. Altundag <sup>7</sup> , B. Lanoue <sup>8</sup> , J. Alam <sup>8</sup> , D. Chandiwana <sup>8</sup> , M. Colleoni <sup>9</sup> ; <sup>1</sup> DE, <sup>2</sup> ES, <sup>3</sup> BR, <sup>4</sup> IN, <sup>5</sup> ON/CA, <sup>6</sup> KR, <sup>7</sup> TR, <sup>8</sup> NJ/US, <sup>9</sup> IT	
11:15 - 11:15	292PD - Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation <u>H. Rugo</u> <sup>1</sup> , R. Quek <sup>1</sup> , J. Ettl <sup>2</sup> , S. Hurvitz <sup>1</sup> , H. Bhattacharyya <sup>3</sup> , A. Hannah <sup>1</sup> , J. Litton <sup>3</sup> ; <sup>1</sup> CA/US, <sup>2</sup> DE, <sup>3</sup> US	
11:15 - 11:30	Invited Discussant 193PD, 290PD, 291PD and 292PD <u>L. Fallowfield</u> , GB	

- 11:30 - 11:40 Q&A led by Discussant
- 11:40 - 11:40 293PD - Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b ComplEEment-1 trial  
C. Zamagni<sup>1</sup>, M. Campone<sup>2</sup>, I. Kudryavcev<sup>3</sup>, U. Brown-Glaberman<sup>4</sup>, P. Cottu<sup>5</sup>, A. Ring<sup>6</sup>, J. Lu<sup>4</sup>, M. Martín<sup>7</sup>, M. De Laurentiis<sup>1</sup>, K. Zhou<sup>4</sup>, J. Wu<sup>4</sup>, L. Menon<sup>4</sup>, H. Azim<sup>8</sup>; <sup>1</sup>IT, <sup>2</sup>CEDEX/FR, <sup>3</sup>RU, <sup>4</sup>US, <sup>5</sup>CEDEX 5/FR, <sup>6</sup>GB, <sup>7</sup>ES, <sup>8</sup>EG
- 11:40 - 11:40 294PD - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program.  
J. Sirieix<sup>1</sup>, J. Fraisse<sup>1</sup>, S. Mathoulin-Pelissier<sup>1</sup>, M. Leheuteur<sup>2</sup>, L. Vanlemmens<sup>3</sup>, C. Jouannaud<sup>3</sup>, V. Dieras<sup>4</sup>, C. Levy<sup>4</sup>, F. Dalenc<sup>5</sup>, M.-A. Mouret-Reynier<sup>1</sup>, T. Petit<sup>1</sup>, B. Coudert<sup>6</sup>, E. Brain<sup>1</sup>, B. PISTILLI<sup>1</sup>, J.-M. Ferrero<sup>7</sup>, A. Gonçalves<sup>1</sup>, L. Uwer<sup>3</sup>, S. Gourgou<sup>1</sup>, J.-S. Frenel<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 1/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 5/FR, <sup>5</sup>CEDEX 3/FR, <sup>6</sup>Cedex/FR, <sup>7</sup>CEDEX 2/FR
- 11:40 - 11:40 273PD - Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients  
M. Reinisch, S. Seiler, T. Hauzenberger, S. Schmatloch, H.-J. Strittmatter, D.-M. Zahm, C. Thode, C. Jackisch, D. Strik, V. Moebus, T. Reimer, B. Sinn, E. Stickeler, F. Marme, W. Janni, A. Kamischke, C. Rudlowski, V. Nekljudova, G. von Minckwitz, S. Loibl; DE
- 11:40 - 11:55 Invited Discussant 293PD, 294PD and 273PD
- 11:55 - 12:05 Q&A led by Discussant



11:15 - 12:20 Type: Multidisciplinary interactive sessions Hall A1 - Room 16  
Title: Recurrent cervical cancer  
Chair(s): A. Oaknin, ES

11:15 - 11:20 Case presentation  
D. Cibula, CZ

11:20 - 11:30 The surgeon's perspective  
D. Cibula, CZ

11:30 - 11:40 The radiotherapist's perspective  
A. Taylor, GB

11:40 - 11:50 The medical oncologist's perspective  
A. Oaknin, ES

11:50 - 12:20 Discussion

12:30 - 13:00 Type: Poster Display session Hall B4 - Room 24  
Title: EONS Poster display

12:30 - 12:30 CN5 - Patients - power sources for cancer nurses  
C. Beisel, DE

12:30 - 12:30 CN6 - BRAF/MEK-inhibition for patients with metastatic melanoma: towards patient-centered care  
J. Koldenhof, S. Vervoort, C. Nierop, K. Suijkerbuijk; NL

12:30 - 12:30 CN7 - Perceptions of Rural Nurses Extending Their Role to Administer Chemotherapy  
Q. Alnasser<sup>1</sup>, K. Cameron<sup>1</sup>, J. Prouse<sup>2</sup>; <sup>1</sup>SA, <sup>2</sup>AU

12:30 - 12:30 CN8 - AYA cancer nursing - An emerging sub-speciality - the first book about AYA cancer nursing, edited and authored by nurses.  
S. Smith, DK

12:30 - 12:30 CN9 - Nurse led follow-up for CML patients on oral cancer treatment  
S. De Wilde, J. De Munter, M. Quaghebeur, D. Mazure, A. De Pauw, B. Casteels; BE

12:30 - 12:30 CN10 - Introducing a new role in cancer care, Coordinating Contact Nurses – patient-reported evaluation.  
B. Westman, H. Ullgren, L. Sharp; SE

12:30 - 12:30 CN11 - The role of the nurse in the detection of geriatric frailty and the risk of chemotherapy toxicity in elderly patients with cancer: preliminary study.  
E. Mahía, G. Simó, E. Heras, M. Pascual, F. Cobo, J. Pujadas, S. Albiol; AD

12:30 - 12:30 CN12 - Systemic Anticancer Therapy Administration Safety

S. Toland, A. Simons; GB

- 12:30 - 12:30 CN13 - Increasing incidence and prevalence of immune-related adrenal insufficiency in patients with cancer: the role of the nurse practitioner for early recognition and management  
C. Roth, M. Labots, A. Eertwegh; NL
- 12:30 - 12:30 CN14 - Experiences from a new advanced cancer nursing role in Sweden, an analysis based on EONS Cancer Nursing Education Framework using the Delphi method  
H. Ullgren, SE
- 12:30 - 12:30 CN15 - Opinions and Experiences of Patients Receiving Oral Chemotherapy: A Qualitative Study  
S. Kutlutürkan, Ö. Yurtal, K. Kirca; TR
- 12:30 - 12:30 CN16 - Introducing cancer nurse led consultations to improve sexuality & fertility outcomes for Adolescents and Young Adults (AYAs) with an hematological disease  
J. De Munter, S. De Wilde, M. Quaghebeur; BE
- 12:30 - 12:30 CN17 - Standardising the psychosocial assessment of oncological patients at Donostia University Hospital  
A. Valverde, E. Uranga, M.A. Landa, M.J. Esnaola, L. Basterretxea, G. Agirre, O. Aizpurua, A. Barrio, M. Centeno, I. Delgado, G. Jauregui, L. Moreno, M. Murguiondo, J. San Francisco, H. Telleria; ES
- 12:30 - 12:30 CN18 - Are there differences between nurses' and patients' perceptions of cancer patients' quality of life in Greece?  
M. LAVDANITI, E. GOGOU, G.-C. Karagiannidou, M. DELIBALTIDOU, E. ZIOGA, K. MARMARA, E. Fradelos; GR
- 12:30 - 12:30 CN19 - How an empowerment program can touch cancer survivor's life by improving posttraumatic growth?  
Y.S. UZAR OZCETIN, TR
- 12:30 - 12:30 CN20 - Organising a general oncology nursing outpatient clinic  
C. Lundgren, A. Lagerquist, M. Högman, U. Östlund; SE
- 12:30 - 12:30 CN21 - Job content of advanced practice nurses in Flanders  
E. Decoene, A. Van Hecke; BE
- 12:30 - 12:30 CN22 - Developing and testing a theory-based e-learning intervention to enhance healthcare professionals self-efficacy when supporting parents newly diagnosed with cancer who have dependent children  
C. Semple, E. McCaughan; GB
- 12:30 - 12:30 CN23 - Supporting melanoma patients and their carers: A qualitative exploration of social interaction between patients, carers and healthcare professionals  
J. Bird, M. Nolan, S. Danson; GB
- 12:30 - 12:30 CN24 - Assessing the effect of telephone support on patients with myeloma Multiple (MM) in The Catalan Oncology Institut in Girona  
C. PUIGMARTI, M. Sole, G. Osca, Y. Gonzalez, N. Kelleher; ES

- 12:30 - 12:30 CN28 - Transmural collaborative care in oncology: Experiences of general practitioners  
M. daem, E. van Rookeghem, M. Grypdonck, P. Pype; BE
- 12:30 - 12:30 CN29 - The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: a systematic review  
S. Colomer-Lahiguera<sup>1</sup>, D. Bryant-Lukosius<sup>2</sup>, S. Rietkoetter<sup>2</sup>, L. Martelli<sup>2</sup>, K. Ribi<sup>1</sup>, A. Orcurto<sup>1</sup>, R. Juergens<sup>2</sup>, M. Eicher<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>ON/CA
- 12:30 - 12:30 CN30 - Laryngectomized patients caregivers' life experience: a phenomenological study  
V. Bressan, E. Dri, S. Stevanin, L. Cadorin, A. Rizzuto, G. Bulfone, L. Ghirotto; IT
- 12:30 - 12:30 CN31 - Comparing nurses' and patients' research priorities in cancer care: A mixed methods systematic review  
L. Cadorin, I. Truccolo, V. Bressan, N. Suter; IT
- 12:30 - 12:30 CN32 - Most prevalent unmet supportive care needs in Greek ambulatory advanced breast cancer female patients receiving chemotherapy  
A. Psychogyiou, S. KATSARAGAKIS, C. Lemonidou, D. Protogiros, E. Patiraki; GR
- 12:30 - 12:30 CN33 - A new beginning of collaboration - the Danish Cancer Nursing Research Network  
K. Dieperink, M. Kjerholt, P. Riis Olsen; DK
- 12:30 - 12:30 CN34 - Individual network meetings in cancer care - From young people with cancer to adults with brain tumours  
P. Riis Olsen, DK
- 12:30 - 12:30 CN35 - Does being cancer patient or family caregiver of cancer patient effect bone marrow donation awareness?  
G. Bagcivan, N. Ozen, D. Bayrak, F.I. Cinar; TR
- 12:30 - 12:30 CN36 - A review of the challenges faced by carers of patients diagnosed with head and neck cancer before, during and after treatment  
C. Johnston, M. Tanay; GB
- 12:30 - 12:30 CN37 - Evaluation of support and information needs for patients with cancer in a Phase I trials unit.  
S. Stapleton, L. O'Leary, M. van Zyl, J. Hanwell, T. Wiseman; GB
- 12:30 - 12:30 CN38 - Dignity of Greek patients with advanced cancer: a cross-sectional study  
S. KATSARAGAKIS, F. Deskou, S. Sgourou, M. Christou, M. Dimoula, K. Maniati, D. Protogiros, E. Patiraki; GR
- 12:30 - 12:30 CN39 - Development and implementation of national guidelines on lifestyle issues and cancer -Report from an on-going quality improvement project  
K. Vuollet Karlsson, C. Landegren, B. Westman; SE
- 12:30 - 12:30 CN40 - Developing a Patient Reported Experience Measure (PREM) in Secondary Breast Cancer (SBC)  
C. Farrell, S. Foy, A. May, R. Lee, C. Gaskell, J. Yorke; GB

- 12:30 - 12:30 CN41 - Cancer situation in sub-Saharan Countries: development of educational, diagnosis and treatment plans.  
J. de la Torre-Montero, N. Gil-Gómez, J. RIBES BERNAL, N. Domenech Climent, A. OJER PEREA, P. BEORLEGUI MURILLO, J.M. GAVALA ARJONA, R. CUMPLIDO CORBACHO, I. MAGALLON PEDRERA, M.A. PEÑUELAS SAIZ; ES
- 12:30 - 12:30 CN42 - The Gastrointestinal and Lymphoma unit Lead Nurse Research role in Royal Marsden Hospital.  
J. Duncan<sup>1</sup>, V. Michalarea<sup>2</sup>, T. Coyne<sup>1</sup>, J. Thomas<sup>1</sup>, D. Cunningham<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Surrey/GB
- 12:30 - 12:30 CN43 - Patients' learning and participation in their breast cancer care  
L. Boman, K. Sandelin, Y. Wengström, C. Silén; SE
- 12:30 - 12:30 CN44 - Incidence and risk factors of phlebitis in patients with peripheral parenteral nutrition administration.  
S.Y. Oh, J.M. Lee, J.W. Kim, S.H. Kim, J.M. Park, G.Y. Yeo, J.E. Hyun, J.-H. Park; KR
- 12:30 - 12:30 CN45 - Specialized nursing interventions in optimizing patient communication undergoing total laryngectomy  
A. Frade, S. Miguel; PT
- 12:30 - 12:30 CN46 - Safe navigation of CARs in a changing landscape  
M. Davies, E. Dolan, S. Neeson, E. Blowers, K. Linton, F. Thistlethwaite; GB
- 12:30 - 12:30 CN47 - Patients' interpretations and experiences of participation in cancer care  
J. Jackson, J. Rundgren; SE
- 12:30 - 12:30 CN48 - Peripherally inserted central venous catheters did not increase the risk of deep venous thrombosis in advanced colorectal cancer and lung cancer patients with bevacizumab  
M. Qiu, Y. Chen, B.-L. Zhang, X.-Y. Wang; CN
- 12:30 - 12:30 CN49 - Cancer nurse perspective on the emerging field of biosimilars in cancer care  
J. De Munter, P. Crombez; BE
- 12:30 - 12:30 CN50 - Overview of an Acute Oncology Service in A UK Cancer Centre  
M. Foulkes, GB
- 12:30 - 12:30 CN51 - The development and evaluation of an online oncology portal  
J. De Munter, E. Decoene, A. Van Hecke; BE
- 12:30 - 12:30 CN52 - Pilot Study – Nurses' Role in Management of Cutaneous Toxicity in Patients with Targeted Therapies Anti EGFR-Is' Treatment.  
O. Diamanti, T. Zacheo, C. Lando, C. Magro, G. Pauletti, E. Zemella, C. Fano, F. Bonadies, E. Sarno, A. Venturi, P. De Vecchi, S. Menuzzo, S. Gallimberti, D. Grosso; IT
- 12:30 - 12:30 CN57 - Does individual genetic background predict acute radiation skin reactions in women undergoing adjuvant breast cancer radiotherapy?  
D. Oliva, F. Lewin, N. Lewin, M. Nilsson, M. Strandéus, B.-Å. Andersson, L. Sharp; SE

- 12:30 - 12:30 CN58 - Effect of Aromatherapy Massage on Chemotherapy-Induced Peripheral Neuropathic Pain and Fatigue in Patients Receiving Oxaliplatin  
N. Izgu, L. Ozdemir, F. Bugdayci Basal; TR
- 12:30 - 12:30 CN59 - Cancer pain knowledge and attitudes of nursing and medical professionals in a Greek general hospital  
C. Palassari, S. KATSARAGAKIS, J. Kaklamanos, D. Protopiros, E. Patiraki; GR
- 12:30 - 12:30 CN60 - The experience of dysgeusia in allogenic hematopoietic cell transplantation survivors: a qualitative study  
D. Bomben, A. Bin, M. Venturini, T. Bulfone, L. Ghirotto, V. Bressan; IT
- 12:30 - 12:30 CN61 - "It may not affect you" -- Lived experiences and support needs of women who developed peripheral neuropathy following chemotherapy treatment for cancer.  
M. Tanay, J. Armes; GB
- 12:30 - 12:30 CN62 - App about chemotherapy - helping the patient with cancer  
B. Espersen, DK
- 12:30 - 12:30 CN63 - Usability Test For a CINV Diary Application For Smartphones at Oncology Nursing  
P. Fernández- Ortega, Y. Escobar, E. Trigoso, R. Blat, M. Cantero, A. Alvarez; ES
- 12:30 - 12:30 CN64 - Perceived symptoms of Greek cancer patients during chemotherapy using the Memorial Symptom Assessment Scale  
D. PALITZIKA, E. Fradelos, V. ALIKARI, P. CHARITOPOULOS, E. ZIOGA, S. ZYGA, M. LAVDANITI; GR
- 12:30 - 12:30 CN65 - How to monitor outpatients undergoing active anticancer treatment? A feasibility study of the web-based tool "Onco'nect®"  
M. Belhadj<sup>1</sup>, E. Kempf<sup>1</sup>, A. Lebel<sup>1</sup>, A. Guillemin<sup>1</sup>, H. BouSSION<sup>1</sup>, C. Joly<sup>1</sup>, I. Baumgaertner<sup>2</sup>, E. Assaf<sup>2</sup>, C. Saldana<sup>2</sup>, B. Rousseau<sup>2</sup>, C. Tournigand<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 12:30 - 12:30 CN66 - Medical makeup in cancer patients and its impact in their quality of life  
R. LECHOU, GR
- 12:30 - 14:30 Type: Patient Advocacy Track ICM - Room 5  
Title: The Hans Keulen Memorial Debate
- 12:45 - 13:45 Type: Poster Display session Hall A3 - Poster Area Networking  
Title: Poster display session: Breast cancer - early stage, locally Hub  
advanced &&
- 12:45 - 12:45 194P - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations  
S. Barni<sup>1</sup>, E. Curtit<sup>2</sup>, F. Cognetti<sup>3</sup>, D. Bourgeois<sup>4</sup>, R. Masetti<sup>3</sup>, S. Zilberman<sup>4</sup>, G. Naso<sup>3</sup>, J. Gligorov<sup>4</sup>; <sup>1</sup>(BG)/IT, <sup>2</sup>CEDEX/FR, <sup>3</sup>IT, <sup>4</sup>FR

- 12:45 - 12:45 195P - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast  
A. De Nonneville<sup>1</sup>, C. Jauffret<sup>2</sup>, A. Gonçalves<sup>2</sup>, J.-M. Classe<sup>3</sup>, M. Cohen<sup>2</sup>, F. Reyal<sup>2</sup>, C. Mazouni<sup>2</sup>, M.-P. Chauvet<sup>2</sup>, N. Chopin<sup>2</sup>, P.-E. Colombo<sup>2</sup>, E. Jouve<sup>2</sup>, E. Darai<sup>2</sup>, R. Rouzier<sup>2</sup>, C. Coutant<sup>4</sup>, P. Gimbergues<sup>2</sup>, A.-S. Azuar<sup>2</sup>, C. Tunon de Lara<sup>2</sup>, E. Lambaudie<sup>2</sup>, G. Houvenaeghel<sup>2</sup>; <sup>1</sup>CEDEX 9/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>Cedex/FR
- 12:45 - 12:45 196P - Baseline lymphocyte counts predict distant recurrence in early breast cancer  
G.M. Kim, H.D. Koh, J.H. Kim, B.-W. Park, Y.U. Cho, S.I. Kim, H.S. Park, J.Y. Kim, M.J. Kim, J.H. Jeong, J. Sohn; KR
- 12:45 - 12:45 197P - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).  
L. Carbognin<sup>1</sup>, I. Sperduti<sup>1</sup>, G. Arpino<sup>1</sup>, M.V. Dieci<sup>1</sup>, F. Schettini<sup>1</sup>, G. Griguolo<sup>2</sup>, M. Brunelli<sup>1</sup>, V. Guarneri<sup>1</sup>, R. Nortilli<sup>1</sup>, E. Fiorio<sup>1</sup>, S. Pilotto<sup>1</sup>, E. Orvieto<sup>1</sup>, E. Manfrin<sup>1</sup>, P. Conte<sup>1</sup>, S. de Placido<sup>1</sup>, G. Scambia<sup>1</sup>, G. Tortora<sup>1</sup>, E. Bria<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>CH
- 12:45 - 12:45 198P - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas  
A. De Nonneville<sup>1</sup>, A. Gonçalves<sup>2</sup>, J.-M. Boher<sup>2</sup>, J.-M. Classe<sup>3</sup>, M. Cohen<sup>2</sup>, P.-E. Colombo<sup>2</sup>, F. Reyal<sup>2</sup>, M.-P. Chauvet<sup>2</sup>, E. Jouve<sup>2</sup>, E. Darai<sup>2</sup>, G. Blache<sup>2</sup>, C. Coutant<sup>4</sup>, P. Gimbergues<sup>2</sup>, C. Mazouni<sup>2</sup>, R. Rouzier<sup>2</sup>, R. Villet<sup>2</sup>, P. Crochet<sup>2</sup>, A.-S. Azuar<sup>2</sup>, E. Lambaudie<sup>2</sup>, G. Houvenaeghel<sup>2</sup>; <sup>1</sup>CEDEX 9/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>Cedex/FR
- 12:45 - 12:45 199P - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study  
A. Prat<sup>1</sup>, B. Adamo<sup>2</sup>, J.A. Perez Fidalgo<sup>3</sup>, S. Blanch<sup>1</sup>, N. Martinez<sup>1</sup>, P. Gomez Pardo<sup>1</sup>, A. López González<sup>1</sup>, L. Murillo Juso<sup>1</sup>, K. Amillano<sup>4</sup>, M. Vidal<sup>1</sup>, T. Pascual<sup>1</sup>, L. Pare<sup>1</sup>, J. Canes<sup>5</sup>, P. Galvan<sup>1</sup>, B. Gonzalez Farre<sup>1</sup>, V. Ortega Cebrian<sup>1</sup>, X. Gonzalez<sup>1</sup>, M. Bellet Ezquerria<sup>1</sup>, P. Villagrasa<sup>1</sup>, E. Ciruelos<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>IT, <sup>3</sup>Valencia/ES, <sup>4</sup>Tarragona/ES, <sup>5</sup>BARCELONA/ES
- 12:45 - 12:45 200P - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer  
E.Y. Kim, C.H. Park, S.-I. Do; KR
- 12:45 - 12:45 201P - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience  
A. Alsayed, T. Al-Twejeri, K. Suleman, A. Tulbah, D. Ajarim; SA
- 12:45 - 12:45 202P - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.  
S. Elmorshidy, O. Abd Elffatah, H. Essa, A. Ibrahim, D. Sayed, S. Shehata; EG
- 12:45 - 12:45 203P - Molecular subtyping of breast cancer by dedicated breast PET  
S. Sueoka<sup>1</sup>, S. Sasada<sup>2</sup>, E. Suzuki<sup>1</sup>, N. Goda<sup>1</sup>, K. Kajitani<sup>1</sup>, A. Emi<sup>1</sup>, N. Masumoto<sup>1</sup>, T. Kadoya<sup>1</sup>, R. Haruta<sup>1</sup>, T. Kataoka<sup>1</sup>, M. Okada<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hiroshima/JP

- 12:45 - 12:45 204P - Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer  
T. Loughman<sup>1</sup>, A. Chan-Ju Wang<sup>1</sup>, P. Dynoodt<sup>1</sup>, B. Fender<sup>1</sup>, C. Lopez Ruiz<sup>1</sup>, S. Barron<sup>2</sup>, S. Stapleton<sup>1</sup>, D. O'Leary<sup>3</sup>, A. Fabre<sup>1</sup>, C. Quinn<sup>1</sup>, B. Nodin<sup>4</sup>, K. Jirstrom<sup>4</sup>, A. Bracken<sup>1</sup>, W. Gallagher<sup>1</sup>; <sup>1</sup>IE, <sup>2</sup>Dublin/IE, <sup>3</sup>Ireland/IE, <sup>4</sup>SE
- 12:45 - 12:45 205P - Comparing the prognosis of favourable-histology breast cancers between younger women of less than 45 years of age at diagnosis with their older counterparts.  
G.E. Lee, W.H. Hor; SG
- 12:45 - 12:45 206P - TNBC universe: a monocentric retrospective analyses of TILs and AR as prognostic markers  
A. Losurdo<sup>1</sup>, R. De Sanctis<sup>1</sup>, B. Fernandes<sup>1</sup>, V. Errico<sup>1</sup>, A. Sagona<sup>1</sup>, G. Masci<sup>2</sup>, M. Zuradelli<sup>1</sup>, E. Agostinetto<sup>1</sup>, R. Torrisi<sup>1</sup>, W. Gatzemeier<sup>1</sup>, A. Testori<sup>1</sup>, M. Roncalli<sup>1</sup>, M. Alloisio<sup>1</sup>, C. Tinterri<sup>1</sup>, A. Santoro<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>(MI)/IT
- 12:45 - 12:45 207P - Genomic spectrum of Asian breast cancer based on targeted next-generation sequencing in 150 consecutive primary breast cancer  
C. Cha, S.J. Bae, C.-I. Yoon, S.E. Park, Y. Kim, S.G. Ahn, K.A. Lee, J. Jeong; KR
- 12:45 - 12:45 208P - The Impact of the 21 Gene Recurrence Score (RS) on Chemotherapy (CHemoRx) Prescribing in Hormone Receptor (HR) Positive, Lymph Node Positive (LN+) Early-Stage Breast Cancer (BC) in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)  
A. Hassan<sup>1</sup>, N. Keegan<sup>2</sup>, C. O'Leary<sup>2</sup>, L. McSorley<sup>2</sup>, T. Mahgoub<sup>2</sup>, S. O'Reilly<sup>2</sup>, J. Walshe<sup>2</sup>, M. Kennedy<sup>2</sup>, L. Coate<sup>2</sup>, M. O'connor<sup>2</sup>, M. Keane<sup>2</sup>, C. Kelly<sup>2</sup>, M. Milewski<sup>2</sup>, S. Molloy<sup>2</sup>, K. Eagan<sup>2</sup>, V. Murphy<sup>2</sup>, O. Breathnach<sup>2</sup>, L. Grogan<sup>2</sup>, B. Hennessy<sup>2</sup>, P. Morris<sup>2</sup>; <sup>1</sup>Dublin/IE, <sup>2</sup>IE
- 12:45 - 12:45 209P - Lymphocyte-predominant breast cancer has a significant lower mean of absolute neutrophil counts compared to non-lymphocyte-predominant breast cancer: Analyses with 576 cases  
D.Y. Lee, S.E. Park, C. Cha, C.-I. Yoon, S.J. Bae, S.G. Ahn, J. Jeong; KR
- 12:45 - 12:45 210P - Genetic Alterations of Early-Stage Breast Cancers by next-generation sequencing (NGS)  
Y. Xu, M. Zhang, R. Chen, X. Xia; CN
- 12:45 - 12:45 211P - Oncotype Dx results in patients ≤40 years, Does age matters?: new insights  
F. Namuche<sup>1</sup>, R. Ruiz<sup>2</sup>, Z. Morante Cruz<sup>2</sup>, D. Urrunaga<sup>2</sup>, G. Ziegler<sup>2</sup>, R. Mantilla<sup>2</sup>, M. Leon Rivera<sup>3</sup>, M. Chavez Mac Gregor<sup>4</sup>, H. Gomez Moreno<sup>2</sup>; <sup>1</sup>PE/PE, <sup>2</sup>PE, <sup>3</sup>LIMA/PE, <sup>4</sup>TX/US
- 12:45 - 12:45 212P - Impact of BRCA status on outcomes and survival in high-risk early breast cancers  
E. Klajer<sup>1</sup>, S. Paget-Bailly<sup>2</sup>, G. Meynard<sup>2</sup>, A. Meurisse<sup>2</sup>, F. Bazan<sup>1</sup>, L. Chaigneau<sup>2</sup>, E. Dobi<sup>1</sup>, N. Meneveau<sup>2</sup>, P. Montcuquet<sup>1</sup>, C. Villanueva<sup>2</sup>, A. Thiery-Vuillemin<sup>1</sup>, E. Kalbacher<sup>1</sup>, C. Populaire<sup>2</sup>, M.-A. Collonge-Rame<sup>2</sup>, J. Gligorov<sup>2</sup>, E. Curtit<sup>1</sup>, X. Pivot<sup>1</sup>, L. Mansi<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR
- 12:45 - 12:45 213P - Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy  
N. Hajjaji<sup>1</sup>, Y.M. Robin<sup>2</sup>, D. Bertin<sup>2</sup>, J. Bonnetterre<sup>3</sup>; <sup>1</sup>CEDEX 9/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR

- 12:45 - 12:45 214P - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer  
F. Namuche<sup>1</sup>, R. Ruiz<sup>2</sup>, Z. Morante Cruz<sup>2</sup>, D. Urrunaga<sup>2</sup>, A. Aguilar Cartagena<sup>3</sup>, H. Gomez Moreno<sup>2</sup>; <sup>1</sup>PE/PE, <sup>2</sup>PE, <sup>3</sup>San Borja/PE
- 12:45 - 12:45 215P - Genetic signatures always suggest undertreatment? Experience with PAM50  
C. Sales, I. Vieira, M. Cassiano, C. Oliveira, C. Vieira, M. Ferreira, A. Rodrigues, A. Ferreira, M.I. Pousa, R. Couto, C. Leal, J. Abreu, M. Teixeira, D. Pereira, S. Sousa, M. Abreu; PT
- 12:45 - 12:45 216P - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score  
M. Nesrine, H. El Benna, Y. Berrazegua, S. Labidi, N. Daoud, H. Boussen; TN
- 12:45 - 12:45 217P - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients  
J. Cortes Castan<sup>1</sup>, M. Pegram<sup>2</sup>, X. Pivot<sup>3</sup>, G. Curigliano<sup>4</sup>, J.Y. Lim<sup>5</sup>, S. Song<sup>5</sup>, Y.C. Yoon<sup>5</sup>; <sup>1</sup>ES, <sup>2</sup>US, <sup>3</sup>CEDEX/FR, <sup>4</sup>IT, <sup>5</sup>KR
- 12:45 - 12:45 218P - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial  
A. Sonnenblick<sup>1</sup>, A. Bailey<sup>2</sup>, B. Uziely<sup>1</sup>, M. Untch<sup>3</sup>, I. Smith<sup>2</sup>, L. Gianni<sup>4</sup>, J. Baselga<sup>5</sup>, C. Jackisch<sup>3</sup>, D. Cameron<sup>6</sup>, R. Bell<sup>7</sup>, D. Zardavas<sup>8</sup>, N. Al-Sakaff<sup>9</sup>, R. Gelber<sup>10</sup>, M. Dowsett<sup>2</sup>, B. Leyland-Jones<sup>11</sup>, M. Piccart<sup>8</sup>, E. de Azambuja<sup>8</sup>; <sup>1</sup>IL, <sup>2</sup>GB, <sup>3</sup>DE, <sup>4</sup>IT, <sup>5</sup>NY/US, <sup>6</sup>Midlothian/GB, <sup>7</sup>VIC/AU, <sup>8</sup>BE, <sup>9</sup>CH, <sup>10</sup>MA/US, <sup>11</sup>SD/US
- 12:45 - 12:45 219P - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era  
A. De Nonneville<sup>1</sup>, A. Gonçalves<sup>2</sup>, J.-M. Boher<sup>2</sup>, M. Cohen<sup>2</sup>, F. Reyal<sup>2</sup>, J.-M. Classe<sup>3</sup>, S. Giard<sup>2</sup>, P.-E. Colombo<sup>2</sup>, X. Muraccioli<sup>2</sup>, E. Darai<sup>2</sup>, E. Jouve<sup>2</sup>, C. Mazouni<sup>2</sup>, P. Gimbergues<sup>2</sup>, A.-S. Azuar<sup>2</sup>, E. Barranger<sup>4</sup>, R. Rouzier<sup>2</sup>, R. Villet<sup>2</sup>, N. Chopin<sup>2</sup>, E. Lambaudie<sup>2</sup>, G. Houvenaeghel<sup>2</sup>; <sup>1</sup>CEDEX 9/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 2/FR
- 12:45 - 12:45 220P - Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study  
J.-P. Jacquin<sup>1</sup>, L. Uwer<sup>2</sup>, A. Savignoni<sup>1</sup>, J.-M. Ferrero<sup>3</sup>, A. Lortholary<sup>3</sup>, D. Solub<sup>4</sup>, H. Attar-Rabia<sup>1</sup>, S. Deblay<sup>1</sup>, S. Pibre<sup>1</sup>, Y. Belkacemi<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 2/FR, <sup>4</sup>Eure et Loire/FR
- 12:45 - 12:45 221P - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.  
R. De Sanctis<sup>1</sup>, F. D'Antonio<sup>1</sup>, E. Agostinetti<sup>1</sup>, A. Marinello<sup>1</sup>, G. Masci<sup>2</sup>, M. Zuradelli<sup>1</sup>, A. Losurdo<sup>2</sup>, D. Guiducci<sup>1</sup>, C. Tinterri<sup>1</sup>, A. Testori<sup>1</sup>, W. Gatzemeier<sup>1</sup>, V. Errico<sup>1</sup>, R. Torrissi<sup>1</sup>, A. Santoro<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>(MI)/IT
- 12:45 - 12:45 222P - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab  
X. Pivot<sup>1</sup>, Y.J. Lee<sup>2</sup>, J.Y. Lim<sup>2</sup>, S.J. Song<sup>2</sup>, H.S. Kim<sup>2</sup>, Y.C. Yoon<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>KR



- 12:45 - 12:45 223P - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience  
S. Forner<sup>1</sup>, V.R. Sim<sup>1</sup>, J. Glendenning<sup>1</sup>, R. Burcombe<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>Kent/GB
- 12:45 - 12:45 224P - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)  
J. Litton<sup>1</sup>, S. Moulder<sup>2</sup>, K. Hess<sup>1</sup>, S. Damodaran<sup>1</sup>, G. Rauch<sup>1</sup>, R. Candelaria<sup>2</sup>, B. Adrada<sup>1</sup>, F. Symmans<sup>2</sup>, R. Murthy<sup>1</sup>, T. Helgason<sup>1</sup>, A. Clayborn<sup>2</sup>, S. Prabhakaran<sup>1</sup>, V. Valero<sup>2</sup>, A.M. Thompson<sup>2</sup>, E.A. Mittendorf<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>TX/US
- 12:45 - 12:45 225P - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)  
C. Hall<sup>1</sup>, K. Hess<sup>1</sup>, L. Ravenberg<sup>1</sup>, A. Clayborn<sup>2</sup>, G. Rauch<sup>1</sup>, R. Candelaria<sup>2</sup>, E.A. Mittendorf<sup>1</sup>, S. Moulder<sup>2</sup>, A. thompson<sup>1</sup>, A. Lucci<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>TX/US
- 12:45 - 12:45 226P - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients  
L. Häberle, R. Erber, P. Gaß, A. Hein, S. Jud, H. Langemann, C. Rauh, C. Hack, R. Schulz-Wendtland, A. Hartmann, M. Beckmann, M. Lux, P.A. Fasching; DE
- 12:45 - 12:45 227P - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes  
P.A. Fasching<sup>1</sup>, M. Laible<sup>1</sup>, K. Weber<sup>1</sup>, R.M. Wirtz<sup>1</sup>, C. Denkert<sup>1</sup>, K. Schlombs<sup>1</sup>, S. Schmatloch<sup>1</sup>, O. Camara<sup>1</sup>, H.J. Lück<sup>1</sup>, J. Huober<sup>1</sup>, T. Karn<sup>1</sup>, M. van Mackelenbergh<sup>1</sup>, F. Marme<sup>1</sup>, V. Müller<sup>1</sup>, C. Schem<sup>2</sup>, E. Stickeler<sup>1</sup>, U. Sahin<sup>1</sup>, S. Loibl<sup>1</sup>, M. Untch<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>Schleswig-Holstein/DE
- 12:45 - 12:45 228P - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)  
C. Yam<sup>1</sup>, S. Seth<sup>1</sup>, K. Hess<sup>1</sup>, E.A. Mittendorf<sup>1</sup>, R. Murthy<sup>1</sup>, S. Damodaran<sup>1</sup>, T. Helgason<sup>1</sup>, L. Huo<sup>1</sup>, A.M. Thompson<sup>2</sup>, M. Barton<sup>1</sup>, M. Huang<sup>1</sup>, E. Arribas<sup>1</sup>, D. Lane<sup>1</sup>, G. Rauch<sup>1</sup>, B. Adrada<sup>1</sup>, M. Gilcrease<sup>1</sup>, J. Chang<sup>1</sup>, S. Moulder<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>TX/US
- 12:45 - 12:45 229P - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)  
D. Machado, F. Branco, F. Silva, S. André, M. Brito, M. Casanova, M. Nave, A. Moreira, J. Passos-Coelho; PT
- 12:45 - 12:45 230P - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens  
M. Marin Alcala, G. Lloret Pursals, J.H. Del Riego Ferrari, J. Giner, F.X. Andreu Navarro, S. Medina, O. Aparicio, E. Dalmau Portulas, P. Ribera Fernandez, H. Oliveres, C. Martinez Vila, J. Cabrera Romero, M.A. Segui Palmer, L.A. Fernandez Morales; ES
- 12:45 - 12:45 231P - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)  
B. Seliger, DE

- 12:45 - 12:45 232P - A multicentre, international neoadjuvant, double-blind, randomized phase III trial comparing fulvestrant to a combination of fulvestrant and palbociclib (CDK 4/6 inhibitor) in patients with operable luminal breast cancer responding to fulvestrant (SAFIA study).  
J.-M. Nabholz<sup>1</sup>, K. Al Saleh<sup>2</sup>, A. Bounedjar<sup>3</sup>, H. Abdel-Razeq<sup>4</sup>, H. Errihani<sup>5</sup>, A. Saadeddin<sup>2</sup>, M. Al Foheidi<sup>2</sup>, M. Ghosn<sup>6</sup>, H. El Zawahry<sup>7</sup>, A. Kandil<sup>7</sup>, N. Abdel-Aziz<sup>2</sup>, F. Dabouz<sup>8</sup>, S. Kullab<sup>2</sup>; <sup>1</sup>CEDEX 1/FR, <sup>2</sup>SA, <sup>3</sup>DZ, <sup>4</sup>JO, <sup>5</sup>MA, <sup>6</sup>LB, <sup>7</sup>EG, <sup>8</sup>AE
- 12:45 - 12:45 233P - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer  
Y.-C. Tsai, H.C. Cheng, C.C. Horng; TW
- 12:45 - 12:45 234P - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario  
T. Sood<sup>1</sup>, A. Rauthan<sup>2</sup>, P. Patil<sup>2</sup>, S. Kulkarni<sup>1</sup>, S.P. Somashekhar<sup>1</sup>, S. Zaveri<sup>2</sup>, V. Ahuja<sup>1</sup>, K.R. Ashwin<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>Karnataka/IN
- 12:45 - 12:45 235P - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.  
B. Rapoport, J. Barnard-Tidy, T. Smit, S. Nayler, C. Benn; ZA
- 12:45 - 12:45 236P - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience  
N. Sistani Allahabadi, H. Yahyazadeh, M. Hashemian, M. Rajabpour, S. Aminmozaffari, M. Zaree, A. Rezazadeh Mafi; IR
- 12:45 - 12:45 237P - Index BRCA1/2 testing under a multidisciplinary program  
D. Machado, S. Fragoso, A. Opinião, A. Clara, S. Bento, A.C. Luís, I. Miguel, S. Santos, P. Machado, P. Rodrigues, J. Parreira, F. Vaz; PT
- 12:45 - 12:45 238P - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients  
A. Friedlaender<sup>1</sup>, A. Vuillemier<sup>1</sup>, V. Viassolo<sup>1</sup>, A. Ayme<sup>1</sup>, S. De Talhouet<sup>2</sup>, J.-D. Combes<sup>3</sup>, J. Peron<sup>3</sup>, A. Bodmer<sup>1</sup>, S. Giraud<sup>3</sup>, A. Buisson<sup>3</sup>, V. Bonadona<sup>3</sup>, I. Gauchat-Bouchardy<sup>1</sup>, O. Tredan<sup>4</sup>, P. Chappuis<sup>1</sup>, S.I. Labidi-Galy<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>Cedex 08/FR, <sup>3</sup>FR, <sup>4</sup>CEDEX/FR
- 12:45 - 12:45 239P - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors  
E. Imyanitov, E. Preobrazhenskaya, A. Shlejkina, A. Sokolenko, E. Anisimova, A. Ivantsov, A. Togo; RU
- 12:45 - 12:45 240P - Landscape of germline mutations in HBOC patients in Russia revealed by target panel sequencing  
E. Shagimardanova, L. Shigapova, R. Enikeev, M. Druzhkov, A. Nikitin, O. Gusev, M. Gordiev; RU
- 12:45 - 12:45 241P - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Hereditary Oncogenomics project  
M. Gordiev, L. Shigapova, O. Brovkina, R. Enikeev, M. Druzhkov, A. Nikitin, E. Shagimardanova, O. Gusev; RU

- 12:45 - 12:45 242P - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)  
N. OLYMPIOS<sup>1</sup>, M. Lambertini<sup>2</sup>, C. Calbrix<sup>1</sup>, M. Saint-Ghislain<sup>1</sup>, M. Fontanilles<sup>1</sup>, A. Loeb<sup>1</sup>, M. Leheurteur<sup>3</sup>, I. Demeestere<sup>2</sup>, F. Di Fiore<sup>1</sup>, A. Perdrix<sup>1</sup>, F. Clatot<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>BE, <sup>3</sup>CEDEX 1/FR
- 12:45 - 12:45 243P - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study  
E. Pohl, A. Schneeweiss, J. Hauke, V. Moebus, J. Furlanetto, C. Denkert, P.A. Fasching, C. Hanusch, H. Tesch, N. Weber-Lassalle, V. Müller, K. Rhiem, M. Untch, K. Luebbe, B. Lederer, C. Jackisch, V. Nekljudova, R. Schmutzler, E. Hahnen, S. Loibl; DE
- 12:45 - 12:45 244P - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity  
D. O Reilly, L. Dooley, G. Watson, R. Clarke, A. Nolan, C. Nolan, E. Berkeley, M. Farrell, D. Gallagher; IE
- 12:45 - 12:45 245P - Incidence and Survival among Young Women with Stage I-III Breast Cancer  
A. Thomas<sup>1</sup>, A. Rhoads<sup>2</sup>, E. Pinkerton<sup>2</sup>, M. Schroeder<sup>2</sup>, J. Oelson<sup>2</sup>, L. McNally<sup>1</sup>, W. Hundley<sup>1</sup>, K. Conway<sup>2</sup>, C. Lynch<sup>2</sup>, P. Romitti<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>IA/US
- 12:45 - 12:45 246P - Toxicity and Clinical Outcomes of Partial Breast Irradiation (PBI) Compared to Whole Breast Irradiation (WBI) for Early Stage Breast Cancer: A Systematic Review and Meta-analysis  
H. Goldvaser<sup>1</sup>, A. Fyles<sup>1</sup>, D. Shepshelovich<sup>1</sup>, E. Amir<sup>2</sup>, Y. Korzets<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA
- 12:45 - 12:45 247P - Should anthracyclines always be present in the adjuvant treatment of breast cancer (BC)? A systematic review and meta-analysis of randomized controlled trials (RCTs)  
R. Caparica<sup>1</sup>, M. Bruzzone<sup>2</sup>, F. Poggio<sup>2</sup>, M. Ceppi<sup>2</sup>, E. de Azambuja<sup>1</sup>, M. Lambertini<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>IT
- 12:45 - 12:45 248P - Taxane &&  
P. Ntellas<sup>1</sup>, N. Spathas<sup>1</sup>, D. Zylis<sup>1</sup>, S. Agelaki<sup>1</sup>, E. Zintzaras<sup>1</sup>, E. Saloustris<sup>2</sup>; <sup>1</sup>GR, <sup>2</sup>Crete/GR
- 12:45 - 12:45 249P - Risk of cardiovascular late effects in breast cancer survivors: a population-based study  
J. Lee, I.Y. Chung, Z. Kim, H. Hur, J.W. Lee, H.J. Youn; KR
- 12:45 - 12:45 250P - Diagnostic Value of Contrast Enhanced Digital Mammography versus Contrast Enhanced MRI for Preoperative Evaluation of Breast Cancer  
E.Y. Kim, I. Youn, C.H. Park, S.H. Kook; KR
- 12:45 - 12:45 251P - Pregnancies after breast cancer, is there a real need for fertility preservation ? Results from the ARTEMIS cohort of 60 young patients  
J. Martin-Babau<sup>1</sup>, F. Toudic-Emily<sup>2</sup>, A.-H. Boivin<sup>2</sup>, P. Burban-Provost<sup>2</sup>, B. Vie<sup>3</sup>, P.-L. Etienne<sup>2</sup>, B. Lamezec<sup>2</sup>, E. Le Fur<sup>2</sup>, A. Vincent<sup>2</sup>, D. Besson<sup>2</sup>, A.-C. Hardy-Bessard<sup>2</sup>; <sup>1</sup>Cedex 2/FR, <sup>2</sup>FR, <sup>3</sup>Cedex 4/FR
- 12:45 - 12:45 252P - Relationship between androgen receptor and tumor infiltrating lymphocytes in triple negative breast cancer

L.F. Sánchez-Cousido, A. López-González, E. Honrado Franco, E. Vallejo Pascual, O. Sanz, L. Lopez Gonzalez, I. Delgado, M. López-Flores, A. García Palomo; ES

- 12:45 - 12:45 253P - Use of red clover in premenopausal breast cancer patients receiving hormonal adjuvant treatment: biological and clinical implications from a randomized clinical trial  
C. Ferraris, B. Ballestra, V. Cappelletti, C. Listorti, P. Miodini, I. Pulice, L. Mariani, E. Ferrari, A. Gambaro, I. Maugeri, G. Martelli, S. Folli; IT
- 12:45 - 12:45 254P - PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study  
I. Kindts<sup>1</sup>, A. Laenen<sup>1</sup>, M. van den Akker<sup>2</sup>, C. Weltens<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>NL
- 12:45 - 12:45 255P - Impact on disease-free survival (DFS) of the surgical waiting time (SWT) for patients (Pts) with early breast cancer (BC)  
R. Nakamura<sup>1</sup>, N. Yamamoto<sup>1</sup>, T. Miyaki<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP
- 12:45 - 12:45 256P - Oncological outcome of fat grafting for breast reconstruction after cancer  
G. Griguolo<sup>1</sup>, F. Miglietta<sup>2</sup>, M.V. Dieci<sup>2</sup>, V. Vindigni<sup>2</sup>, F. Bassetto<sup>2</sup>, E. De Antoni<sup>2</sup>, I. Polico<sup>2</sup>, A. Marchet<sup>2</sup>, E. Baldan<sup>2</sup>, G. Vernaci<sup>2</sup>, T. Saibene<sup>2</sup>, S. Michieletto<sup>2</sup>, V. Guarneri<sup>2</sup>; <sup>1</sup>CH, <sup>2</sup>IT
- 12:45 - 12:45 257P - Changes in body weight over 18-months follow-up among Chinese patients after breast cancer diagnosis  
W. Yeo, Y. Lei, A. Cheng, C. Kwok, K. Cheung, I. Lee, R. Lee, S. Ho; HK
- 12:45 - 12:45 258P - Incidence of clinically significant toxicities in patients with high endoxifen concentrations  
S. Groenland, A. Sanchez-Spitman, D.J.A.R. Moes, S. Koolen, V. Dezentjé, N. van Erp, R. Mathijssen, H.-J. Guchelaar, A. Huitema, N. Steeghs; NL
- 12:45 - 12:45 259P - Male Breast Cancer: Clinical and Epidemiological Patterns in the United States  
M. Gouda, Menoufia Governorate/EG
- 12:45 - 12:45 260P - The aesthetic results after oncoplastic surgery in early breast cancer  
A. ZIKIRYAHODJAEV, A. Sukhotko, A. Tukmakov; RU
- 12:45 - 12:45 261P - The application of indocyanine green fluorescence navigation method to a sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer  
K. Yamagami, H. Matsumoto, T. Hashimoto, S. Yanai, S. Yuen, Y. Yata, Y. Ichinose, T. Deai, M. Toi; JP
- 12:45 - 12:45 262P - Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Cytology Proven Axillary Node-Positive Breast Cancer at Diagnosis  
H.J. Choi, S.M. Jung, J.M. Ryu, I. Kim, S.J. Nam, S.W. Kim, J. Yu, S.K. Lee, J.E. Lee; KR
- 12:45 - 12:45 263P - Omission of Axillary Lymph Node Dissection after Positive Sentinel Lymph Node: Validity and Safety among Early Breast Cancer Patients Treated with Mastectomy  
A. Matsumoto, Y. Umemoto, H. Jinno; JP
- 12:45 - 12:45 264P - Pathologic response as a strong predictor of survival irrespective of phenotype in early Breast Cancer

A. Gasol Cudos, S. Morales Murillo, J. Veas Rodriguez, F. Vilardell Vilellas, D. Sanchez Guzman, E. Iglesias Martinez; ES

- 12:45 - 12:45 265P - Nomogram to predict non-sentinel lymph node status of breast cancer using total tumor load determined by one-step nucleic acid amplification (OSNA)  
P. O-charoenrat, D. Sa-nguanraksa, A. Kulprom; TH
- 12:45 - 12:45 266P - Detecting Bone Density in Early Breast Cancer Survivors: The Arm-DXA method  
Y. Al-Farhat, HU
- 12:45 - 12:45 267P - Voluntary Deep Inspiration Breathhold (DIBH) experience in the Radiotherapy for Left Sided Breast Cancer Gueorguiev I, Nedev N, Avramov A, Velikova N, Tonev A Radiation Oncology Clinic, Acibadem City Clinic Oncology Center - Sofia, Bulgaria  
I. Gueorguiev, N. Nedev; BG
- 12:45 - 12:45 268P - Psychological distress and health-related quality of life in women recently diagnosed with breast cancer in the Epi-GEICAM study.  
N., Fernández-De-Larrea, B. Pérez-Gómez, A. Ruiz, A.M. Casas, B. Bermejo, J.M. Baena-Cañada, S. Antolin, P. Sánchez Rovira, M. Ramos Vázquez, J.A. Garcia-Saénz, A. Anton Torres, M. Muñoz, C. Jara, M. Gil-Gil, E. Adrover, A. Oltra, J. Brunet, S. Bezares, M. Martín, M. Pollán; ES
- 12:45 - 12:45 269TiP - Multicenter study to evaluate the efficacy and standardize radiofrequency ablation therapy for early breast cancer (RAFAELO study)  
T. Kinoshita<sup>1</sup>, S. Ohtani<sup>2</sup>, H. Doihara<sup>1</sup>, M. Takahashi<sup>3</sup>, T. Fujisawa<sup>1</sup>, N. Yamamoto<sup>1</sup>, K. Aogi<sup>1</sup>, T. Hojo<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hiroshima/JP, <sup>3</sup>Hokkaido/JP
- 12:45 - 12:45 270TiP - Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)  
L. Heesen<sup>1</sup>, K. Frenzel<sup>1</sup>, S. Bolte<sup>1</sup>, V. Bukur<sup>1</sup>, M. Diken<sup>1</sup>, E. Derhovanessian<sup>1</sup>, S. Kreiter<sup>1</sup>, A. Kuhn<sup>1</sup>, K. Kühlcke<sup>1</sup>, M. Löwer<sup>1</sup>, H. Lindman<sup>2</sup>, S. Pascolo<sup>3</sup>, M. Schmidt<sup>1</sup>, A. Schneeweiss<sup>1</sup>, T. Sjöblom<sup>2</sup>, K. Thielemans<sup>4</sup>, L. Zitvogel<sup>5</sup>, Ö. Türeci<sup>1</sup>, U. Sahin<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>SE, <sup>3</sup>CH, <sup>4</sup>BE, <sup>5</sup>CEDEX/FR
- 12:45 - 12:45 271TiP - Preoperative Pembrolizumab (Pembro) with Radiation Therapy (RT) in Patients with Operable Triple-Negative Breast Cancer (TNBC)  
H. McArthur<sup>1</sup>, R. Basho<sup>2</sup>, S. Shiao<sup>2</sup>, D. Park<sup>2</sup>, C. Dang<sup>2</sup>, S. Karlan<sup>2</sup>, S. Knott<sup>2</sup>, M. Mita<sup>2</sup>, C. Dilauro Abaya<sup>2</sup>, A. Giuliano<sup>2</sup>, F. Dadmanesh<sup>2</sup>, A. Ho<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>MA/US
- 12:45 - 12:45 272TiP - Development of mPRO Mamma mobile application and its impact on the quality of life and health resource usage in patients with early stage and locally advanced breast cancer receiving chemotherapy  
C. Grasic Kuhar, T. Gortnar, E. Drmota, T. Kovač, M. Kukar; SI
- 12:45 - 12:45 274P - CD8+, CD4+ and FOXP3+ cell profiles and their change after neoadjuvant chemotherapy in patients with triple negative breast cancer  
N. Verovkina, S. Lyalkin, L. Syvak, A. Askolskyi, N. Majdanevych; UA
- 12:45 - 12:45 275P - Multiplex immunoassays analysis of plasma biomarker levels and response to neoadjuvant chemotherapy for locally advanced breast cancer

J.H. Cho, K. Park, E. Lee, Y. Kim, S. Park, S.E. Yoon, K.K. Lee, J.Y. Hur, S.K. Lee, J.E. Lee, S.W. Kim, S.J. Nam, J. Yu, J.-Y. Kim, H.H. Jung, Y.H. Park; KR

- 12:45 - 12:45 276P - Prognostic role of changes in neutrophil-to-lymphocyte ratio, tumor-infiltrating lymphocyte with programmed death ligand-1 in triple-negative breast cancer  
E.K. Joung, J.E. Lee; KR
- 12:45 - 12:45 277P - Expression of Sp17 and its association with clinicopathological parameters of breast cancer  
Y.-T. Zhou, CN
- 12:45 - 12:45 278P - Intratumoral heterogeneity on dedicated breast positron emission tomography before chemotherapy predicts the outcome of neoadjuvant chemotherapy in breast cancer  
N. masumoto<sup>1</sup>, T. Kadoya<sup>1</sup>, E. Suzuki<sup>1</sup>, S. Sueoka<sup>1</sup>, N. Goda<sup>1</sup>, S. Sasada<sup>2</sup>, A. Emi<sup>1</sup>, R. Haruta<sup>1</sup>, T. Kataoka<sup>1</sup>, M. Okada<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Hiroshima/JP
- 12:45 - 12:45 279P - Results from NRG Oncology/NSABP protocol DMP-1: Physician Counseling  
C. Holmberg<sup>1</sup>, H. Bandos<sup>2</sup>, W. McCaskill-Stevens<sup>3</sup>, D.L. Wickerham<sup>2</sup>, T. Battaglia<sup>2</sup>, T. Bevers<sup>2</sup>, A. Fagerlin<sup>2</sup>; <sup>1</sup>DE, <sup>2</sup>US, <sup>3</sup>MD/US
- 12:45 - 12:45 280P - Neoadjuvant eribulin plus carboplatin vs. paclitaxel plus carboplatin in patients with triple-negative breast cancer (TNBC)  
P. Krivorotko, L. Gigolaeva, S. Khadzimatova, E. Zhiltsova, S. Yerechshenko, M. Nikitina, V. Ni, A. Emelyanov, E. Imyanitov, A. Sokolenko, T. Tabagua; RU
- 12:45 - 12:45 281TiP - A phase Ib/II study of Durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE).  
A. Devaux, J.-L. Canon, F. Duhoux, P. Delrée, C. Galant, P. Coulie, I. Bar, M. Constant, S. Haussy, O. Bricard, K. Missault, M. Berlière, T. Willems, J. Carrasco; BE
- 12:45 - 12:45 282TiP - Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: the RIBANNA study  
P.A. Fasching, T. Decker, G. Guderian, J. Heim, C. Jackisch, H.-J. Lueck, D. Lüftner, F. Marmé, T. Reimer, A. Woeckel; DE
- 12:45 - 12:45 295P - Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer. Final results from the randomized phase II trial VicTORia.  
T. Decker<sup>1</sup>, A. Mündlein<sup>2</sup>, N. Marschner<sup>1</sup>, A. Welt<sup>1</sup>, T. Riedt<sup>1</sup>, V. Hagen<sup>1</sup>, J. Rauh<sup>1</sup>, D. Klein<sup>1</sup>, K. Potthoff<sup>1</sup>, P. Jähmig<sup>1</sup>, H. Schröder<sup>1</sup>, S. Hegewisch-Becker<sup>1</sup>, C. Lerchenmüller<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>AT
- 12:45 - 12:45 296P - Applicability of the Lung Immune Prognostic Index (LIPI) to metastatic Triple negative Breast Cancer (mTNBC) patients treated with Immune Checkpoint Targeted Monoclonal Antibodies (ICT mAbs)  
A. Vozy<sup>1</sup>, A. Simonaggio<sup>1</sup>, E. Auclin<sup>1</sup>, L. Mezquita<sup>1</sup>, C. Baldini<sup>2</sup>, P. Martin-Romano<sup>1</sup>, B. PISTILLI<sup>1</sup>, A. Gazzah<sup>1</sup>, R. Bahleda<sup>2</sup>, V. Ribrag<sup>1</sup>, S. Postel-Vinay<sup>1</sup>, S. Champiat<sup>2</sup>, J.-C. Soria<sup>3</sup>, F. André<sup>2</sup>, C. Massard<sup>2</sup>, B. Besse<sup>2</sup>, S. Delalogue<sup>1</sup>, A. Varga<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX/US

- 12:45 - 12:45 297P - Peripheral Blood Mononuclear Cell Biomarkers Predict Response to Immune Checkpoint Inhibitor Therapy in Metastatic Breast Cancer  
Y. Yuan<sup>1</sup>, W. Hou<sup>2</sup>, S. Padam<sup>2</sup>, P. Frankel<sup>2</sup>, M. Sedrak<sup>2</sup>, J. Portnow<sup>2</sup>, J. Mortimer<sup>2</sup>, C. Yeon<sup>2</sup>, A. Hurria<sup>2</sup>, A. Tang<sup>2</sup>, N. Martinez<sup>2</sup>, P. Lee<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US
- 12:45 - 12:45 298P - Circulating exosomal microRNA profiling to depict mechanisms of chemotherapy resistance among triple negative breast cancer  
Y. He, T. Jinhai; CN
- 12:45 - 12:45 299P - The Prevalence of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)  
K. Wan<sup>1</sup>, Y. Wang<sup>2</sup>, M. Kaper<sup>3</sup>, M. Fritzemeier<sup>2</sup>, N. Babbar<sup>4</sup>; <sup>1</sup>CH, <sup>2</sup>MA/US, <sup>3</sup>NJ/US, <sup>4</sup>US
- 12:45 - 12:45 300P - Differential molecular signature in patients from African origin with Triple-Negative Breast Cancer  
A. Matias, A. Jacinta-Fernandes, R. Magno, J. Xavier, M. Cabral, A. Jacinto, A. Maia, S. Braga; PT
- 12:45 - 12:45 301P - Analysis of the JAK2 gene in TNBC  
L. Stanek<sup>1</sup>, P. Tesarova<sup>1</sup>, M. Vocka<sup>1</sup>, L. Petruzelka<sup>2</sup>; <sup>1</sup>2/CZ, <sup>2</sup>CZ
- 12:45 - 12:45 302P - A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients.  
G. Pelizzari, L. Gerratana, D. Basile, S. Zago, M.G. Vitale, M. Bartoletti, C. Lisanti, V. Fanotto, C. Corvaja, L. Bortot, A. Liguori, M. Cinausero, S. Russo, C. Andreetta, M. Bonotto, M. Mansutti, A. Minisini, F. Curcio, G. Fasola, F. Puglisi; IT
- 12:45 - 12:45 303P - EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment  
M. Martín<sup>1</sup>, W. Eiermann<sup>2</sup>, H. Rugo<sup>3</sup>, J. Ettl<sup>4</sup>, S. Hurvitz<sup>3</sup>, A. Gonçalves<sup>5</sup>, R. Yerushalmi<sup>6</sup>, D. Markova<sup>7</sup>, I.C. Tudor<sup>7</sup>, J. Blum<sup>7</sup>, A. Hannah<sup>3</sup>, J. Litton<sup>7</sup>; <sup>1</sup>ES, <sup>2</sup>IR, <sup>3</sup>CA/US, <sup>4</sup>DE, <sup>5</sup>FR, <sup>6</sup>IL, <sup>7</sup>US
- 12:45 - 12:45 304P - EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis  
A. Gonçalves<sup>1</sup>, W. Eiermann<sup>2</sup>, H. Rugo<sup>3</sup>, J. Ettl<sup>4</sup>, S. Hurvitz<sup>3</sup>, R. Yerushalmi<sup>5</sup>, M. Martín<sup>6</sup>, M. Al-Adhami<sup>7</sup>, I.C. Tudor<sup>7</sup>, J. Blum<sup>7</sup>, A. Hannah<sup>3</sup>, J. Litton<sup>7</sup>; <sup>1</sup>FR, <sup>2</sup>IR, <sup>3</sup>CA/US, <sup>4</sup>DE, <sup>5</sup>IL, <sup>6</sup>ES, <sup>7</sup>US
- 12:45 - 12:45 305P - Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase 3 EMBRACA trial  
Y. Yu<sup>1</sup>, M. Elmeliegy<sup>2</sup>, J. Litton<sup>1</sup>, I.C. Tudor<sup>1</sup>, A. Czibere<sup>1</sup>, J. Zheng<sup>1</sup>, D. Wang<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NJ/US
- 12:45 - 12:45 306P - Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials  
M. Elmeliegy<sup>1</sup>, Y. Yu<sup>2</sup>, J. Litton<sup>2</sup>, N. Turner<sup>3</sup>, A. Czibere<sup>2</sup>, G. Wilson<sup>2</sup>, I.C. Tudor<sup>2</sup>, J. Zheng<sup>2</sup>, D. Wang<sup>2</sup>; <sup>1</sup>NJ/US, <sup>2</sup>US, <sup>3</sup>GB

- 12:45 - 12:45 307P - An international systematic review (SR) of breast cancer (BC) BRCA mutation (BRCAm) prevalence  
N. Armstrong<sup>1</sup>, S. Ryder<sup>1</sup>, C. Forbes<sup>1</sup>, A. Chalker<sup>1</sup>, J. Ross<sup>1</sup>, R. Quek<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>CA/US
- 12:45 - 12:45 308P - Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: a systematic review (SR) of international breast cancer (BC) guidelines  
C. Forbes<sup>1</sup>, D. Fayer<sup>1</sup>, C. Clar<sup>1</sup>, K. Reid<sup>1</sup>, S. de Kock<sup>1</sup>, R. Quek<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>CA/US
- 12:45 - 12:45 309P - Efficacy and toxicity of endocrine therapy + cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status  
L. Bruno, M. Costanzo, C. Ostinelli, A. Nervo, J. Nadal, F. Colo, J. Loza, C. Loza, C. Ponce, V. Fabiano, A. Blanco, C. Perez de la Puente, R. Chacon; AR
- 12:45 - 12:45 310P - Clinical Outcomes, Treatment Patterns and Health Resource Utilization (HRU) Among Metastatic Breast Cancer (mBC) Patients (pts) with Germline BRCA Mutation (gBRCAm)  
R. Quek, J. Mardekian; CA/US
- 12:45 - 12:45 311P - Early Results from an Open-label Phase 1b/2 Study of Eribulin Mesylate (EM) + Pegvorhialuronidase Alfa (PEGHP20) Combination for the Treatment of Patients (Pts) with HER2-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)  
M. Shum<sup>1</sup>, V. Assikis<sup>2</sup>, C. Savulsky<sup>3</sup>, W. Zhu<sup>4</sup>, P. Iyer<sup>4</sup>, D. Xing<sup>4</sup>, C. Berman<sup>1</sup>, N. Lokker<sup>5</sup>, R. Alvarez<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GA/US, <sup>3</sup>GB, <sup>4</sup>NJ/US, <sup>5</sup>CA/US
- 12:45 - 12:45 312P - Phase II clinical trial of first-line eribulin plus trastuzumab for advanced or recurrent HER2-positive breast cancer  
K. Sakaguchi, K. Nakatsukasa, T. Taguchi; JP
- 12:45 - 12:45 313P - Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study  
M. Jafri<sup>1</sup>, H. Kristeleit<sup>1</sup>, V. Misra<sup>1</sup>, M. Baxter<sup>1</sup>, S. Ahmed<sup>1</sup>, A. Jegnnathen<sup>1</sup>, A. Jain<sup>1</sup>, D. Maskell<sup>1</sup>, U. Barthakur<sup>1</sup>, G. Edwards<sup>1</sup>, H. Walter<sup>1</sup>, R. Walter<sup>1</sup>, M. Khan<sup>1</sup>, A. Borley<sup>1</sup>, P. Nightingale<sup>1</sup>, D. Rea<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>West Midlands/GB
- 12:45 - 12:45 314P - Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: a real-world prospective study  
M. Takahashi<sup>1</sup>, K. Inoue<sup>2</sup>, H. Mukai<sup>2</sup>, T. Yamanaka<sup>2</sup>, C. Egawa<sup>2</sup>, Y. Sakata<sup>2</sup>, H. Ikezawa<sup>2</sup>, T. Matsuoka<sup>2</sup>, J. Tsurutani<sup>2</sup>; <sup>1</sup>Hokkaido/JP, <sup>2</sup>JP
- 12:45 - 12:45 315P - Prospective Cohort Study of Real World Chemotherapy Sequence for Metastatic Breast Cancer (KBCRN A001: E-SPEC Study)  
K. Nakatsukasa, Y. Kikawa, T. Kotake, K. Yamagami, S. Tsuyuki, H. Yamashiro, H. Suwa, T. Sugie, T. Okuno, H. Kato, S. Takahara, I. Nakayama, N. Ogura, Y. Moriguchi, M. Takata, E. Suzuki, H. Yoshiyayashi, H. Ishiguro, T. Taguchi, M. Toi; JP
- 12:45 - 12:45 316P - Comparative effectiveness of nab-paclitaxel vs. paclitaxel monotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice  
T. Luhn<sup>1</sup>, S. Chui<sup>2</sup>, A. Hsieh<sup>2</sup>, J. Yi<sup>3</sup>, A. Mecke<sup>4</sup>, P. Bajaj<sup>2</sup>, W. Hasnain<sup>1</sup>, A. Falgas<sup>4</sup>, T. Ton<sup>2</sup>, A. Kurian<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>NJ/US, <sup>4</sup>CH



- 12:45 - 12:45 317P - Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: a phase II randomized study (JBCRG-19)  
K.-I. Watanabe<sup>1</sup>, K. Aogi<sup>1</sup>, M. Kitada<sup>1</sup>, T. Sangai<sup>1</sup>, S. Ohtani<sup>2</sup>, T. Aruga<sup>1</sup>, H. Kawaguchi<sup>1</sup>, T. Fujisawa<sup>1</sup>, S. Maeda<sup>1</sup>, T. Morimoto<sup>1</sup>, S. Morita<sup>1</sup>, N. Masuda<sup>1</sup>, M. Toi<sup>1</sup>, S. Ohno<sup>3</sup>; <sup>1</sup>JP, <sup>2</sup>Hiroshima/J, <sup>3</sup>Fukuoka/J
- 12:45 - 12:45 318P - Clinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: A review of a single institution  
M. Furuta<sup>1</sup>, J. Watanabe<sup>2</sup>, T. Aramaki<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Shizuoka/J
- 12:45 - 12:45 319P - A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)  
P. Krivorotko<sup>1</sup>, B. Karaszewska<sup>2</sup>, S. Chan<sup>3</sup>, M. Wieczorek-Rutkowska<sup>1</sup>, T. Sarosiek<sup>2</sup>, M. Shomova<sup>1</sup>, E. Ovchinnikova<sup>1</sup>, J.P. Zarate<sup>4</sup>, C. Babanrao Pisal<sup>5</sup>, A. Manikhas<sup>1</sup>, L. Smith<sup>4</sup>; <sup>1</sup>RU, <sup>2</sup>PL, <sup>3</sup>GB, <sup>4</sup>US, <sup>5</sup>IN
- 12:45 - 12:45 320P - Nab-paclitaxel (nab-P) in mEtastatic bREast cancer (MBC) In elDerly patiEnts: a real life setting - NEREIDE Study  
V. Adamo<sup>1</sup>, G. Ricciardi<sup>1</sup>, S. Schifano<sup>1</sup>, A. Russo<sup>1</sup>, V. Gebbia<sup>1</sup>, L. Blasi<sup>2</sup>, D. Giuffrida<sup>1</sup>, G. Scandurra<sup>1</sup>, A. Savarino<sup>1</sup>, A. Butera<sup>1</sup>, N. Borsellino<sup>1</sup>, F. Verderame<sup>1</sup>, M. Caruso<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(PA)/IT
- 12:45 - 12:45 321P - Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: a single arm phase 2 study of whole-body magnetic resonance imaging  
M. Kosmin<sup>1</sup>, A. Padhani<sup>2</sup>, A. Gogbashian<sup>2</sup>, D. Woolf<sup>2</sup>, M.-L. Ah-See<sup>2</sup>, P. Ostler<sup>2</sup>, S. Sutherland<sup>2</sup>, D. Miles<sup>2</sup>, J. Noble<sup>2</sup>, A. Marshall<sup>2</sup>, J. Dunn<sup>2</sup>, A. Makris<sup>2</sup>; <sup>1</sup>Middlesex/GB, <sup>2</sup>GB
- 12:45 - 12:45 322P - Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide  
J. Zimmermann, T. Remus, G. Lemercier, D. Barker, D. Obrecht, G. Gambino, G. Douglas; CH
- 12:45 - 12:45 323P - Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis  
S. Kümmel<sup>1</sup>, C. Tondini<sup>2</sup>, J. Abraham<sup>3</sup>, Z. Nowecki<sup>4</sup>, B. Itrych<sup>4</sup>, E. Hitre<sup>5</sup>, B. Karaszewska<sup>4</sup>, A. Juarez<sup>6</sup>, F. Morales-Vásquez<sup>6</sup>, J. Pérez García<sup>7</sup>, S. Cardona-Huerta<sup>6</sup>, D. Heinzmann<sup>8</sup>, J. He<sup>9</sup>, A.N. Duc<sup>8</sup>, A. Crepelle-Fléchaix<sup>8</sup>, M. Martín<sup>7</sup>; <sup>1</sup>DE, <sup>2</sup>IT, <sup>3</sup>GB, <sup>4</sup>PL, <sup>5</sup>HU, <sup>6</sup>MX, <sup>7</sup>ES, <sup>8</sup>CH, <sup>9</sup>US
- 12:45 - 12:45 324P - Settings-Based Efficacy Comparison of Trastuzumab Biosimilars in Breast Cancer: A Systematic Literature Review  
L. Medlen<sup>1</sup>, H. Rugo<sup>2</sup>, G. Curigliano<sup>3</sup>, F. Cardoso<sup>4</sup>, W. Gradishar<sup>5</sup>, M. Pegram<sup>1</sup>, C.H. Barrios<sup>6</sup>, J. Cortes Castan<sup>7</sup>, E. Pennella<sup>1</sup>, R. Muniz<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>IT, <sup>4</sup>PT, <sup>5</sup>IL/US, <sup>6</sup>BR, <sup>7</sup>ES
- 12:45 - 12:45 325P - Pertuzumab, Trastuzumab and Taxane combination for Visceral Organ Metastatic Patients: Real Life Practice Results  
E. Esin<sup>1</sup>, O.B. Cakmak Oksuzoglu<sup>1</sup>, A. Bilici<sup>1</sup>, I. Cicin<sup>1</sup>, S. Aksoy<sup>1</sup>, A. Alacacioglu<sup>1</sup>, M.A. Kaplan<sup>1</sup>, D. Cabuk<sup>1</sup>, A. Sumbul<sup>1</sup>, S. Paydas<sup>1</sup>, A. Sakin<sup>1</sup>, Ö. Er<sup>2</sup>, T. Korkmaz<sup>1</sup>, N. Yildirim<sup>1</sup>, M. Artac<sup>1</sup>, H. Harputluoglu<sup>1</sup>, P. Yumuk<sup>1</sup>, G. Basaran<sup>1</sup>, B. Oyan Uluc<sup>1</sup>, U. Demirci<sup>1</sup>; <sup>1</sup>TR, <sup>2</sup>Sariyer/TR

- 12:45 - 12:45 326P - Effectiveness of trastuzumab emtansine (TDM1) in patients with HER2-positive advanced breast cancer (ABC) progressing after taxane plus pertuzumab plus trastuzumab.  
B. Conte<sup>1</sup>, A. Fabi<sup>1</sup>, F. Poggio<sup>1</sup>, E. Blondeaux<sup>1</sup>, C. Dellepiane<sup>1</sup>, A. D'Alonzo<sup>1</sup>, A. Staiano<sup>1</sup>, G. Buono<sup>1</sup>, G. Arpino<sup>1</sup>, V. Magri<sup>1</sup>, G. Naso<sup>1</sup>, D. Presti<sup>1</sup>, S. Mura<sup>1</sup>, A. Fontana<sup>1</sup>, F. Cognetti<sup>1</sup>, C. Molinelli<sup>1</sup>, S. Pastorino<sup>1</sup>, C. Bighin<sup>1</sup>, M. Lambertini<sup>2</sup>, L. Del Mastro<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>BE
- 12:45 - 12:45 327P - Survival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine – a national population-based study: long-term analysis.  
B. Jagielska<sup>1</sup>, P. Tokajuk<sup>2</sup>, T. Pieńkowski<sup>1</sup>, A. Czubek<sup>1</sup>, M. Krzakowski<sup>1</sup>, M. Wojtukiewicz<sup>2</sup>; <sup>1</sup>PL, <sup>2</sup>Podlaskie/PL
- 12:45 - 12:45 328P - Ribociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b ComPLEEment-1 trial  
H. Abdel-Razek<sup>1</sup>, P. Cottu<sup>2</sup>, A. Ring<sup>3</sup>, M. De Laurentiis<sup>4</sup>, J. Lu<sup>5</sup>, H. Azim<sup>6</sup>, C. Zamagni<sup>4</sup>, K. Zhou<sup>5</sup>, J. Wu<sup>5</sup>, L. Menon<sup>5</sup>, M. Martín<sup>7</sup>; <sup>1</sup>JO, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>GB, <sup>4</sup>IT, <sup>5</sup>US, <sup>6</sup>EG, <sup>7</sup>ES
- 12:45 - 12:45 329P - Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)  
E.-M. Grischke<sup>1</sup>, P. Neven<sup>2</sup>, Y. Lin<sup>3</sup>, P. Kaufman<sup>4</sup>, G. Sledge<sup>3</sup>; <sup>1</sup>DE, <sup>2</sup>BE, <sup>3</sup>US, <sup>4</sup>NH/US
- 12:45 - 12:45 330P - Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis  
A. Bardia<sup>1</sup>, S. Campos-Gomez<sup>2</sup>, S. Hurvitz<sup>3</sup>, Y.-S. Lu<sup>4</sup>, S.-A. Im<sup>5</sup>, F. Franke<sup>6</sup>, L. Chow<sup>7</sup>, P. Wheatley-Price<sup>8</sup>, F. Melo Cruz<sup>6</sup>, J. Alam<sup>9</sup>, O. Kong<sup>9</sup>, I. Diaz-Padilla<sup>10</sup>, M. Miller<sup>9</sup>, D. Tripathy<sup>11</sup>; <sup>1</sup>MA/US, <sup>2</sup>MX, <sup>3</sup>CA/US, <sup>4</sup>TW, <sup>5</sup>KR, <sup>6</sup>BR, <sup>7</sup>HK, <sup>8</sup>ON/CA, <sup>9</sup>NJ/US, <sup>10</sup>CH, <sup>11</sup>TX/US
- 12:45 - 12:45 331P - Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3  
G. Jerusalem<sup>1</sup>, P.A. Fasching<sup>2</sup>, M. Martín<sup>3</sup>, X. Pivot<sup>4</sup>, K. Petrakova<sup>5</sup>, G. Bianchi<sup>6</sup>, A. Nusch<sup>2</sup>, G. Sonke<sup>7</sup>, L. De La Cruz Merino<sup>3</sup>, E. Vagnon<sup>8</sup>, J. Alam<sup>9</sup>, O. Kong<sup>9</sup>, D. Chandiwana<sup>9</sup>, M. De Laurentiis<sup>6</sup>; <sup>1</sup>BE, <sup>2</sup>DE, <sup>3</sup>ES, <sup>4</sup>CEDEX/FR, <sup>5</sup>South Moravian/CZ, <sup>6</sup>IT, <sup>7</sup>NL, <sup>8</sup>CH, <sup>9</sup>NJ/US
- 12:45 - 12:45 332P - Clinical Outcomes in Patients (pts) With Estrogen Receptor–Positive (ER+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer (ABC) With Objective Response (OR) or Without Objective Response (non-OR) in PALOMA-2  
H. Rugo<sup>1</sup>, R. Finn<sup>1</sup>, K. Gelmon<sup>2</sup>, A.A. Joy<sup>3</sup>, O. Lipatov<sup>4</sup>, N. Harbeck<sup>5</sup>, A. Castrellon<sup>6</sup>, H. Mukai<sup>7</sup>, J. Walshe<sup>8</sup>, A. Mori<sup>9</sup>, E. Gauthier<sup>1</sup>, D. Lu<sup>1</sup>, E. Bananis<sup>10</sup>, M. Martín<sup>11</sup>, V. Dieras<sup>12</sup>; <sup>1</sup>CA/US, <sup>2</sup>British Columbia/CA, <sup>3</sup>Alberta/CA, <sup>4</sup>RU, <sup>5</sup>DE, <sup>6</sup>FL/US, <sup>7</sup>JP, <sup>8</sup>IE, <sup>9</sup>IT, <sup>10</sup>NY/US, <sup>11</sup>ES, <sup>12</sup>CEDEX 5/FR
- 12:45 - 12:45 333P - Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase 3b ComPLEEment-1 trial

F. Cardoso<sup>1</sup>, K. Papazisis<sup>2</sup>, M. De Laurentiis<sup>3</sup>, A. Ring<sup>4</sup>, J. Lu<sup>5</sup>, M. Martin<sup>6</sup>, H. Azim<sup>7</sup>, C. Zamagni<sup>3</sup>, K. Zhou<sup>5</sup>, J. Wu<sup>5</sup>, J.P. Zarate<sup>5</sup>, P. Cottu<sup>8</sup>; <sup>1</sup>PT, <sup>2</sup>GR, <sup>3</sup>IT, <sup>4</sup>GB, <sup>5</sup>US, <sup>6</sup>ES, <sup>7</sup>EG, <sup>8</sup>CEDEX 5/FR

- 12:45 - 12:45 334P - Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany  
M. De Laurentiis<sup>1</sup>, A. König<sup>2</sup>, K. Davis<sup>3</sup>, D. Mitra<sup>4</sup>, C.M.A. Nuzzo<sup>1</sup>, M. Ajmera<sup>3</sup>, S. de Placido<sup>1</sup>, S. Brucker<sup>2</sup>, N. Harbeck<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>DE, <sup>3</sup>NC/US, <sup>4</sup>NY/US
- 12:45 - 12:45 335P - Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2-) postmenopausal women: final analysis of the French observational TANGO study  
C. Villanueva<sup>1</sup>, G. Yazbek<sup>1</sup>, P. Beuzeboc<sup>2</sup>, E. Viel<sup>1</sup>, N. Dohollou<sup>3</sup>, E. Luporsi<sup>1</sup>, J.-C. Eymard<sup>3</sup>, E. Levy<sup>1</sup>, M.-A. Mouret-Reynier<sup>1</sup>, L.-M. Dourthe<sup>1</sup>, E. Malaurie<sup>1</sup>, M. Madelenat<sup>1</sup>, A. Denden<sup>1</sup>, E.-C. Antoine<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>CEDEX/FR
- 12:45 - 12:45 336P - Everolimus in advanced breast cancer: a systematic review and meta-analysis  
J. Raphael<sup>1</sup>, C. Lefebvre<sup>2</sup>, A. Allan<sup>2</sup>, J. Helou<sup>2</sup>, G. Boldt<sup>2</sup>, T. Vandenberg<sup>2</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA
- 12:45 - 12:45 337P - First-line treatment for endocrine sensitive bone-only metastatic breast cancer: is more always better?  
A. Toss, M. Venturelli, I. Sperduti, C. Isca, E. Barbieri, F. Piacentini, C. Omarini, L. Cortesi, S. Cascinu, L. Moscetti; IT
- 12:45 - 12:45 338P - Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS Study  
D. Mitra<sup>1</sup>, G. Taylor-Stokes<sup>2</sup>, J. Waller<sup>2</sup>, K. Gibson<sup>2</sup>, G. Milligan<sup>2</sup>, S. Iyer<sup>3</sup>; <sup>1</sup>NY/US, <sup>2</sup>GB, <sup>3</sup>US
- 12:45 - 12:45 339P - Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: analysis of the MONARCH trials  
H. Rugo<sup>1</sup>, S. Tolaney<sup>2</sup>, J. Huober<sup>3</sup>, M. Toi<sup>4</sup>, V. André<sup>5</sup>, S. Barriga<sup>6</sup>, T. Forrester<sup>7</sup>, G. Sledge<sup>8</sup>, M.P. Goetz<sup>8</sup>; <sup>1</sup>CA/US, <sup>2</sup>MA/US, <sup>3</sup>DE, <sup>4</sup>JP, <sup>5</sup>FR, <sup>6</sup>GB, <sup>7</sup>IN/US, <sup>8</sup>US
- 12:45 - 12:45 340P - Progression Free Survival (PFS) Benefit from First line Endocrine Based Therapies in Postmenopausal Women with HR+ HER2- Metastatic Breast Cancer (MBC) according to different Prognostic Subgroups: A Combined Analysis of Data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT Trials  
V. Rossi, D. Giannarelli, P. Berchiolla, C. Nisticò, G. Ferretti, S. Gasparro, P. Malaguti, M. russillo, G. Catania, L. Vigna, R. Mancusi, F. Cognetti, A. Fabi; IT
- 12:45 - 12:45 341P - Palbociclib in combination with letrozole as first or later line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study  
M. Welslau, M. Zaiss, U. Söling, M. Untch, L. Müller, D. Lüftner, J. Meiler, A. Welt, J. Sahlmann, L. Houet, E. Runkel, N. Marschner; DE
- 12:45 - 12:45 342P - Response to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 236 recurrent metastatic patients.

J. Yamamura, S. Kamigaki, M. Tsujie, J. Fujita, H. Osato, C. Higashi, H. Kanaizumi, Y. Tanaka, M. Hamada, W. Shinzaki, Y. Hasimoto, Y. Komoike; JP

- 12:45 - 12:45 343P - Application of CDK4/6 inhibitors in practice: effect of online education on clinician competence and confidence  
C. Day<sup>1</sup>, C. Day<sup>1</sup>, D. Middleton<sup>2</sup>, S. Loibl<sup>3</sup>; <sup>1</sup>GB, <sup>2</sup>US, <sup>3</sup>DE
- 12:45 - 12:45 344P - First Report of Real-World Patient Characteristics and Treatment Patterns From POLARIS: Palbociclib in Hormone Receptor-Positive (HR+) Advanced Breast Cancer – A Prospective, Multicenter, Noninterventional Study  
J. Blum<sup>1</sup>, S. McCune<sup>2</sup>, M. Salkeni<sup>3</sup>, D. Anderson<sup>4</sup>, J. Migas<sup>5</sup>, S. Lakhanpal<sup>6</sup>, K. Patel<sup>7</sup>, A. Bardia<sup>8</sup>, G. Rocque<sup>6</sup>, J. Wang<sup>8</sup>, J. Cappelleri<sup>9</sup>, G. Comstock<sup>10</sup>, Y. Wang<sup>11</sup>, D. Tripathy<sup>12</sup>; <sup>1</sup>US, <sup>2</sup>GA/US, <sup>3</sup>WV/US, <sup>4</sup>MN/US, <sup>5</sup>IL/US, <sup>6</sup>AL/US, <sup>7</sup>AR/US, <sup>8</sup>MA/US, <sup>9</sup>CT/US, <sup>10</sup>CA/US, <sup>11</sup>NY/US, <sup>12</sup>TX/US
- 12:45 - 12:45 345P - Everolimus-based therapy versus conventional therapy for refractory breast cancer patients with PI3K/AKT/mTOR mutations  
Z. Chen, Y. Zheng, W. Cao, Y. Zhang, S. Cai, X. Shao, J. Huang, W. Ye, Y. Huang, Y. Yin, X. Wang; CN
- 12:45 - 12:45 346P - Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses  
P. Neven<sup>1</sup>, K. Petrakova<sup>2</sup>, G. Bianchi<sup>3</sup>, L. De La Cruz Merino<sup>4</sup>, G. Jerusalem<sup>1</sup>, J. Beck<sup>5</sup>, G. Sonke<sup>6</sup>, S. Chia<sup>7</sup>, S. Brucker<sup>8</sup>, Y. Wang<sup>9</sup>, W. He<sup>10</sup>, K. Rodriguez Lorenc<sup>11</sup>, F. Su<sup>12</sup>, S.-A. Im<sup>13</sup>; <sup>1</sup>BE, <sup>2</sup>South Moravian/CZ, <sup>3</sup>IT, <sup>4</sup>ES, <sup>5</sup>AZ/US, <sup>6</sup>NL, <sup>7</sup>CA, <sup>8</sup>DE, <sup>9</sup>CH, <sup>10</sup>MA/US, <sup>11</sup>US, <sup>12</sup>NJ/US, <sup>13</sup>KR
- 12:45 - 12:45 347P - Potential Survival Gains from First-Line (1L) Systemic Therapy Advances in Metastatic Triple-Negative Breast Cancer (mTNBC)  
P. Bajaj, J. Roth, S. Sullivan, A. Stein, R. Mahtani, S. Ramsey; US
- 12:45 - 12:45 348P - Economic evaluation of eribulin in the treatment of triple negative breast cancer in the United Kingdom  
J. Wex, C. Bodnar, C. Simon, F. Fernandes, N. Tanova; GB
- 12:45 - 12:45 349P - Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC).  
M. Chavez Mac Gregor<sup>1</sup>, X. Lei<sup>2</sup>, H. Zhao<sup>2</sup>, C. van Poznak<sup>2</sup>, S. Giordano<sup>1</sup>; <sup>1</sup>TX/US, <sup>2</sup>US
- 12:45 - 12:45 350P - liver surgery of breast cancer liver metastases: rapid surgical decision after diagnosis does not negatively impact long-term results  
V. Lucidi, G. Liberale, D. Germanova, M. Bez, V. Donckier; BE
- 12:45 - 12:45 351P - Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort.  
W. Jacot<sup>1</sup>, G. Louvel<sup>2</sup>, A. Darlix<sup>2</sup>, J. Fraisse<sup>2</sup>, E. Brain<sup>2</sup>, M. Debled<sup>3</sup>, M.A. Mouret Reynier<sup>4</sup>, A. Goncalves<sup>5</sup>, F. Dalenc<sup>6</sup>, P. Augereau<sup>2</sup>, J.-M. Ferrero<sup>7</sup>, C. Levy<sup>1</sup>, J.-D. Fumet<sup>2</sup>, C. Jouannaud<sup>3</sup>, C. Veyret<sup>4</sup>, V. Dieras<sup>1</sup>, M. Robain<sup>2</sup>, C. Courtinard<sup>2</sup>, D. Pasquier<sup>2</sup>, T. Bachelot<sup>3</sup>; <sup>1</sup>CEDEX 5/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 1/FR, <sup>5</sup>CEDEX 9/FR, <sup>6</sup>CEDEX 3/FR, <sup>7</sup>CEDEX 2/FR

- 12:45 - 12:45 352P - Features Associated with Long-Term Survival in Metastatic Breast Cancer  
N. Klar<sup>1</sup>, M. Rosenzweig<sup>2</sup>, B. Diergaard<sup>2</sup>, A. Brufsky<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>PA/US
- 12:45 - 12:45 353P - Physical activity and lifestyle in women with metastatic breast cancer: the ABLE study  
B. Fervers<sup>1</sup>, L. Delrieu<sup>1</sup>, O. Pérol<sup>1</sup>, O. Febvey-Combes<sup>1</sup>, A. Dufresne<sup>2</sup>, T. Bachelot<sup>3</sup>, P. Heudel<sup>3</sup>, O. Tredan<sup>3</sup>, M. Touillaud<sup>1</sup>, V. Pialoux<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 3/FR, <sup>3</sup>CEDEX/FR
- 12:45 - 12:45 (Withdrawn)
- 12:45 - 12:45 355P - Establishment and validation of M1 stage subdivisions for patients with de novo metastatic breast cancer: a population-based study  
C. Lin, J. Wu, L. Zhu; CN
- 12:45 - 12:45 356P - A Prospective Observational Study of Mobile Application-Based Patient-Reported Outcomes (PRO) in Advanced Breast Cancer: Interim Baseline Data From the MADELINE study  
D. Odom<sup>1</sup>, D. Mitra<sup>2</sup>, K. Hollis<sup>1</sup>, D. Richardson<sup>1</sup>, J. Kaye<sup>1</sup>, L. McRoy<sup>2</sup>; <sup>1</sup>NC/US, <sup>2</sup>NY/US
- 12:45 - 12:45 357P - Stereotactic Radiosurgery (SRS) for brain metastases (BM) from breast cancer (BC) – a single centre experience of factors influencing survival  
T. Wilson, T. Robinson, C. Macfarlane, T. Spencer, C. Herbert, J. Braybrooke; GB
- 12:45 - 12:45 358P - Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer  
E. Curtit<sup>1</sup>, F. Bazan<sup>1</sup>, L. Chaigneau<sup>2</sup>, G. Mouillet<sup>1</sup>, E. Dobi<sup>1</sup>, L. Mansi<sup>1</sup>, N. Meneveau<sup>2</sup>, M.-J. Paillard<sup>1</sup>, G. Meynard<sup>2</sup>, E. Klajer<sup>1</sup>, C. Villanueva<sup>2</sup>, P. Montcuquet<sup>1</sup>, X. Pivot<sup>1</sup>, L. Cals<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR
- 12:45 - 12:45 359P - Surgery of the primary tumor for de novo metastatic breast cancer: the controversy continues.  
B. López de San Vicente, E. Galve Calvo, A. Zumarraga, F. Pikabea, J.F. Arango Arteaga, M. López Santillan, C. Figaredo, M.A. Sala Gonzalez, M. Nuño Escolastico, P. Novas Vidal, J. Legaspi, P. Martinez del Prado; ES
- 12:45 - 12:45 360P - Breast cancer in Twitter: a real-world data exploratory study.  
R. Sanchez Bayona, L. Chang-Azancot, M.A. Alvarez de Mon, M. Llaverro, M. Vallejo, I. Gardeazabal, D. Salas, P. Sala Elarre, I. Baraibar Argota, I. Eguren, M. Santisteban Eslava, L. Cenicerros, E. Castanon Alvarez; ES
- 12:45 - 12:45 361TiP - A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer. (JCOG1607 HERB TEA study)  
A. Shimomura<sup>1</sup>, K. Tamura<sup>1</sup>, T. Mizutani<sup>1</sup>, T. Shibata<sup>1</sup>, F. Hara<sup>1</sup>, T. Fujisawa<sup>1</sup>, N. Niikura<sup>2</sup>, T. Hojo<sup>1</sup>, C. Kambayashi<sup>1</sup>, S. Saji<sup>3</sup>, N. Masuda<sup>1</sup>, M. Sawaki<sup>1</sup>, N. Yamamoto<sup>1</sup>, F. Nagashima<sup>1</sup>, T. Shien<sup>1</sup>, H. Iwata<sup>4</sup>; <sup>1</sup>JP, <sup>2</sup>Kanagawa/JP, <sup>3</sup>Fukushima/JP, <sup>4</sup>Aichi/JP
- 12:45 - 12:45 362TiP - ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

D. Tripathy<sup>1</sup>, S. Tolaney<sup>2</sup>, A. Seidman<sup>3</sup>, C. Anders<sup>4</sup>, N. Ibrahim<sup>1</sup>, H. Rugo<sup>5</sup>, C. Twelves<sup>6</sup>, V. Dieras<sup>7</sup>, V. Müller<sup>8</sup>, A. Hannah<sup>5</sup>, M. Tagliaferri<sup>9</sup>, J. Cortes Castan<sup>10</sup>; <sup>1</sup>TX/US, <sup>2</sup>MA/US, <sup>3</sup>NY/US, <sup>4</sup>NC/US, <sup>5</sup>CA/US, <sup>6</sup>Yorkshire/GB, <sup>7</sup>CEDEX 5/FR, <sup>8</sup>DE, <sup>9</sup>US, <sup>10</sup>ES

- 12:45 - 12:45 363TiP - Phase 1b/2a study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68, which prevents nuclear  $\beta$ -catenin Translocation in patients with Triple Negative Breast Cancer  
J. Diamond<sup>1</sup>, E. Andreopoulou<sup>2</sup>, A. Favret<sup>3</sup>, R. Nanda<sup>4</sup>, C. Peterson<sup>1</sup>, E. Benaim<sup>5</sup>; <sup>1</sup>US, <sup>2</sup>NY/US, <sup>3</sup>VA/US, <sup>4</sup>IL/US, <sup>5</sup>MD/US
- 12:45 - 12:45 364TiP - Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: a phase II trial (AMICA) GBG 97  
T. Decker, C. Denkert, K. Lübbe, V. Müller, C. Mundhenke, J. Furlanetto, M. Schmidt, M. Thill, V. Tierbach, F. Seither, S. Loibl; DE
- 12:45 - 12:45 365TiP - SAMANTHA: A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants with HER2-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC)  
G. Steger<sup>1</sup>, F. Puglisi<sup>2</sup>, C. Timcheva<sup>3</sup>, L. Costa<sup>4</sup>, M. Casa-Nova<sup>4</sup>, D. Hitzl<sup>1</sup>, B. Dampier<sup>1</sup>, N. Lindegger<sup>5</sup>; <sup>1</sup>AT, <sup>2</sup>IT, <sup>3</sup>BG, <sup>4</sup>PT, <sup>5</sup>CH
- 12:45 - 12:45 366TiP - The NAME trial: A direct comparison of Oral Navelbine given either classic or Metronomic in metastatic HER2 neg breast cancer.  
S. Langkjer<sup>1</sup>, J. Kenholm<sup>1</sup>, J. Jensen<sup>1</sup>, K. Wedervang<sup>1</sup>, A. Brixen<sup>1</sup>, M. Grunnet<sup>1</sup>, L. Stenbygaard<sup>1</sup>, H. Danø<sup>1</sup>, V. Glavicic<sup>1</sup>, E. Jacobsen<sup>1</sup>, A. Brems-Eskildsen<sup>1</sup>, H. Kruse<sup>1</sup>, T. Dongsgaard<sup>1</sup>, J. Neimann<sup>1</sup>, J. Geisler<sup>2</sup>; <sup>1</sup>DK, <sup>2</sup>NO
- 12:45 - 12:45 367TiP - LUCY: A Phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation  
K. Gelmon<sup>1</sup>, G. Walker<sup>2</sup>, G. Fisher<sup>3</sup>; <sup>1</sup>British Columbia/CA, <sup>2</sup>Bedfordshire/GB, <sup>3</sup>GB
- 12:45 - 12:45 368TiP - START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)  
H. Bonnefoi<sup>1</sup>, C. Levy<sup>2</sup>, G. MacGrogan<sup>3</sup>, T. Grellety<sup>3</sup>, B. Asselain<sup>3</sup>, M. Pulido<sup>3</sup>, S. Everhard<sup>3</sup>, J. Lemonnier<sup>3</sup>, A. Gonçalves<sup>3</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>FR
- 12:45 - 12:45 369TiP - PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy (ET) vs. Anti-HER2 Therapy + ET after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (MBC)  
S. Loibl<sup>1</sup>, O. Metzger<sup>2</sup>, S. Mandrekar<sup>2</sup>, C. Mundhenke<sup>1</sup>, S. Seiler<sup>1</sup>, P. Valagussa<sup>3</sup>, A. DeMichele<sup>4</sup>, E. Lim<sup>5</sup>, D. Tripathy<sup>6</sup>, E. Winer<sup>7</sup>, C. Huang<sup>2</sup>, L. Carey<sup>8</sup>, P. Francis<sup>9</sup>, K. Miller<sup>10</sup>, M.P. Goetz<sup>2</sup>, A. Prat<sup>11</sup>, S. Loi<sup>9</sup>, I. Krop<sup>2</sup>, L. Gianni<sup>3</sup>, E. Ciruelos<sup>11</sup>; <sup>1</sup>DE, <sup>2</sup>US, <sup>3</sup>IT, <sup>4</sup>PA/US, <sup>5</sup>NSW/AU, <sup>6</sup>TX/US, <sup>7</sup>MA/US, <sup>8</sup>NC/US, <sup>9</sup>VIC/AU, <sup>10</sup>IN/US, <sup>11</sup>ES

- 12:45 - 12:45 370TiP - A phase 1b, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer  
S. Hurvitz<sup>1</sup>, M. Galsky<sup>2</sup>, J. Shahidi<sup>3</sup>, G. Zhang<sup>3</sup>, S. Raza<sup>3</sup>, A. Necchi<sup>4</sup>; <sup>1</sup>CA/US, <sup>2</sup>US, <sup>3</sup>NJ/US, <sup>4</sup>IT
- 12:45 - 12:45 383P - Worldwide trends in survival from adult glioma 2000-2014 (CONCORD-3): impact of morphology.  
F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M. Coleman, CONCORD Working Group; GB
- 12:45 - 12:45 384P - Clinical Characteristics of 3,030 Glioblastoma Multiforme (GBM) Patients in High, Upper Middle and Lower Middle Economic Regions Based on Real-World Data (RWD)  
L. Mitrofan<sup>1</sup>, M. Krukas-Hampel<sup>2</sup>, L. Mendoza<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>US, <sup>3</sup>CZ
- 12:45 - 12:45 385P - Radiotherapy versus Combined Radiochemotherapy for Unresectable Glioblastoma: a SEER Based Analysis  
M. Osman, EG
- 12:45 - 12:45 386P - Clinical characteristics of Glioblastoma Multiforme (GBM) Patients Who Reached 400 Days Post Diagnostic from a Retrospective Real-World Data  
L. Mitrofan<sup>1</sup>, M. Krukas-Hampel<sup>2</sup>, L. Mendoza<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>US, <sup>3</sup>CZ
- 12:45 - 12:45 387P - Corticosteroids administration as a prognostic factor in glioblastoma patients: An Egyptian experience  
K. Abdel Karim, M. Kelany, O. Abdelrahman, A. El-Adawy; EG
- 12:45 - 12:45 388P - Impaired survival in resected glioblastoma multiforme patients treated with early chemoradiation.  
L. del Carpio, P. Gomila, S.D. Camacho, S. Moron, M. Riudavets, C. Molto, A. Bujosa, M. Borrell, R. Teres, B. Martin, P. Gallardo, E. Acosta, L. Tilea, A. Soto, C. De Quintana, J. Craven-Bartle, A. Gallardo, B. Gomez, S. Bonilla, O. Gallego; ES
- 12:45 - 12:45 389P - Bevacizumab-induced hypertension correlation with survival in recurrent Glioblastoma multiforme  
N. Tavares, J. Simões, C. Borges, S. Meireles, A. Costa, C. Fernandes, C. Caeiro, M. Damasceno; PT
- 12:45 - 12:45 390P - +405C>G polymorphism of VEGF in randomly selected GBM patients  
I. Djan, M. Djan, N. Vucinic, B. Nikolin, S. Salma, S. Lucic, N. Vuckovic, M. Lucic; RS
- 12:45 - 12:45 391P - Expression and clinical prognostic role of ZWINT in glioma: analysis based on data-mining and integration of gene databases  
Z. Mengxian, CN
- 12:45 - 12:45 392P - Lipid peroxidation and cognitive impairment in patients with brain cancers  
S. Kim, S. Kim; KR
- 12:45 - 12:45 393P - FAT1 on YAP1-TEAD1 interaction augments oncogenic potential of GBM cells  
Y. Gupta, S. Shivajirao, K. Irshad, B. Dikshit, T. Srivastava, P. Chattopadhyay, S. Sinha, K. Chosdol; IN
- 12:45 - 12:45 394P - Extracts of Cerbera manghas L. effectively inhibit the growth of glioblastoma cells and their stemloids  
Y.-J. Lai, J.-C. Tsai, W.-S. Liu, H.-I. Lam; TW

- 12:45 - 12:45 395P - Contrast enhancement in low grade gliomas: a classic prognostic factor in the molecular age  
F. Castet<sup>1</sup>, E. Alanya<sup>2</sup>, M. Gil-Gil<sup>1</sup>, N. Vidal<sup>1</sup>, C. Izquierdo<sup>3</sup>, C. Mesia<sup>1</sup>, J. Bruna<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>PE, <sup>3</sup>FR
- 12:45 - 12:45 396P - can diffusion tensor mr imaging identify glioma idh mutation status?  
S. Bisdas, J. Yuan, L. Mancini, D. Roettger; GB
- 12:45 - 12:45 397P - Comparative Assessment of Orthotopic Brain Tumor Growth Using Bioluminescence and Magnetic Resonance Imaging  
Y. Tsvetkova, C. Green, G. Schuetz, J. Hoffmann, D. Zopf, P. Lejeune; DE
- 12:45 - 12:45 398P - Radiologically evident treatment effects in patients with glioblastoma (GBM) and its clinical implications  
H. Gan<sup>1</sup>, C. Murone<sup>2</sup>, M. Wong<sup>2</sup>, G. Fitt<sup>2</sup>, E. Kennedy<sup>3</sup>, D. Maag<sup>4</sup>, K. Aldape<sup>5</sup>; <sup>1</sup>VIC/AU, <sup>2</sup>AU, <sup>3</sup>IL/US, <sup>4</sup>US, <sup>5</sup>ON/CA
- 12:45 - 12:45 399P - Melanoma with brain metastases. Experience of immunotherapy in a single center.  
D. Naskhletashvili, L. Demidov, A. Bekyashev, V. Aloshin, E. Prozorenko; RU
- 12:45 - 12:45 400P - Systemic management of malignant meningioma: A comparative survival and molecular marker analysis between Ocreotide in combination with Everolimus compared to Sunitinib  
A. Cardona Zorrilla<sup>1</sup>, A. Ruiz-Patiño<sup>1</sup>, O. Arrieta<sup>2</sup>, L. Zatarain-Barron<sup>3</sup>, F. Hakim<sup>1</sup>, E. Jimenez<sup>1</sup>, J.A. Mejia<sup>1</sup>, F. Ramon<sup>1</sup>, N. Useche<sup>1</sup>, S. Bermudez<sup>1</sup>, D. Pineda<sup>1</sup>, H. Cifuentes<sup>1</sup>, L. Rojas<sup>1</sup>, L.E. Pino Villareal<sup>4</sup>, C. Balana<sup>5</sup>; <sup>1</sup>CO, <sup>2</sup>Tlalpan. D.F./MX, <sup>3</sup>MX, <sup>4</sup>Cundinamarca/CO, <sup>5</sup>Barcelona/ES
- 12:45 - 12:45 401P - Impact of postoperative residual tumor and meningeal dissemination in adult medulloblastoma: a retrospective analysis.  
R. Barreto, P. Viveiros, M. Mesquita, V. Santos, O. Feher; BR
- 12:45 - 12:45 402P - Adult medulloblastoma : an oncology radiation therapy department experience with 22 cases  
M. Kallel, Z. Fessi, W. Siala, W. mnejja, N. Fourati, H. daoud, T. Boudawara, Z. Boudawara, M. Frikha, J. Daoud; TN
- 12:45 - 12:45 403P - Pineal parenchymal tumors: Patterns of care from a tertiary cancer centre in India  
B. Devnani, S. Gupta, H. Kp, P. Julka, G. Rath; IN
- 12:45 - 12:45 404P - Advantages of next-generation sequencing in revealing low-level somatic mosaicism in blood samples of retinoblastoma patients  
E. Alekseeva, V. Kozlova, T. Ushakova, A. Tanas, O. Babenko, T. Kazubskaya, V. Strelnikov, D. Zaletaev; RU
- 12:45 - 12:45 405TiP - Avelumab in Newly Diagnosed Glioblastoma Multiforme - The SEJ Study  
F. Jacques<sup>1</sup>, G. Nicholas<sup>2</sup>, I. Lorimer<sup>2</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA
- 12:45 - 12:45 406TiP - Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients – OLA-TMZ-RTE-01



D. Stefan<sup>1</sup>, P. Lesueur<sup>1</sup>, J. Lequesne<sup>1</sup>, E. Coquan<sup>2</sup>, P.E. Brachet<sup>1</sup>, L. Castera<sup>1</sup>, N. Goardon<sup>1</sup>, J. Lacroix<sup>1</sup>, M. Lange<sup>1</sup>, A. Capel<sup>1</sup>, B. Andre<sup>1</sup>, J.-M. Grellard<sup>1</sup>, B. Clarisse<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR

12:45 - 12:45

407TiP - Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)

D. Hargrave<sup>1</sup>, O. Witt<sup>2</sup>, K. Cohen<sup>3</sup>, R. Packer<sup>4</sup>, A. Lissat<sup>2</sup>, U. Kordes<sup>2</sup>, T. Laetsch<sup>5</sup>, L. Hoffman<sup>6</sup>, A. Lassaletta<sup>7</sup>, N. Gerber<sup>8</sup>, S. Gilheeny<sup>9</sup>, S. Holm<sup>10</sup>, C. Kramm<sup>2</sup>, D. Sumerauer<sup>11</sup>, C. Reitmann<sup>12</sup>, M. Russo<sup>12</sup>, E. Bouffet<sup>13</sup>; <sup>1</sup>GB, <sup>2</sup>DE, <sup>3</sup>MD/US, <sup>4</sup>DC/US, <sup>5</sup>US, <sup>6</sup>CO/US, <sup>7</sup>ES, <sup>8</sup>CH, <sup>9</sup>NY/US, <sup>10</sup>SE, <sup>11</sup>CZ, <sup>12</sup>NJ/US, <sup>13</sup>ON/CA

12:45 - 12:45

419P - Double Blind concordance Study Of Colo-Rectal Cancer Treatment Recommendations Between Artificial Intelligence Advisory Programme Watson For Oncology(WFO) & Multidisciplinary Tumor Board(MDT)

S. Sampige Prasannakumar<sup>1</sup>, M. Sepulveda<sup>2</sup>, C. Rohit Kumar<sup>3</sup>, A. Rauthan<sup>1</sup>, P. Patil<sup>1</sup>, Y. Ramya<sup>3</sup>; <sup>1</sup>Karnataka/IN, <sup>2</sup>NY/US, <sup>3</sup>IN

12:45 - 12:45

420P - Phase 1/2 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours

P. Bono<sup>1</sup>, C. Massard<sup>2</sup>, K. Peltola<sup>1</sup>, A. Azaro<sup>3</sup>, A. Italiano<sup>2</sup>, R. Kristeleit<sup>4</sup>, U. Lassen<sup>5</sup>, H.-T. Arkenau<sup>4</sup>, P. Hakulinen<sup>1</sup>, C. Garratt<sup>6</sup>, T. Ikonen<sup>1</sup>, M. Mustonen<sup>1</sup>, J. Rodon<sup>3</sup>; <sup>1</sup>FI, <sup>2</sup>CEDEX/FR, <sup>3</sup>ES, <sup>4</sup>GB, <sup>5</sup>DK, <sup>6</sup>NG1 1AH/GB

12:45 - 12:45

421P - Preliminary Results of Pamiparib (BGB-290), a PARP1/2 Inhibitor, in Combination with Temozolomide (TMZ) in Patients (pts) with Locally Advanced or Metastatic Solid Tumors

M. Johnson<sup>1</sup>, M. Galsky<sup>2</sup>, M. Barve<sup>3</sup>, S. Goel<sup>2</sup>, H. Park<sup>2</sup>, B. Du<sup>2</sup>, S. Mu<sup>4</sup>, V. Ramakrishnan<sup>2</sup>, K. Wood<sup>2</sup>, V. Wang<sup>2</sup>, N. Lakhani<sup>2</sup>; <sup>1</sup>TN/US, <sup>2</sup>US, <sup>3</sup>TX/US, <sup>4</sup>NJ/US

12:45 - 12:45

422P - First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies

P. Lorusso<sup>1</sup>, S. Chawla<sup>2</sup>, J. Bendell<sup>3</sup>, A. Shields<sup>4</sup>, G. Shapiro<sup>4</sup>, P. Rajagopalan<sup>4</sup>, C. Cyris<sup>4</sup>, I. Bruns<sup>4</sup>, J. Mei<sup>4</sup>, F. Souza<sup>4</sup>, D. Rasco<sup>5</sup>, J.P. Eder<sup>6</sup>, A. Tolcher<sup>5</sup>; <sup>1</sup>CT/US, <sup>2</sup>CA/US, <sup>3</sup>TN/US, <sup>4</sup>US, <sup>5</sup>TX/US, <sup>6</sup>CH

12:45 - 12:45

423P - Phase 1 study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors

N. Yamamoto<sup>1</sup>, Y. Fujiwara<sup>1</sup>, S. Kondo<sup>1</sup>, S. Iwasa<sup>1</sup>, K. Yonemori<sup>1</sup>, A. Shimomura<sup>1</sup>, S. Kitano<sup>1</sup>, T. Shimizu<sup>1</sup>, T. Koyama<sup>1</sup>, T. Ebata<sup>2</sup>, N. Sato<sup>1</sup>, K. Nakai<sup>1</sup>, M. Inatani<sup>1</sup>, K. Tamura<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP

12:45 - 12:45

424P - Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: a reality or a myth?

A. Vozy<sup>1</sup>, P. Berlanga Charriel<sup>2</sup>, B. Georger<sup>1</sup>, C. Massard<sup>3</sup>, N. Gaspar<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>ES, <sup>3</sup>CEDEX/FR

12:45 - 12:45

425P - SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer

S. Crabb, S. Danson, D. Dunkley, M. Kalevras, A. Whitehead, S. Hill, K. Fines, C. Robb, J. Bennett, L. Ksiazek, S. Brown, L. Evans, M. Serra, K. Jones, C. McDowell, J. Catto, R. Huddart, G. Griffiths; GB

- 12:45 - 12:45 426P - Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE®) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas  
K. Moek, S. Waaijer, I.C. Kok, F.V. Suurs, A. Brouwers, C.W. Menke-van der Houven van Oordt, T.T. Wind, J. Gietema, C.P. Schroder, S.V.K. Mahesh, A. Jorritsma-Smit, M.N. Lub-De Hooge, R. Fehrmann, D.J. de Groot, E.G.E. de Vries; NL
- 12:45 - 12:45 427P - Phase 1 Study of AMG 211/MEDI-565 Administered as Continuous Intravenous Infusion (cIV) for Relapsed/Refractory Gastrointestinal (GI) Adenocarcinoma  
K. Moek<sup>1</sup>, W. Fiedler<sup>2</sup>, J.C. von Einem<sup>2</sup>, H. Verheul<sup>1</sup>, T. Seufferlein<sup>2</sup>, D.J. de Groot<sup>1</sup>, V. Heinemann<sup>2</sup>, M. Kebenko<sup>2</sup>, C.W. Menke-van der Houven van Oordt<sup>1</sup>, T. Ettrich<sup>2</sup>, E. Rasmussen<sup>3</sup>, P. Bogner<sup>2</sup>, B. Sable<sup>3</sup>, S. Stienen<sup>2</sup>, E.G.E. de Vries<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>DE, <sup>3</sup>US
- 12:45 - 12:45 428P - Interim Results from a Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors  
T. Bauer<sup>1</sup>, M. Barve<sup>2</sup>, E.G. Chiorean<sup>3</sup>, P. Lorusso<sup>4</sup>, K. Courtney<sup>2</sup>, D. Qi<sup>5</sup>, A. Olguin<sup>5</sup>, J. Bullington<sup>5</sup>, M. Sardone<sup>5</sup>, V. Dunn<sup>5</sup>, S. Shemesh<sup>5</sup>, J. Chen<sup>5</sup>, C. Brooks<sup>6</sup>, J. Wang<sup>7</sup>; <sup>1</sup>TN/US, <sup>2</sup>TX/US, <sup>3</sup>WA/US, <sup>4</sup>CT/US, <sup>5</sup>NY/US, <sup>6</sup>US, <sup>7</sup>FL/US
- 12:45 - 12:45 429P - NEO2734 - A novel potent oral dual BET and P300/CBP inhibitor  
F. Giles<sup>1</sup>, M. Witcher<sup>2</sup>, B. Brown<sup>3</sup>; <sup>1</sup>US/US, <sup>2</sup>IL/US, <sup>3</sup>QC/CA
- 12:45 - 12:45 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid tumours  
A. Seet<sup>1</sup>, S.P. Choo<sup>1</sup>, D. Tai<sup>1</sup>, Y.C.J. Lam<sup>1</sup>, W.T. Teng<sup>1</sup>, C. Lim<sup>1</sup>, T. Lim<sup>1</sup>, I. Tan<sup>1</sup>, E. Petricoin<sup>2</sup>, M. Ng<sup>1</sup>; <sup>1</sup>SG, <sup>2</sup>VA/US
- 12:45 - 12:45 431P - Phase 1b study of safety and tolerability of Selinexor in Asian patients with advanced solid cancers  
V. Heong, M.L. Goh, W.P. Yong, R. Soo, C.E. Chee, S. Raghav, B.-C. Goh, S.C. Lee, J. Lim, A. Wong, D. Tan; SG
- 12:45 - 12:45 432P - Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients  
Y. Yu<sup>1</sup>, C. Durairaj<sup>1</sup>, H. Shi<sup>2</sup>, D. Wang<sup>1</sup>; <sup>1</sup>CA/US, <sup>2</sup>CT/US
- 12:45 - 12:45 433P - An open-label, phase 1, dose escalating study evaluating safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients with solid tumors  
J. Palshof, I. Kümler, P. Sørensen, B. Jensen, D. Nielsen; DK
- 12:45 - 12:45 434P - Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: the French national AcSé Program  
G. Vassal<sup>1</sup>, N. Cozic<sup>1</sup>, R. Houot<sup>1</sup>, L. Brugières<sup>1</sup>, T. Aparicio<sup>2</sup>, J.-Y. Blay<sup>2</sup>, M. Perol<sup>2</sup>, P. Brice<sup>1</sup>, E. Meriaux<sup>2</sup>, B. Geoerger<sup>1</sup>, M. El Bejjani<sup>1</sup>, S. Moalla<sup>1</sup>, I. Bièche<sup>1</sup>, S. Lantuejoul<sup>3</sup>, C. Mahier Ait Oukhatar<sup>1</sup>, N. Hoog Labouret<sup>1</sup>, D. Moro-Sibilot<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>CEDEX 9/FR
- 12:45 - 12:45 435P - Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors

V. Boni<sup>1</sup>, J. Garcia-Corbacho<sup>1</sup>, P. Ott<sup>2</sup>, D. Cho<sup>3</sup>, K. Autio<sup>3</sup>, N. Uboha<sup>4</sup>, A. Spira<sup>5</sup>, R. Humphrey<sup>6</sup>, M. Will<sup>6</sup>, A. Naing<sup>7</sup>, F. Thistlethwaite<sup>8</sup>, E.G.E. de Vries<sup>9</sup>, H.-T. Arkenau<sup>8</sup>; <sup>1</sup>ES, <sup>2</sup>MA/US, <sup>3</sup>NY/US, <sup>4</sup>WI/US, <sup>5</sup>VA/US, <sup>6</sup>CA/US, <sup>7</sup>TX/US, <sup>8</sup>GB, <sup>9</sup>NL

- 12:45 - 12:45 436P - Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 Probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
- R. Plummer<sup>1</sup>, R. Sanborn<sup>2</sup>, E.G.E. de Vries<sup>3</sup>, P. Lorusso<sup>4</sup>, H.-T. Arkenau<sup>5</sup>, N. Uboha<sup>6</sup>, J. Wydmanski<sup>7</sup>, M.J. Fidler<sup>8</sup>, V. Boni<sup>9</sup>, J. Garcia-Corbacho<sup>9</sup>, R. Humphrey<sup>10</sup>, M. Will<sup>10</sup>, K. Autio<sup>11</sup>, A. El-Khoueiry<sup>12</sup>, C.W. Menke-van der Houven van Oordt<sup>3</sup>, F. Thistlethwaite<sup>5</sup>; <sup>1</sup>Tyne and Wear/GB, <sup>2</sup>OR/US, <sup>3</sup>NL, <sup>4</sup>CT/US, <sup>5</sup>GB, <sup>6</sup>WI/US, <sup>7</sup>PL, <sup>8</sup>IL/US, <sup>9</sup>ES, <sup>10</sup>CA/US, <sup>11</sup>NY/US, <sup>12</sup>US
- 12:45 - 12:45 437P - PT-112: A Well-Tolerated Novel Immunogenic Cell Death (ICD) Inducer with Activity in Advanced Solid Tumors
- D. Karp<sup>1</sup>, D. Camidge<sup>2</sup>, J. Infante<sup>3</sup>, T. Ames<sup>4</sup>, J. Jimeno<sup>5</sup>, A. Bryce<sup>4</sup>; <sup>1</sup>TX/US, <sup>2</sup>CO/US, <sup>3</sup>TN/US, <sup>4</sup>US, <sup>5</sup>NY/US
- 12:45 - 12:45 438P - Safety and Efficacy of the PD-1 Inhibitor ABBV-181 in Patients with Advanced Solid Tumors: Preliminary Phase 1 Results from Study M15-891
- J. Powderly<sup>1</sup>, P. Cassier<sup>2</sup>, A. Cervantes<sup>3</sup>, B. Gao<sup>4</sup>, A. Gazzah<sup>2</sup>, A. Italiano<sup>5</sup>, C.-C. Lin<sup>6</sup>, J. Luke<sup>7</sup>, V. Moreno<sup>8</sup>, K. Peltola<sup>9</sup>, D. Rasco<sup>10</sup>, A. Spira<sup>11</sup>, M. Tanner<sup>9</sup>, D. Tosi<sup>2</sup>, D. Afar<sup>12</sup>, S. Englert<sup>7</sup>, A. Parikh<sup>12</sup>, A. Reddy<sup>12</sup>, G. Vosganian<sup>7</sup>, A. Tolcher<sup>10</sup>; <sup>1</sup>NC/US, <sup>2</sup>FR, <sup>3</sup>Valencia/ES, <sup>4</sup>NSW/AU, <sup>5</sup>CEDEX/FR, <sup>6</sup>TW, <sup>7</sup>US, <sup>8</sup>ES, <sup>9</sup>FI, <sup>10</sup>TX/US, <sup>11</sup>VA/US, <sup>12</sup>CA/US
- 12:45 - 12:45 439P - Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials
- C. Massard<sup>1</sup>, N. Segal<sup>2</sup>, D. Cho<sup>3</sup>, V. Papadimitrakopoulou<sup>2</sup>, N. Rizvi<sup>3</sup>, B.C. Cho<sup>4</sup>, L. Yu<sup>5</sup>, H. Yang<sup>5</sup>, H.-J. Hsieh<sup>5</sup>, J. Zhang<sup>5</sup>, W. Zhao<sup>5</sup>, G. Gao<sup>5</sup>, X. Guo<sup>5</sup>, S. Abdullah<sup>5</sup>, J. Englert<sup>5</sup>, J.-C. Soria<sup>6</sup>, M. Dar<sup>5</sup>, L. Roskos<sup>2</sup>, C. Ferte<sup>5</sup>, S. Antonia<sup>7</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>US, <sup>3</sup>NY/US, <sup>4</sup>KR, <sup>5</sup>MD/US, <sup>6</sup>CEDEX/US, <sup>7</sup>FL/US
- 12:45 - 12:45 440P - Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect
- A. Karlsson-Parra, G. Fotaki, D. Yu, M. Essand; SE
- 12:45 - 12:45 441P - OT-1096, a first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral Tregs in a humanized TNBC-PDX model.
- O. Orwar, I. Lowstedt, K. Andersson, G. Gannedahl, G. Willman, M. Davidsson, W. Stafford, C. Trkulja; SE
- 12:45 - 12:45 442TiP - A Phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
- S. Blagden<sup>1</sup>, P. Spiliopoulou<sup>1</sup>, L. Spiers<sup>2</sup>, C. Gnanaranjan<sup>1</sup>, C. Qi<sup>1</sup>, V. Woodcock<sup>2</sup>, J. Moschandreass<sup>1</sup>, H. Tyrrell<sup>1</sup>, L. Griffiths<sup>1</sup>, C. Butcher<sup>1</sup>, E. Ghazaly<sup>1</sup>, T.R.J. Evans<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Oxfordshire/GB
- 12:45 - 12:45 443TiP - First-in-Human trial design for W0101, a first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population

C. Gomez-Roca<sup>1</sup>, E. Garralda-Cabanas<sup>2</sup>, F. Cruzalegui<sup>3</sup>, F. Ausseil<sup>3</sup>, G. Zorza<sup>3</sup>, O. Delfour<sup>3</sup>, J. Besse<sup>3</sup>, B. Akla<sup>3</sup>, S. Gautier<sup>3</sup>, J. Adam<sup>3</sup>, M. Lacroix-Triki<sup>1</sup>, A. Passiukov<sup>3</sup>, R. Roche<sup>3</sup>, M. Pavlyuk<sup>3</sup>, C. Massard<sup>4</sup>; <sup>1</sup>Haute-Garonne/FR, <sup>2</sup>ES, <sup>3</sup>FR, <sup>4</sup>CEDEX/FR

12:45 - 12:45 444TiP - Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

J. Desai<sup>1</sup>, M. Voskoboinik<sup>2</sup>, B. Markman<sup>1</sup>, J. Hou<sup>3</sup>, D. Zeng<sup>3</sup>, T. Meniawy<sup>4</sup>; <sup>1</sup>VIC/AU, <sup>2</sup>AU, <sup>3</sup>CA/US, <sup>4</sup>WA/AU

12:45 - 12:45 445TiP - Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO – A Phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy

A. Krämer<sup>1</sup>, F. Losa<sup>2</sup>, L. Gay<sup>3</sup>, D. Page<sup>4</sup>, S. Foser<sup>4</sup>, T. Mughal<sup>3</sup>, J. Ross<sup>3</sup>, G. Baciarello<sup>5</sup>, L. Mileskin<sup>6</sup>, S. Osborne<sup>4</sup>, H. Moch<sup>4</sup>; <sup>1</sup>DE, <sup>2</sup>ES, <sup>3</sup>MA/US, <sup>4</sup>CH, <sup>5</sup>CEDEX/FR, <sup>6</sup>AU

12:45 - 12:45 446TiP - REVEAL: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies

A. Diab<sup>1</sup>, M. Marcondes<sup>1</sup>, M. Tagliaferri<sup>1</sup>, U. Hoch<sup>2</sup>, J. Zhang<sup>1</sup>, W. Rubas<sup>1</sup>, S. Kivimae<sup>1</sup>, J. Zalevsky<sup>1</sup>, A. Conley<sup>1</sup>, E. Borazanci<sup>3</sup>, S. D'Angelo<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>AZ/US, <sup>4</sup>NY/US

12:45 - 12:45 447TiP - The Cancer Molecular Screening and Therapeutics Program (MoST) – A molecular screening platform with multiple, parallel, signal-seeking therapeutic substudies

S. Thavaneswaran<sup>1</sup>, L. Sebastian<sup>2</sup>, M. Ballinger<sup>2</sup>, M. Cowley<sup>2</sup>, J. Grady<sup>2</sup>, A. Joshua<sup>2</sup>, C. Lee<sup>2</sup>, K. Sjoquist<sup>2</sup>, W. Hague<sup>2</sup>, J. Simes<sup>2</sup>, D. Thomas<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>NSW/AU

12:45 - 12:45 448TiP - MEDIOLA: A Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts

R. Penson<sup>1</sup>, Y. Drew<sup>2</sup>, M. de Jonge<sup>3</sup>, S.-H. Hong<sup>4</sup>, Y.H. Park<sup>4</sup>, A. Wolfer<sup>5</sup>, J. Brown<sup>2</sup>, M. Ferguson<sup>2</sup>, M. Gore<sup>2</sup>, R. Alvarez<sup>1</sup>, B. Kaufman<sup>6</sup>, C. Gresty<sup>2</sup>, H. Angell<sup>2</sup>, K. Meyer<sup>7</sup>, M. Lanasa<sup>1</sup>, P. Herbolzheimer<sup>1</sup>, S. Domchek<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>GB, <sup>3</sup>NL, <sup>4</sup>KR, <sup>5</sup>CH, <sup>6</sup>IL, <sup>7</sup>MD/US

12:45 - 12:45 449TiP - MASTER KEY Project – a basket/umbrella trial for rare cancers in Japan

S. Noda, K. Yonemori, N. Shirakawa, H. Okuma, T. Shimizu, A. Hirakawa, T. Shibata, T. Sukigara, N. Okita, A. Kawai, N. Yamamoto, K. Nakamura, H. Mano, T. Nishida, Y. Fujiwara; JP

12:45 - 12:45 800P - The prognostic value of the proportion and subtype patterns of intraductal carcinoma of the prostate in patients with de novo metastatic prostate cancer: a propensity score matching study

J. Zhao, J. Liu, G. Sun, P. Shen, J. Chen, X. Zhang, H. Zhang, Z. Liu, Y. Bao, Y. Yang, P. Zhao, K. Shu, H. Zeng; CN

12:45 - 12:45 801P - Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

P. Lara<sup>1</sup>, E. Mayerson<sup>2</sup>, E. Gertz<sup>1</sup>, C. Tangen<sup>2</sup>, A. Goldkorn<sup>3</sup>, M. van Loan<sup>1</sup>, M. Hussain<sup>3</sup>, S. Gupta<sup>3</sup>, J. Zhang<sup>4</sup>, P. Twardowski<sup>1</sup>, D. Quinn<sup>1</sup>, N. Vogelzang<sup>5</sup>, I. Thompson<sup>6</sup>, N. Agarwal<sup>3</sup>; <sup>1</sup>CA/US, <sup>2</sup>WA/US, <sup>3</sup>US, <sup>4</sup>FL/US, <sup>5</sup>NV/US, <sup>6</sup>TX/US

- 12:45 - 12:45 802P - Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China  
W. Jiang, S. Qu, Y. Liu, X. Yao, M. Liu; CN
- 12:45 - 12:45 803P - Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)  
U. Vaishampayan<sup>1</sup>, L. Heilbrun<sup>2</sup>, P. Monk<sup>3</sup>, G. Sonpavde<sup>4</sup>, S. Tejwani<sup>2</sup>, E. Heath<sup>1</sup>, J. Fontana<sup>2</sup>, S. Chinni<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MI/US, <sup>3</sup>OH/US, <sup>4</sup>MA/US
- 12:45 - 12:45 804P - Health-Related Quality of Life (HRQoL) After Progressive Disease (PD) in SPARTAN: a Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)  
E. Small<sup>1</sup>, D. Cella<sup>2</sup>, K. McQuarrie<sup>1</sup>, F. Saad<sup>3</sup>, B. Hadaschik<sup>4</sup>, J. Graff<sup>1</sup>, H. Uemura<sup>5</sup>, S. Oudard<sup>6</sup>, M. Yu<sup>1</sup>, S. Hudgens<sup>1</sup>, A. Lopez-Gitlitz<sup>1</sup>, B. Rooney<sup>7</sup>, M. Morris<sup>7</sup>, M. Smith<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>IL/US, <sup>3</sup>CA, <sup>4</sup>DE, <sup>5</sup>JP, <sup>6</sup>FR, <sup>7</sup>GB
- 12:45 - 12:45 805P - A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): results of PROSPER by age and region  
K. Fizazi<sup>1</sup>, M. Hussain<sup>2</sup>, F. Saad<sup>3</sup>, N. Shore<sup>2</sup>, U. De Giorgi<sup>4</sup>, E. Efstathiou<sup>5</sup>, U. Ferreira<sup>6</sup>, P. Ivashchenko<sup>7</sup>, K. Madziarska<sup>8</sup>, M. Al-Adhami<sup>2</sup>, K. Modelska<sup>2</sup>, D. Phung<sup>9</sup>, J. Steinberg<sup>10</sup>, C. Sternberg<sup>4</sup>; <sup>1</sup>FR, <sup>2</sup>US, <sup>3</sup>CA, <sup>4</sup>IT, <sup>5</sup>TX/US, <sup>6</sup>BR, <sup>7</sup>UA, <sup>8</sup>PL, <sup>9</sup>NL, <sup>10</sup>IL/US
- 12:45 - 12:45 806P - Relationship Between Apalutamide (APA) Exposure and Metastasis-Free Survival (MFS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN  
M. Smith<sup>1</sup>, C. Perez-Ruixo<sup>2</sup>, O. Ackaert<sup>2</sup>, D. Ouellet<sup>1</sup>, C. Chien<sup>1</sup>, H. Uemura<sup>3</sup>, D. Olmos<sup>4</sup>, P. Mainwaring<sup>5</sup>, J.Y. Lee<sup>6</sup>, M. Yu<sup>7</sup>, J.-J. Perez-Ruixo<sup>2</sup>, E. Small<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>BE, <sup>3</sup>JP, <sup>4</sup>ES, <sup>5</sup>QLD/AU, <sup>6</sup>KR, <sup>7</sup>CA/US
- 12:45 - 12:45 807P - Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: results from the PROSPER study  
B. Tombal<sup>1</sup>, M. Hussain<sup>2</sup>, D. Penson<sup>2</sup>, G. Attard<sup>1</sup>, C. Sternberg<sup>3</sup>, D. Phung<sup>4</sup>, R. Morlock<sup>2</sup>, K. Modelska<sup>2</sup>, K. Ramaswamy<sup>2</sup>, C. Ivanescu<sup>4</sup>, F. Saad<sup>5</sup>; <sup>1</sup>GB, <sup>2</sup>US, <sup>3</sup>IT, <sup>4</sup>NL, <sup>5</sup>CA
- 12:45 - 12:45 808P - Non-metastatic castration-resistant prostate cancer (nmCRPC): meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide  
D. Almeida<sup>1</sup>, C. de Oliveira<sup>1</sup>, R. Mariano<sup>1</sup>, F. Kater<sup>2</sup>, M.C. Souza<sup>1</sup>, V. Ruiz-Schutz<sup>1</sup>, R. Yamamura<sup>2</sup>, R. Saraiva De Carvalho<sup>2</sup>, F. Maluf<sup>1</sup>, A. Morgans<sup>3</sup>, S. Srinivas<sup>4</sup>, S. Gupta<sup>5</sup>, T. Dorff<sup>4</sup>, E. Yu<sup>6</sup>, F.A. Schutz<sup>2</sup>; <sup>1</sup>BR, <sup>2</sup>SP/BR, <sup>3</sup>US, <sup>4</sup>CA/US, <sup>5</sup>FL/US, <sup>6</sup>WA/US
- 12:45 - 12:45 809P - Statin Use and Outcome in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Treated in the TROPIC trial  
D. Lorente<sup>1</sup>, G.A. De Velasco Oria<sup>2</sup>, J. Carles<sup>3</sup>, S. Gillissen<sup>4</sup>, K. Fizazi<sup>5</sup>, A. Joshua<sup>6</sup>, M. Eisenberger<sup>7</sup>, O. Sartor<sup>7</sup>, J. de Bono<sup>8</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>MA/ES, <sup>3</sup>ES, <sup>4</sup>CH, <sup>5</sup>FR, <sup>6</sup>NSW/AU, <sup>7</sup>US, <sup>8</sup>GB

- 12:45 - 12:45 810P - Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: results from the SPARE-trial (NCT02077634)  
C. Ohlmann, Z. Roger, C. Rüssel, E. Hellmis, H. Suttmann, M. Janssen, A. Hübner, J. Dahm, J. Gleißner, M. Scheffler, S. Feyerabend, J. Telle, J. Klier; DE
- 12:45 - 12:45 811P - Association of Grade  $\geq 3$  neutropenia (NP) with outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel  
A. Meisel<sup>1</sup>, R. de Wit<sup>2</sup>, S. Oudard<sup>3</sup>, O. Sartor<sup>4</sup>, F. Stenner-Liewen<sup>1</sup>, Z. Shun<sup>4</sup>, A. Ozatilgan<sup>5</sup>, M. Eisenberger<sup>4</sup>, J. de Bono<sup>6</sup>; <sup>1</sup>CH, <sup>2</sup>NL, <sup>3</sup>FR, <sup>4</sup>US, <sup>5</sup>MA/US, <sup>6</sup>GB
- 12:45 - 12:45 812P - Post hoc responder analysis of healthrelated quality of life (HRQL) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the Phase III PROSELICA and FIRSTANA trials  
A. Thiery Vuillemin<sup>1</sup>, K. Fizazi<sup>2</sup>, O. Sartor<sup>3</sup>, S. Oudard<sup>2</sup>, D. Bury<sup>3</sup>, S. Guillonnet<sup>2</sup>, A. Ozatilgan<sup>4</sup>, M. Eisenberger<sup>3</sup>, J. de Bono<sup>5</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>US, <sup>4</sup>MA/US, <sup>5</sup>GB
- 12:45 - 12:45 813P - Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment  
D. Robbrecht<sup>1</sup>, R. van Soest<sup>1</sup>, I. Tannock<sup>2</sup>, S. Oudard<sup>3</sup>, B. Tombal<sup>4</sup>, M. Eisenberger<sup>5</sup>, F. Mercier<sup>3</sup>, R. de Wit<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>Ontario/CA, <sup>3</sup>FR, <sup>4</sup>BE, <sup>5</sup>US
- 12:45 - 12:45 814P - Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects – a multicentre retrospective analysis  
S. Gillessen<sup>1</sup>, S. Schmid<sup>1</sup>, H. Beltran<sup>2</sup>, D. Almeida<sup>3</sup>, N. Mehra<sup>4</sup>, P. Lavaud<sup>5</sup>, R. Morales Barrera<sup>6</sup>, D. Pignataro<sup>7</sup>, E. Castro Marcos<sup>6</sup>, V. Conteduca<sup>8</sup>, E. Efstathiou<sup>9</sup>, H.M.L. Le<sup>10</sup>, C. Pezaro<sup>11</sup>, H. Suzuki<sup>12</sup>, A. Zivi<sup>7</sup>, D. Klingbiel<sup>1</sup>, A. Omlin<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>US, <sup>3</sup>BR, <sup>4</sup>Surrey/NL, <sup>5</sup>FR, <sup>6</sup>ES, <sup>7</sup>IT, <sup>8</sup>Forlì-Cesena/IT, <sup>9</sup>TX/US, <sup>10</sup>AE, <sup>11</sup>VIC/AU, <sup>12</sup>JP
- 12:45 - 12:45 815P - Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: results from CAPRI  
M. Kuppen<sup>1</sup>, H. Westgeest<sup>1</sup>, A.J.M. van den Eertwegh<sup>1</sup>, J. Van Moorselaar<sup>1</sup>, N. Mehra<sup>2</sup>, I. van Oort<sup>1</sup>, A. van den Bergh<sup>1</sup>, J.L. Coenen<sup>1</sup>, K. Aben<sup>1</sup>, R. Somford<sup>1</sup>, J. Lavalaye<sup>1</sup>, A. Bergman<sup>1</sup>, C. Uyl-de Groot<sup>1</sup>, W. Gerritsen<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>Surrey/NL
- 12:45 - 12:45 816P - Androgen Decline and Outcome in Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Docetaxel (Doc), Prednisone +/- Bevacizumab (B)  
C. Ryan<sup>1</sup>, S. Dutta<sup>1</sup>, W. Kelly<sup>1</sup>, M. Morris<sup>2</sup>, M.-E. Taplin<sup>3</sup>, S. Halabi<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>NY/US, <sup>3</sup>MA/US, <sup>4</sup>NC/US
- 12:45 - 12:45 817P - Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: an observational study in the Netherlands.  
H. Westgeest<sup>1</sup>, M. Kuppen<sup>1</sup>, A. van den Eertwegh<sup>1</sup>, J. Van Moorselaar<sup>1</sup>, N. Mehra<sup>2</sup>, I. van Oort<sup>1</sup>, A. van den Bergh<sup>1</sup>, J.L. Coenen<sup>1</sup>, K. Aben<sup>1</sup>, R. Somford<sup>1</sup>, R. de Wit<sup>1</sup>, A. Bergman<sup>1</sup>, J. Lavalaye<sup>1</sup>, C. Uyl-de Groot<sup>1</sup>, W. Gerritsen<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>Surrey/NL

- 12:45 - 12:45 818P - Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry  
Z. Malik<sup>1</sup>, A. Pichler<sup>2</sup>, G. Di Lorenzo<sup>3</sup>, U. De Giorgi<sup>4</sup>, S. Hitier<sup>5</sup>, E. Ecstein-Fraisse<sup>5</sup>, A. Ozatilgan<sup>6</sup>, J. Carles<sup>7</sup>; <sup>1</sup>GB, <sup>2</sup>AT, <sup>3</sup>IT, <sup>4</sup>Forli-Cesena/IT, <sup>5</sup>FR, <sup>6</sup>MA/US, <sup>7</sup>ES
- 12:45 - 12:45 819P - Prognostic associations of early prostate-specific antigen (PSA) changes in patients with Metastatic Castration-resistant Prostate Cancer treated with with abiraterone acetate or enzalutamide  
F. López Campos<sup>1</sup>, I. Moreno<sup>1</sup>, A. Conde-Moreno<sup>1</sup>, A. Gómez-Iturriaga<sup>1</sup>, M. Ruiz Vico<sup>1</sup>, N. Romero Laorden<sup>2</sup>, I. Henríquez López<sup>1</sup>, P. Peleteiro Higuero<sup>1</sup>, R. Lozano Mejorada<sup>1</sup>, T. Piquer<sup>1</sup>, M. Couselo<sup>1</sup>, J. Gómez Ramos<sup>1</sup>, J. Navarro<sup>1</sup>, P. Barrionuevo Castillo<sup>1</sup>, R. García<sup>1</sup>, R. Villatoro<sup>1</sup>, A. Montesa<sup>1</sup>, M. Saez<sup>1</sup>, B. Herrera<sup>1</sup>, E. Castro Marcos<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Madrid/ES
- 12:45 - 12:45 820P - Cabazitaxel under routine conditions for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) - Interim results of the non-interventional SCOPE study.  
J. Gschwend, C. Lange, C. Bokemeyer; DE
- 12:45 - 12:45 821P - Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)  
S. España Fernandez<sup>1</sup>, J.M. Piulats<sup>1</sup>, N. Sala<sup>1</sup>, J.M. Velarde<sup>1</sup>, U. Ferrandiz<sup>1</sup>, O. Etxaniz Ulazia<sup>2</sup>, L. Heras Lopez<sup>1</sup>, M.P. Barretina Ginesta<sup>1</sup>, X. Garcia del Muro<sup>1</sup>, A. Font<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 12:45 - 12:45 822P - Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel.  
J. Puente<sup>1</sup>, M.J. Mendez Vidal<sup>1</sup>, M. Saez<sup>1</sup>, A. Font Pous<sup>2</sup>, I. Duran<sup>1</sup>, D. Castellano<sup>1</sup>, M.J. Juan Fita<sup>1</sup>, C. Santander<sup>1</sup>, J. Arranz Arijia<sup>1</sup>, A. Sanchez-Hernandez<sup>1</sup>, B. Mellado<sup>1</sup>, T. Alonso<sup>1</sup>, M.A. Gonzalez del Alba Baamonde<sup>1</sup>, P. Maroto<sup>1</sup>, M. Lazaro<sup>1</sup>, E. Esteban<sup>1</sup>, J. Cassinello<sup>1</sup>, M.A. Climent Duran<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Barcelona/ES
- 12:45 - 12:45 823P - Efficacy of therapies after progression to up-front Docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)  
P. Gajate Borau<sup>1</sup>, A. Martin Marino<sup>2</sup>, I. Gallegos Sancho<sup>2</sup>, J.C. Villa Guzman<sup>3</sup>, A. Velastegui<sup>2</sup>, T. Alonso Gordo<sup>2</sup>, D. Castellano<sup>2</sup>, G. Rubio Romero<sup>2</sup>, A. Pinto Marin<sup>2</sup>, L. Villalobos Leon<sup>2</sup>, C. Maximiano Alonso<sup>1</sup>, M. Sotelo-Lezama<sup>2</sup>, M. Sereno Moyano<sup>2</sup>, J.F. Rodríguez<sup>2</sup>, C. Perezagua Marin<sup>2</sup>, J. Ballesteros<sup>2</sup>, D. Marrupe Gonzalez<sup>1</sup>, L. Rodriguez Lajusticia<sup>2</sup>, J.J. Tafalla García<sup>2</sup>, C. Aguado<sup>2</sup>; <sup>1</sup>Madrid/ES, <sup>2</sup>ES, <sup>3</sup>Ciudad Real/ES
- 12:45 - 12:45 824P - Radium-223 (Ra-223) therapy after abiraterone (Abi): analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)  
K. Miller<sup>1</sup>, D. Heinrich<sup>2</sup>, J. O'Sullivan<sup>3</sup>, J. Carles<sup>4</sup>, M. Wirth<sup>1</sup>, S. Nilsson<sup>5</sup>, L. Huang<sup>6</sup>, J. Kalinovsky<sup>7</sup>, A. Heidenreich<sup>1</sup>, F. Saad<sup>8</sup>; <sup>1</sup>DE, <sup>2</sup>NO, <sup>3</sup>GB, <sup>4</sup>ES, <sup>5</sup>SE, <sup>6</sup>US, <sup>7</sup>CH, <sup>8</sup>CA
- 12:45 - 12:45 825P - Randomized Phase II Trial of Radium-223 (RA) plus Enzalutamide (EZ) vs. EZ alone in Metastatic Castration Refractory Prostate Cancer (mCRPC)

B. Maughan<sup>1</sup>, A. Hahn<sup>2</sup>, J. Hoffman<sup>1</sup>, K. Morton<sup>1</sup>, S. Gupta<sup>1</sup>, J. Batten<sup>1</sup>, J. Thorley<sup>1</sup>, J. Hawks<sup>1</sup>, G. Nachaegari<sup>1</sup>, R. Nussenzeig<sup>1</sup>, K. Boucher<sup>1</sup>, N. Agarwal<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>UT/US

- 12:45 - 12:45 826P - Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE
- C. Sternberg<sup>1</sup>, B. Tombal<sup>2</sup>, K. Miller<sup>3</sup>, F. Saad<sup>4</sup>, O. Sartor<sup>5</sup>, J.P. Sade<sup>6</sup>, C. Logothetis<sup>5</sup>, J. Bellmunt<sup>7</sup>, S. Dizdarevic<sup>8</sup>, L. Harshman<sup>9</sup>, J. Logue<sup>8</sup>, S. Baldari<sup>1</sup>, T. Richardson<sup>5</sup>, D. Bottomley<sup>8</sup>, M. Schostak<sup>3</sup>, I. Bayh<sup>3</sup>, J. Kalinovsky<sup>10</sup>, C. Higano<sup>5</sup>; <sup>1</sup>IT, <sup>2</sup>BE, <sup>3</sup>DE, <sup>4</sup>CA, <sup>5</sup>US, <sup>6</sup>AR, <sup>7</sup>ES, <sup>8</sup>GB, <sup>9</sup>MA/US, <sup>10</sup>CH
- 12:45 - 12:45 827P - Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)
- C. Higano<sup>1</sup>, B. Tombal<sup>2</sup>, K. Miller<sup>3</sup>, F. Saad<sup>4</sup>, O. Sartor<sup>1</sup>, K. Tangirala<sup>1</sup>, X. Jiao<sup>1</sup>, J. Kalinovsky<sup>5</sup>, C. Sternberg<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>BE, <sup>3</sup>DE, <sup>4</sup>CA, <sup>5</sup>CH, <sup>6</sup>IT
- 12:45 - 12:45 828P - Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, non-interventional study (PARABO)
- T. Poeppel<sup>1</sup>, S. Eschmann<sup>1</sup>, A. Werner<sup>1</sup>, I. Selinski<sup>1</sup>, M.-O. Möllers<sup>1</sup>, T. Neußer<sup>1</sup>, A. Benson<sup>2</sup>, J. Kalinovsky<sup>3</sup>, H. Palmedo<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>NJ/US, <sup>3</sup>CH
- 12:45 - 12:45 829P - Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry); a prospective observational registry in a non-study population
- R. Louhanepessy, S. Badrising, V. Vd Noort, J.L. Coenen, A. Oostdijk, P. Hamberg, J.M. Zuetenhorst, A. Beeker, N. Wagenaar, M. Lam, F. Celik, E. Vegt, W. Zwart, A. Bergman; NL
- 12:45 - 12:45 830P - Synthetic DNA Immunotherapy in Biochemically Relapsed Prostate Cancer
- N. Shore<sup>1</sup>, E. Heath<sup>1</sup>, L. Nordquist<sup>1</sup>, H. Cheng<sup>1</sup>, K. Bhatt<sup>1</sup>, M. Morrow<sup>1</sup>, T. McMullan<sup>1</sup>, K. Kraynyak<sup>1</sup>, J. Lee<sup>1</sup>, B. Sacchetta<sup>1</sup>, L. Liu<sup>1</sup>, S. Rosencranz<sup>1</sup>, S. Tagawa<sup>2</sup>, L. Appleman<sup>3</sup>, R. Tutrone<sup>1</sup>, J. Garcia<sup>4</sup>, Y. Whang<sup>5</sup>, W. Kelly<sup>1</sup>, I. Csiki<sup>1</sup>, M. Bagarazzi<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>US/US, <sup>3</sup>PA/US, <sup>4</sup>OH/US, <sup>5</sup>NC/US
- 12:45 - 12:45 831P - Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer – final analysis
- R. Tauber, K. Knorr, S. Schwaiger, M. Retz, T. Maurer, C. D'Alessandria, H.-J. Wester, J. Gschwend, W. Weber, M. Schwaiger, M. Heck, M. Eiber; DE
- 12:45 - 12:45 832P - Association Between Patient Reported Quality of Life (QOL) and Survival: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
- A. Morgans<sup>1</sup>, Y.-H. Chen<sup>1</sup>, D. Jerrard<sup>1</sup>, M. Carducci<sup>2</sup>, R. Dipaola<sup>1</sup>, L. Wagner<sup>1</sup>, D. Cella<sup>3</sup>, C. Sweeney<sup>4</sup>; <sup>1</sup>US, <sup>2</sup>MD/US, <sup>3</sup>IL/US, <sup>4</sup>MA/US
- 12:45 - 12:45 834P - Interim Results of a Phase 1b Study of Niraparib plus Androgen Receptor-Targeted Therapy in Men with Metastatic Castration-Resistant Prostate Cancer
- F. Saad<sup>1</sup>, K. Chi<sup>2</sup>, N. Shore<sup>3</sup>, J. Graff<sup>3</sup>, E. Posadas<sup>4</sup>, S. Freeman<sup>4</sup>, J. Tryon<sup>3</sup>, G. Trudel<sup>4</sup>, J. de Jong<sup>3</sup>, J. Meltzer<sup>3</sup>, X. Zhao<sup>3</sup>, N. Tran<sup>3</sup>, A. Rezaadeh<sup>3</sup>; <sup>1</sup>CA, <sup>2</sup>British Columbia/CA, <sup>3</sup>US, <sup>4</sup>CA/US



- 12:45 - 12:45 835P - CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer  
R. Oksala, K. Räsänen, M. Karimaa, R. Riikonen, M. Ramela, P. Vehmaan-Kreula, O. Simola, P. Rummakko, G. Wohlfahrt, M. Mustonen; FI
- 12:45 - 12:45 837P - Prediction of Prostate Cancer Gleason Score Upgrading from Biopsy to Radical Prostatectomy (RP) using a Validated 17-Gene Panel Assay  
J. Cullen, H. Lawrence, Y. Chen, R. Lu, S. Srivastava, I. Rosner, T. Brand, I. Sesterhenn; US
- 12:45 - 12:45 836P - Use of Nuclear-Localized Androgen Receptor Splice Variant 7 Protein in CTCs after 1st Androgen Receptor Signaling Inhibitor (ARSi) as a Predictive Biomarker for Overall Survival on a Second ARSi or Taxane Chemotherapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)  
H. Scher<sup>1</sup>, R. Graf<sup>2</sup>, M. Hulling<sup>1</sup>, E. Carbone<sup>1</sup>, R. Dittamore<sup>3</sup>; <sup>1</sup>NY/US, <sup>2</sup>CA/US, <sup>3</sup>US
- 12:45 - 12:45 838P - PI3K/AKT pathway deleterious mutations in lethal prostate cancer  
P. Rescigno<sup>1</sup>, M. Rediti<sup>2</sup>, D. Dolling<sup>2</sup>, D.N. Rodrigues<sup>2</sup>, D. Bianchini<sup>2</sup>, R. Riisnaes<sup>2</sup>, C. Messina<sup>2</sup>, M. Barrero<sup>2</sup>, A. Petremolo<sup>2</sup>, A. Sharp<sup>2</sup>, S. Sumanasuriya<sup>2</sup>, G. Seed<sup>2</sup>, I. Figueiredo<sup>2</sup>, S. Miranda<sup>2</sup>, J. Goodall<sup>2</sup>, J. Mateo<sup>2</sup>, R. Chandler<sup>2</sup>, W. Yuan<sup>2</sup>, S. Carreira<sup>2</sup>, J. de Bono<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>GB
- 12:45 - 12:45 842P - CTC-based biomarkers & PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)  
M. Morris<sup>1</sup>, N. Vogelzang<sup>2</sup>, O. Sartor<sup>3</sup>, A. Armour<sup>4</sup>, R. Messmann<sup>3</sup>, M. Groaning<sup>3</sup>, A. Robarts<sup>1</sup>, A. Tolcher<sup>5</sup>, M. Gordon<sup>6</sup>, H. Babiker<sup>3</sup>, P. Kuo<sup>3</sup>, M. Kearney<sup>3</sup>, A. Jendrisak<sup>3</sup>, Y. Wang<sup>3</sup>, M. Landers<sup>3</sup>, D. Petrylak<sup>7</sup>; <sup>1</sup>NY/US, <sup>2</sup>NV/US, <sup>3</sup>US, <sup>4</sup>Pennsylvania/US, <sup>5</sup>TX/US, <sup>6</sup>AZ/US, <sup>7</sup>CT/US
- 12:45 - 12:45 843P - The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study  
T. LOUBERSAC<sup>1</sup>, S. Chakak<sup>2</sup>, M. Nguile-Makao<sup>2</sup>, V. Fradet<sup>2</sup>, P. Toren<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>QC/CA
- 12:45 - 12:45 845P - Phase 3 Double-Blind Study Evaluating Lens Opacifications (LO) in Patients with Nonmetastatic Prostate Cancer (PCa) Receiving Denosumab (Dmab) for Bone Loss Due to Androgen Deprivation Therapy (ADT)  
S. Tagawa<sup>1</sup>, T. Dai<sup>2</sup>, D. Jandial<sup>2</sup>; <sup>1</sup>US/US, <sup>2</sup>US
- 12:45 - 12:45 844P - The Clinical Impact of Targeted Next Generation Sequencing (tNGS) In the Treatment of Metastatic Prostate Cancer  
P.M. Coelho Barata<sup>1</sup>, P. Mendiratta<sup>2</sup>, M. Sadaps<sup>2</sup>, S. Klek<sup>2</sup>, M. Ornstein<sup>2</sup>, T. Gilligan<sup>2</sup>, P. Grivas<sup>2</sup>, B. Rini<sup>2</sup>, D. Sohal<sup>2</sup>, J. Garcia<sup>2</sup>; <sup>1</sup>PT, <sup>2</sup>OH/US
- 12:45 - 12:45 840P - Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).  
C. Reuter, S. Brunotte, P. Ivanyi, M. Morgan, V. Grünwald; DE
- 12:45 - 12:45 846P - Patterns of Therapy in Pelvic Lymph Node Positive Prostate Cancer in Europe and Asia: A Real-world Data Analysis  
M. Prentice, S. Mpima, P. Nasuti, A. Martinez-Pinillos, I. Wong, K. Durno, R. Davda, H. Payne; GB

- 12:45 - 12:45 841P - Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC)  
A. Hahn<sup>1</sup>, A. Kapron<sup>1</sup>, J. Boyle<sup>1</sup>, W. Kohlmann<sup>2</sup>, A. Poole<sup>2</sup>, D. Gill<sup>2</sup>, S. Greenberg<sup>2</sup>, P. Hale<sup>2</sup>, C. Teerlink<sup>1</sup>, B. Maughan<sup>2</sup>, L. Cannon-Albright<sup>1</sup>, N. Agarwal<sup>1</sup>, K. Cooney<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>UT/US
- 12:45 - 12:45 848P - Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems  
J. Hornberger<sup>1</sup>, R. Graf<sup>1</sup>, M. Hulling<sup>2</sup>, G. Attard<sup>3</sup>, A. Allan<sup>4</sup>, R. Dittamore<sup>5</sup>, H. Scher<sup>2</sup>; <sup>1</sup>CA/US, <sup>2</sup>NY/US, <sup>3</sup>GB, <sup>4</sup>CA, <sup>5</sup>US
- 12:45 - 12:45 853P - Long-term Adverse Effects (AEs) after dose-escalation with High-Dose Rate Brachytherapy in combination with External Beam Radiation Therapy (BT/RT). Comparison to External Beam Radiation Therapy alone (RT)  
T. Wedde, S. Fosså, A. Dahl, M.-B. Schulz, W. Lilleby; NO
- 12:45 - 12:45 851P - Pharmacokinetic/Pharmacodynamic relationship of Enzalutamide and its active metabolite N-desmethyl Enzalutamide in metastatic castration-resistant prostate cancer patients  
M.-L. Joulia<sup>1</sup>, E. Carton Vienet Legue<sup>1</sup>, M. Allard<sup>1</sup>, O. Huillard<sup>2</sup>, M. Peyromaure<sup>1</sup>, M. Zerbib<sup>1</sup>, M. Vidal<sup>1</sup>, F. Goldwasser<sup>2</sup>, J. Alexandre<sup>3</sup>, B. Blanchet<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 14/FR, <sup>3</sup>CEDEX 4/FR
- 12:45 - 12:45 849P - Quality of Docetaxel Toxicity Reporting for Castration Resistant Prostate Cancer (CRPC): A Systematic Review  
S. Cheng<sup>1</sup>, M. Qureshi<sup>2</sup>, V. Arciero<sup>2</sup>, K.K.-W. Chan<sup>2</sup>, U. Emmenegger<sup>3</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA, <sup>3</sup>Ontario/CA
- 12:45 - 12:45 839P - Clinico-genomic profiling and outcome prediction of neuroendocrine prostate cancer (NEPC)  
V. Conteduca<sup>1</sup>, C. Oromendia<sup>2</sup>, M. Sigouros<sup>2</sup>, A. Sborner<sup>2</sup>, D.M. Nanus<sup>2</sup>, S. Tagawa<sup>3</sup>, K. Ballman<sup>2</sup>, H. Beltran<sup>2</sup>; <sup>1</sup>Forli-Cesena/IT, <sup>2</sup>US, <sup>3</sup>US/US
- 12:45 - 12:45 850P - Intermittent Short Course Enzalutamide in Biochemically Recurrent Prostate Cancer: Analysis of PSA Recovery, Testosterone Levels and Tolerability  
M. Al Harthy<sup>1</sup>, H. Singh<sup>1</sup>, F. Karzai<sup>1</sup>, P. Arlen<sup>1</sup>, M. Theoret<sup>1</sup>, J. Marte<sup>1</sup>, M. Bilusic<sup>2</sup>, A. Couvillon<sup>1</sup>, H. Owens<sup>1</sup>, A. Hankin<sup>3</sup>, L. Cordes<sup>3</sup>, I. Rosner<sup>1</sup>, J. Strauss<sup>3</sup>, W. Figg<sup>1</sup>, J. Schlom<sup>1</sup>, W. Dahut<sup>3</sup>, J. Gulley<sup>3</sup>, R. Madan<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>PA/US, <sup>3</sup>MD/US
- 12:45 - 12:45 847P - The Prognostic Significance of the 2014 International Society of Urological Pathology (ISUP) Grading System in Patients with High-Risk Prostate Cancer  
J. Liu, J. Zhao; CN
- 12:45 - 12:45 854P - Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate (NEPC)  
L. Apostolidis, C. Nientiedt, E. Winkler, A. Berger, C. Kratochwil, A. Kaiser, D. Jäger, M. Hohenfellner, C. Hüttenbrink, S. Pahernik, F. Distler, C. Grulich; DE
- 12:45 - 12:45 852P - Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)

A. tripathi<sup>1</sup>, J. Supko<sup>2</sup>, K. Gray<sup>2</sup>, Z. Melnick<sup>2</sup>, M.-E. Taplin<sup>2</sup>, A. Choudhury<sup>2</sup>, M. Pomerantz<sup>2</sup>, J. Bellmunt<sup>3</sup>, C. Yu<sup>2</sup>, Z. Sun<sup>4</sup>, S. Srinivas<sup>4</sup>, P. Kantoff<sup>2</sup>, C. Sweeney<sup>2</sup>, L. Harshman<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MA/US, <sup>3</sup>ES, <sup>4</sup>CA/US

- 12:45 - 12:45 855P - Effect of Prednisone on Docetaxel Pharmacokinetics in Metastatic Prostate Cancer: A Randomized Drug-drug Interaction Study.  
B. Belderbos, K. Husaarts, L. van Harten, E. Oomen-De Hoop, P. de Bruijn, P. Hamberg, R. van Alphen, B. Haberkorn, R. van Soest, R. de Wit, R. Mathijssen; NL
- 12:45 - 12:45 857P - United in Fight against prostate cancer registry (UFO): first results from a large, multi-center, prospective, longitudinal cohort study in Asia  
H. Uemura<sup>1</sup>, D. Ye<sup>2</sup>, R. Kanesvaran<sup>3</sup>, H. Zeng<sup>2</sup>, Y.-S. Pu<sup>4</sup>, E. Chiong<sup>3</sup>, B. Lojanapiwat<sup>5</sup>, S.K. Rawal<sup>6</sup>, B.H. Chung<sup>7</sup>, A.H.A. Razack<sup>8</sup>, Y.-S. Tsai<sup>4</sup>, Y. Liu<sup>9</sup>, M. Asinas-Tan<sup>3</sup>, W. Liu<sup>2</sup>, G.K.M. Low<sup>3</sup>, M. van Kooten Losio<sup>10</sup>; <sup>1</sup>JP, <sup>2</sup>CN, <sup>3</sup>SG, <sup>4</sup>TW, <sup>5</sup>TH, <sup>6</sup>IN, <sup>7</sup>KR, <sup>8</sup>MY, <sup>9</sup>US, <sup>10</sup>AU
- 12:45 - 12:45 856P - Differences in treatment recommendations for advanced prostate cancer according to region and medical specialization – analysis of the APCCC 2017 voting results  
S. Fischer<sup>1</sup>, S. Gillessen<sup>1</sup>, M. Sydes<sup>2</sup>, A. Omlin<sup>1</sup>; <sup>1</sup>CH, <sup>2</sup>UK/GB
- 12:45 - 12:45 858P - Deployment of advanced real-world data (RWD) analytics for the accelerated recruitment of patients into an ongoing metastatic castrate-resistant prostate cancer (mCRPC) trial, together with the development of a sophisticated patient referral network  
M. Cushion, GB
- 12:45 - 13:05 859TiP - TALAPRO-1: An open-label, response rate phase 2 study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥1 novel hormonal therapy (NHT)  
J. de Bono<sup>1</sup>, C. Higano<sup>2</sup>, F. Saad<sup>3</sup>, K. Miller<sup>4</sup>, M. Casey<sup>2</sup>, A. Czibere<sup>2</sup>, C. Healy<sup>2</sup>, K. Fizazi<sup>5</sup>; <sup>1</sup>GB, <sup>2</sup>US, <sup>3</sup>CA, <sup>4</sup>DE, <sup>5</sup>FR
- 13:05 - 13:05 860TiP - Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response  
M.J. Juan Fita, L. Heras Lopez, B. Mellado, M.J. Mendez Vidal, U. Anido, D. Lorente, J.M. Sepulveda, C. Alvarez; ES
- 13:05 - 13:05 861TiP - Multimodality treatment for pN1 prostate cancer - Adding elective para-aortic radiation in the PART trial  
C. Berghen, S. Joniau, C. Draulans, G. De Meerleer; BE
- 13:05 - 13:05 862TiP - ReCab II: A phase II trial of Cabazitaxel +/- Rhenium -188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment  
E. Bouman-Wammes, J.M. van Dodewaard-De Jong, H. Bloemendal, H. Verheul, J.M.H. de Klerk, A.J.M. van den Eertwegh; NL
- 13:05 - 13:05 871P - KEYNOTE-427 Cohort A: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

F. Donskov<sup>1</sup>, D. McDermott<sup>2</sup>, J. Lee<sup>3</sup>, C. Szczylik<sup>4</sup>, J. Malik<sup>5</sup>, B. Alekseev<sup>6</sup>, J. Larkin<sup>5</sup>, V.B. Matveev<sup>6</sup>, R. Airatovich Gafanov<sup>6</sup>, P. Tomczak<sup>4</sup>, S. Tykodi<sup>7</sup>, P. Geertsen<sup>1</sup>, P. Wiechno<sup>4</sup>, S.J. Shin<sup>3</sup>, F. Pouliot<sup>8</sup>, T. Alonso Gordo<sup>9</sup>, R. Kloss Silverman<sup>10</sup>, R. Perini<sup>10</sup>, C. Schloss<sup>10</sup>, M. Atkins<sup>11</sup>; <sup>1</sup>DK, <sup>2</sup>MA/US, <sup>3</sup>KR, <sup>4</sup>PL, <sup>5</sup>GB, <sup>6</sup>RU, <sup>7</sup>US, <sup>8</sup>CA, <sup>9</sup>ES, <sup>10</sup>NJ/US, <sup>11</sup>DC/US

- 13:05 - 13:05 872P - Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)  
N. Agarwal<sup>1</sup>, U. Vaishampayan<sup>2</sup>, M. Green<sup>3</sup>, F. di Nucci<sup>3</sup>, P.-Y. Chang<sup>3</sup>, C. Scheffold<sup>4</sup>, S. Pal<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>MI/US, <sup>3</sup>CA/US, <sup>4</sup>California/US
- 13:05 - 13:05 873P - Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): pooled analysis of IMmotion150 and IMmotion151  
C. Suarez<sup>1</sup>, T. Choueiri<sup>2</sup>, D. McDermott<sup>3</sup>, B. Escudier<sup>4</sup>, M. Atkins<sup>2</sup>, T. Powles<sup>5</sup>, B. Rini<sup>6</sup>, R. Motzer<sup>7</sup>, S. Pal<sup>8</sup>, L. Fong<sup>8</sup>, U. De Giorgi<sup>9</sup>, Y. Wang<sup>8</sup>, T. Khaznadar<sup>10</sup>, F. Di Nucci<sup>8</sup>, C. Kaiser<sup>8</sup>, D. Tayama<sup>2</sup>, F. Donskov<sup>11</sup>; <sup>1</sup>ES, <sup>2</sup>US, <sup>3</sup>MA/US, <sup>4</sup>CEDEX/FR, <sup>5</sup>GB, <sup>6</sup>OH/US, <sup>7</sup>NY/US, <sup>8</sup>CA/US, <sup>9</sup>IT, <sup>10</sup>CH, <sup>11</sup>DK
- 13:05 - 13:05 874P - Treatment-Free Interval (TFI) Following Discontinuation of First-Line Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Advanced Renal Cell Carcinoma (aRCC): CheckMate 214 Analysis  
D. McDermott<sup>1</sup>, B. Rini<sup>2</sup>, R. Motzer<sup>3</sup>, N. Tannir<sup>4</sup>, B. Escudier<sup>5</sup>, C. Kollmannsberger<sup>6</sup>, H. Hammers<sup>7</sup>, C. Porta<sup>8</sup>, S. George<sup>3</sup>, F. Donskov<sup>9</sup>, H. Gurney<sup>10</sup>, M.-O. Grimm<sup>11</sup>, M. Harrison<sup>12</sup>, T. Hutson<sup>4</sup>, J. Doan<sup>13</sup>, S. Yang<sup>12</sup>, S. Rao<sup>12</sup>, S. Mekan<sup>12</sup>, A. Ambavane<sup>14</sup>, T. Powles<sup>14</sup>; <sup>1</sup>MA/US, <sup>2</sup>OH/US, <sup>3</sup>NY/US, <sup>4</sup>TX/US, <sup>5</sup>CEDEX/FR, <sup>6</sup>British Columbia/CA, <sup>7</sup>MD/US, <sup>8</sup>IT, <sup>9</sup>DK, <sup>10</sup>NSW/AU, <sup>11</sup>DE, <sup>12</sup>US, <sup>13</sup>FL/US, <sup>14</sup>GB
- 13:05 - 13:05 875P - Characterization of Response to Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Patients (Pts) With Previously Untreated Advanced Renal Cell Carcinoma (aRCC): CheckMate 214  
B. Rini<sup>1</sup>, N. Tannir<sup>2</sup>, B. Escudier<sup>3</sup>, D. McDermott<sup>4</sup>, M.-O. Grimm<sup>5</sup>, C. Porta<sup>6</sup>, T. Powles<sup>7</sup>, C. Kollmannsberger<sup>8</sup>, H. Gurney<sup>9</sup>, S. Tykodi<sup>10</sup>, M. Harrison<sup>10</sup>, D. Heng<sup>1</sup>, V. Grünwald<sup>5</sup>, T. Choueiri<sup>10</sup>, S. Mekan<sup>10</sup>, M.B. McHenry<sup>10</sup>, H. Hammers<sup>11</sup>, R. Motzer<sup>12</sup>, S. George<sup>12</sup>; <sup>1</sup>OH/US, <sup>2</sup>TX/US, <sup>3</sup>CEDEX/FR, <sup>4</sup>MA/US, <sup>5</sup>DE, <sup>6</sup>IT, <sup>7</sup>GB, <sup>8</sup>British Columbia/CA, <sup>9</sup>NSW/AU, <sup>10</sup>US, <sup>11</sup>MD/US, <sup>12</sup>NY/US
- 13:05 - 13:05 876P - A new prognostic model for overall survival (OS) in second line (2L) for metastatic renal cell carcinoma (mRCC): Development and external validation  
L. Derosa<sup>1</sup>, M.A. Bayar<sup>1</sup>, L. Albiges<sup>2</sup>, G. Le Teuff<sup>1</sup>, B. Escudier<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 13:05 - 13:05 877P - First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase 1b JAVELIN Solid Tumor trial  
U. Vaishampayan<sup>1</sup>, P. Schöffski<sup>2</sup>, A. Ravaud<sup>3</sup>, C. Borel<sup>4</sup>, T. Song<sup>5</sup>, S. Guenther<sup>6</sup>, J. Grewal<sup>1</sup>, J. Gulley<sup>7</sup>; <sup>1</sup>US, <sup>2</sup>BE, <sup>3</sup>FR, <sup>4</sup>CEDEX/FR, <sup>5</sup>MA/US, <sup>6</sup>DE, <sup>7</sup>MD/US
- 13:05 - 13:05 878P - TiNivo: Tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC).  
P. Barthelemy<sup>1</sup>, B. Escudier<sup>1</sup>, A. Ravaud<sup>2</sup>, S. Negrier<sup>1</sup>, M. Needle<sup>3</sup>, L. Albiges<sup>1</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>US

- 13:05 - 13:05 879P - Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)  
B. McGregor<sup>1</sup>, A.-K. Lalani<sup>2</sup>, W. Xie<sup>3</sup>, J. Steinharter<sup>1</sup>, D. Martini<sup>4</sup>, P. Nuzzo<sup>1</sup>, N. Martinez Chanza<sup>1</sup>, L. Harshman<sup>3</sup>, M. Bilen<sup>1</sup>, T. Choueiri<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CA, <sup>3</sup>MA/US, <sup>4</sup>GA/US
- 13:05 - 13:05 880P - Subgroups analysis and circulating biomarkers evaluation of RESORT trial: a randomized phase 2 study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of Sorafenib after metastasectomy  
G. Procopio<sup>1</sup>, F. Cognetti<sup>1</sup>, R. Miceli<sup>1</sup>, M. Milella<sup>1</sup>, A. Mosca<sup>1</sup>, V. Chiuri<sup>1</sup>, A. Bearz<sup>1</sup>, F. Morelli<sup>1</sup>, C. Ortega<sup>2</sup>, F. Atzori<sup>3</sup>, R. Passalacqua<sup>4</sup>, R. Ratta<sup>1</sup>, F.G. de Braud<sup>1</sup>, V. Cappelletti<sup>1</sup>, E. Verzoni<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(TO)/IT, <sup>3</sup>(CA)/IT, <sup>4</sup>(CR)/IT
- 13:05 - 13:05 881P - Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial  
D. George<sup>1</sup>, A. Pantuck<sup>2</sup>, R. Figlin<sup>3</sup>, B. Escudier<sup>4</sup>, S. Halabi<sup>1</sup>, M. Casey<sup>3</sup>, X. Lin<sup>2</sup>, L. Serfass<sup>5</sup>, M. Lechuga Freañ<sup>6</sup>, A. Ravaud<sup>5</sup>; <sup>1</sup>NC/US, <sup>2</sup>CA/US, <sup>3</sup>US, <sup>4</sup>CEDEX/FR, <sup>5</sup>FR, <sup>6</sup>IT
- 13:05 - 13:05 882P - Potent Natural Killer (NK) and myeloid blood cell remodeling by Cabozantinib (Cabo) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts)  
E. Verzoni<sup>1</sup>, S. Ferro<sup>1</sup>, G. Procopio<sup>1</sup>, A. Cova<sup>1</sup>, R. Ratta<sup>1</sup>, A. RAIMONDI<sup>1</sup>, P. Sepe<sup>1</sup>, P. Squarcina<sup>1</sup>, L. Lalli<sup>1</sup>, V. Huber<sup>1</sup>, D. Rinchai<sup>2</sup>, D. Bedognetti<sup>2</sup>, L. Rivoltini<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>QA
- 13:05 - 13:05 883P - Metastatic clear cell renal cell carcinoma patients with ECOG Performance Status 2 treated with Pazopanib: The Pazo2 trial of efficacy and safety.  
E. Porfiri<sup>1</sup>, S. Pirrie<sup>1</sup>, A.-M. Hodgkins<sup>1</sup>, D. Farrugia<sup>1</sup>, K. Fife<sup>2</sup>, C. McDonald-Smith<sup>1</sup>, N. Vasudev<sup>3</sup>, G. Nixon<sup>1</sup>, N. James<sup>1</sup>, C. Stubbs<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>Cambridgeshire/GB, <sup>3</sup>Yorkshire/GB
- 13:05 - 13:05 884P - Real-world effectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL Study)  
G. Procopio<sup>1</sup>, A. Bamias<sup>2</sup>, M. Schmidinger<sup>3</sup>, R. Hawkins<sup>4</sup>, A. Rodriguez Sanchez<sup>5</sup>, S. Vazquez<sup>5</sup>, N. Srihari<sup>4</sup>, H. Kalofonos<sup>6</sup>, P. Bono<sup>7</sup>, C. Pisal<sup>8</sup>, Y. Hirschberg<sup>9</sup>, L. Dezzani<sup>9</sup>, Q. Ahmad<sup>9</sup>, C. Suarez Rodriguez<sup>5</sup>, E. Jonasch<sup>10</sup>; <sup>1</sup>IT, <sup>2</sup>Attiki/GR, <sup>3</sup>AT, <sup>4</sup>GB, <sup>5</sup>ES, <sup>6</sup>GR, <sup>7</sup>FI, <sup>8</sup>IN, <sup>9</sup>US, <sup>10</sup>TX/US
- 13:05 - 13:05 885P - Are adverse events (AEs) predictive of Nivolumab activity? Data from the Italian Expanded Access Program in metastatic renal cell carcinoma (mRCC)  
E. Verzoni<sup>1</sup>, G. Carteni<sup>1</sup>, E. Cortesi<sup>1</sup>, F. Roila<sup>1</sup>, M.G. Vitale<sup>1</sup>, S. Buti<sup>1</sup>, S. Pignata<sup>1</sup>, F. Cognetti<sup>1</sup>, L. Giustini<sup>1</sup>, A. Damiani<sup>1</sup>, D. Turci<sup>1</sup>, C. Sternberg<sup>1</sup>, C. Porta<sup>1</sup>, F. Carrozza<sup>1</sup>, G. Tortora<sup>1</sup>, D. Tassinari<sup>1</sup>, R. Passalacqua<sup>2</sup>, A. Pazzola<sup>1</sup>, G. Surico<sup>1</sup>, G. Procopio<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(CR)/IT
- 13:05 - 13:05 886P - Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance  
G. Sun, X. Zhang, J. Zhao, J. Chen, P. Shen, Z. Liu, H. Zeng; CN
- 13:05 - 13:05 887P - Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC)

A. Guida<sup>1</sup>, G. Le Teuff<sup>2</sup>, E. Colomba<sup>2</sup>, G. Baciarello<sup>3</sup>, L. Derosa<sup>2</sup>, Y. Lorient<sup>2</sup>, K. Fizazi<sup>2</sup>, C. Massard<sup>3</sup>, B. Escudier<sup>3</sup>, L. Albiges<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>FR, <sup>3</sup>CEDEX/FR

13:05 - 13:05 888P - Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

S. Verhoeff<sup>1</sup>, S. Es<sup>1</sup>, E. Boon<sup>1</sup>, E. van Helden<sup>1</sup>, L. Angus<sup>1</sup>, S. Elias<sup>1</sup>, S. Oosting<sup>1</sup>, E. Aarntzen<sup>1</sup>, A. Brouwers<sup>1</sup>, S. Heskamp<sup>1</sup>, O. Hoekstra<sup>1</sup>, H. Verheul<sup>1</sup>, A. Van der Veldt<sup>1</sup>, E.G.E. de Vries<sup>1</sup>, O. Boerman<sup>1</sup>, W. van der Graaf<sup>2</sup>, W. Oyen<sup>1</sup>, C. van Herpen<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>Surrey/GB

13:05 - 13:05 889P - Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors (TKI) and Mammalian Target of Rapamycin Inhibitors (mTORI) after Immuno-oncology (IO) Checkpoint Inhibitors

J. Graham<sup>1</sup>, J. Wells<sup>1</sup>, R. McKay<sup>2</sup>, U. Vaishampayan<sup>2</sup>, A. Hansen<sup>3</sup>, F. Donskov<sup>4</sup>, G. Bjarnason<sup>3</sup>, B. Beuselinck<sup>5</sup>, G. De Velasco<sup>6</sup>, M. Duh<sup>2</sup>, L. Huynh<sup>2</sup>, R. Chang<sup>2</sup>, G. Zanotti<sup>2</sup>, K. Ramaswamy<sup>2</sup>, T. Choueiri<sup>2</sup>, D. Heng<sup>7</sup>; <sup>1</sup>CA, <sup>2</sup>US, <sup>3</sup>Ontario/CA, <sup>4</sup>DK, <sup>5</sup>BE, <sup>6</sup>ES, <sup>7</sup>OH/US

13:05 - 13:05 890P - Everolimus as first-line or after cytokine therapy in patients with metastatic recurrent and/or unresectable renal cell carcinoma (RCC) (EVERMORE)

A. Abdel Hakim<sup>1</sup>, Y. Noura<sup>2</sup>, R. Taran<sup>3</sup>, D. Amokrane<sup>4</sup>, M. Ghosn<sup>5</sup>, B. Larbaoui<sup>4</sup>, C. Pripatnanont<sup>6</sup>, K. Slimane<sup>7</sup>, V. Pilipovic<sup>8</sup>, H. Boussen<sup>2</sup>; <sup>1</sup>EG, <sup>2</sup>TN, <sup>3</sup>IN, <sup>4</sup>DZ, <sup>5</sup>LB, <sup>6</sup>TH, <sup>7</sup>FR, <sup>8</sup>CH

13:05 - 13:05 891P - Correlation between Immuno-Related Adverse Events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study.

M.G. Vitale, S. Pipitone, S. Scagliarini, P.A. Zucali, L. Galli, S. Rossetti, C. Caserta, R. Iacovelli, C. Masini, C. Ficorella, S. Di Girolamo, S. Buti, B. Benedetti, M. Santoni, C. Porta, S. Bracarda, C. Baldessari, S. Giaquinta, S. Cascinu, R. Sabbatini; IT

13:05 - 13:05 892P - Treatment sequences in metastatic renal cell carcinoma: efficacy results from the Czech registry (RENIS)

J. Finek<sup>1</sup>, R. Demlova<sup>2</sup>, K. Kopeckova<sup>3</sup>, T. Buchler<sup>4</sup>, B. Melichar<sup>5</sup>, J. Prausova<sup>3</sup>, A. Poprach<sup>2</sup>, T. Hrnčiarova<sup>5</sup>, T. Mlcoch<sup>5</sup>, T. Dolezal<sup>5</sup>; <sup>1</sup>Pízen/CZ, <sup>2</sup>South Moravian/CZ, <sup>3</sup>5/CZ, <sup>4</sup>4/CZ, <sup>5</sup>CZ

13:05 - 13:05 893P - Cabozantinib in metastatic renal cell carcinoma (mRCC): data from UK expanded access program (EAP)

A. Gomez de Liano Lista<sup>1</sup>, B. Venugopal<sup>2</sup>, K. Fife<sup>3</sup>, S. Symeonides<sup>2</sup>, N. Vasudev<sup>4</sup>, S. Rudman<sup>2</sup>, S. Vohra<sup>2</sup>, L. Khasati<sup>2</sup>, C. Pettinger<sup>2</sup>, B. Szabados<sup>2</sup>, L. Morrison<sup>2</sup>, T. Powles<sup>2</sup>, E. Boleti<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>GB, <sup>3</sup>Cambridgeshire/GB, <sup>4</sup>Yorkshire/GB

13:05 - 13:05 894P - Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)

N. Dizman<sup>1</sup>, P. Bergerot<sup>2</sup>, C. Bergerot<sup>2</sup>, E. Philip<sup>1</sup>, M. Salgia<sup>1</sup>, J. Hsu<sup>2</sup>, J. Adashek<sup>2</sup>, S. Pal<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>CA/US

13:05 - 13:05 895P - Advanced Treatment Line (ATL) with Lenvatinib and Everolimus (Len+Eve) for Metastatic Renal Cell Carcinoma (mRCC); Analysis of a National Early Access Program (EAP).

A. Peer, M. Kolin, K. Rouvinov, D. Keizman, D. Sarid, R. Leibowitz-Amit, R. Berger, A. Sella, A. Rasco, E. Rosenbaum, C. maurice-drdr, A. Neumann, V. Neiman; IL

- 13:05 - 13:05 896P - Predictive radiomics signature for treatment response to nivolumab in patients (pts) with advanced renal cell carcinoma (RCC)  
H.-W. Sim<sup>1</sup>, A. Stundzia<sup>2</sup>, S. Pierre<sup>2</sup>, U. Metser<sup>2</sup>, M. O'Malley<sup>2</sup>, E. Elimova<sup>2</sup>, S. Sridhar<sup>1</sup>, A. Hansen<sup>1</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA
- 13:05 - 13:05 897P - A phase 1b study of safety and preliminary efficacy of extracranial stereotactic body radiation therapy (SBRT) in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy  
N. Dengina<sup>1</sup>, T. Mitin<sup>2</sup>, S. Gamayunov<sup>1</sup>, S. Safina<sup>1</sup>, Y. Kreinina<sup>1</sup>, I. Tsimafeyu<sup>1</sup>; <sup>1</sup>RU, <sup>2</sup>OR/US
- 13:05 - 13:05 898P - VOTRAGE study Pazopanib in a population of "frail" elderly patients after geriatric assessment. A phase I study with geriatric criteria.  
L. Mourey<sup>1</sup>, A. Ravaud<sup>1</sup>, L. Digue<sup>1</sup>, B. Cabarro<sup>1</sup>, C. Gomez-Roca<sup>2</sup>, T. Valentin<sup>1</sup>, P. Olivier<sup>1</sup>, A. Fabre<sup>1</sup>, M. Mounier<sup>1</sup>, L. Balardy<sup>1</sup>, T. Filleron<sup>3</sup>; <sup>1</sup>FR, <sup>2</sup>Haute-Garonne/FR, <sup>3</sup>CEDEX 3/FR
- 13:05 - 13:05 899P - A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS)  
D. Castellano<sup>1</sup>, I. Duran<sup>1</sup>, A. Rodríguez-Vida<sup>1</sup>, S. Crabb<sup>2</sup>, M. van der Heijden<sup>3</sup>, A. Font Pous<sup>4</sup>, G. Gravis<sup>5</sup>, U. Anido Herranz<sup>6</sup>, A. Protheroe<sup>7</sup>, A. Ravaud<sup>8</sup>, D. Maillet<sup>9</sup>, M. Mendez-Vidal<sup>1</sup>, C. Suarez<sup>1</sup>, A. Lorch<sup>10</sup>, C. Sternberg<sup>11</sup>, M. Linch<sup>2</sup>, S.-J. Sarker<sup>2</sup>, J. Notta<sup>2</sup>, K. Mousa<sup>2</sup>, T. Powles<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>GB, <sup>3</sup>NL, <sup>4</sup>Barcelona/ES, <sup>5</sup>CEDEX 9/FR, <sup>6</sup>La Coruña/ES, <sup>7</sup>Oxfordshire/GB, <sup>8</sup>FR, <sup>9</sup>CEDEX/FR, <sup>10</sup>DE, <sup>11</sup>IT
- 13:05 - 13:05 900P - Interim results of fight-201, a phase 2, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)  
A. Necchi<sup>1</sup>, D. Pouessel<sup>2</sup>, R. Leibowitz-Amit<sup>3</sup>, A. Flechon<sup>2</sup>, S. Gupta<sup>4</sup>, P. Barthelemy<sup>2</sup>, M. Maio<sup>1</sup>, X. Zhu<sup>5</sup>, E. Asatiani<sup>6</sup>, G. Serbest<sup>4</sup>, H. Zhen<sup>4</sup>, Y. Loriot<sup>7</sup>; <sup>1</sup>IT, <sup>2</sup>CEDEX/FR, <sup>3</sup>IL, <sup>4</sup>US, <sup>5</sup>NY/US, <sup>6</sup>DC/CH, <sup>7</sup>FR
- 13:05 - 13:05 901P - Impact of Prognostic Factors and Risk Groups on Overall Survival (OS) in Patients Treated With Pembrolizumab vs Investigator's Choice Chemotherapy for advanced Urothelial Cancer (UC): Post Hoc Analysis of KEYNOTE-045  
J. Bellmunt<sup>1</sup>, R. de Wit<sup>2</sup>, D. Vaughn<sup>3</sup>, Y. Fradet<sup>4</sup>, J.L. Lee<sup>5</sup>, L. Fong<sup>6</sup>, N. Vogelzang<sup>7</sup>, M. Climent<sup>8</sup>, D. Petrylak<sup>9</sup>, T. Choueiri<sup>1</sup>, A. Necchi<sup>10</sup>, W. Gerritsen<sup>2</sup>, H. Gurney<sup>11</sup>, D. Quinn<sup>6</sup>, S. Culine<sup>12</sup>, C. Sternberg<sup>10</sup>, E. Jensen<sup>13</sup>, T. Frenkl<sup>13</sup>, R. Perini<sup>13</sup>, D. Bajorin<sup>9</sup>; <sup>1</sup>MA/US, <sup>2</sup>NL, <sup>3</sup>PA/US, <sup>4</sup>QC/CA, <sup>5</sup>KR, <sup>6</sup>CA/US, <sup>7</sup>NV/US, <sup>8</sup>ES, <sup>9</sup>US, <sup>10</sup>IT, <sup>11</sup>NSW/AU, <sup>12</sup>CEDEX 10/FR, <sup>13</sup>NJ/US
- 13:05 - 13:05 902P - Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)  
M. Galsky<sup>1</sup>, R. Banchereau<sup>2</sup>, E. Kadel, III<sup>2</sup>, T. Ramirez-Montagut<sup>2</sup>, S. Mariathasan<sup>1</sup>, A. Thåström<sup>2</sup>, J. Rosenberg<sup>3</sup>, T. Powles<sup>4</sup>, M. van der Heijden<sup>5</sup>, A. Necchi<sup>6</sup>; <sup>1</sup>US, <sup>2</sup>CA/US, <sup>3</sup>NY/US, <sup>4</sup>GB, <sup>5</sup>NL, <sup>6</sup>IT
- 13:05 - 13:05 903P - Neuroendocrine carcinoma of the urinary bladder: a large analysis of the French GETUG consortium

M. Sroussi<sup>1</sup>, M. Lorcet<sup>1</sup>, M. Tardy<sup>1</sup>, M. Guerin<sup>2</sup>, F. Estrade<sup>1</sup>, R. Delva<sup>1</sup>, P. Barthelemy<sup>3</sup>, P. Lavaud<sup>1</sup>, Y. Neuzillet<sup>1</sup>, N. Penel<sup>3</sup>, N. Houede<sup>1</sup>, D. Pouessel<sup>1</sup>, E. Mussat<sup>1</sup>, M. Gross Goupil<sup>1</sup>, H. Gauthier<sup>1</sup>, A. Gobert<sup>1</sup>, O. Huillard<sup>4</sup>, Y. Allory<sup>1</sup>, R.-T. Elaidi<sup>1</sup>, S. Oudard<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 9/FR, <sup>3</sup>CEDEX/FR, <sup>4</sup>CEDEX 14/FR

- 13:05 - 13:05 904P - Impact of different programmed cell death ligand-1 (PD-L1) expression algorithms on patient selection and durvalumab efficacy in urothelial carcinoma (UC)  
J. Walker<sup>1</sup>, M. Zajac<sup>2</sup>, J. Ye<sup>3</sup>, M. Scott<sup>2</sup>, M. Ratcliffe<sup>2</sup>, P. Scorer<sup>2</sup>, C. Barker<sup>2</sup>, H. Al-Masri<sup>4</sup>, M. Rebelatto<sup>3</sup>, A. Gupta<sup>2</sup>, P. Mukhopadhyay<sup>3</sup>, S. Ferro<sup>3</sup>, T. Powles<sup>2</sup>, J. Williams<sup>2</sup>; <sup>1</sup>NL, <sup>2</sup>GB, <sup>3</sup>US, <sup>4</sup>IL/US
- 13:05 - 13:05 905P - CD103+ Tissue-resident CD8+ T Cells Correlate with Protective Anti-tumoral Immune Responses in Muscle-invasive Bladder Cancer Patients  
Z. Liu, J. Zhang, B. Dai; CN
- 13:05 - 13:05 906P - Immune-checkpoint inhibitors in previously treated patients with urothelial carcinoma: a systematic review and meta-analysis.  
E. De Luca, V. Di Nunno, C. Buttigliero, M. Tucci, F. Vignani, C. Zichi, A. Ardizzoni, F. Massari, M. Di Maio; IT
- 13:05 - 13:05 907P - Match-adjusted indirect comparison of durvalumab and chemotherapy for locally advanced or metastatic urothelial carcinoma (UC) following failure of platinum-based therapy  
C. Hoyle<sup>1</sup>, A. Klein<sup>1</sup>, K. Patel<sup>1</sup>, N. Shire<sup>1</sup>, H. Wang<sup>1</sup>, B.C. Chu<sup>2</sup>, M. Ouwens<sup>1</sup>, B. Nordstrom<sup>3</sup>, L. Horne<sup>1</sup>, H.-T. Arkenau<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>CA/US, <sup>3</sup>MA/US
- 13:05 - 13:05 908P - Comparative effectiveness of neoadjuvant chemotherapy followed by cystectomy versus cystectomy followed by adjuvant chemotherapy versus palliative chemotherapy versus cystectomy for node –positive bladder cancer: A retrospective analysis: KCSG GU 17-03  
J.H. Byun<sup>1</sup>, H.A. Jung<sup>2</sup>, W.-K. Bae<sup>1</sup>, H.-J. Lee<sup>1</sup>, S.H. Park<sup>1</sup>, H.J. Kim<sup>1</sup>, C.H. Maeng<sup>1</sup>, I. Park<sup>1</sup>, B.S. Sohn<sup>1</sup>, J.A. Kim<sup>1</sup>, K.H. Lee<sup>1</sup>, D.H. Im<sup>1</sup>, J.H. Kim<sup>1</sup>, H. Jang<sup>1</sup>, S.M. Kim<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>Gyeong-Ki-Do/KR
- 13:05 - 13:05 909P - Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer  
L. Nappi<sup>1</sup>, M. Thi<sup>1</sup>, B. Eigl<sup>2</sup>, A. Lum<sup>1</sup>, D. Huntsman<sup>2</sup>, C. Martin<sup>3</sup>, B. O Neil<sup>3</sup>, D. Khalaf<sup>4</sup>, K. Chi<sup>2</sup>, M. Gleave<sup>4</sup>, A. So<sup>1</sup>, P. Black<sup>1</sup>, S. Daneshmand<sup>5</sup>, C. Nichols<sup>6</sup>, C. Kollmannsberger<sup>2</sup>; <sup>1</sup>BC/CA, <sup>2</sup>British Columbia/CA, <sup>3</sup>UT/US, <sup>4</sup>CA, <sup>5</sup>CA/US, <sup>6</sup>US
- 13:05 - 13:05 910P - Increased risk of non-germ cell second cancer (SC) after cisplatin-based chemotherapy (CBCT) in 1-year testicular cancer (TC) survivors (TCS)  
R. Hellesnes, Ø. Kvammen, R. Bremnes, A. Karlsdottir, T.Å. Myklebust, H. Negaard, T. Tandstad, T. Wilsgaard, S. Fosså, H. Haugnes; NO
- 13:05 - 13:05 911P - Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy (CT)  
J. Stelwagen, S. Lubberts, L. Steggink, G. Steursma, L. Kruyt, J. Donkerbroek, A. van Roon, A. van Gessel, S. van de Zande, C. Meijer, J. Wempe, C. Gräfin zu Eulenburg, J. Nuver, A. Walenkamp, J. Lefrandt, J. Gietema; NL
- 13:05 - 13:05 912P - Sexual function and quality of life in a national cohort of bilateral testicular cancer survivors



M. Bandak, J. Lauritsen, C. Johansen, M. Kreiberg, J. Skøtt, M. Agerbaek, N. Holm, K.G. Daugaard; DK

- 13:05 - 13:05 913P - The prognostic value of DNA damage level in peripheral blood lymphocytes in germ cell cancer patients.  
M. Mego<sup>1</sup>, Z. Sestakova<sup>1</sup>, K. Kalavska<sup>1</sup>, L. Hurbanova<sup>1</sup>, D. Jurkovicova<sup>1</sup>, J. Gursky<sup>1</sup>, M. Chovanec<sup>1</sup>, D. Svetlovska<sup>1</sup>, V. Miskovska<sup>2</sup>, J. Obertova<sup>1</sup>, P. Palacka<sup>1</sup>, K. Rejlekova<sup>1</sup>, Z. Sycova-Mila<sup>1</sup>, J. Mardiak<sup>1</sup>, M. Chovanec<sup>1</sup>; <sup>1</sup>SK, <sup>2</sup>Slovak republic/SK
- 13:05 - 13:05 914P - Intermediate prognosis in metastatic germ cell tumors (IPGCT) – Outcome and prognostic stratification  
C. Seidel<sup>1</sup>, K.G. Daugaard<sup>2</sup>, A. Tryakin<sup>3</sup>, A. Necchi<sup>4</sup>, G. Cohn Cedermark<sup>5</sup>, O. Ståhl<sup>5</sup>, M. Hentrich<sup>1</sup>, M. Brito<sup>6</sup>, C. Albany<sup>7</sup>, F. Taza<sup>7</sup>, A. Gerl<sup>1</sup>, K. Oechsle<sup>1</sup>, C. Oing<sup>1</sup>, C. Bokemeyer<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>DK, <sup>3</sup>RU, <sup>4</sup>IT, <sup>5</sup>SE, <sup>6</sup>PT, <sup>7</sup>US
- 13:05 - 13:05 915P - Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)  
R. Huddart<sup>1</sup>, F. Cafferty<sup>2</sup>, J. White<sup>2</sup>, J. Shamash<sup>2</sup>, I. Hennig<sup>3</sup>, M. Cullen<sup>2</sup>, S. Stenning<sup>2</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>GB, <sup>3</sup>Nottinghamshire/GB
- 13:05 - 13:05 916P - Sunitinib tolerance following an initial exposure period: results of longitudinal PRO data from S-TRAC study  
D. George<sup>1</sup>, R. Figlin<sup>2</sup>, R. Motzer<sup>3</sup>, J. Paty<sup>2</sup>, M. Lechuga Freañ<sup>4</sup>, G. Zanotti<sup>2</sup>, H. Bhattacharyya<sup>2</sup>, K. Ramaswamy<sup>2</sup>, L. Deannuntis<sup>5</sup>, A. Ravaud<sup>6</sup>; <sup>1</sup>NC/US, <sup>2</sup>US, <sup>3</sup>NY/US, <sup>4</sup>IT, <sup>5</sup>PA/US, <sup>6</sup>FR
- 13:05 - 13:05 917TiP - Phase II study of paclitaxel and TAK-228 in metastatic urothelial carcinoma and the impact of PI3K-mTOR pathway genomic alterations  
A. Rodríguez-Vida<sup>1</sup>, J.L. Pérez-Gracia<sup>1</sup>, A. Taus<sup>1</sup>, T. Bonfill<sup>1</sup>, F. Vázquez-Mazón<sup>1</sup>, S. Galtes<sup>1</sup>, B. Pons<sup>1</sup>, L. Cano<sup>1</sup>, S. Macia<sup>2</sup>, P. Maroto<sup>1</sup>, J. Bellmunt<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>Madrid/ES
- 13:05 - 13:05 918TiP - EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy  
J. Rosenberg<sup>1</sup>, A. Balar<sup>2</sup>, P. O'Donnell<sup>3</sup>, E. Heath<sup>2</sup>, N. Hahn<sup>2</sup>, N. Cavazos<sup>4</sup>, A. Melhem-Bertrandt<sup>3</sup>, D. Petrylak<sup>5</sup>; <sup>1</sup>NY/US, <sup>2</sup>US, <sup>3</sup>IL/US, <sup>4</sup>WA/US, <sup>5</sup>CT/US
- 13:05 - 13:05 919TiP - The potential of patient reported outcomes in urothelial cancer patients receiving immuno- or chemotherapy – a feasibility study of electronic reporting in an aging and comorbid population.  
G. Taarnhøj, H. Lindberg, H. Pappot, L. Dohn, C. Johansen; DK
- 13:05 - 13:05 920TiP - Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients (pts) With Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRalt): the Phase 3 THOR Study  
Y. Loriot<sup>1</sup>, A. Necchi<sup>2</sup>, S.H. Park<sup>3</sup>, R. Huddart<sup>4</sup>, E. Burgess<sup>5</sup>, B. Zhong<sup>6</sup>, A. Santiago-Walker<sup>7</sup>, S. Little<sup>6</sup>, T. Roccia<sup>8</sup>, P. De Porre<sup>9</sup>, A. Siefker-Radtke<sup>10</sup>; <sup>1</sup>FR, <sup>2</sup>IT, <sup>3</sup>KR, <sup>4</sup>Surrey/GB, <sup>5</sup>NC/US, <sup>6</sup>PA/US, <sup>7</sup>US, <sup>8</sup>New Jersey/US, <sup>9</sup>BE, <sup>10</sup>TX/US

- 13:05 - 13:05 921TiP - An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease Associated Renal Cell Carcinoma  
E. Jonasch<sup>1</sup>, E. Park<sup>2</sup>, S. Thamake<sup>3</sup>, M. Hirmand<sup>2</sup>, R. Srinivasan<sup>2</sup>; <sup>1</sup>TX/US, <sup>2</sup>US, <sup>3</sup>CA/US
- 13:05 - 13:05 922TiP - EV-301: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (la/mUC)  
D. Petrylak<sup>1</sup>, J. Rosenberg<sup>2</sup>, I. Duran<sup>3</sup>, Y. Loriot<sup>4</sup>, G. Sonpavde<sup>5</sup>, C. Wu<sup>6</sup>, E. Gartner<sup>7</sup>, A. Melhem-Bertrandt<sup>6</sup>, T. Powles<sup>8</sup>; <sup>1</sup>CT/US, <sup>2</sup>NY/US, <sup>3</sup>ES, <sup>4</sup>FR, <sup>5</sup>MA/US, <sup>6</sup>IL/US, <sup>7</sup>US, <sup>8</sup>GB
- 13:05 - 13:05 923TiP - A phase 2 study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations  
A. Necchi<sup>1</sup>, J.L. Pérez-Gracia<sup>2</sup>, Y. Loriot<sup>3</sup>, W. Witjes<sup>4</sup>, F. Montorsi<sup>1</sup>, A. Bjartell<sup>5</sup>, S. Shariat<sup>6</sup>; <sup>1</sup>IT, <sup>2</sup>ES, <sup>3</sup>FR, <sup>4</sup>NL, <sup>5</sup>SE, <sup>6</sup>AT
- 13:05 - 13:05 924TiP - A Phase I Study of HERV-E TCR Transduced Autologous T Cells (HERV-E TCR T Cells) in Patients (pts) with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)  
R. Nadal, E. Cherkasova, S. Barisic, D. Granadier, G. Aue, B. Wells, G. Hawks, T. Hughes, R. Shalabi, D. Stroncek, S. Highfill, G. Scurti, L. Chen, R. Reger, M. Nishimura, R. Childs; US
- 13:05 - 13:05 925TiP - Phase 1b/2 study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression  
J. Rosenberg<sup>1</sup>, A. Necchi<sup>2</sup>, R. Sweis<sup>3</sup>, K. Nakajima<sup>4</sup>, C. Lu<sup>4</sup>, H. Nogai<sup>5</sup>; <sup>1</sup>NY/US, <sup>2</sup>IT, <sup>3</sup>IL/US, <sup>4</sup>NJ/US, <sup>5</sup>DE
- 13:05 - 13:05 926TiP - Neo-adjuvant ipilimumab and nivolumab in high risk resectable bladder urothelial cancer (NABUCCO)  
N. van Dijk, C. Blank, P. Kvistborg, T. Schumacher, E. Hooijberg, K. Sikorska, B. Rhijn, M. van der Heijden; NL
- 13:05 - 13:05 927TiP - A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Nivolumab Plus Ipilimumab in Patients (pts) With Localized Renal Cell Carcinoma (RCC) Who Are at High Risk Of Relapse After Radical or Partial Nephrectomy (CheckMate 914)  
A. Bex<sup>1</sup>, V. Grünwald<sup>2</sup>, P. Russo<sup>3</sup>, Y. Tomita<sup>4</sup>, E. Berghorn<sup>3</sup>, M.B. McHenry<sup>3</sup>, R. Motzer<sup>5</sup>; <sup>1</sup>NL, <sup>2</sup>DE, <sup>3</sup>US, <sup>4</sup>JP, <sup>5</sup>NY/US
- 13:05 - 13:05 928TiP - ATLAS: a phase 2, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma  
S. Chowdhury<sup>1</sup>, S. Feyerabend<sup>2</sup>, Y. Loriot<sup>3</sup>, A. Necchi<sup>4</sup>, S. Gupta<sup>5</sup>, D. Josephs<sup>1</sup>, A. Rodríguez-Vida<sup>6</sup>, S. Srinivas<sup>7</sup>, Y. Zakharia<sup>5</sup>, D. Nepert<sup>5</sup>, K. Wride<sup>5</sup>, D. Thomas<sup>5</sup>, A. Loehr<sup>5</sup>, A. Simmons<sup>7</sup>, P. Grivas<sup>8</sup>; <sup>1</sup>GB, <sup>2</sup>DE, <sup>3</sup>FR, <sup>4</sup>IT, <sup>5</sup>US, <sup>6</sup>ES, <sup>7</sup>CA/US, <sup>8</sup>OH/US
- 13:05 - 13:05 929TiP - BAYOU: Phase 2 Study of Efficacy and Safety of Durvalumab plus Olaparib as First-line Therapy in Platinum-ineligible Patients (pts) with Stage IV Urothelial Cancer (UC)  
J. Rosenberg<sup>1</sup>, D. Bajorin<sup>2</sup>, A. Smith<sup>3</sup>, C. D'cruz<sup>2</sup>, M. Lanasa<sup>2</sup>; <sup>1</sup>NY/US, <sup>2</sup>US, <sup>3</sup>GB

- 13:05 - 13:05 930TiP - Phase 2/3 study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression  
C. Sternberg<sup>1</sup>, J. Bellmunt<sup>2</sup>, H. Nishiyama<sup>3</sup>, D. Petrylak<sup>4</sup>, D. Quinn<sup>5</sup>, K. Nakajima<sup>6</sup>, C. Lu<sup>6</sup>, A. Holynskij<sup>7</sup>; <sup>1</sup>IT, <sup>2</sup>MA/US, <sup>3</sup>JP, <sup>4</sup>CT/US, <sup>5</sup>CA/US, <sup>6</sup>NJ/US, <sup>7</sup>US
- 13:05 - 13:05 931TiP - PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma  
F. Collinson<sup>1</sup>, S. Brown<sup>1</sup>, H. Buckley<sup>1</sup>, G. Ainsworth<sup>1</sup>, H. Howard<sup>1</sup>, H. Poad<sup>1</sup>, G. Carr<sup>1</sup>, R. Banks<sup>1</sup>, J. Brown<sup>1</sup>, G. Velikova<sup>2</sup>, J. Larkin<sup>1</sup>, P. Nathan<sup>3</sup>, T. Powles<sup>1</sup>, N. Vasudev<sup>2</sup>; <sup>1</sup>GB, <sup>2</sup>Yorkshire/GB, <sup>3</sup>Middlesex/GB
- 13:05 - 13:05 1516P - Effectiveness of a Randomized Control Trial of an Individualized, Interactive Advance Care Planning Intervention in Improving Terminally Ill Cancer Patients' Psychological Symptoms, Quality of Life and Concordance between Preferred and Received Life-Sustaining Treatments  
S.T. Tang, J.-S. Chen, W.-C. Chou; TW
- 13:05 - 13:05 1517P - Current status of the integration of oncology and palliative care in Japan: A nationwide survey.  
U. Yu, K. Sato, T. Morita, M. Mori, C. Shimizu, Y. Horie, M. Hirakawa, T. Nakajima, S. Tsuneto, M. Muto; JP
- 13:05 - 13:05 1518P - Access to Palliative Care before death in French cancer patients during the two first years after diagnosis: the national cancer cohort  
M. Bendiane, A. Janah, D. Leufeuve, P.-J. Bousquet; FR
- 13:05 - 13:05 1519P - Anticancer therapy at the end of life of breast, prostate, and colorectal cancer patients  
V. Heidt, K. Hermes-Moll, K. Blaschke, V. Lappe, P. Ihle, I. Schubert, W. Baumann; DE
- 13:05 - 13:05 1520P - Perspectives and attitudes towards the integration of oncology and palliative care in Japan: A nationwide survey.  
U. Yu, K. Sato, T. Morita, M. Mori, C. Shimizu, Y. Horie, M. Hirakawa, T. Nakajima, S. Tsuneto, M. Muto; JP
- 13:05 - 13:05 1521P - Evolving Concurrent Integration of Oncology and Palliative Care at an ESMO Designated Center over a Decade  
F. Strasser, T. Silzle, E. Schmidt; CH
- 13:05 - 13:05 1522P - The impact of inclusion in home palliative program and distance to hospital on chemotherapy near end of life  
J. Balsalobre, A. Checa-Soriano, P. Cerezuela-Fuentes, M. Martínez-Penella, M.J. Martínez-Ortiz, J.L. Alonso-Romero, M.I. Luengo-Alcázar, M.T. García-García; ES
- 13:05 - 13:05 1523P - Cancer patients' perceptions of palliative care  
J. Yoong<sup>1</sup>, B. Chosich<sup>2</sup>, M. Burgess<sup>2</sup>, A. Earnest<sup>2</sup>, F. Runacres<sup>2</sup>, L. William<sup>1</sup>, M. Franco<sup>2</sup>, P. Poon<sup>1</sup>; <sup>1</sup>AU, <sup>2</sup>VIC/AU
- 13:05 - 13:05 1524P - Multicenter Feasibility Study of Physician Orders for Life-Sustaining Treatment (POLST) for Terminal Cancer Patients

H.J. An, H.J. Jeon, J. Cheon, S.H. Chun, H.A. Jung, H.K. Ahn, K.H. Lee, M.-H. Kim, J.H. Kim, S. Kim, S.-J. Koh; KR

- 13:05 - 13:05 1525P - Palliative care in advanced cancer, a clinical and ethical goal achieved?  
J. Sanchez<sup>1</sup>, R. Gomez-Bravo<sup>1</sup>, A. Morito Aguilar<sup>1</sup>, A. Royuela<sup>1</sup>, B. Núñez García<sup>1</sup>, T. Tojar<sup>1</sup>, A. Ruano Ravina<sup>1</sup>, C. Parejo<sup>1</sup>, B. Cantos<sup>1</sup>, M. Provencio Pulla<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>Madrid/ES
- 13:05 - 13:05 1526P - The experience of Onco-Palliative care Multidisciplinary Meetings in Hotel Dieu de France University Hospital, an ESMO Designated Center of Integrated Oncology and Palliative Care  
A. Houchan<sup>1</sup>, T. Assi<sup>2</sup>, Z. Bakouny<sup>1</sup>, E. El Rassy<sup>1</sup>, A. Tohme<sup>1</sup>, M.C. Mouhawej<sup>1</sup>, J. Kattan<sup>1</sup>; <sup>1</sup>LB, <sup>2</sup>FR
- 13:05 - 13:05 1527P - End of life resource utilization among patients receiving immunotherapy for advanced cancer  
J. Burkart<sup>1</sup>, S. Patel<sup>2</sup>, A. Noonan<sup>2</sup>, P. Monk<sup>2</sup>, C. Presley<sup>2</sup>, T. Olencki<sup>2</sup>, K. Kendra<sup>2</sup>, G. Otterson<sup>2</sup>, J. Gustin<sup>2</sup>, L. Wei<sup>2</sup>, D. Owen<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>OH/US
- 13:05 - 13:05 1528P - Palliative chemotherapy for patient with advanced tumor and poor performance status: are oncologists' hopes of benefit justified?  
V. Vasconcellos, R. Bonadio, G. Avanco, M. Negrão, R. Riechelmann; BR
- 13:05 - 13:05 1529P - Integration of Oncology and Palliative Care  
S. Kaasa<sup>1</sup>, J.H. Loge<sup>1</sup>, T. Albrecht<sup>2</sup>, E. Bruera<sup>3</sup>, A. Caraceni<sup>4</sup>, A. Cervantes<sup>5</sup>, I. Higginson<sup>6</sup>, K. Jordan<sup>7</sup>, P. Sjøgren<sup>8</sup>, P. Stone<sup>6</sup>, C. Zimmermann<sup>9</sup>, T. Lundebj<sup>1</sup>; <sup>1</sup>NO, <sup>2</sup>SI, <sup>3</sup>US, <sup>4</sup>IT, <sup>5</sup>ES, <sup>6</sup>GB, <sup>7</sup>DE, <sup>8</sup>DK, <sup>9</sup>CA
- 13:05 - 13:05 1530P - Understandability of the Standard Arabic Translation of the EORTC QLQ-C15-PAL Questionnaire by Egyptian Patients with Incurable Cancer  
H. Masoud, S.-E. Abdelmoneim, M. Ismael, S. Alsirafy; EG
- 13:05 - 13:05 1531P - How to Practice Oncology With a Supportive and Palliative Care Ambulatory Unit: A French Experience (HOASIS)  
A. Gonzalez Moya, H. Bourgeois; FR
- 13:05 - 13:05 1532P - Prognostic impact of end-of-life chemotherapy in the last weeks for patients with advanced cancer  
S. Hiramoto<sup>1</sup>, A. Kikuch<sup>2</sup>, T. Hori<sup>2</sup>, A. Yoshioka<sup>2</sup>, T. Tamaki<sup>2</sup>; <sup>1</sup>Shiga Otsu/JP, <sup>2</sup>JP
- 13:05 - 13:05 1533P - A novel electronic tool to implement palliative sedation (PS) in a department of Oncologic Medicine  
A. Saviola, S. Cascinu, M. Salati, G. Longo, C. Fiorani, L. Ferrara, N. Malavasi, R. Postiglione, F. Cantile, L. Scarabelli, M. Rimini, F. Ferri; IT
- 13:05 - 13:05 1534P - Congruence between actual place of death and preferences of Egyptian patients with advanced cancer and their family caregivers  
S. Alsirafy<sup>1</sup>, O. Zaki<sup>2</sup>, N. Ibrahim<sup>1</sup>, W. Elsherief<sup>1</sup>, A. Hammad<sup>1</sup>; <sup>1</sup>EG, <sup>2</sup>Cairo/EG
- 13:05 - 13:05 1535P - Sarawak, Healthcare Professionals' Perception Of Palliative Care at End Of Life  
C. Cheah<sup>1</sup>, L. Winnie<sup>1</sup>, A. Merriman<sup>2</sup>, N.I. Mohd Naseri<sup>1</sup>, S. Chew<sup>3</sup>; <sup>1</sup>MY, <sup>2</sup>UG, <sup>3</sup>GB

- 13:05 - 13:05 1536P - Factors associated with length of stay in an acute palliative care unit - a retrospective analysis  
D. Hausner<sup>1</sup>, A. Pope<sup>1</sup>, N. Kevork<sup>2</sup>, L. Le<sup>2</sup>, C. Zimmermann<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>ON/CA
- 13:05 - 13:05 1537P - Medical-Aid-in-Dying Use in the US Pacific Northwest  
C. Blanke<sup>1</sup>, M. Leblanc<sup>1</sup>, D. Hershman<sup>1</sup>, F. Meyskens<sup>1</sup>, L. Taylor<sup>2</sup>, L. Ellis<sup>3</sup>; <sup>1</sup>OR/US, <sup>2</sup>US, <sup>3</sup>TX/US
- 13:05 - 13:05 1538TiP - Brain Metastases in Norway - A Prospective Cohort Study  
O. Yri, M. Smebye, M. Hjermsstad, A. Karlson, N. Aass, J.H. Loge, S. Kaasa; NO
- 13:05 - 13:05 1541P - Partners' perceptions of women's body image problems and satisfaction of breast reconstruction long-term after risk-reducing mastectomy  
L. Bai, B. Arver, H. Johansson, M. Wickman, K. Sandelin, Y. Brandberg; SE
- 13:05 - 13:05 1542P - The Effect of Music on the Instant Anxiety Levels of Oncologic Patients Receiving Chemotherapy Treatment  
A. Alacacioglu, G. Dissiz, S. iriz, A. USLUOGLU, N. ASIK; TR
- 13:05 - 13:05 1543P - Ostracism In Adolescent Cancer Patients And Predictors (OSTRACA Study): A Study Of The Palliative Care Working Committee Of The Turkish Oncology Group (TOG)  
A. Alkan, Z.G. Güç, T. Şakalar, G. Zengin, A. Yaşar, Y. Karakas, T. Yavuzsen, O. Oksuzoglu, F. Çay Şenler; TR
- 13:05 - 13:05 1544P - Cognitive functions, coping strategies and psychological distress in patients with resected non-advanced cancer receiving chemotherapy: NEOcoping study data.  
O. Higuera Gomez, C. Calderón, I. Ghanem, A. Carmona-Bayonas, C. Jara, R. Hernández, B. Castelo, M.M. Muñoz, C. Beato, S. García, E. Martínez, M. Mut, A. Ramchandani Vaswani, M. Mangas, O. Donnay, M.T. García-García, M.C. Soriano, R. Carrión, C. Iglesias Gomez, P. Jimenez Fonseca; ES
- 13:05 - 13:05 1545P - Cancer Stigma related beliefs patients and Providers  
G.S. Bhattacharyya<sup>1</sup>, H. Malhotra<sup>2</sup>, G. Babu<sup>2</sup>, A. Vora<sup>2</sup>, S. Bhattacharyya<sup>2</sup>; <sup>1</sup>West Bengal/IN, <sup>2</sup>IN
- 13:05 - 13:05 1546P - Relationship between depressive symptoms at social cognitive processing in partners of long term breast cancer survivors.  
G.S. Bhattacharyya<sup>1</sup>, H. Malhotra<sup>2</sup>, G. Babu<sup>2</sup>, A. Vora<sup>2</sup>, T. Shahid<sup>2</sup>, S. Misra Ghosh<sup>2</sup>; <sup>1</sup>West Bengal/IN, <sup>2</sup>IN
- 13:05 - 13:05 1547P - Evaluation of the distinction and temporal relationship between prolonged grief disorder and depression in terminally ill cancer patients' caregivers' first two years of bereavement  
W.-I. TSAI, S.-C. Kuo, F.-H. Wen, J.-S. Chen, S.T. Tang; TW
- 13:05 - 13:05 1548P - Patients' and partners' views of treatment and care provided for metastatic castrate resistant prostate cancer (mCRPC) in the UK  
S. Catt, L. Matthews, H. Payne, M. Mason, V. Jenkins; GB
- 13:05 - 13:05 1549P - Exploring the effectiveness of crisis counselling and psycho-education in relation to improving mental wellbeing, quality of life and treatment compliance of breast cancer patients in Qatar

R. Alsulaiman<sup>1</sup>, S. Bujassoum<sup>1</sup>, A. Bener<sup>2</sup>, L. Doodson<sup>3</sup>, S. Ghuloum<sup>1</sup>, A. Lemaux<sup>1</sup>, H. Bugrein<sup>1</sup>, R. Alasaam<sup>1</sup>, A. Karim<sup>1</sup>; <sup>1</sup>QA, <sup>2</sup>TR, <sup>3</sup>GB

- 13:05 - 13:05 1550P - Pilot Study of Anxiety, Depression, and Quality of Life in Patients with the Diagnosis of Metastatic Uveal Melanoma  
R. Nshimiyimana<sup>1</sup>, C. Guzzetta<sup>1</sup>, M.-M. Brown<sup>1</sup>, Q. Zhou<sup>2</sup>, J. Johnson<sup>1</sup>, T. Sato<sup>1</sup>, S. Keith<sup>3</sup>; <sup>1</sup>US, <sup>2</sup>VA/US, <sup>3</sup>PA/US
- 13:05 - 13:05 1551P - Making sense of self-conscious and emotion: linking theory of mind and emotion in women with breast cancer.  
A. Datta<sup>1</sup>, P. (chaudhuri)<sup>2</sup>; <sup>1</sup>West Bengal/IN, <sup>2</sup>IN
- 13:05 - 13:05 1552P - Characteristics of the psychosomatic state of patients with lung cancer  
G. Zhukova, A. Shikhlyarova, E. Shirnina, M. Zinkovich, N. Maschenko, E. Zlatnik, S. Pyltsin, P. Anistratov, M. Bragina, A. Zhadobina, L. Vladimirova; RU
- 13:05 - 13:05 1553P - Perception, Magnitude and Implications of Cancer Related Fatigue in Breast Cancer Survivors: Study from a Developing Country  
A. Gupta, S. Hussain, R. Manaktala; IN
- 13:05 - 13:05 1554P - Impact of cancer on the quality of life of Tunisian pediatric patients  
F. Letaief-ksontini, F. letaief-ksontini, S. masmoudi, K. Meddeb, A. Mokrani, Y. Yahyaoui, A. Gabsi, M. Ayadi, N. Chraiet, H. Raies, A. Mezlini; TN
- 13:05 - 13:05 1569P - The impact of primary care access on mortality in lung cancer patients from Bronx, New York  
C. Su, H. Cheng; US
- 13:05 - 13:05 1570P - Are socioeconomic position and region of residence barriers for referral to phase I trials?  
K. Gad, S.O. Dalton, A.K. Duun-Henriksen, A. Krøyer, C. Johansen, M. Mau-Sorensen, U. Lassen; DK
- 13:05 - 13:05 1571P - Breast cancer treatment waiting time, Patient and provider contributions; An Egyptian breast cancer centre experience  
A. Abdelaziz, A. Abdou, C. Habeeb; EG
- 13:05 - 13:05 1572P - Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: a national registry study  
N. Battisti<sup>1</sup>, M. Wallington<sup>2</sup>, A. Ring<sup>2</sup>, S. Payne<sup>2</sup>, R. Birch<sup>2</sup>, M. Bomb<sup>2</sup>, J. Seligmann<sup>3</sup>, T. Kalsi<sup>2</sup>, L. Hounsome<sup>2</sup>, D. Dodwell<sup>2</sup>, S. Underhill<sup>2</sup>, L. Mensah<sup>2</sup>, E. Morris<sup>2</sup>, P. Selby<sup>3</sup>, J. Mansi<sup>2</sup>; <sup>1</sup>Surrey/GB, <sup>2</sup>GB, <sup>3</sup>Yorkshire/GB
- 13:05 - 13:05 1573P - Awareness and attitude towards breast cancer among Egyptian nurses at university affiliated hospitals: Tanta university hospitals experience  
M. Alm El-Din<sup>1</sup>, S. Amer<sup>2</sup>, M. Elsayed<sup>2</sup>, A. Elgohary<sup>2</sup>, A. Ismael<sup>2</sup>, A. Zakzouk<sup>2</sup>, K. Emara<sup>2</sup>, F. Elkady<sup>2</sup>, S. Elnahrawy<sup>2</sup>, F. Nada<sup>2</sup>, A. Eissa<sup>2</sup>; <sup>1</sup>Gharbia/EG, <sup>2</sup>EG
- 13:05 - 13:05 1574P - Women oncologists participation at the Spanish Society of Medical Oncology (SEOM) annual meetings from 2009 to 2017 and their position at Spanish scientific societies.

J. Hidalgo Coloma, A. Ruiz Hernández; ES

- 13:05 - 13:05 1575P - Working arrangements after cancer diagnosis: who, what, when and how?  
C. Alleaume, A.-D. Bouhnik, M. Bendiane, P. Peretti-Watel; FR
- 13:05 - 13:05 1576P - Financial toxicity in German cancer patients. How does a chronic disease impact the economic situation?  
E. Winkler, K. Mehlis, B. Surmann, J. Witte, R. Lingnau, L. Apostolidis, J. Walther, W. Greiner; DE
- 13:05 - 13:05 1577P - Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreaticobiliary cancers: a UK study  
N. Flaum, G. Papaxoinis, K. Hockenull, J. Barriuso, W. Mansoor; GB
- 13:05 - 13:05 (Withdrawn)
- 13:05 - 13:05 1579P - Influenza vaccine effectiveness among cancer patients: a population-based study using health administrative and laboratory testing data from Ontario, Canada  
P. Blanchette<sup>1</sup>, H. Chung<sup>1</sup>, K. Pritchard<sup>2</sup>, C. Earle<sup>1</sup>, M. Campitelli<sup>1</sup>, N. Crowcroft<sup>1</sup>, J. Gubbay<sup>1</sup>, T. Karnauchow<sup>1</sup>, K. Katz<sup>1</sup>, A. McGeer<sup>1</sup>, D. McNally<sup>1</sup>, D. Richardson<sup>1</sup>, S. Richardson<sup>1</sup>, L. Rosella<sup>1</sup>, A. Simor<sup>1</sup>, M. Smieja<sup>1</sup>, G. Zahariadis<sup>1</sup>, A. Campigotto<sup>1</sup>, J. Kwong<sup>1</sup>; <sup>1</sup>CA, <sup>2</sup>Ontario/CA
- 13:05 - 13:05 1580P - How advanced lung cancer patients are really treated at the population level? The Ontario, Canada experience  
W. Evans<sup>1</sup>, W. Flanagan<sup>2</sup>, C. Gauvreau<sup>2</sup>, P. Manivong<sup>2</sup>, S. Memon<sup>2</sup>, N. Fitzgerald<sup>2</sup>, J. Goffin<sup>2</sup>, R. Garner<sup>2</sup>, E. Khoo<sup>2</sup>, N. Mittmann<sup>2</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA
- 13:05 - 13:05 1581P - Anticoagulant treatment of patients (pts) with cancer associated thromboembolism (CAT) in Germany. Real world data from a 4 Million people sample generated by insurance captured data  
A. Kretzschmar, M. May, A. Heinken, H. Riess; DE
- 13:05 - 13:05 1582P - Age Distribution for Different Types of Cancer in the United States (1996-2015)  
M. Gouda, Menoufia Governorate/EG
- 13:05 - 13:05 1583P - Patient reported stressors in the practical domain of a cancer diagnosis: The impact of socioeconomic status and geographic location  
C. Ho<sup>1</sup>, B. Leung<sup>2</sup>, H. Rennie<sup>2</sup>, J. Laskin<sup>1</sup>, J. Wu<sup>2</sup>, A. Bates<sup>2</sup>; <sup>1</sup>British Columbia/CA, <sup>2</sup>CA
- 13:05 - 13:05 1584P - Overview on the use of patient reported outcomes in colorectal cancer care  
L. Neamtiu<sup>1</sup>, S. Deandrea<sup>1</sup>, L. Pykkanen<sup>2</sup>, Z. Saz Parkinson<sup>3</sup>; <sup>1</sup>IT, <sup>2</sup>FI, <sup>3</sup>Varese/IT
- 13:05 - 13:05 1585P - Completeness of staging investigation for colorectal cancer: exploring the role of increasing age and comorbidity using mediation analysis  
S. Benitez Majano<sup>1</sup>, S. Vansteelandt<sup>2</sup>, C. Di Girolamo<sup>1</sup>, M. Morris<sup>1</sup>, S. Walters<sup>1</sup>, B. Rachet<sup>1</sup>; <sup>1</sup>GB, <sup>2</sup>BE
- 13:05 - 13:05 1586P - The Quality Oncology Practice Initiative program: Experience in Spain.

R. Lopez Lopez<sup>1</sup>, A. Anton Torres<sup>2</sup>, E. Aranda Aguilar<sup>2</sup>, A. Carrato Mena<sup>2</sup>, M. Constenla Figueiras<sup>2</sup>, J.J. Cruz Hernandez<sup>2</sup>, E. Diaz Rubio<sup>2</sup>, M. Feyjoo<sup>2</sup>, J. Garcia Foncillas<sup>2</sup>, P. Gascon<sup>2</sup>, V. Guillem Porta<sup>2</sup>, I. Lugo Cuan<sup>2</sup>, A. Rogado<sup>2</sup>, C. Camps<sup>2</sup>; <sup>1</sup>La Coruña/ES, <sup>2</sup>ES

- 13:05 - 13:05 1587P - Can Measuring Quality Lead to Improvement? Evidence from International Participants of ASCO's Quality Oncology Practice Initiative (QOPI®) During 2015-2017  
M. Jahanzeb<sup>1</sup>, T. Gilmore<sup>2</sup>, A. Roach<sup>2</sup>, S. Grubbs<sup>3</sup>, D. Blayne<sup>3</sup>, J. Hamm<sup>4</sup>, A. Kamal<sup>5</sup>, R. Kelly<sup>3</sup>, E. Martin<sup>6</sup>, J. Sanchez<sup>7</sup>, R. Siegel<sup>8</sup>, S.T.S. Crist<sup>2</sup>, J. Rosenthal<sup>2</sup>, C. Hendricks<sup>9</sup>; <sup>1</sup>FL/US, <sup>2</sup>VA/US, <sup>3</sup>US, <sup>4</sup>KY/US, <sup>5</sup>NC/US, <sup>6</sup>DE/US, <sup>7</sup>HN, <sup>8</sup>SC/US, <sup>9</sup>MD/US
- 13:05 - 13:05 1588P - Treatment algorithm for multiple myeloma: real-world insights across five European countries  
A. Rocci, P. Bulger, A. Martinez de Pinillos, P. Nasuti, C. Anger, F. Manuguid; GB
- 13:05 - 13:05 1589P - Are treatment recommendations provided by cognitive computing supported by real world data (Watson for Oncology with Cota RWE) concordant with expert opinions?  
D. Atieh Graham<sup>1</sup>, D. McNamara<sup>1</sup>, S. Waintraub<sup>1</sup>, S. Goldberg<sup>2</sup>, A. Norden<sup>3</sup>, J. Hervey<sup>3</sup>, A. Pecora<sup>3</sup>, C. Landstrom<sup>3</sup>, J. Snowdon<sup>4</sup>, P. Francis<sup>4</sup>, N. Jungbluth<sup>4</sup>, C. Wang<sup>4</sup>, L. Latts<sup>4</sup>; <sup>1</sup>NJ/US, <sup>2</sup>US, <sup>3</sup>NY/US, <sup>4</sup>MA/US
- 13:05 - 13:05 1590P - Body shape trajectories and risk of breast cancer: results from The SUN Study Project  
R. Sanchez Bayona, C. Sayon, I. Gardeazabal, M.A. Martínez-González, M. Santisteban Eslava, E. Toledo-Atucha; ES
- 13:05 - 13:05 1591P - Total polyphenol intake and breast cancer risk in the SUN Project  
I. Gardeazabal, A. Romanos-Nanclares, R. Sanchez Bayona, J. Graforio, M.A. Martínez-González, E. Toledo-Atucha; ES
- 13:05 - 13:05 1592P - No effect of length time bias on the genomic risk in ER+ HER2- Stage I-IIA Breast Cancer (BC) patients according to diagnosis in a screening programme: An exploratory analysis  
I. Gonzalez Barrallo<sup>1</sup>, J.A. Perez Fidalgo<sup>2</sup>, J. Ramirez<sup>1</sup>, O. Burgues<sup>1</sup>, J.V. Sorlí<sup>1</sup>, O. Portoles<sup>1</sup>, C. Hernando<sup>1</sup>, D. Salas<sup>1</sup>, A. Lluch<sup>2</sup>; <sup>1</sup>ES, <sup>2</sup>Valencia/ES
- 13:05 - 13:05 1593P - Breast cancer screening: impact on care pathways  
D. Lefevre, N. Catajar, C. Le Bihan Benjamin, F. De Bels, J. Viguier, P.-J. Bousquet; FR
- 13:05 - 13:05 1594P - Indicators of non-uptake of breast cancer screening: results from the EDIFICE 6 survey  
J.-F. Morere<sup>1</sup>, J. Viguier<sup>2</sup>, L. Greillier<sup>2</sup>, M. Roupert<sup>2</sup>, C. Touboul<sup>2</sup>, C. Lhomel<sup>2</sup>, S. Couraud<sup>1</sup>, T. de La Motte Rouge<sup>2</sup>, F. Eisinger<sup>3</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX 9/FR
- 13:05 - 13:05 1595P - 10-year results of the Breast Cancer Screening Program in Khanty-Mansiysk State Region – Ugra.  
N. Zakharova<sup>1</sup>, A. Brentnall<sup>2</sup>, J. Belaya<sup>1</sup>, E. Bilan<sup>1</sup>; <sup>1</sup>RU, <sup>2</sup>AE
- 13:05 - 13:05 1596P - Malignant lymphoma detected by screening program with esophagogastroduodenoscopy of one private screening center in Japan



T. Nakamura<sup>1</sup>, M. Ikeda<sup>2</sup>, S. Shibata<sup>2</sup>, Y. Kon<sup>2</sup>, K. Konuma<sup>2</sup>, T. Sanada<sup>2</sup>, H. Gonda<sup>2</sup>, Y. Suto<sup>2</sup>, K. Kobayashi<sup>2</sup>, H. Tamura<sup>2</sup>, M. Kobayashi<sup>2</sup>, A. Hasegawa<sup>2</sup>, Y. Amagasa<sup>2</sup>, A. Suzuki<sup>2</sup>, M. Fukuda<sup>2</sup>, C. Aoyagi<sup>2</sup>, N. Matsuura<sup>2</sup>, Y. Kawashima<sup>2</sup>, M. Shimura<sup>2</sup>, N. Takita<sup>2</sup>; <sup>1</sup>Gunma/JP, <sup>2</sup>JP

- 13:05 - 13:05 1597P - Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): preliminary findings and plans for further research.  
F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M. Coleman, CONCORD Working Group; GB
- 13:05 - 13:05 1598P - Referral patterns and predictors of survival for Stage IV pancreatic ductal adenocarcinoma  
A. Suo<sup>1</sup>, P. Tang<sup>2</sup>, D. Tilley<sup>2</sup>, W. Cheung<sup>3</sup>, R. Lee-Ying<sup>2</sup>; <sup>1</sup>CA/CA, <sup>2</sup>CA, <sup>3</sup>AB/CA
- 13:05 - 13:05 1599P - Gender difference in cancer survivors' perceived information 5-years after diagnosis. Data from the French national study: VICAN 5.  
G. Gravis<sup>1</sup>, R. Touzani<sup>2</sup>, A.-D. Bouhnik<sup>2</sup>, P. Marino<sup>2</sup>, G. Pignot<sup>2</sup>, M. Bendiane<sup>2</sup>; <sup>1</sup>CEDEX 9/FR, <sup>2</sup>FR
- 13:05 - 13:05 1600P - Survival Difference Between Microscopically Confirmed and Microscopically Non-Confirmed Cancers  
M. Gouda, Menoufia Governorate/EG
- 13:05 - 13:05 1616P - Quantitative Multiplexed Immune Profiling of Advanced Gastrointestinal Stromal Tumors (GISTs): Impact of tyrosine kinase inhibitors on immune environment  
C. Yoo<sup>1</sup>, S.-Y. Kim<sup>2</sup>, J. Kim<sup>2</sup>, Y.-M. Ryu<sup>2</sup>, M.-H. Ryu<sup>2</sup>, Y.-K. Kang<sup>1</sup>; <sup>1</sup>Songpa-gu/KR, <sup>2</sup>KR
- 13:05 - 13:05 1617P - Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST.  
A. Callejo Goena<sup>1</sup>, S. Faouzi<sup>2</sup>, O. Bouche<sup>2</sup>, T. Chevalier<sup>2</sup>, N. Isambert<sup>3</sup>, F. Duffaud<sup>4</sup>, O. Collard<sup>2</sup>, O. Mir<sup>2</sup>, P. Terrier<sup>2</sup>, J.-Y. Blay<sup>2</sup>, A. Le Cesne<sup>5</sup>; <sup>1</sup>ES, <sup>2</sup>FR, <sup>3</sup>Cedex/FR, <sup>4</sup>CEDEX 5/FR, <sup>5</sup>CEDEX/FR
- 13:05 - 13:05 1618P - Prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced gastrointestinal stromal tumor (GIST)  
H. Cho<sup>1</sup>, M.-H. Ryu<sup>1</sup>, H. Chae<sup>1</sup>, S.M. Lee<sup>1</sup>, Y. Park<sup>1</sup>, K.-H. Kim<sup>1</sup>, C.W. Kim<sup>1</sup>, B.S. Kim<sup>1</sup>, M.-W. Yoo<sup>1</sup>, J. Ma<sup>1</sup>, M.Y. Beck<sup>1</sup>, M. Kim<sup>1</sup>, Y.-K. Kang<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR
- 13:05 - 13:05 1619P - Systemic steroid treatment for severe skin rash induced by imatinib in patients with gastrointestinal stromal tumor (GIST): A phase II study  
E. Kim<sup>1</sup>, M.-H. Ryu<sup>1</sup>, S.R. Park<sup>1</sup>, M.Y. Beck<sup>1</sup>, W.J. Lee<sup>1</sup>, M.W. Lee<sup>1</sup>, Y.-K. Kang<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR
- 13:05 - 13:05 1620P - Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib  
H. Cho<sup>1</sup>, M.-H. Ryu<sup>1</sup>, B.J. Kim<sup>1</sup>, Y. Park<sup>1</sup>, Y.-S. Na<sup>1</sup>, J. Ma<sup>1</sup>, M.Y. Beck<sup>1</sup>, Y.-K. Kang<sup>2</sup>; <sup>1</sup>KR, <sup>2</sup>Songpa-gu/KR
- 13:05 - 13:05 1621P - Correlation between different C-kit exon mutations and clinical response to Imatinib mesylate treatment in GIST patients.  
G. Zakaria, N. Allahloubi, O. Khorshid, A. Bahnassy; EG

- 13:05 - 13:05 1622P - Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors  
M. Yamamura, A. Yamauchi, N. Katase, Y. Katata, H. Tanioka, M. Okawaki, T. Nagasaka, Y. Yamaguchi; JP
- 13:05 - 13:05 1623P - Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib  
S. George<sup>1</sup>, S. Bauer<sup>2</sup>, R. Jones<sup>3</sup>, C. Serrano<sup>4</sup>, M. von Mehren<sup>5</sup>, Y.-K. Kang<sup>6</sup>, P. Schöffski<sup>7</sup>, P. Cassier<sup>8</sup>, F. Eskens<sup>9</sup>, O. Mir<sup>8</sup>, W. Tap<sup>10</sup>, S. Chawla<sup>11</sup>, P. Rutkowski<sup>12</sup>, H. Shi<sup>10</sup>, O. Schmidt-Kittler<sup>1</sup>, B. Mar<sup>10</sup>, M. Heinrich<sup>10</sup>; <sup>1</sup>MA/US, <sup>2</sup>DE, <sup>3</sup>WA/GB, <sup>4</sup>ES, <sup>5</sup>PA/US, <sup>6</sup>Songpa-gu/KR, <sup>7</sup>BE, <sup>8</sup>FR, <sup>9</sup>NL, <sup>10</sup>US, <sup>11</sup>CA/US, <sup>12</sup>PL
- 13:05 - 13:05 1624P - Pathological Grade of Tumorregression after neoadjuvant Chemotherapy with Doxorubicin/Ifosfamid and Regional Hyperthermia correlates with Survival Outcomes in Patients with high-risk Soft Tissue Sarcoma  
G.-E. Schuebbe, T. Knösel, H.R. Dürr, M. Angele, F. Röder, S. Abdel-Rahman, A. Alig, R. Issels, D. Di Gioia, L. Lindner; DE
- 13:05 - 13:05 1625P - Efficacy of metastasectomy on survival in patients with metachronous soft tissue sarcoma-metastasis. Results of a bi-centre study including 135 patients.  
M. Smolle<sup>1</sup>, V. van Praag<sup>2</sup>, F. Posch<sup>1</sup>, M. Bergovec<sup>1</sup>, L. Leitner<sup>1</sup>, J. Friesenbichler<sup>1</sup>, R. Heregger<sup>1</sup>, F.-M. Smolle-Jüttner<sup>1</sup>, M. Fiocco<sup>2</sup>, M. van de Sande<sup>2</sup>, J. Riedl<sup>1</sup>, M. Pichler<sup>1</sup>, A. Gerger<sup>1</sup>, J. Szkandera<sup>1</sup>, H. Stöger<sup>1</sup>, B. Liegl-Atzwanger<sup>1</sup>, A. Leithner<sup>1</sup>; <sup>1</sup>AT, <sup>2</sup>NL
- 13:05 - 13:05 1626P - Trabectedin and radiotherapy in advanced sarcoma: experience of a Reference Center  
I. Carrasco Garcia, N. Hindi, J. Peinado, I. Rincon, M. Cordeiro, F. Jimenez, A. Falcon Gonzalez, R. Lasso de la Vega, M. Nogueer Mediavilla, P. Sancho Marquez, J. Martin-Broto; ES
- 13:05 - 13:05 1627P - Single arm prospective study evaluating the role of neoadjuvant chemotherapy in soft tissue sarcoma  
A. Tiwari, S. Rastogi, S.V.S. Deo, D.N. Sharma, M. Sharma, S. Bakshi; IN
- 13:05 - 13:05 1628P - Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: interim analysis of prospective phase II clinical trial  
M. Spalek<sup>1</sup>, H. Kosela Paterczyk<sup>1</sup>, A. Borkowska<sup>1</sup>, M. Wagrodzki<sup>1</sup>, A. Cieszanowski<sup>1</sup>, P. Castaneda-Wysocka<sup>1</sup>, T. Switaj<sup>2</sup>, M. Dudzisz-Sledz<sup>1</sup>, A. Czarnecka<sup>1</sup>, E. Dabrowska-Szewczyk<sup>1</sup>, P. Rutkowski<sup>1</sup>; <sup>1</sup>PL, <sup>2</sup>IR
- 13:05 - 13:05 1629P - Basket trial in advanced cancers: a clinical observation of Apatinib in lung metastases and non-lung metastases  
C. Tu, Y. Zhou, K. Yao, Y. Luo, W. Zhang, H. Duan, L. Min; CN
- 13:05 - 13:05 1630P - Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification  
Y. Yao<sup>1</sup>, Y. Chi<sup>1</sup>, Z. Fang<sup>1</sup>, S. Wang<sup>2</sup>, G. Huang<sup>1</sup>, Q. Cai<sup>1</sup>, G. Shang<sup>1</sup>, G. Wang<sup>1</sup>, G. Qu<sup>1</sup>, Q. Wu<sup>1</sup>, Y. Jiang<sup>3</sup>, J. Song<sup>1</sup>, J. Chen<sup>1</sup>, X. Zhu<sup>1</sup>, Z. Cai<sup>1</sup>, C. Bai<sup>1</sup>, Y. Lu<sup>1</sup>, Z. Yu<sup>1</sup>, J. Shen<sup>1</sup>, J. Cai<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>Guangdong/CN, <sup>3</sup>Sichuan/CN

- 13:05 - 13:05 1631P - Efficacy and safety of apatinib in advanced sarcoma  
J. Chen, T. Ye, Z. Zhang, Z. Wang, S. Yang, K. Yang, T. Li; CN
- 13:05 - 13:05 1632P - Characterizing the risk of drug-drug interactions in sarcoma treated patients: role of pharmacist integration.  
A. Bellesoeur<sup>1</sup>, I. Gataa<sup>1</sup>, A. Jouinot<sup>2</sup>, S. El Mershati<sup>2</sup>, J. Arrondeau<sup>1</sup>, C. Tlemsani<sup>1</sup>, B. Blanchet<sup>1</sup>, J. Alexandre<sup>3</sup>, F. Goldwasser<sup>1</sup>, A. Thomas-Schoemann<sup>2</sup>, P. Boudou Rouquette<sup>1</sup>; <sup>1</sup>CEDEX 14/FR, <sup>2</sup>FR, <sup>3</sup>CEDEX 4/FR
- 13:05 - 13:05 1633P - Evaluation of hypertension and hand-foot syndrome as Markers of anlotinib Efficacy in advanced soft tissue sarcoma  
Z. Fang<sup>1</sup>, Y. Chi<sup>1</sup>, Y. Yao<sup>1</sup>, S. Wang<sup>2</sup>, G. Huang<sup>1</sup>, Q. Cai<sup>1</sup>, G. Shang<sup>1</sup>, G. Wang<sup>1</sup>, G. Qu<sup>1</sup>, Q. Wu<sup>1</sup>, Y. Jiang<sup>3</sup>, J. Song<sup>1</sup>, J. Chen<sup>1</sup>, X. Zhu<sup>1</sup>, Z. Cai<sup>1</sup>, C. Bai<sup>1</sup>, Y. Lu<sup>1</sup>, Z. Yu<sup>1</sup>, J. Shen<sup>1</sup>, J. Cai<sup>1</sup>; <sup>1</sup>CN, <sup>2</sup>Guangdong/CN, <sup>3</sup>Sichuan/CN
- 13:05 - 13:05 1634P - "Evolution of Novel, Low Cost, Sustainable Osteosarcoma Care over Two Decades: Reducing Ineciencies, & Improving Outcomes"  
J. Bajpai<sup>1</sup>, T. Mondal<sup>1</sup>, V. Simha<sup>1</sup>, A. Chandrashekhara<sup>1</sup>, S. Hingmire<sup>2</sup>, B. Rangarajan<sup>3</sup>, N. Shetty<sup>1</sup>, K. Shah<sup>1</sup>, R. Dusane<sup>1</sup>, B. Rekhi<sup>1</sup>, T. Vora<sup>1</sup>, J. Ghosh<sup>1</sup>, S. Banavali<sup>1</sup>, S. Gupta<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>Maharashtra/IN, <sup>3</sup>Tamil Nadu/IN
- 13:05 - 13:05 1635P - HBP-bound doxorubicin: promising new therapy for bone cancer  
E. David, S. Cagnol, J.-Y. Goujon, M. Egorov, R. Le Bot; FR
- 13:05 - 13:05 1636P - Perceptions of Clinical Trial Enrollment in Patients with Bone and Soft Tissue Sarcoma  
A. Rosenberg<sup>1</sup>, S. Kircher<sup>2</sup>, E. Hahn<sup>1</sup>, A. Rademaker<sup>1</sup>, K. Bilimoria<sup>1</sup>, J. Wayne<sup>1</sup>, M. Agulnik<sup>2</sup>; <sup>1</sup>IL/US, <sup>2</sup>US
- 13:05 - 13:05 1637P - Pneumothorax is a novel sensitivity biomarker for targeting VEGFR2 in lung metastatic bone sarcoma  
Q. Bao, Y. Shen, W. Zhang; CN
- 13:05 - 13:05 1638P - Do Royal Marsden Hospital (RMH) and MD Anderson cancer centre (MDACC) prognostic scoring systems predict survival in patients with Bone sarcoma?  
W. Alselwi<sup>1</sup>, F. Azam<sup>2</sup>, M. Latif<sup>3</sup>, I. Osman<sup>2</sup>, W. Taha<sup>2</sup>, K. Bawazir<sup>2</sup>, A. Farooq<sup>4</sup>, N. Bukhari<sup>2</sup>, F. Ibnshamsah<sup>2</sup>; <sup>1</sup>YE, <sup>2</sup>SA, <sup>3</sup>Merseyside/GB, <sup>4</sup>GB
- 13:05 - 13:05 1639P - The study of molecular and genetic markers of apoptosis and proliferation, their role in the treatment and prevention of osteogenic sarcoma  
M. Tillyashaykhov, D. Polatova, M.-A. Gafur-Akhunov, K. Abdikarimov, U. Islamov, R. Davletov; UZ
- 13:05 - 13:05 1640P - Outcome of treatment in giant cell tumors of bones. A single institutional retrospective review  
M. Elshenawy<sup>1</sup>, A. Badran<sup>2</sup>, M. Memon<sup>3</sup>, A. Elshentenawy<sup>2</sup>, T. Elhassan<sup>3</sup>; <sup>1</sup>Menoufia Governorate/EG, <sup>2</sup>EG, <sup>3</sup>SA

- 13:05 - 13:05 1641P - Adriamycin and Ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: results of a retrospective single-center study on 34 patients  
T. Assi<sup>1</sup>, A. Le Cesne<sup>2</sup>, E. Nassif<sup>1</sup>, A. Cavalcanti<sup>1</sup>, M. Faron<sup>1</sup>, T. Ibrahim<sup>3</sup>, C. Le Pechoux<sup>2</sup>, O. Mir<sup>1</sup>, J. Adam<sup>1</sup>, S. Dumont<sup>1</sup>, P. Terrier<sup>1</sup>, C. Honore<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR, <sup>3</sup>LB
- 13:05 - 13:05 1642P - Determination of biological behavior of solitary fibrous tumors  
L. Krsková, M. Kalinova, I. Odintsov, P. Galgonková, R. Kodet; CZ
- 13:05 - 13:05 1643P - Pazopanib in advanced or metastatic synovial sarcoma: the Gustave Roussy experience  
M. Sroussi<sup>1</sup>, S. De Percin<sup>1</sup>, A.M. Grecea<sup>1</sup>, M.A. Benderra<sup>1</sup>, M. Velev<sup>1</sup>, S. Akla<sup>1</sup>, N. Lezghed<sup>1</sup>, S. Dumont<sup>1</sup>, C. Le Pechoux<sup>1</sup>, C. Honore<sup>1</sup>, L. Haddag<sup>1</sup>, M. Faron<sup>1</sup>, P. Terrier<sup>1</sup>, O. Mir<sup>1</sup>, A. Le Cesne<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 13:05 - 13:05 1644P - Identification of effective drug combinations with regorafenib (REG) for the treatment of pediatric rhabdomyosarcomas (RMS)  
Y. Tsvetkova, J. Hoffmann, D. Zopf; DE
- 13:05 - 13:05 1645P - KS In The Era Of HAART: A Single Institutional Retrospective Review  
K. Sankar<sup>1</sup>, K. Foster<sup>1</sup>, C. Achenbach<sup>1</sup>, M. Agulnik<sup>2</sup>; <sup>1</sup>IL/US, <sup>2</sup>US
- 13:05 - 13:05 1646P - Carcinosarcoma: Clinical and Epidemiological Patterns in the United States  
M. Gouda, Menoufia Governorate/EG
- 13:05 - 13:05 1647P - First-line Treatment of Desmoid Tumor: Systemic Therapy versus Upfront Surgery  
J. Souza, H. Lourenço, G. Mendes; BR
- 13:05 - 13:05 1648P - Adult rhabdomyosarcoma in Tunisia : Clinical presentation, treatment and outcome  
M. Saadi, D. Tajina, F. Letaief-ksontini, K. Meddeb, A. Gabsi, Y. Yahyaoui, A. Mokrani, M. Ayadi, N. Chraiet, H. Rais, A. Mezlini; TN
- 13:05 - 13:05 1649P - A Pan-Cancer Landscape analysis reveals a subset of Endometrial Stromal and Pediatric Tumors defined by Internal tandem duplications of BCOR  
L. Juckett<sup>1</sup>, D. Lin<sup>2</sup>, R. Madison<sup>1</sup>, C. Patriquin<sup>1</sup>, G. Frampton<sup>2</sup>, V. Miller<sup>2</sup>, J. Ross<sup>2</sup>, J. Chung<sup>2</sup>, A. Schrock<sup>1</sup>, S. Ali<sup>2</sup>, J. Elvin<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>MA/US
- 13:05 - 13:05 1650P - The efficacy of eribulin for patients with taxane-resistant cutaneous angiosarcoma: interim result of multi-center, prospective observational study.  
Y. Fujisawa<sup>1</sup>, K. Yoshino<sup>2</sup>, T. Fujimura<sup>2</sup>, S. Matsushita<sup>2</sup>, H. Uchi<sup>2</sup>, Y. Yamamoto<sup>2</sup>, H. Hata<sup>2</sup>, A. Otsuka<sup>2</sup>, T. Miyagi<sup>2</sup>, M. Ishii<sup>2</sup>, T. Funakoshi<sup>2</sup>; <sup>1</sup>Ibaraki/JP, <sup>2</sup>JP
- 13:05 - 13:05 1651P - Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma  
M. Agulnik<sup>1</sup>, B. van Tine<sup>2</sup>, S. Attia<sup>1</sup>, A. Rademaker<sup>3</sup>, M. Milhem<sup>1</sup>, S. Okuno<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>Missouri/US, <sup>3</sup>IL/US
- 13:05 - 13:05 1652P - Outcomes and Prognostic Factors for Angiosarcoma: a 19-yr Single Institution Experience

M. Chirila, D. Eniu, N. Todor, V.M. Nagy, M. Galatir, D. Coza, V. Cernea, D. Martin, Z. Fekete; RO

- 13:05 - 13:05 1653P - Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: results of a retrospective series in a tertiary care center.  
C. Honoré<sup>1</sup>, M. Faron<sup>1</sup>, O. Mir<sup>1</sup>, L. Haddag<sup>1</sup>, S. Dumont<sup>1</sup>, P. Terrier<sup>1</sup>, J. Adam<sup>1</sup>, C. Lepéchox<sup>1</sup>, A. Le Cesne<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 13:05 - 13:05 1654P - Soft tissue sarcomas (STS) in elder patients: No impact of age on overall survival (OS) in an unselected cohort.  
J.A. Perez Fidalgo<sup>1</sup>, A. Lopez<sup>2</sup>, V. Gambardella<sup>1</sup>, S. Navarro<sup>2</sup>, A. Iranzo<sup>2</sup>, N. Diaz Fernandez<sup>2</sup>, P. Tolosa<sup>2</sup>, A. Silvestre<sup>2</sup>, E. Iriarte Moncho<sup>2</sup>, M.C. Garcia Mora<sup>2</sup>, A. De la Paz<sup>2</sup>, J.J. Soler<sup>2</sup>, A. Cervantes<sup>1</sup>; <sup>1</sup>Valencia/ES, <sup>2</sup>ES
- 13:05 - 13:05 1657P - Return to work and quality of life in disease-free adult sarcoma patients  
A. Kollar, S. Müller, N. Fankhauser, I. Briner, F. Klenke, J. Bernhard; CH
- 13:05 - 13:05 1658P - No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: results from a single center propensity-matched analysis.  
M. Faron<sup>1</sup>, S. Dumont<sup>1</sup>, J. Adam<sup>1</sup>, O. Mir<sup>1</sup>, L. Haddag<sup>1</sup>, C. Le Pechoux<sup>2</sup>, P. Terrier<sup>1</sup>, A. Le Cesne<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX/FR
- 13:05 - 13:05 1659P - Combination of Eribulin plus Gemcitabine in L-Sarcomas  
D. Moura, M. Lopez-Alvarez, A. Salinas-Villegas, P. Sanchez-Bustos, N. Hindi, M. Taron Roca, J. Martin-Broto; ES
- 13:05 - 13:05 1660P - The role of chemotherapy in the landscape of liposarcoma  
A. De Vita<sup>1</sup>, F. Recine<sup>1</sup>, L. Mercatali<sup>1</sup>, G. Miserocchi<sup>1</sup>, C. Liverani<sup>1</sup>, C. Spadazzi<sup>1</sup>, R. Casadei<sup>1</sup>, D. Cavaliere<sup>1</sup>, A. Bongiovanni<sup>2</sup>, F. Pieri<sup>1</sup>, L. Medri<sup>1</sup>, N. Riva<sup>1</sup>, V. Fausti<sup>2</sup>, T. Ibrahim<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>Forli-Cesena/IT
- 13:05 - 13:05 1661TiP - A Randomized Phase III Study of Denosumab before Curettage for Giant Cell Tumor of Bone: Japan Clinical Oncology Group Study JCOG1610  
H. Urakawa, J. Mizusawa, K. Tanaka, J. Eba, H. Hiraga, M. Hosaka, A. Kawai, F. Nakatani, E. Kobayashi, Y. Nishida, T. Okamoto, T. Matsunobu, Y. Iwamoto, H. Fukuda, T. Ozaki; JP
- 13:05 - 13:05 1662TiP - VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)  
S. Bauer<sup>1</sup>, S. George<sup>2</sup>, Y.-K. Kang<sup>3</sup>, W. Tap<sup>2</sup>, T. Zhou<sup>2</sup>, N. Picazio<sup>2</sup>, A. Boral<sup>2</sup>, M. Heinrich<sup>2</sup>; <sup>1</sup>DE, <sup>2</sup>US, <sup>3</sup>KR
- 13:05 - 13:05 1691P - Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients  
K. Thein<sup>1</sup>, S. Ball<sup>2</sup>, M. Zaw<sup>3</sup>, A. Tun<sup>3</sup>, M. Quirch<sup>2</sup>, F. Hardwicke<sup>2</sup>, N. D'Cunha<sup>2</sup>, L. Tijani<sup>2</sup>, C. Jones<sup>2</sup>, T. Oo<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>NY/US

- 13:05 - 13:05 1692P - Physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): results from the BCY3/BCC 2017 survey  
M. Lambertini<sup>1</sup>, M. Di Maio<sup>2</sup>, F. Poggio<sup>2</sup>, O. Pagani<sup>3</sup>, G. Curigliano<sup>2</sup>, L. Del Mastro<sup>2</sup>, S. Paluch-Shimon<sup>4</sup>, S. Loibl<sup>5</sup>, A. Partridge<sup>6</sup>, H. Azim Jr.<sup>7</sup>, F. Peccatori<sup>2</sup>, I. Demeestere<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>IT, <sup>3</sup>CH, <sup>4</sup>IL, <sup>5</sup>DE, <sup>6</sup>US, <sup>7</sup>LB
- 13:05 - 13:05 1693P - Analysis of parameters to predict the effectiveness of scalp cooling to prevent chemotherapy-induced alopecia in breast cancer patients  
C. Kurbacher, S. Herz, A.T. Kurbacher, G. Kolberg, N. Kettelhoit, A. Schott, J. Kurbacher; DE
- 13:05 - 13:05 1694P - A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results  
M. Lacouture<sup>1</sup>, H. Dion<sup>2</sup>, S. Ravipaty<sup>3</sup>, V. Akmaev<sup>3</sup>, R. Sarangarajan<sup>2</sup>, J. Jimenez<sup>4</sup>, N. Narain<sup>2</sup>, B. Berman<sup>4</sup>, S. Goldfarb<sup>1</sup>; <sup>1</sup>NY/US, <sup>2</sup>US, <sup>3</sup>MA/US, <sup>4</sup>FL/US
- 13:05 - 13:05 1695P - Acupuncture for peripheral neuropathy in cancer patients: TCM diagnosis as a predictor of treatment response  
W. Liu, A. Qdaisat, G. Lopez, S. Underwood, M. Spano, A.R. Akhila Reddy, Y. Guo, S.-C. Yeung, E. Bruera, M.K. Garcia, L. Cohen; US
- 13:05 - 13:05 1696P - A randomized, open-label, non-inferiority study comparing the efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B-cell Non-Hodgkin lymphomas (B-NHL) - AVOID Neutropenia.  
H. Link<sup>1</sup>, G. Illerhaus<sup>1</sup>, U. Martens<sup>1</sup>, A. Salar<sup>2</sup>, R. Depenbusch<sup>1</sup>, A. Kohler<sup>1</sup>, M. Engelhardt<sup>1</sup>, S. Mahlmann<sup>1</sup>, M. Zaiss<sup>1</sup>, A. Lammerich<sup>1</sup>, P. Bias<sup>1</sup>, A. Buchner<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>ES
- 13:05 - 13:05 1697P - Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: pan-European non-interventional study  
G. Steger<sup>1</sup>, P. Pichler<sup>1</sup>, M. Airolidi<sup>2</sup>, P. Mazza<sup>2</sup>, C. Fontaine<sup>3</sup>, J. Timmer Bonte<sup>4</sup>, J. Walewski<sup>5</sup>, J. Katolicka<sup>6</sup>, M. Mikulova<sup>7</sup>, M. Gasparic<sup>4</sup>; <sup>1</sup>AT, <sup>2</sup>IT, <sup>3</sup>BE, <sup>4</sup>NL, <sup>5</sup>PL, <sup>6</sup>South Moravian/CZ, <sup>7</sup>Slovak republic/SK
- 13:05 - 13:05 1698P - Safety analysis of proposed biosimilar pegfilgrastim in Phase I and Phase III studies  
N. Harbeck<sup>1</sup>, J. Wang<sup>2</sup>, G. Otto<sup>1</sup>, A. Krendyukov<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>US
- 13:05 - 13:05 1699P - New approach to evaluate survival benefit of granulocyte colony-stimulating factor in cancer patients receiving myelosuppressive chemotherapy  
A. Krendyukov, L. Yau; DE
- 13:05 - 13:05 1700P - Safe switch of treatment from the reference product to RGB-02, a proposed biosimilar pegfilgrastim: analysis of the results of three clinical trials  
A. Illes<sup>1</sup>, L. Perjesi<sup>1</sup>, K. Horvat-Karajz<sup>1</sup>, N. Jeszenoi<sup>1</sup>, I. Aradi<sup>1</sup>, N. Singh<sup>2</sup>, S. Mair<sup>2</sup>, Z. Kahan<sup>1</sup>; <sup>1</sup>HU, <sup>2</sup>GB
- 13:05 - 13:05 1701P - Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: findings from a large study in German clinical practice (PROTECT)  
C. Kurbacher, M. Schmidt, M. Geberth, B. Otremba, H. Eschenburg, P. Ramdohr; DE

- 13:05 - 13:05 1702P - Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials  
A. Kristensen, T. Solheim, Ø. Fløtten, B. Grønberg; NO
- 13:05 - 13:05 1703P - Incidence of hypocalcemia in a non-inferiority Phase III trial assessing prevention of symptomatic skeletal events (SSE) with Denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)  
R. von Moos, H. Hawle, S. Hayoz, R. Cathomas, A. Müller, S. Schmid, O. Pagani, T. Wehrhahn, D. Rauch, S. Anchisi, T. Hermanns, M. Fehr, S. Stoll, P. Bützberger, M. Zweifel, U. Huber, A. Fuhrer, C. Schär, S. Gillessen, A. Templeton; CH
- 13:05 - 13:05 1704P - A Prospective Randomized Controlled Trial of Metoclopramide Combined with Triple Antiemetic Therapy to Prevent Anthracycline-Based Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer  
U. Oflazoglu, U. Varol, A. Alacacioglu, T. Salman, Y. Kucukzeybek, H. Taskaynatan, Y. Yildiz, G. Dissiz, S. Iriz, M. TARHAN; TR
- 13:05 - 13:05 1705P - Ramosetron Versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting  
J.H. Kwon, J.-H. Kang, Y.-G. Lee, K.U. Park, H.J. An, J. Sohn, Y.M. Seol, H. Lee, H.-J. Yun, J.S. Ahn, H.J. Kim; KR
- 13:05 - 13:05 1706P - Prognostic factors associated with prevalence of nausea, and time to development of nausea in patients receiving guideline-based anti-emetic prophylaxis. A prospective, observational, real world study.  
T. Smit, B. Rapoport; ZA
- 13:05 - 13:05 1707P - Usefulness of bone modifying agents for non-weight bearing bone metastasis in breast cancer.  
K. KAWAGUCHI, M. Latif, K. Hayashi, S. Ogita; JP
- 13:05 - 13:05 1708P - Analysis of bone events in patients with aromatase inhibitors (AI)  
S. Arrojo, E. Garcia-Carús, C. Gómez, P. Rodriguez, D. Rivas, L. Faez, C. Iglesias Gomez, M.E. Izquierdo Manuel, Y. Fernandez Perez; ES
- 13:05 - 13:05 1709P - Assessment and treatment of breakthrough cancer pain in Spain: a self-audit study  
R. Lopez Lopez<sup>1</sup>, J.J. Reina Zoilo<sup>2</sup>, D. Monge<sup>2</sup>, F. Caballero<sup>2</sup>, V. Guillem Porta<sup>2</sup>, E. Aranda Aguilar<sup>2</sup>, A. Carrato Mena<sup>2</sup>, E. Diaz Rubio<sup>2</sup>, J. Garcia Foncillas<sup>2</sup>, M. Feyjoo<sup>2</sup>, C. Camps<sup>2</sup>; <sup>1</sup>La Coruña/ES, <sup>2</sup>ES
- 13:05 - 13:05 1710P - Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project.  
J. Salvador Bofill<sup>1</sup>, V. Guillem Porta<sup>1</sup>, M. Feyjoo<sup>1</sup>, A. Anton Torres<sup>1</sup>, E. Aranda Aguilar<sup>1</sup>, C. Camps<sup>1</sup>, A. Carrato Mena<sup>1</sup>, M. Constenla Figueiras<sup>1</sup>, J.J. Cruz Hernandez<sup>1</sup>, E. Diaz Rubio<sup>1</sup>, J. Garcia Foncillas<sup>1</sup>, P. Gascon<sup>1</sup>, R. Lopez Lopez<sup>2</sup>, B. Soler<sup>1</sup>, Y. Escobar<sup>1</sup>; <sup>1</sup>ES, <sup>2</sup>La Coruña/ES
- 13:05 - 13:05 1711P - Opioid-induced Constipation in Patients with Cancer Pain in Japan: Prospective Observational Study Using Rome IV OIC Diagnostic Criteria (OIC-J Study)  
H. Imai<sup>1</sup>, S. Fumita<sup>1</sup>, T. Harada<sup>1</sup>, T. Noriyuki<sup>1</sup>, M. Gamoh<sup>2</sup>, Y. Akashi<sup>1</sup>, H. Sato<sup>1</sup>, Y. Kizawa<sup>1</sup>, A. Tokoro<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>Miyagi/JP

- 13:05 - 13:05 1712P - Efficacy and Tolerability of Naldemedine in Patient with Cancer and Opioid-Induced Constipation: A Pooled Subgroup Analysis of 2 Randomized Placebo Controlled Studies  
E. Satomi<sup>1</sup>, H. Ishiki<sup>1</sup>, T. Yokota<sup>2</sup>, Y. Tada<sup>1</sup>, H. Sato<sup>1</sup>, M. Okamoto<sup>1</sup>, I. Osaka<sup>1</sup>; <sup>1</sup>JP, <sup>2</sup>GB
- 13:05 - 13:05 1713P - Left ventricular ejection fraction(LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance.  
J.H. Yeo, H. Ahn, I. Park, Y.S. Kim, S.J. Sym, E.K. Cho, D.B. Shin; KR
- 13:05 - 13:05 1714P - Predicting the occurrence and prevention of early anthracycline cardiotoxicity of chemotherapy in patients with breast cancer  
A. Askolskyi, L. Syvak, O. Zharinov, N. Khranovska; UA
- 13:05 - 13:05 1715P - Baseline prevalence of cardiovascular disease (CVD) risk factors in women with breast cancer  
N. Bhoo-Pathy, S. Subramaniam, H. Zaharah, Y.C. Kong, N.A. Taib, A. Deniel, K.-H. Chee, R.S. Bustamam, M.-H. See, A. Fong, C.H. Yip; MY
- 13:05 - 13:05 1716P - Cardiovascular and other competing causes of death among cancer patients, 2006-2015: An Australian population-based study  
Y. Ye<sup>1</sup>, P. Otahal<sup>2</sup>, T. Marwick<sup>3</sup>, K. Wills<sup>2</sup>, A. Neil<sup>2</sup>, A. Venn<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>TAS/AU, <sup>3</sup>VIC/AU
- 13:05 - 13:05 1717P - Cancer Associated Thrombosis with Primary Prophylaxis in a Tertiary Hospital in the Philippines from 2010-2015  
A.T. Gerona, PH
- 13:05 - 13:05 1718P - The incidence of recurrent venous thromboembolism (VTE) and bleeding depending on practical treatment pattern of anticoagulation in the cancer patients with VTE  
S.-M. Bang, J.-H. Kang, M.H. Hong, J.S. Ahn, S.Y. Oh, J.H. Baek, Y.J. Choi, S.H. Shin, Y.-J. Kim, J.-H. Cha, J. Lee; KR
- 13:05 - 13:05 1719P - Prevention and Prophylaxis of Thrombosis in Cancer Patients  
N. Tsoukalas<sup>1</sup>, P. Papakotoulas<sup>1</sup>, A. Christopoulou<sup>2</sup>, A. Ardavanis<sup>1</sup>, G. Koumakis<sup>1</sup>, C. Papandreou<sup>1</sup>, G. Papatsimpas<sup>1</sup>, P. Papakostas<sup>1</sup>, C. Andreadis<sup>1</sup>, G. Aravantinos<sup>3</sup>, N. Ziras<sup>1</sup>, H. Kalofonos<sup>1</sup>, E. Samantas<sup>3</sup>, M. Sougleri<sup>1</sup>, P. Makrantonakis<sup>1</sup>, G. Pentheroudakis<sup>1</sup>, A. Athanasiadis<sup>1</sup>, E. Bournakis<sup>1</sup>, I.I. Varthalitis<sup>1</sup>, I. Boukovinas<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>West Greece/GR, <sup>3</sup>Attica/GR
- 13:05 - 13:05 1720P - Is it appropriate to use a fixed prophylactic dose of enoxaparin for hospitalized cancer patients? Results from a prospective tertiary referral single center study  
C. Maurice-Dror, M. Litvak, A. Keren, S. Akerman, B. Brenner, N. Haim, Y. Nadir; IL
- 13:05 - 13:05 1721P - Long-term prognosis of acute pulmonary embolism: a focus on idiopathic and neoplastic etiologies  
I. Guerreiro, H. Magalhães, S. Coelho, A.M. Ribeiro, S. Ferreira, E. Araújo, M. Fontes-Sousa, P. Bettencourt, P. Lourenço; PT
- 13:05 - 13:05 1722P - Systematic Literature Review and Network Meta-analysis of oral Anticoagulants for the Treatment of Venous Thromboembolism in patients with cancer  
H. Park, J.-C. Kim, J. Cho, J.H. Lim, M.H. Lee; KR



- 13:05 - 13:05 1723P - Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy  
K. Talasiewicz, P. Ozdowska, B. Milanowska, K. Gepner, B. Jagielska; PL
- 13:05 - 13:05 1724P - Personalised Nutritional care during chemotherapy using survey on taste changes during chemotherapy: first experience from tertiary chemotherapy day care Center in Northern India  
A. VORA, S. Chatterjee, A. Upadhyay, N. Hazarika, G.S. Bhattacharya; IN
- 13:05 - 13:05 1725P - Role of Megestrol acetate versus Dexamethasone for improvement in appetite in patients with cancer associated anorexia cachexia: A randomized controlled Pilot trial  
S. Ostwal, N. Salins, J. Deodhar, M. Maryann; IN
- 13:05 - 13:05 1726P - Population pharmacokinetics (PPK) of anamorelin (ANAM), an oral selective ghrelin receptor agonist  
A. Bernareggi<sup>1</sup>, S. Kaasa<sup>2</sup>, M. Fallon<sup>3</sup>, R. Skipworth<sup>3</sup>, D. Currow<sup>4</sup>; <sup>1</sup>CH, <sup>2</sup>NO, <sup>3</sup>GB, <sup>4</sup>AU
- 13:05 - 13:05 1727P - Health care providers' experiences of positive and negative effects of parenteral nutrition therapy in cancer patients  
K. Sand, L. Thoresen, T. Solheim, R. Helgås, E. Løhre, T. Balstad; NO
- 13:05 - 13:05 1728P - Assessment of anorexia and weight loss in newly diagnosed upper gastrointestinal cancer patients with localised and metastatic disease, using the Functional Assessment of Anorexia Cachexia Therapy Anorexia/Cachexia Subscale (FAACT A/CS)  
M. Abraham, Z. Kordatou, W. Mansoor; GB
- 13:05 - 13:05 1729P - Body composition factor is independent prognosticator in advanced pancreatic cancer patients  
S. Kang, H.S. Park, H.-C. Jeung; KR
- 13:05 - 13:05 1730P - Current use of clinical nutrition in oncology patients – real world evidence from big data in Italy  
F. Di Costanzo<sup>1</sup>, R. Caccialanza<sup>1</sup>, A. Santoro<sup>2</sup>, C. Gavazzi<sup>1</sup>, P. Pedrazzoli<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>(MI)/IT
- 13:05 - 13:05 1731P - Nutritional cancer care: slowly evolving clinical practice reveals regional and professional HCP variability  
F. Strasser<sup>1</sup>, J. Arends<sup>2</sup>, A. Laviano<sup>3</sup>, A. O'Callaghan<sup>4</sup>, R. Audisio<sup>5</sup>, M. Sawyer<sup>6</sup>, S. Kaasa<sup>7</sup>; <sup>1</sup>CH, <sup>2</sup>DE, <sup>3</sup>IT, <sup>4</sup>NL, <sup>5</sup>Merseyside/GB, <sup>6</sup>Alberta/CA, <sup>7</sup>NO
- 13:05 - 13:05 1732P - Unidentified cachexia patients in the Oncologic setting: cachexia UFO's do exist.  
E. De Waele<sup>1</sup>, J. Demol<sup>1</sup>, R. Caccialanza<sup>2</sup>, P. Cotogni<sup>2</sup>, H. Spapen<sup>1</sup>, M. Malbrain<sup>1</sup>, J. De Grève<sup>1</sup>, J. Pen<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>IT
- 13:05 - 13:05 1733P - The Effect of Sarcopenia on Acute Chemotherapy Toxicity in Gastrointestinal Cancer Patients Undergoing Systemic Therapy  
N. Ozdemir, O. Yazici, K. Silay, G. Ucar, T. Eren, D. sener dede, M.A.N. Sendur, M. Akinci, A. Baykal, B. Yalcin, N. Zengin; TR
- 13:05 - 13:05 1734P - Early detection of skeletal muscle atrophy using a multiple plasma-free amino acid index in the advanced aged patients with advanced pancreatic cancer

S. Mitsunaga<sup>1</sup>, M. Takada<sup>1</sup>, S. Nishikawa<sup>1</sup>, A. Imaizumi<sup>1</sup>, M. Ishii<sup>1</sup>, M. Ikeda<sup>2</sup>; <sup>1</sup>JP, <sup>2</sup>Chiba/JP

- 13:05 - 13:05 1735P - Trajectory of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) predicts time to progression (TTP) in metastatic colorectal cancer (mCRC) patients.  
S.A. Kurk, R. Stellato, P. Peeters, M. Oskam, B. Dorresteijn, M. Jourdan, C. Punt, M. Koopman, A. May; NL
- 13:05 - 13:05 1736P - Clinical impact of Whey protein and Nutritional Counseling in Gastrointestinal cancer Patients  
M. Roberto<sup>1</sup>, E. Sarfati<sup>1</sup>, M. Di Girolamo<sup>1</sup>, F.M. Schipilliti<sup>1</sup>, E. Crimini<sup>1</sup>, A. Botticelli<sup>1</sup>, L. Marchetti<sup>1</sup>, M. Muscaritoli<sup>2</sup>, P. Marchetti<sup>1</sup>, F. Mazzuca<sup>1</sup>; <sup>1</sup>IT, <sup>2</sup>RM/IT
- 13:05 - 13:05 1737P - Impact of taste alterations during systemic anti-tumour therapy on the liking of oral nutritional supplements with adapted flavours  
J. De Haan, Y. Moshage, D. Kluijfhooft, R. Renken, C. Corbier, H. Blanchard, A. Reyners; NL
- 13:05 - 13:05 1738P - Overweight, obesity and weight gain after breast cancer (BC): a prospective clinical study  
A. Di Meglio<sup>1</sup>, M. El-Mouhebb<sup>2</sup>, S. Michiels<sup>2</sup>, L. Jones<sup>3</sup>, M. Annonay<sup>4</sup>, A. Zingarello<sup>2</sup>, M. Matias<sup>2</sup>, S. EVERHARD<sup>2</sup>, A.L. Martin<sup>2</sup>, P. Arveux<sup>2</sup>, O. Tredan<sup>4</sup>, P. SOULIE<sup>2</sup>, P. Cottu<sup>5</sup>, A. Partridge<sup>6</sup>, L. Del Mastro<sup>1</sup>, J. Ligibel<sup>6</sup>, F. André<sup>4</sup>, I. Vaz-Luis<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>FR, <sup>3</sup>NY/US, <sup>4</sup>CEDEX/FR, <sup>5</sup>CEDEX 5/FR, <sup>6</sup>US
- 13:05 - 13:05 1739P - Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)  
A. Di Meglio<sup>1</sup>, M. El-Mouhebb<sup>2</sup>, S. Michiels<sup>2</sup>, L. Jones<sup>3</sup>, E. Martin<sup>2</sup>, M. Matias<sup>2</sup>, A.E. Lohmann Palhares<sup>4</sup>, F. Joly<sup>2</sup>, L. Vanlemmens<sup>5</sup>, S. EVERHARD<sup>2</sup>, A.L. Martin<sup>2</sup>, J. Lemonnier<sup>2</sup>, P. Arveux<sup>2</sup>, P. Cottu<sup>6</sup>, C. Coutant<sup>7</sup>, L. Del Mastro<sup>1</sup>, A. Partridge<sup>8</sup>, F. André<sup>5</sup>, J. Ligibel<sup>8</sup>, I. Vaz-Luis<sup>2</sup>; <sup>1</sup>IT, <sup>2</sup>FR, <sup>3</sup>NY/US, <sup>4</sup>RJ/BR, <sup>5</sup>CEDEX/FR, <sup>6</sup>CEDEX 5/FR, <sup>7</sup>Cedex/FR, <sup>8</sup>US
- 13:05 - 13:05 1740P - Patient reported outcomes: Web-monitoring versus nurse assessment to improve anticancer therapies?  
M. Korostelev<sup>1</sup>, K. Sejean<sup>1</sup>, C. Lepage<sup>1</sup>, J. Stevens<sup>1</sup>, B. Bonan<sup>1</sup>, P. Beuzebec<sup>2</sup>, F. Scotté<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR
- 13:05 - 13:05 1741P - Poly medication in elderly cancer patients treated with chemotherapy  
A.-L. COUDERC<sup>1</sup>, F. Correard<sup>1</sup>, C. Tabele<sup>1</sup>, E. Nouguerede<sup>1</sup>, L. Greillier<sup>1</sup>, F. Duffaud<sup>2</sup>, P. Auquier<sup>1</sup>, A. Daumas<sup>1</sup>, P. Bertault-Peres<sup>1</sup>, P. Villani<sup>1</sup>, S. Honore<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR
- 13:05 - 13:05 1742P - Geriatric oncology (GO): long term follow-up of a prospective series of the GO Unit, at A. C. Camargo Cancer Center.  
A. DETTINO, M. Donadio, A. Cabral, V. Jesus, M. Fanelli, S. Sanches; BR
- 13:05 - 13:05 1743P - Developing a predictive model for chemotherapy related toxicities in older Asian adults.  
S.L.A. Pang, F. Ho, Y.S. Ng, C. Cai, M. Wang, W.C. Yong, B.C. Tai; SG
- 13:05 - 13:05 1744P - Palliative Local Therapy of advanced Breast Cancer  
T. Letodiani, M. Shavdia, N. Shavdia, K. Chaava, N. Gegeshidze; GE

- 13:05 - 13:05 1745P - General and dedicated cancer emergency room: clinical and financial implications  
N. Malavasi, C. Fiorani, L. Ferrara, R. Postiglione, L. Scarabelli, F. Cantile, A. Saviola, G. Longo, A. Luciani, S. Cascinu; IT
- 13:05 - 13:05 1746P - Comparing cancer patients' and support persons' preferences for the type of consultation and the format of information provided when making a treatment decision  
A. Herrmann, R. Sanson-Fisher, A. Hall, L. Wall, N. Zdenkowski, A. Waller; AU
- 13:05 - 13:05 1747P - EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide (ENZ) in Combination with Conventional Androgen Deprivation Therapy (ADT) for Hormone Naïve Prostate Cancer (HSPC)  
M. Harrison<sup>1</sup>, P. Davis<sup>2</sup>, M. Khouri<sup>2</sup>, R. Gupta<sup>1</sup>, A. Armstrong<sup>1</sup>, M. McNamara<sup>2</sup>, T. Zhang<sup>2</sup>, M. Anand<sup>2</sup>, K. Onyenwoke<sup>2</sup>, H. Hood<sup>2</sup>, S. Edwardson<sup>2</sup>, D. Craig<sup>2</sup>, Y. Wu<sup>2</sup>, P. Healy<sup>2</sup>, B. Coyne<sup>2</sup>, L. Jones<sup>3</sup>, D. George<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>NC/US, <sup>3</sup>NY/US
- 13:05 - 13:05 1748P - Cancer care-related social media (SM) and internet usage differences between adolescents and young adults (AYA), adults and elderly patients with cancer.  
L. Eng<sup>1</sup>, J. Bender<sup>2</sup>, K. Hueniken<sup>2</sup>, S. Kassirian<sup>2</sup>, D. Yang<sup>2</sup>, L. Mitchell<sup>2</sup>, C. Paulo<sup>2</sup>, A. Magony<sup>2</sup>, E.C. Smith<sup>2</sup>, M. Liang<sup>2</sup>, M.C. Brown<sup>2</sup>, W. Xu<sup>2</sup>, S. Alibhai<sup>2</sup>, G. Liu<sup>2</sup>, A. Gupta<sup>2</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA
- 13:05 - 13:05 1749P - Ultrasound-guided femoro-popliteal block in lower limb sarcoma and cutaneous malignancy patients- Is it the time to abandon spinal anaesthesia for foot and ankle surgeries.  
N. Moda, IN
- 13:05 - 13:05 1750P - Assessment of socio-economic, physical and mental health status of long-term cancer survivors  
A. Gallego Martínez, B. Martínez, I. Ghanem, E. Espinosa, B. Castelo, M.P. Zamora Aunon, A. Pinto Marin, L. Ruiz-Giménez, A. Redondo, J. Feliu Batlle; ES
- 13:05 - 13:05 1751P - Usability testing of EirV3-a computer-based tool for patient reported outcome measures in cancer  
H. Krogstad, S. Sundt-Hansen, M. Hjermstad, L. Hågensen, S. Kaasa, J.H. Loge, S. Raj, A. Steinsbekk, K. Sand; NO
- 13:05 - 13:05 1752P - Monitoring Quality of Life in Dutch women with breast cancer: 'the Care Notebook study'  
R.T. Lugtenberg<sup>1</sup>, M. Fischer<sup>1</sup>, F. de Jongh<sup>1</sup>, K. Inoue<sup>2</sup>, A. Matsuda<sup>2</sup>, S.R.S. Ramai<sup>1</sup>, J. Nortier<sup>1</sup>, H. Putter<sup>1</sup>, K. Yamaoka<sup>2</sup>, K. Kubota<sup>2</sup>, K. Kobayashi<sup>2</sup>, A.A. Kaptein<sup>1</sup>, J. Kroep<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>JP
- 13:05 - 13:05 1753P - Benefits of Physical Activity and Sport integrated into the care pathway of oncology patient.  
L. Vanleemmens<sup>1</sup>, H. Mocaer<sup>2</sup>, T. Ginsbourger<sup>2</sup>, J.M. Descotes<sup>2</sup>, N. Masselin<sup>2</sup>, H. Deroubaix<sup>2</sup>, C. Fabre<sup>2</sup>, J. Devriendt<sup>2</sup>, T. Bouillet<sup>2</sup>, E. Lartigau<sup>2</sup>; <sup>1</sup>CEDEX/FR, <sup>2</sup>FR
- 13:05 - 13:05 1754P - Prognostic factors for critically ill patients with solid cancer tumours admitted to a medical intensive care unit.  
C. Baylot, A. Francopoulo, A. Quivy, O. Guisset, G. Hilbert, E. Frison, A. Ravaud, A. Daste; FR
- 13:05 - 13:05 1755P - A pilot study of exercise intervention in patients with metastatic cancer: feasibility, safety, and patient reported outcome

J.-H. Park<sup>1</sup>, E.Y. Kim<sup>1</sup>, K.D. Park<sup>1</sup>, S.M. Kang<sup>2</sup>, H. Ahn<sup>1</sup>, Y.S. Kim<sup>1</sup>, I. Park<sup>1</sup>, S.J. Sym<sup>1</sup>, D.B. Shin<sup>1</sup>; <sup>1</sup>KR, <sup>2</sup>KP

- 13:05 - 13:05 1756P - A prospective analysis of 30 day mortality following palliative chemotherapy at an Australian tertiary cancer centre.  
J. McCracken<sup>1</sup>, A. Dabscheck<sup>1</sup>, M. Coperchini<sup>1</sup>, I. Hornung<sup>1</sup>, A. Jalali<sup>2</sup>, G. Akers<sup>1</sup>, A. Karahalios<sup>2</sup>, L. Lipton<sup>2</sup>; <sup>1</sup>AU, <sup>2</sup>VIC/AU
- 13:05 - 13:05 1757P - Characterisation of oncologic patient visits at the ED at an austrian tertiary care center  
B. Pauzenberger, T. Fuereder, A. Laggner, C. Zielinski, C. Minichsdorfer; AT
- 13:05 - 13:05 1758P - High proportion of prostate cancer survivors continue to experience a negative impact on quality of life long after diagnosis: Patient reported outcomes for an Australian population-based sample.  
Q. Tran<sup>1</sup>, A. Ward<sup>2</sup>, K. Lisy<sup>2</sup>, J. Bishop<sup>2</sup>, M. Jefford<sup>2</sup>; <sup>1</sup>QLD/AU, <sup>2</sup>VIC/AU
- 13:05 - 13:05 1759P - A systematic approach to smoking cessation in regional cancer centres in Ontario, Canada  
W. Evans<sup>1</sup>, E. cameron<sup>2</sup>, M. Haque<sup>2</sup>, N. Schwartz<sup>2</sup>, S. Khan<sup>2</sup>, R. Truscott<sup>2</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA
- 13:05 - 13:05 1760P - A Longitudinal Study of a New Point-of-Care Nerve Conduction Device for Quantitative Assessment of Chemotherapy-Induced Peripheral Neurotoxicity  
A. Matsuoka<sup>1</sup>, O. Maeda<sup>2</sup>, A. Mitsuma<sup>2</sup>, K. Uehara<sup>2</sup>, G. Nakayama<sup>1</sup>, M. Nagino<sup>2</sup>, Y. Kodera<sup>2</sup>, Y. Ando<sup>1</sup>; <sup>1</sup>Aichi/JP, <sup>2</sup>JP
- 13:05 - 13:05 1761P - Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance  
K. Thein<sup>1</sup>, A. Sultan<sup>2</sup>, M. Zaw<sup>3</sup>, M. Han<sup>2</sup>, N. Yu<sup>3</sup>, H. Igid<sup>2</sup>, C. Jones<sup>2</sup>, N. D'Cunha<sup>2</sup>, S. Awasthi<sup>2</sup>, F. Hardwicke<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>TX/US, <sup>3</sup>NY/US
- 13:05 - 13:05 1762P - Chemotherapy-Induced Peripheral Neurotoxicity (CIPN): what are patients telling us?  
G. Cavaletti, IT
- 13:05 - 13:05 1763P - Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care?  
C. Tlemsani<sup>1</sup>, G. Zalcmann<sup>1</sup>, R. Bernard<sup>1</sup>, A. Zerouali<sup>1</sup>, F. Goldwasser<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 14/FR
- 13:05 - 13:05 1764P - A Survey on acceptable nomenclature in addressing patient needs among the delegates of a national conference on supportive medicine  
R. Arora, IN
- 13:05 - 13:05 1765P - A Survey on purview of palliative medicine services among the delegates of a national conference on supportive medicine  
R. Arora, IN
- 13:05 - 13:05 1766P - Sexual Functioning and Depression among Egyptian Breast Cancer Patients following surgery and neoadjuvant/adjuvant chemotherapy  
S. Al Hassanin<sup>1</sup>, S. Alsirafy<sup>2</sup>; <sup>1</sup>Menoufia Governorate/EG, <sup>2</sup>EG

- 13:05 - 13:05 1767P - Supportive care: patient expectations, availability and uptake  
H. Simon<sup>1</sup>, J. Viguier<sup>1</sup>, G. Ganem<sup>1</sup>, C. Touboul<sup>1</sup>, C. Lhommel<sup>1</sup>, H. Naman<sup>1</sup>, J.F. Morère<sup>1</sup>, F. Eisinger<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 9/FR
- 13:05 - 13:05 1768P - Novel approach for counselling of young cancer patients  
U. Seifart, T. Langer, I.-K. Na, J. Schulze, M. Freund; DE
- 13:05 - 13:05 1769P - Health-related quality of life priorities in adolescents and young adults (AYA) with cancer: discrepancies with health care professionals' perceptions  
S. Kaal<sup>1</sup>, J. Prins<sup>1</sup>, R. Jansen<sup>1</sup>, E. Manten-Horst<sup>1</sup>, P. Servaes<sup>1</sup>, W. van der Graaf<sup>2</sup>, O. Husson<sup>3</sup>; <sup>1</sup>NL, <sup>2</sup>Surrey/GB, <sup>3</sup>GB
- 13:05 - 13:05 1770P - What Information and Features do Young and Older Adults with Cancer Want in their Hospital-based Social Media Cancer Resource?  
C. Paulo, L. Eng, L. Mitchell, I. Geist, S. Kassirian, A. Magony, E.C. Smith, C. Brown, M. Liang, K. Hueniken, D. Yang, W. Xu, G. Liu, A. Gupta, J. Bender; CA
- 13:05 - 13:05 1771P - Hypothyroidism in cancer patients received multikinase inhibitors: Risk Factors and Outcomes  
S. Hansuranant, H. Nimitphong, O. Pattanaprateep, R. Phraewphiphat, D. Muntham, T. Reungwetwattana; TH
- 13:05 - 13:05 1772P - Immune related adverse events across cancer types: incidence, risk factors, and survival  
D. Owen<sup>1</sup>, J. Burkart<sup>2</sup>, S. Patel<sup>2</sup>, L. Wei<sup>2</sup>, G. Tinoco<sup>2</sup>, D. Liebner<sup>2</sup>, K. He<sup>2</sup>, P. Shields<sup>2</sup>, E. Bertino<sup>2</sup>, C. Presley<sup>2</sup>, A. Johns<sup>2</sup>, E. Folefac<sup>2</sup>, T. Olencki<sup>2</sup>, D. Carbone<sup>2</sup>, C. Verschraegen<sup>3</sup>, G. Otterson<sup>2</sup>, K. Kendra<sup>2</sup>; <sup>1</sup>US, <sup>2</sup>OH/US, <sup>3</sup>Vermont/US
- 13:05 - 13:05 1773P - Effect of yoga on Chemo-Radiotherapy induced Diabetes and Hypertension (CRID-H) among cervical cancer patients at a regional cancer institute in South India.  
N. Nelson<sup>1</sup>, I. Khaleel<sup>1</sup>, M. ROY<sup>1</sup>, R. C<sup>1</sup>, H.B. Govardhan<sup>2</sup>, N. Jasti<sup>1</sup>, S. Suresh<sup>1</sup>, R. Kashyap<sup>1</sup>, L. Lokanath<sup>1</sup>; <sup>1</sup>IN, <sup>2</sup>Karnatka/IN
- 13:05 - 13:05 1774P - Fatigue prevalence and adherence to treatment. A real-world data survey and mathematical model application.  
D. Vorobiof<sup>1</sup>, E. Malki<sup>2</sup>, I. Deutsch<sup>2</sup>, M. Bivasbenita<sup>2</sup>; <sup>1</sup>Gauteng/IL, <sup>2</sup>ZA
- 13:05 - 13:05 1775P - A survey on attitude towards Euthanasia among delegates of a national conference on supportive medicine  
R. Arora, IN
- 13:05 - 13:05 1776P - Acute toxicity of concurrent radiochemotherapy for locally advanced head and neck cancer, a prospective study  
E. Dewaele<sup>1</sup>, P.J. van Dam<sup>1</sup>, B. De Laere<sup>2</sup>, C. Verschueren<sup>1</sup>, P. Specenier<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>Antwerp/BE
- 13:05 - 13:05 1777P - Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study  
Q. Tran<sup>1</sup>, A. Schimdt<sup>2</sup>, Z. Lwin<sup>1</sup>, B. Hughes<sup>2</sup>; <sup>1</sup>QLD/AU, <sup>2</sup>AU

- 13:05 - 13:05 1778P - Chemotherapy effect on daytime sleepiness and contributing factors in older adults with cancer  
S. Sadighi, B. Saberzadeh-Ardestani, B. Khosravi, J. Zebardast; IR
- 13:05 - 13:05 1779P - Group Pre-Chemotherapy Education: Improving patient experience through education and empowerment  
K. McIntyre, R. Blackwood, V. Riley, L. Carballo, H. Plant, T. Marler-Hausen; GB
- 13:05 - 13:05 1780P - Clinical and Psychometric validation of the BreSAS Questionnaire for Symptom Assessment among Breast Cancer Survivors.  
R. Giusti, E. Scarpi, K. Cannita, R.R. Silva, M. Filetti, M. Mazzotta, R. Rossi, V. Cocciolone, T. Sidoni, M. Tudini, C. Ficorella, A. Botticelli, P. Marchetti, G. Porzio, L. Verna; IT
- 13:05 - 13:05 1781P - Association of phase angle and chemotherapy toxicity among Mexican patients with nonmetastatic breast cancer  
M.T. Nieto Coronel, C. Arce- Salinas, A. Peña-Ruiz, M. Espinoza Cuevas, J. Santamaria-Galicia; MX
- 13:05 - 13:05 1782P - Hepatitis screening for patients to undergo chemotherapy in Cyprus  
P. Kountourakis<sup>1</sup>, A. Agathocleous<sup>1</sup>, E. Kakouri<sup>1</sup>, Y. Marcou<sup>1</sup>, G. Orphanos<sup>1</sup>, F. Kyriacou<sup>1</sup>, D. Papamichael<sup>1</sup>, H. Charalambous<sup>2</sup>; <sup>1</sup>CY, <sup>2</sup>Nicosia/CY
- 13:05 - 13:05 1783P - Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency virus (HIV) screening prior to chemotherapy initiation among patients with solid tumors.  
S. Giordano<sup>1</sup>, Z. Duan<sup>2</sup>, H. Zhao<sup>2</sup>, J. Hwang<sup>2</sup>, M. Chavez Mac Gregor<sup>1</sup>; <sup>1</sup>TX/US, <sup>2</sup>US
- 13:05 - 13:05 1784P - Rapid identification of bloodstream infection pathogens  
N. Panova, O. Kit, O. Kutsevalova, I. Lysenko, V. Dmitrieva, D. Rozenko, Y. Gevorkyan, E. Pak, O. Kozyuk, E. Kapuza, O. Shatokhina, N. Nikolaeva, E. Kalabanova, I. Mitashok, L. Vladimirova; RU
- 13:05 - 13:05 1785P - Pathogens and characteristics of candidemia in hospitals of Rostov-on-Don. Multicenter study in Russia  
O. Kutsevalova, O. Kit, N. Panova, I. Lysenko, V. Dmitrieva, D. Rozenko, E. Kalabanova, I. Mitashok, G. Klyasova, Y. Shatokhin, I. Snezhko, D. Martynov, V. Malygin, O. Korosteleva, A. Matsuga, K. Aslanyan, L. Vladimirova; RU
- 13:05 - 13:05 1786P - Antiviral Prophylaxis Cannot Reduce the Risk of Hepatitis B Reactivation During Chemotherapy for non HCC Solid Tumor Patients with Lower HBV DNA TiterA Retrospective Cohort Study.  
Q. qin, A. Zhou, L. Yang, D. Zhong; CN
- 13:05 - 13:05 1787P - Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: final analysis  
F. Haslbauer<sup>1</sup>, A. Petzer<sup>1</sup>, M. Safanda<sup>2</sup>, A. Tomova<sup>3</sup>, M. Porubská<sup>4</sup>, Z. Bajory<sup>5</sup>, D. Niepel<sup>6</sup>, C. Jäger<sup>1</sup>, D. Kalinin<sup>7</sup>, R. Greil<sup>1</sup>; <sup>1</sup>AT, <sup>2</sup>CZ, <sup>3</sup>BG, <sup>4</sup>SK, <sup>5</sup>HU, <sup>6</sup>CH, <sup>7</sup>UA
- 13:05 - 13:05 1788P - A multicenter retrospective investigation on the efficacy of perioperative oral management in cancer patients  
S.-I. Yamada, S. Soutome, T. Hasegawa, I. Toujou, H. Nakahara, M. Kawakami, M. Hirose, S. Fujita, T. Komori, T. Kirita, Y. Shibuya, M. Umeda, H. Kurita; JP

- 13:05 - 13:05 (Withdrawn)
- 13:05 - 13:05 1790P - Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study  
J. Desrame<sup>1</sup>, J. Loup Mouysset<sup>1</sup>, T. Altwegg<sup>1</sup>, L. Zelek<sup>1</sup>, N. Baize<sup>2</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 9/FR
- 13:05 - 13:05 1792P - Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study.  
M. Araz, M. Karaağaç, L. Korkmaz, L. Koral, F. İnci, I. Beypinar, M. Uysal, M. Artac; TR
- 13:05 - 13:05 1793P - Painkiller-related dizziness in malignant tumors - A systematic review  
R. Spiegel<sup>1</sup>, S. Rothschild<sup>2</sup>, R. Sutter<sup>2</sup>, R. Kalla<sup>2</sup>; <sup>1</sup>DE, <sup>2</sup>CH
- 13:05 - 13:05 1794P - Prevalence, risk factors and management of opioid-induced constipation in cancer pain: a nationwide, cross-sectional study in Korea  
S.Y. Lee, Y.S. Hong, K.T. Lee, S.H. Shin, M.Y. Choi, S.J. Sym, H.-S. Oh, S.N. Lee, E.-K. Song; KR
- 13:05 - 13:05 1795P - Bald is beautiful: no more. The stigma of alopecia during chemotherapy: Brindisi Oncology Dpt experience.  
D. Loparco, L. Orlando, M. Caloro, P. Fedele, P. Schiavone, A. Quaranta, C. Calio, M. Cinefra, P. Ferrara, L.L. Falcone, V. Capone, C. Destro, A. Morleo, A. Ricco, V. Bonuso, G. Lotti, M. D'amico, P. Rizzo, A. Marino, S. Cinieri; IT
- 13:05 - 13:05 1796P - A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: methodological approach  
R. Nakov<sup>1</sup>, S. Schussler<sup>2</sup>, S. Schier-Mumzhiu<sup>1</sup>, A. Skerjanec<sup>1</sup>, A. Bellon<sup>1</sup>, J. Wang<sup>3</sup>, A. Krendyukov<sup>1</sup>, G. Otto<sup>1</sup>; <sup>1</sup>DE, <sup>2</sup>NJ/US, <sup>3</sup>US
- 13:05 - 13:05 1797P - Quality of Life in Breast Cancer Tunisian Women : A monocentric survey  
S. Labidi, C. Bousrih, M. Saadi, H. El Benna, M. Nesrine, N. Daoud, H. Boussen; TN
- 13:05 - 13:05 1798P - Anticancer therapy within the last 30 days of life in a regional cancer centre  
M. Nguyen, AU
- 13:05 - 13:05 1799P - Febrile Neutropenia Management And Concordance Of Institutional Protocol With Clinical Practice  
A. Oliveira, L. Bretes, I. Furtado, B. Gosalbez Pequeno, J. Magalhaes; PT
- 13:05 - 13:05 1800P - Salient features of an indigenous integrated inpatient model of delivery of supportive medicine services - a narrative review  
R. Arora, IN
- 13:05 - 13:05 1801P - Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches

N. Lankheet<sup>1</sup>, K. Ferrier<sup>1</sup>, S. Gibbons<sup>2</sup>, D. Burger<sup>1</sup>, K. McAllister<sup>2</sup>, J. Martin<sup>2</sup>, S. Khoo<sup>2</sup>, N. van Erp<sup>1</sup>, F. Jansman<sup>1</sup>; <sup>1</sup>NL, <sup>2</sup>GB

- 13:05 - 13:05 1802P - The concordance with antiemetic guideline for pediatric, adolescent and young adult patients with cancer using a large-scale administrative database.  
S. Bun, S. Kunisawa, N. Sasaki, K. Fushimi, K. Matsumoto, A. Yamatani, Y. Imanaka; JP
- 13:05 - 13:05 1803P - Effectiveness of surgical glove compression therapy as a prophylactic method against nab-Paclitaxel induced peripheral neuropathy  
S. Tsuyuki, K. Yamagami, H. Yoshibayashi, T. Sugie, Y. Mizuno, S. Tanaka, H. Kato, T. Okuno, N. Ogura, H. Yamashiro, H. Takuwa, Y. Kikawa, T. Hashimoto, T. Kato, S. Takahara, A. Yamauchi, T. Inamoto; JP
- 13:05 - 13:05 1804P - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)  
H. Piessevaux, W. Demey, A. Bols, J. Janssens, M. Polus, H. Rezaei Kalantari, S. Laurent, A. Demols, Y. Humblet, G. Deboever, K. Kargar Samani, M. Ferrante, E. Monsaert, T. Rondou, J.-L. van Laethem, S. Tejpar; BE
- 13:05 - 13:05 1805TiP - Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV)  
A. Mersiades<sup>1</sup>, A. Tognela<sup>2</sup>, P. Haber<sup>2</sup>, M. Stockler<sup>2</sup>, N. Lintzeris<sup>2</sup>, J. Simes<sup>1</sup>, I. McGregor<sup>2</sup>, I. Olver<sup>2</sup>, D. Allsop<sup>2</sup>, C. Gedye<sup>2</sup>, A. Kirby<sup>1</sup>, R. Morton<sup>1</sup>, K. Briscoe<sup>2</sup>, P. Fox<sup>2</sup>, M. Aghmesheh<sup>1</sup>, N. Wong<sup>1</sup>, A. Bhardwaj<sup>1</sup>, A. Tran<sup>2</sup>, C. Hahn<sup>2</sup>, P. Grimison<sup>2</sup>; <sup>1</sup>NSW/AU, <sup>2</sup>AU

13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 1  
Title: Industry satellite symposium 42 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 14b  
Title: Industry satellite symposium 43 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium ICM - Room 13  
Title: Industry satellite symposium 44 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium Hall A1 - Room 15  
Title: Industry satellite symposium 45 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium Hall A1 - Room 16  
Title: Industry satellite symposium 46 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium Hall B3 - Room 23  
Title: Industry satellite symposium (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium Hall B3 - Room 20  
Title: Industry satellite symposium 47 (TBC)



13:00 - 14:30 Type: Industry Satellite Symposium Hall B3 - Room 22  
Title: Industry satellite symposium 48 (TBC)

13:00 - 14:30 Type: Industry Satellite Symposium Hall B4 - Room 19  
Title: Industry satellite symposium 49 (TBC)

13:00 - 14:00 Type: Young Oncologist session ICM - Room  
Title: YO Clinical Case Discussion: Clinical Cases of Solid Tumours - Discussion Forum for 14a  
Young Oncologists

13:00 - 13:00 Soft tissue sarcoma  
P.G. Casali, IT

13:00 - 13:00 Prostate cancer  
J. de Bono, GB

13:00 - 13:00 Non-small cell lung cancer  
T. Cufer, SI

14:15 - 15:45 Type: Young Oncologist session ICM - Room  
Title: YO Fellowship Session: Fellowships in Europe: Educational opportunities for Young 14a  
Oncologists  
Chair(s): E. de Azambuja, BE; G. Argiles, ES

14:15 - 14:20 Introduction  
E. de Azambuja, BE

14:20 - 14:35 The ESMO Fellowship Programme  
E. de Azambuja, BE

14:35 - 14:50 Practical tips from a former fellow  
L. Vecchione, NL

14:50 - 15:05 Best fellowship project 1

15:05 - 15:20 Best fellowship project 2

15:20 - 15:45 Award Ceremony: Presentation of the ESMO 2018 Fellowships and Best Examination Award 2017

14:45 - 16:15 Type: Special Symposium Hall A1 - Room 17  
 Title: Early detection of cancer using minimally invasive biomarkers  
 Chair(s): J.-C. Soria, US; C. Dive, GB

14:45 - 14:50 Introduction  
J.-C. Soria, CEDEX/US

14:50 - 15:05 Plasma DNA for early cancer screening  
D.(-M. Lo, HK

15:05 - 15:20 Changes in the innate immune system as early events in cancer  
E. Vivier, FR

15:20 - 15:35 Single cells for doing a diagnostic work-up for suspicion of lung cancer  
P. Kuhn, US

15:35 - 15:50 Circulating microRNA biomarkers for early detection of lung cancer  
G. Sozzi, IT

15:50 - 16:05 Pharma perspective: Screening, diagnosis or prognosis  
M. Lee, US

16:05 - 16:15 Conclusions and clinical perspectives  
C. Dive, GB

14:45 - 16:15 Type: Educational session Hall A2 - Room 18  
 Title: The force awakens: Immunotherapy in thoracic malignancies  
 Chair(s): M. Reck, DE; K. Kerr, GB

14:45 - 15:10 Recent updates on biomarkers for immunotherapy beyond PDL1 expression  
K. Kerr, GB

15:10 - 15:35 Mechanisms and management of immunotherapy resistance  
N. Rizvi, NY/US

15:35 - 16:00 Combination and novel approaches to immunotherapy in lung cancer  
M. Reck, DE

16:00 - 16:15 Discussion

14:45 - 16:15 Type: Proffered Paper session ICM - Room 14b  
Title: Proffered paper session - Head & Neck cancer

14:45 - 15:00 One LBA TBC

15:00 - 15:15 1044O - A Phase 1b/2 Study (SCORES) of Durvalumab (D) Plus Danvitarsen (DAN; AZD9150) or AZD5069 (CX2i) in Advanced Solid Malignancies and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC): Updated Results

E. Cohen<sup>1</sup>, K. Harrington<sup>2</sup>, D. Hong<sup>3</sup>, R. Mesia<sup>4</sup>, I. Brana<sup>4</sup>, P. Perez Segura<sup>4</sup>, T. Wise-Draper<sup>5</sup>, M. Scott<sup>5</sup>, P. Mitchell<sup>5</sup>, G. Mugundu<sup>5</sup>, P. McCoon<sup>5</sup>, C. Cook<sup>5</sup>, M. Mehta<sup>5</sup>, U. Keilholz<sup>6</sup>; <sup>1</sup>IL/US, <sup>2</sup>GB, <sup>3</sup>TX/US, <sup>4</sup>ES, <sup>5</sup>US, <sup>6</sup>DE

15:15 - 15:30 Invited Discussant One LBA TBC and 1044O

S. Faivre, FR

15:30 - 15:45 1045O - A phase II window of opportunity study of preoperative olaparib (O) with cisplatin (C) or durvalumab (D) or olaparib alone in in patients with operable squamous cell head and neck carcinoma (HNSCC) (OPHELIA)

A. Psyrri<sup>1</sup>, P. Economopoulou<sup>1</sup>, I. Kotsantis<sup>1</sup>, G. Koutsodontis<sup>1</sup>, M. Cheila<sup>1</sup>, G. Papaxoinis<sup>2</sup>, D. Pectasides<sup>1</sup>, G. Fountzilas<sup>1</sup>, L. Krikoni<sup>1</sup>, V. Souliotis<sup>1</sup>; <sup>1</sup>GR, <sup>2</sup>GB

15:45 - 16:00 1046O - Preliminary results from a phase 2 trial of tipifarnib in Squamous Cell Carcinomas (SCCs) with HRAS mutations.

A. Ho<sup>1</sup>, N. Chau<sup>1</sup>, J. Bauman<sup>1</sup>, K. Bible<sup>1</sup>, A. Chintakuntlawar<sup>2</sup>, M. Cabanillas<sup>3</sup>, D. Wong<sup>1</sup>, I. Braña Garcia<sup>4</sup>, M. Brose<sup>1</sup>, V. Boni<sup>4</sup>, C. Even<sup>5</sup>, M. Razaq<sup>1</sup>, V. Mishra<sup>1</sup>, K. Bracken<sup>1</sup>, D. Wages<sup>1</sup>, C. Scholz<sup>1</sup>, A. Gualberto<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>MN/US, <sup>3</sup>TX/US, <sup>4</sup>ES, <sup>5</sup>FR

16:00 - 16:15 Invited Discussant 1045O and 1046O

L. Siu, Ontario/CA

14:45 - 16:15	Type: Special Symposium Title: Drugging non-conventional targets Chair(s): A.A. Adjei, US; C. Dittich, AT	ICM - Room 13
14:45 - 14:50	Introduction	
14:50 - 15:10	Inhibiting RAS signaling <u>A.A. Adjei</u> , MN/US	
15:10 - 15:30	DNA repair and Microsatellite Instability <u>A. Duval</u> , FR	
15:30 - 15:50	Nuclear transporters <u>M. Mau-Sorensen</u> , DK	
15:50 - 16:10	Tumour metabolism <u>B. van Tine</u> , Missouri/US	
16:10 - 16:15	Conclusions and perspectives <u>A.A. Adjei</u> , MN/US	

14:45 - 16:15	Type: Proffered Paper session Title: Proffered paper session - NETs and endocrine tumours Chair(s): R. Garcia-Carbonero, ES; M. Pavel, DE	Hall A1 - Room 16
14:45 - 14:57	1307O - Efficacy of Lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)  <u>J. Capdevila</u> <sup>1</sup> , N. Fazio <sup>2</sup> , C. Lopez <sup>1</sup> , A. Teule <sup>1</sup> , J. Valle <sup>3</sup> , S. Tafuto <sup>2</sup> , A. Custodio <sup>1</sup> , N. Reed <sup>3</sup> , M. Raderer <sup>4</sup> , E. Grande <sup>1</sup> , R. Garcia-Carbonero <sup>1</sup> , P. Jimenez Fonseca <sup>1</sup> , V. Alonso <sup>1</sup> , L. Antonuzzo <sup>2</sup> , A. Spallanzani <sup>2</sup> , A. Berruti <sup>2</sup> , I. Sevilla Garcia <sup>1</sup> , A. La Casta <sup>1</sup> , J. Hernando <sup>1</sup> , T. Ibrahim <sup>5</sup> ; <sup>1</sup> ES, <sup>2</sup> IT, <sup>3</sup> GB, <sup>4</sup> AT, <sup>5</sup> Forlì-Cesena/IT	
14:57 - 15:09	Invited Discussant 1307O <u>E. Baudin</u> , CEDEX/FR	
15:09 - 15:21	1819O - Tumor Growth Rate and Lenvatinib Efficacy in Radioiodine-refractory Differentiated Thyroid Cancer  <u>S. Leboulleux</u> <sup>1</sup> , E. Lee <sup>2</sup> , L. Bastholt <sup>3</sup> , M. Tahara <sup>4</sup> , L. Wirth <sup>5</sup> , S. Sherman <sup>6</sup> , B. Robinson <sup>7</sup> , A. Teng <sup>6</sup> , P. Joshi <sup>6</sup> , S. Misir <sup>6</sup> , C. Dutcus <sup>8</sup> , R. Tuttle <sup>6</sup> , M. Schlumberger <sup>9</sup> ; <sup>1</sup> FR, <sup>2</sup> KR, <sup>3</sup> DK, <sup>4</sup> Chiba/JP, <sup>5</sup> MA/US, <sup>6</sup> US, <sup>7</sup> AU, <sup>8</sup> New Jersey/US, <sup>9</sup> CEDEX/FR	
15:21 - 15:33	Invited Discussant 1819O	
15:33 - 15:45	1308O - Activity &&  <u>J. Yao</u> <sup>1</sup> , J. Strosberg <sup>2</sup> , N. Fazio <sup>3</sup> , M. Pavel <sup>4</sup> , P. Ruzniewski <sup>5</sup> , E. Bergsland <sup>6</sup> , D. Li <sup>2</sup> , S. Tafuto <sup>3</sup> , N. Raj <sup>2</sup> , D. Campana <sup>3</sup> , S. Hijioka <sup>7</sup> , M. Raderer <sup>8</sup> , R. Guimbaud <sup>5</sup> , P. Gajate <sup>9</sup> , S. Pusceddu <sup>3</sup> , A. Reising <sup>2</sup> , E. Degtyarev <sup>10</sup> , B. Mookerjee <sup>11</sup> , P. Aimone <sup>10</sup> , S. Singh <sup>12</sup> ; <sup>1</sup> TX/US, <sup>2</sup> US, <sup>3</sup> IT, <sup>4</sup> DE, <sup>5</sup> FR, <sup>6</sup> CA/US, <sup>7</sup> JP, <sup>8</sup> AT, <sup>9</sup> ES, <sup>10</sup> CH, <sup>11</sup> NJ/US, <sup>12</sup> ON/CA	
15:45 - 15:57	1309O - Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase 1b trial  <u>P. Zhang</u> , M. Lu, J. Li, L. Shen; CN	
15:57 - 16:09	Invited Discussant 1308O and 1309O <u>K. Oberg</u> , SE	

14:45 - 16:15	Type: Educational session Title: Undifferentiated sarcomas: From MFH to UPS with more distance still to travel Chair(s): J.A. Fletcher, US; A. Italiano, FR	Hall B3 - Room 21
14:45 - 15:10	History of UPS over 2 decades: From MFH to UPS <u>K. Thway</u> , GB	
15:10 - 15:35	Genomic landscape of sarcomas with complex genomics: Separate the wheat from the chaff <u>J.A. Fletcher</u> , MA/US	
15:35 - 16:00	Clinical management of UPS: Retrospective and perspectives in the era of next generation sequencing and immuno-oncology <u>A. Italiano</u> , CEDEX/FR	
16:00 - 16:15	Discussion	
14:45 - 16:00	Type: Poster Discussion session Title: Poster discussion - Basic science Chair(s): L. David, PT	Hall B3 - Room 20
14:45 - 14:45	3PD - Human melanoma cells from different disease stages prime amino acid signature of conditional media indicating signalling in the tumor microenvironment <u>M. Hohenegger</u> , C. Wasinger, A. Hofer, O. Spadiut; AT	
14:45 - 14:45	1893PD - A joint metabolic profile of plasma and tissue samples for discovering novel biomarkers in breast cancer <u>N. Harada</u> , H. Tada, M. Miyashita, Y. Hamanaka, A. Sato, T. Ishida; JP	
14:45 - 15:00	Invited Discussant 3PD and 1893PD	
15:00 - 15:10	Q&A led by Discussant	
15:10 - 15:10	1894PD - Single-cell RNA Sequencing of Triple Negative Breast Cancer Patient-Derived Xenograft Reveals Distinct Cellular Populations Spatially Mapped to Histological Sections <u>C. Martinez Ramirez</u> <sup>1</sup> , H. Kuasne <sup>2</sup> , M. Park <sup>2</sup> , D. Zuo <sup>2</sup> , C. Kleinman <sup>2</sup> , Y. Yang <sup>2</sup> , A. Blanchet-Cohen <sup>2</sup> , P. Savage <sup>2</sup> , J. Ragoussis <sup>2</sup> ; <sup>1</sup> CA, <sup>2</sup> QC/CA	
15:10 - 15:10	1895PD - Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA) <u>N. Karachaliou</u> <sup>1</sup> , M. Lefterova <sup>2</sup> , J. Draper <sup>2</sup> , M.-A. Molina <sup>1</sup> , I. Chaib <sup>1</sup> , R. Palmero <sup>1</sup> , A. Taus <sup>1</sup> , S. Viteri <sup>1</sup> , M. González Cao <sup>1</sup> , M. Majem Tarruella <sup>1</sup> , E. Carcereny Costa <sup>3</sup> , T. Moran <sup>1</sup> , J. Garde Noguera <sup>1</sup> , E. Felip Font <sup>1</sup> , S. Olsen <sup>2</sup> , M. Jackson <sup>2</sup> , M. Sampayo <sup>1</sup> , I. Faull <sup>1</sup> , D. Dix <sup>2</sup> , R. Rosell <sup>3</sup> ; <sup>1</sup> ES, <sup>2</sup> US, <sup>3</sup> Barcelona/ES	

- 15:10 - 15:10 1896PD - Joined analysis of Sarcomatoid Carcinoma (SC) mutational profiles: comparison of lung versus head and neck cancer.  
N. Pecuchet, R. Touachi, A. Ben Lakhdar, V. Fallet, N. Rabbe, H. Blons, A. Lemoine, M. Antoine, S. Tenam, P. Laurent-Puig, M. Wislez; FR
- 15:10 - 15:25 Invited Discussant 1894PD, 1895PD and 1896PD
- 15:25 - 15:35 Q&A led by Discussant
- 15:35 - 15:35 1897PD - Differential expression of Immune Checkpoints (PD-L1, HHLA2, B7x and B7H3) and their Association with Driver Mutations in Pulmonary Sarcomatoid Carcinoma (PSC)  
H. Cheng<sup>1</sup>, J. Sharma<sup>2</sup>, C. Su<sup>2</sup>, S. Li<sup>1</sup>, X. Zang<sup>1</sup>, R. Perez-Soler<sup>2</sup>, B. Halmos<sup>2</sup>, A. Borczuk<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>NY/US
- 15:35 - 15:35 4PD - Immunomodulatory effect of Hepatocyte growth factor on monocytes in human gastric cancer  
L. Hirsch, J. Palle, A. Lapeyre-Prost, S. Pernot, T. Voron, E. Tartour, J. Taieb, M. Terme; FR
- 15:35 - 15:35 5PD - Patritumab (anti-HER3 antibody) augments anti-tumor immune response of adoptive transfer of autologous activated T cells for patient-derived xenograft models of breast cancer.  
E. Suzuki, T. Kotake, T. Nishimura, A. Yamaguchi, F. Pu, M. Toi; JP
- 15:35 - 15:50 Invited Discussant 1897PD, 4PD and 5PD  
L. David, PT
- 15:50 - 16:00 Q&A led by Discussant

14:45 - 16:15	Type: Proffered Paper session Title: Proffered paper session - Public health Chair(s): C. Uyl-de Groot, NL; M. Coleman, GB	Hall B3 - Room 22
14:45 - 14:57	1555O - Magnitude of Clinical Benefit of Cancer Drugs and Time to Health Technology Assessment (HTA) Decisions in Europe <u>T. Hwang</u> <sup>1</sup> , K. Vokinger <sup>2</sup> , A. Tibau <sup>3</sup> , B. Gyawali <sup>4</sup> , H. Naci <sup>5</sup> , J. Franklin <sup>6</sup> , R. Beall <sup>6</sup> , A. Kesselheim <sup>6</sup> ; <sup>1</sup> US, <sup>2</sup> CH, <sup>3</sup> ES, <sup>4</sup> Aichi/US, <sup>5</sup> GB, <sup>6</sup> MA/US	
14:57 - 15:09	1556O - Potential for value-based prescribing of oral oncology drugs <u>M. Ratain</u> <sup>1</sup> , A. Lichter <sup>2</sup> ; <sup>1</sup> IL/US, <sup>2</sup> VA/US	
15:09 - 15:21	1557O - Relation between center volumes for pancreatic and esophageal cancer surgeries and outcome in Belgium: a plea for centralization <u>H. De Schutter</u> , G. Silversmit, K. Haustermans, L. Van Eycken; BE	
15:21 - 15:36	Invited Discussant 1555O, 1556O and 1557O <u>M. Coleman</u> , GB	
15:36 - 15:48	1558O - Worldwide comparison of colorectal cancer survival, by topography and stage at diagnosis (CONCORD-2) <u>S. Benitez Majano</u> , V. Di Carlo, M. Nikšić, M. Coleman, C. Allemani, CONCORD Working Group; GB	
15:48 - 16:00	1559O - Increasing colorectal cancer incidence among young adults in England diagnosed during 2001-2014 <u>A. Exarchakou</u> , L. Donaldson, M. Coleman; GB	
16:00 - 16:15	Invited Discussant 1558O and 1559O <u>B. Jönsson</u> , SE	
14:45 - 16:15	Type: Joint Symposium Title: Joint symposium	Hall B4 - Room 19



14:45 - 16:15 Type: EONS session Hall B4 - Room 24  
 Title: New cancer nursing roles: Innovation in action  
 Chair(s): E. Furlong, IE

14:45 - 15:00 Linking patient-reported outcomes and symptom management: The e-SMART study  
L. McCann, GB

15:00 - 15:15 Establishing a paediatric palliative care service in the State of Palestine  
M.H. Albotma, PS

15:15 - 15:30 Proffered paper 1

15:30 - 15:45 Proffered paper 2

15:45 - 16:00 Proffered paper 3

16:00 - 16:15 Discussion  
E. Furlong, IE

15:00 - 16:00 Type: Multidisciplinary interactive sessions Hall A1 - Room 15  
 Title: Optimal management of bone metastases in 2018  
 Chair(s): P. Francis, AU

15:00 - 15:10 Biology and basis for prediction and prevention  
R. Gomis, ES

15:10 - 15:20 Medical management  
P. Francis, VIC/AU

15:20 - 15:30 New radiation techniques  
P. Poortmans, FR

15:30 - 16:00 Discussion

15:00 - 16:00 Type: Multidisciplinary interactive sessions Hall B3 - Room 23  
 Title: The challenges of toxicities from endocrine treatment in men with prostate cancer  
 Chair(s): I. Duran, ES

15:00 - 15:20 Case on bone health  
M. Smith, US

15:20 - 15:40 Case on cardiac toxicity  
B. Tombal, BE

15:40 - 16:00 Case on fatigue / cognition  
I. Duran, ES

16:00 - 17:30 Type: Young Oncologist session ICM - Room 14a  
 Title: YO Forum: Research projects: From ideas to papers  
 Chair(s): L. De Mattos-Arruda, ES; A.S. Berghoff, AT

16:00 - 16:20 How to select and define your project  
A. Ribas, CA/US

16:20 - 16:40 How to write a proficient project and get it financed

16:40 - 17:00 Dealing with obstacles faced during your project

17:00 - 17:20 Maximising your clinical investigations: How to structure your paper  
F. Ciardiello, IT

17:20 - 17:30 Discussion

16:30 - 18:00 Type: Educational session ICM - Room 1  
 Title: Clinical implementation of PI3K inhibitors  
 Chair(s): F. André, FR

16:30 - 16:55 Who, when and how to test for PIK3CA mutations  
C. Sotiriou, BE

16:55 - 17:20 What is the true impact of PI3K inhibitors in clinical practice?  
F. André, CEDEX/FR

17:20 - 17:45 Managing side effects of PI3K inhibitors  
C. Saura, ES

17:45 - 18:00 Discussion

16:30 - 18:00 Type: Educational session Hall A1 - Room 15  
 Title: State of the art management of GEP- NET  
 Chair(s): N. Fazio, IT

16:30 - 16:55 Pathological diagnosis: What is important for the clinician?  
G. Rindi, IT

16:55 - 17:20 Therapeutic approaches for syndrome management  
J. Chan, US

17:20 - 17:45 Therapeutic approaches for tumour growth control  
N. Fazio, IT

17:45 - 18:00 Discussion

16:30 - 17:30 Type: Multidisciplinary interactive sessions Hall A1 - Room 16  
Title: Different approaches and advances in the management of HPV+ patients

16:30 - 16:40 New staging system (for HPV+ patients)  
H. Mehanna, West Midlands/GB

16:40 - 16:50 Unique radiation considerations (in HPV+ patients)  
E.M. Ozsahin, CH

16:50 - 17:00 Integrating systemic therapy (in HPV+ patients)  
J.-P. Machiels, BE

17:00 - 17:30 Discussion

16:30 - 18:00 Type: Proffered Paper session Hall A2 - Room 18  
Title: Presidential Symposium 3

16:30 - 17:30 Type: Poster Discussion session Hall B3 - Room 21  
Title: Poster Discussion session - Supportive and palliative care 2  
Chair(s): C. Ruhlmann, DK

16:30 - 16:30 1540PD - Health-related quality of life in randomized controlled trials: a systematic review of prognostic significance  
J. Mierzynska<sup>1</sup>, M. Pe<sup>1</sup>, C. Piccinin<sup>1</sup>, F. Martinelli<sup>1</sup>, C. Coens<sup>1</sup>, C. Gotay<sup>2</sup>, A. Eggermont<sup>3</sup>, M. Groenvold<sup>4</sup>, J. Reijneveld<sup>5</sup>, L. Dirven<sup>5</sup>, A. Bottomley<sup>1</sup>; <sup>1</sup>BE, <sup>2</sup>BC/CA, <sup>3</sup>FR, <sup>4</sup>DK, <sup>5</sup>NL

16:30 - 16:30 1690PD - Acceptability in Cancer Outpatients of Completing Routine Assessments of Patient Reported Outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE) versus Other Patient Reported Symptom Outcome Tools  
H. Albaba<sup>1</sup>, M.C. Brown<sup>1</sup>, S. Shakik<sup>1</sup>, S. Su<sup>1</sup>, H. Naik<sup>2</sup>, T. Wang<sup>3</sup>, M. Liang<sup>1</sup>, A. Perez-Cosio<sup>1</sup>, L. Eng<sup>1</sup>, N. Mittmann<sup>1</sup>, W. Xu<sup>1</sup>, G. Liu<sup>1</sup>, D. Howell<sup>1</sup>, T. Barnes<sup>4</sup>; <sup>1</sup>CA, <sup>2</sup>BC/CA, <sup>3</sup>ON/CA, <sup>4</sup>AU

16:30 - 16:45 Invited Discussant 1540PD and 1690PD

16:45 - 16:55 Q&A led by Discussant

16:55 - 16:55 1686PD - Plinabulin (Plin), a Novel non-G-CSF Molecule for the Prevention of Chemotherapy-Induced Neutropenia (CIN), has the Potential to Positively Impact Tumor Micro Environment  
D. Blayney<sup>1</sup>, S. Ogenstad<sup>1</sup>, Y.-K. Shi<sup>2</sup>, Q. Zhang<sup>2</sup>, L. Du<sup>2</sup>, L. Huang<sup>3</sup>, R. Mohanlal<sup>1</sup>; <sup>1</sup>US, <sup>2</sup>CN, <sup>3</sup>NY/US

16:55 - 16:55 1687PD - Neuropathy and Health Behaviors in Cancer Survivors treated with Chemotherapy (CT)

M. Matias<sup>1</sup>, A. Di Meglio<sup>1</sup>, A. Zingarello<sup>1</sup>, S. Michiels<sup>1</sup>, A. Partridge<sup>2</sup>, M. Bendiane<sup>1</sup>, M. Ducreux<sup>3</sup>, F. André<sup>3</sup>, I. Vaz Luis<sup>1</sup>; <sup>1</sup>FR, <sup>2</sup>US, <sup>3</sup>CEDEX/FR

- 16:55 - 16:55 1688PD - Awareness of the cancer and non-cancer related harms of continued smoking in cancer survivors.  
L. Eng<sup>1</sup>, S. Liu<sup>2</sup>, D. Farzanfar<sup>2</sup>, E.C. Smith<sup>2</sup>, A. McCartney<sup>2</sup>, A. Basgaran<sup>2</sup>, K. Balaratnam<sup>2</sup>, S. Yeung<sup>2</sup>, M.C. Brown<sup>2</sup>, D. Howell<sup>2</sup>, J. Jones<sup>2</sup>, W. Xu<sup>2</sup>, D. Goldstein<sup>3</sup>, W. Evans<sup>1</sup>, P. Selby<sup>2</sup>, M. Giuliani<sup>2</sup>, G. Liu<sup>2</sup>; <sup>1</sup>Ontario/CA, <sup>2</sup>CA, <sup>3</sup>ON/CA
- 16:55 - 16:55 1689PD - Breast Cancer (BC) related fatigue: a longitudinal investigation of its prevalence, domains and correlates  
I. Vaz Luis<sup>1</sup>, A. Di Meglio<sup>1</sup>, M. El-Mouhebb<sup>1</sup>, A. Dumas<sup>1</sup>, C. Charles<sup>1</sup>, G. Menvielle<sup>1</sup>, C. Mesleard<sup>1</sup>, A.L. Martin<sup>1</sup>, P. Cottu<sup>2</sup>, F. Lerebours<sup>1</sup>, C. Coutant<sup>3</sup>, A. Lesur<sup>1</sup>, S. Dauchy<sup>1</sup>, P. Arveux<sup>1</sup>, S. Delaloge<sup>1</sup>, N. Lin<sup>4</sup>, P. Ganz<sup>5</sup>, A. Partridge<sup>6</sup>, S. Michiels<sup>1</sup>, F. André<sup>7</sup>; <sup>1</sup>FR, <sup>2</sup>CEDEX 5/FR, <sup>3</sup>Cedex/FR, <sup>4</sup>MA/US, <sup>5</sup>CA/US, <sup>6</sup>US, <sup>7</sup>CEDEX/FR
- 16:55 - 17:15 Invited Discussant 1686PD, 1687PD, 1688PD and 1689PD  
C. Ruhlmann, DK
- 17:15 - 17:25 Q&A led by Discussant

16:30 - 18:00 Type: Educational session Hall B3 - Room 22  
Title: Affordability and sustainability of new cancer drugs  
Chair(s): C. Uyl-de Groot, NL

16:30 - 16:55 The economics of innovative medicines  
C. Uyl-de Groot, NL

16:55 - 17:20 The use of scales to determine the magnitude of benefit of drugs  
E.G.E. de Vries, NL

17:20 - 17:45 Differential pricing across Europe: addressing needs of middle- and low income countries  
Z. Kaló, HU

17:45 - 18:00 Discussion about the role of social media

16:30 - 18:00	Type: EONS session Title: Awards and closing remarks Chair(s): A. Charalambous, CY	Hall B4 - Room 24
16:30 - 16:45	Novice Dissemination Award 1	
16:45 - 17:00	Novice Dissemination Award 2	
17:00 - 17:15	Lifetime Achievement Award	
17:15 - 17:30	Recognising Cancer Nursing Award	
17:30 - 17:40	Poster winner L. Sharp, SE	
17:40 - 17:40	Closing remarks <u>L. Sharp</u> , SE	
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 50 (TBC)	ICM - Room 14b
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 51 (TBC)	ICM - Room 13
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 52 (TBC)	Hall A1 - Room 15
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 53 (TBC)	Hall A1 - Room 16
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 54 (TBC)	Hall B3 - Room 20
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 55 (TBC)	Hall B3 - Room 22
18:30 - 20:00	Type: Industry Satellite Symposium Title: Industry satellite symposium 56 (TBC)	Hall B4 - Room 19

23.10.2018

09:00 - 12:40	Type: Congress Highlights Title: Congress Highlights 2: The best of the Munich 2018 Congress Chair(s): A. Cervantes, ES; J. Tabernero, ES	Hall A1 - Room 17
09:00 - 09:20	Gastrointestinal tumours, colorectal <u>D. Arnold</u> , DE	
09:20 - 09:40	Gastrointestinal tumours, non-colorectal <u>M. Hidalgo</u> , US	
09:40 - 10:00	NETs and endocrine tumours <u>G. Pentheroudakis</u> , GR	
10:00 - 10:20	Public health policy and health economics <u>F. Perrone</u> , IT	
10:20 - 10:40	Haematological malignancies <u>M. Ladetto</u> , IT	
10:40 - 11:00	Break	
11:00 - 11:20	Supportive and palliative care <u>F. Scotté</u> , FR	
11:20 - 11:40	Sarcoma <u>G.D. Demetri</u> , MA/US	
11:40 - 12:00	Gynaecological cancers <u>K. Steffensen</u> , DK	
12:00 - 12:20	Immunotherapy of cancer <u>G. Coukos</u> , CH	
12:20 - 12:40	Melanoma <u>G. Long</u> , NSW/AU	

09:00 - 13:00	Type: Congress Highlights Title: Congress Highlights 1: The best of the Munich 2018 Congress Chair(s): S. Peters, CH; A. Berns, NL	Hall A2 - Room 18
09:00 - 09:20	Basic science <u>T. Helleday</u> , GB	
09:20 - 09:40	Translational research <u>E. Calvo</u> , ES	
09:40 - 10:00	Genitourinary tumours, prostate <u>S. Gillessen</u> , CH	
10:00 - 10:20	Genitourinary tumours, non-prostate <u>P. Bono</u> , FI	
10:20 - 10:40	CNS tumours <u>C. Balana</u> , Barcelona/ES	
10:40 - 11:00	Break	
11:00 - 11:20	Head and neck cancer <u>L. Licitra</u> , IT	
11:20 - 11:40	Developmental therapeutics <u>T. Troiani</u> , IT	
11:40 - 12:00	Breast cancer, early <u>A. di Leo</u> , PO/IT	
12:00 - 12:20	Breast cancer, metastatic <u>S. Loibl</u> , DE	
12:20 - 12:40	Non-metastatic NSCLC and other thoracic malignancies <u>S. Ramalingam</u> , GA/US	
12:40 - 13:00	NSCLC, metastatic <u>J. Spicer</u> , GB	